Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,26139379,formation clearance,"The formation clearance of paracetamol-sulphate was 1.46 mL/min/kg(1.4), which was about 5.5 times higher than the formation clearance of the glucuronide of 0.266 mL/min/kg.",Developmental changes rather than repeated administration drive paracetamol glucuronidation in neonates and infants. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26139379/),[ml] / [kg·min],1.46,141,DB00316,Acetaminophen
,26139379,formation clearance,"The formation clearance of paracetamol-sulphate was 1.46 mL/min/kg(1.4), which was about 5.5 times higher than the formation clearance of the glucuronide of 0.266 mL/min/kg.",Developmental changes rather than repeated administration drive paracetamol glucuronidation in neonates and infants. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26139379/),[ml] / [kg·min],0.266,142,DB00316,Acetaminophen
,26139379,renal excretion rate constants,"The renal excretion rate constants of both metabolites was estimated to be 11.4 times higher than the excretion rate constant of unchanged paracetamol, yielding values of 0.580 mL/min/kg.",Developmental changes rather than repeated administration drive paracetamol glucuronidation in neonates and infants. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26139379/),[ml] / [kg·min],0.580,143,DB00316,Acetaminophen
,27537754,plasma Tmax,The median plasma Tmax in the 1 g IV group was 105 and 75 minutes earlier than in the 1 and 1.5 g oral groups.,Comparative Plasma and Cerebrospinal Fluid Pharmacokinetics of Paracetamol After Intravenous and Oral Administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27537754/),min,105,613,DB00316,Acetaminophen
,27537754,plasma Tmax,The median plasma Tmax in the 1 g IV group was 105 and 75 minutes earlier than in the 1 and 1.5 g oral groups.,Comparative Plasma and Cerebrospinal Fluid Pharmacokinetics of Paracetamol After Intravenous and Oral Administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27537754/),min,75,614,DB00316,Acetaminophen
,10991959,hepatic clearance,"Mean +/- S. D. hepatic clearance, apparent intrinsic clearance, hepatic extraction ratio, and biliary excretion half-life of GG were 10.4 +/- 1.4 ml/min, 94.1 +/- 17.9 ml/min, 0.346 +/- 0.046, and 30.9 +/- 4.9 min, respectively, and approximately 73% of GG was excreted into bile.","Hepatic disposition of the acyl glucuronide 1-O-gemfibrozil-beta-D-glucuronide: effects of clofibric acid, acetaminophen, and acetaminophen glucuronide. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991959/),[ml] / [min],10.4,727,DB00316,Acetaminophen
,10991959,apparent intrinsic clearance,"Mean +/- S. D. hepatic clearance, apparent intrinsic clearance, hepatic extraction ratio, and biliary excretion half-life of GG were 10.4 +/- 1.4 ml/min, 94.1 +/- 17.9 ml/min, 0.346 +/- 0.046, and 30.9 +/- 4.9 min, respectively, and approximately 73% of GG was excreted into bile.","Hepatic disposition of the acyl glucuronide 1-O-gemfibrozil-beta-D-glucuronide: effects of clofibric acid, acetaminophen, and acetaminophen glucuronide. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991959/),[ml] / [min],94.1,728,DB00316,Acetaminophen
,10991959,hepatic extraction ratio,"Mean +/- S. D. hepatic clearance, apparent intrinsic clearance, hepatic extraction ratio, and biliary excretion half-life of GG were 10.4 +/- 1.4 ml/min, 94.1 +/- 17.9 ml/min, 0.346 +/- 0.046, and 30.9 +/- 4.9 min, respectively, and approximately 73% of GG was excreted into bile.","Hepatic disposition of the acyl glucuronide 1-O-gemfibrozil-beta-D-glucuronide: effects of clofibric acid, acetaminophen, and acetaminophen glucuronide. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991959/),[ml] / [min],94.1,729,DB00316,Acetaminophen
,10991959,biliary excretion half-life,"Mean +/- S. D. hepatic clearance, apparent intrinsic clearance, hepatic extraction ratio, and biliary excretion half-life of GG were 10.4 +/- 1.4 ml/min, 94.1 +/- 17.9 ml/min, 0.346 +/- 0.046, and 30.9 +/- 4.9 min, respectively, and approximately 73% of GG was excreted into bile.","Hepatic disposition of the acyl glucuronide 1-O-gemfibrozil-beta-D-glucuronide: effects of clofibric acid, acetaminophen, and acetaminophen glucuronide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991959/),min,30.9,730,DB00316,Acetaminophen
,1134883,excretion rates,"Tweleve healthy 2- to 3-day-old full-term infants with plasma bilirubin concentrations of 1.0 to 11.6 mg/100 ml and D-glucaric acid excretion rates of 0.131 to 0.345 mg/kg/day received a single oral dose of acetaminophen, 12 mg/kg.",Pharmacokinetics of acetaminophen in the human neonate: formation of acetaminophen glucuronide and sulfate in relation to plasma bilirubin concentration and D-glucaric acid excretion. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1134883/),[mg] / [d·kg],0.131 to 0.345,731,DB00316,Acetaminophen
,1134883,biologic half-life,The biologic half-life of acetaminophen was 3.5 plus or minus 0.85 hours (average plus or minus SD) as compared to average values of 1.9 to 2.2 hours observed in five reported studies on a total of 39 adults.,Pharmacokinetics of acetaminophen in the human neonate: formation of acetaminophen glucuronide and sulfate in relation to plasma bilirubin concentration and D-glucaric acid excretion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1134883/),h,3.5,732,DB00316,Acetaminophen
,1134883,biologic half-life,The biologic half-life of acetaminophen was 3.5 plus or minus 0.85 hours (average plus or minus SD) as compared to average values of 1.9 to 2.2 hours observed in five reported studies on a total of 39 adults.,Pharmacokinetics of acetaminophen in the human neonate: formation of acetaminophen glucuronide and sulfate in relation to plasma bilirubin concentration and D-glucaric acid excretion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1134883/),h,1.9 to 2.2,733,DB00316,Acetaminophen
,24028565,Total delivery,"Total delivery across human and porcine skin was found to be statistically equivalent (243.2 ± 33.1 and 235.6 ± 13.7 μg · cm(-2), respectively).",Controlled iontophoretic transport of huperzine A across skin in vitro and in vivo: effect of delivery conditions and comparison of pharmacokinetic models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24028565/),[μg] / [(cm)^2],243.2,965,DB00316,Acetaminophen
,24028565,Total delivery,"Total delivery across human and porcine skin was found to be statistically equivalent (243.2 ± 33.1 and 235.6 ± 13.7 μg · cm(-2), respectively).",Controlled iontophoretic transport of huperzine A across skin in vitro and in vivo: effect of delivery conditions and comparison of pharmacokinetic models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24028565/),[μg] / [(cm)^2],235.6,966,DB00316,Acetaminophen
,24028565,transport efficiency,"Although the transport efficiency was ∼ 1%, the iontophoretic delivery efficiency (i.e., the fraction of the drug load delivered) was extremely high, in the range of 46-81% depending on the current density.",Controlled iontophoretic transport of huperzine A across skin in vitro and in vivo: effect of delivery conditions and comparison of pharmacokinetic models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24028565/),%,1,967,DB00316,Acetaminophen
,24028565,Cumulative permeation,"Cumulative permeation of HupA from a Carbopol gel formulation after iontophoresis for 6 h at 0.5 mA · cm(-2) was less than that from solution (135.3 ± 25.2 and 202.9 ± 5.2 μg · cm(-2), respectively) but sufficient for therapeutic delivery.",Controlled iontophoretic transport of huperzine A across skin in vitro and in vivo: effect of delivery conditions and comparison of pharmacokinetic models. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24028565/),[μg] / [(cm)^2],135.3,968,DB00316,Acetaminophen
,24028565,Cumulative permeation,"Cumulative permeation of HupA from a Carbopol gel formulation after iontophoresis for 6 h at 0.5 mA · cm(-2) was less than that from solution (135.3 ± 25.2 and 202.9 ± 5.2 μg · cm(-2), respectively) but sufficient for therapeutic delivery.",Controlled iontophoretic transport of huperzine A across skin in vitro and in vivo: effect of delivery conditions and comparison of pharmacokinetic models. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24028565/),[μg] / [(cm)^2],202.9,969,DB00316,Acetaminophen
,15071761,volume of distribution,The population volume of distribution estimate and between-subject variability (%) for a one-compartment model with zero-order input and first-order elimination was 70.4 l (30.7%)/70 kg.,Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15071761/),l,70.4,1113,DB00316,Acetaminophen
,15071761,Clearance,"Clearance increased from 2.85 l/70 kg, CV 40.7% at 27 weeks PCA to reach 7.05 l/h per 70 kg by 42 weeks PCA (standardised to a 70-kg person using allometric ""1/4-power"" models).",Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15071761/),[l] / [70·kg],2.85,1114,DB00316,Acetaminophen
,15071761,Clearance,"Clearance increased from 2.85 l/70 kg, CV 40.7% at 27 weeks PCA to reach 7.05 l/h per 70 kg by 42 weeks PCA (standardised to a 70-kg person using allometric ""1/4-power"" models).",Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15071761/),[l] / [70·h·kg],7.05,1115,DB00316,Acetaminophen
above,15071761,steady-state target concentration,"A mean paracetamol steady-state target concentration above 10 mg/l at trough can be achieved using a loading dose of 40 mg/kg and maintenance doses of 20 mg/kg 6 h in 28-week PCA neonates, 25 mg/kg 6 h at 32 weeks, 30 mg/kg 6 h at 36 weeks and 20 mg/kg 4 h at term (propacetamol doses).",Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15071761/),[mg] / [l],10,1116,DB00316,Acetaminophen
,15071761,clearance,"Since the role of the oxidative enzyme CYP2E1 and production of the hepatotoxic metabolite N-acetyl-p-benzoquinone-imine still is unknown in premature neonates, lower doses scaled by age-related clearance and centred on a daily dose of 60 mg/kg per day in a child of 6-8 years with a clearance of 0.25 l/h per kg (12.5 l/h per 70 kg) may be more appropriate.",Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15071761/),[l] / [h·kg],0.25,1117,DB00316,Acetaminophen
,15071761,clearance,"Since the role of the oxidative enzyme CYP2E1 and production of the hepatotoxic metabolite N-acetyl-p-benzoquinone-imine still is unknown in premature neonates, lower doses scaled by age-related clearance and centred on a daily dose of 60 mg/kg per day in a child of 6-8 years with a clearance of 0.25 l/h per kg (12.5 l/h per 70 kg) may be more appropriate.",Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15071761/),[l] / [70·h·kg],12.5,1118,DB00316,Acetaminophen
,3792438,peak plasma oxaprozin concentration,"No significant differences existed among the four treatment conditions in peak plasma oxaprozin concentration (86 micrograms/ml), volume of distribution (0.23 l/kg), time of peak concentration (3.7 h after dosage), or elimination half-life (54 h).","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),[μg] / [ml],86,1264,DB00316,Acetaminophen
,3792438,volume of distribution,"No significant differences existed among the four treatment conditions in peak plasma oxaprozin concentration (86 micrograms/ml), volume of distribution (0.23 l/kg), time of peak concentration (3.7 h after dosage), or elimination half-life (54 h).","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),[l] / [kg],0.23,1265,DB00316,Acetaminophen
,3792438,time of peak concentration,"No significant differences existed among the four treatment conditions in peak plasma oxaprozin concentration (86 micrograms/ml), volume of distribution (0.23 l/kg), time of peak concentration (3.7 h after dosage), or elimination half-life (54 h).","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),h,3.7,1266,DB00316,Acetaminophen
,3792438,elimination half-life,"No significant differences existed among the four treatment conditions in peak plasma oxaprozin concentration (86 micrograms/ml), volume of distribution (0.23 l/kg), time of peak concentration (3.7 h after dosage), or elimination half-life (54 h).","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),h,54,1267,DB00316,Acetaminophen
,3792438,oral clearance,"Oxaprozin oral clearance was significantly lower (by 20%) during both the cimetidine and ranitidine trials versus control (0.047 vs 0.047 vs 0.059 ml/min/kg), but clearance during acetaminophen was not significantly different from control.","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),[ml] / [kg·min],0.047,1268,DB00316,Acetaminophen
,3792438,oral clearance,"Oxaprozin oral clearance was significantly lower (by 20%) during both the cimetidine and ranitidine trials versus control (0.047 vs 0.047 vs 0.059 ml/min/kg), but clearance during acetaminophen was not significantly different from control.","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),[ml] / [kg·min],0.059,1269,DB00316,Acetaminophen
,18211024,peak plasma concentration ( C max),"The main metabolite, a pelargonidin- O-glucuronide, reached a peak plasma concentration ( C max) of 274 +/- 24 nmol/L after 1.1 +/- 0.4 h ( t max) when only strawberries were ingested.",Bioavailability of pelargonidin-3-O-glucoside and its metabolites in humans following the ingestion of strawberries with and without cream. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18211024/),[nM] / [l],274,1397,DB00316,Acetaminophen
,18211024,t max,"The main metabolite, a pelargonidin- O-glucuronide, reached a peak plasma concentration ( C max) of 274 +/- 24 nmol/L after 1.1 +/- 0.4 h ( t max) when only strawberries were ingested.",Bioavailability of pelargonidin-3-O-glucoside and its metabolites in humans following the ingestion of strawberries with and without cream. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18211024/),h,1.1,1398,DB00316,Acetaminophen
,18211024,t max,"When the strawberries were eaten with cream, the C max was not statistically different but the t max at 2.4 +/- 0.5 h was delayed significantly ( p < 0.001).",Bioavailability of pelargonidin-3-O-glucoside and its metabolites in humans following the ingestion of strawberries with and without cream. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18211024/),h,2.4,1399,DB00316,Acetaminophen
,10496299,absolute bioavailability,It is rapidly absorbed with an absolute bioavailability of between 40 and 50%.,Clinical pharmacokinetics of troglitazone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496299/),%,40 and 50,2272,DB00316,Acetaminophen
,10496299,elimination half-life,"The mean elimination half-life ranges from 7.6 to 24 hours, which facilitates a once daily administration regimen.",Clinical pharmacokinetics of troglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496299/),h,7.6 to 24,2273,DB00316,Acetaminophen
,19464026,peak plasma concentration (C(max)),"In 9 evaluable subjects, plasma pramlintide concentrations increased dose-proportionately; mean peak plasma concentration (C(max)) (15-microg dose, 93 +/- 9 pg/mL; 30-microg dose, 202 +/- 21 pg/mL) occurred approximately 0.3 h (median time to peak concentration) after administration.","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),[pg] / [ml],93,2983,DB00316,Acetaminophen
,19464026,peak plasma concentration (C(max)),"In 9 evaluable subjects, plasma pramlintide concentrations increased dose-proportionately; mean peak plasma concentration (C(max)) (15-microg dose, 93 +/- 9 pg/mL; 30-microg dose, 202 +/- 21 pg/mL) occurred approximately 0.3 h (median time to peak concentration) after administration.","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),[pg] / [ml],202,2984,DB00316,Acetaminophen
,19464026,time to peak concentration,"In 9 evaluable subjects, plasma pramlintide concentrations increased dose-proportionately; mean peak plasma concentration (C(max)) (15-microg dose, 93 +/- 9 pg/mL; 30-microg dose, 202 +/- 21 pg/mL) occurred approximately 0.3 h (median time to peak concentration) after administration.","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),h,0.3,2985,DB00316,Acetaminophen
,19464026,area under the concentration curve (AUC(0-3h)),"Pramlintide reduced incremental area under the concentration curve (AUC(0-3h)) for glucagon and glucose versus placebo (glucagon: 15-microg dose, 4 +/- 7 pg(*)h/mL; 30-microg dose, 5 +/- 7 pg(*)h/mL; placebo, 35 +/- 9 pg(*)h/mL; glucose: 15-microg dose, 129 +/- 43 mg(*)h/dL; 30-microg dose, 132 +/- 37 mg(*)h/dL; placebo, 217 +/- 56 mg(*)h/dL).","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),p,4,2986,DB00316,Acetaminophen
,19464026,area under the concentration curve (AUC(0-3h)),"Pramlintide reduced incremental area under the concentration curve (AUC(0-3h)) for glucagon and glucose versus placebo (glucagon: 15-microg dose, 4 +/- 7 pg(*)h/mL; 30-microg dose, 5 +/- 7 pg(*)h/mL; placebo, 35 +/- 9 pg(*)h/mL; glucose: 15-microg dose, 129 +/- 43 mg(*)h/dL; 30-microg dose, 132 +/- 37 mg(*)h/dL; placebo, 217 +/- 56 mg(*)h/dL).","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),p,5,2987,DB00316,Acetaminophen
,19464026,area under the concentration curve (AUC(0-3h)),"Pramlintide reduced incremental area under the concentration curve (AUC(0-3h)) for glucagon and glucose versus placebo (glucagon: 15-microg dose, 4 +/- 7 pg(*)h/mL; 30-microg dose, 5 +/- 7 pg(*)h/mL; placebo, 35 +/- 9 pg(*)h/mL; glucose: 15-microg dose, 129 +/- 43 mg(*)h/dL; 30-microg dose, 132 +/- 37 mg(*)h/dL; placebo, 217 +/- 56 mg(*)h/dL).","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),pg,35,2988,DB00316,Acetaminophen
,19464026,area under the concentration curve (AUC(0-3h)),"Pramlintide reduced incremental area under the concentration curve (AUC(0-3h)) for glucagon and glucose versus placebo (glucagon: 15-microg dose, 4 +/- 7 pg(*)h/mL; 30-microg dose, 5 +/- 7 pg(*)h/mL; placebo, 35 +/- 9 pg(*)h/mL; glucose: 15-microg dose, 129 +/- 43 mg(*)h/dL; 30-microg dose, 132 +/- 37 mg(*)h/dL; placebo, 217 +/- 56 mg(*)h/dL).","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),mg,129,2989,DB00316,Acetaminophen
,19464026,area under the concentration curve (AUC(0-3h)),"Pramlintide reduced incremental area under the concentration curve (AUC(0-3h)) for glucagon and glucose versus placebo (glucagon: 15-microg dose, 4 +/- 7 pg(*)h/mL; 30-microg dose, 5 +/- 7 pg(*)h/mL; placebo, 35 +/- 9 pg(*)h/mL; glucose: 15-microg dose, 129 +/- 43 mg(*)h/dL; 30-microg dose, 132 +/- 37 mg(*)h/dL; placebo, 217 +/- 56 mg(*)h/dL).","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),,132,2990,DB00316,Acetaminophen
,19464026,area under the concentration curve (AUC(0-3h)),"Pramlintide reduced incremental area under the concentration curve (AUC(0-3h)) for glucagon and glucose versus placebo (glucagon: 15-microg dose, 4 +/- 7 pg(*)h/mL; 30-microg dose, 5 +/- 7 pg(*)h/mL; placebo, 35 +/- 9 pg(*)h/mL; glucose: 15-microg dose, 129 +/- 43 mg(*)h/dL; 30-microg dose, 132 +/- 37 mg(*)h/dL; placebo, 217 +/- 56 mg(*)h/dL).","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),mg,217,2991,DB00316,Acetaminophen
,1768561,area under the plasma concentration-time curves (AUC),The area under the plasma concentration-time curves (AUC) for the final dose of levodopa (150.8 +/- 22.0 micrograms ml-1 min) was lower than for the two preceding doses (205.7 +/- 41.8 and 199.5 +/- 51.8 micrograms ml-1 min) but not different from that of the single dose given at the same time of day (141.7 +/- 29.1 micrograms ml-1 min).,Gastric emptying in healthy volunteers after multiple doses of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768561/),[min·μg] / [ml],150.8,3087,DB00316,Acetaminophen
,1768561,area under the plasma concentration-time curves (AUC),The area under the plasma concentration-time curves (AUC) for the final dose of levodopa (150.8 +/- 22.0 micrograms ml-1 min) was lower than for the two preceding doses (205.7 +/- 41.8 and 199.5 +/- 51.8 micrograms ml-1 min) but not different from that of the single dose given at the same time of day (141.7 +/- 29.1 micrograms ml-1 min).,Gastric emptying in healthy volunteers after multiple doses of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768561/),[min·μg] / [ml],205.7,3088,DB00316,Acetaminophen
,1768561,area under the plasma concentration-time curves (AUC),The area under the plasma concentration-time curves (AUC) for the final dose of levodopa (150.8 +/- 22.0 micrograms ml-1 min) was lower than for the two preceding doses (205.7 +/- 41.8 and 199.5 +/- 51.8 micrograms ml-1 min) but not different from that of the single dose given at the same time of day (141.7 +/- 29.1 micrograms ml-1 min).,Gastric emptying in healthy volunteers after multiple doses of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768561/),[min·μg] / [ml],199.5,3089,DB00316,Acetaminophen
,1768561,area under the plasma concentration-time curves (AUC),The area under the plasma concentration-time curves (AUC) for the final dose of levodopa (150.8 +/- 22.0 micrograms ml-1 min) was lower than for the two preceding doses (205.7 +/- 41.8 and 199.5 +/- 51.8 micrograms ml-1 min) but not different from that of the single dose given at the same time of day (141.7 +/- 29.1 micrograms ml-1 min).,Gastric emptying in healthy volunteers after multiple doses of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768561/),[min·μg] / [ml],141.7,3090,DB00316,Acetaminophen
,1403775,total plasma,"After i.v. administration, total plasma clearance of L-689,502 in rats decreased with increasing dose; the clearance decreased from 181 ml/min/kg at 1 mg/kg to 86 ml/min/kg at 20 mg/kg.","Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403775/),[ml] / [kg·min],181,4261,DB00316,Acetaminophen
,1403775,clearance,"After i.v. administration, total plasma clearance of L-689,502 in rats decreased with increasing dose; the clearance decreased from 181 ml/min/kg at 1 mg/kg to 86 ml/min/kg at 20 mg/kg.","Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403775/),[ml] / [kg·min],181,4262,DB00316,Acetaminophen
,1403775,clearance,"After i.v. administration, total plasma clearance of L-689,502 in rats decreased with increasing dose; the clearance decreased from 181 ml/min/kg at 1 mg/kg to 86 ml/min/kg at 20 mg/kg.","Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403775/),[ml] / [kg·min],86,4263,DB00316,Acetaminophen
,1403775,clearance,Similar results were observed in dogs; clearance fell from 29 ml/min/kg at 0.5 mg/kg to 17 ml/min/kg at 10 mg/kg.,"Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403775/),[ml] / [kg·min],29,4264,DB00316,Acetaminophen
,1403775,clearance,Similar results were observed in dogs; clearance fell from 29 ml/min/kg at 0.5 mg/kg to 17 ml/min/kg at 10 mg/kg.,"Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403775/),[ml] / [kg·min],17,4265,DB00316,Acetaminophen
,4020675,half-life,"Acetaminophen half-life was prolonged during probenecid treatment (mean +/- S.E., 4.30 +/- 0.23 vs. 2.51 +/- 0.16 hr; P less than .001) due to markedly decreased clearance (178 +/- 13 vs. 329 +/- 24 ml/min; P less than .001) with no change in volume of distribution (65 +/- 4 vs. 69 +/- 3 l; NS).",Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),h,4.30,4627,DB00316,Acetaminophen
,4020675,half-life,"Acetaminophen half-life was prolonged during probenecid treatment (mean +/- S.E., 4.30 +/- 0.23 vs. 2.51 +/- 0.16 hr; P less than .001) due to markedly decreased clearance (178 +/- 13 vs. 329 +/- 24 ml/min; P less than .001) with no change in volume of distribution (65 +/- 4 vs. 69 +/- 3 l; NS).",Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),h,2.51,4628,DB00316,Acetaminophen
,4020675,clearance,"Acetaminophen half-life was prolonged during probenecid treatment (mean +/- S.E., 4.30 +/- 0.23 vs. 2.51 +/- 0.16 hr; P less than .001) due to markedly decreased clearance (178 +/- 13 vs. 329 +/- 24 ml/min; P less than .001) with no change in volume of distribution (65 +/- 4 vs. 69 +/- 3 l; NS).",Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),[ml] / [min],178,4629,DB00316,Acetaminophen
,4020675,clearance,"Acetaminophen half-life was prolonged during probenecid treatment (mean +/- S.E., 4.30 +/- 0.23 vs. 2.51 +/- 0.16 hr; P less than .001) due to markedly decreased clearance (178 +/- 13 vs. 329 +/- 24 ml/min; P less than .001) with no change in volume of distribution (65 +/- 4 vs. 69 +/- 3 l; NS).",Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),[ml] / [min],329,4630,DB00316,Acetaminophen
,4020675,volume of distribution,"Acetaminophen half-life was prolonged during probenecid treatment (mean +/- S.E., 4.30 +/- 0.23 vs. 2.51 +/- 0.16 hr; P less than .001) due to markedly decreased clearance (178 +/- 13 vs. 329 +/- 24 ml/min; P less than .001) with no change in volume of distribution (65 +/- 4 vs. 69 +/- 3 l; NS).",Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),l,65,4631,DB00316,Acetaminophen
,4020675,volume of distribution,"Acetaminophen half-life was prolonged during probenecid treatment (mean +/- S.E., 4.30 +/- 0.23 vs. 2.51 +/- 0.16 hr; P less than .001) due to markedly decreased clearance (178 +/- 13 vs. 329 +/- 24 ml/min; P less than .001) with no change in volume of distribution (65 +/- 4 vs. 69 +/- 3 l; NS).",Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),l,69,4632,DB00316,Acetaminophen
,4020675,Urinary excretion,Urinary excretion of acetaminophen glucuronide during 24 hr was decreased (84 +/- 9 vs.,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),,84,4633,DB00316,Acetaminophen
,4020675,excretion,260 +/- 21 mg of acetaminophen as glucuronide; P less than .001) and acetaminophen sulfate excretion was increased (323 +/- 25 vs.,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),,323,4634,DB00316,Acetaminophen
,4020675,half-life,Lorazepam half-life was also prolonged during probenecid treatment (33.0 +/- 3.9 vs. 14.3 +/- 1.08 hr; P less than .001) due to decreased clearance (44.7 +/- 5.4 vs. 80.3 +/- 13.2 ml/min; P less than .001) with no change in volume of distribution (111 +/- 5 vs. 111 +/- 7 l; NS).,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),h,33.0,4635,DB00316,Acetaminophen
,4020675,half-life,Lorazepam half-life was also prolonged during probenecid treatment (33.0 +/- 3.9 vs. 14.3 +/- 1.08 hr; P less than .001) due to decreased clearance (44.7 +/- 5.4 vs. 80.3 +/- 13.2 ml/min; P less than .001) with no change in volume of distribution (111 +/- 5 vs. 111 +/- 7 l; NS).,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),h,14.3,4636,DB00316,Acetaminophen
,4020675,clearance,Lorazepam half-life was also prolonged during probenecid treatment (33.0 +/- 3.9 vs. 14.3 +/- 1.08 hr; P less than .001) due to decreased clearance (44.7 +/- 5.4 vs. 80.3 +/- 13.2 ml/min; P less than .001) with no change in volume of distribution (111 +/- 5 vs. 111 +/- 7 l; NS).,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),[ml] / [min],44.7,4637,DB00316,Acetaminophen
,4020675,clearance,Lorazepam half-life was also prolonged during probenecid treatment (33.0 +/- 3.9 vs. 14.3 +/- 1.08 hr; P less than .001) due to decreased clearance (44.7 +/- 5.4 vs. 80.3 +/- 13.2 ml/min; P less than .001) with no change in volume of distribution (111 +/- 5 vs. 111 +/- 7 l; NS).,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),[ml] / [min],80.3,4638,DB00316,Acetaminophen
,4020675,volume of distribution,Lorazepam half-life was also prolonged during probenecid treatment (33.0 +/- 3.9 vs. 14.3 +/- 1.08 hr; P less than .001) due to decreased clearance (44.7 +/- 5.4 vs. 80.3 +/- 13.2 ml/min; P less than .001) with no change in volume of distribution (111 +/- 5 vs. 111 +/- 7 l; NS).,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),l,111,4639,DB00316,Acetaminophen
,4020675,volume of distribution,Lorazepam half-life was also prolonged during probenecid treatment (33.0 +/- 3.9 vs. 14.3 +/- 1.08 hr; P less than .001) due to decreased clearance (44.7 +/- 5.4 vs. 80.3 +/- 13.2 ml/min; P less than .001) with no change in volume of distribution (111 +/- 5 vs. 111 +/- 7 l; NS).,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),l,111,4640,DB00316,Acetaminophen
,1681957,fractions of drug removed,"For paracetamol (1 g, single oral dose) and diclofenac (100 mg, single oral dose), the fractions of drug removed during PE effected within 2 h of drug intake, were respectively 5.0 +/- 3.1 per cent and 13.6 +/- 9.5 per cent, while plasmapheretic clearance reached, respectively, 13.0 +/- 10.7 per cent of the systemic clearance for paracetamol and 23.0 +/- 1.0 per cent for diclofenac.","Diclofenac, paracetamol, and vidarabine removal during plasma exchange in polyarteritis nodosa patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1681957/),%,5.0,5290,DB00316,Acetaminophen
,1681957,fractions of drug removed,"For paracetamol (1 g, single oral dose) and diclofenac (100 mg, single oral dose), the fractions of drug removed during PE effected within 2 h of drug intake, were respectively 5.0 +/- 3.1 per cent and 13.6 +/- 9.5 per cent, while plasmapheretic clearance reached, respectively, 13.0 +/- 10.7 per cent of the systemic clearance for paracetamol and 23.0 +/- 1.0 per cent for diclofenac.","Diclofenac, paracetamol, and vidarabine removal during plasma exchange in polyarteritis nodosa patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1681957/),%,13.6,5291,DB00316,Acetaminophen
,1681957,systemic clearance,"For paracetamol (1 g, single oral dose) and diclofenac (100 mg, single oral dose), the fractions of drug removed during PE effected within 2 h of drug intake, were respectively 5.0 +/- 3.1 per cent and 13.6 +/- 9.5 per cent, while plasmapheretic clearance reached, respectively, 13.0 +/- 10.7 per cent of the systemic clearance for paracetamol and 23.0 +/- 1.0 per cent for diclofenac.","Diclofenac, paracetamol, and vidarabine removal during plasma exchange in polyarteritis nodosa patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1681957/),%,13.0,5292,DB00316,Acetaminophen
,3197750,elimination t1/2,"Between Trials 1 and 3, antipyrine elimination t1/2 (17.2 vs 17.4 h), clearance (0.44 vs 0.43 ml.min-1.kg-1) and 24-h recovery of antipyrine and metabolites (313 vs 293 mg) did not differ significantly.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),h,17.2,5484,DB00316,Acetaminophen
,3197750,elimination t1/2,"Between Trials 1 and 3, antipyrine elimination t1/2 (17.2 vs 17.4 h), clearance (0.44 vs 0.43 ml.min-1.kg-1) and 24-h recovery of antipyrine and metabolites (313 vs 293 mg) did not differ significantly.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),h,17.4,5485,DB00316,Acetaminophen
,3197750,clearance,"Between Trials 1 and 3, antipyrine elimination t1/2 (17.2 vs 17.4 h), clearance (0.44 vs 0.43 ml.min-1.kg-1) and 24-h recovery of antipyrine and metabolites (313 vs 293 mg) did not differ significantly.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[ml] / [kg·min],0.44,5486,DB00316,Acetaminophen
,3197750,clearance,"Between Trials 1 and 3, antipyrine elimination t1/2 (17.2 vs 17.4 h), clearance (0.44 vs 0.43 ml.min-1.kg-1) and 24-h recovery of antipyrine and metabolites (313 vs 293 mg) did not differ significantly.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[ml] / [kg·min],0.43,5487,DB00316,Acetaminophen
,3197750,clearance,"Between Trials 1 and 3, antipyrine elimination t1/2 (17.2 vs 17.4 h), clearance (0.44 vs 0.43 ml.min-1.kg-1) and 24-h recovery of antipyrine and metabolites (313 vs 293 mg) did not differ significantly.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),,24,5488,DB00316,Acetaminophen
,3197750,VZ,"Between Trials 2 and 3, acetaminophen VZ was reduced (1.14 vs 1.00 l.kg-1), t1/2 prolonged (2.7 vs 3.3 h), clearance reduced (4.8 vs 3.6 ml.min-1.kg-1), and fractional urinary recovery of acetaminophen glucuronide reduced.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[l] / [kg],1.14,5489,DB00316,Acetaminophen
,3197750,VZ,"Between Trials 2 and 3, acetaminophen VZ was reduced (1.14 vs 1.00 l.kg-1), t1/2 prolonged (2.7 vs 3.3 h), clearance reduced (4.8 vs 3.6 ml.min-1.kg-1), and fractional urinary recovery of acetaminophen glucuronide reduced.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[l] / [kg],1.00,5490,DB00316,Acetaminophen
,3197750,t1/2,"Between Trials 2 and 3, acetaminophen VZ was reduced (1.14 vs 1.00 l.kg-1), t1/2 prolonged (2.7 vs 3.3 h), clearance reduced (4.8 vs 3.6 ml.min-1.kg-1), and fractional urinary recovery of acetaminophen glucuronide reduced.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),h,2.7,5491,DB00316,Acetaminophen
,3197750,t1/2,"Between Trials 2 and 3, acetaminophen VZ was reduced (1.14 vs 1.00 l.kg-1), t1/2 prolonged (2.7 vs 3.3 h), clearance reduced (4.8 vs 3.6 ml.min-1.kg-1), and fractional urinary recovery of acetaminophen glucuronide reduced.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),h,3.3,5492,DB00316,Acetaminophen
,3197750,clearance,"Between Trials 2 and 3, acetaminophen VZ was reduced (1.14 vs 1.00 l.kg-1), t1/2 prolonged (2.7 vs 3.3 h), clearance reduced (4.8 vs 3.6 ml.min-1.kg-1), and fractional urinary recovery of acetaminophen glucuronide reduced.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[ml] / [kg·min],4.8,5493,DB00316,Acetaminophen
,3197750,clearance,"Between Trials 2 and 3, acetaminophen VZ was reduced (1.14 vs 1.00 l.kg-1), t1/2 prolonged (2.7 vs 3.3 h), clearance reduced (4.8 vs 3.6 ml.min-1.kg-1), and fractional urinary recovery of acetaminophen glucuronide reduced.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[ml] / [kg·min],3.6,5494,DB00316,Acetaminophen
,3197750,VZ,"The two trials did not differ significantly in lidocaine VZ (2.6 vs 2.7 l.kg-1), t1/2 (2.0 vs 2.4 h) or clearance (15.0 vs 13.5 ml.min-1.kg-1).",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[l] / [kg],2.6,5495,DB00316,Acetaminophen
,3197750,VZ,"The two trials did not differ significantly in lidocaine VZ (2.6 vs 2.7 l.kg-1), t1/2 (2.0 vs 2.4 h) or clearance (15.0 vs 13.5 ml.min-1.kg-1).",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[l] / [kg],2.7,5496,DB00316,Acetaminophen
,3197750,t1/2,"The two trials did not differ significantly in lidocaine VZ (2.6 vs 2.7 l.kg-1), t1/2 (2.0 vs 2.4 h) or clearance (15.0 vs 13.5 ml.min-1.kg-1).",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),h,2.0,5497,DB00316,Acetaminophen
,3197750,t1/2,"The two trials did not differ significantly in lidocaine VZ (2.6 vs 2.7 l.kg-1), t1/2 (2.0 vs 2.4 h) or clearance (15.0 vs 13.5 ml.min-1.kg-1).",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),h,2.4,5498,DB00316,Acetaminophen
,3197750,clearance,"The two trials did not differ significantly in lidocaine VZ (2.6 vs 2.7 l.kg-1), t1/2 (2.0 vs 2.4 h) or clearance (15.0 vs 13.5 ml.min-1.kg-1).",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[ml] / [kg·min],15.0,5499,DB00316,Acetaminophen
,3197750,clearance,"The two trials did not differ significantly in lidocaine VZ (2.6 vs 2.7 l.kg-1), t1/2 (2.0 vs 2.4 h) or clearance (15.0 vs 13.5 ml.min-1.kg-1).",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[ml] / [kg·min],13.5,5500,DB00316,Acetaminophen
,2051160,capillary permeability-area product,Plasma and whole striatal tissue samples were used to describe plasma kinetics and to estimate a capillary permeability-area product of 0.07 min-1.,Quantitative microdialysis: analysis of transients and application to pharmacokinetics in brain. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2051160/),1/[min],0.07,6302,DB00316,Acetaminophen
,27624471,half-lives,"Non-compartmental PK analysis resulted in estimates for half-lives of 10.9 and 23.8 days for ferroquine and SSR97213, respectively.",A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27624471/),d,10.9,8029,DB00316,Acetaminophen
,27624471,half-lives,"Non-compartmental PK analysis resulted in estimates for half-lives of 10.9 and 23.8 days for ferroquine and SSR97213, respectively.",A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27624471/),d,23.8,8030,DB00316,Acetaminophen
,27624471,parasite clearance half-life,Parasite clearance as reported by parasite reduction ratio was 162.9 (95 % CI 141-188) corresponding to a parasite clearance half-life of 6.5 h (95 % CI: 6.4-6.7 h).,A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27624471/),h,6.5,8031,DB00316,Acetaminophen
,27624471,minimal parasiticidal concentration,"PK/PD modelling resulted in a predicted minimal parasiticidal concentration of 20 ng/mL, and the single dosing tested in this study was predicted to maintain an exposure above this threshold for 454 h (37.8 days).",A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27624471/),[ng] / [ml],20,8032,DB00316,Acetaminophen
,1823871,half life,Plasma levels of apyramide quickly decreased and the mean (+/- SD) half life was 0.15 +/- 0.08 h.,Pharmacokinetics of an indomethacin pro-drug: apyramide after intravenous administration in dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823871/),h,0.15,8459,DB00316,Acetaminophen
,1823871,area under curve,"For metabolic indomethacin, the mean (+/- SD) area under curve was 12.36 +/- 4.80 mg.h/l and the mean (+/- SD) half life of terminal phase was 16.71 +/- 9.46 h.",Pharmacokinetics of an indomethacin pro-drug: apyramide after intravenous administration in dog. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823871/),[h·mg] / [l],12.36,8460,DB00316,Acetaminophen
,1823871,half life of terminal phase,"For metabolic indomethacin, the mean (+/- SD) area under curve was 12.36 +/- 4.80 mg.h/l and the mean (+/- SD) half life of terminal phase was 16.71 +/- 9.46 h.",Pharmacokinetics of an indomethacin pro-drug: apyramide after intravenous administration in dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823871/),h,16.71,8461,DB00316,Acetaminophen
,7957542,maximal serum concentration,"The maximum serum concentration (Cmax) was reached 48 min after administration in both groups, and the mean maximal serum concentration was similar in the pregnant and non-pregnant women (11.16 and 11.58 micrograms.ml-1).",Paracetamol pharmacokinetics during the first trimester of human pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957542/),[μg] / [ml],11.16,8535,DB00316,Acetaminophen
,7957542,maximal serum concentration,"The maximum serum concentration (Cmax) was reached 48 min after administration in both groups, and the mean maximal serum concentration was similar in the pregnant and non-pregnant women (11.16 and 11.58 micrograms.ml-1).",Paracetamol pharmacokinetics during the first trimester of human pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957542/),[μg] / [ml],11.58,8536,DB00316,Acetaminophen
,830879,percentage of,The mean percentage of dose excreted as salicylamide sulfate was significantly higher in children (78%) than in adults (36%).,Age-related differences in salicylamide and acetaminophen conjugation in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/830879/),%,78,9948,DB00316,Acetaminophen
,830879,percentage of,The mean percentage of dose excreted as salicylamide sulfate was significantly higher in children (78%) than in adults (36%).,Age-related differences in salicylamide and acetaminophen conjugation in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/830879/),%,36,9949,DB00316,Acetaminophen
,10579478,peak serum concentrations,"Mean peak serum concentrations (+/-SD) during multiple-dose administration were 10.79 +/- 6.39 mg/L, 15.34 +/- 5.21 mg/L, and 6.24 +/- 3.64 mg/L for the entire group, boys, and girls, respectively.",Multiple-dose pharmacokinetics of rectally administered acetaminophen in term infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579478/),[mg] / [l],10.79,11627,DB00316,Acetaminophen
,10579478,peak serum concentrations,"Mean peak serum concentrations (+/-SD) during multiple-dose administration were 10.79 +/- 6.39 mg/L, 15.34 +/- 5.21 mg/L, and 6.24 +/- 3.64 mg/L for the entire group, boys, and girls, respectively.",Multiple-dose pharmacokinetics of rectally administered acetaminophen in term infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579478/),[mg] / [l],15.34,11628,DB00316,Acetaminophen
,10579478,peak serum concentrations,"Mean peak serum concentrations (+/-SD) during multiple-dose administration were 10.79 +/- 6.39 mg/L, 15.34 +/- 5.21 mg/L, and 6.24 +/- 3.64 mg/L for the entire group, boys, and girls, respectively.",Multiple-dose pharmacokinetics of rectally administered acetaminophen in term infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579478/),[mg] / [l],6.24,11629,DB00316,Acetaminophen
,10579478,time to peak serum concentration,Median time to peak serum concentration was 1.5 hours after the first dose and 15 hours for multiple doses.,Multiple-dose pharmacokinetics of rectally administered acetaminophen in term infants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579478/),h,1.5,11630,DB00316,Acetaminophen
,10579478,time to peak serum concentration,Median time to peak serum concentration was 1.5 hours after the first dose and 15 hours for multiple doses.,Multiple-dose pharmacokinetics of rectally administered acetaminophen in term infants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579478/),h,15,11631,DB00316,Acetaminophen
,10579478,half-life,Mean (+/-SD) half-life was 2.7 +/- 1.4 hours in eight patients.,Multiple-dose pharmacokinetics of rectally administered acetaminophen in term infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579478/),h,2.7,11632,DB00316,Acetaminophen
,9178933,steady state concentration,"Following the intravenous bolus injection of APAP, plasma elimination of APAP was accelerated and the distribution volume of APAP was increased under a steady state concentration (about 10 microg APAP eq/ml) of AOAPS or APAPS, but not AMAPS, as compared with saline infusion.",Biopharmaceutical studies on drug/conjugated-metabolite interactions. Effect of acetaminophen sulfate and its positional isomers on the pharmacokinetics of acetaminophen in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9178933/),[apap·eq·μg] / [ml],10,12472,DB00316,Acetaminophen
,9178933,Total body clearances,"Total body clearances of APAP were increased from 18.3 ml/min/kg for the control to 23.9 and 26.9 ml/min/kg for AOAPS and APAPS coadministration, respectively.",Biopharmaceutical studies on drug/conjugated-metabolite interactions. Effect of acetaminophen sulfate and its positional isomers on the pharmacokinetics of acetaminophen in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9178933/),[ml] / [kg·min],18.3,12473,DB00316,Acetaminophen
,9178933,Total body clearances,"Total body clearances of APAP were increased from 18.3 ml/min/kg for the control to 23.9 and 26.9 ml/min/kg for AOAPS and APAPS coadministration, respectively.",Biopharmaceutical studies on drug/conjugated-metabolite interactions. Effect of acetaminophen sulfate and its positional isomers on the pharmacokinetics of acetaminophen in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9178933/),[ml] / [kg·min],23.9,12474,DB00316,Acetaminophen
,9178933,Total body clearances,"Total body clearances of APAP were increased from 18.3 ml/min/kg for the control to 23.9 and 26.9 ml/min/kg for AOAPS and APAPS coadministration, respectively.",Biopharmaceutical studies on drug/conjugated-metabolite interactions. Effect of acetaminophen sulfate and its positional isomers on the pharmacokinetics of acetaminophen in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9178933/),[ml] / [kg·min],26.9,12475,DB00316,Acetaminophen
,24558011,time to reach t0.25 μ,"Following the hot drink, paracetamol absorption was both significantly faster and greater over the first 60 min post-dose compared with the tablet, as evidenced by the median time to reach t0.25 μg/mL of 4.6 and 23.1 min, respectively, and AUC0-60 of 4668.00 and 1331.17 h*ng/mL, respectively.",Does a hot drink provide faster absorption of paracetamol than a tablet? A pharmacoscintigraphic study in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24558011/),min,4.6,14143,DB00316,Acetaminophen
,24558011,time to reach t0.25 μ,"Following the hot drink, paracetamol absorption was both significantly faster and greater over the first 60 min post-dose compared with the tablet, as evidenced by the median time to reach t0.25 μg/mL of 4.6 and 23.1 min, respectively, and AUC0-60 of 4668.00 and 1331.17 h*ng/mL, respectively.",Does a hot drink provide faster absorption of paracetamol than a tablet? A pharmacoscintigraphic study in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24558011/),min,23.1,14144,DB00316,Acetaminophen
,24558011,AUC0-60,"Following the hot drink, paracetamol absorption was both significantly faster and greater over the first 60 min post-dose compared with the tablet, as evidenced by the median time to reach t0.25 μg/mL of 4.6 and 23.1 min, respectively, and AUC0-60 of 4668.00 and 1331.17 h*ng/mL, respectively.",Does a hot drink provide faster absorption of paracetamol than a tablet? A pharmacoscintigraphic study in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24558011/),[h·ng] / [ml],4668.00,14145,DB00316,Acetaminophen
,24558011,AUC0-60,"Following the hot drink, paracetamol absorption was both significantly faster and greater over the first 60 min post-dose compared with the tablet, as evidenced by the median time to reach t0.25 μg/mL of 4.6 and 23.1 min, respectively, and AUC0-60 of 4668.00 and 1331.17 h*ng/mL, respectively.",Does a hot drink provide faster absorption of paracetamol than a tablet? A pharmacoscintigraphic study in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24558011/),[h·ng] / [ml],1331.17,14146,DB00316,Acetaminophen
,24558011,time,"In addition, tmax was significantly shorter for the hot drink (median time = 1.50 h) compared with the tablet (1.99 h).",Does a hot drink provide faster absorption of paracetamol than a tablet? A pharmacoscintigraphic study in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24558011/),h,1.50,14147,DB00316,Acetaminophen
,24558011,time,"In addition, tmax was significantly shorter for the hot drink (median time = 1.50 h) compared with the tablet (1.99 h).",Does a hot drink provide faster absorption of paracetamol than a tablet? A pharmacoscintigraphic study in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24558011/),h,1.99,14148,DB00316,Acetaminophen
,24558011,Cmax,"However, Cmax was significantly greater following the tablet (9,077 ng/mL) compared with the hot drink (8,062 ng/mL).",Does a hot drink provide faster absorption of paracetamol than a tablet? A pharmacoscintigraphic study in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24558011/),[ng] / [ml],"9,077",14149,DB00316,Acetaminophen
,24558011,Cmax,"However, Cmax was significantly greater following the tablet (9,077 ng/mL) compared with the hot drink (8,062 ng/mL).",Does a hot drink provide faster absorption of paracetamol than a tablet? A pharmacoscintigraphic study in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24558011/),[ng] / [ml],"8,062",14150,DB00316,Acetaminophen
,24558011,Onset of gastric emptying,"Onset of gastric emptying after the hot drink was significantly faster than after the standard tablet (7.9 versus 54.2 min), as confirmed scintigraphically.",Does a hot drink provide faster absorption of paracetamol than a tablet? A pharmacoscintigraphic study in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24558011/),min,7.9,14151,DB00316,Acetaminophen
,24558011,Onset of gastric emptying,"Onset of gastric emptying after the hot drink was significantly faster than after the standard tablet (7.9 versus 54.2 min), as confirmed scintigraphically.",Does a hot drink provide faster absorption of paracetamol than a tablet? A pharmacoscintigraphic study in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24558011/),min,54.2,14152,DB00316,Acetaminophen
,29883885,area under the concentration-time curve,"The mean age, weight and area under the concentration-time curve for the sampled dosing interval were 34.5 yr, 82.3 kg and 39.9 ± 19.8 mg.h/L, respectively.",Population pharmacokinetics of intravenous paracetamol in critically ill patients with traumatic brain injury. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29883885/),[h·mg] / [l],39.9,14268,DB00316,Acetaminophen
,29883885,clearance,"Paracetamol clearance was found to be high and variable (25.7 L.h-1, coefficient of variation (CV) 40.9%), and a wide range of volume of distribution observed (27.6 L, CV 30.6%).",Population pharmacokinetics of intravenous paracetamol in critically ill patients with traumatic brain injury. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29883885/),[l] / [h],25.7,14269,DB00316,Acetaminophen
,23146239,half-life,At pH 7.4 and 37 °C the transformation of TREO followed first-order kinetics with a half-life 1.5h.,Direct high-performance liquid chromatography method with refractometric detection designed for stability studies of treosulfan and its biologically active epoxy-transformers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23146239/),h,1.5,14289,DB00316,Acetaminophen
,27112532,clearance (IV),SBI-087 clearance (IV) ranged from 22 to 229 mL/h; volume of distribution at steady state ranged from 5 to 12 L.,"Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27112532/),[ml] / [h],22 to 229,14829,DB00316,Acetaminophen
,27112532,volume of distribution at steady state,SBI-087 clearance (IV) ranged from 22 to 229 mL/h; volume of distribution at steady state ranged from 5 to 12 L.,"Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27112532/),l,5 to 12,14830,DB00316,Acetaminophen
,27112532,Apparent clearance (SC),Apparent clearance (SC) ranged from 44.7 to 105 mL/h; volume of distribution ranged from 14.3 to 32.1 L.,"Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27112532/),[ml] / [h],44.7 to 105,14831,DB00316,Acetaminophen
,27112532,volume of distribution,Apparent clearance (SC) ranged from 44.7 to 105 mL/h; volume of distribution ranged from 14.3 to 32.1 L.,"Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27112532/),l,14.3 to 32.1,14832,DB00316,Acetaminophen
,27112532,t½ (IV),Mean t½ (IV) ranged from 2.1 to 10.7 days (less at lower doses).,"Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27112532/),d,2.1 to 10.7,14833,DB00316,Acetaminophen
,26309104,terminal half-life,"The terminal half-life, maximum serum concentration, and time to maximum serum concentration for tramadol following naïve pooled modeling were 1.56 hours, 155.6 ng/mL, and 3.90 hours, respectively.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),h,1.56,15188,DB00316,Acetaminophen
,26309104,maximum serum concentration,"The terminal half-life, maximum serum concentration, and time to maximum serum concentration for tramadol following naïve pooled modeling were 1.56 hours, 155.6 ng/mL, and 3.90 hours, respectively.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),[ng] / [ml],155.6,15189,DB00316,Acetaminophen
,26309104,time to maximum serum concentration,"The terminal half-life, maximum serum concentration, and time to maximum serum concentration for tramadol following naïve pooled modeling were 1.56 hours, 155.6 ng/mL, and 3.90 hours, respectively.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),h,3.90,15190,DB00316,Acetaminophen
,26309104,maximum serum concentration,"For hydrocodone, maximum serum concentration determined by naïve pooled modeling was 7.90 ng/mL, and time to maximum serum concentration was 3.47 hours.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),[ng] / [ml],7.90,15191,DB00316,Acetaminophen
,26309104,time to maximum serum concentration,"For hydrocodone, maximum serum concentration determined by naïve pooled modeling was 7.90 ng/mL, and time to maximum serum concentration was 3.47 hours.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),h,3.47,15192,DB00316,Acetaminophen
,26309104,terminal half-life,"The terminal half-life for hydrocodone was 15.85 hours, but was likely influenced by delayed drug absorption in some dogs and may not have been a robust estimate.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),h,15.85,15193,DB00316,Acetaminophen
,1576053,area under the saliva flow-time curves,"2. Pirenzepine significantly reduced the area under the saliva flow-time curves (7.29 +/- 3.30 g min-1 h without pirenzepine; 4.19 +/- 2.59 g min-1 h with pirenzepine, P less than 0.01).",The effect of pirenzepine on gastric emptying and salivary flow rate: constraints on the use of saliva paracetamol concentrations for the determination of paracetamol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576053/),[g·h] / [min],7.29,15248,DB00316,Acetaminophen
,1576053,area under the saliva flow-time curves,"2. Pirenzepine significantly reduced the area under the saliva flow-time curves (7.29 +/- 3.30 g min-1 h without pirenzepine; 4.19 +/- 2.59 g min-1 h with pirenzepine, P less than 0.01).",The effect of pirenzepine on gastric emptying and salivary flow rate: constraints on the use of saliva paracetamol concentrations for the determination of paracetamol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576053/),[g·h] / [min],4.19,15249,DB00316,Acetaminophen
,1576053,Cmax,"Pirenzepine had no significant effect on plasma paracetamol Cmax (17.5 +/- 7.8 micrograms ml-1 without pirenzepine; 12.6 +/- 7.7 micrograms ml-1 with pirenzepine), plasma tmax (0.2 h (0.2-0.8 h) without pirenzepine; (0.2 h 0.2-0.8 h) with pirenzepine) and plasma AUC(0.6 h) (32.3 +/- 7.2 micrograms ml-1 h without pirenzepine; 30.3 +/- 6.5 micrograms ml-1 h with pirenzepine).",The effect of pirenzepine on gastric emptying and salivary flow rate: constraints on the use of saliva paracetamol concentrations for the determination of paracetamol pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576053/),[μg] / [ml],17.5,15250,DB00316,Acetaminophen
,1576053,Cmax,"Pirenzepine had no significant effect on plasma paracetamol Cmax (17.5 +/- 7.8 micrograms ml-1 without pirenzepine; 12.6 +/- 7.7 micrograms ml-1 with pirenzepine), plasma tmax (0.2 h (0.2-0.8 h) without pirenzepine; (0.2 h 0.2-0.8 h) with pirenzepine) and plasma AUC(0.6 h) (32.3 +/- 7.2 micrograms ml-1 h without pirenzepine; 30.3 +/- 6.5 micrograms ml-1 h with pirenzepine).",The effect of pirenzepine on gastric emptying and salivary flow rate: constraints on the use of saliva paracetamol concentrations for the determination of paracetamol pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576053/),[μg] / [ml],12.6,15251,DB00316,Acetaminophen
,1576053,plasma tmax,"Pirenzepine had no significant effect on plasma paracetamol Cmax (17.5 +/- 7.8 micrograms ml-1 without pirenzepine; 12.6 +/- 7.7 micrograms ml-1 with pirenzepine), plasma tmax (0.2 h (0.2-0.8 h) without pirenzepine; (0.2 h 0.2-0.8 h) with pirenzepine) and plasma AUC(0.6 h) (32.3 +/- 7.2 micrograms ml-1 h without pirenzepine; 30.3 +/- 6.5 micrograms ml-1 h with pirenzepine).",The effect of pirenzepine on gastric emptying and salivary flow rate: constraints on the use of saliva paracetamol concentrations for the determination of paracetamol pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576053/),h,0.2,15252,DB00316,Acetaminophen
,1576053,plasma AUC,"Pirenzepine had no significant effect on plasma paracetamol Cmax (17.5 +/- 7.8 micrograms ml-1 without pirenzepine; 12.6 +/- 7.7 micrograms ml-1 with pirenzepine), plasma tmax (0.2 h (0.2-0.8 h) without pirenzepine; (0.2 h 0.2-0.8 h) with pirenzepine) and plasma AUC(0.6 h) (32.3 +/- 7.2 micrograms ml-1 h without pirenzepine; 30.3 +/- 6.5 micrograms ml-1 h with pirenzepine).",The effect of pirenzepine on gastric emptying and salivary flow rate: constraints on the use of saliva paracetamol concentrations for the determination of paracetamol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576053/),[h·μg] / [ml],0.6,15253,DB00316,Acetaminophen
,1576053,plasma AUC,"Pirenzepine had no significant effect on plasma paracetamol Cmax (17.5 +/- 7.8 micrograms ml-1 without pirenzepine; 12.6 +/- 7.7 micrograms ml-1 with pirenzepine), plasma tmax (0.2 h (0.2-0.8 h) without pirenzepine; (0.2 h 0.2-0.8 h) with pirenzepine) and plasma AUC(0.6 h) (32.3 +/- 7.2 micrograms ml-1 h without pirenzepine; 30.3 +/- 6.5 micrograms ml-1 h with pirenzepine).",The effect of pirenzepine on gastric emptying and salivary flow rate: constraints on the use of saliva paracetamol concentrations for the determination of paracetamol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576053/),[h·μg] / [ml],32.3,15254,DB00316,Acetaminophen
,1576053,plasma AUC,"Pirenzepine had no significant effect on plasma paracetamol Cmax (17.5 +/- 7.8 micrograms ml-1 without pirenzepine; 12.6 +/- 7.7 micrograms ml-1 with pirenzepine), plasma tmax (0.2 h (0.2-0.8 h) without pirenzepine; (0.2 h 0.2-0.8 h) with pirenzepine) and plasma AUC(0.6 h) (32.3 +/- 7.2 micrograms ml-1 h without pirenzepine; 30.3 +/- 6.5 micrograms ml-1 h with pirenzepine).",The effect of pirenzepine on gastric emptying and salivary flow rate: constraints on the use of saliva paracetamol concentrations for the determination of paracetamol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576053/),[h·μg] / [ml],30.3,15255,DB00316,Acetaminophen
,9712458,apparent oral clearance,"Compared with values observed in controls not exposed to cigarette smoking, subjects who smoked 7 to 40 (median, 20) cigarettes per day exhibited a 2.5-fold higher phenacetin apparent oral clearance (7.2, 4.3-12.0 L x h(-1) x kg(-1) vs 2.9, 1.8-4.6 L x h(-1) x kg(-1) [geometric means, 95% confidence intervals]; n = 12, p < 0.05).",Effect of active and passive cigarette smoking on CYP1A2-mediated phenacetin disposition in Chinese subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712458/),[l] / [h·kg],7.2,15368,DB00316,Acetaminophen
,9712458,apparent oral clearance,"Compared with values observed in controls not exposed to cigarette smoking, subjects who smoked 7 to 40 (median, 20) cigarettes per day exhibited a 2.5-fold higher phenacetin apparent oral clearance (7.2, 4.3-12.0 L x h(-1) x kg(-1) vs 2.9, 1.8-4.6 L x h(-1) x kg(-1) [geometric means, 95% confidence intervals]; n = 12, p < 0.05).",Effect of active and passive cigarette smoking on CYP1A2-mediated phenacetin disposition in Chinese subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712458/),[l] / [h·kg],2.9,15369,DB00316,Acetaminophen
,9712458,apparent oral clearance,"In subjects exposed to passive smoking, phenacetin's apparent oral clearance (3.6, 2.0-46.6 L x h(-1) x kg(-1), n = 12) was intermediate between the values observed in the two other groups.",Effect of active and passive cigarette smoking on CYP1A2-mediated phenacetin disposition in Chinese subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712458/),[l] / [h·kg],3.6,15370,DB00316,Acetaminophen
,17563126,AUC(infinity),"Concomitant administration of paracetamol slightly increased ciprofloxacin AUC(infinity) from 14.37 +/- 0.91 to 16.71 +/- 0.99 microg . h/mL (p = 0.073) and ciprofloxacin maximum plasma concentration (C(max)) from 2.52 +/- 0.18 to 2.61 +/- 0.24 microg/mL (p = 0.113), while slightly decreasing time to ciprofloxacin C(max) from 1.5 to 1.3 hours (p = 0.376).",Effects of paracetamol on the pharmacokinetics of ciprofloxacin in plasma using a microbiological assay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17563126/),[h·μg] / [ml],14.37,15640,DB00316,Acetaminophen
,17563126,AUC(infinity),"Concomitant administration of paracetamol slightly increased ciprofloxacin AUC(infinity) from 14.37 +/- 0.91 to 16.71 +/- 0.99 microg . h/mL (p = 0.073) and ciprofloxacin maximum plasma concentration (C(max)) from 2.52 +/- 0.18 to 2.61 +/- 0.24 microg/mL (p = 0.113), while slightly decreasing time to ciprofloxacin C(max) from 1.5 to 1.3 hours (p = 0.376).",Effects of paracetamol on the pharmacokinetics of ciprofloxacin in plasma using a microbiological assay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17563126/),[h·μg] / [ml],16.71,15641,DB00316,Acetaminophen
,17563126,maximum plasma concentration (C(max)),"Concomitant administration of paracetamol slightly increased ciprofloxacin AUC(infinity) from 14.37 +/- 0.91 to 16.71 +/- 0.99 microg . h/mL (p = 0.073) and ciprofloxacin maximum plasma concentration (C(max)) from 2.52 +/- 0.18 to 2.61 +/- 0.24 microg/mL (p = 0.113), while slightly decreasing time to ciprofloxacin C(max) from 1.5 to 1.3 hours (p = 0.376).",Effects of paracetamol on the pharmacokinetics of ciprofloxacin in plasma using a microbiological assay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17563126/),[μg] / [ml],2.52,15642,DB00316,Acetaminophen
,17563126,maximum plasma concentration (C(max)),"Concomitant administration of paracetamol slightly increased ciprofloxacin AUC(infinity) from 14.37 +/- 0.91 to 16.71 +/- 0.99 microg . h/mL (p = 0.073) and ciprofloxacin maximum plasma concentration (C(max)) from 2.52 +/- 0.18 to 2.61 +/- 0.24 microg/mL (p = 0.113), while slightly decreasing time to ciprofloxacin C(max) from 1.5 to 1.3 hours (p = 0.376).",Effects of paracetamol on the pharmacokinetics of ciprofloxacin in plasma using a microbiological assay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17563126/),[μg] / [ml],2.61,15643,DB00316,Acetaminophen
,17563126,time to c,"Concomitant administration of paracetamol slightly increased ciprofloxacin AUC(infinity) from 14.37 +/- 0.91 to 16.71 +/- 0.99 microg . h/mL (p = 0.073) and ciprofloxacin maximum plasma concentration (C(max)) from 2.52 +/- 0.18 to 2.61 +/- 0.24 microg/mL (p = 0.113), while slightly decreasing time to ciprofloxacin C(max) from 1.5 to 1.3 hours (p = 0.376).",Effects of paracetamol on the pharmacokinetics of ciprofloxacin in plasma using a microbiological assay. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17563126/),h,1.5,15644,DB00316,Acetaminophen
,20096354,transport rate,"Furthermore, in the absence of Na(+) in the formulation, no dependence of iontophoretic flux on drug concentration was reported (at a granisetron concentration of 40 mM, the transport rate was 2.93+/-0.62 microg cm(-2)min(-1)).",Using transdermal iontophoresis to increase granisetron delivery across skin in vitro and in vivo: effect of experimental conditions and a comparison with other enhancement strategies. ,Km-Q52,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20096354/),[μg] / [(cm)^2],2.93,15667,DB00316,Acetaminophen
,20096354,input rate (k(input)),In vivo studies in Wistar rats (40 mM granisetron; application of 0.3 mA cm(-2) for 5h with Ag/AgCl electrodes and salt bridges) showed an average iontophoretic input rate (k(input)) of 0.83+/-0.26 microg min(-1) and a maximum plasma concentration (C(max)) of 0.092+/-0.004 microg ml(-1).,Using transdermal iontophoresis to increase granisetron delivery across skin in vitro and in vivo: effect of experimental conditions and a comparison with other enhancement strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20096354/),[μg] / [min],0.83,15668,DB00316,Acetaminophen
,20096354,maximum plasma concentration (C(max)),In vivo studies in Wistar rats (40 mM granisetron; application of 0.3 mA cm(-2) for 5h with Ag/AgCl electrodes and salt bridges) showed an average iontophoretic input rate (k(input)) of 0.83+/-0.26 microg min(-1) and a maximum plasma concentration (C(max)) of 0.092+/-0.004 microg ml(-1).,Using transdermal iontophoresis to increase granisetron delivery across skin in vitro and in vivo: effect of experimental conditions and a comparison with other enhancement strategies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20096354/),[μg] / [ml],0.092,15669,DB00316,Acetaminophen
,12151025,half-life,"Preliminary pharmacokinetics, determined by isocratic high-performance liquid chromatography (HPLC), revealed no difference in the half-life of paracetamol (2.5+/-0.3 h) vs. meloxicam (3.4+/-0.4 h).",Observer-blinded comparison of two nonopioid analgesics for postoperative pain in piglets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12151025/),h,2.5,15741,DB00316,Acetaminophen
,12151025,half-life,"Preliminary pharmacokinetics, determined by isocratic high-performance liquid chromatography (HPLC), revealed no difference in the half-life of paracetamol (2.5+/-0.3 h) vs. meloxicam (3.4+/-0.4 h).",Observer-blinded comparison of two nonopioid analgesics for postoperative pain in piglets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12151025/),h,3.4,15742,DB00316,Acetaminophen
>,10708180,gastric residual volumes,"Ten adult, critically ill, mechanically ventilated patients not tolerating a fiber-containing EN product defined as a single aspirated gastric residual volume >150 mL or two aspirated gastric residual volumes >120 mL during a 12-hr period.","Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),,120,15818,DB00316,Acetaminophen
,10708180,mean residence time of absorption,"Metoclopramide and cisapride had a significantly shorter mean residence time of absorption than erythromycin (6.3+/-4.5 [SEM] mins and 10.9+/-5.8 vs. 30.1+/-4.5 mins, respectively [p<.05]).","Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,6.3,15819,DB00316,Acetaminophen
,10708180,mean residence time of absorption,"Metoclopramide and cisapride had a significantly shorter mean residence time of absorption than erythromycin (6.3+/-4.5 [SEM] mins and 10.9+/-5.8 vs. 30.1+/-4.5 mins, respectively [p<.05]).","Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,10.9,15820,DB00316,Acetaminophen
,10708180,mean residence time of absorption,"Metoclopramide and cisapride had a significantly shorter mean residence time of absorption than erythromycin (6.3+/-4.5 [SEM] mins and 10.9+/-5.8 vs. 30.1+/-4.5 mins, respectively [p<.05]).","Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,30.1,15821,DB00316,Acetaminophen
,10708180,time to peak concentration,"Metoclopramide (9.7+/-15.3 mins) had a significantly shorter time to peak concentration compared with erythromycin and placebo (60.7+/-8.1 and 50.9+/-13.5 mins, respectively [p<.05]).","Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,9.7,15822,DB00316,Acetaminophen
,10708180,time to peak concentration,"Metoclopramide (9.7+/-15.3 mins) had a significantly shorter time to peak concentration compared with erythromycin and placebo (60.7+/-8.1 and 50.9+/-13.5 mins, respectively [p<.05]).","Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,60.7,15823,DB00316,Acetaminophen
,10708180,time to peak concentration,"Metoclopramide (9.7+/-15.3 mins) had a significantly shorter time to peak concentration compared with erythromycin and placebo (60.7+/-8.1 and 50.9+/-13.5 mins, respectively [p<.05]).","Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,50.9,15824,DB00316,Acetaminophen
,10708180,time to onset of absorption,The time to onset of absorption was significantly shorter for metoclopramide vs. cisapride (5.7+/-4.5 vs. 22.9+/-5.7 mins [p<.05]).,"Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,5.7,15825,DB00316,Acetaminophen
,10708180,time to onset of absorption,The time to onset of absorption was significantly shorter for metoclopramide vs. cisapride (5.7+/-4.5 vs. 22.9+/-5.7 mins [p<.05]).,"Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,22.9,15826,DB00316,Acetaminophen
,6631711,elimination half-life,"Average values of the elimination half-life and plasma clearance were 1.12 +/- 0.48 hr and 148.0 +/- 39.9 ml/min, respectively.",Pharmacokinetics of chlorzoxazone in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631711/),h,1.12,15870,DB00316,Acetaminophen
,6631711,plasma clearance,"Average values of the elimination half-life and plasma clearance were 1.12 +/- 0.48 hr and 148.0 +/- 39.9 ml/min, respectively.",Pharmacokinetics of chlorzoxazone in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631711/),[ml] / [min],148.0,15871,DB00316,Acetaminophen
,10517354,flow-rate,Samples were separated in a pH 2.2 sodium sulfate-acetonitrile mobile phase at a flow-rate of 1.5 ml/min on a 15 cm octadecylsilyl column at room temperature.,Simple and rapid assay for acetaminophen and conjugated metabolites in low-volume serum samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10517354/),[ml] / [min],1.5,16781,DB00316,Acetaminophen
,11452248,area under the concentration-time curve [AUC],"Acetaminophen plasma concentrations were higher in patients receiving rectal acetaminophen (mean area under the concentration-time curve [AUC], 171.2 mg x h/L) than in patients receiving oral acetaminophen (mean AUC, 111.9 mg x h/L).",Analgesic efficacy of rectal versus oral acetaminophen in children after major craniofacial surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452248/),[h·mg] / [l],171.2,17054,DB00316,Acetaminophen
,11452248,AUC,"Acetaminophen plasma concentrations were higher in patients receiving rectal acetaminophen (mean area under the concentration-time curve [AUC], 171.2 mg x h/L) than in patients receiving oral acetaminophen (mean AUC, 111.9 mg x h/L).",Analgesic efficacy of rectal versus oral acetaminophen in children after major craniofacial surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452248/),[h·mg] / [l],111.9,17055,DB00316,Acetaminophen
,22824731,runtime,The plasma samples were extracted by liquid-liquid extraction with ethyl acetate and separated on Shim-pack XR-ODS II column by a gradient elution within a runtime of 8.0 min.,Identification and dynamic analysis of the purine alkaloids in rat plasma after oral administration of green tea by liquid chromatography hybrid ion trap time-of-flight mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22824731/),min,8.0,17333,DB00316,Acetaminophen
,22824731,flow rate,The mobile phase consisted of A (0.1% formic acid in acetonitrile) and B (0.1% formic acid in water) at a flow rate of 0.4 ml/min.,Identification and dynamic analysis of the purine alkaloids in rat plasma after oral administration of green tea by liquid chromatography hybrid ion trap time-of-flight mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22824731/),[ml] / [min],0.4,17334,DB00316,Acetaminophen
,22824731,linear,"The linear range was 10-10,000 ng/ml for caffeine, 2.0-2000 ng/ml for theobromine and 1.0-1000 ng/ml for theophylline, respectively.",Identification and dynamic analysis of the purine alkaloids in rat plasma after oral administration of green tea by liquid chromatography hybrid ion trap time-of-flight mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22824731/),[ng] / [ml],"10-10,000",17335,DB00316,Acetaminophen
,22824731,linear,"The linear range was 10-10,000 ng/ml for caffeine, 2.0-2000 ng/ml for theobromine and 1.0-1000 ng/ml for theophylline, respectively.",Identification and dynamic analysis of the purine alkaloids in rat plasma after oral administration of green tea by liquid chromatography hybrid ion trap time-of-flight mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22824731/),[ng] / [ml],2.0-2000,17336,DB00316,Acetaminophen
,22824731,linear,"The linear range was 10-10,000 ng/ml for caffeine, 2.0-2000 ng/ml for theobromine and 1.0-1000 ng/ml for theophylline, respectively.",Identification and dynamic analysis of the purine alkaloids in rat plasma after oral administration of green tea by liquid chromatography hybrid ion trap time-of-flight mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22824731/),[ng] / [ml],1.0-1000,17337,DB00316,Acetaminophen
,9952146,volume of distribution,"Mean (% CV) estimates of population pharmacokinetic parameters with percent coefficient of variation, standardized to a 70-kg person, for a one-compartment model with first-order input, lag time, and first order-elimination were a volume of distribution of 60 (21) 1 and a clearance of 13.5 (46) 1/h.",Perioperative pharmacodynamics of acetaminophen analgesia in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952146/),1,60,18284,DB00316,Acetaminophen
,9952146,clearance,"Mean (% CV) estimates of population pharmacokinetic parameters with percent coefficient of variation, standardized to a 70-kg person, for a one-compartment model with first-order input, lag time, and first order-elimination were a volume of distribution of 60 (21) 1 and a clearance of 13.5 (46) 1/h.",Perioperative pharmacodynamics of acetaminophen analgesia in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952146/),[1] / [h],13.5,18285,DB00316,Acetaminophen
,9952146,absorption half-life,Rectally administered acetaminophen had an absorption half-life of 35 (63) min with a lag time of 40 min.,Perioperative pharmacodynamics of acetaminophen analgesia in children. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952146/),min,35,18286,DB00316,Acetaminophen
,9952146,lag time,Rectally administered acetaminophen had an absorption half-life of 35 (63) min with a lag time of 40 min.,Perioperative pharmacodynamics of acetaminophen analgesia in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952146/),min,40,18287,DB00316,Acetaminophen
,9952146,absorption half-life,The absorption half-life for the oral preparation was 4.5 (63) min without a detectable lag time.,Perioperative pharmacodynamics of acetaminophen analgesia in children. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952146/),min,4.5,18288,DB00316,Acetaminophen
,9952146,relative bioavailability,The relative bioavailability of the rectal compared with the oral formulation was 0.54.,Perioperative pharmacodynamics of acetaminophen analgesia in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952146/),,0.54,18289,DB00316,Acetaminophen
,9952146,half-time of an effect compartment,The equilibration half-time of an effect compartment was 1.6 (131) h.,Perioperative pharmacodynamics of acetaminophen analgesia in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952146/),h,1.6,18290,DB00316,Acetaminophen
,9952146,Emax,"Pharmacodynamic population parameter estimates (percent coefficient of variation) for a fractional sigmoidal Emax model, in which the greatest possible pain relief equates to an Emax of 1, were Emax = 1, EC50 (the concentration producing 50% of Emax) = 3.4 (94) mg/l, and Hill coefficient = 0.54 (42).",Perioperative pharmacodynamics of acetaminophen analgesia in children. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952146/),,1,18291,DB00316,Acetaminophen
,9952146,EC50,"Pharmacodynamic population parameter estimates (percent coefficient of variation) for a fractional sigmoidal Emax model, in which the greatest possible pain relief equates to an Emax of 1, were Emax = 1, EC50 (the concentration producing 50% of Emax) = 3.4 (94) mg/l, and Hill coefficient = 0.54 (42).",Perioperative pharmacodynamics of acetaminophen analgesia in children. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952146/),[mg] / [l],3.4,18292,DB00316,Acetaminophen
,9952146,Hill coefficient,"Pharmacodynamic population parameter estimates (percent coefficient of variation) for a fractional sigmoidal Emax model, in which the greatest possible pain relief equates to an Emax of 1, were Emax = 1, EC50 (the concentration producing 50% of Emax) = 3.4 (94) mg/l, and Hill coefficient = 0.54 (42).",Perioperative pharmacodynamics of acetaminophen analgesia in children. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952146/),,0.54,18293,DB00316,Acetaminophen
,9952146,effect compartment concentration,"To achieve a mean posttonsillectomy pain score of 3.6 of 10, an effect compartment concentration of 10 mg/l is necessary.",Perioperative pharmacodynamics of acetaminophen analgesia in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952146/),[mg] / [l],10,18294,DB00316,Acetaminophen
,34418143,plasma concentration (Cavg ),An analgesic plasma target was defined as an average plasma concentration (Cavg ) of 10 mg/L.,Pharmacokinetics of 2 oral paracetamol formulations in hospitalized octogenarians. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34418143/),[mg] / [l],10,20004,DB00316,Acetaminophen
above,34418143,Cavg,Seven (21%) patients had a Cavg above 10 mg/L.,Pharmacokinetics of 2 oral paracetamol formulations in hospitalized octogenarians. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34418143/),[mg] / [l],10,20005,DB00316,Acetaminophen
,34418143,time to reach the peak concentration,"The median [interquartile range] time to reach the peak concentration was 50.5 [31.50-92.50] and 42.50 [33.75-106.75] min for the tablet and granulate, respectively.",Pharmacokinetics of 2 oral paracetamol formulations in hospitalized octogenarians. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34418143/),min,50.5,20006,DB00316,Acetaminophen
,34418143,time to reach the peak concentration,"The median [interquartile range] time to reach the peak concentration was 50.5 [31.50-92.50] and 42.50 [33.75-106.75] min for the tablet and granulate, respectively.",Pharmacokinetics of 2 oral paracetamol formulations in hospitalized octogenarians. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34418143/),min,42.50,20007,DB00316,Acetaminophen
,23052410,Formation rates,"Formation rates for adducts were faster for IR than the ER formulation (0.420 ± 0.157 vs. 0.203 ± 0.080 1/h), respectively.",Acetaminophen protein adduct formation following low-dose acetaminophen exposure: comparison of immediate-release vs extended-release formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23052410/),[1] / [h],0.420,20777,DB00316,Acetaminophen
,23052410,Formation rates,"Formation rates for adducts were faster for IR than the ER formulation (0.420 ± 0.157 vs. 0.203 ± 0.080 1/h), respectively.",Acetaminophen protein adduct formation following low-dose acetaminophen exposure: comparison of immediate-release vs extended-release formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23052410/),[1] / [h],0.203,20778,DB00316,Acetaminophen
,23052410,Maximum plasma concentrations (Cmax),"Maximum plasma concentrations (Cmax) of adducts for IR and ER were 0.108 (±0.020) and 0.100 (±0.028) nmol/ml serum, respectively, and were two orders of magnitude lower than adduct levels previously reported in adults with acute liver failure secondary to APAP.",Acetaminophen protein adduct formation following low-dose acetaminophen exposure: comparison of immediate-release vs extended-release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23052410/),[nM] / [ml·serum],0.108,20779,DB00316,Acetaminophen
,23052410,Maximum plasma concentrations (Cmax),"Maximum plasma concentrations (Cmax) of adducts for IR and ER were 0.108 (±0.020) and 0.100 (±0.028) nmol/ml serum, respectively, and were two orders of magnitude lower than adduct levels previously reported in adults with acute liver failure secondary to APAP.",Acetaminophen protein adduct formation following low-dose acetaminophen exposure: comparison of immediate-release vs extended-release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23052410/),[nM] / [ml·serum],0.100,20780,DB00316,Acetaminophen
,7288620,apparent half-life,Peak concentrations of acetaminophen were high in all tissues (1500-2000 nmol/g) and declined with an apparent half-life of 1 hr.,Levels of acetaminophen and its metabolites in mouse tissues after a toxic dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7288620/),h,1,21372,DB00316,Acetaminophen
,22524979,bioavailability over 6 hours (AUC(0-6)),"CSF bioavailability over 6 hours (AUC(0-6)) for IV, PO, and PR 1 g was 24.9, 14.2, and 10.3 μg·h/mL, respectively.","Plasma and cerebrospinal fluid pharmacokinetic parameters after single-dose administration of intravenous, oral, or rectal acetaminophen. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22524979/),[h·μg] / [ml],24.9,22018,DB00316,Acetaminophen
,22524979,bioavailability over 6 hours (AUC(0-6)),"CSF bioavailability over 6 hours (AUC(0-6)) for IV, PO, and PR 1 g was 24.9, 14.2, and 10.3 μg·h/mL, respectively.","Plasma and cerebrospinal fluid pharmacokinetic parameters after single-dose administration of intravenous, oral, or rectal acetaminophen. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22524979/),[h·μg] / [ml],14.2,22019,DB00316,Acetaminophen
,22524979,bioavailability over 6 hours (AUC(0-6)),"CSF bioavailability over 6 hours (AUC(0-6)) for IV, PO, and PR 1 g was 24.9, 14.2, and 10.3 μg·h/mL, respectively.","Plasma and cerebrospinal fluid pharmacokinetic parameters after single-dose administration of intravenous, oral, or rectal acetaminophen. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22524979/),[h·μg] / [ml],10.3,22020,DB00316,Acetaminophen
,30317077,run time,"The separation was carried out on a ZORBAX Eclipse Plus C18 Rapid Resolution High Definition column with a gradient elution, using water containing 0.1% formic acid (A) and acetonitrile (B) in a run time of only 3.0 min.","A UHPLC-MS/MS method coupled with liquid-liquid extraction for the quantitation of phenacetin, omeprazole, metoprolol, midazolam and their metabolites in rat plasma and its application to the study of four CYP450 activities. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30317077/),min,3.0,22823,DB00316,Acetaminophen
,12761605,Clearances,"Clearances of paracetamol to paracetamol-glucuronide (%CV) and to paracetamol-sulphate were 6.6 (11.5) l/h and 7.5 (11.5) l/h respectively, standardised to a 70-kg person using allometric ""1/4 power"" models.",Paracetamol and metabolite pharmacokinetics in infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12761605/),[l] / [h],6.6,23110,DB00316,Acetaminophen
,12761605,Clearances,"Clearances of paracetamol to paracetamol-glucuronide (%CV) and to paracetamol-sulphate were 6.6 (11.5) l/h and 7.5 (11.5) l/h respectively, standardised to a 70-kg person using allometric ""1/4 power"" models.",Paracetamol and metabolite pharmacokinetics in infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12761605/),[l] / [h],7.5,23111,DB00316,Acetaminophen
,12761605,formation clearance,"Glucuronide formation clearance, but not sulphate formation, was related to age and increased with age from a predicted value in a neonate of 2.73 l/h/70 kg to a mature value of 6.6 l/h/70 kg with a maturation half-life of 8.09 months.",Paracetamol and metabolite pharmacokinetics in infants. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12761605/),[l] / [70·h·kg],2.73,23112,DB00316,Acetaminophen
,12761605,formation clearance,"Glucuronide formation clearance, but not sulphate formation, was related to age and increased with age from a predicted value in a neonate of 2.73 l/h/70 kg to a mature value of 6.6 l/h/70 kg with a maturation half-life of 8.09 months.",Paracetamol and metabolite pharmacokinetics in infants. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12761605/),[l] / [70·h·kg],6.6,23113,DB00316,Acetaminophen
,12761605,maturation half-life,"Glucuronide formation clearance, but not sulphate formation, was related to age and increased with age from a predicted value in a neonate of 2.73 l/h/70 kg to a mature value of 6.6 l/h/70 kg with a maturation half-life of 8.09 months.",Paracetamol and metabolite pharmacokinetics in infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12761605/),month,8.09,23114,DB00316,Acetaminophen
,12761605,Urine clearance,"Urine clearance of paracetamol-glucuronide, paracetamol-sulphate and unchanged paracetamol (%CV) were, respectively, 2.65, 3.03 and 0.55 (28) l/h/70 kg.",Paracetamol and metabolite pharmacokinetics in infants. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12761605/),[l] / [70·h·kg],2.65,23115,DB00316,Acetaminophen
,12761605,Urine clearance,"Urine clearance of paracetamol-glucuronide, paracetamol-sulphate and unchanged paracetamol (%CV) were, respectively, 2.65, 3.03 and 0.55 (28) l/h/70 kg.",Paracetamol and metabolite pharmacokinetics in infants. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12761605/),[l] / [70·h·kg],3.03,23116,DB00316,Acetaminophen
,12761605,Urine clearance,"Urine clearance of paracetamol-glucuronide, paracetamol-sulphate and unchanged paracetamol (%CV) were, respectively, 2.65, 3.03 and 0.55 (28) l/h/70 kg.",Paracetamol and metabolite pharmacokinetics in infants. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12761605/),[l] / [70·h·kg],0.55,23117,DB00316,Acetaminophen
,12761605,g,The glucuronide/sulphate formation clearance ratio was 0.69 at 12 months of age.,Paracetamol and metabolite pharmacokinetics in infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12761605/),,0.69,23118,DB00316,Acetaminophen
,12761605,formation clearance ratio,The glucuronide/sulphate formation clearance ratio was 0.69 at 12 months of age.,Paracetamol and metabolite pharmacokinetics in infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12761605/),,0.69,23119,DB00316,Acetaminophen
,7833225,target concentrations,"An aqueous solution (0.1 to 0.2 ml) containing paracetamol, salicylate, diclofenac and [125I]-albumin was injected into a given joint to yield target concentrations of approximately 20 micrograms ml-1 for diclofenac, salicylate and paracetamol and 10(8) counts ml-1 for [125I]-albumin.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),[μg] / [ml],20,23157,DB00316,Acetaminophen
,7833225,target concentrations,"An aqueous solution (0.1 to 0.2 ml) containing paracetamol, salicylate, diclofenac and [125I]-albumin was injected into a given joint to yield target concentrations of approximately 20 micrograms ml-1 for diclofenac, salicylate and paracetamol and 10(8) counts ml-1 for [125I]-albumin.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),[counts] / [ml],10,23158,DB00316,Acetaminophen
,7833225,clearances,"3. The clearances (+/- s.d.) obtained for the solutes were [125I]-albumin (0.0053 +/- 0.0019 l h-1), diclofenac (0.0096 +/- 0.0061 l h-1), salicylate (0.024 +/- 0.022 l h-1) and paracetamol (0.055 +/- 0.041 l h-1).",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),[l] / [h],0.0053,23159,DB00316,Acetaminophen
,7833225,clearances,"3. The clearances (+/- s.d.) obtained for the solutes were [125I]-albumin (0.0053 +/- 0.0019 l h-1), diclofenac (0.0096 +/- 0.0061 l h-1), salicylate (0.024 +/- 0.022 l h-1) and paracetamol (0.055 +/- 0.041 l h-1).",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),[l] / [h],0.0096,23160,DB00316,Acetaminophen
,7833225,clearances,"3. The clearances (+/- s.d.) obtained for the solutes were [125I]-albumin (0.0053 +/- 0.0019 l h-1), diclofenac (0.0096 +/- 0.0061 l h-1), salicylate (0.024 +/- 0.022 l h-1) and paracetamol (0.055 +/- 0.041 l h-1).",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),[l] / [h],0.024,23161,DB00316,Acetaminophen
,7833225,clearances,"3. The clearances (+/- s.d.) obtained for the solutes were [125I]-albumin (0.0053 +/- 0.0019 l h-1), diclofenac (0.0096 +/- 0.0061 l h-1), salicylate (0.024 +/- 0.022 l h-1) and paracetamol (0.055 +/- 0.041 l h-1).",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),[l] / [h],0.055,23162,DB00316,Acetaminophen
,7833225,fractions unbound,"The corresponding fractions unbound of these solutes in synovial fluid were 0.0, < or = 0.01, 0.34 +/- 0.09 and 0.85 +/- 0.10, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,0.0,23163,DB00316,Acetaminophen
,7833225,fractions unbound,"The corresponding fractions unbound of these solutes in synovial fluid were 0.0, < or = 0.01, 0.34 +/- 0.09 and 0.85 +/- 0.10, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,<,23164,DB00316,Acetaminophen
,7833225,fractions unbound,"The corresponding fractions unbound of these solutes in synovial fluid were 0.0, < or = 0.01, 0.34 +/- 0.09 and 0.85 +/- 0.10, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,0.01,23165,DB00316,Acetaminophen
,7833225,fractions unbound,"The corresponding fractions unbound of these solutes in synovial fluid were 0.0, < or = 0.01, 0.34 +/- 0.09 and 0.85 +/- 0.10, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,0.34,23166,DB00316,Acetaminophen
,7833225,fractions unbound,"The corresponding fractions unbound of these solutes in synovial fluid were 0.0, < or = 0.01, 0.34 +/- 0.09 and 0.85 +/- 0.10, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,0.85,23167,DB00316,Acetaminophen
,7833225,Diffusion,"4. Diffusion of unbound solute through the synovium is estimated to account for (+/- s.d.) 0.52 +/- 0.08, 0.87 +/- 0.06 and 0.99 +/- 0.01 of the total clearance of diclofenac, salicylate and paracetamol from the joint space, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,0,23168,DB00316,Acetaminophen
,7833225,Diffusion,"4. Diffusion of unbound solute through the synovium is estimated to account for (+/- s.d.) 0.52 +/- 0.08, 0.87 +/- 0.06 and 0.99 +/- 0.01 of the total clearance of diclofenac, salicylate and paracetamol from the joint space, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,0.87,23169,DB00316,Acetaminophen
,7833225,Diffusion,"4. Diffusion of unbound solute through the synovium is estimated to account for (+/- s.d.) 0.52 +/- 0.08, 0.87 +/- 0.06 and 0.99 +/- 0.01 of the total clearance of diclofenac, salicylate and paracetamol from the joint space, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,0.99,23170,DB00316,Acetaminophen
,9764964,clearance,"NONMEM parameter estimates were clearance 10.21 h(-1) (CV 47%), volume of distribution 67.11 (CV 58%) and absorption rate constant 0.77 h(-1) (CV 49%).",Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764964/),1/[h],10.21,23314,DB00316,Acetaminophen
,9764964,volume of distribution,"NONMEM parameter estimates were clearance 10.21 h(-1) (CV 47%), volume of distribution 67.11 (CV 58%) and absorption rate constant 0.77 h(-1) (CV 49%).",Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764964/),,67.11,23315,DB00316,Acetaminophen
,9764964,absorption rate constant,"NONMEM parameter estimates were clearance 10.21 h(-1) (CV 47%), volume of distribution 67.11 (CV 58%) and absorption rate constant 0.77 h(-1) (CV 49%).",Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764964/),1/[h],0.77,23316,DB00316,Acetaminophen
,9764964,half time,The equilibration half time was 0.72 h (CV 117%).,Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764964/),h,0.72,23317,DB00316,Acetaminophen
,9764964,CSF/plasma partition coefficient,The CSF/plasma partition coefficient was 1.18 (CV 8%).,Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764964/),,1.18,23318,DB00316,Acetaminophen
,32715494,Clearance,"Clearance, volume at steady state and half-life of acetaminophen in Labrador Retrievers were 0.42 L/kg hr, 0.87 L/kg and 1.35 hr, respectively.",Pharmacokinetics of acetaminophen after intravenous and oral administration in fasted and fed Labrador Retriever dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32715494/),[l] / [h·kg],0.42,24098,DB00316,Acetaminophen
,32715494,volume at steady state,"Clearance, volume at steady state and half-life of acetaminophen in Labrador Retrievers were 0.42 L/kg hr, 0.87 L/kg and 1.35 hr, respectively.",Pharmacokinetics of acetaminophen after intravenous and oral administration in fasted and fed Labrador Retriever dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32715494/),[l] / [kg],0.87,24099,DB00316,Acetaminophen
,32715494,half-life,"Clearance, volume at steady state and half-life of acetaminophen in Labrador Retrievers were 0.42 L/kg hr, 0.87 L/kg and 1.35 hr, respectively.",Pharmacokinetics of acetaminophen after intravenous and oral administration in fasted and fed Labrador Retriever dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32715494/),h,1.35,24100,DB00316,Acetaminophen
,22595262,flow rate,"The separation was performed on LichroCART RP-18e with particle size of 5 µm (250 × 4.6 mm) with mobile phase acetonitrile-50 mM KH(2)PO(4) buffer, pH 7.1, using a gradient mode with a 1.0 mL/min flow rate.",New HPLC method to detect individual opioids (heroin and tramadol) and their metabolites in the blood of rats on combination treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22595262/),[ml] / [min],1.0,24703,DB00316,Acetaminophen
,22595262,Recovery,Recovery values for the substances ranged between 59 and 83%.,New HPLC method to detect individual opioids (heroin and tramadol) and their metabolites in the blood of rats on combination treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22595262/),%,59 and 83,24704,DB00316,Acetaminophen
,1618258,AUC,"Mean plasma paracetamol AUC at 60 min were 1070, 1051 and 1031 micrograms.",No effect of cisapride on paracetamol absorption after oral simultaneous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618258/),μg,1070,25049,DB00316,Acetaminophen
,1618258,AUC,"Mean plasma paracetamol AUC at 60 min were 1070, 1051 and 1031 micrograms.",No effect of cisapride on paracetamol absorption after oral simultaneous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618258/),μg,1051,25050,DB00316,Acetaminophen
,1618258,AUC,"Mean plasma paracetamol AUC at 60 min were 1070, 1051 and 1031 micrograms.",No effect of cisapride on paracetamol absorption after oral simultaneous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618258/),μg,1031,25051,DB00316,Acetaminophen
,1618258,maximum paracetamol concentrations,"ml-1 and maximum paracetamol concentrations were 31.5, 29.3 and 27.4 micrograms.",No effect of cisapride on paracetamol absorption after oral simultaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618258/),μg,31.5,25052,DB00316,Acetaminophen
,1618258,maximum paracetamol concentrations,"ml-1 and maximum paracetamol concentrations were 31.5, 29.3 and 27.4 micrograms.",No effect of cisapride on paracetamol absorption after oral simultaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618258/),μg,29.3,25053,DB00316,Acetaminophen
,1618258,maximum paracetamol concentrations,"ml-1 and maximum paracetamol concentrations were 31.5, 29.3 and 27.4 micrograms.",No effect of cisapride on paracetamol absorption after oral simultaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618258/),μg,27.4,25054,DB00316,Acetaminophen
,1618258,time to maximum paracetamol concentration,"There was no difference also in time to maximum paracetamol concentration [median (range) 30 (15-120), 30 (15-90) and 30 (15-60) min, respectively].",No effect of cisapride on paracetamol absorption after oral simultaneous administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618258/),min,30,25055,DB00316,Acetaminophen
,1618258,time to maximum paracetamol concentration,"There was no difference also in time to maximum paracetamol concentration [median (range) 30 (15-120), 30 (15-90) and 30 (15-60) min, respectively].",No effect of cisapride on paracetamol absorption after oral simultaneous administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618258/),min,30,25056,DB00316,Acetaminophen
,1618258,time to maximum paracetamol concentration,"There was no difference also in time to maximum paracetamol concentration [median (range) 30 (15-120), 30 (15-90) and 30 (15-60) min, respectively].",No effect of cisapride on paracetamol absorption after oral simultaneous administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618258/),min,30,25057,DB00316,Acetaminophen
,1676661,partial clearance,"However, BSO exposure increased the partial clearance of acetaminophen to acetaminophen glucuronide by 47% (1.29 +/- 0.08 vs. 1.90 +/- 0.23 ml/min/kg; p less than 0.01) and significantly (p less than 0.02) increased the percentage of the dose recovered as the glucuronide conjugate from 17.6 +/- 2.5 to 26.5 +/- 0.6",Drug metabolizing enzyme changes after chronic buthionine sulfoximine exposure modify acetaminophen disposition in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676661/),[ml] / [kg·min],1.29,26054,DB00316,Acetaminophen
,1676661,partial clearance,"However, BSO exposure increased the partial clearance of acetaminophen to acetaminophen glucuronide by 47% (1.29 +/- 0.08 vs. 1.90 +/- 0.23 ml/min/kg; p less than 0.01) and significantly (p less than 0.02) increased the percentage of the dose recovered as the glucuronide conjugate from 17.6 +/- 2.5 to 26.5 +/- 0.6",Drug metabolizing enzyme changes after chronic buthionine sulfoximine exposure modify acetaminophen disposition in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676661/),[ml] / [kg·min],1.90,26055,DB00316,Acetaminophen
,1676661,percentage,"However, BSO exposure increased the partial clearance of acetaminophen to acetaminophen glucuronide by 47% (1.29 +/- 0.08 vs. 1.90 +/- 0.23 ml/min/kg; p less than 0.01) and significantly (p less than 0.02) increased the percentage of the dose recovered as the glucuronide conjugate from 17.6 +/- 2.5 to 26.5 +/- 0.6",Drug metabolizing enzyme changes after chronic buthionine sulfoximine exposure modify acetaminophen disposition in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676661/),,17,26056,DB00316,Acetaminophen
,1676661,partial clearance,"The partial clearance of acetaminophen to acetaminophen sulfate was decreased, although not significantly, from 4.46 +/- 0.62 to 3.39 +/- 0.82 ml/min/kg.",Drug metabolizing enzyme changes after chronic buthionine sulfoximine exposure modify acetaminophen disposition in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676661/),[ml] / [kg·min],4.46,26057,DB00316,Acetaminophen
,1676661,partial clearance,"The partial clearance of acetaminophen to acetaminophen sulfate was decreased, although not significantly, from 4.46 +/- 0.62 to 3.39 +/- 0.82 ml/min/kg.",Drug metabolizing enzyme changes after chronic buthionine sulfoximine exposure modify acetaminophen disposition in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676661/),[ml] / [kg·min],3.39,26058,DB00316,Acetaminophen
,19007165,peak concentration (C(max)),"HPLC-MS(2) analysis revealed the accumulation of hesperetin-7-O-glucuronide, and an unassigned hesperetin-O-glucuronide metabolite in plasma reached a peak concentration (C(max)) of 924 +/- 224 nmol/L, 4.4 +/- 0.5 h (T(max)) after orange juice ingestion.",Bioavailability and metabolism of orange juice flavanones in humans: impact of a full-fat yogurt. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19007165/),[nM] / [l],924,26347,DB00316,Acetaminophen
,19007165,T(max),"HPLC-MS(2) analysis revealed the accumulation of hesperetin-7-O-glucuronide, and an unassigned hesperetin-O-glucuronide metabolite in plasma reached a peak concentration (C(max)) of 924 +/- 224 nmol/L, 4.4 +/- 0.5 h (T(max)) after orange juice ingestion.",Bioavailability and metabolism of orange juice flavanones in humans: impact of a full-fat yogurt. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19007165/),h,4.4,26348,DB00316,Acetaminophen
,19007165,C(max),"When the juice was consumed with yogurt, neither the C(max) at 661 +/- 170 nmol/L nor the T(max) at 5.1 +/- 0.4 h were significantly different from those obtained with juice alone.",Bioavailability and metabolism of orange juice flavanones in humans: impact of a full-fat yogurt. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19007165/),[nM] / [l],661,26349,DB00316,Acetaminophen
,19007165,T(max),"When the juice was consumed with yogurt, neither the C(max) at 661 +/- 170 nmol/L nor the T(max) at 5.1 +/- 0.4 h were significantly different from those obtained with juice alone.",Bioavailability and metabolism of orange juice flavanones in humans: impact of a full-fat yogurt. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19007165/),h,5.1,26350,DB00316,Acetaminophen
,2760849,biological half-life,"When cystathionine (100 mg/kg) was administered i.p. in rats, it was eliminated from rat serum with a biological half-life of 1.19 +/- 0.23 hr.",Hepatoprotective effects of cystathionine against acetaminophen-induced necrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760849/),h,1.19,26756,DB00316,Acetaminophen
,2760849,half-life,"Subsequent to the decrease of serum cystathionine, the concentration of cyst(e)ine increased up to 14.5 +/- 1.2 mg/l, and then decreased with a half-life of 4.12 +/- 0.82 hr.",Hepatoprotective effects of cystathionine against acetaminophen-induced necrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760849/),h,4.12,26757,DB00316,Acetaminophen
,2760849,half-life,"The concomitant administration of taurine (100 mg/kg) did not change the half-life of cystathionine (1.42 +/- 0.33 hr), but significantly increased the half-life of cyst(e)ine (19.1 +/- 0.56 hr).",Hepatoprotective effects of cystathionine against acetaminophen-induced necrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760849/),h,1.42,26758,DB00316,Acetaminophen
,2760849,half-life,"The concomitant administration of taurine (100 mg/kg) did not change the half-life of cystathionine (1.42 +/- 0.33 hr), but significantly increased the half-life of cyst(e)ine (19.1 +/- 0.56 hr).",Hepatoprotective effects of cystathionine against acetaminophen-induced necrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760849/),h,19.1,26759,DB00316,Acetaminophen
,9792524,flow-rates,"The activity of the BG-IMER was followed by measurement of percent deconjugation and the parameters investigated were: substrate concentration, pH (4 to 6), temperature (r.t., 37 degrees C), enzyme-substrate contact time using flow-rates of 0.1 to 1.0 min/min (15-1.5 min).",On-line deconjugation of glucuronides using an immobilized enzyme reactor based upon beta-glucuronidase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9792524/),[min] / [min],0.1 to 1.0,27522,DB00316,Acetaminophen
,8464345,half-lives of hepatic uptake,"Endothelial cells blockade obtained by the addition of large excess (30 uM) of formaldehyde-treated serum albumin to the perfusion fluid does not affect the hepatic clearance of RPK (the half-lives of hepatic uptake were 15.5 +/- 1.0 min in the absence versus 16.5 +/- 1.4 min in the presence of the treated protein, p > 0.05).",Plasma-kallikrein clearance by the liver of acetaminophen-intoxicated rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8464345/),min,15.5,27642,DB00316,Acetaminophen
,8464345,half-lives of hepatic uptake,"Endothelial cells blockade obtained by the addition of large excess (30 uM) of formaldehyde-treated serum albumin to the perfusion fluid does not affect the hepatic clearance of RPK (the half-lives of hepatic uptake were 15.5 +/- 1.0 min in the absence versus 16.5 +/- 1.4 min in the presence of the treated protein, p > 0.05).",Plasma-kallikrein clearance by the liver of acetaminophen-intoxicated rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8464345/),min,16.5,27643,DB00316,Acetaminophen
,8464345,hepatic clearance,"A 66-hour period of fast does not affect by itself the hepatic clearance of RPK (16.9 +/- 1.3 min of half-life of hepatic uptake) when compared with the control group (15.5 +/- 1.0 min, p > 0.05).",Plasma-kallikrein clearance by the liver of acetaminophen-intoxicated rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8464345/),min,16.9,27644,DB00316,Acetaminophen
,8464345,half-life of hepatic uptake,"A 66-hour period of fast does not affect by itself the hepatic clearance of RPK (16.9 +/- 1.3 min of half-life of hepatic uptake) when compared with the control group (15.5 +/- 1.0 min, p > 0.05).",Plasma-kallikrein clearance by the liver of acetaminophen-intoxicated rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8464345/),min,16.9,27645,DB00316,Acetaminophen
,8464345,half-life of hepatic uptake,On the other hand the RPK clearance by the livers of rats previously intoxicated with acetaminophen was markedly deficient (the half-life of hepatic uptake was 39.2 +/- 3.2 min).,Plasma-kallikrein clearance by the liver of acetaminophen-intoxicated rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8464345/),min,39.2,27646,DB00316,Acetaminophen
,20444020,T(1/2),"Codeine was rapidly eliminated after i.v. administration (T(1/2) = 1.22 h; clearance = 29.94 mL/min/kg; volume of distribution = 3.17 L/kg) with negligible amounts of morphine present, but large amounts of codeine-6-glucuronide (C(max) = 735.75 ng/mL) were detected.","Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),h,1.22,28839,DB00316,Acetaminophen
,20444020,clearance,"Codeine was rapidly eliminated after i.v. administration (T(1/2) = 1.22 h; clearance = 29.94 mL/min/kg; volume of distribution = 3.17 L/kg) with negligible amounts of morphine present, but large amounts of codeine-6-glucuronide (C(max) = 735.75 ng/mL) were detected.","Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),[ml] / [kg·min],29.94,28840,DB00316,Acetaminophen
,20444020,volume of distribution,"Codeine was rapidly eliminated after i.v. administration (T(1/2) = 1.22 h; clearance = 29.94 mL/min/kg; volume of distribution = 3.17 L/kg) with negligible amounts of morphine present, but large amounts of codeine-6-glucuronide (C(max) = 735.75 ng/mL) were detected.","Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),[l] / [kg],3.17,28841,DB00316,Acetaminophen
,20444020,C(max),"Codeine was rapidly eliminated after i.v. administration (T(1/2) = 1.22 h; clearance = 29.94 mL/min/kg; volume of distribution = 3.17 L/kg) with negligible amounts of morphine present, but large amounts of codeine-6-glucuronide (C(max) = 735.75 ng/mL) were detected.","Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),[ng] / [ml],735.75,28842,DB00316,Acetaminophen
,20444020,oral bioavailability,"The oral bioavailability of codeine was 4%, morphine concentrations were negligible, but large amounts of codeine-6-glucuronide (C(max) = 1952.86 ng/mL) were detected suggesting substantial first pass metabolism.","Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),%,4,28843,DB00316,Acetaminophen
,20444020,C(max),"The oral bioavailability of codeine was 4%, morphine concentrations were negligible, but large amounts of codeine-6-glucuronide (C(max) = 1952.86 ng/mL) were detected suggesting substantial first pass metabolism.","Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),[ng] / [ml],1952.86,28844,DB00316,Acetaminophen
,20444020,C(max),Acetaminophen was rapidly absorbed (C(max) = 6.74 microg/mL; T(max) = 0.85 h) and eliminated (T(1/2) = 0.96 h).,"Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),[μg] / [ml],6.74,28845,DB00316,Acetaminophen
,20444020,T(max),Acetaminophen was rapidly absorbed (C(max) = 6.74 microg/mL; T(max) = 0.85 h) and eliminated (T(1/2) = 0.96 h).,"Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),h,0.85,28846,DB00316,Acetaminophen
,20444020,T(1/2),Acetaminophen was rapidly absorbed (C(max) = 6.74 microg/mL; T(max) = 0.85 h) and eliminated (T(1/2) = 0.96 h).,"Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),h,0.96,28847,DB00316,Acetaminophen
,29756216,maximal concentration (CMAX,"In healthy dogs, oral APAP maximal concentration (CMAX =2.69 μg/ml) was reached quickly (TMAX =1.04 hr) and eliminated rapidly (T1/2 = 1.81 hr).",Bioavailability of suppository acetaminophen in healthy and hospitalized ill dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29756216/),[μg] / [ml],2.69,29407,DB00316,Acetaminophen
,29756216,TMAX,"In healthy dogs, oral APAP maximal concentration (CMAX =2.69 μg/ml) was reached quickly (TMAX =1.04 hr) and eliminated rapidly (T1/2 = 1.81 hr).",Bioavailability of suppository acetaminophen in healthy and hospitalized ill dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29756216/),h,1.04,29408,DB00316,Acetaminophen
,29756216,T1/2,"In healthy dogs, oral APAP maximal concentration (CMAX =2.69 μg/ml) was reached quickly (TMAX =1.04 hr) and eliminated rapidly (T1/2 = 1.81 hr).",Bioavailability of suppository acetaminophen in healthy and hospitalized ill dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29756216/),h,1.81,29409,DB00316,Acetaminophen
,29756216,CMAX,"Suppository APAP was rapidly, but variably absorbed (CMAX =0.52 μg/ml TMAX =0.67 hr) and eliminated (T1/2 = 3.21 hr).",Bioavailability of suppository acetaminophen in healthy and hospitalized ill dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29756216/),[μg] / [ml],0.52,29410,DB00316,Acetaminophen
,29756216,TMAX,"Suppository APAP was rapidly, but variably absorbed (CMAX =0.52 μg/ml TMAX =0.67 hr) and eliminated (T1/2 = 3.21 hr).",Bioavailability of suppository acetaminophen in healthy and hospitalized ill dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29756216/),h,0.67,29411,DB00316,Acetaminophen
,29756216,T1/2,"Suppository APAP was rapidly, but variably absorbed (CMAX =0.52 μg/ml TMAX =0.67 hr) and eliminated (T1/2 = 3.21 hr).",Bioavailability of suppository acetaminophen in healthy and hospitalized ill dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29756216/),h,3.21,29412,DB00316,Acetaminophen
,29756216,mean plasma concentration,"In hospitalized ill dogs, the suppository APAP mean plasma concentration at 2 hr and 6 hr was 1.317 μg/ml and 0.283 μg/ml.",Bioavailability of suppository acetaminophen in healthy and hospitalized ill dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29756216/),[μg] / [ml],1.317,29413,DB00316,Acetaminophen
,29756216,mean plasma concentration,"In hospitalized ill dogs, the suppository APAP mean plasma concentration at 2 hr and 6 hr was 1.317 μg/ml and 0.283 μg/ml.",Bioavailability of suppository acetaminophen in healthy and hospitalized ill dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29756216/),[μg] / [ml],0.283,29414,DB00316,Acetaminophen
,15662506,clearance,"Pharmacokinetics of paracetamol after intravenous administration was best described by a two-compartment model with clearance of 13.2 l/h per 70 kg (between-subject variability: 30%), intercompartmental clearance of 45.7 l/h per 70 kg (both parameters standardized to a 70-kg person using allometric ""1/4 power models""), central volume of distribution of 13.2 l per 70 kg (between-subject variability: 71%) and peripheral volume of distribution of 33.0 l per 70 kg.",Pharmacokinetics of intravenous paracetamol in children and adolescents under major surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15662506/),[l] / [70·h·kg],13.2,29602,DB00316,Acetaminophen
,15662506,intercompartmental clearance,"Pharmacokinetics of paracetamol after intravenous administration was best described by a two-compartment model with clearance of 13.2 l/h per 70 kg (between-subject variability: 30%), intercompartmental clearance of 45.7 l/h per 70 kg (both parameters standardized to a 70-kg person using allometric ""1/4 power models""), central volume of distribution of 13.2 l per 70 kg (between-subject variability: 71%) and peripheral volume of distribution of 33.0 l per 70 kg.",Pharmacokinetics of intravenous paracetamol in children and adolescents under major surgery. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15662506/),[l] / [70·h·kg],45.7,29603,DB00316,Acetaminophen
,15662506,central volume of distribution,"Pharmacokinetics of paracetamol after intravenous administration was best described by a two-compartment model with clearance of 13.2 l/h per 70 kg (between-subject variability: 30%), intercompartmental clearance of 45.7 l/h per 70 kg (both parameters standardized to a 70-kg person using allometric ""1/4 power models""), central volume of distribution of 13.2 l per 70 kg (between-subject variability: 71%) and peripheral volume of distribution of 33.0 l per 70 kg.",Pharmacokinetics of intravenous paracetamol in children and adolescents under major surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15662506/),[l] / [70·kg],13.2,29604,DB00316,Acetaminophen
,15662506,peripheral volume of distribution,"Pharmacokinetics of paracetamol after intravenous administration was best described by a two-compartment model with clearance of 13.2 l/h per 70 kg (between-subject variability: 30%), intercompartmental clearance of 45.7 l/h per 70 kg (both parameters standardized to a 70-kg person using allometric ""1/4 power models""), central volume of distribution of 13.2 l per 70 kg (between-subject variability: 71%) and peripheral volume of distribution of 33.0 l per 70 kg.",Pharmacokinetics of intravenous paracetamol in children and adolescents under major surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15662506/),[l] / [70·kg],33.0,29605,DB00316,Acetaminophen
>,22471366,recoveries,Mean recoveries for all analytes were > 88%.,Investigating paracetamol pharmacokinetics using venous and capillary blood and saliva sampling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22471366/),%,88,31140,DB00316,Acetaminophen
,22471366,area under the concentration-time curve,The value for area under the concentration-time curve over the 6h dosing interval of venous plasma (45.3±12.9mg/l.h) was significantly higher than that observed for capillary plasma (33.8±12.9mg/l.h) or saliva (35.1±9.4mg/l.h; P>0.01).,Investigating paracetamol pharmacokinetics using venous and capillary blood and saliva sampling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22471366/),[mg] / [h·l],45.3,31141,DB00316,Acetaminophen
,22471366,area under the concentration-time curve,The value for area under the concentration-time curve over the 6h dosing interval of venous plasma (45.3±12.9mg/l.h) was significantly higher than that observed for capillary plasma (33.8±12.9mg/l.h) or saliva (35.1±9.4mg/l.h; P>0.01).,Investigating paracetamol pharmacokinetics using venous and capillary blood and saliva sampling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22471366/),[mg] / [h·l],33.8,31142,DB00316,Acetaminophen
,22471366,area under the concentration-time curve,The value for area under the concentration-time curve over the 6h dosing interval of venous plasma (45.3±12.9mg/l.h) was significantly higher than that observed for capillary plasma (33.8±12.9mg/l.h) or saliva (35.1±9.4mg/l.h; P>0.01).,Investigating paracetamol pharmacokinetics using venous and capillary blood and saliva sampling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22471366/),[mg] / [h·l],35.1,31143,DB00316,Acetaminophen
,6970498,detection limit,"As an example, the practical detection limit for naproxen in plasma was about 0.2 microgram ml-1.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[μg] / [ml],0.2,31759,DB00316,Acetaminophen
,6970498,Vc,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[1] / [kg],0.038,31760,DB00316,Acetaminophen
,6970498,Vdss,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[1] / [kg],0.138,31761,DB00316,Acetaminophen
,6970498,t 1/2 (beta,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,21.3,31762,DB00316,Acetaminophen
,6970498,t 1/2 (alpha),"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,0.99,31763,DB00316,Acetaminophen
,6970498,t 1/2 (ka),"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,0.67,31764,DB00316,Acetaminophen
,31175627,inhibition constant (Ki),"Honokiol inhibited the formation of acetaminophen from phenacetin and 4-hydroxytolbutamide from tolbutamide in RLMs, with inhibition constant (Ki) values of 1.6 μM and 16.5 μM, respectively.","Inhibition of Rat CYP1A2 and CYP2C11 by Honokiol, a Component of Traditional Chinese Medicine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31175627/),μM,1.6,32654,DB00316,Acetaminophen
,31175627,inhibition constant (Ki),"Honokiol inhibited the formation of acetaminophen from phenacetin and 4-hydroxytolbutamide from tolbutamide in RLMs, with inhibition constant (Ki) values of 1.6 μM and 16.5 μM, respectively.","Inhibition of Rat CYP1A2 and CYP2C11 by Honokiol, a Component of Traditional Chinese Medicine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31175627/),μM,16.5,32655,DB00316,Acetaminophen
,19701261,pulse,"Her pulse was 70 bpm, BP 149/63 mmHg with an unremarkable physical examination.",Early presentation following overdose of modified-release paracetamol (Panadol Osteo) with biphasic and prolonged paracetamol absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19701261/),bpm,70,32876,DB00316,Acetaminophen
,19701261,concentration,"Two-hour paracetamol concentration was 2628 micromol/L falling to 2216 micromol/L, 4 hours post-ingestion.",Early presentation following overdose of modified-release paracetamol (Panadol Osteo) with biphasic and prolonged paracetamol absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19701261/),,262,32877,DB00316,Acetaminophen
,19701261,concentration,"Two-hour paracetamol concentration was 2628 micromol/L falling to 2216 micromol/L, 4 hours post-ingestion.",Early presentation following overdose of modified-release paracetamol (Panadol Osteo) with biphasic and prolonged paracetamol absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19701261/),,2216,32878,DB00316,Acetaminophen
,2029805,peak plasma concentration,After an oral dose of N-acetylcysteine 200 to 400 mg the peak plasma concentration of 0.35 to 4 mg/L is achieved within 1 to 2 hours.,Clinical pharmacokinetics of N-acetylcysteine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029805/),[mg] / [l],0.35 to 4,33002,DB00316,Acetaminophen
,2029805,volume of distribution,"The volume of distribution ranges from 0.33 to 0.47 L/kg and protein binding is significant, reaching approximately 50% 4 hours after the dose.",Clinical pharmacokinetics of N-acetylcysteine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029805/),[l] / [kg],0.33 to 0.47,33003,DB00316,Acetaminophen
,2029805,Renal clearance,Renal clearance has been reported as 0.190 to 0.211 L/h/kg and approximately 70% of the total body clearance is nonrenal.,Clinical pharmacokinetics of N-acetylcysteine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029805/),[l] / [h·kg],0.190 to 0.211,33004,DB00316,Acetaminophen
,2029805,terminal half-life,"Following oral administration, reduced N-acetylcysteine has a terminal half-life of 6.25h.",Clinical pharmacokinetics of N-acetylcysteine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029805/),h,6.25,33005,DB00316,Acetaminophen
,14571283,AUC(0-infinity),Mean AUC(0-infinity) ranged from 52.6 (B) to 56.3 microg x h/ml (D); mean Cmax varied between 17.98 (C) and 20.73 microg/ml (E); mean tmax ranged from 0.40 (E) to 0.88 h (C); and median t(1/2) varied between 2.65 (C) and 2.81 h (A).,"Bioavailability of two new formulations of paracetamol, compared with three marketed formulations, in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571283/),[h·μg] / [ml],52.6,33353,DB00316,Acetaminophen
,14571283,AUC(0-infinity),Mean AUC(0-infinity) ranged from 52.6 (B) to 56.3 microg x h/ml (D); mean Cmax varied between 17.98 (C) and 20.73 microg/ml (E); mean tmax ranged from 0.40 (E) to 0.88 h (C); and median t(1/2) varied between 2.65 (C) and 2.81 h (A).,"Bioavailability of two new formulations of paracetamol, compared with three marketed formulations, in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571283/),[h·μg] / [ml],56.3,33354,DB00316,Acetaminophen
,14571283,Cmax,Mean AUC(0-infinity) ranged from 52.6 (B) to 56.3 microg x h/ml (D); mean Cmax varied between 17.98 (C) and 20.73 microg/ml (E); mean tmax ranged from 0.40 (E) to 0.88 h (C); and median t(1/2) varied between 2.65 (C) and 2.81 h (A).,"Bioavailability of two new formulations of paracetamol, compared with three marketed formulations, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571283/),[μg] / [ml],17.98,33355,DB00316,Acetaminophen
,14571283,Cmax,Mean AUC(0-infinity) ranged from 52.6 (B) to 56.3 microg x h/ml (D); mean Cmax varied between 17.98 (C) and 20.73 microg/ml (E); mean tmax ranged from 0.40 (E) to 0.88 h (C); and median t(1/2) varied between 2.65 (C) and 2.81 h (A).,"Bioavailability of two new formulations of paracetamol, compared with three marketed formulations, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571283/),[μg] / [ml],20.73,33356,DB00316,Acetaminophen
,14571283,tmax,Mean AUC(0-infinity) ranged from 52.6 (B) to 56.3 microg x h/ml (D); mean Cmax varied between 17.98 (C) and 20.73 microg/ml (E); mean tmax ranged from 0.40 (E) to 0.88 h (C); and median t(1/2) varied between 2.65 (C) and 2.81 h (A).,"Bioavailability of two new formulations of paracetamol, compared with three marketed formulations, in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571283/),h,0.40,33357,DB00316,Acetaminophen
,14571283,tmax,Mean AUC(0-infinity) ranged from 52.6 (B) to 56.3 microg x h/ml (D); mean Cmax varied between 17.98 (C) and 20.73 microg/ml (E); mean tmax ranged from 0.40 (E) to 0.88 h (C); and median t(1/2) varied between 2.65 (C) and 2.81 h (A).,"Bioavailability of two new formulations of paracetamol, compared with three marketed formulations, in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571283/),h,0.88,33358,DB00316,Acetaminophen
,14571283,t(1/2),Mean AUC(0-infinity) ranged from 52.6 (B) to 56.3 microg x h/ml (D); mean Cmax varied between 17.98 (C) and 20.73 microg/ml (E); mean tmax ranged from 0.40 (E) to 0.88 h (C); and median t(1/2) varied between 2.65 (C) and 2.81 h (A).,"Bioavailability of two new formulations of paracetamol, compared with three marketed formulations, in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571283/),h,2.65,33359,DB00316,Acetaminophen
,14571283,t(1/2),Mean AUC(0-infinity) ranged from 52.6 (B) to 56.3 microg x h/ml (D); mean Cmax varied between 17.98 (C) and 20.73 microg/ml (E); mean tmax ranged from 0.40 (E) to 0.88 h (C); and median t(1/2) varied between 2.65 (C) and 2.81 h (A).,"Bioavailability of two new formulations of paracetamol, compared with three marketed formulations, in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571283/),h,2.81,33360,DB00316,Acetaminophen
∼,21677062,IC(50),"However, it did inhibit the RLS9-catalyzed N-acetylation of procainamide (IC(50) ∼ 30 μM), and no preincubation time dependence was evident.","1-Aminobenzotriazole, a known cytochrome P450 inhibitor, is a substrate and inhibitor of N-acetyltransferase. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21677062/),μM,30,33629,DB00316,Acetaminophen
,21677062,IC(50),Additional studies with human forms of NAT (hNAT1 and hNAT2) revealed that ABT is a more potent inhibitor of hNAT2 compared with hNAT1 (IC(50) 158 μM versus > 1 mM).,"1-Aminobenzotriazole, a known cytochrome P450 inhibitor, is a substrate and inhibitor of N-acetyltransferase. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21677062/),μM,158,33630,DB00316,Acetaminophen
>,21677062,IC(50),Additional studies with human forms of NAT (hNAT1 and hNAT2) revealed that ABT is a more potent inhibitor of hNAT2 compared with hNAT1 (IC(50) 158 μM versus > 1 mM).,"1-Aminobenzotriazole, a known cytochrome P450 inhibitor, is a substrate and inhibitor of N-acetyltransferase. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21677062/),mM,1,33631,DB00316,Acetaminophen
,21677062,inhibition constant,"Consistent with the IC(50) estimate, formal inhibition studies revealed that inhibition of hNAT2 was competitive with an inhibition constant of 67 μM.","1-Aminobenzotriazole, a known cytochrome P450 inhibitor, is a substrate and inhibitor of N-acetyltransferase. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21677062/),μM,67,33632,DB00316,Acetaminophen
,27668024,Cmax,"The concentration-versus-time profiles were similar for the 2 formulations, with mean Cmax of 26.5 μg/mL for effervescent NAC tablets and 28.4 μg/mL for oral solution NAC.","Effervescent N-Acetylcysteine Tablets versus Oral Solution N-Acetylcysteine in Fasting Healthy Adults: An Open-Label, Randomized, Single-Dose, Crossover, Relative Bioavailability Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27668024/),[μg] / [ml],26.5,33651,DB00316,Acetaminophen
,27668024,Cmax,"The concentration-versus-time profiles were similar for the 2 formulations, with mean Cmax of 26.5 μg/mL for effervescent NAC tablets and 28.4 μg/mL for oral solution NAC.","Effervescent N-Acetylcysteine Tablets versus Oral Solution N-Acetylcysteine in Fasting Healthy Adults: An Open-Label, Randomized, Single-Dose, Crossover, Relative Bioavailability Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27668024/),[μg] / [ml],28.4,33652,DB00316,Acetaminophen
,262181,Analytical recovery,Analytical recovery is 97% for acetaminophen concentrations ranging from 5 to 300 mg/L.,Liquid-chromatographic determination of acetaminophen in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/262181/),%,97,34525,DB00316,Acetaminophen
,31347013,"Css,avg","Predictions resulted in the lowest Css,avg in the third trimester (median [interquartile range]: 4.5 [3.8-5.1] mg/L), while Css,avg was 6.7 [5.9-7.4], 5.6 [4.7-6.3], and 4.9 [4.1-5.5] mg/L in non-pregnant, first trimester, and second trimester populations, respectively.",Physiologically Based Pharmacokinetic Modeling to Characterize Acetaminophen Pharmacokinetics and N-Acetyl-p-Benzoquinone Imine (NAPQI) Formation in Non-Pregnant and Pregnant Women. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31347013/),[mg] / [l],4.5,34782,DB00316,Acetaminophen
,31347013,"Css,avg","Predictions resulted in the lowest Css,avg in the third trimester (median [interquartile range]: 4.5 [3.8-5.1] mg/L), while Css,avg was 6.7 [5.9-7.4], 5.6 [4.7-6.3], and 4.9 [4.1-5.5] mg/L in non-pregnant, first trimester, and second trimester populations, respectively.",Physiologically Based Pharmacokinetic Modeling to Characterize Acetaminophen Pharmacokinetics and N-Acetyl-p-Benzoquinone Imine (NAPQI) Formation in Non-Pregnant and Pregnant Women. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31347013/),[mg] / [l],6.7,34783,DB00316,Acetaminophen
,31347013,"Css,avg","Predictions resulted in the lowest Css,avg in the third trimester (median [interquartile range]: 4.5 [3.8-5.1] mg/L), while Css,avg was 6.7 [5.9-7.4], 5.6 [4.7-6.3], and 4.9 [4.1-5.5] mg/L in non-pregnant, first trimester, and second trimester populations, respectively.",Physiologically Based Pharmacokinetic Modeling to Characterize Acetaminophen Pharmacokinetics and N-Acetyl-p-Benzoquinone Imine (NAPQI) Formation in Non-Pregnant and Pregnant Women. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31347013/),[mg] / [l],5.6,34784,DB00316,Acetaminophen
,31347013,"Css,avg","Predictions resulted in the lowest Css,avg in the third trimester (median [interquartile range]: 4.5 [3.8-5.1] mg/L), while Css,avg was 6.7 [5.9-7.4], 5.6 [4.7-6.3], and 4.9 [4.1-5.5] mg/L in non-pregnant, first trimester, and second trimester populations, respectively.",Physiologically Based Pharmacokinetic Modeling to Characterize Acetaminophen Pharmacokinetics and N-Acetyl-p-Benzoquinone Imine (NAPQI) Formation in Non-Pregnant and Pregnant Women. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31347013/),[mg] / [l],4.9,34785,DB00316,Acetaminophen
,2253663,24 h serum concentrations,Average 24 h serum concentrations were 360 microM and the difference between minimum and maximum levels was on average 25.8%.,Circadian rhythm of serum sulfate levels in man and acetaminophen pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253663/),μM,360,35001,DB00316,Acetaminophen
,6716239,bioavailability,"The average (+/- SD) bioavailability of the tablet relative to that of the solution was 85.0 +/- 31.1 and 88.6 +/- 13.1% for pentazocine and acetaminophen, respectively.",Relative bioavailability and pharmacokinetics: a combination of pentazocine and acetaminophen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716239/),%,85.0,36067,DB00316,Acetaminophen
,6716239,bioavailability,"The average (+/- SD) bioavailability of the tablet relative to that of the solution was 85.0 +/- 31.1 and 88.6 +/- 13.1% for pentazocine and acetaminophen, respectively.",Relative bioavailability and pharmacokinetics: a combination of pentazocine and acetaminophen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716239/),%,88.6,36068,DB00316,Acetaminophen
,6716239,apparent first-order regression,"The apparent first-order regression-dependent elimination rate constants for pentazocine from the tablet and solution preparations were 0.19 +/- 0.08 and 0.20 +/- 0.06 h-1, respectively, while the rate constants for acetaminophen were 0.26 +/- 0.03 and 0.25 +/- 0.03 h-1 for the tablet and solution preparations, respectively.",Relative bioavailability and pharmacokinetics: a combination of pentazocine and acetaminophen. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716239/),1/[h],0.19,36069,DB00316,Acetaminophen
,6716239,apparent first-order regression,"The apparent first-order regression-dependent elimination rate constants for pentazocine from the tablet and solution preparations were 0.19 +/- 0.08 and 0.20 +/- 0.06 h-1, respectively, while the rate constants for acetaminophen were 0.26 +/- 0.03 and 0.25 +/- 0.03 h-1 for the tablet and solution preparations, respectively.",Relative bioavailability and pharmacokinetics: a combination of pentazocine and acetaminophen. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716239/),1/[h],0.20,36070,DB00316,Acetaminophen
,6716239,elimination rate constants,"The apparent first-order regression-dependent elimination rate constants for pentazocine from the tablet and solution preparations were 0.19 +/- 0.08 and 0.20 +/- 0.06 h-1, respectively, while the rate constants for acetaminophen were 0.26 +/- 0.03 and 0.25 +/- 0.03 h-1 for the tablet and solution preparations, respectively.",Relative bioavailability and pharmacokinetics: a combination of pentazocine and acetaminophen. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716239/),1/[h],0.19,36071,DB00316,Acetaminophen
,6716239,elimination rate constants,"The apparent first-order regression-dependent elimination rate constants for pentazocine from the tablet and solution preparations were 0.19 +/- 0.08 and 0.20 +/- 0.06 h-1, respectively, while the rate constants for acetaminophen were 0.26 +/- 0.03 and 0.25 +/- 0.03 h-1 for the tablet and solution preparations, respectively.",Relative bioavailability and pharmacokinetics: a combination of pentazocine and acetaminophen. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716239/),1/[h],0.20,36072,DB00316,Acetaminophen
,6716239,rate constants,"The apparent first-order regression-dependent elimination rate constants for pentazocine from the tablet and solution preparations were 0.19 +/- 0.08 and 0.20 +/- 0.06 h-1, respectively, while the rate constants for acetaminophen were 0.26 +/- 0.03 and 0.25 +/- 0.03 h-1 for the tablet and solution preparations, respectively.",Relative bioavailability and pharmacokinetics: a combination of pentazocine and acetaminophen. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716239/),1/[h],0.26,36073,DB00316,Acetaminophen
,6716239,rate constants,"The apparent first-order regression-dependent elimination rate constants for pentazocine from the tablet and solution preparations were 0.19 +/- 0.08 and 0.20 +/- 0.06 h-1, respectively, while the rate constants for acetaminophen were 0.26 +/- 0.03 and 0.25 +/- 0.03 h-1 for the tablet and solution preparations, respectively.",Relative bioavailability and pharmacokinetics: a combination of pentazocine and acetaminophen. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716239/),1/[h],0.25,36074,DB00316,Acetaminophen
,6716239,terminal elimination half-lives,These rate constants correspond to terminal elimination half-lives of approximately 3.6 h for pentazocine and approximately 2.7 h for acetaminophen.,Relative bioavailability and pharmacokinetics: a combination of pentazocine and acetaminophen. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716239/),h,3.6,36075,DB00316,Acetaminophen
,6716239,terminal elimination half-lives,These rate constants correspond to terminal elimination half-lives of approximately 3.6 h for pentazocine and approximately 2.7 h for acetaminophen.,Relative bioavailability and pharmacokinetics: a combination of pentazocine and acetaminophen. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716239/),h,2.7,36076,DB00316,Acetaminophen
,12170045,volume of distribution,"Population pharmacokinetic parameter estimates and their variability (percent) for a one-compartment model with first-order input, lag time, and first-order elimination were as follows: volume of distribution, 66.6 l (20%); clearance, 12.5 l/h (44%); standardized to a 70-kg person using allometric ""1/4 power"" models.",Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12170045/),l,66.6,36343,DB00316,Acetaminophen
,12170045,clearance,"Population pharmacokinetic parameter estimates and their variability (percent) for a one-compartment model with first-order input, lag time, and first-order elimination were as follows: volume of distribution, 66.6 l (20%); clearance, 12.5 l/h (44%); standardized to a 70-kg person using allometric ""1/4 power"" models.",Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12170045/),[l] / [h],12.5,36344,DB00316,Acetaminophen
,12170045,maturation half-life,The volume of distribution decreased exponentially with a maturation half-life of 11.5 weeks from 109.7 l/70 kg at 28 weeks after conception to 72.9 l/70 kg by 60 weeks.,Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12170045/),weeks,11.5,36345,DB00316,Acetaminophen
,12170045,maturation half-life,The volume of distribution decreased exponentially with a maturation half-life of 11.5 weeks from 109.7 l/70 kg at 28 weeks after conception to 72.9 l/70 kg by 60 weeks.,Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12170045/),[l] / [70·kg],109.7,36346,DB00316,Acetaminophen
,12170045,maturation half-life,The volume of distribution decreased exponentially with a maturation half-life of 11.5 weeks from 109.7 l/70 kg at 28 weeks after conception to 72.9 l/70 kg by 60 weeks.,Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12170045/),[l] / [70·kg],72.9,36347,DB00316,Acetaminophen
,12170045,Clearance,Clearance increased from 28 weeks after conception (0.74 l x h(-1) x 70 kg(-1)) with a maturation half-life of 11.3 weeks to reach 10.8 l x h(-1) x 70 kg(-1) by 60 weeks.,Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12170045/),[l] / [70·h·kg],0.74,36348,DB00316,Acetaminophen
,12170045,maturation half-life,Clearance increased from 28 weeks after conception (0.74 l x h(-1) x 70 kg(-1)) with a maturation half-life of 11.3 weeks to reach 10.8 l x h(-1) x 70 kg(-1) by 60 weeks.,Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12170045/),weeks,11.3,36349,DB00316,Acetaminophen
,12170045,maturation half-life,Clearance increased from 28 weeks after conception (0.74 l x h(-1) x 70 kg(-1)) with a maturation half-life of 11.3 weeks to reach 10.8 l x h(-1) x 70 kg(-1) by 60 weeks.,Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12170045/),[l] / [70·h·kg],10.8,36350,DB00316,Acetaminophen
,12170045,absorption half-life,"The absorption half-life for the oral elixir preparation was 0.21 h (120%) with a lag time of 0.42 h (70%), but absorption was further delayed (2 h) in premature neonates in the first few days of life.",Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12170045/),h,0.21,36351,DB00316,Acetaminophen
,12170045,lag time,"The absorption half-life for the oral elixir preparation was 0.21 h (120%) with a lag time of 0.42 h (70%), but absorption was further delayed (2 h) in premature neonates in the first few days of life.",Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12170045/),h,0.42,36352,DB00316,Acetaminophen
,12170045,Absorption half-life,"Absorption half-life parameters for the triglyceride base and capsule suppositories were 0.80 h (100%) and 1.4 h (57%), respectively.",Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12170045/),h,0.80,36353,DB00316,Acetaminophen
,12170045,Absorption half-life,"Absorption half-life parameters for the triglyceride base and capsule suppositories were 0.80 h (100%) and 1.4 h (57%), respectively.",Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12170045/),h,1.4,36354,DB00316,Acetaminophen
,12170045,absorption half-life,The absorption half-life for the rectal solution was 0.33 h.,Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12170045/),h,0.33,36355,DB00316,Acetaminophen
,12170045,bioavailability,"The bioavailability of the capsule suppository relative to elixir decreased with age from 0.92 (22%) at 28 weeks after conception to 0.86 at 2 yr of age, whereas the triglyceride base decreased from 0.86 (35%) at 28 weeks postconception to 0.5 at 2 yr of age.",Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12170045/),,0.92,36356,DB00316,Acetaminophen
,12170045,bioavailability,"The bioavailability of the capsule suppository relative to elixir decreased with age from 0.92 (22%) at 28 weeks after conception to 0.86 at 2 yr of age, whereas the triglyceride base decreased from 0.86 (35%) at 28 weeks postconception to 0.5 at 2 yr of age.",Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12170045/),,0.86,36357,DB00316,Acetaminophen
,12170045,bioavailability,"The bioavailability of the capsule suppository relative to elixir decreased with age from 0.92 (22%) at 28 weeks after conception to 0.86 at 2 yr of age, whereas the triglyceride base decreased from 0.86 (35%) at 28 weeks postconception to 0.5 at 2 yr of age.",Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12170045/),,0.86,36358,DB00316,Acetaminophen
,12170045,bioavailability,"The bioavailability of the capsule suppository relative to elixir decreased with age from 0.92 (22%) at 28 weeks after conception to 0.86 at 2 yr of age, whereas the triglyceride base decreased from 0.86 (35%) at 28 weeks postconception to 0.5 at 2 yr of age.",Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12170045/),,0.5,36359,DB00316,Acetaminophen
,12170045,relative bioavailability,The relative bioavailability of the rectal solution was 0.66.,Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12170045/),,0.66,36360,DB00316,Acetaminophen
greater,12170045,steady state target concentration,"A mean steady state target concentration greater than 10 mg/l at trough can be achieved by an oral dose of 25 mg x kg(-1) x d(-1) in premature neonates at 30 weeks' postconception, 45 mg x kg(-1) x d(-1) at 34 weeks' gestation, 60 mg x kg(-1) x d(-1) at term, and 90 mg x kg(-1) x d(-1) at 6 months of age.",Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12170045/),[mg] / [l],10,36361,DB00316,Acetaminophen
,25149982,maximum entrapment,The formulation showed maximum entrapment (55%) for a lecithin-cholesterol ratio of 6:1.,"Silymarin liposomes improves oral bioavailability of silybin besides targeting hepatocytes, and immune cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25149982/),%,55,36755,DB00316,Acetaminophen
,6416745,systemic bioavailability,"The pharmacokinetic parameters of levonorgestrel in control mice showed some similarity to those observed in human subjects, save the systemic bioavailability which was about 67% in mice compared to 100% in humans.",Influence of acetaminophen-induced hepatic necrosis on the pharmacokinetics of levonorgestrel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6416745/),%,67,36851,DB00316,Acetaminophen
,6416745,systemic bioavailability,"The pharmacokinetic parameters of levonorgestrel in control mice showed some similarity to those observed in human subjects, save the systemic bioavailability which was about 67% in mice compared to 100% in humans.",Influence of acetaminophen-induced hepatic necrosis on the pharmacokinetics of levonorgestrel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6416745/),%,100,36852,DB00316,Acetaminophen
,28535819,Withdrawal rate,"Withdrawal rate was 4%, 0%, and 4%, respectively.",Does the placebo effect modulate drug bioavailability? Randomized cross-over studies of three drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535819/),%,4,37188,DB00316,Acetaminophen
,28535819,Withdrawal rate,"Withdrawal rate was 4%, 0%, and 4%, respectively.",Does the placebo effect modulate drug bioavailability? Randomized cross-over studies of three drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535819/),%,0,37189,DB00316,Acetaminophen
,18165446,Cmax,"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [l],14.12,37687,DB00316,Acetaminophen
,18165446,Cmax,"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [l],9.28,37688,DB00316,Acetaminophen
,18165446,C(60),"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [l],9.62,37689,DB00316,Acetaminophen
,18165446,C(60),"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [l],6.08,37690,DB00316,Acetaminophen
,18165446,AUC(0-60),"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [h·l],10.01,37691,DB00316,Acetaminophen
,18165446,AUC(0-60),"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [h·l],3.93,37692,DB00316,Acetaminophen
,18165446,Tmax,"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),h,0.81,37693,DB00316,Acetaminophen
,18165446,Tmax,"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),h,1.98,37694,DB00316,Acetaminophen
,18165446,Cmax,"After prokinetic therapy, Cmax (15.26 +/- 8.85 mg/L), C(60) (11.96 +/- 5.99 mg/L), and AUC(0-60) (10.90 +/- 6.57 mg/h/L) increased and Tmax (1.07 +/- 1.01 hours) decreased in the intolerant group to values similar to the tolerant group.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [l],15.26,37695,DB00316,Acetaminophen
,18165446,C(60),"After prokinetic therapy, Cmax (15.26 +/- 8.85 mg/L), C(60) (11.96 +/- 5.99 mg/L), and AUC(0-60) (10.90 +/- 6.57 mg/h/L) increased and Tmax (1.07 +/- 1.01 hours) decreased in the intolerant group to values similar to the tolerant group.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [l],11.96,37696,DB00316,Acetaminophen
,18165446,AUC(0-60),"After prokinetic therapy, Cmax (15.26 +/- 8.85 mg/L), C(60) (11.96 +/- 5.99 mg/L), and AUC(0-60) (10.90 +/- 6.57 mg/h/L) increased and Tmax (1.07 +/- 1.01 hours) decreased in the intolerant group to values similar to the tolerant group.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [h·l],10.90,37697,DB00316,Acetaminophen
,18165446,Tmax,"After prokinetic therapy, Cmax (15.26 +/- 8.85 mg/L), C(60) (11.96 +/- 5.99 mg/L), and AUC(0-60) (10.90 +/- 6.57 mg/h/L) increased and Tmax (1.07 +/- 1.01 hours) decreased in the intolerant group to values similar to the tolerant group.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),h,1.07,37698,DB00316,Acetaminophen
,3829578,time of peak excretion rate,"The mean time of peak excretion rate was 1.3 to 3.7 hours for acetaminophen, its glucuronide, sulfate, cysteine, mercapturate, and methoxy metabolites but 13.5 hours for methylthioacetaminophen.",Dose-dependent pharmacokinetics of acetaminophen: evidence of glutathione depletion in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829578/),h,1.3 to 3.7,37952,DB00316,Acetaminophen
,3829578,time of peak excretion rate,"The mean time of peak excretion rate was 1.3 to 3.7 hours for acetaminophen, its glucuronide, sulfate, cysteine, mercapturate, and methoxy metabolites but 13.5 hours for methylthioacetaminophen.",Dose-dependent pharmacokinetics of acetaminophen: evidence of glutathione depletion in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829578/),h,13.5,37953,DB00316,Acetaminophen
,3829578,half-life,The mean half-life of acetaminophen was 3.1 hours and the mean half-life of the metabolites other than methylthioacetaminophen ranged from 4.1 to 5.7 hours.,Dose-dependent pharmacokinetics of acetaminophen: evidence of glutathione depletion in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829578/),h,3.1,37954,DB00316,Acetaminophen
,3829578,half-life,The mean half-life of acetaminophen was 3.1 hours and the mean half-life of the metabolites other than methylthioacetaminophen ranged from 4.1 to 5.7 hours.,Dose-dependent pharmacokinetics of acetaminophen: evidence of glutathione depletion in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829578/),h,4.1 to 5.7,37955,DB00316,Acetaminophen
,6644552,maximum velocity,"The Michaelis-Menten equation gave maximum velocity and Michaelis constant (Km) values of 4.92 mumol/min/kg and 109 microM for AS formation, and 2.76 mumol/min/kg and 915 microM for AG formation.",Pharmacokinetic study of the fate of acetaminophen and its conjugates in rats. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6644552/),[μM] / [kg·min],4.92,38441,DB00316,Acetaminophen
,6644552,maximum velocity,"The Michaelis-Menten equation gave maximum velocity and Michaelis constant (Km) values of 4.92 mumol/min/kg and 109 microM for AS formation, and 2.76 mumol/min/kg and 915 microM for AG formation.",Pharmacokinetic study of the fate of acetaminophen and its conjugates in rats. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6644552/),[μM] / [kg·min],2.76,38442,DB00316,Acetaminophen
,6644552,Michaelis constant (Km),"The Michaelis-Menten equation gave maximum velocity and Michaelis constant (Km) values of 4.92 mumol/min/kg and 109 microM for AS formation, and 2.76 mumol/min/kg and 915 microM for AG formation.",Pharmacokinetic study of the fate of acetaminophen and its conjugates in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6644552/),μM,109,38443,DB00316,Acetaminophen
,6644552,Michaelis constant (Km),"The Michaelis-Menten equation gave maximum velocity and Michaelis constant (Km) values of 4.92 mumol/min/kg and 109 microM for AS formation, and 2.76 mumol/min/kg and 915 microM for AG formation.",Pharmacokinetic study of the fate of acetaminophen and its conjugates in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6644552/),μM,915,38444,DB00316,Acetaminophen
,26218586,clearance (CL/F),"The average PK estimates for OC were 75 L/hour for clearance (CL/F), 756 L for volume of distribution (V/F), and 0.581 per hour for absorption rate constant (Ka ).",Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),[l] / [h],75,38897,DB00316,Acetaminophen
,26218586,volume of distribution (V/F),"The average PK estimates for OC were 75 L/hour for clearance (CL/F), 756 L for volume of distribution (V/F), and 0.581 per hour for absorption rate constant (Ka ).",Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),l,756,38898,DB00316,Acetaminophen
,26218586,absorption rate constant (Ka ),"The average PK estimates for OC were 75 L/hour for clearance (CL/F), 756 L for volume of distribution (V/F), and 0.581 per hour for absorption rate constant (Ka ).",Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),1/[h],0.581,38899,DB00316,Acetaminophen
,26218586,CL/F,Average estimates for APAP were 25 L/hour for CL/F and 119 L for V/F.,Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),[l] / [h],25,38900,DB00316,Acetaminophen
,26218586,V/F,Average estimates for APAP were 25 L/hour for CL/F and 119 L for V/F.,Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),l,119,38901,DB00316,Acetaminophen
,26218586,CL/F,Sex was identified as a statistically significant source of variability in CL/F with predicted values for APAP of 25 L/hour in men and 21 L/hour in women.,Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),[l] / [h],25,38902,DB00316,Acetaminophen
,26218586,CL/F,Sex was identified as a statistically significant source of variability in CL/F with predicted values for APAP of 25 L/hour in men and 21 L/hour in women.,Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),[l] / [h],21,38903,DB00316,Acetaminophen
,26218586,V/F,"Body weight affected variability in V/F, with a predicted value of 193 L in men and 174 L in women for a 72-kg participant at steady state.",Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),l,193,38904,DB00316,Acetaminophen
,26218586,V/F,"Body weight affected variability in V/F, with a predicted value of 193 L in men and 174 L in women for a 72-kg participant at steady state.",Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),l,174,38905,DB00316,Acetaminophen
,3789044,half-life,The mean half-life of acetaminophen during pregnancy (3.7 hours) was not significantly different from the nonpregnant value (3.1 hours).,Acetaminophen pharmacokinetics: comparison between pregnant and nonpregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3789044/),h,3.7,39111,DB00316,Acetaminophen
,3789044,half-life,The mean half-life of acetaminophen during pregnancy (3.7 hours) was not significantly different from the nonpregnant value (3.1 hours).,Acetaminophen pharmacokinetics: comparison between pregnant and nonpregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3789044/),h,3.1,39112,DB00316,Acetaminophen
,3789044,maximum plasma concentration,The maximum plasma concentration occurred at 0.8 hours and was 20.8 +/- 6.9 micrograms/ml during pregnancy and 23.7 +/- 6.0 micrograms/ml in the nonpregnant state.,Acetaminophen pharmacokinetics: comparison between pregnant and nonpregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3789044/),[μg] / [ml],20.8,39113,DB00316,Acetaminophen
,3789044,maximum plasma concentration,The maximum plasma concentration occurred at 0.8 hours and was 20.8 +/- 6.9 micrograms/ml during pregnancy and 23.7 +/- 6.0 micrograms/ml in the nonpregnant state.,Acetaminophen pharmacokinetics: comparison between pregnant and nonpregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3789044/),[μg] / [ml],23.7,39114,DB00316,Acetaminophen
,25619398,clearance (CL),"The respective mean clearance (CL) values (SDs in parentheses) for these dosed groups were 1.46 (1.00) l h(-1), 1.76 (1.07) l h(-1), 2.93 (2.08) l h(-1) and 2.72 (3.10) l h(-1), t(1/2) values 2.65 h, 2.55 h, 8.36 h and 7.16 h and dose normalized AUC(0-t) (mg l(-1) h) values were 0.90 (0.43), 0.84 (0.57), 0.7 (0.79) and 0.54 (0.26).",Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25619398/),[l] / [h],1.46,39881,DB00316,Acetaminophen
,25619398,clearance (CL),"The respective mean clearance (CL) values (SDs in parentheses) for these dosed groups were 1.46 (1.00) l h(-1), 1.76 (1.07) l h(-1), 2.93 (2.08) l h(-1) and 2.72 (3.10) l h(-1), t(1/2) values 2.65 h, 2.55 h, 8.36 h and 7.16 h and dose normalized AUC(0-t) (mg l(-1) h) values were 0.90 (0.43), 0.84 (0.57), 0.7 (0.79) and 0.54 (0.26).",Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25619398/),[l] / [h],1.76,39882,DB00316,Acetaminophen
,25619398,clearance (CL),"The respective mean clearance (CL) values (SDs in parentheses) for these dosed groups were 1.46 (1.00) l h(-1), 1.76 (1.07) l h(-1), 2.93 (2.08) l h(-1) and 2.72 (3.10) l h(-1), t(1/2) values 2.65 h, 2.55 h, 8.36 h and 7.16 h and dose normalized AUC(0-t) (mg l(-1) h) values were 0.90 (0.43), 0.84 (0.57), 0.7 (0.79) and 0.54 (0.26).",Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25619398/),[l] / [h],2.93,39883,DB00316,Acetaminophen
,25619398,clearance (CL),"The respective mean clearance (CL) values (SDs in parentheses) for these dosed groups were 1.46 (1.00) l h(-1), 1.76 (1.07) l h(-1), 2.93 (2.08) l h(-1) and 2.72 (3.10) l h(-1), t(1/2) values 2.65 h, 2.55 h, 8.36 h and 7.16 h and dose normalized AUC(0-t) (mg l(-1) h) values were 0.90 (0.43), 0.84 (0.57), 0.7 (0.79) and 0.54 (0.26).",Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25619398/),[l] / [h],2.72,39884,DB00316,Acetaminophen
,25619398,t(1/2),"The respective mean clearance (CL) values (SDs in parentheses) for these dosed groups were 1.46 (1.00) l h(-1), 1.76 (1.07) l h(-1), 2.93 (2.08) l h(-1) and 2.72 (3.10) l h(-1), t(1/2) values 2.65 h, 2.55 h, 8.36 h and 7.16 h and dose normalized AUC(0-t) (mg l(-1) h) values were 0.90 (0.43), 0.84 (0.57), 0.7 (0.79) and 0.54 (0.26).",Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25619398/),h,2.65,39885,DB00316,Acetaminophen
,25619398,t(1/2),"The respective mean clearance (CL) values (SDs in parentheses) for these dosed groups were 1.46 (1.00) l h(-1), 1.76 (1.07) l h(-1), 2.93 (2.08) l h(-1) and 2.72 (3.10) l h(-1), t(1/2) values 2.65 h, 2.55 h, 8.36 h and 7.16 h and dose normalized AUC(0-t) (mg l(-1) h) values were 0.90 (0.43), 0.84 (0.57), 0.7 (0.79) and 0.54 (0.26).",Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25619398/),h,2.55,39886,DB00316,Acetaminophen
,25619398,t(1/2),"The respective mean clearance (CL) values (SDs in parentheses) for these dosed groups were 1.46 (1.00) l h(-1), 1.76 (1.07) l h(-1), 2.93 (2.08) l h(-1) and 2.72 (3.10) l h(-1), t(1/2) values 2.65 h, 2.55 h, 8.36 h and 7.16 h and dose normalized AUC(0-t) (mg l(-1) h) values were 0.90 (0.43), 0.84 (0.57), 0.7 (0.79) and 0.54 (0.26).",Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25619398/),h,8.36,39887,DB00316,Acetaminophen
,25619398,t(1/2),"The respective mean clearance (CL) values (SDs in parentheses) for these dosed groups were 1.46 (1.00) l h(-1), 1.76 (1.07) l h(-1), 2.93 (2.08) l h(-1) and 2.72 (3.10) l h(-1), t(1/2) values 2.65 h, 2.55 h, 8.36 h and 7.16 h and dose normalized AUC(0-t) (mg l(-1) h) values were 0.90 (0.43), 0.84 (0.57), 0.7 (0.79) and 0.54 (0.26).",Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25619398/),h,7.16,39888,DB00316,Acetaminophen
,25619398,dose normalized AUC(0-t),"The respective mean clearance (CL) values (SDs in parentheses) for these dosed groups were 1.46 (1.00) l h(-1), 1.76 (1.07) l h(-1), 2.93 (2.08) l h(-1) and 2.72 (3.10) l h(-1), t(1/2) values 2.65 h, 2.55 h, 8.36 h and 7.16 h and dose normalized AUC(0-t) (mg l(-1) h) values were 0.90 (0.43), 0.84 (0.57), 0.7 (0.79) and 0.54 (0.26).",Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25619398/),[h·mg] / [l],0.90,39889,DB00316,Acetaminophen
,25619398,dose normalized AUC(0-t),"The respective mean clearance (CL) values (SDs in parentheses) for these dosed groups were 1.46 (1.00) l h(-1), 1.76 (1.07) l h(-1), 2.93 (2.08) l h(-1) and 2.72 (3.10) l h(-1), t(1/2) values 2.65 h, 2.55 h, 8.36 h and 7.16 h and dose normalized AUC(0-t) (mg l(-1) h) values were 0.90 (0.43), 0.84 (0.57), 0.7 (0.79) and 0.54 (0.26).",Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25619398/),[h·mg] / [l],0.84,39890,DB00316,Acetaminophen
,25619398,dose normalized AUC(0-t),"The respective mean clearance (CL) values (SDs in parentheses) for these dosed groups were 1.46 (1.00) l h(-1), 1.76 (1.07) l h(-1), 2.93 (2.08) l h(-1) and 2.72 (3.10) l h(-1), t(1/2) values 2.65 h, 2.55 h, 8.36 h and 7.16 h and dose normalized AUC(0-t) (mg l(-1) h) values were 0.90 (0.43), 0.84 (0.57), 0.7 (0.79) and 0.54 (0.26).",Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25619398/),[h·mg] / [l],0.7,39891,DB00316,Acetaminophen
,25619398,dose normalized AUC(0-t),"The respective mean clearance (CL) values (SDs in parentheses) for these dosed groups were 1.46 (1.00) l h(-1), 1.76 (1.07) l h(-1), 2.93 (2.08) l h(-1) and 2.72 (3.10) l h(-1), t(1/2) values 2.65 h, 2.55 h, 8.36 h and 7.16 h and dose normalized AUC(0-t) (mg l(-1) h) values were 0.90 (0.43), 0.84 (0.57), 0.7 (0.79) and 0.54 (0.26).",Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25619398/),[h·mg] / [l],0.54,39892,DB00316,Acetaminophen
,26898420,LogPow,"In this study, we developed nano-fiber-based tablets with acetaminophen (AAP; LogPow=0.51) for controlled-release delivery systems and evaluated in vitro drug dissolution and in vivo pharmacokinetics in rats.",Preparation and pharmaceutical evaluation of acetaminophen nano-fiber tablets: Application of a solvent-based electrospinning method for tableting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26898420/),,0.,40941,DB00316,Acetaminophen
,17339870,peak plasma concentration (C(max)),"Following the first 15-min i.v. administration of paracetamol 2 g, plasma concentrations ranged from 67.9+/-21.8 mug/ml (peak plasma concentration (C(max)) at the end of infusion) to 6.2+/-2.3 mug/ml (trough plasma concentration (C(min)) measured just before the next infusion) without any C(max) in the toxic range for any subject.",Safety and pharmacokinetics of paracetamol following intravenous administration of 5 g during the first 24 h with a 2-g starting dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339870/),[μg] / [ml],67.9,41255,DB00316,Acetaminophen
,17339870,trough plasma concentration (C(min)),"Following the first 15-min i.v. administration of paracetamol 2 g, plasma concentrations ranged from 67.9+/-21.8 mug/ml (peak plasma concentration (C(max)) at the end of infusion) to 6.2+/-2.3 mug/ml (trough plasma concentration (C(min)) measured just before the next infusion) without any C(max) in the toxic range for any subject.",Safety and pharmacokinetics of paracetamol following intravenous administration of 5 g during the first 24 h with a 2-g starting dose. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339870/),[μg] / [ml],6.2,41256,DB00316,Acetaminophen
,19014836,Serum t((1/2)),Serum t((1/2)) ranged from 12 to 19 days.,"Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19014836/),d,12 to 19,41795,DB00316,Acetaminophen
,19014836,t((1/2)),The mean t((1/2)) ranged from 12 to 19 days.,"Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19014836/),d,12 to 19,41796,DB00316,Acetaminophen
,7975718,total clearance (ClT),"2. At a dose of 50 mg/kg, neither total clearance (ClT) (controls, 20.3 +/- 0.5; MI, 19.9 +/- 0.9, ml/min/kg; mean +/- SD, p > 0.05) nor the renal clearance of P (ClR) were affected by MI.",Effect of malaria infection on the pharmacokinetics of paracetamol in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975718/),[ml] / [kg·min],20.3,41835,DB00316,Acetaminophen
,7975718,total clearance (ClT),"2. At a dose of 50 mg/kg, neither total clearance (ClT) (controls, 20.3 +/- 0.5; MI, 19.9 +/- 0.9, ml/min/kg; mean +/- SD, p > 0.05) nor the renal clearance of P (ClR) were affected by MI.",Effect of malaria infection on the pharmacokinetics of paracetamol in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975718/),[ml] / [kg·min],19.9,41836,DB00316,Acetaminophen
,7975718,formation clearance of,"Although the formation clearance of PG (Clf PG) was decreased by about 40% (controls, 6.6 +/- 1.1; MI, 3.9 +/- 0.9, ml/min/kg, p < 0.05), the formation clearance of PS (Clf PS) was increased by 30% in the MI rat (controls, 8.8 +/- 0.9; MI, 11.2 +/- 1.7, ml/min/kg, p < 0.05), and therefore Clm (controls, 19.7 +/- 0.5; MI, 19.2 +/- 0.8, ml/min/kg, p > 0.05) was unchanged by MI.",Effect of malaria infection on the pharmacokinetics of paracetamol in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975718/),[ml] / [kg·min],6.6,41837,DB00316,Acetaminophen
,7975718,formation clearance of,"Although the formation clearance of PG (Clf PG) was decreased by about 40% (controls, 6.6 +/- 1.1; MI, 3.9 +/- 0.9, ml/min/kg, p < 0.05), the formation clearance of PS (Clf PS) was increased by 30% in the MI rat (controls, 8.8 +/- 0.9; MI, 11.2 +/- 1.7, ml/min/kg, p < 0.05), and therefore Clm (controls, 19.7 +/- 0.5; MI, 19.2 +/- 0.8, ml/min/kg, p > 0.05) was unchanged by MI.",Effect of malaria infection on the pharmacokinetics of paracetamol in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975718/),[ml] / [kg·min],3.9,41838,DB00316,Acetaminophen
,7975718,formation clearance of,"Although the formation clearance of PG (Clf PG) was decreased by about 40% (controls, 6.6 +/- 1.1; MI, 3.9 +/- 0.9, ml/min/kg, p < 0.05), the formation clearance of PS (Clf PS) was increased by 30% in the MI rat (controls, 8.8 +/- 0.9; MI, 11.2 +/- 1.7, ml/min/kg, p < 0.05), and therefore Clm (controls, 19.7 +/- 0.5; MI, 19.2 +/- 0.8, ml/min/kg, p > 0.05) was unchanged by MI.",Effect of malaria infection on the pharmacokinetics of paracetamol in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975718/),[ml] / [kg·min],8.8,41839,DB00316,Acetaminophen
,7975718,formation clearance of,"Although the formation clearance of PG (Clf PG) was decreased by about 40% (controls, 6.6 +/- 1.1; MI, 3.9 +/- 0.9, ml/min/kg, p < 0.05), the formation clearance of PS (Clf PS) was increased by 30% in the MI rat (controls, 8.8 +/- 0.9; MI, 11.2 +/- 1.7, ml/min/kg, p < 0.05), and therefore Clm (controls, 19.7 +/- 0.5; MI, 19.2 +/- 0.8, ml/min/kg, p > 0.05) was unchanged by MI.",Effect of malaria infection on the pharmacokinetics of paracetamol in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975718/),[ml] / [kg·min],11.2,41840,DB00316,Acetaminophen
,7975718,Clm,"Although the formation clearance of PG (Clf PG) was decreased by about 40% (controls, 6.6 +/- 1.1; MI, 3.9 +/- 0.9, ml/min/kg, p < 0.05), the formation clearance of PS (Clf PS) was increased by 30% in the MI rat (controls, 8.8 +/- 0.9; MI, 11.2 +/- 1.7, ml/min/kg, p < 0.05), and therefore Clm (controls, 19.7 +/- 0.5; MI, 19.2 +/- 0.8, ml/min/kg, p > 0.05) was unchanged by MI.",Effect of malaria infection on the pharmacokinetics of paracetamol in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975718/),[ml] / [kg·min],19.7,41841,DB00316,Acetaminophen
,7975718,Clm,"Although the formation clearance of PG (Clf PG) was decreased by about 40% (controls, 6.6 +/- 1.1; MI, 3.9 +/- 0.9, ml/min/kg, p < 0.05), the formation clearance of PS (Clf PS) was increased by 30% in the MI rat (controls, 8.8 +/- 0.9; MI, 11.2 +/- 1.7, ml/min/kg, p < 0.05), and therefore Clm (controls, 19.7 +/- 0.5; MI, 19.2 +/- 0.8, ml/min/kg, p > 0.05) was unchanged by MI.",Effect of malaria infection on the pharmacokinetics of paracetamol in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975718/),[ml] / [kg·min],19.2,41842,DB00316,Acetaminophen
,7975718,total clearance of P (ClT),"3. At a dose of 300 mg/kg, MI produced a significant decrease in the total clearance of P (ClT) (controls, 16.9 +/- 1.0; MI, 11.9 +/- 0.9, ml/min/kg, p < 0.05), metabolic clearance (Clm) (controls, 15.9 +/- 1.4; MI, 11.3 +/- 0.9, ml/min/kg, p < 0.05) and the formation clearance of PG (Clf PG) (controls, 7.9 +/- 1.3; MI, 4.7 +/- 1.5, ml/min/kg, p < 0.05) without affecting Clf PS and ClR of P. 4.",Effect of malaria infection on the pharmacokinetics of paracetamol in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975718/),[ml] / [kg·min],16.9,41843,DB00316,Acetaminophen
,7975718,total clearance of P (ClT),"3. At a dose of 300 mg/kg, MI produced a significant decrease in the total clearance of P (ClT) (controls, 16.9 +/- 1.0; MI, 11.9 +/- 0.9, ml/min/kg, p < 0.05), metabolic clearance (Clm) (controls, 15.9 +/- 1.4; MI, 11.3 +/- 0.9, ml/min/kg, p < 0.05) and the formation clearance of PG (Clf PG) (controls, 7.9 +/- 1.3; MI, 4.7 +/- 1.5, ml/min/kg, p < 0.05) without affecting Clf PS and ClR of P. 4.",Effect of malaria infection on the pharmacokinetics of paracetamol in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975718/),[ml] / [kg·min],11.9,41844,DB00316,Acetaminophen
,7975718,metabolic clearance (Clm),"3. At a dose of 300 mg/kg, MI produced a significant decrease in the total clearance of P (ClT) (controls, 16.9 +/- 1.0; MI, 11.9 +/- 0.9, ml/min/kg, p < 0.05), metabolic clearance (Clm) (controls, 15.9 +/- 1.4; MI, 11.3 +/- 0.9, ml/min/kg, p < 0.05) and the formation clearance of PG (Clf PG) (controls, 7.9 +/- 1.3; MI, 4.7 +/- 1.5, ml/min/kg, p < 0.05) without affecting Clf PS and ClR of P. 4.",Effect of malaria infection on the pharmacokinetics of paracetamol in rat. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975718/),[ml] / [kg·min],15.9,41845,DB00316,Acetaminophen
,7975718,metabolic clearance (Clm),"3. At a dose of 300 mg/kg, MI produced a significant decrease in the total clearance of P (ClT) (controls, 16.9 +/- 1.0; MI, 11.9 +/- 0.9, ml/min/kg, p < 0.05), metabolic clearance (Clm) (controls, 15.9 +/- 1.4; MI, 11.3 +/- 0.9, ml/min/kg, p < 0.05) and the formation clearance of PG (Clf PG) (controls, 7.9 +/- 1.3; MI, 4.7 +/- 1.5, ml/min/kg, p < 0.05) without affecting Clf PS and ClR of P. 4.",Effect of malaria infection on the pharmacokinetics of paracetamol in rat. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975718/),[ml] / [kg·min],11.3,41846,DB00316,Acetaminophen
,7975718,formation clearance of,"3. At a dose of 300 mg/kg, MI produced a significant decrease in the total clearance of P (ClT) (controls, 16.9 +/- 1.0; MI, 11.9 +/- 0.9, ml/min/kg, p < 0.05), metabolic clearance (Clm) (controls, 15.9 +/- 1.4; MI, 11.3 +/- 0.9, ml/min/kg, p < 0.05) and the formation clearance of PG (Clf PG) (controls, 7.9 +/- 1.3; MI, 4.7 +/- 1.5, ml/min/kg, p < 0.05) without affecting Clf PS and ClR of P. 4.",Effect of malaria infection on the pharmacokinetics of paracetamol in rat. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975718/),[ml] / [kg·min],7.9,41847,DB00316,Acetaminophen
,7975718,formation clearance of,"3. At a dose of 300 mg/kg, MI produced a significant decrease in the total clearance of P (ClT) (controls, 16.9 +/- 1.0; MI, 11.9 +/- 0.9, ml/min/kg, p < 0.05), metabolic clearance (Clm) (controls, 15.9 +/- 1.4; MI, 11.3 +/- 0.9, ml/min/kg, p < 0.05) and the formation clearance of PG (Clf PG) (controls, 7.9 +/- 1.3; MI, 4.7 +/- 1.5, ml/min/kg, p < 0.05) without affecting Clf PS and ClR of P. 4.",Effect of malaria infection on the pharmacokinetics of paracetamol in rat. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975718/),[ml] / [kg·min],4.7,41848,DB00316,Acetaminophen
,2404503,time to 90% emptying,3. In the presence of levodopa the time to 90% emptying was prolonged from 32 +/- 24 min to 81 +/- 20 min (P less than 0.01).,The influence of levodopa on gastric emptying in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2404503/),min,32,42414,DB00316,Acetaminophen
,2404503,time to 90% emptying,3. In the presence of levodopa the time to 90% emptying was prolonged from 32 +/- 24 min to 81 +/- 20 min (P less than 0.01).,The influence of levodopa on gastric emptying in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2404503/),min,81,42415,DB00316,Acetaminophen
,9114910,Cmax,"2. The absorption rate of paracetamol was significantly impaired in the vegetarians compared with the non-vegetarians as shown by a lower mean Cmax (11.7 +/- 1.4 vs 15.6 +/- 1.6 mg l-1; 95% confidence interval of the difference 2.49 to 5.36), increased tmax (median 1.75, range 0.75 to 3 h compared with 0.75 and 0.25 to 2 h) and an increase in the time for input of 50% of the total amount absorbed (0.54 +/- 0.38 compared with 0.20 +/- 0.10 h; 95% confidence interval of the difference 0.063 to 0.61).",Impaired absorption of paracetamol in vegetarians. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114910/),[mg] / [l],11.7,43027,DB00316,Acetaminophen
,9114910,Cmax,"2. The absorption rate of paracetamol was significantly impaired in the vegetarians compared with the non-vegetarians as shown by a lower mean Cmax (11.7 +/- 1.4 vs 15.6 +/- 1.6 mg l-1; 95% confidence interval of the difference 2.49 to 5.36), increased tmax (median 1.75, range 0.75 to 3 h compared with 0.75 and 0.25 to 2 h) and an increase in the time for input of 50% of the total amount absorbed (0.54 +/- 0.38 compared with 0.20 +/- 0.10 h; 95% confidence interval of the difference 0.063 to 0.61).",Impaired absorption of paracetamol in vegetarians. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114910/),[mg] / [l],15.6,43028,DB00316,Acetaminophen
,9114910,tmax,"2. The absorption rate of paracetamol was significantly impaired in the vegetarians compared with the non-vegetarians as shown by a lower mean Cmax (11.7 +/- 1.4 vs 15.6 +/- 1.6 mg l-1; 95% confidence interval of the difference 2.49 to 5.36), increased tmax (median 1.75, range 0.75 to 3 h compared with 0.75 and 0.25 to 2 h) and an increase in the time for input of 50% of the total amount absorbed (0.54 +/- 0.38 compared with 0.20 +/- 0.10 h; 95% confidence interval of the difference 0.063 to 0.61).",Impaired absorption of paracetamol in vegetarians. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114910/),h,1.75,43029,DB00316,Acetaminophen
,9114910,tmax,"2. The absorption rate of paracetamol was significantly impaired in the vegetarians compared with the non-vegetarians as shown by a lower mean Cmax (11.7 +/- 1.4 vs 15.6 +/- 1.6 mg l-1; 95% confidence interval of the difference 2.49 to 5.36), increased tmax (median 1.75, range 0.75 to 3 h compared with 0.75 and 0.25 to 2 h) and an increase in the time for input of 50% of the total amount absorbed (0.54 +/- 0.38 compared with 0.20 +/- 0.10 h; 95% confidence interval of the difference 0.063 to 0.61).",Impaired absorption of paracetamol in vegetarians. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114910/),h,0.75,43030,DB00316,Acetaminophen
,9114910,tmax,"2. The absorption rate of paracetamol was significantly impaired in the vegetarians compared with the non-vegetarians as shown by a lower mean Cmax (11.7 +/- 1.4 vs 15.6 +/- 1.6 mg l-1; 95% confidence interval of the difference 2.49 to 5.36), increased tmax (median 1.75, range 0.75 to 3 h compared with 0.75 and 0.25 to 2 h) and an increase in the time for input of 50% of the total amount absorbed (0.54 +/- 0.38 compared with 0.20 +/- 0.10 h; 95% confidence interval of the difference 0.063 to 0.61).",Impaired absorption of paracetamol in vegetarians. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114910/),h,0.25 to 2,43031,DB00316,Acetaminophen
,9114910,time for input,"2. The absorption rate of paracetamol was significantly impaired in the vegetarians compared with the non-vegetarians as shown by a lower mean Cmax (11.7 +/- 1.4 vs 15.6 +/- 1.6 mg l-1; 95% confidence interval of the difference 2.49 to 5.36), increased tmax (median 1.75, range 0.75 to 3 h compared with 0.75 and 0.25 to 2 h) and an increase in the time for input of 50% of the total amount absorbed (0.54 +/- 0.38 compared with 0.20 +/- 0.10 h; 95% confidence interval of the difference 0.063 to 0.61).",Impaired absorption of paracetamol in vegetarians. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114910/),h,0.54,43032,DB00316,Acetaminophen
,9114910,time for input,"2. The absorption rate of paracetamol was significantly impaired in the vegetarians compared with the non-vegetarians as shown by a lower mean Cmax (11.7 +/- 1.4 vs 15.6 +/- 1.6 mg l-1; 95% confidence interval of the difference 2.49 to 5.36), increased tmax (median 1.75, range 0.75 to 3 h compared with 0.75 and 0.25 to 2 h) and an increase in the time for input of 50% of the total amount absorbed (0.54 +/- 0.38 compared with 0.20 +/- 0.10 h; 95% confidence interval of the difference 0.063 to 0.61).",Impaired absorption of paracetamol in vegetarians. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114910/),h,0.20,43033,DB00316,Acetaminophen
,25391549,C(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[ng] / [ml],49.2,44070,DB00316,Acetaminophen
,25391549,C(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[ng] / [ml],32.6,44071,DB00316,Acetaminophen
,25391549,C(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[ng] / [ml],28.4,44072,DB00316,Acetaminophen
,25391549,C(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[ng] / [ml],37.3,44073,DB00316,Acetaminophen
,25391549,t(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),h,5.9,44074,DB00316,Acetaminophen
,25391549,t(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),h,8.0,44075,DB00316,Acetaminophen
,25391549,t(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),h,1.0,44076,DB00316,Acetaminophen
,25391549,AUC(0-∞),"Total systemic exposure to hydrocodone (AUC(0-∞)) was comparable between hydrocodone ER tablet prototypes (640, 600, and 578 ng·h/mL, respectively) and hydrocodone IR/APAP (581 ng·h/mL).",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[h·ng] / [ml],640,44077,DB00316,Acetaminophen
,25391549,AUC(0-∞),"Total systemic exposure to hydrocodone (AUC(0-∞)) was comparable between hydrocodone ER tablet prototypes (640, 600, and 578 ng·h/mL, respectively) and hydrocodone IR/APAP (581 ng·h/mL).",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[h·ng] / [ml],600,44078,DB00316,Acetaminophen
,25391549,AUC(0-∞),"Total systemic exposure to hydrocodone (AUC(0-∞)) was comparable between hydrocodone ER tablet prototypes (640, 600, and 578 ng·h/mL, respectively) and hydrocodone IR/APAP (581 ng·h/mL).",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[h·ng] / [ml],578,44079,DB00316,Acetaminophen
,25391549,AUC(0-∞),"Total systemic exposure to hydrocodone (AUC(0-∞)) was comparable between hydrocodone ER tablet prototypes (640, 600, and 578 ng·h/mL, respectively) and hydrocodone IR/APAP (581 ng·h/mL).",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[h·ng] / [ml],581,44080,DB00316,Acetaminophen
,24676873,maximum plasma concentration,"The maximum plasma concentration of paracetamol glucuronide tended to be higher in group PC 213.27 μg/mL (90 % CI 1.06, 1.25; p = 0.0267).",The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24676873/),[μg] / [ml],213.27,44107,DB00316,Acetaminophen
,24676873,t max,"The mean t max of paracetamol glucuronide was similar in both groups: SUN + PC and group PC (15 and 20 min, respectively).",The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24676873/),min,15,44108,DB00316,Acetaminophen
,24676873,t max,"The mean t max of paracetamol glucuronide was similar in both groups: SUN + PC and group PC (15 and 20 min, respectively).",The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24676873/),min,20,44109,DB00316,Acetaminophen
,24676873,t max,"The mean t max of sunitinib was different in groups SUN + PC and SUN (10.0 and 7.0, respectively; p = 0.0134).",The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24676873/),,10.0,44110,DB00316,Acetaminophen
,24676873,t max,"The mean t max of sunitinib was different in groups SUN + PC and SUN (10.0 and 7.0, respectively; p = 0.0134).",The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24676873/),,7.0,44111,DB00316,Acetaminophen
,4009442,lag times,The lag times ranged from 2.5 to 23 min for preparation I and from 2.2 to 29 min for preparation II.,Impact of dilution on the pharmacokinetic behavior of acetaminophen in rabbits after oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009442/),min,2.5 to 23,44114,DB00316,Acetaminophen
,4009442,lag times,The lag times ranged from 2.5 to 23 min for preparation I and from 2.2 to 29 min for preparation II.,Impact of dilution on the pharmacokinetic behavior of acetaminophen in rabbits after oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009442/),min,2.2 to 29,44115,DB00316,Acetaminophen
,4009442,peak plasma concentrations,The mean peak plasma concentrations (12.38 micrograms/mL for preparation I and 9.14 micrograms/mL for preparation II) and the mean time-to-peak concentrations (26.57 min for preparation I and 36.57 min for preparation II) were significantly different.,Impact of dilution on the pharmacokinetic behavior of acetaminophen in rabbits after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009442/),[μg] / [ml],12.38,44116,DB00316,Acetaminophen
,4009442,peak plasma concentrations,The mean peak plasma concentrations (12.38 micrograms/mL for preparation I and 9.14 micrograms/mL for preparation II) and the mean time-to-peak concentrations (26.57 min for preparation I and 36.57 min for preparation II) were significantly different.,Impact of dilution on the pharmacokinetic behavior of acetaminophen in rabbits after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009442/),[μg] / [ml],9.14,44117,DB00316,Acetaminophen
,4009442,time-to-peak concentrations,The mean peak plasma concentrations (12.38 micrograms/mL for preparation I and 9.14 micrograms/mL for preparation II) and the mean time-to-peak concentrations (26.57 min for preparation I and 36.57 min for preparation II) were significantly different.,Impact of dilution on the pharmacokinetic behavior of acetaminophen in rabbits after oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009442/),min,26.57,44118,DB00316,Acetaminophen
,4009442,time-to-peak concentrations,The mean peak plasma concentrations (12.38 micrograms/mL for preparation I and 9.14 micrograms/mL for preparation II) and the mean time-to-peak concentrations (26.57 min for preparation I and 36.57 min for preparation II) were significantly different.,Impact of dilution on the pharmacokinetic behavior of acetaminophen in rabbits after oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009442/),min,36.57,44119,DB00316,Acetaminophen
,284720,biological half-life,"The average biological half-life after oral administration of 1 g paracetamol was significantly prolonged in patients with hepatic cirrhosis compared to the controls (3.7 hr vs.2.1 hr) and, correspondingly, the average plasma clearance was significantly reduced from 337 ml x min-1 in the controls to 162 ml x min-1 in the patients with cirrhosis of the liver.",Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/284720/),h,3.7,44120,DB00316,Acetaminophen
,284720,biological half-life,"The average biological half-life after oral administration of 1 g paracetamol was significantly prolonged in patients with hepatic cirrhosis compared to the controls (3.7 hr vs.2.1 hr) and, correspondingly, the average plasma clearance was significantly reduced from 337 ml x min-1 in the controls to 162 ml x min-1 in the patients with cirrhosis of the liver.",Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/284720/),h,2.1,44121,DB00316,Acetaminophen
,284720,plasma clearance,"The average biological half-life after oral administration of 1 g paracetamol was significantly prolonged in patients with hepatic cirrhosis compared to the controls (3.7 hr vs.2.1 hr) and, correspondingly, the average plasma clearance was significantly reduced from 337 ml x min-1 in the controls to 162 ml x min-1 in the patients with cirrhosis of the liver.",Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/284720/),[ml] / [min],337,44122,DB00316,Acetaminophen
,284720,plasma clearance,"The average biological half-life after oral administration of 1 g paracetamol was significantly prolonged in patients with hepatic cirrhosis compared to the controls (3.7 hr vs.2.1 hr) and, correspondingly, the average plasma clearance was significantly reduced from 337 ml x min-1 in the controls to 162 ml x min-1 in the patients with cirrhosis of the liver.",Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/284720/),[ml] / [min],162,44123,DB00316,Acetaminophen
,23217302,flow rate,Methanol and water was used as the mobile phase with a gradient elution at a flow rate of 1mL/min.,Development and validation of a LC-MS/MS method for the quantification of the regioisomers of dihydroxybutylether in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23217302/),[ml] / [min],1,44958,DB00316,Acetaminophen
,8618248,area under the curves,"The area under the curves for extended relief acetaminophen and regular release acetaminophen were 426 mg h/L and 432 mg h/L, respectively (p = 0.768).",Pharmacokinetics of extended relief vs regular release Tylenol in simulated human overdose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8618248/),[h·mg] / [l],426,46010,DB00316,Acetaminophen
,8618248,area under the curves,"The area under the curves for extended relief acetaminophen and regular release acetaminophen were 426 mg h/L and 432 mg h/L, respectively (p = 0.768).",Pharmacokinetics of extended relief vs regular release Tylenol in simulated human overdose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8618248/),[h·mg] / [l],432,46011,DB00316,Acetaminophen
,8618248,half times,"The mean half times for extended relief acetaminophen and regular release acetaminophen were 4.02 h and 2.56 h, respectively (p < 0.001).",Pharmacokinetics of extended relief vs regular release Tylenol in simulated human overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8618248/),h,4.02,46012,DB00316,Acetaminophen
,8618248,half times,"The mean half times for extended relief acetaminophen and regular release acetaminophen were 4.02 h and 2.56 h, respectively (p < 0.001).",Pharmacokinetics of extended relief vs regular release Tylenol in simulated human overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8618248/),h,2.56,46013,DB00316,Acetaminophen
,8618248,maximum serum acetaminophen concentrations,"The mean maximum serum acetaminophen concentrations were 62.6 mg/L (414.4 mmol/L:) and 94.3 mg/L (624.3 mmol/L) for extended relief acetaminophen and regular release acetaminophen, respectively (p < 0.001) and the mean time to maximum serum acetaminophen concentrations were 0.87 h and 0.75 h for extended relief acetaminophen and regular release acetaminophen, respectively (p = 0.508).",Pharmacokinetics of extended relief vs regular release Tylenol in simulated human overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8618248/),[mg] / [l],62.6,46014,DB00316,Acetaminophen
,8618248,maximum serum acetaminophen concentrations,"The mean maximum serum acetaminophen concentrations were 62.6 mg/L (414.4 mmol/L:) and 94.3 mg/L (624.3 mmol/L) for extended relief acetaminophen and regular release acetaminophen, respectively (p < 0.001) and the mean time to maximum serum acetaminophen concentrations were 0.87 h and 0.75 h for extended relief acetaminophen and regular release acetaminophen, respectively (p = 0.508).",Pharmacokinetics of extended relief vs regular release Tylenol in simulated human overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8618248/),[mg] / [l],94.3,46015,DB00316,Acetaminophen
,8618248,time to maximum serum acetaminophen concentrations,"The mean maximum serum acetaminophen concentrations were 62.6 mg/L (414.4 mmol/L:) and 94.3 mg/L (624.3 mmol/L) for extended relief acetaminophen and regular release acetaminophen, respectively (p < 0.001) and the mean time to maximum serum acetaminophen concentrations were 0.87 h and 0.75 h for extended relief acetaminophen and regular release acetaminophen, respectively (p = 0.508).",Pharmacokinetics of extended relief vs regular release Tylenol in simulated human overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8618248/),h,0.87,46016,DB00316,Acetaminophen
,8618248,time to maximum serum acetaminophen concentrations,"The mean maximum serum acetaminophen concentrations were 62.6 mg/L (414.4 mmol/L:) and 94.3 mg/L (624.3 mmol/L) for extended relief acetaminophen and regular release acetaminophen, respectively (p < 0.001) and the mean time to maximum serum acetaminophen concentrations were 0.87 h and 0.75 h for extended relief acetaminophen and regular release acetaminophen, respectively (p = 0.508).",Pharmacokinetics of extended relief vs regular release Tylenol in simulated human overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8618248/),h,0.75,46017,DB00316,Acetaminophen
,8824692,concentrations,"Saliva paracetamol concentrations at 1, 2 and 3 h after ingestion in the haemodialysis group during haemodialysis were 31.5 +/- 20.1, 14.1 +/- 10.4 and 7.3 +/- 3.8 micrograms ml-1 respectively, significantly (P < 0.05; paired t-test) higher than the corresponding plasma paracetamol concentrations which were 11.0 +/- 2.8, 6.5 +/- 2.8 and 3.2 +/- 0.9 micrograms ml-1 respectively.",Paracetamol and its metabolites in saliva and plasma in chronic dialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824692/),,14,46521,DB00316,Acetaminophen
,16260165,total excretion,The oxidation of the galactosemics was slow with a broad peak of 13CO2 at 10 h and a total excretion of 25-39% of the [13C]galactose administered.,Pathways of galactose metabolism by galactosemics: evidence for galactose conversion to hepatic UDPglucose. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16260165/),%,25-39,46644,DB00316,Acetaminophen
,1936060,plasma elimination half-life,A plasma elimination half-life of 23 +/- 2.3 h was calculated.,Chlormezanone plasma and blood levels in patients after single and repeated oral doses and after suicidal drug overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936060/),h,23,47993,DB00316,Acetaminophen
,1936060,peak chlormezanone plasma level,"The mean peak chlormezanone plasma level was 1.86 +/- 0.2 micrograms/ml, 1 h after ingestion.",Chlormezanone plasma and blood levels in patients after single and repeated oral doses and after suicidal drug overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936060/),[μg] / [ml],1.86,47994,DB00316,Acetaminophen
,1936060,plasma levels,"After 5 days of repeated daily doses of 3 x 200 mg (group 2; 12 patients) or 3 x 400 mg (group 3; 10 patients) of chlormezanone, mean predose chlormezanone plasma levels were 12.0 +/- 2.0 micrograms/ml (group 2) and 22.7 +/- 4.0 micrograms/ml (group 3), respectively.",Chlormezanone plasma and blood levels in patients after single and repeated oral doses and after suicidal drug overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936060/),μ,12.0,47995,DB00316,Acetaminophen
,1936060,plasma levels,"After 5 days of repeated daily doses of 3 x 200 mg (group 2; 12 patients) or 3 x 400 mg (group 3; 10 patients) of chlormezanone, mean predose chlormezanone plasma levels were 12.0 +/- 2.0 micrograms/ml (group 2) and 22.7 +/- 4.0 micrograms/ml (group 3), respectively.",Chlormezanone plasma and blood levels in patients after single and repeated oral doses and after suicidal drug overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936060/),[μg] / [ml],22.7,47996,DB00316,Acetaminophen
,978441,apparent biological half-life,The apparent biological half-life of acetaminophen increased from 2.3 +/- 0.2 (mean +/- SD) to 3.1 +/- 0.5 hr.,Drug biotransformation interactions in man VI: acetaminophen and ascorbic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/978441/),h,2.3,48404,DB00316,Acetaminophen
,978441,apparent biological half-life,The apparent biological half-life of acetaminophen increased from 2.3 +/- 0.2 (mean +/- SD) to 3.1 +/- 0.5 hr.,Drug biotransformation interactions in man VI: acetaminophen and ascorbic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/978441/),h,3.1,48405,DB00316,Acetaminophen
,29667449,Tlag,"Ibuprofen was absorbed more rapidly from the salt formulations than the reference; Tlag was 3.3-6.4 min for salt formulations compared with 10.9 min for the reference, and 100% of subjects had a Tlag ≤ 5 min for ibuprofen lysine, compared with 61% for ibuprofen liquid capsule, 21% for ibuprofen sodium, and 7% for the reference.","Predicting rapid analgesic onset of ibuprofen salts compared with ibuprofen acid: Tlag, Tlow, Tmed, and a novel parameter, TCmaxRef. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29667449/),min,3.3-6.4,48526,DB00316,Acetaminophen
,29667449,Tlag,"Ibuprofen was absorbed more rapidly from the salt formulations than the reference; Tlag was 3.3-6.4 min for salt formulations compared with 10.9 min for the reference, and 100% of subjects had a Tlag ≤ 5 min for ibuprofen lysine, compared with 61% for ibuprofen liquid capsule, 21% for ibuprofen sodium, and 7% for the reference.","Predicting rapid analgesic onset of ibuprofen salts compared with ibuprofen acid: Tlag, Tlow, Tmed, and a novel parameter, TCmaxRef. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29667449/),min,10.9,48527,DB00316,Acetaminophen
≤,29667449,Tlag,"Ibuprofen was absorbed more rapidly from the salt formulations than the reference; Tlag was 3.3-6.4 min for salt formulations compared with 10.9 min for the reference, and 100% of subjects had a Tlag ≤ 5 min for ibuprofen lysine, compared with 61% for ibuprofen liquid capsule, 21% for ibuprofen sodium, and 7% for the reference.","Predicting rapid analgesic onset of ibuprofen salts compared with ibuprofen acid: Tlag, Tlow, Tmed, and a novel parameter, TCmaxRef. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29667449/),min,5,48528,DB00316,Acetaminophen
,29667449,Tlag,"Ibuprofen was absorbed more rapidly from the salt formulations than the reference; Tlag was 3.3-6.4 min for salt formulations compared with 10.9 min for the reference, and 100% of subjects had a Tlag ≤ 5 min for ibuprofen lysine, compared with 61% for ibuprofen liquid capsule, 21% for ibuprofen sodium, and 7% for the reference.","Predicting rapid analgesic onset of ibuprofen salts compared with ibuprofen acid: Tlag, Tlow, Tmed, and a novel parameter, TCmaxRef. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29667449/),%,61,48529,DB00316,Acetaminophen
,29667449,Tlag,"Ibuprofen was absorbed more rapidly from the salt formulations than the reference; Tlag was 3.3-6.4 min for salt formulations compared with 10.9 min for the reference, and 100% of subjects had a Tlag ≤ 5 min for ibuprofen lysine, compared with 61% for ibuprofen liquid capsule, 21% for ibuprofen sodium, and 7% for the reference.","Predicting rapid analgesic onset of ibuprofen salts compared with ibuprofen acid: Tlag, Tlow, Tmed, and a novel parameter, TCmaxRef. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29667449/),%,21,48530,DB00316,Acetaminophen
,29667449,Tlag,"Ibuprofen was absorbed more rapidly from the salt formulations than the reference; Tlag was 3.3-6.4 min for salt formulations compared with 10.9 min for the reference, and 100% of subjects had a Tlag ≤ 5 min for ibuprofen lysine, compared with 61% for ibuprofen liquid capsule, 21% for ibuprofen sodium, and 7% for the reference.","Predicting rapid analgesic onset of ibuprofen salts compared with ibuprofen acid: Tlag, Tlow, Tmed, and a novel parameter, TCmaxRef. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29667449/),%,7,48531,DB00316,Acetaminophen
,31564501,maximum blood concentration,"The maximum blood concentration were 0.153 mmol L-1 and 0.0243 mmol L-1, respectively for paracetamol and ketoprofen.",A new gastro-intestinal mathematical model to study drug bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31564501/),[mM] / [l],0.153,48681,DB00316,Acetaminophen
,31564501,maximum blood concentration,"The maximum blood concentration were 0.153 mmol L-1 and 0.0243 mmol L-1, respectively for paracetamol and ketoprofen.",A new gastro-intestinal mathematical model to study drug bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31564501/),[mM] / [l],0.0243,48682,DB00316,Acetaminophen
,31564501,time to reach the maximum concentration,The time to reach the maximum concentration for the paracetamol and ketoprofen was around 55 min.,A new gastro-intestinal mathematical model to study drug bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31564501/),min,55,48683,DB00316,Acetaminophen
,31564501,maximum concentration,"In case of contemporary meal digestion, the maximum concentration of paracetamol in the blood was 0.100 mmol L-1 and 0.0135 mmol L-1 for ketoprofen; the time to reach the maximum concentration was 3 h and 45 min for paracetamol and 3 h and 35 min for ketoprofen.",A new gastro-intestinal mathematical model to study drug bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31564501/),[mM] / [l],0.100,48684,DB00316,Acetaminophen
,31564501,maximum concentration,"In case of contemporary meal digestion, the maximum concentration of paracetamol in the blood was 0.100 mmol L-1 and 0.0135 mmol L-1 for ketoprofen; the time to reach the maximum concentration was 3 h and 45 min for paracetamol and 3 h and 35 min for ketoprofen.",A new gastro-intestinal mathematical model to study drug bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31564501/),[mM] / [l],0.0135,48685,DB00316,Acetaminophen
,31564501,time to reach the maximum concentration,"In case of contemporary meal digestion, the maximum concentration of paracetamol in the blood was 0.100 mmol L-1 and 0.0135 mmol L-1 for ketoprofen; the time to reach the maximum concentration was 3 h and 45 min for paracetamol and 3 h and 35 min for ketoprofen.",A new gastro-intestinal mathematical model to study drug bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31564501/),h,3,48686,DB00316,Acetaminophen
,31564501,time to reach the maximum concentration,"In case of contemporary meal digestion, the maximum concentration of paracetamol in the blood was 0.100 mmol L-1 and 0.0135 mmol L-1 for ketoprofen; the time to reach the maximum concentration was 3 h and 45 min for paracetamol and 3 h and 35 min for ketoprofen.",A new gastro-intestinal mathematical model to study drug bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31564501/),min,45,48687,DB00316,Acetaminophen
,31564501,time to reach the maximum concentration,"In case of contemporary meal digestion, the maximum concentration of paracetamol in the blood was 0.100 mmol L-1 and 0.0135 mmol L-1 for ketoprofen; the time to reach the maximum concentration was 3 h and 45 min for paracetamol and 3 h and 35 min for ketoprofen.",A new gastro-intestinal mathematical model to study drug bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31564501/),min,35,48688,DB00316,Acetaminophen
,22793028,dynamic,The validated assay dynamic range was from 50.0 to 5000 ng/ml for each compound using a 1/8´´ (3-mm) disc punched from a DBS sample.,Simultaneous LC-MS/MS quantitation of acetaminophen and its glucuronide and sulfate metabolites in human dried blood spot samples collected by subjects in a pilot clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22793028/),[ng] / [ml],50.0 to 5000,50116,DB00316,Acetaminophen
,22793028,overall extraction efficiency,The overall extraction efficiency was from 61.3 to 78.8% for the three analytes by direct extraction using methanol.,Simultaneous LC-MS/MS quantitation of acetaminophen and its glucuronide and sulfate metabolites in human dried blood spot samples collected by subjects in a pilot clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22793028/),%,61.3 to 78.8,50117,DB00316,Acetaminophen
,2491461,tmax,"One group (n = 5) were fast absorbers with a tmax of 1 h and a motility pattern characterized by antral activity, a high motility index and a short duration of phase II (33-60 min); the phase IIIs were complete except in one case.",Antroduodenal motility and gastric emptying. Gastroduodenal motility and pH following ingestion of paracetamol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2491461/),h,1,50623,DB00316,Acetaminophen
,2491461,tmax,"The second group (n = 4) had tmax at 1.5 h and their phase II motility was characterized by a longer duration (80-133 min) (P less than 0.05), by antral activity, and by a high motility index; their phase IIIs were all incomplete.",Antroduodenal motility and gastric emptying. Gastroduodenal motility and pH following ingestion of paracetamol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2491461/),h,1.5,50624,DB00316,Acetaminophen
,15906167,maximum concentrations,"Food increased the maximum concentrations significantly (223 +/- 76 microg/ml vs. 315 +/- 122 microg/ml, p < 0.05) and shifted the second peak of talinolol to shorter t(max) values (3.8 +/- 1.2 h vs. 2.1 +/- 0.6 h, p < 0.05), which was associated with faster absorption of retinyl palmitate.",The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15906167/),[μg] / [ml],223,50845,DB00316,Acetaminophen
,15906167,maximum concentrations,"Food increased the maximum concentrations significantly (223 +/- 76 microg/ml vs. 315 +/- 122 microg/ml, p < 0.05) and shifted the second peak of talinolol to shorter t(max) values (3.8 +/- 1.2 h vs. 2.1 +/- 0.6 h, p < 0.05), which was associated with faster absorption of retinyl palmitate.",The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15906167/),[μg] / [ml],315,50846,DB00316,Acetaminophen
,15906167,t(max),"Food increased the maximum concentrations significantly (223 +/- 76 microg/ml vs. 315 +/- 122 microg/ml, p < 0.05) and shifted the second peak of talinolol to shorter t(max) values (3.8 +/- 1.2 h vs. 2.1 +/- 0.6 h, p < 0.05), which was associated with faster absorption of retinyl palmitate.",The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15906167/),h,3.8,50847,DB00316,Acetaminophen
,15906167,t(max),"Food increased the maximum concentrations significantly (223 +/- 76 microg/ml vs. 315 +/- 122 microg/ml, p < 0.05) and shifted the second peak of talinolol to shorter t(max) values (3.8 +/- 1.2 h vs. 2.1 +/- 0.6 h, p < 0.05), which was associated with faster absorption of retinyl palmitate.",The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15906167/),h,2.1,50848,DB00316,Acetaminophen
,10492416,maximum plasma concentration (Cmax),"The mean maximum plasma concentration (Cmax) was 72.4 micromol/l (+/-33.5 micromol/l) and the time to Cmax, i.e. the mean Tmax was 102.4 min (_+59.1 min).",Plasma paracetamol concentrations and pharmacokinetics following rectal administration in neonates and young infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492416/),[μM] / [l],72.4,51346,DB00316,Acetaminophen
,10492416,Tmax,"The mean maximum plasma concentration (Cmax) was 72.4 micromol/l (+/-33.5 micromol/l) and the time to Cmax, i.e. the mean Tmax was 102.4 min (_+59.1 min).",Plasma paracetamol concentrations and pharmacokinetics following rectal administration in neonates and young infants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492416/),min,102.4,51347,DB00316,Acetaminophen
,10492416,"""apparent"" terminal half-life","The mean ""apparent"" terminal half-life (n=10) was 243.6 min (+/-114.1 min).",Plasma paracetamol concentrations and pharmacokinetics following rectal administration in neonates and young infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492416/),min,243.6,51348,DB00316,Acetaminophen
,27110534,maximum plasma concentrations,"The maximum plasma concentrations of acetaminophen and AM404 in the rat brain were 15.8 µg/g and 150 pg/g, respectively, with corresponding AUC0-2h values of 8.96 μg hour/g and 117 pg hour/g.",Metabolism of AM404 From Acetaminophen at Human Therapeutic Dosages in the Rat Brain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27110534/),[μg] / [g],15.8,51917,DB00316,Acetaminophen
,27110534,maximum plasma concentrations,"The maximum plasma concentrations of acetaminophen and AM404 in the rat brain were 15.8 µg/g and 150 pg/g, respectively, with corresponding AUC0-2h values of 8.96 μg hour/g and 117 pg hour/g.",Metabolism of AM404 From Acetaminophen at Human Therapeutic Dosages in the Rat Brain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27110534/),[pg] / [g],150,51918,DB00316,Acetaminophen
,27110534,AUC0-2h,"The maximum plasma concentrations of acetaminophen and AM404 in the rat brain were 15.8 µg/g and 150 pg/g, respectively, with corresponding AUC0-2h values of 8.96 μg hour/g and 117 pg hour/g.",Metabolism of AM404 From Acetaminophen at Human Therapeutic Dosages in the Rat Brain. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27110534/),[h·μg] / [g],8.96,51919,DB00316,Acetaminophen
,27110534,AUC0-2h,"The maximum plasma concentrations of acetaminophen and AM404 in the rat brain were 15.8 µg/g and 150 pg/g, respectively, with corresponding AUC0-2h values of 8.96 μg hour/g and 117 pg hour/g.",Metabolism of AM404 From Acetaminophen at Human Therapeutic Dosages in the Rat Brain. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27110534/),[h·pg] / [g],117,51920,DB00316,Acetaminophen
,27110534,tmax,The tmax for both acetaminophen and AM404 was 0.25 hour.,Metabolism of AM404 From Acetaminophen at Human Therapeutic Dosages in the Rat Brain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27110534/),h,0.25,51921,DB00316,Acetaminophen
,27137142,excretion,"Mean PGI-M excretion was 33.7%, 55.9%, and 64.6% on day 1 and 49.4%, 65.1%, and 80.3% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,33.7,52863,DB00316,Acetaminophen
,27137142,excretion,"Mean PGI-M excretion was 33.7%, 55.9%, and 64.6% on day 1 and 49.4%, 65.1%, and 80.3% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,55.9,52864,DB00316,Acetaminophen
,27137142,excretion,"Mean PGI-M excretion was 33.7%, 55.9%, and 64.6% on day 1 and 49.4%, 65.1%, and 80.3% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,64.6,52865,DB00316,Acetaminophen
,27137142,excretion,"Mean PGI-M excretion was 33.7%, 55.9%, and 64.6% on day 1 and 49.4%, 65.1%, and 80.3% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,49.4,52866,DB00316,Acetaminophen
,27137142,excretion,"Mean PGI-M excretion was 33.7%, 55.9%, and 64.6% on day 1 and 49.4%, 65.1%, and 80.3% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,65.1,52867,DB00316,Acetaminophen
,27137142,excretion,"Mean PGI-M excretion was 33.7%, 55.9%, and 64.6% on day 1 and 49.4%, 65.1%, and 80.3% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,80.3,52868,DB00316,Acetaminophen
,27137142,excretion,"Mean Tx-M excretion was 16.2%, 45.2%, and 86.6% on day 1 and 46.2%, 58.4%, and 92.6% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,16.2,52869,DB00316,Acetaminophen
,27137142,excretion,"Mean Tx-M excretion was 16.2%, 45.2%, and 86.6% on day 1 and 46.2%, 58.4%, and 92.6% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,45.2,52870,DB00316,Acetaminophen
,27137142,excretion,"Mean Tx-M excretion was 16.2%, 45.2%, and 86.6% on day 1 and 46.2%, 58.4%, and 92.6% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,86.6,52871,DB00316,Acetaminophen
,27137142,excretion,"Mean Tx-M excretion was 16.2%, 45.2%, and 86.6% on day 1 and 46.2%, 58.4%, and 92.6% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,46.2,52872,DB00316,Acetaminophen
,27137142,excretion,"Mean Tx-M excretion was 16.2%, 45.2%, and 86.6% on day 1 and 46.2%, 58.4%, and 92.6% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,58.4,52873,DB00316,Acetaminophen
,27137142,excretion,"Mean Tx-M excretion was 16.2%, 45.2%, and 86.6% on day 1 and 46.2%, 58.4%, and 92.6% on day 5 (placebo, acetaminophen, and indomethacin, respectively).",Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137142/),%,92.6,52874,DB00316,Acetaminophen
,28816033,plasma concentration (TC ),The primary end point was duration of time that plasma APAP concentration exceeded a plasma concentration (TC ) of 4 μg/mL.,"Selection of 12-Hour Sustained-Release Acetaminophen (Paracetamol) Formulation Through Comparison of Pharmacokinetic Profiles of 4 Sustained-Release Prototype Formulations and Standard Acetaminophen Formulation: An Open-Label, Randomized, Proof-of-Principle Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28816033/),[μg] / [ml],4,53787,DB00316,Acetaminophen
>,28816033,TC,"Of the 4 SR APAP formulations studied, a single 2000-mg dose of a bilayer SR formulation had the longest mean TC>4μg/mL (8.1 hours), similar to that of 2 doses of IR APAP (8.3 hours).","Selection of 12-Hour Sustained-Release Acetaminophen (Paracetamol) Formulation Through Comparison of Pharmacokinetic Profiles of 4 Sustained-Release Prototype Formulations and Standard Acetaminophen Formulation: An Open-Label, Randomized, Proof-of-Principle Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28816033/),[μg] / [ml],4,53788,DB00316,Acetaminophen
,28816033,TC,"Of the 4 SR APAP formulations studied, a single 2000-mg dose of a bilayer SR formulation had the longest mean TC>4μg/mL (8.1 hours), similar to that of 2 doses of IR APAP (8.3 hours).","Selection of 12-Hour Sustained-Release Acetaminophen (Paracetamol) Formulation Through Comparison of Pharmacokinetic Profiles of 4 Sustained-Release Prototype Formulations and Standard Acetaminophen Formulation: An Open-Label, Randomized, Proof-of-Principle Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28816033/),h,8.1,53789,DB00316,Acetaminophen
,28816033,TC,"Of the 4 SR APAP formulations studied, a single 2000-mg dose of a bilayer SR formulation had the longest mean TC>4μg/mL (8.1 hours), similar to that of 2 doses of IR APAP (8.3 hours).","Selection of 12-Hour Sustained-Release Acetaminophen (Paracetamol) Formulation Through Comparison of Pharmacokinetic Profiles of 4 Sustained-Release Prototype Formulations and Standard Acetaminophen Formulation: An Open-Label, Randomized, Proof-of-Principle Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28816033/),h,8.3,53790,DB00316,Acetaminophen
>,28816033,TC,"Mean TC>4μg/mL was 7.3 hours with a single-layer SR APAP, 7.5 hours with another single-layer SR APAP formulation using a different excipient, and 7.1 hours with an enteric-coated SR APAP coupled with a fast-dissolving IR APAP.","Selection of 12-Hour Sustained-Release Acetaminophen (Paracetamol) Formulation Through Comparison of Pharmacokinetic Profiles of 4 Sustained-Release Prototype Formulations and Standard Acetaminophen Formulation: An Open-Label, Randomized, Proof-of-Principle Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28816033/),h,4,53791,DB00316,Acetaminophen
,28816033,TC,"Mean TC>4μg/mL was 7.3 hours with a single-layer SR APAP, 7.5 hours with another single-layer SR APAP formulation using a different excipient, and 7.1 hours with an enteric-coated SR APAP coupled with a fast-dissolving IR APAP.","Selection of 12-Hour Sustained-Release Acetaminophen (Paracetamol) Formulation Through Comparison of Pharmacokinetic Profiles of 4 Sustained-Release Prototype Formulations and Standard Acetaminophen Formulation: An Open-Label, Randomized, Proof-of-Principle Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28816033/),h,7.3,53792,DB00316,Acetaminophen
,28816033,TC,"Mean TC>4μg/mL was 7.3 hours with a single-layer SR APAP, 7.5 hours with another single-layer SR APAP formulation using a different excipient, and 7.1 hours with an enteric-coated SR APAP coupled with a fast-dissolving IR APAP.","Selection of 12-Hour Sustained-Release Acetaminophen (Paracetamol) Formulation Through Comparison of Pharmacokinetic Profiles of 4 Sustained-Release Prototype Formulations and Standard Acetaminophen Formulation: An Open-Label, Randomized, Proof-of-Principle Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28816033/),h,7.5,53793,DB00316,Acetaminophen
,28816033,TC,"Mean TC>4μg/mL was 7.3 hours with a single-layer SR APAP, 7.5 hours with another single-layer SR APAP formulation using a different excipient, and 7.1 hours with an enteric-coated SR APAP coupled with a fast-dissolving IR APAP.","Selection of 12-Hour Sustained-Release Acetaminophen (Paracetamol) Formulation Through Comparison of Pharmacokinetic Profiles of 4 Sustained-Release Prototype Formulations and Standard Acetaminophen Formulation: An Open-Label, Randomized, Proof-of-Principle Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28816033/),h,7.1,53794,DB00316,Acetaminophen
,24258704,flow rate,"After protein precipitation with methanol, satisfactory separation was achieved on a Hypersil® BDS C18 column (250 mm × 4.6 mm, 5 μm) using a mobile phase comprising 20 mM sodium dihydrogen phosphate buffer (pH=3) and methanol at a ratio of 80:20, v/v; the elution was isocratic at ambient temperature with a flow rate of 1.2 ml/min.",Simultaneous determination of paracetamol and methocarbamol in human plasma By HPLC using UV detection with time programming: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24258704/),[ml] / [min],1.2,53876,DB00316,Acetaminophen
,24258704,drug recovery,Mean drug recovery was 99.8 for PAR and 99.0% for MET.,Simultaneous determination of paracetamol and methocarbamol in human plasma By HPLC using UV detection with time programming: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24258704/),%,99.8,53877,DB00316,Acetaminophen
,24258704,drug recovery,Mean drug recovery was 99.8 for PAR and 99.0% for MET.,Simultaneous determination of paracetamol and methocarbamol in human plasma By HPLC using UV detection with time programming: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24258704/),%,99.0,53878,DB00316,Acetaminophen
,27734219,maximum plasma concentration,"The geometric mean values for maximum plasma concentration obtained for the reference and test products were 9.46 ± 34.21 and 9.72 ± 32.38 µg/mL, respectively, whereas for the area under the curve from time zero to the last sampling time the values obtained were 34.93 ± 32.58 and 35.89 ± 31.03 µg h/mL for the reference and test formulations, respectively.",Bioequivalence and Pharmacokinetic Evaluation Study of Acetaminophen vs. Acetaminophen Plus Caffeine Tablets in Healthy Mexican Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27734219/),[μg] / [ml],9.46,54009,DB00316,Acetaminophen
,27734219,maximum plasma concentration,"The geometric mean values for maximum plasma concentration obtained for the reference and test products were 9.46 ± 34.21 and 9.72 ± 32.38 µg/mL, respectively, whereas for the area under the curve from time zero to the last sampling time the values obtained were 34.93 ± 32.58 and 35.89 ± 31.03 µg h/mL for the reference and test formulations, respectively.",Bioequivalence and Pharmacokinetic Evaluation Study of Acetaminophen vs. Acetaminophen Plus Caffeine Tablets in Healthy Mexican Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27734219/),[μg] / [ml],9.72,54010,DB00316,Acetaminophen
,27734219,area under the curve from time zero to the last sampling time,"The geometric mean values for maximum plasma concentration obtained for the reference and test products were 9.46 ± 34.21 and 9.72 ± 32.38 µg/mL, respectively, whereas for the area under the curve from time zero to the last sampling time the values obtained were 34.93 ± 32.58 and 35.89 ± 31.03 µg h/mL for the reference and test formulations, respectively.",Bioequivalence and Pharmacokinetic Evaluation Study of Acetaminophen vs. Acetaminophen Plus Caffeine Tablets in Healthy Mexican Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27734219/),[h·μg] / [ml],34.93,54011,DB00316,Acetaminophen
,27734219,area under the curve from time zero to the last sampling time,"The geometric mean values for maximum plasma concentration obtained for the reference and test products were 9.46 ± 34.21 and 9.72 ± 32.38 µg/mL, respectively, whereas for the area under the curve from time zero to the last sampling time the values obtained were 34.93 ± 32.58 and 35.89 ± 31.03 µg h/mL for the reference and test formulations, respectively.",Bioequivalence and Pharmacokinetic Evaluation Study of Acetaminophen vs. Acetaminophen Plus Caffeine Tablets in Healthy Mexican Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27734219/),[h·μg] / [ml],35.89,54012,DB00316,Acetaminophen
,862649,clearance,Paracetamol levels declined multiphasically with a mean clearance after intravenous administration of 352 +/- 40 ml/min.,Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/862649/),[ml] / [min],352,54184,DB00316,Acetaminophen
,862649,oral bioavailability,"Comparison of the areas under the plasma concentration-time curves (AUC) indicated that oral bioavailability increased from 0.63 +/- 0.02 after 500 mg, to 0.89 +/- 0.04 and 0.87 +/- 0.08 after 1000 mg and 2000 mg, respectively.",Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/862649/),,0.63,54185,DB00316,Acetaminophen
,862649,oral bioavailability,"Comparison of the areas under the plasma concentration-time curves (AUC) indicated that oral bioavailability increased from 0.63 +/- 0.02 after 500 mg, to 0.89 +/- 0.04 and 0.87 +/- 0.08 after 1000 mg and 2000 mg, respectively.",Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/862649/),,0.89,54186,DB00316,Acetaminophen
,862649,oral bioavailability,"Comparison of the areas under the plasma concentration-time curves (AUC) indicated that oral bioavailability increased from 0.63 +/- 0.02 after 500 mg, to 0.89 +/- 0.04 and 0.87 +/- 0.08 after 1000 mg and 2000 mg, respectively.",Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/862649/),,0.87,54187,DB00316,Acetaminophen
,26095480,C0-1havg,A 4 μg/mL C0-1havg of acetaminophen (dose: 1.5 g) may be used as cutoff point in future clinical investigations of acetaminophen to clarify the role of gastric emptying.,Acetaminophen absorption kinetics in altered gastric emptying: establishing a relevant pharmacokinetic surrogate using published data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26095480/),[μg] / [ml],4,54536,DB00316,Acetaminophen
,8613932,Cl(f),"In phenobarbital-induced rats receiving a nontoxic dose of APAP (100 mg/kg i.v.), a single dose of caffeine (100 mg/kg i.p.) co-administered with APAP increased the Cl(f) of NAPQI formation from 0.58 +/- 0.47 to 2.08 +/- 1.1 1 ml/min/kg (P = .01).",Effects of caffeine and theophylline on acetaminophen pharmacokinetics: P450 inhibition and activation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8613932/),[1·ml] / [kg·min],0.58,54661,DB00316,Acetaminophen
,8613932,Cl(f),"In phenobarbital-induced rats receiving a nontoxic dose of APAP (100 mg/kg i.v.), a single dose of caffeine (100 mg/kg i.p.) co-administered with APAP increased the Cl(f) of NAPQI formation from 0.58 +/- 0.47 to 2.08 +/- 1.1 1 ml/min/kg (P = .01).",Effects of caffeine and theophylline on acetaminophen pharmacokinetics: P450 inhibition and activation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8613932/),[1·ml] / [kg·min],2.08,54662,DB00316,Acetaminophen
,6688407,maximum plasma concentrations,"After doses of 250, 500, and 1000 mg nabumetone, maximum plasma concentrations of the major metabolite, 6-methoxy-2-naphthylacetic acid, were 9.76, 24.19, and 36.59 micrograms/ml, in nonfasting subjects.","Nabumetone--a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688407/),[μg] / [ml],9.76,54725,DB00316,Acetaminophen
,6688407,maximum plasma concentrations,"After doses of 250, 500, and 1000 mg nabumetone, maximum plasma concentrations of the major metabolite, 6-methoxy-2-naphthylacetic acid, were 9.76, 24.19, and 36.59 micrograms/ml, in nonfasting subjects.","Nabumetone--a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688407/),[μg] / [ml],24.19,54726,DB00316,Acetaminophen
,6688407,maximum plasma concentrations,"After doses of 250, 500, and 1000 mg nabumetone, maximum plasma concentrations of the major metabolite, 6-methoxy-2-naphthylacetic acid, were 9.76, 24.19, and 36.59 micrograms/ml, in nonfasting subjects.","Nabumetone--a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688407/),[μg] / [ml],36.59,54727,DB00316,Acetaminophen
,22935956,clearance,Mean (SD) paracetamol clearance was 22.4 l h(-1) (9.3) or - when corrected for body surface area - 11.5 l h(-1) m(-2) (4.0).,The pharmacokinetics of a high intravenous dose of paracetamol after caesarean delivery: the effect of gestational age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22935956/),[l] / [h],22.4,54828,DB00316,Acetaminophen
,22935956,clearance,Mean (SD) paracetamol clearance was 22.4 l h(-1) (9.3) or - when corrected for body surface area - 11.5 l h(-1) m(-2) (4.0).,The pharmacokinetics of a high intravenous dose of paracetamol after caesarean delivery: the effect of gestational age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22935956/),[l] / [(m)^2·h],11.5,54829,DB00316,Acetaminophen
,22935956,clearance,"No significant effects of twin pregnancy (n = 8) or maternal co-morbidity (n = 3) were observed, but mean clearance after preterm delivery (n = 12, <37 weeks gestational age) was significantly higher [13.8 (5.7) vs. 10.2 l h(-1) m(-2) (1.9), P = 0.028] compared with term delivery (n = 22).",The pharmacokinetics of a high intravenous dose of paracetamol after caesarean delivery: the effect of gestational age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22935956/),[l] / [(m)^2·h],13.8,54830,DB00316,Acetaminophen
,22935956,clearance,"No significant effects of twin pregnancy (n = 8) or maternal co-morbidity (n = 3) were observed, but mean clearance after preterm delivery (n = 12, <37 weeks gestational age) was significantly higher [13.8 (5.7) vs. 10.2 l h(-1) m(-2) (1.9), P = 0.028] compared with term delivery (n = 22).",The pharmacokinetics of a high intravenous dose of paracetamol after caesarean delivery: the effect of gestational age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22935956/),[l] / [(m)^2·h],10.2,54831,DB00316,Acetaminophen
,22935956,distribution volume,"Similarly, there was a difference in mean distribution volume [0.83 (0.25) vs. 0.69 l kg(-1) (0.1), P = 0.037], resulting in the absence of differences in median elimination half-life [112 (28) vs. 119 min (19)].",The pharmacokinetics of a high intravenous dose of paracetamol after caesarean delivery: the effect of gestational age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22935956/),[l] / [kg],0.83,54832,DB00316,Acetaminophen
,22935956,distribution volume,"Similarly, there was a difference in mean distribution volume [0.83 (0.25) vs. 0.69 l kg(-1) (0.1), P = 0.037], resulting in the absence of differences in median elimination half-life [112 (28) vs. 119 min (19)].",The pharmacokinetics of a high intravenous dose of paracetamol after caesarean delivery: the effect of gestational age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22935956/),[l] / [kg],0.69,54833,DB00316,Acetaminophen
,22935956,elimination half-life,"Similarly, there was a difference in mean distribution volume [0.83 (0.25) vs. 0.69 l kg(-1) (0.1), P = 0.037], resulting in the absence of differences in median elimination half-life [112 (28) vs. 119 min (19)].",The pharmacokinetics of a high intravenous dose of paracetamol after caesarean delivery: the effect of gestational age. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22935956/),min,112,54834,DB00316,Acetaminophen
,22935956,elimination half-life,"Similarly, there was a difference in mean distribution volume [0.83 (0.25) vs. 0.69 l kg(-1) (0.1), P = 0.037], resulting in the absence of differences in median elimination half-life [112 (28) vs. 119 min (19)].",The pharmacokinetics of a high intravenous dose of paracetamol after caesarean delivery: the effect of gestational age. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22935956/),min,119,54835,DB00316,Acetaminophen
,22341787,plasma concentrations,"Median paracetamol plasma concentrations after 1, 2, 4 and 6 h were 22.5, 15.25, 7.9, and 3.9 mg/L respectively.",Pharmacokinetics of a loading dose of intravenous paracetamol post caesarean delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22341787/),[mg] / [l],22.5,55848,DB00316,Acetaminophen
,22341787,plasma concentrations,"Median paracetamol plasma concentrations after 1, 2, 4 and 6 h were 22.5, 15.25, 7.9, and 3.9 mg/L respectively.",Pharmacokinetics of a loading dose of intravenous paracetamol post caesarean delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22341787/),[mg] / [l],15.25,55849,DB00316,Acetaminophen
,22341787,plasma concentrations,"Median paracetamol plasma concentrations after 1, 2, 4 and 6 h were 22.5, 15.25, 7.9, and 3.9 mg/L respectively.",Pharmacokinetics of a loading dose of intravenous paracetamol post caesarean delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22341787/),[mg] / [l],7.9,55850,DB00316,Acetaminophen
,22341787,plasma concentrations,"Median paracetamol plasma concentrations after 1, 2, 4 and 6 h were 22.5, 15.25, 7.9, and 3.9 mg/L respectively.",Pharmacokinetics of a loading dose of intravenous paracetamol post caesarean delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22341787/),[mg] / [l],3.9,55851,DB00316,Acetaminophen
,22341787,clearance,"Paracetamol clearance was 20.3 (11.8-62.8) L/h or 10.9 (7-23.8)L/hm(2), distribution volume 58.3 (42.9-156) L or 0.72 (0.52-1.56) L/kg.",Pharmacokinetics of a loading dose of intravenous paracetamol post caesarean delivery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22341787/),[l] / [h],20.3,55852,DB00316,Acetaminophen
,22341787,clearance,"Paracetamol clearance was 20.3 (11.8-62.8) L/h or 10.9 (7-23.8)L/hm(2), distribution volume 58.3 (42.9-156) L or 0.72 (0.52-1.56) L/kg.",Pharmacokinetics of a loading dose of intravenous paracetamol post caesarean delivery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22341787/),[l] / [hm(2],10.9,55853,DB00316,Acetaminophen
,22341787,distribution volume,"Paracetamol clearance was 20.3 (11.8-62.8) L/h or 10.9 (7-23.8)L/hm(2), distribution volume 58.3 (42.9-156) L or 0.72 (0.52-1.56) L/kg.",Pharmacokinetics of a loading dose of intravenous paracetamol post caesarean delivery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22341787/),l,58.3,55854,DB00316,Acetaminophen
,22341787,distribution volume,"Paracetamol clearance was 20.3 (11.8-62.8) L/h or 10.9 (7-23.8)L/hm(2), distribution volume 58.3 (42.9-156) L or 0.72 (0.52-1.56) L/kg.",Pharmacokinetics of a loading dose of intravenous paracetamol post caesarean delivery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22341787/),[l] / [kg],0.72,55855,DB00316,Acetaminophen
,7039926,systemic bioavailability,"Following oral administration it is rapidly absorbed from the gastrointestinal tract, its systemic bioavailability being dose-dependent and ranging from 70 to 90%.",Clinical pharmacokinetics of paracetamol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),%,70 to 90,56310,DB00316,Acetaminophen
,7039926,volume of distribution,It distributes rapidly and evenly throughout most tissues and fluids and has a volume of distribution of approximately 0.9L/kg.,Clinical pharmacokinetics of paracetamol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),[l] / [kg],0.9,56311,DB00316,Acetaminophen
,7039926,plasma half-life,The plasma half-life in such subjects ranges from 1.9 to 2.5 hours and the total body clearance from 4.5 to 5.5 ml/kg/min.,Clinical pharmacokinetics of paracetamol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),h,1.9 to 2.5,56312,DB00316,Acetaminophen
,7039926,total body clearance,The plasma half-life in such subjects ranges from 1.9 to 2.5 hours and the total body clearance from 4.5 to 5.5 ml/kg/min.,Clinical pharmacokinetics of paracetamol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),[ml] / [kg·min],4.5 to 5.5,56313,DB00316,Acetaminophen
,17717235,Gastric emptying T([1/2]),Gastric emptying T([1/2]) was not different after ingestion of 300 mL water compared with 50 mL (23 +/- 11 min vs 32 +/- 15 min).,Gastric emptying of water in obese pregnant women at term. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17717235/),min,23,56592,DB00316,Acetaminophen
,17717235,Gastric emptying T([1/2]),Gastric emptying T([1/2]) was not different after ingestion of 300 mL water compared with 50 mL (23 +/- 11 min vs 32 +/- 15 min).,Gastric emptying of water in obese pregnant women at term. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17717235/),min,32,56593,DB00316,Acetaminophen
,3998201,half-life,"Cimetidine did not significantly affect acetaminophen half-life, 2.38 hours (A), 2.65 hours (A + C), and 2.50 hours (A + C*).",Cimetidine--acetaminophen interaction in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3998201/),h,2.38,57103,DB00316,Acetaminophen
,3998201,half-life,"Cimetidine did not significantly affect acetaminophen half-life, 2.38 hours (A), 2.65 hours (A + C), and 2.50 hours (A + C*).",Cimetidine--acetaminophen interaction in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3998201/),h,2.65,57104,DB00316,Acetaminophen
,3998201,half-life,"Cimetidine did not significantly affect acetaminophen half-life, 2.38 hours (A), 2.65 hours (A + C), and 2.50 hours (A + C*).",Cimetidine--acetaminophen interaction in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3998201/),h,2.50,57105,DB00316,Acetaminophen
,3998201,clearance,Acetaminophen clearance was minimally affected by cimetidine; the mean clearance of acetaminophen ranged from 4.16 (A + C*) to 5.57 mL/min/kg (A).,Cimetidine--acetaminophen interaction in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3998201/),[ml] / [kg·min],4.16,57106,DB00316,Acetaminophen
,3998201,clearance,Acetaminophen clearance was minimally affected by cimetidine; the mean clearance of acetaminophen ranged from 4.16 (A + C*) to 5.57 mL/min/kg (A).,Cimetidine--acetaminophen interaction in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3998201/),[ml] / [kg·min],5.57,57107,DB00316,Acetaminophen
,3998201,Area under the ace,"Area under the acetaminophen plasma concentration-time curve was slightly increased by cimetidine, 35.4 (A), 41.6 (A + C), and 47.6 micrograms/mL/h (A + C*).",Cimetidine--acetaminophen interaction in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3998201/),[μg] / [h·ml],35.4,57108,DB00316,Acetaminophen
,3998201,Area under the ace,"Area under the acetaminophen plasma concentration-time curve was slightly increased by cimetidine, 35.4 (A), 41.6 (A + C), and 47.6 micrograms/mL/h (A + C*).",Cimetidine--acetaminophen interaction in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3998201/),[μg] / [h·ml],41.6,57109,DB00316,Acetaminophen
,3998201,Area under the ace,"Area under the acetaminophen plasma concentration-time curve was slightly increased by cimetidine, 35.4 (A), 41.6 (A + C), and 47.6 micrograms/mL/h (A + C*).",Cimetidine--acetaminophen interaction in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3998201/),[μg] / [h·ml],47.6,57110,DB00316,Acetaminophen
,18923390,k(e),"The mean (+/-SD)k(e) and half-life were 0.486 +/- 0.084 days(-1) and 1.47+/- 0.30 days, respectively, and the C(max) was 1.2 (+/-2.92) nmol/ml serum.",Acetaminophen-associated hepatic injury: evaluation of acetaminophen protein adducts in children and adolescents with acetaminophen overdose. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18923390/),1/[days],0.486,57729,DB00316,Acetaminophen
,18923390,half-life,"The mean (+/-SD)k(e) and half-life were 0.486 +/- 0.084 days(-1) and 1.47+/- 0.30 days, respectively, and the C(max) was 1.2 (+/-2.92) nmol/ml serum.",Acetaminophen-associated hepatic injury: evaluation of acetaminophen protein adducts in children and adolescents with acetaminophen overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18923390/),d,1.47,57730,DB00316,Acetaminophen
,18923390,C(max),"The mean (+/-SD)k(e) and half-life were 0.486 +/- 0.084 days(-1) and 1.47+/- 0.30 days, respectively, and the C(max) was 1.2 (+/-2.92) nmol/ml serum.",Acetaminophen-associated hepatic injury: evaluation of acetaminophen protein adducts in children and adolescents with acetaminophen overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18923390/),[nM] / [ml·serum],1.2,57731,DB00316,Acetaminophen
>,12518392,C45,"In addition, the following simple criteria for diagnosis of delayed GE has been proposed based on the pharmacokinetic theories: after ingestion of 20 mg/kg APAP dissolved in a 200 kcal-containing liquid meal, 1) the delayed GE is excluded when C45 > 5.0 micrograms/ml, 2) whether GE is delayed or not is inconclusive when 2.0 < C45 < 5.0 micrograms/ml, and 3) the delayed GE is confirmed when C45 < 2.0 micrograms/ml.",[The validity of serum acetaminophen concentration at 45 min as an index of gastric emptying rate: a study based on pharmacokinetic theories]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518392/),[μg] / [m],5.0,57766,DB00316,Acetaminophen
<,12518392,C45,"In addition, the following simple criteria for diagnosis of delayed GE has been proposed based on the pharmacokinetic theories: after ingestion of 20 mg/kg APAP dissolved in a 200 kcal-containing liquid meal, 1) the delayed GE is excluded when C45 > 5.0 micrograms/ml, 2) whether GE is delayed or not is inconclusive when 2.0 < C45 < 5.0 micrograms/ml, and 3) the delayed GE is confirmed when C45 < 2.0 micrograms/ml.",[The validity of serum acetaminophen concentration at 45 min as an index of gastric emptying rate: a study based on pharmacokinetic theories]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518392/),,5.,57767,DB00316,Acetaminophen
<,12518392,C45,"In addition, the following simple criteria for diagnosis of delayed GE has been proposed based on the pharmacokinetic theories: after ingestion of 20 mg/kg APAP dissolved in a 200 kcal-containing liquid meal, 1) the delayed GE is excluded when C45 > 5.0 micrograms/ml, 2) whether GE is delayed or not is inconclusive when 2.0 < C45 < 5.0 micrograms/ml, and 3) the delayed GE is confirmed when C45 < 2.0 micrograms/ml.",[The validity of serum acetaminophen concentration at 45 min as an index of gastric emptying rate: a study based on pharmacokinetic theories]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518392/),[μg] / [ml],2.0,57768,DB00316,Acetaminophen
,19439490,elimination rate constant,"The mean elimination rate constant and elimination half-life were 0.42 +/- 0.09 days(-1) and 1.72 +/- 0.34 days, respectively, and estimates from the population model were in strong agreement with these data.",Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19439490/),1/[days],0.42,57790,DB00316,Acetaminophen
,19439490,elimination half-life,"The mean elimination rate constant and elimination half-life were 0.42 +/- 0.09 days(-1) and 1.72 +/- 0.34 days, respectively, and estimates from the population model were in strong agreement with these data.",Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19439490/),d,1.72,57791,DB00316,Acetaminophen
,15330953,peak plasma concentration,The mean (min-max) peak plasma concentration of total ropivacaine was 0.83 (0.05-1.57) mg x l(-1) at 0.5-5.7 h (median: 1.0 h) and the plasma concentration of unbound ropivacaine was 0.042 (0.012-0.081) mg x l(-1) within 0.5-1 h.,Ropivacaine in neonates and infants: a population pharmacokinetic evaluation following single caudal block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15330953/),[mg] / [l],0.83,58011,DB00316,Acetaminophen
,15330953,plasma concentration of unbound ropivacaine,The mean (min-max) peak plasma concentration of total ropivacaine was 0.83 (0.05-1.57) mg x l(-1) at 0.5-5.7 h (median: 1.0 h) and the plasma concentration of unbound ropivacaine was 0.042 (0.012-0.081) mg x l(-1) within 0.5-1 h.,Ropivacaine in neonates and infants: a population pharmacokinetic evaluation following single caudal block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15330953/),[mg] / [l],0.042,58012,DB00316,Acetaminophen
,15330953,unbound fraction,The observed unbound fraction in plasma was 6% (1%-14%).,Ropivacaine in neonates and infants: a population pharmacokinetic evaluation following single caudal block. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15330953/),%,6,58013,DB00316,Acetaminophen
,15330953,Clu/F,This predicts a Clu/F of 3.5 l x h(-1) x kg(-1) at 30 days and 10.8 l x h(-1) x kg(-1) at 270 days with corresponding terminal half-lives of 6.7 and 2.2 h.,Ropivacaine in neonates and infants: a population pharmacokinetic evaluation following single caudal block. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15330953/),[l] / [h·kg],3.5,58014,DB00316,Acetaminophen
,15330953,Clu/F,This predicts a Clu/F of 3.5 l x h(-1) x kg(-1) at 30 days and 10.8 l x h(-1) x kg(-1) at 270 days with corresponding terminal half-lives of 6.7 and 2.2 h.,Ropivacaine in neonates and infants: a population pharmacokinetic evaluation following single caudal block. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15330953/),[l] / [h·kg],10.8,58015,DB00316,Acetaminophen
,15330953,terminal half-lives,This predicts a Clu/F of 3.5 l x h(-1) x kg(-1) at 30 days and 10.8 l x h(-1) x kg(-1) at 270 days with corresponding terminal half-lives of 6.7 and 2.2 h.,Ropivacaine in neonates and infants: a population pharmacokinetic evaluation following single caudal block. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15330953/),h,6.7,58016,DB00316,Acetaminophen
,15330953,terminal half-lives,This predicts a Clu/F of 3.5 l x h(-1) x kg(-1) at 30 days and 10.8 l x h(-1) x kg(-1) at 270 days with corresponding terminal half-lives of 6.7 and 2.2 h.,Ropivacaine in neonates and infants: a population pharmacokinetic evaluation following single caudal block. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15330953/),h,2.2,58017,DB00316,Acetaminophen
,15330953,ka,"The population estimate (CV) of ka was 1.65 h(-1) (30%), Vu/F was 33.6 (l x kg(-1)) (45%) and Ka was 1.78 l x mg(-1) (14%).",Ropivacaine in neonates and infants: a population pharmacokinetic evaluation following single caudal block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15330953/),1/[h],1.65,58018,DB00316,Acetaminophen
,15330953,Vu/F,"The population estimate (CV) of ka was 1.65 h(-1) (30%), Vu/F was 33.6 (l x kg(-1)) (45%) and Ka was 1.78 l x mg(-1) (14%).",Ropivacaine in neonates and infants: a population pharmacokinetic evaluation following single caudal block. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15330953/),[l] / [kg],33.6,58019,DB00316,Acetaminophen
,15330953,Ka,"The population estimate (CV) of ka was 1.65 h(-1) (30%), Vu/F was 33.6 (l x kg(-1)) (45%) and Ka was 1.78 l x mg(-1) (14%).",Ropivacaine in neonates and infants: a population pharmacokinetic evaluation following single caudal block. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15330953/),[l] / [mg],1.78,58020,DB00316,Acetaminophen
,15330953,time to first supplementary analgesic,The median time to first supplementary analgesic (based on all 37 patients) was 3.9 h.,Ropivacaine in neonates and infants: a population pharmacokinetic evaluation following single caudal block. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15330953/),h,3.9,58021,DB00316,Acetaminophen
,10493642,Tmax,"Tmax was 31 mins in the control group, and this increased significantly (P<.05) after sedation.",The effect of sedation on gastric emptying of a liquid marker in ponies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10493642/),min,31,58609,DB00316,Acetaminophen
,25475358,relative bioavailability,"The relative bioavailability of phenylephrine 10 mg was doubled (Fbio 2.11, 95%CI 1.89, 2.31) when combined with acetaminophen 1000 mg, while the absorption half-time was reduced by 50 %.","Increased bioavailability of phenylephrine by co-administration of acetaminophen: results of four open-label, crossover pharmacokinetic trials in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25475358/),,2.11,58874,DB00316,Acetaminophen
,25475358,Fbio,"When combined with 500 mg of acetaminophen, bioavailability increased by 64 % (Fbio 1.64).","Increased bioavailability of phenylephrine by co-administration of acetaminophen: results of four open-label, crossover pharmacokinetic trials in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25475358/),,1.64,58875,DB00316,Acetaminophen
,8590508,maximum plasma concentration,The maximum plasma concentration was 88 +/- 39 mumol.L-1 (13 +/- 6 micrograms.ml-1) and the time of peak plasma concentration was 198 +/- 70 min (mean +/- SD).,Plasma concentrations after high-dose (45 mg.kg-1) rectal acetaminophen in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8590508/),[μM] / [l],88,58918,DB00316,Acetaminophen
,8590508,maximum plasma concentration,The maximum plasma concentration was 88 +/- 39 mumol.L-1 (13 +/- 6 micrograms.ml-1) and the time of peak plasma concentration was 198 +/- 70 min (mean +/- SD).,Plasma concentrations after high-dose (45 mg.kg-1) rectal acetaminophen in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8590508/),[μg] / [ml],13,58919,DB00316,Acetaminophen
,8590508,time of peak plasma concentration,The maximum plasma concentration was 88 +/- 39 mumol.L-1 (13 +/- 6 micrograms.ml-1) and the time of peak plasma concentration was 198 +/- 70 min (mean +/- SD).,Plasma concentrations after high-dose (45 mg.kg-1) rectal acetaminophen in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8590508/),min,198,58920,DB00316,Acetaminophen
,8590508,mean plasma concentration,"At 420 min, the mean plasma concentration was 46 +/- 18 mumol.L-1 (7.0 +/- 0.9 micrograms.ml-1).",Plasma concentrations after high-dose (45 mg.kg-1) rectal acetaminophen in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8590508/),[μM] / [l],46,58921,DB00316,Acetaminophen
,8590508,mean plasma concentration,"At 420 min, the mean plasma concentration was 46 +/- 18 mumol.L-1 (7.0 +/- 0.9 micrograms.ml-1).",Plasma concentrations after high-dose (45 mg.kg-1) rectal acetaminophen in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8590508/),[μg] / [ml],7.0,58922,DB00316,Acetaminophen
≥,26946423,Extraction efficiency,Extraction efficiency for all analytes was ≥70%.,"Stereoselective method to quantify bupropion and its three major metabolites, hydroxybupropion, erythro-dihydrobupropion, and threo-dihydrobupropion using HPLC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26946423/),%,70,59094,DB00316,Acetaminophen
,17667791,Time to maximum concentration (T(max)),"Time to maximum concentration (T(max)) of acetaminophen was significantly longer in diabetics [D: 74.1 minute versus nondiabetics (ND): 29.3 minutes, P = 0.02]; however, tacrolimus T(max) was not significantly different (D: 121 minutes versus ND: 87 minutes, P = 0.15).",Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17667791/),min,74.1,59752,DB00316,Acetaminophen
,17667791,Time to maximum concentration (T(max)),"Time to maximum concentration (T(max)) of acetaminophen was significantly longer in diabetics [D: 74.1 minute versus nondiabetics (ND): 29.3 minutes, P = 0.02]; however, tacrolimus T(max) was not significantly different (D: 121 minutes versus ND: 87 minutes, P = 0.15).",Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17667791/),min,29.3,59753,DB00316,Acetaminophen
,17667791,T(max),"Time to maximum concentration (T(max)) of acetaminophen was significantly longer in diabetics [D: 74.1 minute versus nondiabetics (ND): 29.3 minutes, P = 0.02]; however, tacrolimus T(max) was not significantly different (D: 121 minutes versus ND: 87 minutes, P = 0.15).",Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17667791/),min,121,59754,DB00316,Acetaminophen
,17667791,T(max),"Time to maximum concentration (T(max)) of acetaminophen was significantly longer in diabetics [D: 74.1 minute versus nondiabetics (ND): 29.3 minutes, P = 0.02]; however, tacrolimus T(max) was not significantly different (D: 121 minutes versus ND: 87 minutes, P = 0.15).",Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17667791/),min,87,59755,DB00316,Acetaminophen
,17667791,AUC(0-12),Median (interquartile range) of tacrolimus AUC(0-12) was 114 (101-161) microg*hr/L in patients with diabetes and 113 (87-189) microg*hr/L in nondiabetics (P = 0.62).,Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17667791/),[h·μg] / [l],114,59756,DB00316,Acetaminophen
,17667791,AUC(0-12),Median (interquartile range) of tacrolimus AUC(0-12) was 114 (101-161) microg*hr/L in patients with diabetes and 113 (87-189) microg*hr/L in nondiabetics (P = 0.62).,Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17667791/),[h·μg] / [l],113,59757,DB00316,Acetaminophen
,3602088,clearance,"Results showed that mean (+/- SD, n = 3) acetaminophen clearance was similar in both horses (4.84 +/- 0.637 ml/min/kg) and humans (4.68 +/- 0.691 ml/min/kg).",Antipyrine and lidocaine are cleared faster in horses than in humans: acetaminophen may be handled similarly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3602088/),[ml] / [kg·min],4.84,61109,DB00316,Acetaminophen
,3602088,clearance,"Results showed that mean (+/- SD, n = 3) acetaminophen clearance was similar in both horses (4.84 +/- 0.637 ml/min/kg) and humans (4.68 +/- 0.691 ml/min/kg).",Antipyrine and lidocaine are cleared faster in horses than in humans: acetaminophen may be handled similarly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3602088/),[ml] / [kg·min],4.68,61110,DB00316,Acetaminophen
,3602088,clearance,"However, antipyrine clearance was 10 times greater in horses (5.83 +/- 2.21 ml/min/kg) than in humans (0.536 +/- 0.110 ml/min/kg), which may reflect enhanced hepatic microsomal activity in horses.",Antipyrine and lidocaine are cleared faster in horses than in humans: acetaminophen may be handled similarly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3602088/),[ml] / [kg·min],5.83,61111,DB00316,Acetaminophen
,3602088,clearance,"However, antipyrine clearance was 10 times greater in horses (5.83 +/- 2.21 ml/min/kg) than in humans (0.536 +/- 0.110 ml/min/kg), which may reflect enhanced hepatic microsomal activity in horses.",Antipyrine and lidocaine are cleared faster in horses than in humans: acetaminophen may be handled similarly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3602088/),[ml] / [kg·min],0.536,61112,DB00316,Acetaminophen
,3602088,clearance,"Although lidocaine clearance in humans was similar to estimated hepatic blood flow (20.6 +/- 5.81 ml/min/kg), clearance in horses was more than 2 times greater (52.0 +/- 11.7 ml/min/kg).",Antipyrine and lidocaine are cleared faster in horses than in humans: acetaminophen may be handled similarly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3602088/),[ml] / [kg·min],20.6,61113,DB00316,Acetaminophen
,3602088,clearance,"Although lidocaine clearance in humans was similar to estimated hepatic blood flow (20.6 +/- 5.81 ml/min/kg), clearance in horses was more than 2 times greater (52.0 +/- 11.7 ml/min/kg).",Antipyrine and lidocaine are cleared faster in horses than in humans: acetaminophen may be handled similarly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3602088/),[ml] / [kg·min],52.0,61114,DB00316,Acetaminophen
,17931082,T(max),The rate of absorption was significantly greater (p < 0.03) for T (T(max) = 20.4 min) compared with R (T(max) = 38.4 min).,Relative bioavailability of new formulation of paracetamol effervescent powder containing sodium bicarbonate versus paracetamol tablets: a comparative pharmacokinetic study in fed subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17931082/),min,20.4,61115,DB00316,Acetaminophen
,17931082,T(max),The rate of absorption was significantly greater (p < 0.03) for T (T(max) = 20.4 min) compared with R (T(max) = 38.4 min).,Relative bioavailability of new formulation of paracetamol effervescent powder containing sodium bicarbonate versus paracetamol tablets: a comparative pharmacokinetic study in fed subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17931082/),min,38.4,61116,DB00316,Acetaminophen
,29505100,run time,A very small injection volume (3 μL) was applied and the run time was 2.0 min.,"Liquid chromatography-tandem MS/MS method for simultaneous quantification of paracetamol, chlorzoxazone and aceclofenac in human plasma: An application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29505100/),min,2.0,62206,DB00316,Acetaminophen
,8992964,Relative bioavailability,"Relative bioavailability of paracetamol was 102% for 125 mg and 93% for 250 mg suppositories, compared with that of cut-in-half 500 mg tablets.",[The relative bioavailability of paracetamol in suppositories in comparison to tablets]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992964/),%,102,63814,DB00316,Acetaminophen
,8992964,Relative bioavailability,"Relative bioavailability of paracetamol was 102% for 125 mg and 93% for 250 mg suppositories, compared with that of cut-in-half 500 mg tablets.",[The relative bioavailability of paracetamol in suppositories in comparison to tablets]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992964/),%,93,63815,DB00316,Acetaminophen
,8992964,maximum paracetamol plasma concentrations (Cmax),"Mean maximum paracetamol plasma concentrations (Cmax) were determined as 2.1 micrograms/ml (CV = 31%; (CV = Coefficient of Variation), 2.0 micrograms/ml (CV = 27%) and 3.5 micrograms/ml (CV = 27%) after administration of 125 mg and 250 mg suppositories and 500 mg cut-in-half tablets, respectively.",[The relative bioavailability of paracetamol in suppositories in comparison to tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992964/),[μg] / [ml],2.1,63816,DB00316,Acetaminophen
,8992964,maximum paracetamol plasma concentrations (Cmax),"Mean maximum paracetamol plasma concentrations (Cmax) were determined as 2.1 micrograms/ml (CV = 31%; (CV = Coefficient of Variation), 2.0 micrograms/ml (CV = 27%) and 3.5 micrograms/ml (CV = 27%) after administration of 125 mg and 250 mg suppositories and 500 mg cut-in-half tablets, respectively.",[The relative bioavailability of paracetamol in suppositories in comparison to tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992964/),[μg] / [ml],2.0,63817,DB00316,Acetaminophen
,8992964,maximum paracetamol plasma concentrations (Cmax),"Mean maximum paracetamol plasma concentrations (Cmax) were determined as 2.1 micrograms/ml (CV = 31%; (CV = Coefficient of Variation), 2.0 micrograms/ml (CV = 27%) and 3.5 micrograms/ml (CV = 27%) after administration of 125 mg and 250 mg suppositories and 500 mg cut-in-half tablets, respectively.",[The relative bioavailability of paracetamol in suppositories in comparison to tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992964/),[μg] / [ml],3.5,63818,DB00316,Acetaminophen
,8992964,maximum concentrations,"These maximum concentrations were achieved 2.2 +/- 0.7, 1.8 +/- 0.7 and 0.6 +/- 0.3 h (tmax) after administration of the respective preparations.",[The relative bioavailability of paracetamol in suppositories in comparison to tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992964/),h,2.2,63819,DB00316,Acetaminophen
,8992964,maximum concentrations,"These maximum concentrations were achieved 2.2 +/- 0.7, 1.8 +/- 0.7 and 0.6 +/- 0.3 h (tmax) after administration of the respective preparations.",[The relative bioavailability of paracetamol in suppositories in comparison to tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992964/),h,1.8,63820,DB00316,Acetaminophen
,8992964,maximum concentrations,"These maximum concentrations were achieved 2.2 +/- 0.7, 1.8 +/- 0.7 and 0.6 +/- 0.3 h (tmax) after administration of the respective preparations.",[The relative bioavailability of paracetamol in suppositories in comparison to tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992964/),h,0.6,63821,DB00316,Acetaminophen
,8992964,tmax,"These maximum concentrations were achieved 2.2 +/- 0.7, 1.8 +/- 0.7 and 0.6 +/- 0.3 h (tmax) after administration of the respective preparations.",[The relative bioavailability of paracetamol in suppositories in comparison to tablets]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992964/),h,1.8,63822,DB00316,Acetaminophen
,8992964,tmax,"These maximum concentrations were achieved 2.2 +/- 0.7, 1.8 +/- 0.7 and 0.6 +/- 0.3 h (tmax) after administration of the respective preparations.",[The relative bioavailability of paracetamol in suppositories in comparison to tablets]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992964/),h,0.6,63823,DB00316,Acetaminophen
,8992964,HVD,"The corresponding HVD-values were 3.8 +/- 1.0, 3.5 +/- 0.9 and 1.8 +/- 0.8 h, respectively.",[The relative bioavailability of paracetamol in suppositories in comparison to tablets]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992964/),h,3.8,63824,DB00316,Acetaminophen
,8992964,HVD,"The corresponding HVD-values were 3.8 +/- 1.0, 3.5 +/- 0.9 and 1.8 +/- 0.8 h, respectively.",[The relative bioavailability of paracetamol in suppositories in comparison to tablets]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992964/),h,3.5,63825,DB00316,Acetaminophen
,8992964,HVD,"The corresponding HVD-values were 3.8 +/- 1.0, 3.5 +/- 0.9 and 1.8 +/- 0.8 h, respectively.",[The relative bioavailability of paracetamol in suppositories in comparison to tablets]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992964/),h,1.8,63826,DB00316,Acetaminophen
,1633071,elimination half-life,The elimination half-life of paracetamol calculated from pooled data was shorter in plasma (2.4 h) than in CSF (3.2 h).,Plasma and cerebrospinal fluid concentrations of paracetamol after a single intravenous dose of propacetamol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1633071/),h,2.4,64147,DB00316,Acetaminophen
,1633071,elimination half-life,The elimination half-life of paracetamol calculated from pooled data was shorter in plasma (2.4 h) than in CSF (3.2 h).,Plasma and cerebrospinal fluid concentrations of paracetamol after a single intravenous dose of propacetamol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1633071/),h,3.2,64148,DB00316,Acetaminophen
,32710209,bioavailability,"In contrast, the predicted bioavailability of posaconazole, a poorly soluble drug, decreased from 12% pre-RYGBS to 5% post-RYGBS.",PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32710209/),%,12,65654,DB00316,Acetaminophen
,32710209,bioavailability,"In contrast, the predicted bioavailability of posaconazole, a poorly soluble drug, decreased from 12% pre-RYGBS to 5% post-RYGBS.",PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32710209/),%,5,65655,DB00316,Acetaminophen
,27320817,mean absorption time (MAT),"The mean absorption time (MAT) and absorption half-life (t1/2ka) were 1.61 ± 0.61 and 1.51 ± 0.38 hr, respectively, and bioavailability was nearly 100%.",Rapid absorption of diclofenac and acetaminophen after their oral administration to cattle. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27320817/),h,1.61,65797,DB00316,Acetaminophen
,27320817,absorption half-life (t1/2ka),"The mean absorption time (MAT) and absorption half-life (t1/2ka) were 1.61 ± 0.61 and 1.51 ± 0.38 hr, respectively, and bioavailability was nearly 100%.",Rapid absorption of diclofenac and acetaminophen after their oral administration to cattle. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27320817/),h,1.51,65798,DB00316,Acetaminophen
,27320817,bioavailability,"The mean absorption time (MAT) and absorption half-life (t1/2ka) were 1.61 ± 0.61 and 1.51 ± 0.38 hr, respectively, and bioavailability was nearly 100%.",Rapid absorption of diclofenac and acetaminophen after their oral administration to cattle. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27320817/),%,100,65799,DB00316,Acetaminophen
,27320817,MAT,"MAT and t1/2ka were 2.85 ± 0.93 and 1.53 ± 0.28 hr, respectively, and bioavailability was approximately 70%.",Rapid absorption of diclofenac and acetaminophen after their oral administration to cattle. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27320817/),h,2.85,65800,DB00316,Acetaminophen
,27320817,t1/2ka,"MAT and t1/2ka were 2.85 ± 0.93 and 1.53 ± 0.28 hr, respectively, and bioavailability was approximately 70%.",Rapid absorption of diclofenac and acetaminophen after their oral administration to cattle. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27320817/),h,1.53,65801,DB00316,Acetaminophen
,27320817,bioavailability,"MAT and t1/2ka were 2.85 ± 0.93 and 1.53 ± 0.28 hr, respectively, and bioavailability was approximately 70%.",Rapid absorption of diclofenac and acetaminophen after their oral administration to cattle. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27320817/),%,70,65802,DB00316,Acetaminophen
,9305490,area under the serum concentration-time curve,The area under the serum concentration-time curve was increased (152.34 mg/L.h +/- 50.38 s.d.) in cirrhotics compared with normal controls (93.86 mg/L.h +/- 9.60 s.d.) (P < 0.05).,Pharmacokinetics of N-acetylcysteine are altered in patients with chronic liver disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9305490/),[mg] / [h·l],152.34,66589,DB00316,Acetaminophen
,9305490,area under the serum concentration-time curve,The area under the serum concentration-time curve was increased (152.34 mg/L.h +/- 50.38 s.d.) in cirrhotics compared with normal controls (93.86 mg/L.h +/- 9.60 s.d.) (P < 0.05).,Pharmacokinetics of N-acetylcysteine are altered in patients with chronic liver disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9305490/),[mg] / [h·l],93.86,66590,DB00316,Acetaminophen
,9305490,clearance,The clearance of NAC was reduced in patients with chronic liver disease (4.52 L/h +/- 1.87 s.d.) compared with controls (6.47 L/h +/- 0.78: P < 0.01).,Pharmacokinetics of N-acetylcysteine are altered in patients with chronic liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9305490/),[l] / [h],4.52,66591,DB00316,Acetaminophen
,9305490,clearance,The clearance of NAC was reduced in patients with chronic liver disease (4.52 L/h +/- 1.87 s.d.) compared with controls (6.47 L/h +/- 0.78: P < 0.01).,Pharmacokinetics of N-acetylcysteine are altered in patients with chronic liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9305490/),[l] / [h],6.47,66592,DB00316,Acetaminophen
,30187443,Cmax (maximum comcentration),"Pharmacokinetic parameters (mean [SD]) of APAP in the DG and NDG groups were as follows: Cmax (maximum comcentration) = 21.50 [11.23] vs. 23.42 [9.79] mg/L, AUC0-t (area under the concentration-time curve) = 44.23 [17.93] vs. 41.43 [14.57] mg·h/L, t1/2kel (elimination half-life) = 2.28 [0.80] vs. 2.11 [0.80] h.",The Influence of Diabetes Mellitus on Glucuronidation and Sulphation of Paracetamol in Patients with Febrile Neutropenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30187443/),[mg] / [l],21.50,66686,DB00316,Acetaminophen
,30187443,Cmax (maximum comcentration),"Pharmacokinetic parameters (mean [SD]) of APAP in the DG and NDG groups were as follows: Cmax (maximum comcentration) = 21.50 [11.23] vs. 23.42 [9.79] mg/L, AUC0-t (area under the concentration-time curve) = 44.23 [17.93] vs. 41.43 [14.57] mg·h/L, t1/2kel (elimination half-life) = 2.28 [0.80] vs. 2.11 [0.80] h.",The Influence of Diabetes Mellitus on Glucuronidation and Sulphation of Paracetamol in Patients with Febrile Neutropenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30187443/),[mg] / [l],23.42,66687,DB00316,Acetaminophen
,30187443,AUC0-t (area under the concentration-time curve),"Pharmacokinetic parameters (mean [SD]) of APAP in the DG and NDG groups were as follows: Cmax (maximum comcentration) = 21.50 [11.23] vs. 23.42 [9.79] mg/L, AUC0-t (area under the concentration-time curve) = 44.23 [17.93] vs. 41.43 [14.57] mg·h/L, t1/2kel (elimination half-life) = 2.28 [0.80] vs. 2.11 [0.80] h.",The Influence of Diabetes Mellitus on Glucuronidation and Sulphation of Paracetamol in Patients with Febrile Neutropenia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30187443/),[h·mg] / [l],44.23,66688,DB00316,Acetaminophen
,30187443,AUC0-t (area under the concentration-time curve),"Pharmacokinetic parameters (mean [SD]) of APAP in the DG and NDG groups were as follows: Cmax (maximum comcentration) = 21.50 [11.23] vs. 23.42 [9.79] mg/L, AUC0-t (area under the concentration-time curve) = 44.23 [17.93] vs. 41.43 [14.57] mg·h/L, t1/2kel (elimination half-life) = 2.28 [0.80] vs. 2.11 [0.80] h.",The Influence of Diabetes Mellitus on Glucuronidation and Sulphation of Paracetamol in Patients with Febrile Neutropenia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30187443/),[h·mg] / [l],41.43,66689,DB00316,Acetaminophen
,30187443,t1/2kel (elimination half-life),"Pharmacokinetic parameters (mean [SD]) of APAP in the DG and NDG groups were as follows: Cmax (maximum comcentration) = 21.50 [11.23] vs. 23.42 [9.79] mg/L, AUC0-t (area under the concentration-time curve) = 44.23 [17.93] vs. 41.43 [14.57] mg·h/L, t1/2kel (elimination half-life) = 2.28 [0.80] vs. 2.11 [0.80] h.",The Influence of Diabetes Mellitus on Glucuronidation and Sulphation of Paracetamol in Patients with Febrile Neutropenia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30187443/),h,2.28,66690,DB00316,Acetaminophen
,30187443,t1/2kel (elimination half-life),"Pharmacokinetic parameters (mean [SD]) of APAP in the DG and NDG groups were as follows: Cmax (maximum comcentration) = 21.50 [11.23] vs. 23.42 [9.79] mg/L, AUC0-t (area under the concentration-time curve) = 44.23 [17.93] vs. 41.43 [14.57] mg·h/L, t1/2kel (elimination half-life) = 2.28 [0.80] vs. 2.11 [0.80] h.",The Influence of Diabetes Mellitus on Glucuronidation and Sulphation of Paracetamol in Patients with Febrile Neutropenia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30187443/),h,2.11,66691,DB00316,Acetaminophen
,16987360,Plasma concentration,"Plasma concentration before the 4th dose was 74 +/- 51 and 50 +/- 27 in the rectal and i.v. groups, respectively.",Plasma concentrations following repeated rectal or intravenous administration of paracetamol after heart surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16987360/),,74,66966,DB00316,Acetaminophen
,16987360,Plasma concentration,"Plasma concentration before the 4th dose was 74 +/- 51 and 50 +/- 27 in the rectal and i.v. groups, respectively.",Plasma concentrations following repeated rectal or intravenous administration of paracetamol after heart surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16987360/),,50,66967,DB00316,Acetaminophen
,34080498,relative bioavailability,The relative bioavailability of MR paracetamol compared to IR (FMR/IR) was estimated as 0.81.,Population pharmacokinetics of immediate-release and modified-release paracetamol and its major metabolites in a supratherapeutic dosing study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34080498/),,0.81,67037,DB00316,Acetaminophen
,1872890,half-maximal production (P50,"The O2 concentrations required for half-maximal production (P50 values) of glucuronide (2.3 microM O2) and sulfate (1.8 microM O2) conjugates in cells from hypoxic animals were lower than for control cells (5.3 microM and 3.9 microM O2 for glucuronide and sulfate conjugates, respectively).",Effect of chronic hypoxia on acetaminophen metabolism in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1872890/),μM,2.3,67266,DB00316,Acetaminophen
,1872890,half-maximal production (P50,"The O2 concentrations required for half-maximal production (P50 values) of glucuronide (2.3 microM O2) and sulfate (1.8 microM O2) conjugates in cells from hypoxic animals were lower than for control cells (5.3 microM and 3.9 microM O2 for glucuronide and sulfate conjugates, respectively).",Effect of chronic hypoxia on acetaminophen metabolism in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1872890/),,1,67267,DB00316,Acetaminophen
,1872890,half-maximal production (P50,"The O2 concentrations required for half-maximal production (P50 values) of glucuronide (2.3 microM O2) and sulfate (1.8 microM O2) conjugates in cells from hypoxic animals were lower than for control cells (5.3 microM and 3.9 microM O2 for glucuronide and sulfate conjugates, respectively).",Effect of chronic hypoxia on acetaminophen metabolism in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1872890/),μM,5.3,67268,DB00316,Acetaminophen
,1872890,half-maximal production (P50,"The O2 concentrations required for half-maximal production (P50 values) of glucuronide (2.3 microM O2) and sulfate (1.8 microM O2) conjugates in cells from hypoxic animals were lower than for control cells (5.3 microM and 3.9 microM O2 for glucuronide and sulfate conjugates, respectively).",Effect of chronic hypoxia on acetaminophen metabolism in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1872890/),μM,3.9,67269,DB00316,Acetaminophen
,1872890,P50,"In comparison, the P50 for glutathione conjugation (4.1 microM O2) was not statistically different from control (4.6 microM O2), but the maximal rate was 65% higher.",Effect of chronic hypoxia on acetaminophen metabolism in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1872890/),μM,4.1,67270,DB00316,Acetaminophen
,1872890,P50,"In comparison, the P50 for glutathione conjugation (4.1 microM O2) was not statistically different from control (4.6 microM O2), but the maximal rate was 65% higher.",Effect of chronic hypoxia on acetaminophen metabolism in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1872890/),μM,4.6,67271,DB00316,Acetaminophen
,12079004,concentration,"The plasma nizatidine concentration was highest (2420.0+/-192.4 and 996.0+/-54.6 ng mL(-1)) in the sample taken 1 h after administration of 300 mg nizatidine (high dose) and 150mg nizatidine (low dose), respectively.",Effect of nizatidine on paracetamol and its metabolites in human plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12079004/),[ng] / [ml],2420.0,67405,DB00316,Acetaminophen
,12079004,concentration,"The plasma nizatidine concentration was highest (2420.0+/-192.4 and 996.0+/-54.6 ng mL(-1)) in the sample taken 1 h after administration of 300 mg nizatidine (high dose) and 150mg nizatidine (low dose), respectively.",Effect of nizatidine on paracetamol and its metabolites in human plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12079004/),[ng] / [ml],996.0,67406,DB00316,Acetaminophen
,12079004,total area under the plasma paracetamol concentration-time curve from 0 to 180 min,"The total area under the plasma paracetamol concentration-time curve from 0 to 180 min (2361.5+/-146.4 and 2085.75+/-73.5 microg min mL(-1)) significantly increased after coadministration of nizatidine (high and low doses), respectively (P < 0.01 vs placebo).",Effect of nizatidine on paracetamol and its metabolites in human plasma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12079004/),[min·μg] / [ml],2361.5,67407,DB00316,Acetaminophen
,12079004,total area under the plasma paracetamol concentration-time curve from 0 to 180 min,"The total area under the plasma paracetamol concentration-time curve from 0 to 180 min (2361.5+/-146.4 and 2085.75+/-73.5 microg min mL(-1)) significantly increased after coadministration of nizatidine (high and low doses), respectively (P < 0.01 vs placebo).",Effect of nizatidine on paracetamol and its metabolites in human plasma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12079004/),[min·μg] / [ml],2085.75,67408,DB00316,Acetaminophen
,8448070,partial clearance,"Paracetamol clearance, half-life and the partial clearance to paracetamol glucuronide were not significantly different, but the partial clearance to paracetamol sulphate was significantly reduced (62 +/- 18 vs 86 +/- 17 ml h-1 kg-1 (mean +/- s.d.)) and the renal clearance of paracetamol was significantly increased (56 +/- 20 vs 22 +/- 6 ml h-1 kg-1 (mean +/- s.d.)) in the non-insulin dependent diabetic patients, compared with the control group.",Paracetamol elimination in patients with non-insulin dependent diabetes mellitus. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8448070/),[ml] / [h·kg],62,69356,DB00316,Acetaminophen
,8448070,partial clearance,"Paracetamol clearance, half-life and the partial clearance to paracetamol glucuronide were not significantly different, but the partial clearance to paracetamol sulphate was significantly reduced (62 +/- 18 vs 86 +/- 17 ml h-1 kg-1 (mean +/- s.d.)) and the renal clearance of paracetamol was significantly increased (56 +/- 20 vs 22 +/- 6 ml h-1 kg-1 (mean +/- s.d.)) in the non-insulin dependent diabetic patients, compared with the control group.",Paracetamol elimination in patients with non-insulin dependent diabetes mellitus. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8448070/),[ml] / [h·kg],86,69357,DB00316,Acetaminophen
,8448070,renal clearance,"Paracetamol clearance, half-life and the partial clearance to paracetamol glucuronide were not significantly different, but the partial clearance to paracetamol sulphate was significantly reduced (62 +/- 18 vs 86 +/- 17 ml h-1 kg-1 (mean +/- s.d.)) and the renal clearance of paracetamol was significantly increased (56 +/- 20 vs 22 +/- 6 ml h-1 kg-1 (mean +/- s.d.)) in the non-insulin dependent diabetic patients, compared with the control group.",Paracetamol elimination in patients with non-insulin dependent diabetes mellitus. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8448070/),[ml] / [h·kg],56,69358,DB00316,Acetaminophen
,8448070,renal clearance,"Paracetamol clearance, half-life and the partial clearance to paracetamol glucuronide were not significantly different, but the partial clearance to paracetamol sulphate was significantly reduced (62 +/- 18 vs 86 +/- 17 ml h-1 kg-1 (mean +/- s.d.)) and the renal clearance of paracetamol was significantly increased (56 +/- 20 vs 22 +/- 6 ml h-1 kg-1 (mean +/- s.d.)) in the non-insulin dependent diabetic patients, compared with the control group.",Paracetamol elimination in patients with non-insulin dependent diabetes mellitus. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8448070/),[ml] / [h·kg],22,69359,DB00316,Acetaminophen
,2305419,elimination half-life,"For elimination half-life, values from the complete study (mean 2.42 h) were highly correlated (r = 0.87 and 0.84) with methods a and b (means 2.41 and 2.43 h), with regression slopes of 1.00 and 0.99, respectively.",Validity of a two-point acetaminophen pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305419/),h,2.42,70348,DB00316,Acetaminophen
,2305419,elimination half-life,"For elimination half-life, values from the complete study (mean 2.42 h) were highly correlated (r = 0.87 and 0.84) with methods a and b (means 2.41 and 2.43 h), with regression slopes of 1.00 and 0.99, respectively.",Validity of a two-point acetaminophen pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305419/),h,2.41,70349,DB00316,Acetaminophen
,2305419,elimination half-life,"For elimination half-life, values from the complete study (mean 2.42 h) were highly correlated (r = 0.87 and 0.84) with methods a and b (means 2.41 and 2.43 h), with regression slopes of 1.00 and 0.99, respectively.",Validity of a two-point acetaminophen pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305419/),h,2.43,70350,DB00316,Acetaminophen
,2058179,plasma clearance,"2. Across all subjects acetaminophen plasma clearance was reduced from 0.249 +/- 0.061 to 0.217 +/- 0.066 l/min after disulfiram treatment (mean +/- SD, P less than 0.05).",The influence of disulfiram on acetaminophen metabolism in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058179/),[l] / [min],0.249,71004,DB00316,Acetaminophen
,2058179,plasma clearance,"2. Across all subjects acetaminophen plasma clearance was reduced from 0.249 +/- 0.061 to 0.217 +/- 0.066 l/min after disulfiram treatment (mean +/- SD, P less than 0.05).",The influence of disulfiram on acetaminophen metabolism in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058179/),[l] / [min],0.217,71005,DB00316,Acetaminophen
,24356809,C(max),C(max) of phenacetin was significantly (p < 0.01) decreased to 19.50 ± 2.74 μg mL(-1) in inflamed conditions compared to 38.13 ± 2.20 μg mL(-1) obtained in normal rats.,Turpentine oil induced inflammation decreases absorption and increases distribution of phenacetin without altering its elimination process in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24356809/),[μg] / [ml],19.50,71037,DB00316,Acetaminophen
,24356809,C(max),C(max) of phenacetin was significantly (p < 0.01) decreased to 19.50 ± 2.74 μg mL(-1) in inflamed conditions compared to 38.13 ± 2.20 μg mL(-1) obtained in normal rats.,Turpentine oil induced inflammation decreases absorption and increases distribution of phenacetin without altering its elimination process in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24356809/),[μg] / [ml],38.13,71038,DB00316,Acetaminophen
,24356809,volume of distribution at steady state (V(dss)),"Except, for significant (p < 0.001) increase in volume of distribution at steady state (V(dss)) from 2.87 ± 0.37 to 8.03 ± 1.26 L kg(-1) and increased the rate of absorption with shorter absorption half-life (t(1/2ka)) for phenacetin in inflammation.",Turpentine oil induced inflammation decreases absorption and increases distribution of phenacetin without altering its elimination process in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24356809/),[l] / [kg],2.87,71039,DB00316,Acetaminophen
,24356809,volume of distribution at steady state (V(dss)),"Except, for significant (p < 0.001) increase in volume of distribution at steady state (V(dss)) from 2.87 ± 0.37 to 8.03 ± 1.26 L kg(-1) and increased the rate of absorption with shorter absorption half-life (t(1/2ka)) for phenacetin in inflammation.",Turpentine oil induced inflammation decreases absorption and increases distribution of phenacetin without altering its elimination process in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24356809/),[l] / [kg],8.03,71040,DB00316,Acetaminophen
,3955446,plasma half-life (beta t/2),"The plasma half-life (beta t/2) (mean +/- SD) of acetaminophen was 1.87 +/- 0.30 h, while that of the only metabolite detected in plasma, the glucuronide, was 2.41 +/- 0.64 h.","Acetaminophen in the guinea pig: metabolite identification in blood, urine, and bile. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3955446/),h,1.87,71134,DB00316,Acetaminophen
,3955446,plasma half-life (beta t/2),"The plasma half-life (beta t/2) (mean +/- SD) of acetaminophen was 1.87 +/- 0.30 h, while that of the only metabolite detected in plasma, the glucuronide, was 2.41 +/- 0.64 h.","Acetaminophen in the guinea pig: metabolite identification in blood, urine, and bile. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3955446/),h,2.41,71135,DB00316,Acetaminophen
,25500485,relative bioavailability,"The estimates of relative bioavailability of new SR with IR formulation based on dose-adjusted AUC0-inf were 91% (0.86-0.96) for the fasted state and 99% (0.95-1.02) for the fed state, while these estimates comparing new SR with ER formulation were 99% (0.96-1.03) in the fasted state and 98% (0.95-1.02) in the fed state.",Bioavailability and pharmacokinetic profile of a newly-developed twice-a-day sustained-release paracetamol formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500485/),%,91,71288,DB00316,Acetaminophen
,25500485,relative bioavailability,"The estimates of relative bioavailability of new SR with IR formulation based on dose-adjusted AUC0-inf were 91% (0.86-0.96) for the fasted state and 99% (0.95-1.02) for the fed state, while these estimates comparing new SR with ER formulation were 99% (0.96-1.03) in the fasted state and 98% (0.95-1.02) in the fed state.",Bioavailability and pharmacokinetic profile of a newly-developed twice-a-day sustained-release paracetamol formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500485/),%,99,71289,DB00316,Acetaminophen
,25500485,relative bioavailability,"The estimates of relative bioavailability of new SR with IR formulation based on dose-adjusted AUC0-inf were 91% (0.86-0.96) for the fasted state and 99% (0.95-1.02) for the fed state, while these estimates comparing new SR with ER formulation were 99% (0.96-1.03) in the fasted state and 98% (0.95-1.02) in the fed state.",Bioavailability and pharmacokinetic profile of a newly-developed twice-a-day sustained-release paracetamol formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500485/),%,99,71290,DB00316,Acetaminophen
,25500485,relative bioavailability,"The estimates of relative bioavailability of new SR with IR formulation based on dose-adjusted AUC0-inf were 91% (0.86-0.96) for the fasted state and 99% (0.95-1.02) for the fed state, while these estimates comparing new SR with ER formulation were 99% (0.96-1.03) in the fasted state and 98% (0.95-1.02) in the fed state.",Bioavailability and pharmacokinetic profile of a newly-developed twice-a-day sustained-release paracetamol formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500485/),%,98,71291,DB00316,Acetaminophen
more,25500485,relative bioavailability,"The new SR formulation was well absorbed, with more than 90% relative bioavailability as compared to the currently marketed IR and ER products and better sustained-release PK characteristics, which make it suitable for twice-daily paracetamol treatment.",Bioavailability and pharmacokinetic profile of a newly-developed twice-a-day sustained-release paracetamol formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500485/),%,90,71292,DB00316,Acetaminophen
,12207865,limit of detection,"The assay proved inexpensive, accurate and reproducible with a limit of detection of 100 ng/ml that makes it suitable for bioavailability studies.",A quantitative thin layer chromatography method for determination of theophylline in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207865/),[ng] / [ml],100,71889,DB00316,Acetaminophen
,7398738,bioavailability,The bioavailability of the suppositories was approximately 80% of that of the tablets at both dose levels.,Relative bioavailability of a paracetamol suppository. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7398738/),%,80,72581,DB00316,Acetaminophen
,6694118,Biliary excretion,Biliary excretion of the various metabolites of acetaminophen increased from 20 to 49% as the dosage was increased from 37.5 to 600 mg/kg.,Glucuronidation and biliary excretion of acetaminophen in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6694118/),%,20,73728,DB00316,Acetaminophen
,22845052,Total clearance,"Total clearance was higher in women at delivery compared with 12th post-partum week (21.1 vs. 11.7 l h⁻¹) due to higher clearances to paracetamol glucuronide (11.6 vs. 4.76 l h⁻¹), to oxidative metabolites (4.95 vs. 2.77 l h⁻¹) and of unchanged paracetamol (1.15 vs. 0.75 l h⁻¹).",Pharmacokinetics of paracetamol and its metabolites in women at delivery and post-partum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22845052/),h⁻¹·l,21.1,73912,DB00316,Acetaminophen
,22845052,Total clearance,"Total clearance was higher in women at delivery compared with 12th post-partum week (21.1 vs. 11.7 l h⁻¹) due to higher clearances to paracetamol glucuronide (11.6 vs. 4.76 l h⁻¹), to oxidative metabolites (4.95 vs. 2.77 l h⁻¹) and of unchanged paracetamol (1.15 vs. 0.75 l h⁻¹).",Pharmacokinetics of paracetamol and its metabolites in women at delivery and post-partum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22845052/),h⁻¹·l,11.7,73913,DB00316,Acetaminophen
,22845052,clearances,"Total clearance was higher in women at delivery compared with 12th post-partum week (21.1 vs. 11.7 l h⁻¹) due to higher clearances to paracetamol glucuronide (11.6 vs. 4.76 l h⁻¹), to oxidative metabolites (4.95 vs. 2.77 l h⁻¹) and of unchanged paracetamol (1.15 vs. 0.75 l h⁻¹).",Pharmacokinetics of paracetamol and its metabolites in women at delivery and post-partum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22845052/),h⁻¹·l,11.6,73914,DB00316,Acetaminophen
,22845052,clearances,"Total clearance was higher in women at delivery compared with 12th post-partum week (21.1 vs. 11.7 l h⁻¹) due to higher clearances to paracetamol glucuronide (11.6 vs. 4.76 l h⁻¹), to oxidative metabolites (4.95 vs. 2.77 l h⁻¹) and of unchanged paracetamol (1.15 vs. 0.75 l h⁻¹).",Pharmacokinetics of paracetamol and its metabolites in women at delivery and post-partum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22845052/),h⁻¹·l,4.76,73915,DB00316,Acetaminophen
,22845052,clearances,"Total clearance was higher in women at delivery compared with 12th post-partum week (21.1 vs. 11.7 l h⁻¹) due to higher clearances to paracetamol glucuronide (11.6 vs. 4.76 l h⁻¹), to oxidative metabolites (4.95 vs. 2.77 l h⁻¹) and of unchanged paracetamol (1.15 vs. 0.75 l h⁻¹).",Pharmacokinetics of paracetamol and its metabolites in women at delivery and post-partum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22845052/),h⁻¹·l,4.95,73916,DB00316,Acetaminophen
,22845052,clearances,"Total clearance was higher in women at delivery compared with 12th post-partum week (21.1 vs. 11.7 l h⁻¹) due to higher clearances to paracetamol glucuronide (11.6 vs. 4.76 l h⁻¹), to oxidative metabolites (4.95 vs. 2.77 l h⁻¹) and of unchanged paracetamol (1.15 vs. 0.75 l h⁻¹).",Pharmacokinetics of paracetamol and its metabolites in women at delivery and post-partum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22845052/),h⁻¹·l,2.77,73917,DB00316,Acetaminophen
,22845052,clearances,"Total clearance was higher in women at delivery compared with 12th post-partum week (21.1 vs. 11.7 l h⁻¹) due to higher clearances to paracetamol glucuronide (11.6 vs. 4.76 l h⁻¹), to oxidative metabolites (4.95 vs. 2.77 l h⁻¹) and of unchanged paracetamol (1.15 vs. 0.75 l h⁻¹).",Pharmacokinetics of paracetamol and its metabolites in women at delivery and post-partum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22845052/),h⁻¹·l,1.15,73918,DB00316,Acetaminophen
,22845052,clearances,"Total clearance was higher in women at delivery compared with 12th post-partum week (21.1 vs. 11.7 l h⁻¹) due to higher clearances to paracetamol glucuronide (11.6 vs. 4.76 l h⁻¹), to oxidative metabolites (4.95 vs. 2.77 l h⁻¹) and of unchanged paracetamol (1.15 vs. 0.75 l h⁻¹).",Pharmacokinetics of paracetamol and its metabolites in women at delivery and post-partum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22845052/),h⁻¹·l,0.75,73919,DB00316,Acetaminophen
,3557735,relative bioavailabilities,"The relative bioavailabilities for Brands A, B and C were found to be 97.87, 95.41 and 98.78%, respectively, with respect to the solution.",Comparative bioavailability of three commercial acetaminophen tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557735/),%,97.87,73928,DB00316,Acetaminophen
,3557735,relative bioavailabilities,"The relative bioavailabilities for Brands A, B and C were found to be 97.87, 95.41 and 98.78%, respectively, with respect to the solution.",Comparative bioavailability of three commercial acetaminophen tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557735/),%,95.41,73929,DB00316,Acetaminophen
,3557735,relative bioavailabilities,"The relative bioavailabilities for Brands A, B and C were found to be 97.87, 95.41 and 98.78%, respectively, with respect to the solution.",Comparative bioavailability of three commercial acetaminophen tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557735/),%,98.78,73930,DB00316,Acetaminophen
,10628898,absolute bioavailability,The absolute bioavailability of the active metabolite from orally administered oseltamivir is 80%.,Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10628898/),%,80,74584,DB00316,Acetaminophen
,10628898,apparent half-life,"After peak plasma concentrations are attained, the concentration of the active metabolite declines with an apparent half-life of 6 to 10 hours.",Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10628898/),h,6 to 10,74585,DB00316,Acetaminophen
,30856016,elimination half-life,Initial paracetamol elimination half-life was 14.5 h.,A case of accidental neonatal paracetamol overdose with prolonged half-life and measured metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30856016/),h,14.5,75216,DB00316,Acetaminophen
,2049250,AUC,"4. By contrast, the AUC for levodopa following the low protein meal (193.9 +/- 15.7 micrograms ml-1 min) was significantly lower compared with administration in the fasted state (216.5 +/- 26.1 micrograms ml-1 min).",The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049250/),[min·μg] / [ml],193.9,76030,DB00316,Acetaminophen
,2049250,AUC,"4. By contrast, the AUC for levodopa following the low protein meal (193.9 +/- 15.7 micrograms ml-1 min) was significantly lower compared with administration in the fasted state (216.5 +/- 26.1 micrograms ml-1 min).",The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049250/),[min·μg] / [ml],216.5,76031,DB00316,Acetaminophen
,2775340,AUC0-12h,"The plasma concentration-time curves of paracetamol following administration of the oral formulations were very similar; consequently there were only minor differences of the AUC0-12h (21.4, 21.9; 23.0, 22.8 micrograms.h/ml), cmax (8.8, 9.1; 10.0, 10.7 micrograms/ml), tmax (35, 25; 20, 19 min), and the terminal plasma elimination half-life t1/2 beta (2.95, 2.85; 2.86, 2.99 h) for the solid and the liquid test and reference preparations, respectively.",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),[h·μg] / [ml],21.4,76543,DB00316,Acetaminophen
,2775340,AUC0-12h,"The plasma concentration-time curves of paracetamol following administration of the oral formulations were very similar; consequently there were only minor differences of the AUC0-12h (21.4, 21.9; 23.0, 22.8 micrograms.h/ml), cmax (8.8, 9.1; 10.0, 10.7 micrograms/ml), tmax (35, 25; 20, 19 min), and the terminal plasma elimination half-life t1/2 beta (2.95, 2.85; 2.86, 2.99 h) for the solid and the liquid test and reference preparations, respectively.",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),[h·μg] / [ml],21.9,76544,DB00316,Acetaminophen
,2775340,AUC0-12h,"The plasma concentration-time curves of paracetamol following administration of the oral formulations were very similar; consequently there were only minor differences of the AUC0-12h (21.4, 21.9; 23.0, 22.8 micrograms.h/ml), cmax (8.8, 9.1; 10.0, 10.7 micrograms/ml), tmax (35, 25; 20, 19 min), and the terminal plasma elimination half-life t1/2 beta (2.95, 2.85; 2.86, 2.99 h) for the solid and the liquid test and reference preparations, respectively.",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),[h·μg] / [ml],23.0,76545,DB00316,Acetaminophen
,2775340,AUC0-12h,"The plasma concentration-time curves of paracetamol following administration of the oral formulations were very similar; consequently there were only minor differences of the AUC0-12h (21.4, 21.9; 23.0, 22.8 micrograms.h/ml), cmax (8.8, 9.1; 10.0, 10.7 micrograms/ml), tmax (35, 25; 20, 19 min), and the terminal plasma elimination half-life t1/2 beta (2.95, 2.85; 2.86, 2.99 h) for the solid and the liquid test and reference preparations, respectively.",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),[h·μg] / [ml],22.8,76546,DB00316,Acetaminophen
,2775340,cmax,"The plasma concentration-time curves of paracetamol following administration of the oral formulations were very similar; consequently there were only minor differences of the AUC0-12h (21.4, 21.9; 23.0, 22.8 micrograms.h/ml), cmax (8.8, 9.1; 10.0, 10.7 micrograms/ml), tmax (35, 25; 20, 19 min), and the terminal plasma elimination half-life t1/2 beta (2.95, 2.85; 2.86, 2.99 h) for the solid and the liquid test and reference preparations, respectively.",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),[μg] / [ml],8.8,76547,DB00316,Acetaminophen
,2775340,cmax,"The plasma concentration-time curves of paracetamol following administration of the oral formulations were very similar; consequently there were only minor differences of the AUC0-12h (21.4, 21.9; 23.0, 22.8 micrograms.h/ml), cmax (8.8, 9.1; 10.0, 10.7 micrograms/ml), tmax (35, 25; 20, 19 min), and the terminal plasma elimination half-life t1/2 beta (2.95, 2.85; 2.86, 2.99 h) for the solid and the liquid test and reference preparations, respectively.",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),[μg] / [ml],9.1,76548,DB00316,Acetaminophen
,2775340,cmax,"The plasma concentration-time curves of paracetamol following administration of the oral formulations were very similar; consequently there were only minor differences of the AUC0-12h (21.4, 21.9; 23.0, 22.8 micrograms.h/ml), cmax (8.8, 9.1; 10.0, 10.7 micrograms/ml), tmax (35, 25; 20, 19 min), and the terminal plasma elimination half-life t1/2 beta (2.95, 2.85; 2.86, 2.99 h) for the solid and the liquid test and reference preparations, respectively.",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),[μg] / [ml],10.0,76549,DB00316,Acetaminophen
,2775340,cmax,"The plasma concentration-time curves of paracetamol following administration of the oral formulations were very similar; consequently there were only minor differences of the AUC0-12h (21.4, 21.9; 23.0, 22.8 micrograms.h/ml), cmax (8.8, 9.1; 10.0, 10.7 micrograms/ml), tmax (35, 25; 20, 19 min), and the terminal plasma elimination half-life t1/2 beta (2.95, 2.85; 2.86, 2.99 h) for the solid and the liquid test and reference preparations, respectively.",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),[μg] / [ml],10.7,76550,DB00316,Acetaminophen
,2775340,tmax,"The plasma concentration-time curves of paracetamol following administration of the oral formulations were very similar; consequently there were only minor differences of the AUC0-12h (21.4, 21.9; 23.0, 22.8 micrograms.h/ml), cmax (8.8, 9.1; 10.0, 10.7 micrograms/ml), tmax (35, 25; 20, 19 min), and the terminal plasma elimination half-life t1/2 beta (2.95, 2.85; 2.86, 2.99 h) for the solid and the liquid test and reference preparations, respectively.",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),min,35,76551,DB00316,Acetaminophen
,2775340,tmax,"The plasma concentration-time curves of paracetamol following administration of the oral formulations were very similar; consequently there were only minor differences of the AUC0-12h (21.4, 21.9; 23.0, 22.8 micrograms.h/ml), cmax (8.8, 9.1; 10.0, 10.7 micrograms/ml), tmax (35, 25; 20, 19 min), and the terminal plasma elimination half-life t1/2 beta (2.95, 2.85; 2.86, 2.99 h) for the solid and the liquid test and reference preparations, respectively.",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),min,25,76552,DB00316,Acetaminophen
,2775340,tmax,"The plasma concentration-time curves of paracetamol following administration of the oral formulations were very similar; consequently there were only minor differences of the AUC0-12h (21.4, 21.9; 23.0, 22.8 micrograms.h/ml), cmax (8.8, 9.1; 10.0, 10.7 micrograms/ml), tmax (35, 25; 20, 19 min), and the terminal plasma elimination half-life t1/2 beta (2.95, 2.85; 2.86, 2.99 h) for the solid and the liquid test and reference preparations, respectively.",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),min,20,76553,DB00316,Acetaminophen
,2775340,tmax,"The plasma concentration-time curves of paracetamol following administration of the oral formulations were very similar; consequently there were only minor differences of the AUC0-12h (21.4, 21.9; 23.0, 22.8 micrograms.h/ml), cmax (8.8, 9.1; 10.0, 10.7 micrograms/ml), tmax (35, 25; 20, 19 min), and the terminal plasma elimination half-life t1/2 beta (2.95, 2.85; 2.86, 2.99 h) for the solid and the liquid test and reference preparations, respectively.",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),min,19,76554,DB00316,Acetaminophen
,2775340,terminal plasma elimination half-life t1/2 beta,"The plasma concentration-time curves of paracetamol following administration of the oral formulations were very similar; consequently there were only minor differences of the AUC0-12h (21.4, 21.9; 23.0, 22.8 micrograms.h/ml), cmax (8.8, 9.1; 10.0, 10.7 micrograms/ml), tmax (35, 25; 20, 19 min), and the terminal plasma elimination half-life t1/2 beta (2.95, 2.85; 2.86, 2.99 h) for the solid and the liquid test and reference preparations, respectively.",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),h,2.95,76555,DB00316,Acetaminophen
,2775340,terminal plasma elimination half-life t1/2 beta,"The plasma concentration-time curves of paracetamol following administration of the oral formulations were very similar; consequently there were only minor differences of the AUC0-12h (21.4, 21.9; 23.0, 22.8 micrograms.h/ml), cmax (8.8, 9.1; 10.0, 10.7 micrograms/ml), tmax (35, 25; 20, 19 min), and the terminal plasma elimination half-life t1/2 beta (2.95, 2.85; 2.86, 2.99 h) for the solid and the liquid test and reference preparations, respectively.",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),h,2.85,76556,DB00316,Acetaminophen
,2775340,terminal plasma elimination half-life t1/2 beta,"The plasma concentration-time curves of paracetamol following administration of the oral formulations were very similar; consequently there were only minor differences of the AUC0-12h (21.4, 21.9; 23.0, 22.8 micrograms.h/ml), cmax (8.8, 9.1; 10.0, 10.7 micrograms/ml), tmax (35, 25; 20, 19 min), and the terminal plasma elimination half-life t1/2 beta (2.95, 2.85; 2.86, 2.99 h) for the solid and the liquid test and reference preparations, respectively.",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),h,2.86,76557,DB00316,Acetaminophen
,2775340,terminal plasma elimination half-life t1/2 beta,"The plasma concentration-time curves of paracetamol following administration of the oral formulations were very similar; consequently there were only minor differences of the AUC0-12h (21.4, 21.9; 23.0, 22.8 micrograms.h/ml), cmax (8.8, 9.1; 10.0, 10.7 micrograms/ml), tmax (35, 25; 20, 19 min), and the terminal plasma elimination half-life t1/2 beta (2.95, 2.85; 2.86, 2.99 h) for the solid and the liquid test and reference preparations, respectively.",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),h,2.99,76558,DB00316,Acetaminophen
,2775340,AUC0-12h,"The suppositories (test and reference formulation) differed from the oral dosage forms, but were comparable to each other with respect to AUC0-12h (18.2, 18.8 micrograms.h/ml), cmax (3.3, 3.5 micrograms/ml), tmax (1.6, 2.45 h), and t1/2 beta (3.55, 3.54 h).",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),[h·μg] / [ml],18.2,76559,DB00316,Acetaminophen
,2775340,AUC0-12h,"The suppositories (test and reference formulation) differed from the oral dosage forms, but were comparable to each other with respect to AUC0-12h (18.2, 18.8 micrograms.h/ml), cmax (3.3, 3.5 micrograms/ml), tmax (1.6, 2.45 h), and t1/2 beta (3.55, 3.54 h).",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),[h·μg] / [ml],18.8,76560,DB00316,Acetaminophen
,2775340,cmax,"The suppositories (test and reference formulation) differed from the oral dosage forms, but were comparable to each other with respect to AUC0-12h (18.2, 18.8 micrograms.h/ml), cmax (3.3, 3.5 micrograms/ml), tmax (1.6, 2.45 h), and t1/2 beta (3.55, 3.54 h).",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),[μg] / [ml],3.3,76561,DB00316,Acetaminophen
,2775340,cmax,"The suppositories (test and reference formulation) differed from the oral dosage forms, but were comparable to each other with respect to AUC0-12h (18.2, 18.8 micrograms.h/ml), cmax (3.3, 3.5 micrograms/ml), tmax (1.6, 2.45 h), and t1/2 beta (3.55, 3.54 h).",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),[μg] / [ml],3.5,76562,DB00316,Acetaminophen
,2775340,tmax,"The suppositories (test and reference formulation) differed from the oral dosage forms, but were comparable to each other with respect to AUC0-12h (18.2, 18.8 micrograms.h/ml), cmax (3.3, 3.5 micrograms/ml), tmax (1.6, 2.45 h), and t1/2 beta (3.55, 3.54 h).",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),h,1.6,76563,DB00316,Acetaminophen
,2775340,tmax,"The suppositories (test and reference formulation) differed from the oral dosage forms, but were comparable to each other with respect to AUC0-12h (18.2, 18.8 micrograms.h/ml), cmax (3.3, 3.5 micrograms/ml), tmax (1.6, 2.45 h), and t1/2 beta (3.55, 3.54 h).",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),h,2.45,76564,DB00316,Acetaminophen
,2775340,t1/2 beta,"The suppositories (test and reference formulation) differed from the oral dosage forms, but were comparable to each other with respect to AUC0-12h (18.2, 18.8 micrograms.h/ml), cmax (3.3, 3.5 micrograms/ml), tmax (1.6, 2.45 h), and t1/2 beta (3.55, 3.54 h).",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),h,3.55,76565,DB00316,Acetaminophen
,2775340,t1/2 beta,"The suppositories (test and reference formulation) differed from the oral dosage forms, but were comparable to each other with respect to AUC0-12h (18.2, 18.8 micrograms.h/ml), cmax (3.3, 3.5 micrograms/ml), tmax (1.6, 2.45 h), and t1/2 beta (3.55, 3.54 h).",[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775340/),h,3.54,76566,DB00316,Acetaminophen
,24792825,gastric transit times,"Mean gastric transit times were determined to be 0.63 h, 1.36 h, and 0.73 h for solution, capsules, and tablets, respectively.",Pharmacokinetics of paracetamol in Göttingen minipigs: in vivo studies and modeling to elucidate physiological determinants of absorption. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24792825/),h,0.63,76895,DB00316,Acetaminophen
,24792825,gastric transit times,"Mean gastric transit times were determined to be 0.63 h, 1.36 h, and 0.73 h for solution, capsules, and tablets, respectively.",Pharmacokinetics of paracetamol in Göttingen minipigs: in vivo studies and modeling to elucidate physiological determinants of absorption. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24792825/),h,1.36,76896,DB00316,Acetaminophen
,24792825,gastric transit times,"Mean gastric transit times were determined to be 0.63 h, 1.36 h, and 0.73 h for solution, capsules, and tablets, respectively.",Pharmacokinetics of paracetamol in Göttingen minipigs: in vivo studies and modeling to elucidate physiological determinants of absorption. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24792825/),h,0.73,76897,DB00316,Acetaminophen
,1977396,Recovery,Recovery of the analytical substances ranged from 82.7% for paracetamol to 98.5% for salicylic acid.,High-pressure liquid chromatographic evaluation of cyclic paracetamol-acetylsalicylate and its active metabolites with results of a comparative pharmacokinetic investigation in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1977396/),%,82.7,77492,DB00316,Acetaminophen
,1977396,Recovery,Recovery of the analytical substances ranged from 82.7% for paracetamol to 98.5% for salicylic acid.,High-pressure liquid chromatographic evaluation of cyclic paracetamol-acetylsalicylate and its active metabolites with results of a comparative pharmacokinetic investigation in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1977396/),%,98.5,77493,DB00316,Acetaminophen
,1804863,area under the indomethacin plasma concentration curve AUC 0-alpha,The mean area under the indomethacin plasma concentration curve AUC 0-alpha was 10.4 +/- 4.21 micrograms/mL x hr and did not change during combined paracetamol treatment (11.0 +/- 3.24 micrograms/mL x hr NS).,Lack of effect of paracetamol on the pharmacokinetics of indomethacin and paracetamol in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804863/),[μg] / [h·ml],10.4,77546,DB00316,Acetaminophen
,1804863,area under the indomethacin plasma concentration curve AUC 0-alpha,The mean area under the indomethacin plasma concentration curve AUC 0-alpha was 10.4 +/- 4.21 micrograms/mL x hr and did not change during combined paracetamol treatment (11.0 +/- 3.24 micrograms/mL x hr NS).,Lack of effect of paracetamol on the pharmacokinetics of indomethacin and paracetamol in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804863/),[μg] / [h·ml],11.0,77547,DB00316,Acetaminophen
,20523867,AUC(0-12),"Imatinib AUC(0-12) was 27.04 +/- 0.38 mg.h/ml, C(max) was 7.21 +/- 0.99 mg/ml and elimination half-life was 2.3 hours.",Reduced exposure of imatinib after coadministration with acetaminophen in mice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20523867/),[h·mg] / [ml],27.04,78021,DB00316,Acetaminophen
,20523867,C(max),"Imatinib AUC(0-12) was 27.04 +/- 0.38 mg.h/ml, C(max) was 7.21 +/- 0.99 mg/ml and elimination half-life was 2.3 hours.",Reduced exposure of imatinib after coadministration with acetaminophen in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20523867/),[mg] / [ml],7.21,78022,DB00316,Acetaminophen
,20523867,elimination half-life,"Imatinib AUC(0-12) was 27.04 +/- 0.38 mg.h/ml, C(max) was 7.21 +/- 0.99 mg/ml and elimination half-life was 2.3 hours.",Reduced exposure of imatinib after coadministration with acetaminophen in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20523867/),h,2.3,78023,DB00316,Acetaminophen
,20523867,half-life,"Acetaminophen affected the imatinib disposition profile: AUC(0-12) and C(max) decreased 56% and 59%, respectively and a longer half-life was observed (5.6 hours).",Reduced exposure of imatinib after coadministration with acetaminophen in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20523867/),h,5.6,78024,DB00316,Acetaminophen
,15362593,Cmax,"After the acetaminophen ingestion, median Cmax occurred at 1 h for all three exposures but was lower in the atropine-treated study arm (31+/-19 mg/L) than in the control or charcoal alone intervention arms (49+/-13 and 51+/-16 mg/L, respectively) (P<0.05).",Effect of anticholinergic drugs on the efficacy of activated charcoal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15362593/),[mg] / [l],31,79313,DB00316,Acetaminophen
,15362593,Cmax,"After the acetaminophen ingestion, median Cmax occurred at 1 h for all three exposures but was lower in the atropine-treated study arm (31+/-19 mg/L) than in the control or charcoal alone intervention arms (49+/-13 and 51+/-16 mg/L, respectively) (P<0.05).",Effect of anticholinergic drugs on the efficacy of activated charcoal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15362593/),[mg] / [l],49,79314,DB00316,Acetaminophen
,15362593,Cmax,"After the acetaminophen ingestion, median Cmax occurred at 1 h for all three exposures but was lower in the atropine-treated study arm (31+/-19 mg/L) than in the control or charcoal alone intervention arms (49+/-13 and 51+/-16 mg/L, respectively) (P<0.05).",Effect of anticholinergic drugs on the efficacy of activated charcoal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15362593/),[mg] / [l],51,79315,DB00316,Acetaminophen
,24815417,half-time,Analgesia onset had an equilibration half-time of 0.496 h for acetaminophen and 0.23 h for diclofenac.,Postoperative analgesia using diclofenac and acetaminophen in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815417/),h,0.496,81110,DB00316,Acetaminophen
,24815417,half-time,Analgesia onset had an equilibration half-time of 0.496 h for acetaminophen and 0.23 h for diclofenac.,Postoperative analgesia using diclofenac and acetaminophen in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815417/),h,0.23,81111,DB00316,Acetaminophen
,24815417,maximum effect (EMAX ),The maximum effect (EMAX ) was 4.9.,Postoperative analgesia using diclofenac and acetaminophen in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815417/),,4.9,81112,DB00316,Acetaminophen
,24815417,concentration,The concentration resulting in 50% of EMAX (C50 ) was 1.23 mg·l(-1) for diclofenac and 13.3 mg·l(-1) for acetaminophen.,Postoperative analgesia using diclofenac and acetaminophen in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815417/),[mg] / [l],1.23,81113,DB00316,Acetaminophen
,24815417,concentration,The concentration resulting in 50% of EMAX (C50 ) was 1.23 mg·l(-1) for diclofenac and 13.3 mg·l(-1) for acetaminophen.,Postoperative analgesia using diclofenac and acetaminophen in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815417/),[mg] / [l],13.3,81114,DB00316,Acetaminophen
,24815417,peak placebo effect,A peak placebo effect of 6.8 occurred at 4 h.,Postoperative analgesia using diclofenac and acetaminophen in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815417/),,6.8,81115,DB00316,Acetaminophen
,34281773,Fe',Anaesthesia was maintained with isoflurane in 50% oxygen (Fe'Iso 1.3-1.5%).,Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),%,1.3-1.5,81318,DB00316,Acetaminophen
,34281773,volume of distribution,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),[l] / [kg],1.41,81319,DB00316,Acetaminophen
,34281773,volume of distribution,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),[l] / [kg],1.72,81320,DB00316,Acetaminophen
,34281773,clearance,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),[l] / [h·kg],1.52,81321,DB00316,Acetaminophen
,34281773,clearance,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),[l] / [h·kg],1.60,81322,DB00316,Acetaminophen
,34281773,terminal elimination half-life,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),h,2.45,81323,DB00316,Acetaminophen
,34281773,terminal elimination half-life,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),h,3.57,81324,DB00316,Acetaminophen
,688732,half-time for transfer,The mean half-time for transfer was 6.8 +/- 0.9 min.,Kinetics of acetaminophen absorption and gastric emptying in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688732/),min,6.8,83058,DB00316,Acetaminophen
,7985514,half-life,The half-life of antipyrine was found to be 18.8 +/- 4.89 h in 16 Han and 15.0 +/- 3.02 h in 17 Tibetan (P < 0.05) and the clearance was 1.35 +/- 0.37 L.h-1 in Han and 1.71 +/- 0.44 L.h-1 in Tibetan (P < 0.05).,Ethnic differences in disposition of antipyrine and acetaminophen between Tibetan and Han healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985514/),h,18.8,83279,DB00316,Acetaminophen
,7985514,half-life,The half-life of antipyrine was found to be 18.8 +/- 4.89 h in 16 Han and 15.0 +/- 3.02 h in 17 Tibetan (P < 0.05) and the clearance was 1.35 +/- 0.37 L.h-1 in Han and 1.71 +/- 0.44 L.h-1 in Tibetan (P < 0.05).,Ethnic differences in disposition of antipyrine and acetaminophen between Tibetan and Han healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985514/),h,15.0,83280,DB00316,Acetaminophen
,7985514,clearance,The half-life of antipyrine was found to be 18.8 +/- 4.89 h in 16 Han and 15.0 +/- 3.02 h in 17 Tibetan (P < 0.05) and the clearance was 1.35 +/- 0.37 L.h-1 in Han and 1.71 +/- 0.44 L.h-1 in Tibetan (P < 0.05).,Ethnic differences in disposition of antipyrine and acetaminophen between Tibetan and Han healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985514/),[l] / [h],1.35,83281,DB00316,Acetaminophen
,7985514,clearance,The half-life of antipyrine was found to be 18.8 +/- 4.89 h in 16 Han and 15.0 +/- 3.02 h in 17 Tibetan (P < 0.05) and the clearance was 1.35 +/- 0.37 L.h-1 in Han and 1.71 +/- 0.44 L.h-1 in Tibetan (P < 0.05).,Ethnic differences in disposition of antipyrine and acetaminophen between Tibetan and Han healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985514/),[l] / [h],1.71,83282,DB00316,Acetaminophen
,7985514,half-life,The half-life of acetaminophen was 3.1 +/- 0.86 h in Han and 3.2 +/- 1.12 h in Tibetan (P > 0.05).,Ethnic differences in disposition of antipyrine and acetaminophen between Tibetan and Han healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985514/),h,3.1,83283,DB00316,Acetaminophen
,7985514,half-life,The half-life of acetaminophen was 3.1 +/- 0.86 h in Han and 3.2 +/- 1.12 h in Tibetan (P > 0.05).,Ethnic differences in disposition of antipyrine and acetaminophen between Tibetan and Han healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985514/),h,3.2,83284,DB00316,Acetaminophen
,25965875,m/,"The MRM transitions of m/z 151.2→110.0 and m/z 302.3→199.2 were used to quantify for AAP and DHC, respectively.",Simultaneous determination of acetaminophen and dihydrocodeine in human plasma by UPLC-MS/MS: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25965875/),,151.2,83339,DB00316,Acetaminophen
,25965875,m/,"The MRM transitions of m/z 151.2→110.0 and m/z 302.3→199.2 were used to quantify for AAP and DHC, respectively.",Simultaneous determination of acetaminophen and dihydrocodeine in human plasma by UPLC-MS/MS: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25965875/),,110.0,83340,DB00316,Acetaminophen
,25965875,m/z,"The MRM transitions of m/z 151.2→110.0 and m/z 302.3→199.2 were used to quantify for AAP and DHC, respectively.",Simultaneous determination of acetaminophen and dihydrocodeine in human plasma by UPLC-MS/MS: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25965875/),,302.3,83341,DB00316,Acetaminophen
,25965875,m/z,"The MRM transitions of m/z 151.2→110.0 and m/z 302.3→199.2 were used to quantify for AAP and DHC, respectively.",Simultaneous determination of acetaminophen and dihydrocodeine in human plasma by UPLC-MS/MS: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25965875/),,199.2,83342,DB00316,Acetaminophen
,25965875,analysis time of,The analysis time of per sample was 1.0min.,Simultaneous determination of acetaminophen and dihydrocodeine in human plasma by UPLC-MS/MS: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25965875/),min,1.0,83343,DB00316,Acetaminophen
,18596312,Cmax,"Compared with baseline, erythromycin increased Cmax (9.5 +/- 6.1 mg/L to 17.7 +/- 11.9 mg/L, P < .01), C(60) (5.4 +/- 3.5 mg/L to 12.9 +/- 7.6 mg/L, P < .01), and AUC(0-60) (3.5 +/- 3.0 mg.h/L to 12.5 +/- 8.7 mg.h/L, P < .01), while metoclopramide increased only AUC(0-60) (4.4 +/- 2.8 mg.h/L to 9.5 +/- 3.8 mg.hr/L, P < .05).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[mg] / [l],9.5,83751,DB00316,Acetaminophen
,18596312,Cmax,"Compared with baseline, erythromycin increased Cmax (9.5 +/- 6.1 mg/L to 17.7 +/- 11.9 mg/L, P < .01), C(60) (5.4 +/- 3.5 mg/L to 12.9 +/- 7.6 mg/L, P < .01), and AUC(0-60) (3.5 +/- 3.0 mg.h/L to 12.5 +/- 8.7 mg.h/L, P < .01), while metoclopramide increased only AUC(0-60) (4.4 +/- 2.8 mg.h/L to 9.5 +/- 3.8 mg.hr/L, P < .05).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[mg] / [l],17.7,83752,DB00316,Acetaminophen
,18596312,C(60),"Compared with baseline, erythromycin increased Cmax (9.5 +/- 6.1 mg/L to 17.7 +/- 11.9 mg/L, P < .01), C(60) (5.4 +/- 3.5 mg/L to 12.9 +/- 7.6 mg/L, P < .01), and AUC(0-60) (3.5 +/- 3.0 mg.h/L to 12.5 +/- 8.7 mg.h/L, P < .01), while metoclopramide increased only AUC(0-60) (4.4 +/- 2.8 mg.h/L to 9.5 +/- 3.8 mg.hr/L, P < .05).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[mg] / [l],5.4,83753,DB00316,Acetaminophen
,18596312,C(60),"Compared with baseline, erythromycin increased Cmax (9.5 +/- 6.1 mg/L to 17.7 +/- 11.9 mg/L, P < .01), C(60) (5.4 +/- 3.5 mg/L to 12.9 +/- 7.6 mg/L, P < .01), and AUC(0-60) (3.5 +/- 3.0 mg.h/L to 12.5 +/- 8.7 mg.h/L, P < .01), while metoclopramide increased only AUC(0-60) (4.4 +/- 2.8 mg.h/L to 9.5 +/- 3.8 mg.hr/L, P < .05).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[mg] / [l],12.9,83754,DB00316,Acetaminophen
,18596312,AUC(0-60),"Compared with baseline, erythromycin increased Cmax (9.5 +/- 6.1 mg/L to 17.7 +/- 11.9 mg/L, P < .01), C(60) (5.4 +/- 3.5 mg/L to 12.9 +/- 7.6 mg/L, P < .01), and AUC(0-60) (3.5 +/- 3.0 mg.h/L to 12.5 +/- 8.7 mg.h/L, P < .01), while metoclopramide increased only AUC(0-60) (4.4 +/- 2.8 mg.h/L to 9.5 +/- 3.8 mg.hr/L, P < .05).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[h·mg] / [l],3.5,83755,DB00316,Acetaminophen
,18596312,AUC(0-60),"Compared with baseline, erythromycin increased Cmax (9.5 +/- 6.1 mg/L to 17.7 +/- 11.9 mg/L, P < .01), C(60) (5.4 +/- 3.5 mg/L to 12.9 +/- 7.6 mg/L, P < .01), and AUC(0-60) (3.5 +/- 3.0 mg.h/L to 12.5 +/- 8.7 mg.h/L, P < .01), while metoclopramide increased only AUC(0-60) (4.4 +/- 2.8 mg.h/L to 9.5 +/- 3.8 mg.hr/L, P < .05).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[h·mg] / [l],12.5,83756,DB00316,Acetaminophen
,18596312,AUC(0-60),"Compared with baseline, erythromycin increased Cmax (9.5 +/- 6.1 mg/L to 17.7 +/- 11.9 mg/L, P < .01), C(60) (5.4 +/- 3.5 mg/L to 12.9 +/- 7.6 mg/L, P < .01), and AUC(0-60) (3.5 +/- 3.0 mg.h/L to 12.5 +/- 8.7 mg.h/L, P < .01), while metoclopramide increased only AUC(0-60) (4.4 +/- 2.8 mg.h/L to 9.5 +/- 3.8 mg.hr/L, P < .05).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[h·mg] / [l],4.4,83757,DB00316,Acetaminophen
,18596312,AUC(0-60),"Compared with baseline, erythromycin increased Cmax (9.5 +/- 6.1 mg/L to 17.7 +/- 11.9 mg/L, P < .01), C(60) (5.4 +/- 3.5 mg/L to 12.9 +/- 7.6 mg/L, P < .01), and AUC(0-60) (3.5 +/- 3.0 mg.h/L to 12.5 +/- 8.7 mg.h/L, P < .01), while metoclopramide increased only AUC(0-60) (4.4 +/- 2.8 mg.h/L to 9.5 +/- 3.8 mg.hr/L, P < .05).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[h·mg] / [l],9.5,83758,DB00316,Acetaminophen
,18596312,residual volumes,"Both erythromycin and metoclopramide reduced residual volumes (122 +/- 48 mL to 36 +/- 48 mL, P < .01, and 103 +/- 88 mL to 21 +/- 23 mL, P < .05, respectively) and allowed increased feeding rates (17 +/- 23 mL/h to 45 +/- 21 mL/h, P < .05, and 14 +/- 17 mL/h to 44 +/- 22 mL/h, P < .05, respectively).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),ml,122,83759,DB00316,Acetaminophen
,18596312,residual volumes,"Both erythromycin and metoclopramide reduced residual volumes (122 +/- 48 mL to 36 +/- 48 mL, P < .01, and 103 +/- 88 mL to 21 +/- 23 mL, P < .05, respectively) and allowed increased feeding rates (17 +/- 23 mL/h to 45 +/- 21 mL/h, P < .05, and 14 +/- 17 mL/h to 44 +/- 22 mL/h, P < .05, respectively).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),ml,36,83760,DB00316,Acetaminophen
,18596312,residual volumes,"Both erythromycin and metoclopramide reduced residual volumes (122 +/- 48 mL to 36 +/- 48 mL, P < .01, and 103 +/- 88 mL to 21 +/- 23 mL, P < .05, respectively) and allowed increased feeding rates (17 +/- 23 mL/h to 45 +/- 21 mL/h, P < .05, and 14 +/- 17 mL/h to 44 +/- 22 mL/h, P < .05, respectively).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),ml,103,83761,DB00316,Acetaminophen
,18596312,residual volumes,"Both erythromycin and metoclopramide reduced residual volumes (122 +/- 48 mL to 36 +/- 48 mL, P < .01, and 103 +/- 88 mL to 21 +/- 23 mL, P < .05, respectively) and allowed increased feeding rates (17 +/- 23 mL/h to 45 +/- 21 mL/h, P < .05, and 14 +/- 17 mL/h to 44 +/- 22 mL/h, P < .05, respectively).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),ml,21,83762,DB00316,Acetaminophen
,18596312,feeding rates,"Both erythromycin and metoclopramide reduced residual volumes (122 +/- 48 mL to 36 +/- 48 mL, P < .01, and 103 +/- 88 mL to 21 +/- 23 mL, P < .05, respectively) and allowed increased feeding rates (17 +/- 23 mL/h to 45 +/- 21 mL/h, P < .05, and 14 +/- 17 mL/h to 44 +/- 22 mL/h, P < .05, respectively).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[ml] / [h],17,83763,DB00316,Acetaminophen
,18596312,feeding rates,"Both erythromycin and metoclopramide reduced residual volumes (122 +/- 48 mL to 36 +/- 48 mL, P < .01, and 103 +/- 88 mL to 21 +/- 23 mL, P < .05, respectively) and allowed increased feeding rates (17 +/- 23 mL/h to 45 +/- 21 mL/h, P < .05, and 14 +/- 17 mL/h to 44 +/- 22 mL/h, P < .05, respectively).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[ml] / [h],45,83764,DB00316,Acetaminophen
,18596312,feeding rates,"Both erythromycin and metoclopramide reduced residual volumes (122 +/- 48 mL to 36 +/- 48 mL, P < .01, and 103 +/- 88 mL to 21 +/- 23 mL, P < .05, respectively) and allowed increased feeding rates (17 +/- 23 mL/h to 45 +/- 21 mL/h, P < .05, and 14 +/- 17 mL/h to 44 +/- 22 mL/h, P < .05, respectively).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[ml] / [h],14,83765,DB00316,Acetaminophen
,18596312,feeding rates,"Both erythromycin and metoclopramide reduced residual volumes (122 +/- 48 mL to 36 +/- 48 mL, P < .01, and 103 +/- 88 mL to 21 +/- 23 mL, P < .05, respectively) and allowed increased feeding rates (17 +/- 23 mL/h to 45 +/- 21 mL/h, P < .05, and 14 +/- 17 mL/h to 44 +/- 22 mL/h, P < .05, respectively).",Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18596312/),[ml] / [h],44,83766,DB00316,Acetaminophen
,19189088,AUC(OR),"A statistically significant difference was seen in the AUC(0-infinity) of bromazepam, with nasogastric administration decreasing availability by about 25%: AUC(OR) = 2501 ng mL(-1) h; AUC(NT) = 1855 ng mL(-1) h (p < 0.05); ratio (geometric mean) = 0.74 [90% confidence interval (CI) 0.64-0.87].","The bioavailability of bromazepam, omeprazole and paracetamol given by nasogastric feeding tube. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19189088/),[h·ng] / [ml],2501,83958,DB00316,Acetaminophen
,19189088,AUC(NT),"A statistically significant difference was seen in the AUC(0-infinity) of bromazepam, with nasogastric administration decreasing availability by about 25%: AUC(OR) = 2501 ng mL(-1) h; AUC(NT) = 1855 ng mL(-1) h (p < 0.05); ratio (geometric mean) = 0.74 [90% confidence interval (CI) 0.64-0.87].","The bioavailability of bromazepam, omeprazole and paracetamol given by nasogastric feeding tube. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19189088/),[h·ng] / [ml],1855,83959,DB00316,Acetaminophen
,19189088,half-life,"However, this does not appear to be clinically relevant given the usual dosage range and the drug's half-life (approx. 30 h).","The bioavailability of bromazepam, omeprazole and paracetamol given by nasogastric feeding tube. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19189088/),h,30,83960,DB00316,Acetaminophen
,19189088,AUC(OR),A large interindividual variability in omeprazole parameters prevented any statistical conclusion from being drawn in terms of both modes of administration despite their similar average profile: AUC(OR) = 579 ng mL(-1) h; AUC(NT) = 587 ng mL(-1) h (p > 0.05); ratio (geometric mean) = 1.01 (90% CI 0.64-1.61).,"The bioavailability of bromazepam, omeprazole and paracetamol given by nasogastric feeding tube. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19189088/),[h·ng] / [ml],579,83961,DB00316,Acetaminophen
,19189088,AUC(NT),A large interindividual variability in omeprazole parameters prevented any statistical conclusion from being drawn in terms of both modes of administration despite their similar average profile: AUC(OR) = 579 ng mL(-1) h; AUC(NT) = 587 ng mL(-1) h (p > 0.05); ratio (geometric mean) = 1.01 (90% CI 0.64-1.61).,"The bioavailability of bromazepam, omeprazole and paracetamol given by nasogastric feeding tube. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19189088/),[h·ng] / [ml],587,83962,DB00316,Acetaminophen
,19189088,AUC(OR),The narrow 90% confidence limits of paracetamol indicate bioequivalence: AUC(OR) = 37 microg mL(-1) h; AUC(NT) = 41 microg mL(-1) h(p > 0.05); ratio (geometric mean) = 1.12 (90% CI 0.98-1.28).,"The bioavailability of bromazepam, omeprazole and paracetamol given by nasogastric feeding tube. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19189088/),[h·μg] / [ml],37,83963,DB00316,Acetaminophen
,19189088,AUC(NT),The narrow 90% confidence limits of paracetamol indicate bioequivalence: AUC(OR) = 37 microg mL(-1) h; AUC(NT) = 41 microg mL(-1) h(p > 0.05); ratio (geometric mean) = 1.12 (90% CI 0.98-1.28).,"The bioavailability of bromazepam, omeprazole and paracetamol given by nasogastric feeding tube. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19189088/),[h·μg] / [ml],41,83964,DB00316,Acetaminophen
,31960977,time to peak concentration,"Following RYGBS, peak APAP concentrations at the 3-month and 12-month visits increased by 2.0-fold compared to baseline (p=0.0039 and p=0.0078, respectively) and the median time to peak concentration decreased from 35 to 10 minutes.",The Impact of Proximal Roux-en-Y Gastric Bypass Surgery on Acetaminophen Absorption and Metabolism. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31960977/),min,35,85349,DB00316,Acetaminophen
,31960977,time to peak concentration,"Following RYGBS, peak APAP concentrations at the 3-month and 12-month visits increased by 2.0-fold compared to baseline (p=0.0039 and p=0.0078, respectively) and the median time to peak concentration decreased from 35 to 10 minutes.",The Impact of Proximal Roux-en-Y Gastric Bypass Surgery on Acetaminophen Absorption and Metabolism. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31960977/),min,10,85350,DB00316,Acetaminophen
,2345775,clearance,"The clearance of antipyrine was significantly increased (0.93 vs. 0.60 ml/min/kg, p less than 0.0001) and elimination half-life was correspondingly reduced (8.9 vs. 13.0 h, p less than 0.0001) in smokers compared to nonsmoking controls.",Differential effect of cigarette smoking on antipyrine oxidation versus acetaminophen conjugation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2345775/),[ml] / [kg·min],0.93,85439,DB00316,Acetaminophen
,2345775,clearance,"The clearance of antipyrine was significantly increased (0.93 vs. 0.60 ml/min/kg, p less than 0.0001) and elimination half-life was correspondingly reduced (8.9 vs. 13.0 h, p less than 0.0001) in smokers compared to nonsmoking controls.",Differential effect of cigarette smoking on antipyrine oxidation versus acetaminophen conjugation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2345775/),[ml] / [kg·min],0.60,85440,DB00316,Acetaminophen
,2345775,elimination half-life,"The clearance of antipyrine was significantly increased (0.93 vs. 0.60 ml/min/kg, p less than 0.0001) and elimination half-life was correspondingly reduced (8.9 vs. 13.0 h, p less than 0.0001) in smokers compared to nonsmoking controls.",Differential effect of cigarette smoking on antipyrine oxidation versus acetaminophen conjugation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2345775/),h,8.9,85441,DB00316,Acetaminophen
,2345775,elimination half-life,"The clearance of antipyrine was significantly increased (0.93 vs. 0.60 ml/min/kg, p less than 0.0001) and elimination half-life was correspondingly reduced (8.9 vs. 13.0 h, p less than 0.0001) in smokers compared to nonsmoking controls.",Differential effect of cigarette smoking on antipyrine oxidation versus acetaminophen conjugation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2345775/),h,13.0,85442,DB00316,Acetaminophen
,8983934,clearance,"PSP (200 mg/kg) significantly (P < 0.05) increased the clearance (controls, 19.06 +/- 2.74 ml/min/kg: PSP treated, 26.22 +/- 0.84 ml/min/kg) and volume of distribution (controls, 1.35 +/- 0.11 l/kg: PSP treated, 1.61 +/- 0.04 l/kg) of paracetamol by 37% and 21%, respectively.",Effect of polysaccharide peptide (PSP) on in vivo sulphation and glucuronidation of paracetamol in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983934/),[ml] / [kg·min],19.06,85880,DB00316,Acetaminophen
,8983934,clearance,"PSP (200 mg/kg) significantly (P < 0.05) increased the clearance (controls, 19.06 +/- 2.74 ml/min/kg: PSP treated, 26.22 +/- 0.84 ml/min/kg) and volume of distribution (controls, 1.35 +/- 0.11 l/kg: PSP treated, 1.61 +/- 0.04 l/kg) of paracetamol by 37% and 21%, respectively.",Effect of polysaccharide peptide (PSP) on in vivo sulphation and glucuronidation of paracetamol in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983934/),[ml] / [kg·min],26.22,85881,DB00316,Acetaminophen
,8983934,volume of distribution,"PSP (200 mg/kg) significantly (P < 0.05) increased the clearance (controls, 19.06 +/- 2.74 ml/min/kg: PSP treated, 26.22 +/- 0.84 ml/min/kg) and volume of distribution (controls, 1.35 +/- 0.11 l/kg: PSP treated, 1.61 +/- 0.04 l/kg) of paracetamol by 37% and 21%, respectively.",Effect of polysaccharide peptide (PSP) on in vivo sulphation and glucuronidation of paracetamol in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983934/),[l] / [kg],1.35,85882,DB00316,Acetaminophen
,8983934,volume of distribution,"PSP (200 mg/kg) significantly (P < 0.05) increased the clearance (controls, 19.06 +/- 2.74 ml/min/kg: PSP treated, 26.22 +/- 0.84 ml/min/kg) and volume of distribution (controls, 1.35 +/- 0.11 l/kg: PSP treated, 1.61 +/- 0.04 l/kg) of paracetamol by 37% and 21%, respectively.",Effect of polysaccharide peptide (PSP) on in vivo sulphation and glucuronidation of paracetamol in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983934/),[l] / [kg],1.61,85883,DB00316,Acetaminophen
,8983934,Cmax,The Cmax values of paracetamol sulphate were significantly (P < 0.01) increased by 2.4-fold from 907.8 +/- 157.7 micrograms/ml (controls) to 3061 +/- 331 micrograms/ml after PSP treatment.,Effect of polysaccharide peptide (PSP) on in vivo sulphation and glucuronidation of paracetamol in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983934/),[μg] / [ml],907.8,85884,DB00316,Acetaminophen
,8983934,Cmax,The Cmax values of paracetamol sulphate were significantly (P < 0.01) increased by 2.4-fold from 907.8 +/- 157.7 micrograms/ml (controls) to 3061 +/- 331 micrograms/ml after PSP treatment.,Effect of polysaccharide peptide (PSP) on in vivo sulphation and glucuronidation of paracetamol in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983934/),[μg] / [ml],3061,85885,DB00316,Acetaminophen
,18628444,peak acetaminophen concentration,Pharmacokinetic analysis revealed significantly prolonged acetaminophen absorption and a second peak acetaminophen concentration of 228 microg/mL approximately 48 hours postingestion.,Acetaminophen overdose with altered acetaminophen pharmacokinetics and hepatotoxicity associated with premature cessation of intravenous N-acetylcysteine therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18628444/),[μg] / [ml],228,86359,DB00316,Acetaminophen
,27436437,initial,"His initial and peak apixaban concentration was 1022.6 ng/ml and was associated with only minor bleeding from his femoral central line insertion site, which improved with local compression.",Anti-Xa activity in apixaban overdose: a case report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),[ng] / [ml],1022.6,86365,DB00316,Acetaminophen
,27436437,peak apixaban concentration,"His initial and peak apixaban concentration was 1022.6 ng/ml and was associated with only minor bleeding from his femoral central line insertion site, which improved with local compression.",Anti-Xa activity in apixaban overdose: a case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),[ng] / [ml],1022.6,86366,DB00316,Acetaminophen
,27436437,elimination half-life,Apixaban elimination appeared to display first-order kinetics with an elimination half-life of 7.4 h.,Anti-Xa activity in apixaban overdose: a case report. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),h,7.4,86367,DB00316,Acetaminophen
,10930964,volume of distribution,"Population pharmacokinetic parameter estimates and their coefficients of variation (CV%) for a one compartment model with first order input, lag time and first order elimination were volume of distribution 69.9 (18%) l and clearance 13.0 (41%) l h-1 (standardized to a 70 kg person).","A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930964/),l,69.9,86509,DB00316,Acetaminophen
,10930964,clearance,"Population pharmacokinetic parameter estimates and their coefficients of variation (CV%) for a one compartment model with first order input, lag time and first order elimination were volume of distribution 69.9 (18%) l and clearance 13.0 (41%) l h-1 (standardized to a 70 kg person).","A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930964/),[l] / [h],13.0,86510,DB00316,Acetaminophen
,10930964,half-life,The volume of distribution decreased exponentially with a half-life of 1.9 days from 120 l 70 kg-1 at birth to 69.9 l 70 kg-1 by 14 days.,"A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930964/),d,1.9,86511,DB00316,Acetaminophen
,10930964,half-life,The volume of distribution decreased exponentially with a half-life of 1.9 days from 120 l 70 kg-1 at birth to 69.9 l 70 kg-1 by 14 days.,"A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930964/),[l] / [70·kg],120,86512,DB00316,Acetaminophen
,10930964,half-life,The volume of distribution decreased exponentially with a half-life of 1.9 days from 120 l 70 kg-1 at birth to 69.9 l 70 kg-1 by 14 days.,"A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930964/),[l] / [70·kg],69.9,86513,DB00316,Acetaminophen
,10930964,Clearance,Clearance increased from birth (4.9 l h-1 70 kg-1) with a half-life of 3.25 months to reach 12.4 l h-1 70 kg-1 by 12 months.,"A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930964/),[l] / [70·h·kg],4.9,86514,DB00316,Acetaminophen
,10930964,half-life,Clearance increased from birth (4.9 l h-1 70 kg-1) with a half-life of 3.25 months to reach 12.4 l h-1 70 kg-1 by 12 months.,"A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930964/),month,3.25,86515,DB00316,Acetaminophen
,10930964,half-life,Clearance increased from birth (4.9 l h-1 70 kg-1) with a half-life of 3.25 months to reach 12.4 l h-1 70 kg-1 by 12 months.,"A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930964/),[l] / [70·h·kg],12.4,86516,DB00316,Acetaminophen
,10930964,absorption half-life (tabs),The absorption half-life (tabs) for the oral preparation was 0.13 (154%) h with a lag time (tlag) of 0.39 h (31%).,"A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930964/),h,0.13,86517,DB00316,Acetaminophen
,10930964,lag time (tlag),The absorption half-life (tabs) for the oral preparation was 0.13 (154%) h with a lag time (tlag) of 0.39 h (31%).,"A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930964/),h,0.39,86518,DB00316,Acetaminophen
,10930964,tlag,"Absorption parameters for the triglyceride base and capsule suppositories were tabs 1.34 (90%) h, tlag 0.14 h (31%) and tabs 0.65 (63%) h, tlag 0.54 h (31%), respectively.","A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930964/),h,0.14,86519,DB00316,Acetaminophen
,10930964,tlag,"Absorption parameters for the triglyceride base and capsule suppositories were tabs 1.34 (90%) h, tlag 0.14 h (31%) and tabs 0.65 (63%) h, tlag 0.54 h (31%), respectively.","A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930964/),,0.65,86520,DB00316,Acetaminophen
,10930964,tlag,"Absorption parameters for the triglyceride base and capsule suppositories were tabs 1.34 (90%) h, tlag 0.14 h (31%) and tabs 0.65 (63%) h, tlag 0.54 h (31%), respectively.","A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930964/),h,0.54,86521,DB00316,Acetaminophen
,10930964,relative bioavailability,"The relative bioavailability of rectal formulations compared with elixir were 0.67 (30%) and 0.61 (23%) for the triglyceride base and capsule suppositories, respectively.","A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930964/),,0.67,86522,DB00316,Acetaminophen
,10930964,relative bioavailability,"The relative bioavailability of rectal formulations compared with elixir were 0.67 (30%) and 0.61 (23%) for the triglyceride base and capsule suppositories, respectively.","A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930964/),,0.61,86523,DB00316,Acetaminophen
,9833606,clearance,"Median value and the corresponding 25th and 75th percentiles for the clearance of the sulphate metabolites were 93.6 (82.5-138.8) ml kg(-1)h(-1) and 77.4 (75.5-99.1), patients with ulcerative colitis and control subjects, respectively.",Paracetamol metabolism in patients with ulcerative colitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833606/),[ml] / [kg],93.6,87632,DB00316,Acetaminophen
,9833606,clearance,"Median value and the corresponding 25th and 75th percentiles for the clearance of the sulphate metabolites were 93.6 (82.5-138.8) ml kg(-1)h(-1) and 77.4 (75.5-99.1), patients with ulcerative colitis and control subjects, respectively.",Paracetamol metabolism in patients with ulcerative colitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833606/),,77.4,87633,DB00316,Acetaminophen
,7154136,half-life,Her serum acetaminophen concentration at 22 h was 485 micrograms/mL and declined with an unusually long half-life of 14 h.,Massive intoxication with acetaminophen and propoxyphene: unexpected survival and unusual pharmacokinetics of acetaminophen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7154136/),h,14,87767,DB00316,Acetaminophen
,6548636,absolute bioavailability,The oral administration shows an absolute bioavailability of 60-70% independent of the pharmaceutical form and gastric contents.,Absolute bioavailability of paracetamol after oral or rectal administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6548636/),%,60-70,88461,DB00316,Acetaminophen
,6548636,absolute bioavailability,The rectal administration shows a lower absolute bioavailability (of about 30-40%) substantially independent of dose in the range under consideration.,Absolute bioavailability of paracetamol after oral or rectal administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6548636/),%,30-40,88462,DB00316,Acetaminophen
,26619825,bioavailability,The bioavailability of orally applied caffeine was also significantly decreased (p = 0.022) after the EO treatment in comparison with the control (57 ± 24% vs. 101 ± 29%).,"Pharmacokinetic Herb-Drug Interaction between Essential Oil of Aniseed (Pimpinella anisum L., Apiaceae) and Acetaminophen and Caffeine: A Potential Risk for Clinical Practice. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26619825/),%,57,88607,DB00316,Acetaminophen
,26619825,bioavailability,The bioavailability of orally applied caffeine was also significantly decreased (p = 0.022) after the EO treatment in comparison with the control (57 ± 24% vs. 101 ± 29%).,"Pharmacokinetic Herb-Drug Interaction between Essential Oil of Aniseed (Pimpinella anisum L., Apiaceae) and Acetaminophen and Caffeine: A Potential Risk for Clinical Practice. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26619825/),%,101,88608,DB00316,Acetaminophen
,8259696,relative bioavailabilities,"5. In comparison with a gavage study in the same rat (strain and age), bioavailability was lower in the diet study with relative bioavailabilities of 27, 22 and 61% for paracetamol, antipyrine and phenylbutazone, respectively.",Assessment of drug exposure in rat dietary studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8259696/),%,27,89177,DB00316,Acetaminophen
,8259696,relative bioavailabilities,"5. In comparison with a gavage study in the same rat (strain and age), bioavailability was lower in the diet study with relative bioavailabilities of 27, 22 and 61% for paracetamol, antipyrine and phenylbutazone, respectively.",Assessment of drug exposure in rat dietary studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8259696/),%,22,89178,DB00316,Acetaminophen
,8259696,relative bioavailabilities,"5. In comparison with a gavage study in the same rat (strain and age), bioavailability was lower in the diet study with relative bioavailabilities of 27, 22 and 61% for paracetamol, antipyrine and phenylbutazone, respectively.",Assessment of drug exposure in rat dietary studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8259696/),%,61,89179,DB00316,Acetaminophen
,8259696,elimination half-lives,"6. In conclusion, drug exposure as expressed by AUC24 and Cmax can be accurately determined in rat studies using compound administration in the diet by measuring concentrations at three selected time points for compounds with elimination half-lives ranging from about 1 to 5 h.",Assessment of drug exposure in rat dietary studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8259696/),h,1 to 5,89180,DB00316,Acetaminophen
,28485775,m/z,"HPLC-MS/MS analyses were performed on a triple- quadruple tandem mass spectrometer by monitoring protonated parent→daughter ion pairs at m/z 125.0→56.9 for phloroglucinol, and m/z 150.2→107.0 for paracetamol (IS).",Determination of phloroglucinol by HPLC-MS/MS and its application to a bioequivalence study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28485775/),,125.0,89403,DB00316,Acetaminophen
,28485775,m/z,"HPLC-MS/MS analyses were performed on a triple- quadruple tandem mass spectrometer by monitoring protonated parent→daughter ion pairs at m/z 125.0→56.9 for phloroglucinol, and m/z 150.2→107.0 for paracetamol (IS).",Determination of phloroglucinol by HPLC-MS/MS and its application to a bioequivalence study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28485775/),,56.9,89404,DB00316,Acetaminophen
,28485775,m/z,"HPLC-MS/MS analyses were performed on a triple- quadruple tandem mass spectrometer by monitoring protonated parent→daughter ion pairs at m/z 125.0→56.9 for phloroglucinol, and m/z 150.2→107.0 for paracetamol (IS).",Determination of phloroglucinol by HPLC-MS/MS and its application to a bioequivalence study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28485775/),,150.2,89405,DB00316,Acetaminophen
,28485775,m/z,"HPLC-MS/MS analyses were performed on a triple- quadruple tandem mass spectrometer by monitoring protonated parent→daughter ion pairs at m/z 125.0→56.9 for phloroglucinol, and m/z 150.2→107.0 for paracetamol (IS).",Determination of phloroglucinol by HPLC-MS/MS and its application to a bioequivalence study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28485775/),,107.0,89406,DB00316,Acetaminophen
,28485775,Cmax,"In this study, the Cmax of phloroglucinol were calculated to 515.6 ± 134.4 ng/mL and 536.0 ± 144.8 ng/mL for the test drug and the reference drug, respectively.",Determination of phloroglucinol by HPLC-MS/MS and its application to a bioequivalence study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28485775/),[ng] / [ml],515.6,89407,DB00316,Acetaminophen
,28485775,Cmax,"In this study, the Cmax of phloroglucinol were calculated to 515.6 ± 134.4 ng/mL and 536.0 ± 144.8 ng/mL for the test drug and the reference drug, respectively.",Determination of phloroglucinol by HPLC-MS/MS and its application to a bioequivalence study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28485775/),[ng] / [ml],536.0,89408,DB00316,Acetaminophen
,28485775,AUC0-t,"The AUC0-t values were 459.5 ± 81.03 ng·mL-1·h and 491.8 ± 95.17 ng·mL-1·h for the test drug and the reference drug; 24 subjects completed the study, respectively.",Determination of phloroglucinol by HPLC-MS/MS and its application to a bioequivalence study in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28485775/),[h·ng] / [ml],459.5,89409,DB00316,Acetaminophen
,28485775,AUC0-t,"The AUC0-t values were 459.5 ± 81.03 ng·mL-1·h and 491.8 ± 95.17 ng·mL-1·h for the test drug and the reference drug; 24 subjects completed the study, respectively.",Determination of phloroglucinol by HPLC-MS/MS and its application to a bioequivalence study in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28485775/),[h·ng] / [ml],491.8,89410,DB00316,Acetaminophen
,20602760,Mean plasma levels,"Mean plasma levels at 10 and 20 minutes were 6.64 microg x mL(-1) and 16.81 microg x mL(-1), respectively, for ibuprofen from the combination, compared with 0.58 microg x mL(-1) and 9.00 microg x mL-1, respectively, for monotherapy.",The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20602760/),[μg] / [ml],6.64,91110,DB00316,Acetaminophen
,20602760,Mean plasma levels,"Mean plasma levels at 10 and 20 minutes were 6.64 microg x mL(-1) and 16.81 microg x mL(-1), respectively, for ibuprofen from the combination, compared with 0.58 microg x mL(-1) and 9.00 microg x mL-1, respectively, for monotherapy.",The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20602760/),[μg] / [ml],16.81,91111,DB00316,Acetaminophen
,20602760,Mean plasma levels,"Mean plasma levels at 10 and 20 minutes were 6.64 microg x mL(-1) and 16.81 microg x mL(-1), respectively, for ibuprofen from the combination, compared with 0.58 microg x mL(-1) and 9.00 microg x mL-1, respectively, for monotherapy.",The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20602760/),[μg] / [ml],0.58,91112,DB00316,Acetaminophen
,20602760,Mean plasma levels,"Mean plasma levels at 10 and 20 minutes were 6.64 microg x mL(-1) and 16.81 microg x mL(-1), respectively, for ibuprofen from the combination, compared with 0.58 microg x mL(-1) and 9.00 microg x mL-1, respectively, for monotherapy.",The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20602760/),[μg] / [ml],9.00,91113,DB00316,Acetaminophen
,20602760,mean,"For paracetamol, mean plasma levels at 10 and 20 minutes were 5.43 microg x mL(-1) and 14.54 microg x mL(-, respectively, for the combination compared with 0.33 microg x mL(-1) and 9.19 microg x mL(-1), respectively, for monotherapy.",The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20602760/),[μg] / [ml],5.43,91114,DB00316,Acetaminophen
,20602760,mean,"For paracetamol, mean plasma levels at 10 and 20 minutes were 5.43 microg x mL(-1) and 14.54 microg x mL(-, respectively, for the combination compared with 0.33 microg x mL(-1) and 9.19 microg x mL(-1), respectively, for monotherapy.",The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20602760/),[μg] / [ml],9.19,91115,DB00316,Acetaminophen
,20602760,plasma levels,"For paracetamol, mean plasma levels at 10 and 20 minutes were 5.43 microg x mL(-1) and 14.54 microg x mL(-, respectively, for the combination compared with 0.33 microg x mL(-1) and 9.19 microg x mL(-1), respectively, for monotherapy.",The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20602760/),[μg] / [ml],5.43,91116,DB00316,Acetaminophen
,20602760,plasma levels,"For paracetamol, mean plasma levels at 10 and 20 minutes were 5.43 microg x mL(-1) and 14.54 microg x mL(-, respectively, for the combination compared with 0.33 microg x mL(-1) and 9.19 microg x mL(-1), respectively, for monotherapy.",The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20602760/),ml(-·μg,14.54,91117,DB00316,Acetaminophen
,20602760,plasma levels,"For paracetamol, mean plasma levels at 10 and 20 minutes were 5.43 microg x mL(-1) and 14.54 microg x mL(-, respectively, for the combination compared with 0.33 microg x mL(-1) and 9.19 microg x mL(-1), respectively, for monotherapy.",The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20602760/),[μg] / [ml],0.33,91118,DB00316,Acetaminophen
,20602760,plasma levels,"For paracetamol, mean plasma levels at 10 and 20 minutes were 5.43 microg x mL(-1) and 14.54 microg x mL(-, respectively, for the combination compared with 0.33 microg x mL(-1) and 9.19 microg x mL(-1), respectively, for monotherapy.",The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20602760/),[μg] / [ml],9.19,91119,DB00316,Acetaminophen
,8193419,tmax,"The results showed extremely rapid absorption of both drugs (tmax the time to reach maximum concentration, 10-15 minutes for acetaminophen and 15-20 minutes for zidovudine) and, consequently, relatively high maximum plasma concentration (Cmax).",Pharmacokinetics of zidovudine and acetaminophen in a patient on chronic acetaminophen therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193419/),min,10-15,91599,DB00316,Acetaminophen
,8193419,tmax,"The results showed extremely rapid absorption of both drugs (tmax the time to reach maximum concentration, 10-15 minutes for acetaminophen and 15-20 minutes for zidovudine) and, consequently, relatively high maximum plasma concentration (Cmax).",Pharmacokinetics of zidovudine and acetaminophen in a patient on chronic acetaminophen therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193419/),min,15-20,91600,DB00316,Acetaminophen
,8193419,time to reach maximum concentration,"The results showed extremely rapid absorption of both drugs (tmax the time to reach maximum concentration, 10-15 minutes for acetaminophen and 15-20 minutes for zidovudine) and, consequently, relatively high maximum plasma concentration (Cmax).",Pharmacokinetics of zidovudine and acetaminophen in a patient on chronic acetaminophen therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193419/),min,10-15,91601,DB00316,Acetaminophen
,8193419,time to reach maximum concentration,"The results showed extremely rapid absorption of both drugs (tmax the time to reach maximum concentration, 10-15 minutes for acetaminophen and 15-20 minutes for zidovudine) and, consequently, relatively high maximum plasma concentration (Cmax).",Pharmacokinetics of zidovudine and acetaminophen in a patient on chronic acetaminophen therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193419/),min,15-20,91602,DB00316,Acetaminophen
,3791708,Tmax,"Pharmacokinetic parameters following the first dose including Tmax which was 6.92 h (s.e.m. = 0.80), Cmax 3.87 micrograms/ml (s.e.m. = 0.54), apparent half-life 8.8 h (s.e.m. = 1.0) and AUC 41.92 micrograms.h/ml (s.e.m. = 4.02) were not significantly different from those following the last dose after 3 months of chronic treatment, when these were Tmax 6.38 h (s.e.m. = 0.84) Cmax 3.57 micrograms/ml (s.e.m. = 0.33) apparent half-life 8.8 h (s.e.m. = 1.1) and AUC 43.18 micrograms.h/ml (s.e.m. = 5.34) respectively.",Acute and chronic pharmacokinetic studies of slow release ketoprofen (Oruvail) in rheumatoid arthritis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791708/),h,6.92,92136,DB00316,Acetaminophen
,3791708,Cmax,"Pharmacokinetic parameters following the first dose including Tmax which was 6.92 h (s.e.m. = 0.80), Cmax 3.87 micrograms/ml (s.e.m. = 0.54), apparent half-life 8.8 h (s.e.m. = 1.0) and AUC 41.92 micrograms.h/ml (s.e.m. = 4.02) were not significantly different from those following the last dose after 3 months of chronic treatment, when these were Tmax 6.38 h (s.e.m. = 0.84) Cmax 3.57 micrograms/ml (s.e.m. = 0.33) apparent half-life 8.8 h (s.e.m. = 1.1) and AUC 43.18 micrograms.h/ml (s.e.m. = 5.34) respectively.",Acute and chronic pharmacokinetic studies of slow release ketoprofen (Oruvail) in rheumatoid arthritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791708/),[μg] / [ml],3.87,92137,DB00316,Acetaminophen
,3791708,apparent half-life,"Pharmacokinetic parameters following the first dose including Tmax which was 6.92 h (s.e.m. = 0.80), Cmax 3.87 micrograms/ml (s.e.m. = 0.54), apparent half-life 8.8 h (s.e.m. = 1.0) and AUC 41.92 micrograms.h/ml (s.e.m. = 4.02) were not significantly different from those following the last dose after 3 months of chronic treatment, when these were Tmax 6.38 h (s.e.m. = 0.84) Cmax 3.57 micrograms/ml (s.e.m. = 0.33) apparent half-life 8.8 h (s.e.m. = 1.1) and AUC 43.18 micrograms.h/ml (s.e.m. = 5.34) respectively.",Acute and chronic pharmacokinetic studies of slow release ketoprofen (Oruvail) in rheumatoid arthritis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791708/),h,8.8,92138,DB00316,Acetaminophen
,3791708,AUC,"Pharmacokinetic parameters following the first dose including Tmax which was 6.92 h (s.e.m. = 0.80), Cmax 3.87 micrograms/ml (s.e.m. = 0.54), apparent half-life 8.8 h (s.e.m. = 1.0) and AUC 41.92 micrograms.h/ml (s.e.m. = 4.02) were not significantly different from those following the last dose after 3 months of chronic treatment, when these were Tmax 6.38 h (s.e.m. = 0.84) Cmax 3.57 micrograms/ml (s.e.m. = 0.33) apparent half-life 8.8 h (s.e.m. = 1.1) and AUC 43.18 micrograms.h/ml (s.e.m. = 5.34) respectively.",Acute and chronic pharmacokinetic studies of slow release ketoprofen (Oruvail) in rheumatoid arthritis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791708/),[h·μg] / [ml],41.92,92139,DB00316,Acetaminophen
,3791708,Tmax,"Pharmacokinetic parameters following the first dose including Tmax which was 6.92 h (s.e.m. = 0.80), Cmax 3.87 micrograms/ml (s.e.m. = 0.54), apparent half-life 8.8 h (s.e.m. = 1.0) and AUC 41.92 micrograms.h/ml (s.e.m. = 4.02) were not significantly different from those following the last dose after 3 months of chronic treatment, when these were Tmax 6.38 h (s.e.m. = 0.84) Cmax 3.57 micrograms/ml (s.e.m. = 0.33) apparent half-life 8.8 h (s.e.m. = 1.1) and AUC 43.18 micrograms.h/ml (s.e.m. = 5.34) respectively.",Acute and chronic pharmacokinetic studies of slow release ketoprofen (Oruvail) in rheumatoid arthritis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791708/),h,6.38,92140,DB00316,Acetaminophen
,3791708,Cmax,"Pharmacokinetic parameters following the first dose including Tmax which was 6.92 h (s.e.m. = 0.80), Cmax 3.87 micrograms/ml (s.e.m. = 0.54), apparent half-life 8.8 h (s.e.m. = 1.0) and AUC 41.92 micrograms.h/ml (s.e.m. = 4.02) were not significantly different from those following the last dose after 3 months of chronic treatment, when these were Tmax 6.38 h (s.e.m. = 0.84) Cmax 3.57 micrograms/ml (s.e.m. = 0.33) apparent half-life 8.8 h (s.e.m. = 1.1) and AUC 43.18 micrograms.h/ml (s.e.m. = 5.34) respectively.",Acute and chronic pharmacokinetic studies of slow release ketoprofen (Oruvail) in rheumatoid arthritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791708/),[μg] / [ml],3.57,92141,DB00316,Acetaminophen
,3791708,apparent half-life,"Pharmacokinetic parameters following the first dose including Tmax which was 6.92 h (s.e.m. = 0.80), Cmax 3.87 micrograms/ml (s.e.m. = 0.54), apparent half-life 8.8 h (s.e.m. = 1.0) and AUC 41.92 micrograms.h/ml (s.e.m. = 4.02) were not significantly different from those following the last dose after 3 months of chronic treatment, when these were Tmax 6.38 h (s.e.m. = 0.84) Cmax 3.57 micrograms/ml (s.e.m. = 0.33) apparent half-life 8.8 h (s.e.m. = 1.1) and AUC 43.18 micrograms.h/ml (s.e.m. = 5.34) respectively.",Acute and chronic pharmacokinetic studies of slow release ketoprofen (Oruvail) in rheumatoid arthritis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791708/),h,8.8,92142,DB00316,Acetaminophen
,3791708,AUC,"Pharmacokinetic parameters following the first dose including Tmax which was 6.92 h (s.e.m. = 0.80), Cmax 3.87 micrograms/ml (s.e.m. = 0.54), apparent half-life 8.8 h (s.e.m. = 1.0) and AUC 41.92 micrograms.h/ml (s.e.m. = 4.02) were not significantly different from those following the last dose after 3 months of chronic treatment, when these were Tmax 6.38 h (s.e.m. = 0.84) Cmax 3.57 micrograms/ml (s.e.m. = 0.33) apparent half-life 8.8 h (s.e.m. = 1.1) and AUC 43.18 micrograms.h/ml (s.e.m. = 5.34) respectively.",Acute and chronic pharmacokinetic studies of slow release ketoprofen (Oruvail) in rheumatoid arthritis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791708/),[h·μg] / [ml],43.18,92143,DB00316,Acetaminophen
,17541571,K(,The K(M6G_abs)/K(M6G_M6G) ratio was found to be 10.,Pharmacokinetics of morphine-6-glucuronide following oral administration in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541571/),,10,92595,DB00316,Acetaminophen
,17541571,K,The K(M6G_abs)/K(M6G_M6G) ratio was found to be 10.,Pharmacokinetics of morphine-6-glucuronide following oral administration in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541571/),,10,92596,DB00316,Acetaminophen
,17541571,K,The K(M6G_abs)/K(M6G_M6G) ratio of 10 indicates that the second absorption peak of M6G consists of approximately 10 times more absorbed M6G than reglucuronidated M6G.,Pharmacokinetics of morphine-6-glucuronide following oral administration in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541571/),,10,92597,DB00316,Acetaminophen
,8452199,elimination half-life,"The elimination half-life of acetaminophen was significantly shorter in the alcoholic patients than in the controls (1.70 +/- 0.55 vs. 2.84 +/- 0.30 hr, p < 0.001).",Increased metabolism of acetaminophen in chronically alcoholic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452199/),h,1.70,93244,DB00316,Acetaminophen
,8452199,elimination half-life,"The elimination half-life of acetaminophen was significantly shorter in the alcoholic patients than in the controls (1.70 +/- 0.55 vs. 2.84 +/- 0.30 hr, p < 0.001).",Increased metabolism of acetaminophen in chronically alcoholic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452199/),h,2.84,93245,DB00316,Acetaminophen
,8452199,total plasma acetaminophen clearance,"Similarly, total plasma acetaminophen clearance was significantly higher in the patients than in the controls (29.19 +/- 13.37 vs. 24.45 +/- 11.10 l/hr, p < 0.05).",Increased metabolism of acetaminophen in chronically alcoholic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452199/),[l] / [h],29.19,93246,DB00316,Acetaminophen
,8452199,total plasma acetaminophen clearance,"Similarly, total plasma acetaminophen clearance was significantly higher in the patients than in the controls (29.19 +/- 13.37 vs. 24.45 +/- 11.10 l/hr, p < 0.05).",Increased metabolism of acetaminophen in chronically alcoholic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8452199/),[l] / [h],24.45,93247,DB00316,Acetaminophen
,26233686,Elimination half-times,"Elimination half-times were 3.4-4.3 h for N-acetyl-4-aminophenol, 4.1-5.5 h for the mercapturic acid conjugate, and 1.3-1.6 and 0.6-1.2 h for acetanilide and free aniline, respectively.",Human metabolism and excretion kinetics of aniline after a single oral dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26233686/),h,3.4-4.3,93501,DB00316,Acetaminophen
,26233686,Elimination half-times,"Elimination half-times were 3.4-4.3 h for N-acetyl-4-aminophenol, 4.1-5.5 h for the mercapturic acid conjugate, and 1.3-1.6 and 0.6-1.2 h for acetanilide and free aniline, respectively.",Human metabolism and excretion kinetics of aniline after a single oral dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26233686/),h,4.1-5.5,93502,DB00316,Acetaminophen
,26233686,Elimination half-times,"Elimination half-times were 3.4-4.3 h for N-acetyl-4-aminophenol, 4.1-5.5 h for the mercapturic acid conjugate, and 1.3-1.6 and 0.6-1.2 h for acetanilide and free aniline, respectively.",Human metabolism and excretion kinetics of aniline after a single oral dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26233686/),h,1.3-1.6,93503,DB00316,Acetaminophen
,26233686,Elimination half-times,"Elimination half-times were 3.4-4.3 h for N-acetyl-4-aminophenol, 4.1-5.5 h for the mercapturic acid conjugate, and 1.3-1.6 and 0.6-1.2 h for acetanilide and free aniline, respectively.",Human metabolism and excretion kinetics of aniline after a single oral dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26233686/),h,0.6-1.2,93504,DB00316,Acetaminophen
,16484515,apparent volume of distribution,The mean apparent volume of distribution after administration of a single subcutaneous dose is 28.3 L.,Exenatide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),l,28.3,93631,DB00316,Acetaminophen
,16484515,terminal half-life,The terminal half-life of the drug is 2.4 hours.,Exenatide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),h,2.4,93632,DB00316,Acetaminophen
,16484515,bioavailability,"Based on animal studies, the bioavailability of exenatide after subcutaneous injection has been estimated to be between 65% and 75%.",Exenatide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),%,65,93633,DB00316,Acetaminophen
,16484515,bioavailability,"Based on animal studies, the bioavailability of exenatide after subcutaneous injection has been estimated to be between 65% and 75%.",Exenatide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),%,75,93634,DB00316,Acetaminophen
,7199303,t1/2e,"The mean values of t1/2e, ke, 51/2a, ka and tmax were 1.98 h, 0.3455 h-1, 1.2357 h, 1.2357 h, 0.5653 h-1 and 2.2267 h, respectively.",Pharmacokinetics of diclofenac sodium using a developed HPLC method. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199303/),h,1.98,93636,DB00316,Acetaminophen
,7199303,tmax,"The mean values of t1/2e, ke, 51/2a, ka and tmax were 1.98 h, 0.3455 h-1, 1.2357 h, 1.2357 h, 0.5653 h-1 and 2.2267 h, respectively.",Pharmacokinetics of diclofenac sodium using a developed HPLC method. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199303/),h,2.2267,93637,DB00316,Acetaminophen
,9469995,peak serum aspartate aminotransferase level,"The mean peak serum aspartate aminotransferase level was 10,225 IU/L (n = 45), and the mean serum alanine aminotransferase level was 7355 IU/L (n = 31), which were significantly higher (both p < 0.001) than the mean serum aspartate aminotransferase level of 3500 IU/L and alanine aminotransferase level of 3098 IU/L found in children (n = 12) with non-acetaminophen-associated hepatic failure.",Therapeutic misadventures with acetaminophen: hepatoxicity after multiple doses in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9469995/),[iu] / [l],"10,225",93855,DB00316,Acetaminophen
,7900541,dissolution rates,The dissolution rates of ground and unground drug are 0.0337 min-1 and 0.0152 min-1 (P < 0.001) respectively.,[Studies on formulation and bioavailability of benorilate tablets]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7900541/),1/[min],0.0337,94168,DB00316,Acetaminophen
,7900541,dissolution rates,The dissolution rates of ground and unground drug are 0.0337 min-1 and 0.0152 min-1 (P < 0.001) respectively.,[Studies on formulation and bioavailability of benorilate tablets]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7900541/),1/[min],0.0152,94169,DB00316,Acetaminophen
,7900541,mean dissolution time,The mean dissolution time of B and A are 15.77 min and 42.25 min (P < 0.001) respectively.,[Studies on formulation and bioavailability of benorilate tablets]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7900541/),min,15.77,94170,DB00316,Acetaminophen
,7900541,mean dissolution time,The mean dissolution time of B and A are 15.77 min and 42.25 min (P < 0.001) respectively.,[Studies on formulation and bioavailability of benorilate tablets]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7900541/),min,42.25,94171,DB00316,Acetaminophen
,7900541,relative bioavailability,The relative bioavailability of B to A is 125.59%.,[Studies on formulation and bioavailability of benorilate tablets]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7900541/),%,125.59,94172,DB00316,Acetaminophen
,26720060,peak plasma concentration,The model predicts a peak plasma concentration between 6.38 and 8.55 μg/mL for 10 mg/kg dose and 9.57 and 12.8 μg/mL for 15 mg/kg dose.,Are Recommended Doses of Acetaminophen Effective for Children Aged 2 to 3 Years? A Pharmacokinetic Modeling Answer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26720060/),[μg] / [ml],6,94776,DB00316,Acetaminophen
,26720060,peak plasma concentration,The model predicts a peak plasma concentration between 6.38 and 8.55 μg/mL for 10 mg/kg dose and 9.57 and 12.8 μg/mL for 15 mg/kg dose.,Are Recommended Doses of Acetaminophen Effective for Children Aged 2 to 3 Years? A Pharmacokinetic Modeling Answer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26720060/),[μg] / [ml],8,94777,DB00316,Acetaminophen
,26720060,peak plasma concentration,The model predicts a peak plasma concentration between 6.38 and 8.55 μg/mL for 10 mg/kg dose and 9.57 and 12.8 μg/mL for 15 mg/kg dose.,Are Recommended Doses of Acetaminophen Effective for Children Aged 2 to 3 Years? A Pharmacokinetic Modeling Answer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26720060/),[μg] / [ml],9.57,94778,DB00316,Acetaminophen
,26720060,peak plasma concentration,The model predicts a peak plasma concentration between 6.38 and 8.55 μg/mL for 10 mg/kg dose and 9.57 and 12.8 μg/mL for 15 mg/kg dose.,Are Recommended Doses of Acetaminophen Effective for Children Aged 2 to 3 Years? A Pharmacokinetic Modeling Answer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26720060/),[μg] / [ml],12.8,94779,DB00316,Acetaminophen
,26720060,peak plasma concentration,A peak plasma concentration between 9.36 and 12.6 μg/mL was found for the lower weight limit (10.9 kg child) and 6.42 to 8.61 μg/mL for the upper weight limit (15.9 kg child).,Are Recommended Doses of Acetaminophen Effective for Children Aged 2 to 3 Years? A Pharmacokinetic Modeling Answer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26720060/),[μg] / [ml],9.36 and 12.6,94780,DB00316,Acetaminophen
,26720060,peak plasma concentration,A peak plasma concentration between 9.36 and 12.6 μg/mL was found for the lower weight limit (10.9 kg child) and 6.42 to 8.61 μg/mL for the upper weight limit (15.9 kg child).,Are Recommended Doses of Acetaminophen Effective for Children Aged 2 to 3 Years? A Pharmacokinetic Modeling Answer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26720060/),[μg] / [ml],6.42 to 8.61,94781,DB00316,Acetaminophen
,27476581,BTt1/2,"Following 50 mg enteral camicinal, there was a trend to accelerated gastric emptying [adjusted geometric means: pre-treatment BTt1/2 117 minutes vs. post- treatment 76 minutes; 95 % confidence intervals (CI; 0.39, 1.08) and increased glucose absorption (AUC240min pre-treatment: 28.63 mmol.min/L vs. post-treatment: 71.63 mmol.min/L; 95 % CI (1.68, 3.72)].","The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27476581/),min,117,94864,DB00316,Acetaminophen
,27476581,BTt1/2,"Following 50 mg enteral camicinal, there was a trend to accelerated gastric emptying [adjusted geometric means: pre-treatment BTt1/2 117 minutes vs. post- treatment 76 minutes; 95 % confidence intervals (CI; 0.39, 1.08) and increased glucose absorption (AUC240min pre-treatment: 28.63 mmol.min/L vs. post-treatment: 71.63 mmol.min/L; 95 % CI (1.68, 3.72)].","The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27476581/),min,76,94865,DB00316,Acetaminophen
,27476581,AUC240min,"Following 50 mg enteral camicinal, there was a trend to accelerated gastric emptying [adjusted geometric means: pre-treatment BTt1/2 117 minutes vs. post- treatment 76 minutes; 95 % confidence intervals (CI; 0.39, 1.08) and increased glucose absorption (AUC240min pre-treatment: 28.63 mmol.min/L vs. post-treatment: 71.63 mmol.min/L; 95 % CI (1.68, 3.72)].","The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27476581/),[mM·min] / [l],28.63,94866,DB00316,Acetaminophen
,27476581,AUC240min,"Following 50 mg enteral camicinal, there was a trend to accelerated gastric emptying [adjusted geometric means: pre-treatment BTt1/2 117 minutes vs. post- treatment 76 minutes; 95 % confidence intervals (CI; 0.39, 1.08) and increased glucose absorption (AUC240min pre-treatment: 28.63 mmol.min/L vs. post-treatment: 71.63 mmol.min/L; 95 % CI (1.68, 3.72)].","The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27476581/),[mM·min] / [l],71.63,94867,DB00316,Acetaminophen
,27476581,BTt1/2,"When two patients who did not have detectable plasma concentrations of camicinal were excluded from analysis, camicinal accelerated gastric emptying (adjusted geometric means: pre-treatment BTt1/2 121 minutes vs. post-treatment 65 minutes 95 % CI (0.32, 0.91) and increased glucose absorption (AUC240min pre-treatment: 33.04 mmol.min/L vs. post-treatment: 74.59 mmol.min/L; 95 % CI (1.478, 3.449).","The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27476581/),min,121,94868,DB00316,Acetaminophen
,27476581,BTt1/2,"When two patients who did not have detectable plasma concentrations of camicinal were excluded from analysis, camicinal accelerated gastric emptying (adjusted geometric means: pre-treatment BTt1/2 121 minutes vs. post-treatment 65 minutes 95 % CI (0.32, 0.91) and increased glucose absorption (AUC240min pre-treatment: 33.04 mmol.min/L vs. post-treatment: 74.59 mmol.min/L; 95 % CI (1.478, 3.449).","The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27476581/),min,65,94869,DB00316,Acetaminophen
,27476581,AUC240min,"When two patients who did not have detectable plasma concentrations of camicinal were excluded from analysis, camicinal accelerated gastric emptying (adjusted geometric means: pre-treatment BTt1/2 121 minutes vs. post-treatment 65 minutes 95 % CI (0.32, 0.91) and increased glucose absorption (AUC240min pre-treatment: 33.04 mmol.min/L vs. post-treatment: 74.59 mmol.min/L; 95 % CI (1.478, 3.449).","The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27476581/),[mM·min] / [l],33.04,94870,DB00316,Acetaminophen
,27476581,AUC240min,"When two patients who did not have detectable plasma concentrations of camicinal were excluded from analysis, camicinal accelerated gastric emptying (adjusted geometric means: pre-treatment BTt1/2 121 minutes vs. post-treatment 65 minutes 95 % CI (0.32, 0.91) and increased glucose absorption (AUC240min pre-treatment: 33.04 mmol.min/L vs. post-treatment: 74.59 mmol.min/L; 95 % CI (1.478, 3.449).","The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27476581/),[mM·min] / [l],74.59,94871,DB00316,Acetaminophen
,20973316,"AUC (0, infinity)","Means of the AUC (0, infinity) were 313.7 +/- 29.8 and 184.8 +/- 91.6 mg-h/ L in the control and experimental arm, respectively It was statistically different (p = 0.01).",Effect of activated charcoal in reducing paracetamol absorption at a supra-therapeutic dose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20973316/),[mg-h] / [l],313.7,96010,DB00316,Acetaminophen
,20973316,"AUC (0, infinity)","Means of the AUC (0, infinity) were 313.7 +/- 29.8 and 184.8 +/- 91.6 mg-h/ L in the control and experimental arm, respectively It was statistically different (p = 0.01).",Effect of activated charcoal in reducing paracetamol absorption at a supra-therapeutic dose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20973316/),[mg-h] / [l],184.8,96011,DB00316,Acetaminophen
,11936703,plasma half-life,"Paracetamol was absorbed rapidly, and the mean plasma half-life from 2 h to 8 h was 2.6 +/- 0.5 h.",Paracetamol disposition in renal allograft recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936703/),h,2,96042,DB00316,Acetaminophen
,11936703,plasma half-life,"Paracetamol was absorbed rapidly, and the mean plasma half-life from 2 h to 8 h was 2.6 +/- 0.5 h.",Paracetamol disposition in renal allograft recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936703/),h,8,96043,DB00316,Acetaminophen
,11936703,plasma half-life,"Paracetamol was absorbed rapidly, and the mean plasma half-life from 2 h to 8 h was 2.6 +/- 0.5 h.",Paracetamol disposition in renal allograft recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936703/),h,2.6,96044,DB00316,Acetaminophen
,11936703,elimination half-lives,"Both the glucuronide and sulphate conjugates of paracetamol had slow elimination half-lives of 15.1 +/- 8.8 h and 26.2 +/- 14.6 h, and there were residual amounts of both conjugates in the plasma at 24 h.",Paracetamol disposition in renal allograft recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936703/),h,15.1,96045,DB00316,Acetaminophen
,11936703,elimination half-lives,"Both the glucuronide and sulphate conjugates of paracetamol had slow elimination half-lives of 15.1 +/- 8.8 h and 26.2 +/- 14.6 h, and there were residual amounts of both conjugates in the plasma at 24 h.",Paracetamol disposition in renal allograft recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936703/),h,26.2,96046,DB00316,Acetaminophen
,11936703,renal clearances,"The renal clearances of both conjugates were low (21 +/- 14.2 ml/min and 32.4 +/- 31.4 ml/min) and there was a significant negative correlation between total amount of paracetamol recovered in the urine in 24 h and serum creatinine (r = -0.89, P<0.01).",Paracetamol disposition in renal allograft recipients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936703/),[ml] / [min],21,96047,DB00316,Acetaminophen
,11936703,renal clearances,"The renal clearances of both conjugates were low (21 +/- 14.2 ml/min and 32.4 +/- 31.4 ml/min) and there was a significant negative correlation between total amount of paracetamol recovered in the urine in 24 h and serum creatinine (r = -0.89, P<0.01).",Paracetamol disposition in renal allograft recipients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936703/),[ml] / [min],32.4,96048,DB00316,Acetaminophen
,15242431,plasma concentrations,"At 80 min after oral paracetamol the median plasma concentrations were 36 and 129 micromol/l for the 1- and 2-g groups, respectively, with an overall range between 0 and 306 micromol/l.",Early bioavailability of paracetamol after oral or intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15242431/),,36,98257,DB00316,Acetaminophen
,15242431,plasma concentrations,"At 80 min after oral paracetamol the median plasma concentrations were 36 and 129 micromol/l for the 1- and 2-g groups, respectively, with an overall range between 0 and 306 micromol/l.",Early bioavailability of paracetamol after oral or intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15242431/),,129,98258,DB00316,Acetaminophen
,2038745,systemic clearance (Cls),"The mean systemic clearance (Cls) for AC in the adults and pups was 16.1 and 13.7 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],16.1,99215,DB00316,Acetaminophen
,2038745,systemic clearance (Cls),"The mean systemic clearance (Cls) for AC in the adults and pups was 16.1 and 13.7 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],13.7,99216,DB00316,Acetaminophen
,2038745,half-lives,"The mean half-lives of AC (t1/2) were 25.5 and 33.3 min in the adult and pup groups, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,25.5,99217,DB00316,Acetaminophen
,2038745,half-lives,"The mean half-lives of AC (t1/2) were 25.5 and 33.3 min in the adult and pup groups, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,33.3,99218,DB00316,Acetaminophen
,2038745,t1/2,"In a younger group of pups (18-21 days old) it declined with a longer t1/2 (97.5, 95.1, and 347.6 min in the adults, older pups, and younger pups, respectively).","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,97.5,99219,DB00316,Acetaminophen
,2038745,t1/2,"In a younger group of pups (18-21 days old) it declined with a longer t1/2 (97.5, 95.1, and 347.6 min in the adults, older pups, and younger pups, respectively).","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,95.1,99220,DB00316,Acetaminophen
,2038745,t1/2,"In a younger group of pups (18-21 days old) it declined with a longer t1/2 (97.5, 95.1, and 347.6 min in the adults, older pups, and younger pups, respectively).","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,347.6,99221,DB00316,Acetaminophen
,2038745,Cls,"The mean AN Cls in the adults, the older pups, and the younger pups was 5.34, 6.30, and 1.91 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],5.34,99222,DB00316,Acetaminophen
,2038745,Cls,"The mean AN Cls in the adults, the older pups, and the younger pups was 5.34, 6.30, and 1.91 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],6.30,99223,DB00316,Acetaminophen
,2038745,Cls,"The mean AN Cls in the adults, the older pups, and the younger pups was 5.34, 6.30, and 1.91 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],1.91,99224,DB00316,Acetaminophen
,2038745,t1/2,The time course of SA was prolonged in the suckling pups (t1/2 of 633 min in the pups vs 78.7 min in the adult).,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,633,99225,DB00316,Acetaminophen
,2038745,t1/2,The time course of SA was prolonged in the suckling pups (t1/2 of 633 min in the pups vs 78.7 min in the adult).,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,78.7,99226,DB00316,Acetaminophen
,2038745,Cls,"The mean Cls values in the adults and the pups were 1.05 and 0.27 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],1.05,99227,DB00316,Acetaminophen
,2038745,Cls,"The mean Cls values in the adults and the pups were 1.05 and 0.27 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],0.27,99228,DB00316,Acetaminophen
,2038745,systemic clearance of unbound drug (Clu),The mean systemic clearance of unbound drug (Clu) for SA was 11.2 ml/min/kg in the adults and 0.92 ml/min/kg in the pups.,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],11.2,99229,DB00316,Acetaminophen
,2038745,systemic clearance of unbound drug (Clu),The mean systemic clearance of unbound drug (Clu) for SA was 11.2 ml/min/kg in the adults and 0.92 ml/min/kg in the pups.,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],0.92,99230,DB00316,Acetaminophen
,2038745,free fraction,"The serum protein binding of AC and AN was limited, whereas the mean free fraction for SA was 9.7% in adult serum and 32.5% in pup serum.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),%,9.7,99231,DB00316,Acetaminophen
,2038745,free fraction,"The serum protein binding of AC and AN was limited, whereas the mean free fraction for SA was 9.7% in adult serum and 32.5% in pup serum.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),%,32.5,99232,DB00316,Acetaminophen
,15811172,peak plasma concentration,"In Chinese subjects, the (mean range) peak plasma concentration of paracetamol was 23.8 mug/mL (17.9-32.3) and time to attain this peak 0.66 h (0.5-0.75).",Differences in the single-oral-dose pharmacokinetics and urinary excretion of paracetamol and its conjugates between Hong Kong Chinese and Caucasian subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811172/),[μg] / [ml],23.8,102312,DB00316,Acetaminophen
,15811172,time to attain this peak,"In Chinese subjects, the (mean range) peak plasma concentration of paracetamol was 23.8 mug/mL (17.9-32.3) and time to attain this peak 0.66 h (0.5-0.75).",Differences in the single-oral-dose pharmacokinetics and urinary excretion of paracetamol and its conjugates between Hong Kong Chinese and Caucasian subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811172/),h,0.66,102313,DB00316,Acetaminophen
,9705120,Tmax,"In the control group, Tmax was 31 min and this decreased significantly (P < 0.05) following the administration of metoclopramide.",Acetaminophen as a marker of gastric emptying in ponies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9705120/),min,31,102516,DB00316,Acetaminophen
more,1904550,Peak plasma levels,"Peak plasma levels of more than 10(-4) M have been reported (Forrest et al., 1982) and 2 groups of investigators (Kocisova et al., 1988; Hongslo et al., 1990) found PCM to be weakly clastogenic in human lymphocytes in vivo in the maximum human therapeutic dose range.",Further investigations on the clastogenicity of paracetamol and acetylsalicylic acid in vitro. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904550/),M,10(-4),102685,DB00316,Acetaminophen
,9365970,steady state plasma concentrations,A pharmacokinetic dynamic simulation model was used to predict rectal paracetamol dosing schedules which would maintain steady state plasma concentrations of 10-20 mg.l-1.,Rectal paracetamol dosing regimens: determination by computer simulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9365970/),[mg] / [l],10-20,103730,DB00316,Acetaminophen
,9365970,Steady state concentrations,Steady state concentrations of 8-12 mg.l-1 were only reached after 16 h.,Rectal paracetamol dosing regimens: determination by computer simulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9365970/),[mg] / [l],8-12,103731,DB00316,Acetaminophen
,9365970,plasma concentrations,kg-1 six hourly achieved plasma concentrations of 9-18 mg.,Rectal paracetamol dosing regimens: determination by computer simulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9365970/),mg,9-18,103732,DB00316,Acetaminophen
,2271373,total,"2. The median total and unbound clearance of oxazepam increased significantly during the study period from 0.78 ml min-1 kg-1 (0.40-1.25) to 1.22 ml min-1 kg-1 (0.66-1.94) and from 9.3 ml min-1 kg-1 (5.2-14.2) to 15.9 ml min-1 kg-1 (7.8-21.8), respectively (P less than 0.01).",Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],0.78,104635,DB00316,Acetaminophen
,2271373,unbound clearance,"2. The median total and unbound clearance of oxazepam increased significantly during the study period from 0.78 ml min-1 kg-1 (0.40-1.25) to 1.22 ml min-1 kg-1 (0.66-1.94) and from 9.3 ml min-1 kg-1 (5.2-14.2) to 15.9 ml min-1 kg-1 (7.8-21.8), respectively (P less than 0.01).",Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],1.22,104636,DB00316,Acetaminophen
,2271373,unbound clearance,"2. The median total and unbound clearance of oxazepam increased significantly during the study period from 0.78 ml min-1 kg-1 (0.40-1.25) to 1.22 ml min-1 kg-1 (0.66-1.94) and from 9.3 ml min-1 kg-1 (5.2-14.2) to 15.9 ml min-1 kg-1 (7.8-21.8), respectively (P less than 0.01).",Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],9.3,104637,DB00316,Acetaminophen
,2271373,unbound clearance,"2. The median total and unbound clearance of oxazepam increased significantly during the study period from 0.78 ml min-1 kg-1 (0.40-1.25) to 1.22 ml min-1 kg-1 (0.66-1.94) and from 9.3 ml min-1 kg-1 (5.2-14.2) to 15.9 ml min-1 kg-1 (7.8-21.8), respectively (P less than 0.01).",Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],15.9,104638,DB00316,Acetaminophen
,2271373,elimination half-life,3. The elimination half-life of oxazepam was prolonged by hypothyroidism to a median (range) value of 9.3 h (5.4-21.9) compared with 7.5 h (4.8-10.5) in the euthyroid state (P less than 0.05).,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),h,9.3,104639,DB00316,Acetaminophen
,2271373,elimination half-life,3. The elimination half-life of oxazepam was prolonged by hypothyroidism to a median (range) value of 9.3 h (5.4-21.9) compared with 7.5 h (4.8-10.5) in the euthyroid state (P less than 0.05).,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),h,7.5,104640,DB00316,Acetaminophen
,2271373,free percentage,4. Hypothyroidism did not affect the protein binding of oxazepam; median values of the free percentage being 8.2% as compared with 7.7% when euthyroid.,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),%,8.2,104641,DB00316,Acetaminophen
,2271373,free percentage,4. Hypothyroidism did not affect the protein binding of oxazepam; median values of the free percentage being 8.2% as compared with 7.7% when euthyroid.,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),%,7.7,104642,DB00316,Acetaminophen
,2271373,clearance,5. The median (range) clearance of paracetamol under hypothyroid conditions was 3.12 ml min-1 kg-1 (1.64-4.40) and 4.70 ml min-1 kg-1 (3.18-5.70) following replacement therapy (P less than 0.01).,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],3.12,104643,DB00316,Acetaminophen
,2271373,clearance,5. The median (range) clearance of paracetamol under hypothyroid conditions was 3.12 ml min-1 kg-1 (1.64-4.40) and 4.70 ml min-1 kg-1 (3.18-5.70) following replacement therapy (P less than 0.01).,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],4.70,104644,DB00316,Acetaminophen
,2271373,partial clearance,This increase was associated with a comparable increase in the partial clearance to the glucuronide metabolite: 1.86 ml min-1 kg-1 to 2.70 ml min-1 kg-1.,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],1.86,104645,DB00316,Acetaminophen
,2271373,partial clearance,This increase was associated with a comparable increase in the partial clearance to the glucuronide metabolite: 1.86 ml min-1 kg-1 to 2.70 ml min-1 kg-1.,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],2.70,104646,DB00316,Acetaminophen
,9209234,elimination half-life,"The acetaminophen elimination half-life was 3.1 +/- .8 hours (mean +/- SD; range, 1.3 to 4.0 hours; n = 12).",Tylenol Extended Relief overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209234/),h,3.1,104669,DB00316,Acetaminophen
,30900298,maximum concentration (Cmax ),"Following a single dose, mean maximum concentration (Cmax ) was 16.61 μg/mL at 1.35 h (Tmax ), and drug concentration was below the lower limit of detection in most horses by 24 h.",Pharmacokinetics and safety of repeated oral dosing of acetaminophen in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30900298/),[μg] / [ml],16.61,106041,DB00316,Acetaminophen
,30900298,Elimination half-life (T1/2 ),Elimination half-life (T1/2 ) was 2.78 h.,Pharmacokinetics and safety of repeated oral dosing of acetaminophen in adult horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30900298/),h,2.78,106042,DB00316,Acetaminophen
,30900298,Cmax,"Average Cmax of acetaminophen following multiple oral dosing was 15.85 μg/mL, with a Tmax of 0.99 h and T1/2 of 4 h.",Pharmacokinetics and safety of repeated oral dosing of acetaminophen in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30900298/),[μg] / [ml],15.85,106043,DB00316,Acetaminophen
,30900298,Tmax,"Average Cmax of acetaminophen following multiple oral dosing was 15.85 μg/mL, with a Tmax of 0.99 h and T1/2 of 4 h.",Pharmacokinetics and safety of repeated oral dosing of acetaminophen in adult horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30900298/),h,0.99,106044,DB00316,Acetaminophen
,30900298,T1/2,"Average Cmax of acetaminophen following multiple oral dosing was 15.85 μg/mL, with a Tmax of 0.99 h and T1/2 of 4 h.",Pharmacokinetics and safety of repeated oral dosing of acetaminophen in adult horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30900298/),h,4,106045,DB00316,Acetaminophen
,18389096,t(max),"Pharmacokinetic data from 18 subjects were allowed for estimating fast and high-paracetamol bioavailability: t(max) 20 min (10-45) [median (range)], C(max) 24. 3 mg/l (6.5) [mean (standard deviation)], AUC(0-t) 64.0 mg h/l (16.1) and AUC(0-00) 68.1 mg h/l (17.9).",Study of paracetamol 1-g oral solution bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18389096/),min,20,106554,DB00316,Acetaminophen
,18389096,C(max),"Pharmacokinetic data from 18 subjects were allowed for estimating fast and high-paracetamol bioavailability: t(max) 20 min (10-45) [median (range)], C(max) 24. 3 mg/l (6.5) [mean (standard deviation)], AUC(0-t) 64.0 mg h/l (16.1) and AUC(0-00) 68.1 mg h/l (17.9).",Study of paracetamol 1-g oral solution bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18389096/),[mg] / [l],24. 3,106555,DB00316,Acetaminophen
,18389096,AUC(0-t),"Pharmacokinetic data from 18 subjects were allowed for estimating fast and high-paracetamol bioavailability: t(max) 20 min (10-45) [median (range)], C(max) 24. 3 mg/l (6.5) [mean (standard deviation)], AUC(0-t) 64.0 mg h/l (16.1) and AUC(0-00) 68.1 mg h/l (17.9).",Study of paracetamol 1-g oral solution bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18389096/),[h·mg] / [l],64.0,106556,DB00316,Acetaminophen
,18389096,AUC(0-00),"Pharmacokinetic data from 18 subjects were allowed for estimating fast and high-paracetamol bioavailability: t(max) 20 min (10-45) [median (range)], C(max) 24. 3 mg/l (6.5) [mean (standard deviation)], AUC(0-t) 64.0 mg h/l (16.1) and AUC(0-00) 68.1 mg h/l (17.9).",Study of paracetamol 1-g oral solution bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18389096/),[h·mg] / [l],68.1,106557,DB00316,Acetaminophen
,2778095,Cmax,The pharmacokinetic parameters of droxicam were: Cmax = 1.03 +/- 0.16 micrograms/mL (mean +/- SD).,The influence of gastric emptying on droxicam pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),[μg] / [ml],1.03,107248,DB00316,Acetaminophen
,2778095,Tmax,"Tmax = 11.1 +/- 5.7 hr, AUC = 115.7 +/- 29.6 micrograms hr/mL, T 1/2 a = 2.64 +/- 0.72 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,11.1,107249,DB00316,Acetaminophen
,2778095,AUC,"Tmax = 11.1 +/- 5.7 hr, AUC = 115.7 +/- 29.6 micrograms hr/mL, T 1/2 a = 2.64 +/- 0.72 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),[h·μg] / [ml],115.7,107250,DB00316,Acetaminophen
,2778095,T 1/2 a,"Tmax = 11.1 +/- 5.7 hr, AUC = 115.7 +/- 29.6 micrograms hr/mL, T 1/2 a = 2.64 +/- 0.72 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,2.64,107251,DB00316,Acetaminophen
,2778095,T 1/2 el,"T 1/2 el = 73.6 +/- 16.7 hr, CL/F = 3.06 +/- 0.80 mL/min and MRT = 111.1 +/- 23.5 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,73.6,107252,DB00316,Acetaminophen
,2778095,CL/F,"T 1/2 el = 73.6 +/- 16.7 hr, CL/F = 3.06 +/- 0.80 mL/min and MRT = 111.1 +/- 23.5 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),[ml] / [min],3.06,107253,DB00316,Acetaminophen
,2778095,MRT,"T 1/2 el = 73.6 +/- 16.7 hr, CL/F = 3.06 +/- 0.80 mL/min and MRT = 111.1 +/- 23.5 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,111.1,107254,DB00316,Acetaminophen
,2778095,Tmax,"Following modification of gastric emptying, only Tmax (droxicam + metoclopramide = 25.0 +/- 10.8 hr and droxicam + propantheline = 20.8 +/- 8.8 hr) underwent significant change (P less than 0.05).",The influence of gastric emptying on droxicam pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,25.0,107255,DB00316,Acetaminophen
,2778095,Tmax,"Following modification of gastric emptying, only Tmax (droxicam + metoclopramide = 25.0 +/- 10.8 hr and droxicam + propantheline = 20.8 +/- 8.8 hr) underwent significant change (P less than 0.05).",The influence of gastric emptying on droxicam pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,20.8,107256,DB00316,Acetaminophen
,4076324,bioavailability,"The bioavailability of paracetamol was not altered by either antacid, but they both delayed the time to peak plasma concentration (0.85 h; 1.43 h; 1.25 h, without antacid, with Dimalan and with Maalox respectively).",Effect of two antacids on the bioavailability of paracetamol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076324/),h,0.85,107270,DB00316,Acetaminophen
,4076324,bioavailability,"The bioavailability of paracetamol was not altered by either antacid, but they both delayed the time to peak plasma concentration (0.85 h; 1.43 h; 1.25 h, without antacid, with Dimalan and with Maalox respectively).",Effect of two antacids on the bioavailability of paracetamol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076324/),h,1.43,107271,DB00316,Acetaminophen
,4076324,bioavailability,"The bioavailability of paracetamol was not altered by either antacid, but they both delayed the time to peak plasma concentration (0.85 h; 1.43 h; 1.25 h, without antacid, with Dimalan and with Maalox respectively).",Effect of two antacids on the bioavailability of paracetamol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076324/),h,1.25,107272,DB00316,Acetaminophen
,4076324,time to peak plasma concentration,"The bioavailability of paracetamol was not altered by either antacid, but they both delayed the time to peak plasma concentration (0.85 h; 1.43 h; 1.25 h, without antacid, with Dimalan and with Maalox respectively).",Effect of two antacids on the bioavailability of paracetamol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076324/),h,0.85,107273,DB00316,Acetaminophen
,4076324,time to peak plasma concentration,"The bioavailability of paracetamol was not altered by either antacid, but they both delayed the time to peak plasma concentration (0.85 h; 1.43 h; 1.25 h, without antacid, with Dimalan and with Maalox respectively).",Effect of two antacids on the bioavailability of paracetamol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076324/),h,1.43,107274,DB00316,Acetaminophen
,4076324,time to peak plasma concentration,"The bioavailability of paracetamol was not altered by either antacid, but they both delayed the time to peak plasma concentration (0.85 h; 1.43 h; 1.25 h, without antacid, with Dimalan and with Maalox respectively).",Effect of two antacids on the bioavailability of paracetamol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076324/),h,1.25,107275,DB00316,Acetaminophen
,20002061,terminal elimination half-life (t(1/2)),"The terminal elimination half-life (t(1/2)) of paracetamol was 1.6 (CI 1.4-2.0) and 1.9 (CI 1.5-2.4) hr for 50 and 25 g, respectively (NS), and 2.5 (CI 1.8-3.0) hr for the 5-g dose (p = 0.003).",Dose-dependent adsorptive capacity of activated charcoal for gastrointestinal decontamination of a simulated paracetamol overdose in human volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20002061/),h,1.6,108398,DB00316,Acetaminophen
,20002061,terminal elimination half-life (t(1/2)),"The terminal elimination half-life (t(1/2)) of paracetamol was 1.6 (CI 1.4-2.0) and 1.9 (CI 1.5-2.4) hr for 50 and 25 g, respectively (NS), and 2.5 (CI 1.8-3.0) hr for the 5-g dose (p = 0.003).",Dose-dependent adsorptive capacity of activated charcoal for gastrointestinal decontamination of a simulated paracetamol overdose in human volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20002061/),h,1.9,108399,DB00316,Acetaminophen
,20002061,terminal elimination half-life (t(1/2)),"The terminal elimination half-life (t(1/2)) of paracetamol was 1.6 (CI 1.4-2.0) and 1.9 (CI 1.5-2.4) hr for 50 and 25 g, respectively (NS), and 2.5 (CI 1.8-3.0) hr for the 5-g dose (p = 0.003).",Dose-dependent adsorptive capacity of activated charcoal for gastrointestinal decontamination of a simulated paracetamol overdose in human volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20002061/),h,2.5,108400,DB00316,Acetaminophen
,20002061,activated charcoal-drug ratio,An activated charcoal-drug ratio of 10:1 is therefore still recommendable.,Dose-dependent adsorptive capacity of activated charcoal for gastrointestinal decontamination of a simulated paracetamol overdose in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20002061/),,10:1,108401,DB00316,Acetaminophen
,22358099,C(max),"The main PK for paracetamol in group 1 (n = 17) and 2 (n = 13) were as follows: C(max), 9.46 (3.66) and 12.79 (5.32) μg/ml, respectively (p = 0.0517); AUMC(0-t), 77.64 (30.37) and 51.01 (15.76) μg h(2)/ml (p = 0.0046); AUC(0-inf), 41.61 (23.52) and 30.28 (9.74) μg h/ml (p = 0.0862); t(max), 1.68 (0.63) and 0.50 (0.25) h (p < 0001).",Comparison of the pharmacokinetics of paracetamol from two generic products in patients after total gastric resection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358099/),[μg] / [ml],9.46,109026,DB00316,Acetaminophen
,22358099,C(max),"The main PK for paracetamol in group 1 (n = 17) and 2 (n = 13) were as follows: C(max), 9.46 (3.66) and 12.79 (5.32) μg/ml, respectively (p = 0.0517); AUMC(0-t), 77.64 (30.37) and 51.01 (15.76) μg h(2)/ml (p = 0.0046); AUC(0-inf), 41.61 (23.52) and 30.28 (9.74) μg h/ml (p = 0.0862); t(max), 1.68 (0.63) and 0.50 (0.25) h (p < 0001).",Comparison of the pharmacokinetics of paracetamol from two generic products in patients after total gastric resection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358099/),[μg] / [ml],12.79,109027,DB00316,Acetaminophen
,22358099,AUMC(0-t),"The main PK for paracetamol in group 1 (n = 17) and 2 (n = 13) were as follows: C(max), 9.46 (3.66) and 12.79 (5.32) μg/ml, respectively (p = 0.0517); AUMC(0-t), 77.64 (30.37) and 51.01 (15.76) μg h(2)/ml (p = 0.0046); AUC(0-inf), 41.61 (23.52) and 30.28 (9.74) μg h/ml (p = 0.0862); t(max), 1.68 (0.63) and 0.50 (0.25) h (p < 0001).",Comparison of the pharmacokinetics of paracetamol from two generic products in patients after total gastric resection. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358099/),[h(2·μg] / [ml],77.64,109028,DB00316,Acetaminophen
,22358099,AUMC(0-t),"The main PK for paracetamol in group 1 (n = 17) and 2 (n = 13) were as follows: C(max), 9.46 (3.66) and 12.79 (5.32) μg/ml, respectively (p = 0.0517); AUMC(0-t), 77.64 (30.37) and 51.01 (15.76) μg h(2)/ml (p = 0.0046); AUC(0-inf), 41.61 (23.52) and 30.28 (9.74) μg h/ml (p = 0.0862); t(max), 1.68 (0.63) and 0.50 (0.25) h (p < 0001).",Comparison of the pharmacokinetics of paracetamol from two generic products in patients after total gastric resection. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358099/),[h(2·μg] / [ml],51.01,109029,DB00316,Acetaminophen
,22358099,AUC(0-inf),"The main PK for paracetamol in group 1 (n = 17) and 2 (n = 13) were as follows: C(max), 9.46 (3.66) and 12.79 (5.32) μg/ml, respectively (p = 0.0517); AUMC(0-t), 77.64 (30.37) and 51.01 (15.76) μg h(2)/ml (p = 0.0046); AUC(0-inf), 41.61 (23.52) and 30.28 (9.74) μg h/ml (p = 0.0862); t(max), 1.68 (0.63) and 0.50 (0.25) h (p < 0001).",Comparison of the pharmacokinetics of paracetamol from two generic products in patients after total gastric resection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358099/),[h·μg] / [ml],41.61,109030,DB00316,Acetaminophen
,22358099,AUC(0-inf),"The main PK for paracetamol in group 1 (n = 17) and 2 (n = 13) were as follows: C(max), 9.46 (3.66) and 12.79 (5.32) μg/ml, respectively (p = 0.0517); AUMC(0-t), 77.64 (30.37) and 51.01 (15.76) μg h(2)/ml (p = 0.0046); AUC(0-inf), 41.61 (23.52) and 30.28 (9.74) μg h/ml (p = 0.0862); t(max), 1.68 (0.63) and 0.50 (0.25) h (p < 0001).",Comparison of the pharmacokinetics of paracetamol from two generic products in patients after total gastric resection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358099/),[h·μg] / [ml],30.28,109031,DB00316,Acetaminophen
,22358099,t(max),"The main PK for paracetamol in group 1 (n = 17) and 2 (n = 13) were as follows: C(max), 9.46 (3.66) and 12.79 (5.32) μg/ml, respectively (p = 0.0517); AUMC(0-t), 77.64 (30.37) and 51.01 (15.76) μg h(2)/ml (p = 0.0046); AUC(0-inf), 41.61 (23.52) and 30.28 (9.74) μg h/ml (p = 0.0862); t(max), 1.68 (0.63) and 0.50 (0.25) h (p < 0001).",Comparison of the pharmacokinetics of paracetamol from two generic products in patients after total gastric resection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358099/),h,1.68,109032,DB00316,Acetaminophen
,22358099,t(max),"The main PK for paracetamol in group 1 (n = 17) and 2 (n = 13) were as follows: C(max), 9.46 (3.66) and 12.79 (5.32) μg/ml, respectively (p = 0.0517); AUMC(0-t), 77.64 (30.37) and 51.01 (15.76) μg h(2)/ml (p = 0.0046); AUC(0-inf), 41.61 (23.52) and 30.28 (9.74) μg h/ml (p = 0.0862); t(max), 1.68 (0.63) and 0.50 (0.25) h (p < 0001).",Comparison of the pharmacokinetics of paracetamol from two generic products in patients after total gastric resection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358099/),h,0.50,109033,DB00316,Acetaminophen
,3612498,oral extraction ratio,A mean oral extraction ratio of 0.46 was obtained at 21h00 as compared to 0.39 at 09h00.,Time-dependent variations in the organ extraction ratios of acetaminophen in rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612498/),,0.46,111799,DB00316,Acetaminophen
,3612498,oral extraction ratio,A mean oral extraction ratio of 0.46 was obtained at 21h00 as compared to 0.39 at 09h00.,Time-dependent variations in the organ extraction ratios of acetaminophen in rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612498/),,0.39,111800,DB00316,Acetaminophen
,3612498,extraction ratios,"The mean extraction ratios of the gastrointestine, liver, and lung were 0.05, 0.41, and 0 at 09h00 and 0.18, 0.24, and 0.13 at 21h00, respectively.",Time-dependent variations in the organ extraction ratios of acetaminophen in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612498/),,0.05,111801,DB00316,Acetaminophen
,3612498,extraction ratios,"The mean extraction ratios of the gastrointestine, liver, and lung were 0.05, 0.41, and 0 at 09h00 and 0.18, 0.24, and 0.13 at 21h00, respectively.",Time-dependent variations in the organ extraction ratios of acetaminophen in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612498/),,0.41,111802,DB00316,Acetaminophen
,3612498,extraction ratios,"The mean extraction ratios of the gastrointestine, liver, and lung were 0.05, 0.41, and 0 at 09h00 and 0.18, 0.24, and 0.13 at 21h00, respectively.",Time-dependent variations in the organ extraction ratios of acetaminophen in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612498/),,0,111803,DB00316,Acetaminophen
,3612498,extraction ratios,"The mean extraction ratios of the gastrointestine, liver, and lung were 0.05, 0.41, and 0 at 09h00 and 0.18, 0.24, and 0.13 at 21h00, respectively.",Time-dependent variations in the organ extraction ratios of acetaminophen in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612498/),,0.18,111804,DB00316,Acetaminophen
,3612498,extraction ratios,"The mean extraction ratios of the gastrointestine, liver, and lung were 0.05, 0.41, and 0 at 09h00 and 0.18, 0.24, and 0.13 at 21h00, respectively.",Time-dependent variations in the organ extraction ratios of acetaminophen in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612498/),,0.24,111805,DB00316,Acetaminophen
,3612498,extraction ratios,"The mean extraction ratios of the gastrointestine, liver, and lung were 0.05, 0.41, and 0 at 09h00 and 0.18, 0.24, and 0.13 at 21h00, respectively.",Time-dependent variations in the organ extraction ratios of acetaminophen in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612498/),,0.13,111806,DB00316,Acetaminophen
,9885301,elimination half-life,"Thus, SCP-1 elimination half-life (mean 14.8+/-10.0 min) was shorter than that of the acetaminophen (186.1+/-27.7 min) (t=11.6, P=0.0001).","Hepatic kinetics of SCP-1 (N-[alpha-(1,2-benzisothiazol-3(2H)-ona-1, 1-dioxide-2-yl)-acetyl]-p-aminophenol) compared with acetaminophen in isolated rat liver. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9885301/),min,14.8,112093,DB00316,Acetaminophen
,9885301,elimination half-life,"Thus, SCP-1 elimination half-life (mean 14.8+/-10.0 min) was shorter than that of the acetaminophen (186.1+/-27.7 min) (t=11.6, P=0.0001).","Hepatic kinetics of SCP-1 (N-[alpha-(1,2-benzisothiazol-3(2H)-ona-1, 1-dioxide-2-yl)-acetyl]-p-aminophenol) compared with acetaminophen in isolated rat liver. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9885301/),min,186.1,112094,DB00316,Acetaminophen
,9885301,hepatic clearance,"The hepatic clearance was higher for SCP-1 than acetaminophen (mean 19.01+/-14.5 ml min(-1) vs. 1.29+/-0.08 ml min(-1), respectively) (t=2.44, P<0.05), and it behaved according to dose-dependent kinetics.","Hepatic kinetics of SCP-1 (N-[alpha-(1,2-benzisothiazol-3(2H)-ona-1, 1-dioxide-2-yl)-acetyl]-p-aminophenol) compared with acetaminophen in isolated rat liver. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9885301/),[ml] / [min],19.01,112095,DB00316,Acetaminophen
,9885301,hepatic clearance,"The hepatic clearance was higher for SCP-1 than acetaminophen (mean 19.01+/-14.5 ml min(-1) vs. 1.29+/-0.08 ml min(-1), respectively) (t=2.44, P<0.05), and it behaved according to dose-dependent kinetics.","Hepatic kinetics of SCP-1 (N-[alpha-(1,2-benzisothiazol-3(2H)-ona-1, 1-dioxide-2-yl)-acetyl]-p-aminophenol) compared with acetaminophen in isolated rat liver. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9885301/),[ml] / [min],1.29,112096,DB00316,Acetaminophen
,9885301,extraction ratio,"The SCP-1 extraction ratio was higher (mean 0.63+/-0.49) than for acetaminophen (0.04+/-0.01) (t=2.41, P<0.05) and this parameter tended to decrease as the perfusate concentrations of SCP-1 increased.","Hepatic kinetics of SCP-1 (N-[alpha-(1,2-benzisothiazol-3(2H)-ona-1, 1-dioxide-2-yl)-acetyl]-p-aminophenol) compared with acetaminophen in isolated rat liver. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9885301/),,0.63,112097,DB00316,Acetaminophen
,9885301,extraction ratio,"The SCP-1 extraction ratio was higher (mean 0.63+/-0.49) than for acetaminophen (0.04+/-0.01) (t=2.41, P<0.05) and this parameter tended to decrease as the perfusate concentrations of SCP-1 increased.","Hepatic kinetics of SCP-1 (N-[alpha-(1,2-benzisothiazol-3(2H)-ona-1, 1-dioxide-2-yl)-acetyl]-p-aminophenol) compared with acetaminophen in isolated rat liver. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9885301/),,0.04,112098,DB00316,Acetaminophen
,11240880,Cmax,Mean Cmax was 2.4+/-1.3 microg.,Pharmacokinetics of oral diclofenac and acetaminophen in children after surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240880/),μg,2.4,112268,DB00316,Acetaminophen
,11240880,tmax,ml-1 and mean tmax was 2+/-0.5 h.,Pharmacokinetics of oral diclofenac and acetaminophen in children after surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240880/),h,2,112269,DB00316,Acetaminophen
,11240880,Cmax,Eight of 10 children achieved Cmax of acetaminophen within the 10-20 microg.,Pharmacokinetics of oral diclofenac and acetaminophen in children after surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240880/),μg,10-20,112270,DB00316,Acetaminophen
,11240880,tabs,"Mean tabs was 0.7+/-0.3 h and mean Cmax and tmax were 12.7+/-3.8 microg ml-1 and 1.4+/-0.5 h, respectively.",Pharmacokinetics of oral diclofenac and acetaminophen in children after surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240880/),h,0.7,112271,DB00316,Acetaminophen
,11240880,Cmax,"Mean tabs was 0.7+/-0.3 h and mean Cmax and tmax were 12.7+/-3.8 microg ml-1 and 1.4+/-0.5 h, respectively.",Pharmacokinetics of oral diclofenac and acetaminophen in children after surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240880/),[μg] / [ml],12.7,112272,DB00316,Acetaminophen
,11240880,tmax,"Mean tabs was 0.7+/-0.3 h and mean Cmax and tmax were 12.7+/-3.8 microg ml-1 and 1.4+/-0.5 h, respectively.",Pharmacokinetics of oral diclofenac and acetaminophen in children after surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240880/),h,1.4,112273,DB00316,Acetaminophen
,657721,peak codeine plasma concentrations,"Following administration of codeine phosphate (60 mg) in combination with aspirin (650 mg) or acetaminophen (600 mg) to two separate groups, mean peak codeine plasma concentrations and beta-phase elimination half-lives were 159 ng/ml and 2.9 hr or 138 ng/ml and 2.4 hr, respectively.",Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),[ng] / [ml],159,113220,DB00316,Acetaminophen
,657721,peak codeine plasma concentrations,"Following administration of codeine phosphate (60 mg) in combination with aspirin (650 mg) or acetaminophen (600 mg) to two separate groups, mean peak codeine plasma concentrations and beta-phase elimination half-lives were 159 ng/ml and 2.9 hr or 138 ng/ml and 2.4 hr, respectively.",Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),[ng] / [ml],138,113221,DB00316,Acetaminophen
,657721,beta-phase elimination half-lives,"Following administration of codeine phosphate (60 mg) in combination with aspirin (650 mg) or acetaminophen (600 mg) to two separate groups, mean peak codeine plasma concentrations and beta-phase elimination half-lives were 159 ng/ml and 2.9 hr or 138 ng/ml and 2.4 hr, respectively.",Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),h,2.9,113222,DB00316,Acetaminophen
,657721,beta-phase elimination half-lives,"Following administration of codeine phosphate (60 mg) in combination with aspirin (650 mg) or acetaminophen (600 mg) to two separate groups, mean peak codeine plasma concentrations and beta-phase elimination half-lives were 159 ng/ml and 2.9 hr or 138 ng/ml and 2.4 hr, respectively.",Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),h,2.4,113223,DB00316,Acetaminophen
,657721,maximum concentrations,Mean maximum concentrations of metabolically produced morphine were 6.8 ng/ml (aspirin-codeine phosphate administration) and 7.4 ng/ml (acetaminophen-codeine phosphate).,Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),[ng] / [ml],6.8,113224,DB00316,Acetaminophen
,657721,maximum concentrations,Mean maximum concentrations of metabolically produced morphine were 6.8 ng/ml (aspirin-codeine phosphate administration) and 7.4 ng/ml (acetaminophen-codeine phosphate).,Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),[ng] / [ml],7.4,113225,DB00316,Acetaminophen
,22768009,Total systemic normalized clearance,"Total systemic normalized clearance was 18.4 L/hr per 70 kg, with a plateau reached at approximately 2 years.","Safety and population pharmacokinetic analysis of intravenous acetaminophen in neonates, infants, children, and adolescents with pain or Fever. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22768009/),[l] / [70·h·kg],18.4,113845,DB00316,Acetaminophen
,22768009,Total central,"Total central and peripheral Vds of acetaminophen were 16 and 59.5 L/70 kg, respectively.","Safety and population pharmacokinetic analysis of intravenous acetaminophen in neonates, infants, children, and adolescents with pain or Fever. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22768009/),[l] / [70·kg],16,113846,DB00316,Acetaminophen
,22768009,peripheral Vds,"Total central and peripheral Vds of acetaminophen were 16 and 59.5 L/70 kg, respectively.","Safety and population pharmacokinetic analysis of intravenous acetaminophen in neonates, infants, children, and adolescents with pain or Fever. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22768009/),[l] / [70·kg],59.5,113847,DB00316,Acetaminophen
,22297684,m/,"Domperidone and paracetamol in plasma were extracted with ethyl acetate, separated on a C18 reversed phase column, eluted with mobile phase of acetonitrile-glacial acetic acid (0.3%) (40:60, v/v), ionized by positive ion pneumatically assisted electrospray and detected in the multi-reaction monitoring mode using precursor→product ions of m/z 426.2→175.1 for domperidone and 152→110 for the IS, respectively.",Determination of domperidone in human plasma using liquid chromatography coupled to tandem mass spectrometry and its pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22297684/),,426.2,113848,DB00316,Acetaminophen
,3769898,AUC,"The mean AUC at 90 min was 1,590, 642 and 159 micrograms min ml-1 after saline, morphine and meptazinol respectively.",Effect of meptazinol on drug absorption and gastric emptying. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3769898/),[min·μg] / [ml],"1,590",114075,DB00316,Acetaminophen
,3769898,AUC,"The mean AUC at 90 min was 1,590, 642 and 159 micrograms min ml-1 after saline, morphine and meptazinol respectively.",Effect of meptazinol on drug absorption and gastric emptying. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3769898/),[min·μg] / [ml],642,114076,DB00316,Acetaminophen
,3769898,AUC,"The mean AUC at 90 min was 1,590, 642 and 159 micrograms min ml-1 after saline, morphine and meptazinol respectively.",Effect of meptazinol on drug absorption and gastric emptying. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3769898/),[min·μg] / [ml],159,114077,DB00316,Acetaminophen
,2598989,maximum plasma concentration,The mean maximum plasma concentration after the initial loading dose was 554 mg/l.,The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598989/),[mg] / [l],554,114983,DB00316,Acetaminophen
,2598989,steady-state level,Concentrations then fell rapidly and after 12 h a mean steady-state level of about 35 mg/l was maintained.,The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598989/),[mg] / [l],35,114984,DB00316,Acetaminophen
,2598989,half-life,When the infusion was discontinued N-acetylcysteine disappeared with a half-life of 5.7 h.,The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598989/),h,5.7,114985,DB00316,Acetaminophen
,2598989,steady-state volume of distribution,"The mean steady-state volume of distribution, AUC, mean residence time and total clearance were 536 ml/kg, 1748 mg.h.l-1, 2.91 h and 3.18 ml.min-1.kg-1.",The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598989/),[ml] / [kg],536,114986,DB00316,Acetaminophen
,2598989,AUC,"The mean steady-state volume of distribution, AUC, mean residence time and total clearance were 536 ml/kg, 1748 mg.h.l-1, 2.91 h and 3.18 ml.min-1.kg-1.",The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598989/),[h·mg] / [l],1748,114987,DB00316,Acetaminophen
,2598989,AUC,"The mean steady-state volume of distribution, AUC, mean residence time and total clearance were 536 ml/kg, 1748 mg.h.l-1, 2.91 h and 3.18 ml.min-1.kg-1.",The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598989/),h,2.91,114988,DB00316,Acetaminophen
,2598989,mean residence time,"The mean steady-state volume of distribution, AUC, mean residence time and total clearance were 536 ml/kg, 1748 mg.h.l-1, 2.91 h and 3.18 ml.min-1.kg-1.",The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598989/),[h·mg] / [l],1748,114989,DB00316,Acetaminophen
,2598989,mean residence time,"The mean steady-state volume of distribution, AUC, mean residence time and total clearance were 536 ml/kg, 1748 mg.h.l-1, 2.91 h and 3.18 ml.min-1.kg-1.",The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598989/),h,2.91,114990,DB00316,Acetaminophen
,2598989,total clearance,"The mean steady-state volume of distribution, AUC, mean residence time and total clearance were 536 ml/kg, 1748 mg.h.l-1, 2.91 h and 3.18 ml.min-1.kg-1.",The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598989/),[ml] / [kg·min],3.18,114991,DB00316,Acetaminophen
,6688635,lag time,"Following a lag time averaging 3-4 min, absorption of oral acetaminophen was first order, with apparent absorption half-life values averaging 8.4 (elixir) and 11.4 (tablet) min.",Absolute and relative bioavailability of oral acetaminophen preparations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688635/),min,3-4,115828,DB00316,Acetaminophen
,6688635,apparent absorption half-life,"Following a lag time averaging 3-4 min, absorption of oral acetaminophen was first order, with apparent absorption half-life values averaging 8.4 (elixir) and 11.4 (tablet) min.",Absolute and relative bioavailability of oral acetaminophen preparations. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688635/),min,8.4,115829,DB00316,Acetaminophen
,6688635,apparent absorption half-life,"Following a lag time averaging 3-4 min, absorption of oral acetaminophen was first order, with apparent absorption half-life values averaging 8.4 (elixir) and 11.4 (tablet) min.",Absolute and relative bioavailability of oral acetaminophen preparations. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688635/),min,11.4,115830,DB00316,Acetaminophen
,6688635,time-to-peak concentration,The mean time-to-peak concentration was significantly longer after tablet (0.75 hr) than after elixir (0.48 hr) administration.,Absolute and relative bioavailability of oral acetaminophen preparations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688635/),h,0.75,115831,DB00316,Acetaminophen
,6688635,time-to-peak concentration,The mean time-to-peak concentration was significantly longer after tablet (0.75 hr) than after elixir (0.48 hr) administration.,Absolute and relative bioavailability of oral acetaminophen preparations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688635/),h,0.48,115832,DB00316,Acetaminophen
,6688635,Absolute systemic availability,Absolute systemic availability of the elixir (87%) was significantly greater than for the tablets (79%).,Absolute and relative bioavailability of oral acetaminophen preparations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688635/),%,87,115833,DB00316,Acetaminophen
,6688635,Absolute systemic availability,Absolute systemic availability of the elixir (87%) was significantly greater than for the tablets (79%).,Absolute and relative bioavailability of oral acetaminophen preparations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688635/),%,79,115834,DB00316,Acetaminophen
,7828444,half-life,"The infants aged less than 10 days had higher plasma concentrations of paracetamol, a longer half-life (3.5 vs.",Pharmacokinetics of paracetamol in the neonate and infant after administration of propacetamol chlorhydrate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7828444/),,3.5,115837,DB00316,Acetaminophen
,7828444,plasma clearance,2.1 h) and a lower plasma clearance (0.149 vs. 0.365 l/h/kg) than the older children.,Pharmacokinetics of paracetamol in the neonate and infant after administration of propacetamol chlorhydrate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7828444/),[l] / [h·kg],0.149,115838,DB00316,Acetaminophen
,7828444,plasma clearance,2.1 h) and a lower plasma clearance (0.149 vs. 0.365 l/h/kg) than the older children.,Pharmacokinetics of paracetamol in the neonate and infant after administration of propacetamol chlorhydrate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7828444/),[l] / [h·kg],0.365,115839,DB00316,Acetaminophen
,7828444,steady-state plasma concentrations,Dose simulations were performed on the basis of individual data of each child in order to obtain steady-state plasma concentrations between 4 and 18 mg/l permitting the best antipyretic effect for each child.,Pharmacokinetics of paracetamol in the neonate and infant after administration of propacetamol chlorhydrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7828444/),[mg] / [l],4 and 18,115840,DB00316,Acetaminophen
,22536830,peak,"The final model shows that for commonly used dosing regimens, the population mean PG peak and trough concentrations range between 33-144 and 28-218 mg l(-1) (peak) and 19-109 and 6-112 mg l(-1) (trough) for paracetamol and phenobarbital formulations, respectively, depending on birth weight and age of the neonates.",Developmental pharmacokinetics of propylene glycol in preterm and term neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22536830/),[mg] / [l],33-144,115936,DB00316,Acetaminophen
,22536830,trough concentrations,"The final model shows that for commonly used dosing regimens, the population mean PG peak and trough concentrations range between 33-144 and 28-218 mg l(-1) (peak) and 19-109 and 6-112 mg l(-1) (trough) for paracetamol and phenobarbital formulations, respectively, depending on birth weight and age of the neonates.",Developmental pharmacokinetics of propylene glycol in preterm and term neonates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22536830/),[mg] / [l],28,115937,DB00316,Acetaminophen
,22536830,peak,"The final model shows that for commonly used dosing regimens, the population mean PG peak and trough concentrations range between 33-144 and 28-218 mg l(-1) (peak) and 19-109 and 6-112 mg l(-1) (trough) for paracetamol and phenobarbital formulations, respectively, depending on birth weight and age of the neonates.",Developmental pharmacokinetics of propylene glycol in preterm and term neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22536830/),[mg] / [l],28,115938,DB00316,Acetaminophen
,22536830,trough,"The final model shows that for commonly used dosing regimens, the population mean PG peak and trough concentrations range between 33-144 and 28-218 mg l(-1) (peak) and 19-109 and 6-112 mg l(-1) (trough) for paracetamol and phenobarbital formulations, respectively, depending on birth weight and age of the neonates.",Developmental pharmacokinetics of propylene glycol in preterm and term neonates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22536830/),[mg] / [l],19-109,115939,DB00316,Acetaminophen
,22536830,trough,"The final model shows that for commonly used dosing regimens, the population mean PG peak and trough concentrations range between 33-144 and 28-218 mg l(-1) (peak) and 19-109 and 6-112 mg l(-1) (trough) for paracetamol and phenobarbital formulations, respectively, depending on birth weight and age of the neonates.",Developmental pharmacokinetics of propylene glycol in preterm and term neonates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22536830/),[mg] / [l],6-112,115940,DB00316,Acetaminophen
,10391601,AUC,"Gastric emptying rates were reduced in both group 1 (AUC = 14.98 (3.8) and 11.05 (4.6) pre- and postoperatively, respectively) and group 2 (AUC = 13.93 (3.59) and 6.4 (3.42) pre- and postoperatively, respectively); the magnitude of the reduction was greater in group 2 [AUC (P = 0.04), Cmax (P = 0.05), tCmax (P = 0.13)].",Delayed postoperative gastric emptying following intrathecal morphine and intrathecal bupivacaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391601/),,14.98,116251,DB00316,Acetaminophen
,10391601,AUC,"Gastric emptying rates were reduced in both group 1 (AUC = 14.98 (3.8) and 11.05 (4.6) pre- and postoperatively, respectively) and group 2 (AUC = 13.93 (3.59) and 6.4 (3.42) pre- and postoperatively, respectively); the magnitude of the reduction was greater in group 2 [AUC (P = 0.04), Cmax (P = 0.05), tCmax (P = 0.13)].",Delayed postoperative gastric emptying following intrathecal morphine and intrathecal bupivacaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391601/),,11.05,116252,DB00316,Acetaminophen
,10391601,AUC,"Gastric emptying rates were reduced in both group 1 (AUC = 14.98 (3.8) and 11.05 (4.6) pre- and postoperatively, respectively) and group 2 (AUC = 13.93 (3.59) and 6.4 (3.42) pre- and postoperatively, respectively); the magnitude of the reduction was greater in group 2 [AUC (P = 0.04), Cmax (P = 0.05), tCmax (P = 0.13)].",Delayed postoperative gastric emptying following intrathecal morphine and intrathecal bupivacaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391601/),,13.93,116253,DB00316,Acetaminophen
,10391601,AUC,"Gastric emptying rates were reduced in both group 1 (AUC = 14.98 (3.8) and 11.05 (4.6) pre- and postoperatively, respectively) and group 2 (AUC = 13.93 (3.59) and 6.4 (3.42) pre- and postoperatively, respectively); the magnitude of the reduction was greater in group 2 [AUC (P = 0.04), Cmax (P = 0.05), tCmax (P = 0.13)].",Delayed postoperative gastric emptying following intrathecal morphine and intrathecal bupivacaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391601/),,6.4,116254,DB00316,Acetaminophen
,26187926,flow rate,"The separation was performed on an Agilent HC-C18 column (4.6 × 250 mm, 5 µm) at a flow rate of 1.0 mL/min, using methanol-water containing 0.1% formic acid (39:61, v/v) as mobile phase, and total run time was 8.5 min.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),[ml] / [min],1.0,116281,DB00316,Acetaminophen
,26187926,total run time,"The separation was performed on an Agilent HC-C18 column (4.6 × 250 mm, 5 µm) at a flow rate of 1.0 mL/min, using methanol-water containing 0.1% formic acid (39:61, v/v) as mobile phase, and total run time was 8.5 min.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),min,8.5,116282,DB00316,Acetaminophen
,26187926,m/,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,130.1,116283,DB00316,Acetaminophen
,26187926,m/,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,60.2,116284,DB00316,Acetaminophen
,26187926,m/z,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,268.2,116285,DB00316,Acetaminophen
,26187926,m/z,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,116.1,116286,DB00316,Acetaminophen
,26187926,m/,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,284.2,116287,DB00316,Acetaminophen
,26187926,m/z,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,254.2,116288,DB00316,Acetaminophen
,26187926,m/z,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,152.3,116289,DB00316,Acetaminophen
,26187926,m/z,"The monitored transitions were m/z 130.1 → 60.2 for MTF, m/z 268.2 → 116.1 for MET, m/z 284.2 → 116.1 for HMT, m/z 254.2 → 116.1 for DMT and m/z 152.3 → 110.1 for IS.","Simultaneous Determination of Metformin, Metoprolol and its Metabolites in Rat Plasma by LC-MS-MS: Application to Pharmacokinetic Interaction Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26187926/),,110.1,116290,DB00316,Acetaminophen
,23279615,elimination rate constant (k(e)),The elimination rate constant (k(e)) for the removal of piperacillin in this patent was 0.453 h(-1) and the half-life (λ) was 1.53 h.,Molecular Adsorbent Recirculating System (MARS(®)) removal of piperacillin/tazobactam in a patient with acetaminophen-induced acute liver failure. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23279615/),1/[h],0.453,118180,DB00316,Acetaminophen
,23279615,half-life (λ),The elimination rate constant (k(e)) for the removal of piperacillin in this patent was 0.453 h(-1) and the half-life (λ) was 1.53 h.,Molecular Adsorbent Recirculating System (MARS(®)) removal of piperacillin/tazobactam in a patient with acetaminophen-induced acute liver failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23279615/),h,1.53,118181,DB00316,Acetaminophen
,7621851,apparent oral clearance,"The apparent oral clearance (Malaria, 3.6; Convalescence, 3.9; ml.min-1.kg-1), the elimination half-life (Malaria, 3.8; Convalescence, 3.7 h) and apparent volume of distribution (Malaria, 1.2; Convalescence, 1.2; l.kg-1) of paracetamol were similar during malaria and convalescence.",Paracetamol disposition in Thai patients during and after treatment of falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7621851/),[ml] / [kg·min],3.6,118853,DB00316,Acetaminophen
,7621851,apparent oral clearance,"The apparent oral clearance (Malaria, 3.6; Convalescence, 3.9; ml.min-1.kg-1), the elimination half-life (Malaria, 3.8; Convalescence, 3.7 h) and apparent volume of distribution (Malaria, 1.2; Convalescence, 1.2; l.kg-1) of paracetamol were similar during malaria and convalescence.",Paracetamol disposition in Thai patients during and after treatment of falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7621851/),[ml] / [kg·min],3.9,118854,DB00316,Acetaminophen
,7621851,elimination half-life,"The apparent oral clearance (Malaria, 3.6; Convalescence, 3.9; ml.min-1.kg-1), the elimination half-life (Malaria, 3.8; Convalescence, 3.7 h) and apparent volume of distribution (Malaria, 1.2; Convalescence, 1.2; l.kg-1) of paracetamol were similar during malaria and convalescence.",Paracetamol disposition in Thai patients during and after treatment of falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7621851/),h,3.8,118855,DB00316,Acetaminophen
,7621851,elimination half-life,"The apparent oral clearance (Malaria, 3.6; Convalescence, 3.9; ml.min-1.kg-1), the elimination half-life (Malaria, 3.8; Convalescence, 3.7 h) and apparent volume of distribution (Malaria, 1.2; Convalescence, 1.2; l.kg-1) of paracetamol were similar during malaria and convalescence.",Paracetamol disposition in Thai patients during and after treatment of falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7621851/),h,3.7,118856,DB00316,Acetaminophen
,7621851,apparent volume of distribution,"The apparent oral clearance (Malaria, 3.6; Convalescence, 3.9; ml.min-1.kg-1), the elimination half-life (Malaria, 3.8; Convalescence, 3.7 h) and apparent volume of distribution (Malaria, 1.2; Convalescence, 1.2; l.kg-1) of paracetamol were similar during malaria and convalescence.",Paracetamol disposition in Thai patients during and after treatment of falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7621851/),[l] / [kg],1.2,118857,DB00316,Acetaminophen
,8419064,total run time,"HPLC 1 allows quantification of 5MTHF by absorption at 313 nm; HPLC 2, the quantification of l-FA and d-FA by electrochemical detection in the oxidation mode (total run time 18 min).",HPLC of folinic acid diastereoisomers and 5-methyltetrahydrofolate in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419064/),min,18,119499,DB00316,Acetaminophen
>,8419064,Recoveries,Recoveries are > 80%.,HPLC of folinic acid diastereoisomers and 5-methyltetrahydrofolate in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419064/),%,80,119500,DB00316,Acetaminophen
,8419064,sensitivity,The sensitivity limit is 50 nmol/L for 5MTHF and 20 nmol/L for l-FA and d-FA.,HPLC of folinic acid diastereoisomers and 5-methyltetrahydrofolate in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419064/),[nM] / [l],50,119501,DB00316,Acetaminophen
,8419064,sensitivity,The sensitivity limit is 50 nmol/L for 5MTHF and 20 nmol/L for l-FA and d-FA.,HPLC of folinic acid diastereoisomers and 5-methyltetrahydrofolate in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419064/),,20,119502,DB00316,Acetaminophen
,15333515,systemic clearance,The systemic clearance of propranolol (approximately 1.53 l/h/kg) suggested that the hepatic blood flow in CHPs is comparable to that in humans.,The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: model characterization and application. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15333515/),[l] / [h·kg],1.53,119920,DB00316,Acetaminophen
,17884974,IC(50),"In vitro, acetaminophen elicited a 4.4-fold selectivity toward COX-2 inhibition (IC(50)=113.7 micromol/L for COX-1; IC(50)=25.8 micromol/L for COX-2).",Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17884974/),[μM] / [l],113.7,120191,DB00316,Acetaminophen
,17884974,IC(50),"In vitro, acetaminophen elicited a 4.4-fold selectivity toward COX-2 inhibition (IC(50)=113.7 micromol/L for COX-1; IC(50)=25.8 micromol/L for COX-2).",Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17884974/),[μM] / [l],25.8,120192,DB00316,Acetaminophen
,17884974,maximal,"Following oral administration of the drug, maximal ex vivo inhibitions were 56% (COX-1) and 83% (COX-2).",Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17884974/),%,56,120193,DB00316,Acetaminophen
,17884974,maximal,"Following oral administration of the drug, maximal ex vivo inhibitions were 56% (COX-1) and 83% (COX-2).",Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17884974/),%,83,120194,DB00316,Acetaminophen
,17884974,IC(50),Ex vivo IC(50) values (COX-1: 105.2 micromol/L; COX-2: 26.3 micromol/L) of acetaminophen compared favorably with its in vitro IC(50) values.,Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17884974/),[μM] / [l],105.2,120195,DB00316,Acetaminophen
,17884974,IC(50),Ex vivo IC(50) values (COX-1: 105.2 micromol/L; COX-2: 26.3 micromol/L) of acetaminophen compared favorably with its in vitro IC(50) values.,Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17884974/),[μM] / [l],26.3,120196,DB00316,Acetaminophen
,2257860,urine to plasma para,"Despite the heterogeneity of patients and the diversity of drug treatment, the urine to plasma paracetamol concentration ratio appeared remarkably constant in patients with normal renal function (9.8 +/- 2.7).","Paracetamol test: modification by renal function, urine flow and pH. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257860/),,9.8,120769,DB00316,Acetaminophen
,2257860,concentration ratio,"Despite the heterogeneity of patients and the diversity of drug treatment, the urine to plasma paracetamol concentration ratio appeared remarkably constant in patients with normal renal function (9.8 +/- 2.7).","Paracetamol test: modification by renal function, urine flow and pH. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257860/),,9.8,120770,DB00316,Acetaminophen
,21046686,flow rate,"The separation was carried out on an ACQUITY UPLC™ BEH C₁₈ column with a mobile phase of acetonitrile-5 mM ammonium acetate (90:10, v/v) at a flow rate of 0.2 mL/min.",Determination and pharmacokinetic study of chiisanogenin in rat plasma by ultra performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21046686/),[ml] / [min],0.2,122665,DB00316,Acetaminophen
,21046686,analysis time,A high sample throughput was achieved with an analysis time of 1.1 min per sample.,Determination and pharmacokinetic study of chiisanogenin in rat plasma by ultra performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21046686/),[min] / [sample],1.1,122666,DB00316,Acetaminophen
,30484909,serum concentration,The plasma acetaminophen serum concentration was 17 (SD 4) μg·mL-1 at 10-20 minutes after completion of the infusion and 5 (SD 6) μg·mL-1 at 80-100 minutes.,Acetaminophen pharmacokinetics in severely obese adolescents and young adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30484909/),[μg] / [ml],17,122778,DB00316,Acetaminophen
,30484909,serum concentration,The plasma acetaminophen serum concentration was 17 (SD 4) μg·mL-1 at 10-20 minutes after completion of the infusion and 5 (SD 6) μg·mL-1 at 80-100 minutes.,Acetaminophen pharmacokinetics in severely obese adolescents and young adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30484909/),[μg] / [ml],5,122779,DB00316,Acetaminophen
,30484909,clearance,"A two-compartment model, used to investigate pharmacokinetics, estimated clearance 10.6 (CV 72%) L·h·70 kg-1 , intercompartment clearance 37.3 (CV 63%) L·h·70 kg-1 , central volume of distribution 20.4 (CV 46%) L·70 kg-1 , and peripheral volume of distribution 16.8 (CV 42%) L·70 kg-1 .",Acetaminophen pharmacokinetics in severely obese adolescents and young adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30484909/),[h·l] / [70·kg],10.6,122780,DB00316,Acetaminophen
,30484909,intercompartment clearance,"A two-compartment model, used to investigate pharmacokinetics, estimated clearance 10.6 (CV 72%) L·h·70 kg-1 , intercompartment clearance 37.3 (CV 63%) L·h·70 kg-1 , central volume of distribution 20.4 (CV 46%) L·70 kg-1 , and peripheral volume of distribution 16.8 (CV 42%) L·70 kg-1 .",Acetaminophen pharmacokinetics in severely obese adolescents and young adults. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30484909/),[h·l] / [70·kg],37.3,122781,DB00316,Acetaminophen
,30484909,central volume of distribution,"A two-compartment model, used to investigate pharmacokinetics, estimated clearance 10.6 (CV 72%) L·h·70 kg-1 , intercompartment clearance 37.3 (CV 63%) L·h·70 kg-1 , central volume of distribution 20.4 (CV 46%) L·70 kg-1 , and peripheral volume of distribution 16.8 (CV 42%) L·70 kg-1 .",Acetaminophen pharmacokinetics in severely obese adolescents and young adults. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30484909/),[l] / [70·kg],20.4,122782,DB00316,Acetaminophen
,30484909,peripheral volume of distribution,"A two-compartment model, used to investigate pharmacokinetics, estimated clearance 10.6 (CV 72%) L·h·70 kg-1 , intercompartment clearance 37.3 (CV 63%) L·h·70 kg-1 , central volume of distribution 20.4 (CV 46%) L·70 kg-1 , and peripheral volume of distribution 16.8 (CV 42%) L·70 kg-1 .",Acetaminophen pharmacokinetics in severely obese adolescents and young adults. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30484909/),[l] / [70·kg],16.8,122783,DB00316,Acetaminophen
,10362265,plasma elimination half-lives (t1/2),"The plasma elimination half-lives (t1/2) were 1.2 h for antipyrine, 11.9 h for warfarin and 5.2-12.9 h for paracetamol.","Pharmacokinetics of antipyrine, warfarin and paracetamol in the brushtail possum. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10362265/),h,1.2,123048,DB00316,Acetaminophen
,10362265,plasma elimination half-lives (t1/2),"The plasma elimination half-lives (t1/2) were 1.2 h for antipyrine, 11.9 h for warfarin and 5.2-12.9 h for paracetamol.","Pharmacokinetics of antipyrine, warfarin and paracetamol in the brushtail possum. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10362265/),h,11.9,123049,DB00316,Acetaminophen
,10362265,plasma elimination half-lives (t1/2),"The plasma elimination half-lives (t1/2) were 1.2 h for antipyrine, 11.9 h for warfarin and 5.2-12.9 h for paracetamol.","Pharmacokinetics of antipyrine, warfarin and paracetamol in the brushtail possum. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10362265/),h,5.2-12.9,123050,DB00316,Acetaminophen
,26201306,clearance,"Weight predicted paracetamol clearance and volume of distribution, which were estimated as 0.348 L/h (5.5 % relative standard error; 30.8 % coefficient of variation) and 2.46 L (3.5 % relative standard error; 14.3 % coefficient of variation), respectively, at the mean subject weight of 2.30 kg.",Population Pharmacokinetics of Intravenous Paracetamol (Acetaminophen) in Preterm and Term Neonates: Model Development and External Evaluation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26201306/),[l] / [h],0.348,126261,DB00316,Acetaminophen
,26201306,volume of distribution,"Weight predicted paracetamol clearance and volume of distribution, which were estimated as 0.348 L/h (5.5 % relative standard error; 30.8 % coefficient of variation) and 2.46 L (3.5 % relative standard error; 14.3 % coefficient of variation), respectively, at the mean subject weight of 2.30 kg.",Population Pharmacokinetics of Intravenous Paracetamol (Acetaminophen) in Preterm and Term Neonates: Model Development and External Evaluation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26201306/),l,2.46,126262,DB00316,Acetaminophen
,32732164,Serum concentrations,Serum concentrations of acetaminophen in IA and HD patients were above the therapeutic range four hours after administering the loading dose (31.4 ± 10.39 and 36.3 ± 6.79 versus 5-20 μg/ml).,Bioavailability of rectal acetaminophen in children following anorectal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32732164/),,31.4,127041,DB00316,Acetaminophen
,32732164,Serum concentrations,Serum concentrations of acetaminophen in IA and HD patients were above the therapeutic range four hours after administering the loading dose (31.4 ± 10.39 and 36.3 ± 6.79 versus 5-20 μg/ml).,Bioavailability of rectal acetaminophen in children following anorectal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32732164/),,36.3,127042,DB00316,Acetaminophen
,32732164,Serum concentrations,Serum concentrations of acetaminophen in IA and HD patients were above the therapeutic range four hours after administering the loading dose (31.4 ± 10.39 and 36.3 ± 6.79 versus 5-20 μg/ml).,Bioavailability of rectal acetaminophen in children following anorectal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32732164/),,5-20,127043,DB00316,Acetaminophen
,7194086,relative bioavailabilities,The estimated relative bioavailabilities of the single substances in the suppository formulation vary between 120% for propyphenazone and 83% for phenobarbital in comparison to the tablets.,"[A comparative pharmacokinetic study for tablet and suppository formulations of a combination product of caffeine, ethaverine, propyphenazone, paracetamol and phenobarbital (author's transl)]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194086/),%,120,127131,DB00316,Acetaminophen
,7194086,relative bioavailabilities,The estimated relative bioavailabilities of the single substances in the suppository formulation vary between 120% for propyphenazone and 83% for phenobarbital in comparison to the tablets.,"[A comparative pharmacokinetic study for tablet and suppository formulations of a combination product of caffeine, ethaverine, propyphenazone, paracetamol and phenobarbital (author's transl)]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194086/),%,83,127132,DB00316,Acetaminophen
,17202677,clearance,"The pharmacokinetic and pharmacodynamic parameter (mean+/-S.D.) estimates were as follows: clearance, 18.7+/-4.7 l/h; distribution volume, 30.9+/-6.8 l; absorption rate constant, 2.4+/-1.3 h(-1); rate constant for the elimination of APAP from the effect compartment, 1.3+/-0.5 h(-1); maximum pain relief score, 4.6+/-2.2 units; effect compartment concentration at 50% maximum, 2.0+/-1.2 microg/ml; and sigmoid factor, 1.3+/-0.7.",Pharmacokinetics/pharmacodynamics of acetaminophen analgesia in Japanese patients with chronic pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202677/),[l] / [h],18.7,127678,DB00316,Acetaminophen
,17202677,distribution volume,"The pharmacokinetic and pharmacodynamic parameter (mean+/-S.D.) estimates were as follows: clearance, 18.7+/-4.7 l/h; distribution volume, 30.9+/-6.8 l; absorption rate constant, 2.4+/-1.3 h(-1); rate constant for the elimination of APAP from the effect compartment, 1.3+/-0.5 h(-1); maximum pain relief score, 4.6+/-2.2 units; effect compartment concentration at 50% maximum, 2.0+/-1.2 microg/ml; and sigmoid factor, 1.3+/-0.7.",Pharmacokinetics/pharmacodynamics of acetaminophen analgesia in Japanese patients with chronic pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202677/),l,30.9,127679,DB00316,Acetaminophen
,17202677,absorption rate constant,"The pharmacokinetic and pharmacodynamic parameter (mean+/-S.D.) estimates were as follows: clearance, 18.7+/-4.7 l/h; distribution volume, 30.9+/-6.8 l; absorption rate constant, 2.4+/-1.3 h(-1); rate constant for the elimination of APAP from the effect compartment, 1.3+/-0.5 h(-1); maximum pain relief score, 4.6+/-2.2 units; effect compartment concentration at 50% maximum, 2.0+/-1.2 microg/ml; and sigmoid factor, 1.3+/-0.7.",Pharmacokinetics/pharmacodynamics of acetaminophen analgesia in Japanese patients with chronic pain. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202677/),1/[h],2.4,127680,DB00316,Acetaminophen
,17202677,rate constant for the elimination,"The pharmacokinetic and pharmacodynamic parameter (mean+/-S.D.) estimates were as follows: clearance, 18.7+/-4.7 l/h; distribution volume, 30.9+/-6.8 l; absorption rate constant, 2.4+/-1.3 h(-1); rate constant for the elimination of APAP from the effect compartment, 1.3+/-0.5 h(-1); maximum pain relief score, 4.6+/-2.2 units; effect compartment concentration at 50% maximum, 2.0+/-1.2 microg/ml; and sigmoid factor, 1.3+/-0.7.",Pharmacokinetics/pharmacodynamics of acetaminophen analgesia in Japanese patients with chronic pain. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202677/),1/[h],1.3,127681,DB00316,Acetaminophen
,17202677,maximum pain relief score,"The pharmacokinetic and pharmacodynamic parameter (mean+/-S.D.) estimates were as follows: clearance, 18.7+/-4.7 l/h; distribution volume, 30.9+/-6.8 l; absorption rate constant, 2.4+/-1.3 h(-1); rate constant for the elimination of APAP from the effect compartment, 1.3+/-0.5 h(-1); maximum pain relief score, 4.6+/-2.2 units; effect compartment concentration at 50% maximum, 2.0+/-1.2 microg/ml; and sigmoid factor, 1.3+/-0.7.",Pharmacokinetics/pharmacodynamics of acetaminophen analgesia in Japanese patients with chronic pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202677/),units,4.6,127682,DB00316,Acetaminophen
,17202677,effect compartment concentration at 50% maximum,"The pharmacokinetic and pharmacodynamic parameter (mean+/-S.D.) estimates were as follows: clearance, 18.7+/-4.7 l/h; distribution volume, 30.9+/-6.8 l; absorption rate constant, 2.4+/-1.3 h(-1); rate constant for the elimination of APAP from the effect compartment, 1.3+/-0.5 h(-1); maximum pain relief score, 4.6+/-2.2 units; effect compartment concentration at 50% maximum, 2.0+/-1.2 microg/ml; and sigmoid factor, 1.3+/-0.7.",Pharmacokinetics/pharmacodynamics of acetaminophen analgesia in Japanese patients with chronic pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202677/),[μg] / [ml],2.0,127683,DB00316,Acetaminophen
,17202677,effect compartment concentration at 50% maximum,"The pharmacokinetic and pharmacodynamic parameter (mean+/-S.D.) estimates were as follows: clearance, 18.7+/-4.7 l/h; distribution volume, 30.9+/-6.8 l; absorption rate constant, 2.4+/-1.3 h(-1); rate constant for the elimination of APAP from the effect compartment, 1.3+/-0.5 h(-1); maximum pain relief score, 4.6+/-2.2 units; effect compartment concentration at 50% maximum, 2.0+/-1.2 microg/ml; and sigmoid factor, 1.3+/-0.7.",Pharmacokinetics/pharmacodynamics of acetaminophen analgesia in Japanese patients with chronic pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202677/),,1.3,127684,DB00316,Acetaminophen
,27209292,CLformation,"At the mean weight (2.3 kg) and postnatal age (7.5 days), CLformation estimates (bootstrap 95% confidence interval; between-subject variability) were 0.049 L/h (0.038-0.062; 62 %) for glucuronidation, 0.21 L/h (0.17-0.24; 33 %) for sulfation, and 0.058 L/h (0.044-0.078; 72 %) for oxidation.","Neonatal Maturation of Paracetamol (Acetaminophen) Glucuronidation, Sulfation, and Oxidation Based on a Parent-Metabolite Population Pharmacokinetic Model. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27209292/),[l] / [h],0.049,128081,DB00316,Acetaminophen
,27209292,CLformation,"At the mean weight (2.3 kg) and postnatal age (7.5 days), CLformation estimates (bootstrap 95% confidence interval; between-subject variability) were 0.049 L/h (0.038-0.062; 62 %) for glucuronidation, 0.21 L/h (0.17-0.24; 33 %) for sulfation, and 0.058 L/h (0.044-0.078; 72 %) for oxidation.","Neonatal Maturation of Paracetamol (Acetaminophen) Glucuronidation, Sulfation, and Oxidation Based on a Parent-Metabolite Population Pharmacokinetic Model. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27209292/),[l] / [h],0.21,128082,DB00316,Acetaminophen
,27209292,CLformation,"At the mean weight (2.3 kg) and postnatal age (7.5 days), CLformation estimates (bootstrap 95% confidence interval; between-subject variability) were 0.049 L/h (0.038-0.062; 62 %) for glucuronidation, 0.21 L/h (0.17-0.24; 33 %) for sulfation, and 0.058 L/h (0.044-0.078; 72 %) for oxidation.","Neonatal Maturation of Paracetamol (Acetaminophen) Glucuronidation, Sulfation, and Oxidation Based on a Parent-Metabolite Population Pharmacokinetic Model. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27209292/),[l] / [h],0.058,128083,DB00316,Acetaminophen
,20439170,m/z,"The MS/MS ion transitions monitored were m/z 195.2-->120.2 and 152.1-->110.1 for PAH and acetaminophen, respectively.",Determination of p-aminohippuric acid in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20439170/),,195.2,128545,DB00316,Acetaminophen
,20439170,m/z,"The MS/MS ion transitions monitored were m/z 195.2-->120.2 and 152.1-->110.1 for PAH and acetaminophen, respectively.",Determination of p-aminohippuric acid in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20439170/),,152.1,128546,DB00316,Acetaminophen
≥,28816026,TC,Primary outcome was time that plasma acetaminophen concentration was ≥4 μg/mL (TC≥4μg/mL ).,"Evaluation of a 12-Hour Sustained-Release Acetaminophen (Paracetamol) Formulation: A Randomized, 3-Way Crossover Pharmacokinetic and Safety Study in Healthy Volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28816026/),[μg] / [ml],4,128819,DB00316,Acetaminophen
≥,28816026,TC,"TC≥4μg/mL from 2000-mg SR acetaminophen was similar to that from 2 doses of IR acetaminophen, whereas TC≥4μg/mL for 1500-mg SR acetaminophen was significantly shorter than that for IR acetaminophen (P = .004).","Evaluation of a 12-Hour Sustained-Release Acetaminophen (Paracetamol) Formulation: A Randomized, 3-Way Crossover Pharmacokinetic and Safety Study in Healthy Volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28816026/),[μg] / [ml],4,128820,DB00316,Acetaminophen
,23098635,CMAX,The mean hydrocodone CMAX was 11.73 ng/mL at 0.74 h with a terminal half-life of 1.60 h.,Pharmacokinetics of hydrocodone and hydromorphone after oral hydrocodone in healthy Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23098635/),[ng] / [ml],11.73,129788,DB00316,Acetaminophen
,23098635,terminal half-life,The mean hydrocodone CMAX was 11.73 ng/mL at 0.74 h with a terminal half-life of 1.60 h.,Pharmacokinetics of hydrocodone and hydromorphone after oral hydrocodone in healthy Greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23098635/),h,1.60,129789,DB00316,Acetaminophen
,23098635,CMAX,The mean hydromorphone CMAX was 5.2 ng/mL at 1.37 h with a terminal half-life of 3.07 h.,Pharmacokinetics of hydrocodone and hydromorphone after oral hydrocodone in healthy Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23098635/),[ng] / [ml],5.2,129790,DB00316,Acetaminophen
,23098635,terminal half-life,The mean hydromorphone CMAX was 5.2 ng/mL at 1.37 h with a terminal half-life of 3.07 h.,Pharmacokinetics of hydrocodone and hydromorphone after oral hydrocodone in healthy Greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23098635/),h,3.07,129791,DB00316,Acetaminophen
,1732127,bioactivation,"Acetaminophen glucuronide formation in subjects with Gilbert's syndrome was 31% lower than that in normal controls (0.27 +/- 0.05 vs. 0.39 +/- 0.03; P less than 0.05), and bioactivation was 1.7-fold higher (3.5% +/- 0.4% vs. 2.1% +/- 0.3%; P less than 0.05).",Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732127/),%,3.5,131650,DB00316,Acetaminophen
,1732127,bioactivation,"Acetaminophen glucuronide formation in subjects with Gilbert's syndrome was 31% lower than that in normal controls (0.27 +/- 0.05 vs. 0.39 +/- 0.03; P less than 0.05), and bioactivation was 1.7-fold higher (3.5% +/- 0.4% vs. 2.1% +/- 0.3%; P less than 0.05).",Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732127/),%,2.1,131651,DB00316,Acetaminophen
,23351277,T(max),"The oral and rectal preparations produced similar, rapid peak concentrations (T(max), 1.16 vs 1.17 hours; P = 0.98) and elimination t(½) (1.84 vs 2.10 hours; P = 0.14), respectively.","Pharmacokinetic comparison of acetaminophen elixir versus suppositories in vaccinated infants (aged 3 to 36 months): a single-dose, open-label, randomized, parallel-group design. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23351277/),h,1.16,132213,DB00316,Acetaminophen
,23351277,T(max),"The oral and rectal preparations produced similar, rapid peak concentrations (T(max), 1.16 vs 1.17 hours; P = 0.98) and elimination t(½) (1.84 vs 2.10 hours; P = 0.14), respectively.","Pharmacokinetic comparison of acetaminophen elixir versus suppositories in vaccinated infants (aged 3 to 36 months): a single-dose, open-label, randomized, parallel-group design. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23351277/),h,1.17,132214,DB00316,Acetaminophen
,23351277,elimination t(½),"The oral and rectal preparations produced similar, rapid peak concentrations (T(max), 1.16 vs 1.17 hours; P = 0.98) and elimination t(½) (1.84 vs 2.10 hours; P = 0.14), respectively.","Pharmacokinetic comparison of acetaminophen elixir versus suppositories in vaccinated infants (aged 3 to 36 months): a single-dose, open-label, randomized, parallel-group design. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23351277/),h,1.84,132215,DB00316,Acetaminophen
,23351277,elimination t(½),"The oral and rectal preparations produced similar, rapid peak concentrations (T(max), 1.16 vs 1.17 hours; P = 0.98) and elimination t(½) (1.84 vs 2.10 hours; P = 0.14), respectively.","Pharmacokinetic comparison of acetaminophen elixir versus suppositories in vaccinated infants (aged 3 to 36 months): a single-dose, open-label, randomized, parallel-group design. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23351277/),h,2.10,132216,DB00316,Acetaminophen
,23351277,C(max),"No statistically significant differences were found between either C(max) (7.65 vs 5.68 μg/mL) or total drug exposure (AUC(0-∞), 23.36 vs 20.45 μg-h/mL) for the oral versus rectal preparations.","Pharmacokinetic comparison of acetaminophen elixir versus suppositories in vaccinated infants (aged 3 to 36 months): a single-dose, open-label, randomized, parallel-group design. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23351277/),[μg] / [ml],7.65,132217,DB00316,Acetaminophen
,23351277,C(max),"No statistically significant differences were found between either C(max) (7.65 vs 5.68 μg/mL) or total drug exposure (AUC(0-∞), 23.36 vs 20.45 μg-h/mL) for the oral versus rectal preparations.","Pharmacokinetic comparison of acetaminophen elixir versus suppositories in vaccinated infants (aged 3 to 36 months): a single-dose, open-label, randomized, parallel-group design. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23351277/),[μg] / [ml],5.68,132218,DB00316,Acetaminophen
,23351277,AUC(0-∞),"No statistically significant differences were found between either C(max) (7.65 vs 5.68 μg/mL) or total drug exposure (AUC(0-∞), 23.36 vs 20.45 μg-h/mL) for the oral versus rectal preparations.","Pharmacokinetic comparison of acetaminophen elixir versus suppositories in vaccinated infants (aged 3 to 36 months): a single-dose, open-label, randomized, parallel-group design. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23351277/),[μg-h] / [ml],23.36,132219,DB00316,Acetaminophen
,23351277,AUC(0-∞),"No statistically significant differences were found between either C(max) (7.65 vs 5.68 μg/mL) or total drug exposure (AUC(0-∞), 23.36 vs 20.45 μg-h/mL) for the oral versus rectal preparations.","Pharmacokinetic comparison of acetaminophen elixir versus suppositories in vaccinated infants (aged 3 to 36 months): a single-dose, open-label, randomized, parallel-group design. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23351277/),[μg-h] / [ml],20.45,132220,DB00316,Acetaminophen
,11374595,highest serum concentration,The highest serum concentration with initial or subsequent dosing was 38.6 microg/ml.,Initial and subsequent dosing of rectal acetaminophen in children: a 24-hour pharmacokinetic study of new dose recommendations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11374595/),[μg] / [ml],38.6,132299,DB00316,Acetaminophen
,9118661,area under the acetam,There was no significant change in the area under the acetaminophen absorption curve from 0 to 60 mins from day 1 to day 2 in patients who received placebo or cisapride.,"Double-blind, randomized study of the effect of cisapride on gastric emptying in critically ill patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9118661/),min,0,132600,DB00316,Acetaminophen
,9118661,area under the acetam,There was no significant change in the area under the acetaminophen absorption curve from 0 to 60 mins from day 1 to day 2 in patients who received placebo or cisapride.,"Double-blind, randomized study of the effect of cisapride on gastric emptying in critically ill patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9118661/),min,60,132601,DB00316,Acetaminophen
< or =,9118661,time to maximum acetaminophen concentration,"Using the combination of the time to maximum acetaminophen concentration (< or = 30 mins) with a maximum concentration (> 12 mg/L) to define ""normal"" emptying, on day 1, four of the 11 placebo patients had the ""normal"" gastric emptying, and by day 2, five patients fulfilled this criterion.","Double-blind, randomized study of the effect of cisapride on gastric emptying in critically ill patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9118661/),min,30,132602,DB00316,Acetaminophen
>,9118661,maximum concentration,"Using the combination of the time to maximum acetaminophen concentration (< or = 30 mins) with a maximum concentration (> 12 mg/L) to define ""normal"" emptying, on day 1, four of the 11 placebo patients had the ""normal"" gastric emptying, and by day 2, five patients fulfilled this criterion.","Double-blind, randomized study of the effect of cisapride on gastric emptying in critically ill patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9118661/),[mg] / [l],12,132603,DB00316,Acetaminophen
,7264905,urinary recovery,"The 72-hr urinary recovery of free sulfate following single and divided doses was 53.4 +/- 15.8 and 61.8 +/- 7.8%, respectively (mean +/- SD, n=5, p greater than 0.2).",Absorption of orally administered sodium sulfate in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7264905/),%,53.4,132949,DB00316,Acetaminophen
,7264905,urinary recovery,"The 72-hr urinary recovery of free sulfate following single and divided doses was 53.4 +/- 15.8 and 61.8 +/- 7.8%, respectively (mean +/- SD, n=5, p greater than 0.2).",Absorption of orally administered sodium sulfate in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7264905/),%,61.8,132950,DB00316,Acetaminophen
,7593899,peak paracetamol concentration,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),[mg] / [l],18.5,134403,DB00316,Acetaminophen
,7593899,peak paracetamol concentration,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),[mg] / [l],20.8,134404,DB00316,Acetaminophen
,7593899,time to peak concentration,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),min,20,134405,DB00316,Acetaminophen
,7593899,time to peak concentration,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),min,25,134406,DB00316,Acetaminophen
,7593899,residual volumes,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),ml,14,134407,DB00316,Acetaminophen
,7593899,residual volumes,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),ml,10.5,134408,DB00316,Acetaminophen
,7593899,residual volumes,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),ml,5,134409,DB00316,Acetaminophen
,7593899,residual volumes,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),ml,3,134410,DB00316,Acetaminophen
,7593899,AUC,"In patients with ICP > 20 mmHg, paracetamol concentrations were lower (p < 0.05), and AUC after 30 min was lower (165 mg.min/l versus 411 mg.min/l, p = 0.023).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),[mg·min] / [l],165,134411,DB00316,Acetaminophen
,7593899,AUC,"In patients with ICP > 20 mmHg, paracetamol concentrations were lower (p < 0.05), and AUC after 30 min was lower (165 mg.min/l versus 411 mg.min/l, p = 0.023).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),[mg·min] / [l],411,134412,DB00316,Acetaminophen
,32187884,hydrolyzed plasma concentrations,"The hydrolyzed plasma concentrations of paracetamol, metacetamol, and orthocetamol ranged from 0.787 to 39.8 ng/mL (median 5.87 ng/mL), 0 to 2.13 ng/mL (0.347 ng/mL), and 1.98 to 82.8 ng/mL (16.6 ng/mL), respectively.","Investigation of plasma concentrations of paracetamol, metacetamol, and orthocetamol in Japanese racehorses using liquid chromatography-electrospray ionisation-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32187884/),[ng] / [ml],5.87,135192,DB00316,Acetaminophen
,32187884,hydrolyzed plasma concentrations,"The hydrolyzed plasma concentrations of paracetamol, metacetamol, and orthocetamol ranged from 0.787 to 39.8 ng/mL (median 5.87 ng/mL), 0 to 2.13 ng/mL (0.347 ng/mL), and 1.98 to 82.8 ng/mL (16.6 ng/mL), respectively.","Investigation of plasma concentrations of paracetamol, metacetamol, and orthocetamol in Japanese racehorses using liquid chromatography-electrospray ionisation-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32187884/),[ng] / [ml],0 to 2.13,135193,DB00316,Acetaminophen
,32187884,hydrolyzed plasma concentrations,"The hydrolyzed plasma concentrations of paracetamol, metacetamol, and orthocetamol ranged from 0.787 to 39.8 ng/mL (median 5.87 ng/mL), 0 to 2.13 ng/mL (0.347 ng/mL), and 1.98 to 82.8 ng/mL (16.6 ng/mL), respectively.","Investigation of plasma concentrations of paracetamol, metacetamol, and orthocetamol in Japanese racehorses using liquid chromatography-electrospray ionisation-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32187884/),[ng] / [ml],1.98 to 82.8,135194,DB00316,Acetaminophen
,28663312,oxidation clearance,"However, median oxidation clearance was 37% lower in African-Americans versus European-Americans (0.57 versus 0.90 ml/min per kilogram; P = 0.0001).","Race, Gender, and Genetic Polymorphism Contribute to Variability in Acetaminophen Pharmacokinetics, Metabolism, and Protein-Adduct Concentrations in Healthy African-American and European-American Volunteers. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28663312/),[ml] / [kg·min],0.57,135267,DB00316,Acetaminophen
,28663312,oxidation clearance,"However, median oxidation clearance was 37% lower in African-Americans versus European-Americans (0.57 versus 0.90 ml/min per kilogram; P = 0.0001).","Race, Gender, and Genetic Polymorphism Contribute to Variability in Acetaminophen Pharmacokinetics, Metabolism, and Protein-Adduct Concentrations in Healthy African-American and European-American Volunteers. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28663312/),[ml] / [kg·min],0.90,135268,DB00316,Acetaminophen
,12845506,time,"Median (25-75th percentile) time between APAP loading dose administration and collection of blood samples and median time (25-75th percentile) between APAP loading dose and collection of CSF were, respectively, 125 min (95-210 min) and 133 min (33-202 min).",Acetaminophen in cerebrospinal fluid in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845506/),min,125,135734,DB00316,Acetaminophen
,12845506,time,"Median (25-75th percentile) time between APAP loading dose administration and collection of blood samples and median time (25-75th percentile) between APAP loading dose and collection of CSF were, respectively, 125 min (95-210 min) and 133 min (33-202 min).",Acetaminophen in cerebrospinal fluid in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845506/),min,133,135735,DB00316,Acetaminophen
,12845506,Teq,"The population mean Teq, standardized to a 70-kg person, was 1.93 h (CV 43%), an estimate similar to that described in adults (2.1 h).",Acetaminophen in cerebrospinal fluid in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845506/),h,1.93,135736,DB00316,Acetaminophen
,12845506,Teq,"The population mean Teq, standardized to a 70-kg person, was 1.93 h (CV 43%), an estimate similar to that described in adults (2.1 h).",Acetaminophen in cerebrospinal fluid in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845506/),h,2.1,135737,DB00316,Acetaminophen
,12845506,plasma concentrations,"APAP plasma concentrations ranged from 0.0 mg/l to 33.0 mg/l, APAP CSF concentrations ranged from 0.0 mg/l to 21.0 mg/l.",Acetaminophen in cerebrospinal fluid in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845506/),[mg] / [l],0.0,135738,DB00316,Acetaminophen
,12845506,plasma concentrations,"APAP plasma concentrations ranged from 0.0 mg/l to 33.0 mg/l, APAP CSF concentrations ranged from 0.0 mg/l to 21.0 mg/l.",Acetaminophen in cerebrospinal fluid in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845506/),[mg] / [l],33.0,135739,DB00316,Acetaminophen
,12845506,CSF,"APAP plasma concentrations ranged from 0.0 mg/l to 33.0 mg/l, APAP CSF concentrations ranged from 0.0 mg/l to 21.0 mg/l.",Acetaminophen in cerebrospinal fluid in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845506/),[mg] / [l],0.0,135740,DB00316,Acetaminophen
,12845506,CSF,"APAP plasma concentrations ranged from 0.0 mg/l to 33.0 mg/l, APAP CSF concentrations ranged from 0.0 mg/l to 21.0 mg/l.",Acetaminophen in cerebrospinal fluid in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845506/),[mg] / [l],21.0,135741,DB00316,Acetaminophen
,12845506,concentrations,"APAP plasma concentrations ranged from 0.0 mg/l to 33.0 mg/l, APAP CSF concentrations ranged from 0.0 mg/l to 21.0 mg/l.",Acetaminophen in cerebrospinal fluid in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845506/),[mg] / [l],0.0,135742,DB00316,Acetaminophen
,12845506,concentrations,"APAP plasma concentrations ranged from 0.0 mg/l to 33.0 mg/l, APAP CSF concentrations ranged from 0.0 mg/l to 21.0 mg/l.",Acetaminophen in cerebrospinal fluid in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845506/),[mg] / [l],21.0,135743,DB00316,Acetaminophen
,12845506,Teq,"We predict a neonate (3.5 kg), 1-year-old child (10 kg), 5-year-old child (20 kg), 10-year-old child (30 kg) and adult (70 kg) to have Teq values of 0.9, 1, 1.4, 1.6, and 1.93 h, respectively.",Acetaminophen in cerebrospinal fluid in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845506/),h,0.9,135744,DB00316,Acetaminophen
,12845506,Teq,"We predict a neonate (3.5 kg), 1-year-old child (10 kg), 5-year-old child (20 kg), 10-year-old child (30 kg) and adult (70 kg) to have Teq values of 0.9, 1, 1.4, 1.6, and 1.93 h, respectively.",Acetaminophen in cerebrospinal fluid in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845506/),h,1,135745,DB00316,Acetaminophen
,12845506,Teq,"We predict a neonate (3.5 kg), 1-year-old child (10 kg), 5-year-old child (20 kg), 10-year-old child (30 kg) and adult (70 kg) to have Teq values of 0.9, 1, 1.4, 1.6, and 1.93 h, respectively.",Acetaminophen in cerebrospinal fluid in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845506/),h,1.4,135746,DB00316,Acetaminophen
,12845506,Teq,"We predict a neonate (3.5 kg), 1-year-old child (10 kg), 5-year-old child (20 kg), 10-year-old child (30 kg) and adult (70 kg) to have Teq values of 0.9, 1, 1.4, 1.6, and 1.93 h, respectively.",Acetaminophen in cerebrospinal fluid in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845506/),h,1.6,135747,DB00316,Acetaminophen
,12845506,Teq,"We predict a neonate (3.5 kg), 1-year-old child (10 kg), 5-year-old child (20 kg), 10-year-old child (30 kg) and adult (70 kg) to have Teq values of 0.9, 1, 1.4, 1.6, and 1.93 h, respectively.",Acetaminophen in cerebrospinal fluid in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845506/),h,1.93,135748,DB00316,Acetaminophen
,14756388,Cmax ratio,"After dose correction to 1 g of paracetamol, the mean (+/- SD) Cmax ratio was 0.98 +/- 0.24 and 0.94 +/- 0.08 for AUC ratio.",Bioequivalence study comparing a new paracetamol solution for injection and propacetamol after single intravenous infusion in healthy subjects. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756388/),,0.98,135793,DB00316,Acetaminophen
,14756388,AUC ratio,"After dose correction to 1 g of paracetamol, the mean (+/- SD) Cmax ratio was 0.98 +/- 0.24 and 0.94 +/- 0.08 for AUC ratio.",Bioequivalence study comparing a new paracetamol solution for injection and propacetamol after single intravenous infusion in healthy subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756388/),,0.94,135794,DB00316,Acetaminophen
,25316328,maximum effect,"The population mean estimate of the concentration that induced a response halfway between the baseline and maximal pharmacological effect of paracetamol was 1302 μmol/L (242), the maximum effect of paracetamol was 0.534 (202; from baseline) and the maximum effect of NAC was 0.325 (9.03; from baseline).",Population pharmacokinetic-pharmacodynamic modelling to describe the effects of paracetamol and N-acetylcysteine on the international normalized ratio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25316328/),,0.534,136089,DB00316,Acetaminophen
,25316328,maximum effect,"The population mean estimate of the concentration that induced a response halfway between the baseline and maximal pharmacological effect of paracetamol was 1302 μmol/L (242), the maximum effect of paracetamol was 0.534 (202; from baseline) and the maximum effect of NAC was 0.325 (9.03; from baseline).",Population pharmacokinetic-pharmacodynamic modelling to describe the effects of paracetamol and N-acetylcysteine on the international normalized ratio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25316328/),,0.325,136090,DB00316,Acetaminophen
,22525439,flow rate,"Samples were analyzed by LC-MS/MS on a reverse-phase xTerra MS C18 column which was equilibrated and eluted with an isocratic mixture of acetonitrile-water (1:9, v/v) at a flow rate of 0.3 mL/min.",Simultaneous determination of salidroside and its aglycone metabolite p-tyrosol in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22525439/),[ml] / [min],0.3,136640,DB00316,Acetaminophen
,22525439,precursor/product transitions (m/z),"The precursor/product transitions (m/z) were 299.0 → 118.8 for salidroside, 137.0 → 118.9 for p-tyrosol and 150.1 → 106.9 for the internal standard (IS), paracetamol, respectively.",Simultaneous determination of salidroside and its aglycone metabolite p-tyrosol in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22525439/),,299.0,136641,DB00316,Acetaminophen
,22525439,precursor/product transitions (m/z),"The precursor/product transitions (m/z) were 299.0 → 118.8 for salidroside, 137.0 → 118.9 for p-tyrosol and 150.1 → 106.9 for the internal standard (IS), paracetamol, respectively.",Simultaneous determination of salidroside and its aglycone metabolite p-tyrosol in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22525439/),,118.8,136642,DB00316,Acetaminophen
,22525439,precursor/product transitions (m/z),"The precursor/product transitions (m/z) were 299.0 → 118.8 for salidroside, 137.0 → 118.9 for p-tyrosol and 150.1 → 106.9 for the internal standard (IS), paracetamol, respectively.",Simultaneous determination of salidroside and its aglycone metabolite p-tyrosol in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22525439/),,137.0,136643,DB00316,Acetaminophen
,22525439,precursor/product transitions (m/z),"The precursor/product transitions (m/z) were 299.0 → 118.8 for salidroside, 137.0 → 118.9 for p-tyrosol and 150.1 → 106.9 for the internal standard (IS), paracetamol, respectively.",Simultaneous determination of salidroside and its aglycone metabolite p-tyrosol in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22525439/),,118.9,136644,DB00316,Acetaminophen
,22525439,precursor/product transitions (m/z),"The precursor/product transitions (m/z) were 299.0 → 118.8 for salidroside, 137.0 → 118.9 for p-tyrosol and 150.1 → 106.9 for the internal standard (IS), paracetamol, respectively.",Simultaneous determination of salidroside and its aglycone metabolite p-tyrosol in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22525439/),,150.1,136645,DB00316,Acetaminophen
,22525439,precursor/product transitions (m/z),"The precursor/product transitions (m/z) were 299.0 → 118.8 for salidroside, 137.0 → 118.9 for p-tyrosol and 150.1 → 106.9 for the internal standard (IS), paracetamol, respectively.",Simultaneous determination of salidroside and its aglycone metabolite p-tyrosol in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22525439/),,106.9,136646,DB00316,Acetaminophen
,28155137,apparent total clearance,"Plasma [14C]AAP apparent total clearance was 0.4 (0.1-2.6) L/h/kg, apparent volume of distribution was 1.7 (0.9-8.2) L/kg, and the half-life was 2.8 (1-7) h.",Successful Use of [14C]Paracetamol Microdosing to Elucidate Developmental Changes in Drug Metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28155137/),[l] / [h·kg],0.4,137626,DB00316,Acetaminophen
,28155137,apparent volume of distribution,"Plasma [14C]AAP apparent total clearance was 0.4 (0.1-2.6) L/h/kg, apparent volume of distribution was 1.7 (0.9-8.2) L/kg, and the half-life was 2.8 (1-7) h.",Successful Use of [14C]Paracetamol Microdosing to Elucidate Developmental Changes in Drug Metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28155137/),[l] / [kg],1.7,137627,DB00316,Acetaminophen
,28155137,half-life,"Plasma [14C]AAP apparent total clearance was 0.4 (0.1-2.6) L/h/kg, apparent volume of distribution was 1.7 (0.9-8.2) L/kg, and the half-life was 2.8 (1-7) h.",Successful Use of [14C]Paracetamol Microdosing to Elucidate Developmental Changes in Drug Metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28155137/),h,2.8,137628,DB00316,Acetaminophen
,6480016,elimination half-life,The mean elimination half-life of dextropropoxyphene after multiple dosing was 35.7 h (range 24.0-50.6 h) and the mean half-life of nordextropropoxyphene was 53.3 h (range 25.1-76.3 h).,Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in elderly hospital patients after single and multiple doses of distalgesic. Preliminary analysis of results. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480016/),h,35.7,138019,DB00316,Acetaminophen
,6480016,half-life,The mean elimination half-life of dextropropoxyphene after multiple dosing was 35.7 h (range 24.0-50.6 h) and the mean half-life of nordextropropoxyphene was 53.3 h (range 25.1-76.3 h).,Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in elderly hospital patients after single and multiple doses of distalgesic. Preliminary analysis of results. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480016/),h,53.3,138020,DB00316,Acetaminophen
,23447047,Tmax,"The main pharmacokinetic parameters of nifedipine, as Tmax, t1/2α, t1/2β, t1/2z, Cmax, AUC0~36, AUC0~∞ were 2.80±0.50 h, 6.78±2.52 h, 6.82±2.53 h, 6.69±2.22 h, 76.69±19.51 (ng/mL), 546.49±162.28 (ng · h/mL) and 564.05±176.74 (ng · h/mL), respectively.","A more rapid, sensitive, and specific HPLC-MS/MS method for nifedipine analysis in human plasma and application to a pharmacokinetic study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447047/),h,2.80,138263,DB00316,Acetaminophen
,23447047,AUC0~∞,"The main pharmacokinetic parameters of nifedipine, as Tmax, t1/2α, t1/2β, t1/2z, Cmax, AUC0~36, AUC0~∞ were 2.80±0.50 h, 6.78±2.52 h, 6.82±2.53 h, 6.69±2.22 h, 76.69±19.51 (ng/mL), 546.49±162.28 (ng · h/mL) and 564.05±176.74 (ng · h/mL), respectively.","A more rapid, sensitive, and specific HPLC-MS/MS method for nifedipine analysis in human plasma and application to a pharmacokinetic study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447047/),[h·ng] / [ml],564.05,138264,DB00316,Acetaminophen
,3761200,Vmax,"The formation of acetaminophen sulfate is describable by Michaelis-Menten kinetics, with a Vmax of about 6.5 mumol/min/kg and an in vivo KM (referenced to plasma) of about 100 microM.(ABSTRACT TRUNCATED AT 250 WORDS)",Effect of prevention of inorganic sulfate depletion on the pharmacokinetics of acetaminophen in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3761200/),[μM] / [kg·min],6.5,139783,DB00316,Acetaminophen
,3761200,KM,"The formation of acetaminophen sulfate is describable by Michaelis-Menten kinetics, with a Vmax of about 6.5 mumol/min/kg and an in vivo KM (referenced to plasma) of about 100 microM.(ABSTRACT TRUNCATED AT 250 WORDS)",Effect of prevention of inorganic sulfate depletion on the pharmacokinetics of acetaminophen in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3761200/),μM,100,139784,DB00316,Acetaminophen
,2900724,total clearance,"Prior treatment with 400 mg/kg metyrapone tartrate decreased total clearance of acetaminophen over 30% in the linear range (25.4 +/- 2.0 vs. 36.2 +/- 3.7 ml/min/kg in controls; p less than 0.01) and over 40% in the nonlinear range of disposition (4.42 +/- 1.07 vs 7.76 +/- 1.37 ml/min/kg in controls, p less than 0.01).","Suppression of acetaminophen conjugation and of conjugate elimination in the rat by metyrapone, a classical P-450 inhibitor. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900724/),[ml] / [kg·min],25.4,139981,DB00316,Acetaminophen
,2900724,total clearance,"Prior treatment with 400 mg/kg metyrapone tartrate decreased total clearance of acetaminophen over 30% in the linear range (25.4 +/- 2.0 vs. 36.2 +/- 3.7 ml/min/kg in controls; p less than 0.01) and over 40% in the nonlinear range of disposition (4.42 +/- 1.07 vs 7.76 +/- 1.37 ml/min/kg in controls, p less than 0.01).","Suppression of acetaminophen conjugation and of conjugate elimination in the rat by metyrapone, a classical P-450 inhibitor. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900724/),[ml] / [kg·min],36.2,139982,DB00316,Acetaminophen
,2900724,total clearance,"Prior treatment with 400 mg/kg metyrapone tartrate decreased total clearance of acetaminophen over 30% in the linear range (25.4 +/- 2.0 vs. 36.2 +/- 3.7 ml/min/kg in controls; p less than 0.01) and over 40% in the nonlinear range of disposition (4.42 +/- 1.07 vs 7.76 +/- 1.37 ml/min/kg in controls, p less than 0.01).","Suppression of acetaminophen conjugation and of conjugate elimination in the rat by metyrapone, a classical P-450 inhibitor. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900724/),[ml] / [kg·min],4.42,139983,DB00316,Acetaminophen
,2900724,total clearance,"Prior treatment with 400 mg/kg metyrapone tartrate decreased total clearance of acetaminophen over 30% in the linear range (25.4 +/- 2.0 vs. 36.2 +/- 3.7 ml/min/kg in controls; p less than 0.01) and over 40% in the nonlinear range of disposition (4.42 +/- 1.07 vs 7.76 +/- 1.37 ml/min/kg in controls, p less than 0.01).","Suppression of acetaminophen conjugation and of conjugate elimination in the rat by metyrapone, a classical P-450 inhibitor. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900724/),[ml] / [kg·min],7.76,139984,DB00316,Acetaminophen
,18482233,absorption half-life,"Parameter estimates were: absorption half-life from the rectum 4.6 h, propacetamol hydrolysis half-life 0.028 h, clearance 12 l.h(-1).70 kg(-1), intercompartmental clearance 116 l.h(-1).70 kg(-1), central and peripheral volume of distribution 7.9 and 44 l.70 kg(-1), respectively.",Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18482233/),h,4.6,140032,DB00316,Acetaminophen
,18482233,hydrolysis half-life,"Parameter estimates were: absorption half-life from the rectum 4.6 h, propacetamol hydrolysis half-life 0.028 h, clearance 12 l.h(-1).70 kg(-1), intercompartmental clearance 116 l.h(-1).70 kg(-1), central and peripheral volume of distribution 7.9 and 44 l.70 kg(-1), respectively.",Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18482233/),h,0.028,140033,DB00316,Acetaminophen
,18482233,clearance,"Parameter estimates were: absorption half-life from the rectum 4.6 h, propacetamol hydrolysis half-life 0.028 h, clearance 12 l.h(-1).70 kg(-1), intercompartmental clearance 116 l.h(-1).70 kg(-1), central and peripheral volume of distribution 7.9 and 44 l.70 kg(-1), respectively.",Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18482233/),[l] / [70·h·kg],12,140034,DB00316,Acetaminophen
,18482233,intercompartmental clearance,"Parameter estimates were: absorption half-life from the rectum 4.6 h, propacetamol hydrolysis half-life 0.028 h, clearance 12 l.h(-1).70 kg(-1), intercompartmental clearance 116 l.h(-1).70 kg(-1), central and peripheral volume of distribution 7.9 and 44 l.70 kg(-1), respectively.",Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18482233/),[l] / [70·h·kg],116,140035,DB00316,Acetaminophen
,18482233,central,"Parameter estimates were: absorption half-life from the rectum 4.6 h, propacetamol hydrolysis half-life 0.028 h, clearance 12 l.h(-1).70 kg(-1), intercompartmental clearance 116 l.h(-1).70 kg(-1), central and peripheral volume of distribution 7.9 and 44 l.70 kg(-1), respectively.",Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18482233/),70·l,7.9,140036,DB00316,Acetaminophen
,18482233,peripheral volume of distribution,"Parameter estimates were: absorption half-life from the rectum 4.6 h, propacetamol hydrolysis half-life 0.028 h, clearance 12 l.h(-1).70 kg(-1), intercompartmental clearance 116 l.h(-1).70 kg(-1), central and peripheral volume of distribution 7.9 and 44 l.70 kg(-1), respectively.",Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18482233/),70·l,7.9,140037,DB00316,Acetaminophen
,18482233,peripheral volume of distribution,"Parameter estimates were: absorption half-life from the rectum 4.6 h, propacetamol hydrolysis half-life 0.028 h, clearance 12 l.h(-1).70 kg(-1), intercompartmental clearance 116 l.h(-1).70 kg(-1), central and peripheral volume of distribution 7.9 and 44 l.70 kg(-1), respectively.",Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18482233/),1/[kg],44,140038,DB00316,Acetaminophen
,7263926,half-life,The half-life was the same in the obese patients (2.6 +/- 0.85 hours) and normal subjects (2.6 +/- 0.12 hours).,The effect of obesity on acetaminophen pharmacokinetics in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7263926/),h,2.6,140349,DB00316,Acetaminophen
,7263926,half-life,The half-life was the same in the obese patients (2.6 +/- 0.85 hours) and normal subjects (2.6 +/- 0.12 hours).,The effect of obesity on acetaminophen pharmacokinetics in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7263926/),h,2.6,140350,DB00316,Acetaminophen
<,10701434,run times,"The method has a lower limit of quantification (LLOQ) adequate for sensitive pharmacokinetic studies ( < or = 0.05 microg/ml), has run times of < or = 15 min, and uses aliquot volumes adequate for pediatric studies (0.25 ml).","A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),min,15,140499,DB00316,Acetaminophen
,10701434,lambda(ex),Detection and quantification of ganciclovir is by fluorescence (lambda(ex) = 278 nm; lambda(em) = 380 nm).,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),,278,140500,DB00316,Acetaminophen
,10701434,lambda(em),Detection and quantification of ganciclovir is by fluorescence (lambda(ex) = 278 nm; lambda(em) = 380 nm).,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),,380,140501,DB00316,Acetaminophen
<,10701434,% C.V.,All intra- and inter-assay % C.V. values were < 8%; all recoveries (accuracy) were within 7% of nominal values.,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),%,8,140502,DB00316,Acetaminophen
,18043470,area under the curve(0-12),"Median (range) of MPA area under the curve(0-12) was 36.7 (range, 16.4-116.4) mg*h/L in diabetic and 48.2 (range, 34.9-80.1) mg*h/L in nondiabetic patients (P=0.49).",Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043470/),[h·mg] / [l],36.7,140632,DB00316,Acetaminophen
,18043470,area under the curve(0-12),"Median (range) of MPA area under the curve(0-12) was 36.7 (range, 16.4-116.4) mg*h/L in diabetic and 48.2 (range, 34.9-80.1) mg*h/L in nondiabetic patients (P=0.49).",Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043470/),[h·mg] / [l],48.2,140633,DB00316,Acetaminophen
,18043470,activity,"In contrast, IMPDH activity was 17.5+/-2.8 versus 46.6+/-2.5 nmol XMP/h/microg protein in diabetics and nondiabetics, respectively (P<0.0001) and was significantly lower in the diabetics irrespective of concomitant therapy with cyclosporine or tacrolimus.",Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043470/),[Mp·nM] / [h·μg],17.5,140634,DB00316,Acetaminophen
,18043470,activity,"In contrast, IMPDH activity was 17.5+/-2.8 versus 46.6+/-2.5 nmol XMP/h/microg protein in diabetics and nondiabetics, respectively (P<0.0001) and was significantly lower in the diabetics irrespective of concomitant therapy with cyclosporine or tacrolimus.",Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043470/),[Mp·nM] / [h·μg],46.6,140635,DB00316,Acetaminophen
,8730980,total AUC,Benzhexol administration did not affect the total AUC of levodopa (7.30 +/- 1.09 vs 7.19 +/- 1.26 micrograms ml-1 h; means +/- s.d.).,The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730980/),[h·μg] / [ml],7.30,140754,DB00316,Acetaminophen
,8730980,total AUC,Benzhexol administration did not affect the total AUC of levodopa (7.30 +/- 1.09 vs 7.19 +/- 1.26 micrograms ml-1 h; means +/- s.d.).,The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730980/),[h·μg] / [ml],7.19,140755,DB00316,Acetaminophen
,8730980,total AUC,The total AUC of paracetamol was not affected by benzhexol administration (39.4 +/- 8.2 vs 40.0 +/- 8.9 micrograms ml-1 h; mean +/- s.d.) 4.,The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730980/),[h·μg] / [ml],39.4,140756,DB00316,Acetaminophen
,8730980,total AUC,The total AUC of paracetamol was not affected by benzhexol administration (39.4 +/- 8.2 vs 40.0 +/- 8.9 micrograms ml-1 h; mean +/- s.d.) 4.,The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730980/),[h·μg] / [ml],40.0,140757,DB00316,Acetaminophen
,18628265,clearance (CL),Standardized population parameter estimates for a term neonate were clearance (CL) 5.24 (CV 30.5%) litre h(-1) 70 kg(-1) and volume of distribution (V) 76 (29.6%) litre 70 kg(-1).,I.V. acetaminophen pharmacokinetics in neonates after multiple doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18628265/),[l] / [70·h·kg],5.24,141294,DB00316,Acetaminophen
,18628265,volume of distribution (V),Standardized population parameter estimates for a term neonate were clearance (CL) 5.24 (CV 30.5%) litre h(-1) 70 kg(-1) and volume of distribution (V) 76 (29.6%) litre 70 kg(-1).,I.V. acetaminophen pharmacokinetics in neonates after multiple doses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18628265/),[l] / [70·kg],76,141295,DB00316,Acetaminophen
,18628265,CL,CL increased with PMA from 4.4 litre h(-1) 70 kg(-1) at 34 weeks to 6.3 litre h(-1) 70 kg(-1) at 46 weeks.,I.V. acetaminophen pharmacokinetics in neonates after multiple doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18628265/),[l] / [70·h·kg],4.4,141296,DB00316,Acetaminophen
,18628265,CL,CL increased with PMA from 4.4 litre h(-1) 70 kg(-1) at 34 weeks to 6.3 litre h(-1) 70 kg(-1) at 46 weeks.,I.V. acetaminophen pharmacokinetics in neonates after multiple doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18628265/),[l] / [70·h·kg],6.3,141297,DB00316,Acetaminophen
,18628265,CL,The presence of unconjugated hyperbilirubinaemia was associated with reduced CL: 150 micromol litre(-1) associated with 40% CL reduction.,I.V. acetaminophen pharmacokinetics in neonates after multiple doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18628265/),[μM] / [litre],150,141298,DB00316,Acetaminophen
,31115034,Cmax (maximum plasma concentration),"The main PK parameters for ketoprofen were as follows: Cmax (maximum plasma concentration), 3.41 [2.32] mg/L; AUC0-inf (area under the plasma concentration-time curve from time zero to infinity), 10.45 [5.57] mg⋅h/L; tmax (time to first occurrence of Cmax), 1.94 [1.25] h; Cl (clearance), 0.199 [0.165] L/kg·h, and Vd/kg (volume of distribution per kilogram of body weight), 0.71 [0.58] L/kg.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[mg] / [l],3.41,141678,DB00316,Acetaminophen
,31115034,AUC0-inf (area under the plasma concentration-time curve from time zero to infinity),"The main PK parameters for ketoprofen were as follows: Cmax (maximum plasma concentration), 3.41 [2.32] mg/L; AUC0-inf (area under the plasma concentration-time curve from time zero to infinity), 10.45 [5.57] mg⋅h/L; tmax (time to first occurrence of Cmax), 1.94 [1.25] h; Cl (clearance), 0.199 [0.165] L/kg·h, and Vd/kg (volume of distribution per kilogram of body weight), 0.71 [0.58] L/kg.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[h·mg] / [l],10.45,141679,DB00316,Acetaminophen
,31115034,tmax (time to first occurrence of Cmax,"The main PK parameters for ketoprofen were as follows: Cmax (maximum plasma concentration), 3.41 [2.32] mg/L; AUC0-inf (area under the plasma concentration-time curve from time zero to infinity), 10.45 [5.57] mg⋅h/L; tmax (time to first occurrence of Cmax), 1.94 [1.25] h; Cl (clearance), 0.199 [0.165] L/kg·h, and Vd/kg (volume of distribution per kilogram of body weight), 0.71 [0.58] L/kg.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),h,1.94,141680,DB00316,Acetaminophen
,31115034,Cl (clearance),"The main PK parameters for ketoprofen were as follows: Cmax (maximum plasma concentration), 3.41 [2.32] mg/L; AUC0-inf (area under the plasma concentration-time curve from time zero to infinity), 10.45 [5.57] mg⋅h/L; tmax (time to first occurrence of Cmax), 1.94 [1.25] h; Cl (clearance), 0.199 [0.165] L/kg·h, and Vd/kg (volume of distribution per kilogram of body weight), 0.71 [0.58] L/kg.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[l] / [h·kg],0.199,141681,DB00316,Acetaminophen
,31115034,Vd/kg,"The main PK parameters for ketoprofen were as follows: Cmax (maximum plasma concentration), 3.41 [2.32] mg/L; AUC0-inf (area under the plasma concentration-time curve from time zero to infinity), 10.45 [5.57] mg⋅h/L; tmax (time to first occurrence of Cmax), 1.94 [1.25] h; Cl (clearance), 0.199 [0.165] L/kg·h, and Vd/kg (volume of distribution per kilogram of body weight), 0.71 [0.58] L/kg.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[l] / [kg],0.71,141682,DB00316,Acetaminophen
,31115034,volume of distribution per kilo,"The main PK parameters for ketoprofen were as follows: Cmax (maximum plasma concentration), 3.41 [2.32] mg/L; AUC0-inf (area under the plasma concentration-time curve from time zero to infinity), 10.45 [5.57] mg⋅h/L; tmax (time to first occurrence of Cmax), 1.94 [1.25] h; Cl (clearance), 0.199 [0.165] L/kg·h, and Vd/kg (volume of distribution per kilogram of body weight), 0.71 [0.58] L/kg.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[l] / [kg],0.71,141683,DB00316,Acetaminophen
,31115034,Cmax,"The main PK parameters for TRM and M1 were as follows: Cmax, 226.4 [80.5] and 55.6 [23] ng/mL; AUC0-inf, 1903.3 [874.8] and 790.4 [512.4] ng⋅h/mL; tmax, 1.78 [0.73] and 2.67 [1.19] h, respectively.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[ng] / [ml],226.4,141684,DB00316,Acetaminophen
,31115034,Cmax,"The main PK parameters for TRM and M1 were as follows: Cmax, 226.4 [80.5] and 55.6 [23] ng/mL; AUC0-inf, 1903.3 [874.8] and 790.4 [512.4] ng⋅h/mL; tmax, 1.78 [0.73] and 2.67 [1.19] h, respectively.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[ng] / [ml],55.6,141685,DB00316,Acetaminophen
,31115034,AUC0-inf,"The main PK parameters for TRM and M1 were as follows: Cmax, 226.4 [80.5] and 55.6 [23] ng/mL; AUC0-inf, 1903.3 [874.8] and 790.4 [512.4] ng⋅h/mL; tmax, 1.78 [0.73] and 2.67 [1.19] h, respectively.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[h·ng] / [ml],1903.3,141686,DB00316,Acetaminophen
,31115034,AUC0-inf,"The main PK parameters for TRM and M1 were as follows: Cmax, 226.4 [80.5] and 55.6 [23] ng/mL; AUC0-inf, 1903.3 [874.8] and 790.4 [512.4] ng⋅h/mL; tmax, 1.78 [0.73] and 2.67 [1.19] h, respectively.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[h·ng] / [ml],790.4,141687,DB00316,Acetaminophen
,31115034,tmax,"The main PK parameters for TRM and M1 were as follows: Cmax, 226.4 [80.5] and 55.6 [23] ng/mL; AUC0-inf, 1903.3 [874.8] and 790.4 [512.4] ng⋅h/mL; tmax, 1.78 [0.73] and 2.67 [1.19] h, respectively.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),h,1.78,141688,DB00316,Acetaminophen
,31115034,tmax,"The main PK parameters for TRM and M1 were as follows: Cmax, 226.4 [80.5] and 55.6 [23] ng/mL; AUC0-inf, 1903.3 [874.8] and 790.4 [512.4] ng⋅h/mL; tmax, 1.78 [0.73] and 2.67 [1.19] h, respectively.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),h,2.67,141689,DB00316,Acetaminophen
,28725138,Peff,The optimized Peff ranged 1.44-68.3 × 10-4 cm/s for the drugs under investigation.,Comparative assessment of saliva and plasma for drug bioavailability and bioequivalence studies in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28725138/),[cm] / [s],1.44-68.3 × 10-4,142143,DB00316,Acetaminophen
,28725138,Saliva/plasma concentrations ratios,Saliva/plasma concentrations ratios ranged 0.17-1.5.,Comparative assessment of saliva and plasma for drug bioavailability and bioequivalence studies in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28725138/),,0.17-1.5,142144,DB00316,Acetaminophen
,31371482,volume,"Blood sampling from zebrafish larvae was most successful from the posterior cardinal vein, with a median volume (interquartile range) of 1.12 nl (0.676-1.66 nl) per blood sample.",Mechanistic and Quantitative Understanding of Pharmacokinetics in Zebrafish Larvae through Nanoscale Blood Sampling and Metabolite Modeling of Paracetamol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31371482/),nl,1.12,142247,DB00316,Acetaminophen
above,23357046,extraction recovery,"The extraction recovery was above 70%, the intra-day and inter-day precision of the quality control (QC) samples was less than 12.45% and the accuracy of the QC samples was 96.99-105.79% of the nominal values.","Simultaneous determination of oridonin, ponicidin and rosmarinic acid from Herba Isodi Rubescentis extract by LC-MS-MS in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357046/),%,70,142512,DB00316,Acetaminophen
,18759860,k(m),3. The mean (95% CI) k(m) for APAP glucuronidation was 6.89 mmol/L (3.57-10.22) and the V(max) was 0.97 mmol/h per kg (0.65-1.28).,Simultaneous modelling of the Michaelis-Menten kinetics of paracetamol sulphation and glucuronidation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18759860/),[mM] / [l],6.89,142682,DB00316,Acetaminophen
,18759860,V(max),3. The mean (95% CI) k(m) for APAP glucuronidation was 6.89 mmol/L (3.57-10.22) and the V(max) was 0.97 mmol/h per kg (0.65-1.28).,Simultaneous modelling of the Michaelis-Menten kinetics of paracetamol sulphation and glucuronidation. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18759860/),[mM] / [h·kg],0.97,142683,DB00316,Acetaminophen
,18759860,k(m),The k(m) for APAP sulphation was 0.097 mmol/L (0.041-0.152) and the V(max) was 0.011 mmol/h per kg (0.009-0.013).,Simultaneous modelling of the Michaelis-Menten kinetics of paracetamol sulphation and glucuronidation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18759860/),[mM] / [l],0.097,142684,DB00316,Acetaminophen
,18759860,V(max),The k(m) for APAP sulphation was 0.097 mmol/L (0.041-0.152) and the V(max) was 0.011 mmol/h per kg (0.009-0.013).,Simultaneous modelling of the Michaelis-Menten kinetics of paracetamol sulphation and glucuronidation. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18759860/),[mM] / [h·kg],0.011,142685,DB00316,Acetaminophen
,18759860,k(m),"For the combined excretion of APAP-cysteine and APAP-mercapturate, the k(m) was 0.303 mmol/L (0.131-0.475) and the V(max) was 0.004 mmol/h per kg (0.002-0.005).",Simultaneous modelling of the Michaelis-Menten kinetics of paracetamol sulphation and glucuronidation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18759860/),[mM] / [l],0.303,142686,DB00316,Acetaminophen
,18759860,V(max),"For the combined excretion of APAP-cysteine and APAP-mercapturate, the k(m) was 0.303 mmol/L (0.131-0.475) and the V(max) was 0.004 mmol/h per kg (0.002-0.005).",Simultaneous modelling of the Michaelis-Menten kinetics of paracetamol sulphation and glucuronidation. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18759860/),[mM] / [h·kg],0.004,142687,DB00316,Acetaminophen
,3926661,Ke,PCM children had Ke 0.108 +/- 0.015 h-1 in comparison to the control value of 0.170 +/- 0.022 h-1.,Disposition of acetaminophen in children with protein calorie malnutrition. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3926661/),1/[h],0.108,142900,DB00316,Acetaminophen
,3926661,Ke,PCM children had Ke 0.108 +/- 0.015 h-1 in comparison to the control value of 0.170 +/- 0.022 h-1.,Disposition of acetaminophen in children with protein calorie malnutrition. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3926661/),1/[h],0.170,142901,DB00316,Acetaminophen
,3926661,Plasma half-life (t1/2),Plasma half-life (t1/2) was increased in PCM (8.14 +/- 1.30 h) in comparison of the control (4.33 +/- 0.52 h).,Disposition of acetaminophen in children with protein calorie malnutrition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3926661/),h,8.14,142902,DB00316,Acetaminophen
,3926661,Plasma half-life (t1/2),Plasma half-life (t1/2) was increased in PCM (8.14 +/- 1.30 h) in comparison of the control (4.33 +/- 0.52 h).,Disposition of acetaminophen in children with protein calorie malnutrition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3926661/),h,4.33,142903,DB00316,Acetaminophen
,3926661,Area under the curve (AUC),Area under the curve (AUC) was also significantly increased in PCM (88.88 +/- 21.36 ug h/ml/kg) compared to the control (25.05 +/- 2.99 ug h/ml/kg).,Disposition of acetaminophen in children with protein calorie malnutrition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3926661/),[h·ug] / [kg·ml],88.88,142904,DB00316,Acetaminophen
,3926661,Area under the curve (AUC),Area under the curve (AUC) was also significantly increased in PCM (88.88 +/- 21.36 ug h/ml/kg) compared to the control (25.05 +/- 2.99 ug h/ml/kg).,Disposition of acetaminophen in children with protein calorie malnutrition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3926661/),[h·ug] / [kg·ml],25.05,142905,DB00316,Acetaminophen
,3926661,Time of drug disappearance,Time of drug disappearance was 44.7 +/- 7.1 hours in PCM compared to 24.6 +/- 3.3 hours in the control.,Disposition of acetaminophen in children with protein calorie malnutrition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3926661/),h,44.7,142906,DB00316,Acetaminophen
,3926661,Time of drug disappearance,Time of drug disappearance was 44.7 +/- 7.1 hours in PCM compared to 24.6 +/- 3.3 hours in the control.,Disposition of acetaminophen in children with protein calorie malnutrition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3926661/),h,24.6,142907,DB00316,Acetaminophen
,2225696,Area under the plasma concentration-time curve for lamotrigine [AUC(O-infinity)],"Area under the plasma concentration-time curve for lamotrigine [AUC(O-infinity)] and lamotrigine half-life were statistically decreased by 20% (229.0 +/- 62.5 micrograms.hr/ml versus 191.2 +/- 42.1 micrograms.hr/ml, p less than 0.01) and 15% (35.7 +/- 9.3 hours versus 30.2 +/- 7.3 hours, p less than 0.01), respectively, when concurrently administered with acetaminophen.",Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225696/),[h·μg] / [ml],229.0,144171,DB00316,Acetaminophen
,2225696,Area under the plasma concentration-time curve for lamotrigine [AUC(O-infinity)],"Area under the plasma concentration-time curve for lamotrigine [AUC(O-infinity)] and lamotrigine half-life were statistically decreased by 20% (229.0 +/- 62.5 micrograms.hr/ml versus 191.2 +/- 42.1 micrograms.hr/ml, p less than 0.01) and 15% (35.7 +/- 9.3 hours versus 30.2 +/- 7.3 hours, p less than 0.01), respectively, when concurrently administered with acetaminophen.",Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225696/),[h·μg] / [ml],191.2,144172,DB00316,Acetaminophen
,2225696,Area under the plasma concentration-time curve for lamotrigine [AUC(O-infinity)],"Area under the plasma concentration-time curve for lamotrigine [AUC(O-infinity)] and lamotrigine half-life were statistically decreased by 20% (229.0 +/- 62.5 micrograms.hr/ml versus 191.2 +/- 42.1 micrograms.hr/ml, p less than 0.01) and 15% (35.7 +/- 9.3 hours versus 30.2 +/- 7.3 hours, p less than 0.01), respectively, when concurrently administered with acetaminophen.",Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225696/),h,35.7,144173,DB00316,Acetaminophen
,2225696,half-life,"Area under the plasma concentration-time curve for lamotrigine [AUC(O-infinity)] and lamotrigine half-life were statistically decreased by 20% (229.0 +/- 62.5 micrograms.hr/ml versus 191.2 +/- 42.1 micrograms.hr/ml, p less than 0.01) and 15% (35.7 +/- 9.3 hours versus 30.2 +/- 7.3 hours, p less than 0.01), respectively, when concurrently administered with acetaminophen.",Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225696/),[h·μg] / [ml],191.2,144174,DB00316,Acetaminophen
,2225696,half-life,"Area under the plasma concentration-time curve for lamotrigine [AUC(O-infinity)] and lamotrigine half-life were statistically decreased by 20% (229.0 +/- 62.5 micrograms.hr/ml versus 191.2 +/- 42.1 micrograms.hr/ml, p less than 0.01) and 15% (35.7 +/- 9.3 hours versus 30.2 +/- 7.3 hours, p less than 0.01), respectively, when concurrently administered with acetaminophen.",Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225696/),h,35.7,144175,DB00316,Acetaminophen
,2225696,half-life,"Area under the plasma concentration-time curve for lamotrigine [AUC(O-infinity)] and lamotrigine half-life were statistically decreased by 20% (229.0 +/- 62.5 micrograms.hr/ml versus 191.2 +/- 42.1 micrograms.hr/ml, p less than 0.01) and 15% (35.7 +/- 9.3 hours versus 30.2 +/- 7.3 hours, p less than 0.01), respectively, when concurrently administered with acetaminophen.",Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225696/),h,30.2,144176,DB00316,Acetaminophen
,8054251,oral clearance (CLo),"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),[l] / [h],11.0,145184,DB00316,Acetaminophen
,8054251,renal clearance (CLR),"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),[l] / [h],7.9,145185,DB00316,Acetaminophen
,8054251,percent excreted unchanged,"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),%,72,145186,DB00316,Acetaminophen
,8054251,fraction unbound (fu),"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),,0.54,145187,DB00316,Acetaminophen
,1487229,total AUC,Mean +/- SD total AUC (microgram/ml.h) following the iv formulation was significantly (P < 0.01) greater than following oral paracetamol (25.53 +/- 4.27 vs 21.04 +/- 4.49) corresponding to a mean oral bioavailability of paracetamol of 82.2 +/- 9.4%.,"Tolerance and pharmacokinetics of propacetamol, a paracetamol formulation for intravenous use. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487229/),[μg] / [h·ml],25.53,145286,DB00316,Acetaminophen
,1487229,total AUC,Mean +/- SD total AUC (microgram/ml.h) following the iv formulation was significantly (P < 0.01) greater than following oral paracetamol (25.53 +/- 4.27 vs 21.04 +/- 4.49) corresponding to a mean oral bioavailability of paracetamol of 82.2 +/- 9.4%.,"Tolerance and pharmacokinetics of propacetamol, a paracetamol formulation for intravenous use. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487229/),[μg] / [h·ml],21.04,145287,DB00316,Acetaminophen
,1487229,oral bioavailability,Mean +/- SD total AUC (microgram/ml.h) following the iv formulation was significantly (P < 0.01) greater than following oral paracetamol (25.53 +/- 4.27 vs 21.04 +/- 4.49) corresponding to a mean oral bioavailability of paracetamol of 82.2 +/- 9.4%.,"Tolerance and pharmacokinetics of propacetamol, a paracetamol formulation for intravenous use. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487229/),%,82.2,145288,DB00316,Acetaminophen
,16618296,Cmax,The mean Cmax of 11.4 mg x l(-1) [coefficient of variation (CV) 66%] was achieved at a Tmax of 2.7 h (CV 42%).,The pharmacokinetics of a single rectal dose of paracetamol (40 mg x kg(-1)) in children with liver disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16618296/),[mg] / [l],11.4,146603,DB00316,Acetaminophen
,16618296,Tmax,The mean Cmax of 11.4 mg x l(-1) [coefficient of variation (CV) 66%] was achieved at a Tmax of 2.7 h (CV 42%).,The pharmacokinetics of a single rectal dose of paracetamol (40 mg x kg(-1)) in children with liver disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16618296/),h,2.7,146604,DB00316,Acetaminophen
,16618296,clearance (Cl/F),"The relative bioavailability (F) of the suppository formulation was not estimated, but clearance (Cl/F) estimates 0.73 l x kg(-1) x h(-1) (CV 87%) and time-concentration profiles for these children were similar to the normal pediatric population.",The pharmacokinetics of a single rectal dose of paracetamol (40 mg x kg(-1)) in children with liver disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16618296/),[l] / [h·kg],0.73,146605,DB00316,Acetaminophen
,22675252,clearance,"We documented a higher median paracetamol clearance at delivery when compared to 10-15 weeks postpartum (11.7 to 6.4 L/h·m², P < 0.01), even after correction for weight-related changes.",The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22675252/),[l] / [h·m²],11.7 to 6.4,146695,DB00316,Acetaminophen
,22675252,clearance,"Similar conclusions were drawn for ketorolac: median clearance was higher at delivery with a subsequent decrease (2.03 to 1.43 L/h·m², P < 0.05) in postpartum (17-23 weeks).",The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22675252/),[l] / [h·m²],2.,146696,DB00316,Acetaminophen
,22675252,clearance,"Similar conclusions were drawn for ketorolac: median clearance was higher at delivery with a subsequent decrease (2.03 to 1.43 L/h·m², P < 0.05) in postpartum (17-23 weeks).",The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22675252/),[l] / [h·m²],1,146697,DB00316,Acetaminophen
,22675252,clearance,"Moreover, postpartum paracetamol clearance was significantly lower when compared to estimates published in healthy young volunteers (6.4 versus 9.6 L/h·m²), while this was not the case for ketorolac (1.43 versus 1.48 L/h·m²).",The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22675252/),[l] / [h·m²],6.4,146698,DB00316,Acetaminophen
,22675252,clearance,"Moreover, postpartum paracetamol clearance was significantly lower when compared to estimates published in healthy young volunteers (6.4 versus 9.6 L/h·m²), while this was not the case for ketorolac (1.43 versus 1.48 L/h·m²).",The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22675252/),[l] / [h·m²],9.6,146699,DB00316,Acetaminophen
,22675252,clearance,"Moreover, postpartum paracetamol clearance was significantly lower when compared to estimates published in healthy young volunteers (6.4 versus 9.6 L/h·m²), while this was not the case for ketorolac (1.43 versus 1.48 L/h·m²).",The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22675252/),[l] / [h·m²],1.43,146700,DB00316,Acetaminophen
,22675252,clearance,"Moreover, postpartum paracetamol clearance was significantly lower when compared to estimates published in healthy young volunteers (6.4 versus 9.6 L/h·m²), while this was not the case for ketorolac (1.43 versus 1.48 L/h·m²).",The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22675252/),[l] / [h·m²],1.48,146701,DB00316,Acetaminophen
,20133509,peak plasma concentration,"In contrast, plasma concentrations of dextropropoxyphene were significantly higher (peak plasma concentration, 54.4 ± 25.5 vs 31.0 ± 10.9 ng/mL; area under the plasma concentration-time curve, 260.8 ± 88.1 vs 142.3 ± 42.4 ng x h/mL, both P < .05) and apparent oral clearance value was significantly lower (2.2 ± 0.9 vs 3.6 ± 1.4 L/h/kg, P < .05) in CYP3A5*3/*3 (n = 8) than CYP3A5*1/*3 (n = 5) subjects.",CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20133509/),[ng] / [ml],54.4,147205,DB00316,Acetaminophen
,20133509,peak plasma concentration,"In contrast, plasma concentrations of dextropropoxyphene were significantly higher (peak plasma concentration, 54.4 ± 25.5 vs 31.0 ± 10.9 ng/mL; area under the plasma concentration-time curve, 260.8 ± 88.1 vs 142.3 ± 42.4 ng x h/mL, both P < .05) and apparent oral clearance value was significantly lower (2.2 ± 0.9 vs 3.6 ± 1.4 L/h/kg, P < .05) in CYP3A5*3/*3 (n = 8) than CYP3A5*1/*3 (n = 5) subjects.",CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20133509/),[ng] / [ml],31.0,147206,DB00316,Acetaminophen
,20133509,area under the plasma concentration-time curve,"In contrast, plasma concentrations of dextropropoxyphene were significantly higher (peak plasma concentration, 54.4 ± 25.5 vs 31.0 ± 10.9 ng/mL; area under the plasma concentration-time curve, 260.8 ± 88.1 vs 142.3 ± 42.4 ng x h/mL, both P < .05) and apparent oral clearance value was significantly lower (2.2 ± 0.9 vs 3.6 ± 1.4 L/h/kg, P < .05) in CYP3A5*3/*3 (n = 8) than CYP3A5*1/*3 (n = 5) subjects.",CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20133509/),[h·ng] / [ml],260.8,147207,DB00316,Acetaminophen
,20133509,area under the plasma concentration-time curve,"In contrast, plasma concentrations of dextropropoxyphene were significantly higher (peak plasma concentration, 54.4 ± 25.5 vs 31.0 ± 10.9 ng/mL; area under the plasma concentration-time curve, 260.8 ± 88.1 vs 142.3 ± 42.4 ng x h/mL, both P < .05) and apparent oral clearance value was significantly lower (2.2 ± 0.9 vs 3.6 ± 1.4 L/h/kg, P < .05) in CYP3A5*3/*3 (n = 8) than CYP3A5*1/*3 (n = 5) subjects.",CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20133509/),[h·ng] / [ml],142.3,147208,DB00316,Acetaminophen
,20133509,apparent oral clearance,"In contrast, plasma concentrations of dextropropoxyphene were significantly higher (peak plasma concentration, 54.4 ± 25.5 vs 31.0 ± 10.9 ng/mL; area under the plasma concentration-time curve, 260.8 ± 88.1 vs 142.3 ± 42.4 ng x h/mL, both P < .05) and apparent oral clearance value was significantly lower (2.2 ± 0.9 vs 3.6 ± 1.4 L/h/kg, P < .05) in CYP3A5*3/*3 (n = 8) than CYP3A5*1/*3 (n = 5) subjects.",CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20133509/),[l] / [h·kg],2.2,147209,DB00316,Acetaminophen
,20133509,apparent oral clearance,"In contrast, plasma concentrations of dextropropoxyphene were significantly higher (peak plasma concentration, 54.4 ± 25.5 vs 31.0 ± 10.9 ng/mL; area under the plasma concentration-time curve, 260.8 ± 88.1 vs 142.3 ± 42.4 ng x h/mL, both P < .05) and apparent oral clearance value was significantly lower (2.2 ± 0.9 vs 3.6 ± 1.4 L/h/kg, P < .05) in CYP3A5*3/*3 (n = 8) than CYP3A5*1/*3 (n = 5) subjects.",CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20133509/),[l] / [h·kg],3.6,147210,DB00316,Acetaminophen
,20133509,apparent oral clearance,One subject who was identified as a CYP3A5*1/*1 carrier exhibited a very high apparent oral clearance value of 12.5 L/h/kg.,CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20133509/),[l] / [h·kg],12.5,147211,DB00316,Acetaminophen
,17557737,Retention times,Retention times of bergenin and acetaminophen were approximately 9.9 and 6.1 min and no interfering peak of the blank plasma chromatograms was observed.,Determination of bergenin in rat plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17557737/),min,9.9,147338,DB00316,Acetaminophen
,17557737,Retention times,Retention times of bergenin and acetaminophen were approximately 9.9 and 6.1 min and no interfering peak of the blank plasma chromatograms was observed.,Determination of bergenin in rat plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17557737/),min,6.1,147339,DB00316,Acetaminophen
,17557737,extraction recoveries,"The extraction recoveries of bergenin from plasma was 70.82%, 69.44%, 70.98% at concentrations of 5, 50, 100 microg/ml.",Determination of bergenin in rat plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17557737/),%,70.82,147340,DB00316,Acetaminophen
,17557737,extraction recoveries,"The extraction recoveries of bergenin from plasma was 70.82%, 69.44%, 70.98% at concentrations of 5, 50, 100 microg/ml.",Determination of bergenin in rat plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17557737/),%,69.44,147341,DB00316,Acetaminophen
,17557737,extraction recoveries,"The extraction recoveries of bergenin from plasma was 70.82%, 69.44%, 70.98% at concentrations of 5, 50, 100 microg/ml.",Determination of bergenin in rat plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17557737/),%,70.98,147342,DB00316,Acetaminophen
,12631041,concentrations,"The estimated concentrations immediately (t = 0) after injection were 56 mg l(-1) (H), 28 mg l(-1) (I) and 14 mg l(-1) (L).",Analgesic effect of i.v. paracetamol: possible ceiling effect of paracetamol in postoperative pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631041/),[mg] / [l],56,147482,DB00316,Acetaminophen
,12631041,concentrations,"The estimated concentrations immediately (t = 0) after injection were 56 mg l(-1) (H), 28 mg l(-1) (I) and 14 mg l(-1) (L).",Analgesic effect of i.v. paracetamol: possible ceiling effect of paracetamol in postoperative pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631041/),[mg] / [l],28,147483,DB00316,Acetaminophen
,12631041,concentrations,"The estimated concentrations immediately (t = 0) after injection were 56 mg l(-1) (H), 28 mg l(-1) (I) and 14 mg l(-1) (L).",Analgesic effect of i.v. paracetamol: possible ceiling effect of paracetamol in postoperative pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631041/),[mg] / [l],14,147484,DB00316,Acetaminophen
,30713054,clearance,"For doses of 10 and 20 mg kg-1, respectively, clearance values were 1.70 (1.15-2.27) and 1.62 (1.06-2.86) L kg-1 hour-1 for Beagles and 1.18 (0.70-1.39) and 1.08 (0.67-1.35) L kg-1 hour-1 for GE; elimination half-life values were 2.64 (0.52-4.46) and 2.86 (0.87-4.63) hours for Beagles and 3.49 (1.89-7.80) and 4.57 (2.08-8.90) hours for GE.",Comparative pharmacokinetics and a clinical laboratory evaluation of intravenous acetaminophen in Beagle and Galgo Español dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30713054/),[l] / [h·kg],1.70,148398,DB00316,Acetaminophen
,30713054,clearance,"For doses of 10 and 20 mg kg-1, respectively, clearance values were 1.70 (1.15-2.27) and 1.62 (1.06-2.86) L kg-1 hour-1 for Beagles and 1.18 (0.70-1.39) and 1.08 (0.67-1.35) L kg-1 hour-1 for GE; elimination half-life values were 2.64 (0.52-4.46) and 2.86 (0.87-4.63) hours for Beagles and 3.49 (1.89-7.80) and 4.57 (2.08-8.90) hours for GE.",Comparative pharmacokinetics and a clinical laboratory evaluation of intravenous acetaminophen in Beagle and Galgo Español dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30713054/),[l] / [h·kg],1.62,148399,DB00316,Acetaminophen
,30713054,clearance,"For doses of 10 and 20 mg kg-1, respectively, clearance values were 1.70 (1.15-2.27) and 1.62 (1.06-2.86) L kg-1 hour-1 for Beagles and 1.18 (0.70-1.39) and 1.08 (0.67-1.35) L kg-1 hour-1 for GE; elimination half-life values were 2.64 (0.52-4.46) and 2.86 (0.87-4.63) hours for Beagles and 3.49 (1.89-7.80) and 4.57 (2.08-8.90) hours for GE.",Comparative pharmacokinetics and a clinical laboratory evaluation of intravenous acetaminophen in Beagle and Galgo Español dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30713054/),[l] / [h·kg],1.18,148400,DB00316,Acetaminophen
,30713054,clearance,"For doses of 10 and 20 mg kg-1, respectively, clearance values were 1.70 (1.15-2.27) and 1.62 (1.06-2.86) L kg-1 hour-1 for Beagles and 1.18 (0.70-1.39) and 1.08 (0.67-1.35) L kg-1 hour-1 for GE; elimination half-life values were 2.64 (0.52-4.46) and 2.86 (0.87-4.63) hours for Beagles and 3.49 (1.89-7.80) and 4.57 (2.08-8.90) hours for GE.",Comparative pharmacokinetics and a clinical laboratory evaluation of intravenous acetaminophen in Beagle and Galgo Español dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30713054/),[l] / [h·kg],1.08,148401,DB00316,Acetaminophen
,30713054,elimination half-life,"For doses of 10 and 20 mg kg-1, respectively, clearance values were 1.70 (1.15-2.27) and 1.62 (1.06-2.86) L kg-1 hour-1 for Beagles and 1.18 (0.70-1.39) and 1.08 (0.67-1.35) L kg-1 hour-1 for GE; elimination half-life values were 2.64 (0.52-4.46) and 2.86 (0.87-4.63) hours for Beagles and 3.49 (1.89-7.80) and 4.57 (2.08-8.90) hours for GE.",Comparative pharmacokinetics and a clinical laboratory evaluation of intravenous acetaminophen in Beagle and Galgo Español dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30713054/),h,2.64,148402,DB00316,Acetaminophen
,30713054,elimination half-life,"For doses of 10 and 20 mg kg-1, respectively, clearance values were 1.70 (1.15-2.27) and 1.62 (1.06-2.86) L kg-1 hour-1 for Beagles and 1.18 (0.70-1.39) and 1.08 (0.67-1.35) L kg-1 hour-1 for GE; elimination half-life values were 2.64 (0.52-4.46) and 2.86 (0.87-4.63) hours for Beagles and 3.49 (1.89-7.80) and 4.57 (2.08-8.90) hours for GE.",Comparative pharmacokinetics and a clinical laboratory evaluation of intravenous acetaminophen in Beagle and Galgo Español dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30713054/),h,2.86,148403,DB00316,Acetaminophen
,30713054,elimination half-life,"For doses of 10 and 20 mg kg-1, respectively, clearance values were 1.70 (1.15-2.27) and 1.62 (1.06-2.86) L kg-1 hour-1 for Beagles and 1.18 (0.70-1.39) and 1.08 (0.67-1.35) L kg-1 hour-1 for GE; elimination half-life values were 2.64 (0.52-4.46) and 2.86 (0.87-4.63) hours for Beagles and 3.49 (1.89-7.80) and 4.57 (2.08-8.90) hours for GE.",Comparative pharmacokinetics and a clinical laboratory evaluation of intravenous acetaminophen in Beagle and Galgo Español dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30713054/),h,3.49,148404,DB00316,Acetaminophen
,30713054,elimination half-life,"For doses of 10 and 20 mg kg-1, respectively, clearance values were 1.70 (1.15-2.27) and 1.62 (1.06-2.86) L kg-1 hour-1 for Beagles and 1.18 (0.70-1.39) and 1.08 (0.67-1.35) L kg-1 hour-1 for GE; elimination half-life values were 2.64 (0.52-4.46) and 2.86 (0.87-4.63) hours for Beagles and 3.49 (1.89-7.80) and 4.57 (2.08-8.90) hours for GE.",Comparative pharmacokinetics and a clinical laboratory evaluation of intravenous acetaminophen in Beagle and Galgo Español dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30713054/),h,4.57,148405,DB00316,Acetaminophen
,10704039,recoveries,Mean recoveries of 90.31% with a CV of 1.38% were obtained.,Rapid liquid chromatographic assay for the determination of acetaminophen in plasma after propacetamol administration: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704039/),%,90.31,148413,DB00316,Acetaminophen
,7497581,AUC (AUC,"Specifically, metoclopramide had little effect on the etoposide absorption profile and did not significantly alter the AUC (AUC with etoposide alone, 68.4 +/- 20.3 micrograms ml-1 h, versus 74.3 +/- 25.9 micrograms ml-1 h with metoclopramide), suggesting that in most patients the drug is already emptied rapidly from the stomach.",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],68.4,148763,DB00316,Acetaminophen
,7497581,AUC (AUC,"Specifically, metoclopramide had little effect on the etoposide absorption profile and did not significantly alter the AUC (AUC with etoposide alone, 68.4 +/- 20.3 micrograms ml-1 h, versus 74.3 +/- 25.9 micrograms ml-1 h with metoclopramide), suggesting that in most patients the drug is already emptied rapidly from the stomach.",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],74.3,148764,DB00316,Acetaminophen
,7497581,time of maximal concentration tmax,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),h,1.1,148765,DB00316,Acetaminophen
,7497581,time of maximal concentration tmax,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),h,3.5,148766,DB00316,Acetaminophen
,7497581,AUC,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],78.3,148767,DB00316,Acetaminophen
,7497581,AUC,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],88.1,148768,DB00316,Acetaminophen
,3902377,peak concentrations,Mean peak concentrations were obtained of 4.75 +/- 0.74 mg/ml at 1.75 hours with the new suppositories and of 4.6 +/- 0.67 mg/ml at 2.0 hours with the old suppositories.,"The relative bioavailability of paracetamol after rectal administration of suppositories containing a mixture of paracetamol, codeine phosphate and buclizine hydrochloride in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3902377/),[mg] / [ml],4.75,149218,DB00316,Acetaminophen
,3902377,peak concentrations,Mean peak concentrations were obtained of 4.75 +/- 0.74 mg/ml at 1.75 hours with the new suppositories and of 4.6 +/- 0.67 mg/ml at 2.0 hours with the old suppositories.,"The relative bioavailability of paracetamol after rectal administration of suppositories containing a mixture of paracetamol, codeine phosphate and buclizine hydrochloride in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3902377/),[mg] / [ml],4.6,149219,DB00316,Acetaminophen
,3902377,elimination half-life,"Mean elimination half-life was 4.4 +/- 0.42 hours and 3.73 +/- 0.28 hours, respectively.","The relative bioavailability of paracetamol after rectal administration of suppositories containing a mixture of paracetamol, codeine phosphate and buclizine hydrochloride in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3902377/),h,4.4,149220,DB00316,Acetaminophen
,3902377,elimination half-life,"Mean elimination half-life was 4.4 +/- 0.42 hours and 3.73 +/- 0.28 hours, respectively.","The relative bioavailability of paracetamol after rectal administration of suppositories containing a mixture of paracetamol, codeine phosphate and buclizine hydrochloride in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3902377/),h,3.73,149221,DB00316,Acetaminophen
,1782975,apparent steady-state concentrations,The mean daily plasma concentrations of the sulphate and glucuronide conjugates of paracetamol were markedly higher in the renal failure group and apparent steady-state concentrations of about 25 and 85 mg.l-1 were reached on the 2nd and 6th days respectively.,The disposition of paracetamol and the accumulation of its glucuronide and sulphate conjugates during multiple dosing in patients with chronic renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782975/),[mg] / [l],25,151484,DB00316,Acetaminophen
,1782975,apparent steady-state concentrations,The mean daily plasma concentrations of the sulphate and glucuronide conjugates of paracetamol were markedly higher in the renal failure group and apparent steady-state concentrations of about 25 and 85 mg.l-1 were reached on the 2nd and 6th days respectively.,The disposition of paracetamol and the accumulation of its glucuronide and sulphate conjugates during multiple dosing in patients with chronic renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782975/),[mg] / [l],85,151485,DB00316,Acetaminophen
,9725482,relative bioavailability,The relative bioavailability of the 500 mg suppositories was 77% and that of the 1000 mg suppositories 66%.,Is one paracetamol suppository of 1000 mg bioequivalent with two suppositories of 500 mg. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725482/),%,77,152257,DB00316,Acetaminophen
,9725482,relative bioavailability,The relative bioavailability of the 500 mg suppositories was 77% and that of the 1000 mg suppositories 66%.,Is one paracetamol suppository of 1000 mg bioequivalent with two suppositories of 500 mg. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725482/),%,66,152258,DB00316,Acetaminophen
,19819764,m/z,"The mass spectrometer was operated in multiple reaction monitoring (MRM) mode using the transition m/z 234-->234 for meptazinol and m/z 152-->110 for the IS (acetaminophen), respectively.",Liquid chromatography/positive ion electrospray tandem mass spectrometry method for the quantification of hydrochloride meptazinol in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819764/),,152,153209,DB00316,Acetaminophen
,19819764,m/z,"The mass spectrometer was operated in multiple reaction monitoring (MRM) mode using the transition m/z 234-->234 for meptazinol and m/z 152-->110 for the IS (acetaminophen), respectively.",Liquid chromatography/positive ion electrospray tandem mass spectrometry method for the quantification of hydrochloride meptazinol in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819764/),,110,153210,DB00316,Acetaminophen
more,19819764,absolute recovery,The mean absolute recovery of hydrochloride meptazinol was more than 70.21%.,Liquid chromatography/positive ion electrospray tandem mass spectrometry method for the quantification of hydrochloride meptazinol in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819764/),%,70.21,153211,DB00316,Acetaminophen
,11480539,area under the plasma paracetamol concentration-time curve from 0 to 180 min,The area under the plasma paracetamol concentration-time curve from 0 to 180 min (mean +/- s.d.) increased from 1875.0 +/- 112.8 micrg min mL(-1) (placebo coadministration) to 2238.8 +/- 125.8 microg min mL(-1) (cisapride coadministration) (P < 0.01).,Cisapride raises the bioavailability of paracetamol by inhibiting its glucuronidation in man. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11480539/),[micrg·min] / [ml],1875.0,154696,DB00316,Acetaminophen
,11480539,area under the plasma paracetamol concentration-time curve from 0 to 180 min,The area under the plasma paracetamol concentration-time curve from 0 to 180 min (mean +/- s.d.) increased from 1875.0 +/- 112.8 micrg min mL(-1) (placebo coadministration) to 2238.8 +/- 125.8 microg min mL(-1) (cisapride coadministration) (P < 0.01).,Cisapride raises the bioavailability of paracetamol by inhibiting its glucuronidation in man. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11480539/),[min·μg] / [ml],2238.8,154697,DB00316,Acetaminophen
,11480539,maximum plasma paracetamol concentration,"The mean maximum plasma paracetamol concentration(18.2 microg mL(-1))with placebo was reached 30 min after administration, whereas mean maximum plasma paracetamol concentration (21.2 microg mL(-1)) with cisapride occurred 45 min after administration.",Cisapride raises the bioavailability of paracetamol by inhibiting its glucuronidation in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11480539/),[μg] / [ml],18.2,154698,DB00316,Acetaminophen
,11480539,maximum plasma paracetamol concentration,"The mean maximum plasma paracetamol concentration(18.2 microg mL(-1))with placebo was reached 30 min after administration, whereas mean maximum plasma paracetamol concentration (21.2 microg mL(-1)) with cisapride occurred 45 min after administration.",Cisapride raises the bioavailability of paracetamol by inhibiting its glucuronidation in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11480539/),[μg] / [ml],21.2,154699,DB00316,Acetaminophen
,16418701,time to maximum concentration (Tmax),The time to maximum concentration (Tmax) of MPA was 86.4 +/- 41.4 minutes versus 52.8 +/- 31.8 minutes in D and ND patients respectively (P = 0.04) indicating a delay in MMF absorption.,Pharmacokinetics of mycophenolic acid and metabolites in diabetic kidney transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16418701/),min,86.4,154851,DB00316,Acetaminophen
,16418701,time to maximum concentration (Tmax),The time to maximum concentration (Tmax) of MPA was 86.4 +/- 41.4 minutes versus 52.8 +/- 31.8 minutes in D and ND patients respectively (P = 0.04) indicating a delay in MMF absorption.,Pharmacokinetics of mycophenolic acid and metabolites in diabetic kidney transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16418701/),min,52.8,154852,DB00316,Acetaminophen
,8523630,total clearance,Parenteral nutrition for 10 days decreased the total clearance of acetaminophen by 23% (from 11.5 +/- 1.4 to 8.9 +/- 1.4 mL/min per kg; p < .05) and decreased the formation clearance to acetaminophen sulfate (from 6.2 +/- 0.4 to 3.9 +/- 0.5 mL/min per kg; p < .05).,The depression of hepatic drug conjugation reactions in rats after lipid-free total parenteral nutrition administered via the portal vein. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8523630/),[ml] / [kg·min],11.5,155352,DB00316,Acetaminophen
,8523630,total clearance,Parenteral nutrition for 10 days decreased the total clearance of acetaminophen by 23% (from 11.5 +/- 1.4 to 8.9 +/- 1.4 mL/min per kg; p < .05) and decreased the formation clearance to acetaminophen sulfate (from 6.2 +/- 0.4 to 3.9 +/- 0.5 mL/min per kg; p < .05).,The depression of hepatic drug conjugation reactions in rats after lipid-free total parenteral nutrition administered via the portal vein. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8523630/),[ml] / [kg·min],8.9,155353,DB00316,Acetaminophen
,8523630,formation clearance,Parenteral nutrition for 10 days decreased the total clearance of acetaminophen by 23% (from 11.5 +/- 1.4 to 8.9 +/- 1.4 mL/min per kg; p < .05) and decreased the formation clearance to acetaminophen sulfate (from 6.2 +/- 0.4 to 3.9 +/- 0.5 mL/min per kg; p < .05).,The depression of hepatic drug conjugation reactions in rats after lipid-free total parenteral nutrition administered via the portal vein. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8523630/),[ml] / [kg·min],6.2,155354,DB00316,Acetaminophen
,8523630,formation clearance,Parenteral nutrition for 10 days decreased the total clearance of acetaminophen by 23% (from 11.5 +/- 1.4 to 8.9 +/- 1.4 mL/min per kg; p < .05) and decreased the formation clearance to acetaminophen sulfate (from 6.2 +/- 0.4 to 3.9 +/- 0.5 mL/min per kg; p < .05).,The depression of hepatic drug conjugation reactions in rats after lipid-free total parenteral nutrition administered via the portal vein. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8523630/),[ml] / [kg·min],3.9,155355,DB00316,Acetaminophen
,7596997,systemic bioavailability,"For AAP used as a marker compound here, the systemic bioavailability after oral dosing to intact beagle dogs at doses of 3, 10, and 20 mg/kg was about 55, 63, and 79%, suggesting that AAP undergoes a non-linear hepatic clearance.",Relationship between the phasic period of interdigestive migrating contraction and the systemic bioavailability of acetaminophen in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596997/),%,55,155516,DB00316,Acetaminophen
,7596997,systemic bioavailability,"For AAP used as a marker compound here, the systemic bioavailability after oral dosing to intact beagle dogs at doses of 3, 10, and 20 mg/kg was about 55, 63, and 79%, suggesting that AAP undergoes a non-linear hepatic clearance.",Relationship between the phasic period of interdigestive migrating contraction and the systemic bioavailability of acetaminophen in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596997/),%,63,155517,DB00316,Acetaminophen
,7596997,systemic bioavailability,"For AAP used as a marker compound here, the systemic bioavailability after oral dosing to intact beagle dogs at doses of 3, 10, and 20 mg/kg was about 55, 63, and 79%, suggesting that AAP undergoes a non-linear hepatic clearance.",Relationship between the phasic period of interdigestive migrating contraction and the systemic bioavailability of acetaminophen in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596997/),%,79,155518,DB00316,Acetaminophen
,7596997,systemic bioavailability,"At a dose of AAP 20 mg/kg, the systemic bioavailability of AAP was 100% in the case of dosing at phase III, but was reduced by half when dosing at phase I.",Relationship between the phasic period of interdigestive migrating contraction and the systemic bioavailability of acetaminophen in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596997/),%,100,155519,DB00316,Acetaminophen
,15537171,kab,"The absorption kinetics parameters kab, lag-time, t1/2ab for both test (0.03min(-1), 9min, 18min.) and control (0.03min(-1), 9min, 22.8min.) were identical.","Alteration of oral salivary pharmacokinetics of paracetamol by an investigational anti-malarial phytomedicine, in healthy human volunteers. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15537171/),1/[min],0.03,156395,DB00316,Acetaminophen
,15537171,lag-time,"The absorption kinetics parameters kab, lag-time, t1/2ab for both test (0.03min(-1), 9min, 18min.) and control (0.03min(-1), 9min, 22.8min.) were identical.","Alteration of oral salivary pharmacokinetics of paracetamol by an investigational anti-malarial phytomedicine, in healthy human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15537171/),min,9,156396,DB00316,Acetaminophen
,15537171,lag-time,"The absorption kinetics parameters kab, lag-time, t1/2ab for both test (0.03min(-1), 9min, 18min.) and control (0.03min(-1), 9min, 22.8min.) were identical.","Alteration of oral salivary pharmacokinetics of paracetamol by an investigational anti-malarial phytomedicine, in healthy human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15537171/),min,18,156397,DB00316,Acetaminophen
,15537171,lag-time,"The absorption kinetics parameters kab, lag-time, t1/2ab for both test (0.03min(-1), 9min, 18min.) and control (0.03min(-1), 9min, 22.8min.) were identical.","Alteration of oral salivary pharmacokinetics of paracetamol by an investigational anti-malarial phytomedicine, in healthy human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15537171/),1/[min],0.03,156398,DB00316,Acetaminophen
,15537171,t1/2ab,"The absorption kinetics parameters kab, lag-time, t1/2ab for both test (0.03min(-1), 9min, 18min.) and control (0.03min(-1), 9min, 22.8min.) were identical.","Alteration of oral salivary pharmacokinetics of paracetamol by an investigational anti-malarial phytomedicine, in healthy human volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15537171/),1/[min],0.03,156399,DB00316,Acetaminophen
,15537171,t1/2ab,"The absorption kinetics parameters kab, lag-time, t1/2ab for both test (0.03min(-1), 9min, 18min.) and control (0.03min(-1), 9min, 22.8min.) were identical.","Alteration of oral salivary pharmacokinetics of paracetamol by an investigational anti-malarial phytomedicine, in healthy human volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15537171/),min,22.8,156400,DB00316,Acetaminophen
,15537171,"AUC, Cmax","There were statistically significant reductions in the bioavailability parameters AUC, Cmax, between control (1856microg/ml/min, 8.08microg/ml) and test (847.87microg/ml/min, 4.59microg/ml/) experiments.","Alteration of oral salivary pharmacokinetics of paracetamol by an investigational anti-malarial phytomedicine, in healthy human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15537171/),[μg] / [min·ml],1856,156401,DB00316,Acetaminophen
,15537171,"AUC, Cmax","There were statistically significant reductions in the bioavailability parameters AUC, Cmax, between control (1856microg/ml/min, 8.08microg/ml) and test (847.87microg/ml/min, 4.59microg/ml/) experiments.","Alteration of oral salivary pharmacokinetics of paracetamol by an investigational anti-malarial phytomedicine, in healthy human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15537171/),[μg] / [ml],8.08,156402,DB00316,Acetaminophen
,15537171,"AUC, Cmax","There were statistically significant reductions in the bioavailability parameters AUC, Cmax, between control (1856microg/ml/min, 8.08microg/ml) and test (847.87microg/ml/min, 4.59microg/ml/) experiments.","Alteration of oral salivary pharmacokinetics of paracetamol by an investigational anti-malarial phytomedicine, in healthy human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15537171/),[μg] / [min·ml],847.87,156403,DB00316,Acetaminophen
,15537171,"AUC, Cmax","There were statistically significant reductions in the bioavailability parameters AUC, Cmax, between control (1856microg/ml/min, 8.08microg/ml) and test (847.87microg/ml/min, 4.59microg/ml/) experiments.","Alteration of oral salivary pharmacokinetics of paracetamol by an investigational anti-malarial phytomedicine, in healthy human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15537171/),[μg] / [ml],4.59,156404,DB00316,Acetaminophen
,15537171,elimination phase kinetic parameters,"There were also insignificant but definite alterations in the elimination phase kinetic parameters kel, t1/2el, between control (0.1172min(-1), 69min.) and test (0.01027min(-1), 75min).","Alteration of oral salivary pharmacokinetics of paracetamol by an investigational anti-malarial phytomedicine, in healthy human volunteers. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15537171/),1/[min],0.1172,156405,DB00316,Acetaminophen
,15537171,elimination phase kinetic parameters,"There were also insignificant but definite alterations in the elimination phase kinetic parameters kel, t1/2el, between control (0.1172min(-1), 69min.) and test (0.01027min(-1), 75min).","Alteration of oral salivary pharmacokinetics of paracetamol by an investigational anti-malarial phytomedicine, in healthy human volunteers. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15537171/),1/[min],0.01027,156406,DB00316,Acetaminophen
,15537171,"kel, t1/2el","There were also insignificant but definite alterations in the elimination phase kinetic parameters kel, t1/2el, between control (0.1172min(-1), 69min.) and test (0.01027min(-1), 75min).","Alteration of oral salivary pharmacokinetics of paracetamol by an investigational anti-malarial phytomedicine, in healthy human volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15537171/),1/[min],0.1172,156407,DB00316,Acetaminophen
,15537171,"kel, t1/2el","There were also insignificant but definite alterations in the elimination phase kinetic parameters kel, t1/2el, between control (0.1172min(-1), 69min.) and test (0.01027min(-1), 75min).","Alteration of oral salivary pharmacokinetics of paracetamol by an investigational anti-malarial phytomedicine, in healthy human volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15537171/),min,69,156408,DB00316,Acetaminophen
,15537171,"kel, t1/2el","There were also insignificant but definite alterations in the elimination phase kinetic parameters kel, t1/2el, between control (0.1172min(-1), 69min.) and test (0.01027min(-1), 75min).","Alteration of oral salivary pharmacokinetics of paracetamol by an investigational anti-malarial phytomedicine, in healthy human volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15537171/),1/[min],0.01027,156409,DB00316,Acetaminophen
,15537171,"kel, t1/2el","There were also insignificant but definite alterations in the elimination phase kinetic parameters kel, t1/2el, between control (0.1172min(-1), 69min.) and test (0.01027min(-1), 75min).","Alteration of oral salivary pharmacokinetics of paracetamol by an investigational anti-malarial phytomedicine, in healthy human volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15537171/),min,75,156410,DB00316,Acetaminophen
,21244275,time to complete disintegration,"In Study 1, the mean time to complete disintegration (12.9 vs. 69.6 min, P < 0.0001) and onset of disintegration were both significantly faster with FD-APAP than with standard acetaminophen (P < 0.0001).",Comparison of a novel fast-dissolving acetaminophen tablet formulation (FD-APAP) and standard acetaminophen tablets using gamma scintigraphy and pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21244275/),min,12.9,156431,DB00316,Acetaminophen
,21244275,time to complete disintegration,"In Study 1, the mean time to complete disintegration (12.9 vs. 69.6 min, P < 0.0001) and onset of disintegration were both significantly faster with FD-APAP than with standard acetaminophen (P < 0.0001).",Comparison of a novel fast-dissolving acetaminophen tablet formulation (FD-APAP) and standard acetaminophen tablets using gamma scintigraphy and pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21244275/),min,69.6,156432,DB00316,Acetaminophen
,21244275,T(max),"For Study 2, median T(max) was significantly faster for FD-APAP (0.50 vs. 0.67 h, P < 0.01) and AUC(0-30 min) was significantly greater (4.51 vs. 2.74, P < 0.05).",Comparison of a novel fast-dissolving acetaminophen tablet formulation (FD-APAP) and standard acetaminophen tablets using gamma scintigraphy and pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21244275/),h,0.50,156433,DB00316,Acetaminophen
,21244275,T(max),"For Study 2, median T(max) was significantly faster for FD-APAP (0.50 vs. 0.67 h, P < 0.01) and AUC(0-30 min) was significantly greater (4.51 vs. 2.74, P < 0.05).",Comparison of a novel fast-dissolving acetaminophen tablet formulation (FD-APAP) and standard acetaminophen tablets using gamma scintigraphy and pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21244275/),h,0.67,156434,DB00316,Acetaminophen
,21244275,AUC(0-30 min),"For Study 2, median T(max) was significantly faster for FD-APAP (0.50 vs. 0.67 h, P < 0.01) and AUC(0-30 min) was significantly greater (4.51 vs. 2.74, P < 0.05).",Comparison of a novel fast-dissolving acetaminophen tablet formulation (FD-APAP) and standard acetaminophen tablets using gamma scintigraphy and pharmacokinetic studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21244275/),,4.51,156435,DB00316,Acetaminophen
,21244275,AUC(0-30 min),"For Study 2, median T(max) was significantly faster for FD-APAP (0.50 vs. 0.67 h, P < 0.01) and AUC(0-30 min) was significantly greater (4.51 vs. 2.74, P < 0.05).",Comparison of a novel fast-dissolving acetaminophen tablet formulation (FD-APAP) and standard acetaminophen tablets using gamma scintigraphy and pharmacokinetic studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21244275/),,2.74,156436,DB00316,Acetaminophen
,11709376,plasma T(max),"In acute stroke patients, mean plasma T(max) was delayed compared with that in controls (96.3 vs 46.2 min, P=0.015).",Drug absorption may be delayed after stroke: results of the paracetamol absorption test. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709376/),min,96.3,157569,DB00316,Acetaminophen
,11709376,plasma T(max),"In acute stroke patients, mean plasma T(max) was delayed compared with that in controls (96.3 vs 46.2 min, P=0.015).",Drug absorption may be delayed after stroke: results of the paracetamol absorption test. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709376/),min,46.2,157570,DB00316,Acetaminophen
,11709376,C(max),"The C(max) of paracetamol was also lower (16.1 vs 23.9 mg l(-1), P=0.028).",Drug absorption may be delayed after stroke: results of the paracetamol absorption test. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709376/),[mg] / [l],16.1,157571,DB00316,Acetaminophen
,11709376,C(max),"The C(max) of paracetamol was also lower (16.1 vs 23.9 mg l(-1), P=0.028).",Drug absorption may be delayed after stroke: results of the paracetamol absorption test. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709376/),[mg] / [l],23.9,157572,DB00316,Acetaminophen
,30321459,steady-state concentration (Css-mean ),"Simulations were performed to illustrate target attainment and variability of paracetamol exposure following current dosing regimens (1000 mg every 6 h, every 8 h) using steady-state concentration (Css-mean ) of 10 mg l-1 as target for effective analgesia.",Population pharmacokinetic modelling of intravenous paracetamol in fit older people displays extensive unexplained variability. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30321459/),[mg] / [l],10,158623,DB00316,Acetaminophen
,30321459,Css,"Simulations of the standardized dosing regimens resulted in a Css of 9.2 mg l-1 and 7.2 mg l-1 , for every 6 h and every 8 h respectively.",Population pharmacokinetic modelling of intravenous paracetamol in fit older people displays extensive unexplained variability. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30321459/),[mg] / [l],9.2,158624,DB00316,Acetaminophen
,30321459,Css,"Simulations of the standardized dosing regimens resulted in a Css of 9.2 mg l-1 and 7.2 mg l-1 , for every 6 h and every 8 h respectively.",Population pharmacokinetic modelling of intravenous paracetamol in fit older people displays extensive unexplained variability. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30321459/),[mg] / [l],7.2,158625,DB00316,Acetaminophen
above,30321459,Css,"Variability in paracetamol PK resulted in Css above 5.4 and 4.1 mg l-1 , respectively, in 90% of the population and above 15.5 and 11.7, respectively, in 10% at these dosing regimens.",Population pharmacokinetic modelling of intravenous paracetamol in fit older people displays extensive unexplained variability. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30321459/),[mg] / [l],5.4,158626,DB00316,Acetaminophen
above,30321459,Css,"Variability in paracetamol PK resulted in Css above 5.4 and 4.1 mg l-1 , respectively, in 90% of the population and above 15.5 and 11.7, respectively, in 10% at these dosing regimens.",Population pharmacokinetic modelling of intravenous paracetamol in fit older people displays extensive unexplained variability. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30321459/),[mg] / [l],4.1,158627,DB00316,Acetaminophen
above,30321459,Css,"Variability in paracetamol PK resulted in Css above 5.4 and 4.1 mg l-1 , respectively, in 90% of the population and above 15.5 and 11.7, respectively, in 10% at these dosing regimens.",Population pharmacokinetic modelling of intravenous paracetamol in fit older people displays extensive unexplained variability. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30321459/),,15.5,158628,DB00316,Acetaminophen
above,30321459,Css,"Variability in paracetamol PK resulted in Css above 5.4 and 4.1 mg l-1 , respectively, in 90% of the population and above 15.5 and 11.7, respectively, in 10% at these dosing regimens.",Population pharmacokinetic modelling of intravenous paracetamol in fit older people displays extensive unexplained variability. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30321459/),,11.7,158629,DB00316,Acetaminophen
,2043159,clearance,"Malaria infection (MI) resulted in a significant decrease in clearance (control: 21.6 +/- 5.5 vs test: 11.8 +/- 2.9 mL/min/kg, P less than 0.005) with no change in volume of distribution and a significant prolongation of the elimination half-life (control: 30.7 +/- 6.3 vs 53.3 +/- 12.1 min, P less than 0.005) of paracetamol in malaria infected rats.",The effect of malaria infection on paracetamol disposition in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2043159/),[ml] / [kg·min],21.6,158929,DB00316,Acetaminophen
,2043159,clearance,"Malaria infection (MI) resulted in a significant decrease in clearance (control: 21.6 +/- 5.5 vs test: 11.8 +/- 2.9 mL/min/kg, P less than 0.005) with no change in volume of distribution and a significant prolongation of the elimination half-life (control: 30.7 +/- 6.3 vs 53.3 +/- 12.1 min, P less than 0.005) of paracetamol in malaria infected rats.",The effect of malaria infection on paracetamol disposition in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2043159/),[ml] / [kg·min],11.8,158930,DB00316,Acetaminophen
,2043159,elimination half-life,"Malaria infection (MI) resulted in a significant decrease in clearance (control: 21.6 +/- 5.5 vs test: 11.8 +/- 2.9 mL/min/kg, P less than 0.005) with no change in volume of distribution and a significant prolongation of the elimination half-life (control: 30.7 +/- 6.3 vs 53.3 +/- 12.1 min, P less than 0.005) of paracetamol in malaria infected rats.",The effect of malaria infection on paracetamol disposition in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2043159/),min,30.7,158931,DB00316,Acetaminophen
,2043159,elimination half-life,"Malaria infection (MI) resulted in a significant decrease in clearance (control: 21.6 +/- 5.5 vs test: 11.8 +/- 2.9 mL/min/kg, P less than 0.005) with no change in volume of distribution and a significant prolongation of the elimination half-life (control: 30.7 +/- 6.3 vs 53.3 +/- 12.1 min, P less than 0.005) of paracetamol in malaria infected rats.",The effect of malaria infection on paracetamol disposition in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2043159/),min,53.3,158932,DB00316,Acetaminophen
,7506175,maximum nimesulide plasma concentration,"A mean maximum nimesulide plasma concentration of 3.5 mg/L was achieved within 2 hours of administration, which subsequently declined over the following 12 hours.",Clinical and pharmacokinetic study of nimesulide in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7506175/),[mg] / [l],3.5,162326,DB00316,Acetaminophen
,760753,oral bioavailability,"3 The oral bioavailability (mean +/- s.e. mean) was significantly lower in the epileptic patients than in the normal subjects (0.77 +/- 0.03 and 0.89 +/- 0.02 respectively, P less than 0.01), whereas the urinary excretion total (free+conjugated) paracetamol was almost identical in the two groups.",Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/760753/),,0.77,162430,DB00316,Acetaminophen
,760753,oral bioavailability,"3 The oral bioavailability (mean +/- s.e. mean) was significantly lower in the epileptic patients than in the normal subjects (0.77 +/- 0.03 and 0.89 +/- 0.02 respectively, P less than 0.01), whereas the urinary excretion total (free+conjugated) paracetamol was almost identical in the two groups.",Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/760753/),,0.89,162431,DB00316,Acetaminophen
,29513963,Cl,"The research was carried out on two groups of patients after nephrectomy: total (TN n = 37; mean [SD], age, 60.4 [10.9] years; BMI, 26.5 [3.8] kg/m2; creatinine clearance, Cl, 80.9 [37.1] mL/min) and nephron sparing surgery (NSS n = 17; 57.9 [16.5] years; BMI, 29.5 [5.3] kg/m2; Cl, 97.6 [27.8] mL/min).",THE EFFECT OF TOTAL AND PARTIAL NEPHRECTOMY ON THE PHARMACOKINETICS OF INTRAVENOUS PARACETAMOL IN HUMANS. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29513963/),[ml] / [min],97.6,162472,DB00316,Acetaminophen
,29513963,C.,"The main pharmacokinetic parameters of paracetamol in the TN vs. NSS group were as follows: C.. 29.08 [17.39] vs. 27.54 [15.70] pg/mL (p = 0.6692); AUC5, 29.24 [13.86] vs. 34.85 [14.28] pg.h/mL (p = 0.2896); AUMC5,,,, 47.58 [26.08] vs. 62.02 [27.64] pg-h/mL (p = 0.1345); to. 2.34 [0.96] vs. 1.93 [0.50] h (p = 0.1415), respectively.",THE EFFECT OF TOTAL AND PARTIAL NEPHRECTOMY ON THE PHARMACOKINETICS OF INTRAVENOUS PARACETAMOL IN HUMANS. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29513963/),[pg] / [ml],29.08,162473,DB00316,Acetaminophen
,29513963,C.,"The main pharmacokinetic parameters of paracetamol in the TN vs. NSS group were as follows: C.. 29.08 [17.39] vs. 27.54 [15.70] pg/mL (p = 0.6692); AUC5, 29.24 [13.86] vs. 34.85 [14.28] pg.h/mL (p = 0.2896); AUMC5,,,, 47.58 [26.08] vs. 62.02 [27.64] pg-h/mL (p = 0.1345); to. 2.34 [0.96] vs. 1.93 [0.50] h (p = 0.1415), respectively.",THE EFFECT OF TOTAL AND PARTIAL NEPHRECTOMY ON THE PHARMACOKINETICS OF INTRAVENOUS PARACETAMOL IN HUMANS. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29513963/),[pg] / [ml],27.54,162474,DB00316,Acetaminophen
,29513963,AUC5,"The main pharmacokinetic parameters of paracetamol in the TN vs. NSS group were as follows: C.. 29.08 [17.39] vs. 27.54 [15.70] pg/mL (p = 0.6692); AUC5, 29.24 [13.86] vs. 34.85 [14.28] pg.h/mL (p = 0.2896); AUMC5,,,, 47.58 [26.08] vs. 62.02 [27.64] pg-h/mL (p = 0.1345); to. 2.34 [0.96] vs. 1.93 [0.50] h (p = 0.1415), respectively.",THE EFFECT OF TOTAL AND PARTIAL NEPHRECTOMY ON THE PHARMACOKINETICS OF INTRAVENOUS PARACETAMOL IN HUMANS. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29513963/),[h·pg] / [ml],29.24,162475,DB00316,Acetaminophen
,29513963,AUC5,"The main pharmacokinetic parameters of paracetamol in the TN vs. NSS group were as follows: C.. 29.08 [17.39] vs. 27.54 [15.70] pg/mL (p = 0.6692); AUC5, 29.24 [13.86] vs. 34.85 [14.28] pg.h/mL (p = 0.2896); AUMC5,,,, 47.58 [26.08] vs. 62.02 [27.64] pg-h/mL (p = 0.1345); to. 2.34 [0.96] vs. 1.93 [0.50] h (p = 0.1415), respectively.",THE EFFECT OF TOTAL AND PARTIAL NEPHRECTOMY ON THE PHARMACOKINETICS OF INTRAVENOUS PARACETAMOL IN HUMANS. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29513963/),[h·pg] / [ml],34.85,162476,DB00316,Acetaminophen
,29513963,AUMC5,"The main pharmacokinetic parameters of paracetamol in the TN vs. NSS group were as follows: C.. 29.08 [17.39] vs. 27.54 [15.70] pg/mL (p = 0.6692); AUC5, 29.24 [13.86] vs. 34.85 [14.28] pg.h/mL (p = 0.2896); AUMC5,,,, 47.58 [26.08] vs. 62.02 [27.64] pg-h/mL (p = 0.1345); to. 2.34 [0.96] vs. 1.93 [0.50] h (p = 0.1415), respectively.",THE EFFECT OF TOTAL AND PARTIAL NEPHRECTOMY ON THE PHARMACOKINETICS OF INTRAVENOUS PARACETAMOL IN HUMANS. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29513963/),[pg-h] / [ml],47.58,162477,DB00316,Acetaminophen
,29513963,AUMC5,"The main pharmacokinetic parameters of paracetamol in the TN vs. NSS group were as follows: C.. 29.08 [17.39] vs. 27.54 [15.70] pg/mL (p = 0.6692); AUC5, 29.24 [13.86] vs. 34.85 [14.28] pg.h/mL (p = 0.2896); AUMC5,,,, 47.58 [26.08] vs. 62.02 [27.64] pg-h/mL (p = 0.1345); to. 2.34 [0.96] vs. 1.93 [0.50] h (p = 0.1415), respectively.",THE EFFECT OF TOTAL AND PARTIAL NEPHRECTOMY ON THE PHARMACOKINETICS OF INTRAVENOUS PARACETAMOL IN HUMANS. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29513963/),[pg-h] / [ml],62.02,162478,DB00316,Acetaminophen
,29513963,AUMC5,"The main pharmacokinetic parameters of paracetamol in the TN vs. NSS group were as follows: C.. 29.08 [17.39] vs. 27.54 [15.70] pg/mL (p = 0.6692); AUC5, 29.24 [13.86] vs. 34.85 [14.28] pg.h/mL (p = 0.2896); AUMC5,,,, 47.58 [26.08] vs. 62.02 [27.64] pg-h/mL (p = 0.1345); to. 2.34 [0.96] vs. 1.93 [0.50] h (p = 0.1415), respectively.",THE EFFECT OF TOTAL AND PARTIAL NEPHRECTOMY ON THE PHARMACOKINETICS OF INTRAVENOUS PARACETAMOL IN HUMANS. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29513963/),h,2.34,162479,DB00316,Acetaminophen
,29513963,AUMC5,"The main pharmacokinetic parameters of paracetamol in the TN vs. NSS group were as follows: C.. 29.08 [17.39] vs. 27.54 [15.70] pg/mL (p = 0.6692); AUC5, 29.24 [13.86] vs. 34.85 [14.28] pg.h/mL (p = 0.2896); AUMC5,,,, 47.58 [26.08] vs. 62.02 [27.64] pg-h/mL (p = 0.1345); to. 2.34 [0.96] vs. 1.93 [0.50] h (p = 0.1415), respectively.",THE EFFECT OF TOTAL AND PARTIAL NEPHRECTOMY ON THE PHARMACOKINETICS OF INTRAVENOUS PARACETAMOL IN HUMANS. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29513963/),h,1.93,162480,DB00316,Acetaminophen
,2414066,Peak paracetamol plasma concentrations,"Peak paracetamol plasma concentrations were 11.25 +/- 1.74 micrograms/ml at 0.5 hours, 9.6 +/- 1.04 micrograms/ml at 0.75 hours, and 9.53 +/- 1.66 micrograms/ml at 0.5 hours, respectively, after the standard formulation, the combination without docusate, and paracetamol alone.","The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),[μg] / [ml],11.25,162701,DB00316,Acetaminophen
,2414066,Peak paracetamol plasma concentrations,"Peak paracetamol plasma concentrations were 11.25 +/- 1.74 micrograms/ml at 0.5 hours, 9.6 +/- 1.04 micrograms/ml at 0.75 hours, and 9.53 +/- 1.66 micrograms/ml at 0.5 hours, respectively, after the standard formulation, the combination without docusate, and paracetamol alone.","The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),[μg] / [ml],9.6,162702,DB00316,Acetaminophen
,2414066,Peak paracetamol plasma concentrations,"Peak paracetamol plasma concentrations were 11.25 +/- 1.74 micrograms/ml at 0.5 hours, 9.6 +/- 1.04 micrograms/ml at 0.75 hours, and 9.53 +/- 1.66 micrograms/ml at 0.5 hours, respectively, after the standard formulation, the combination without docusate, and paracetamol alone.","The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),[μg] / [ml],9.53,162703,DB00316,Acetaminophen
,2414066,elimination half-lives,"Mean elimination half-lives for paracetamol were 2.83 +/- 0.51, 1.92 +/- 0.20 and 2.49 +/- 0.46 hours, respectively, and the differences were not significant.","The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),h,2.83,162704,DB00316,Acetaminophen
,2414066,elimination half-lives,"Mean elimination half-lives for paracetamol were 2.83 +/- 0.51, 1.92 +/- 0.20 and 2.49 +/- 0.46 hours, respectively, and the differences were not significant.","The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),h,1.92,162705,DB00316,Acetaminophen
,2414066,elimination half-lives,"Mean elimination half-lives for paracetamol were 2.83 +/- 0.51, 1.92 +/- 0.20 and 2.49 +/- 0.46 hours, respectively, and the differences were not significant.","The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),h,2.49,162706,DB00316,Acetaminophen
,2414066,Peak codeine plasma concentrations,Peak codeine plasma concentrations after the standard formulation were 42.1 +/- 9.4 ng/ml at 0.75 hours compared with 36.9 +/- 3.4 ng/ml at 1.5 hours after the combination without docusate.,"The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),[ng] / [ml],42.1,162707,DB00316,Acetaminophen
,2414066,Peak codeine plasma concentrations,Peak codeine plasma concentrations after the standard formulation were 42.1 +/- 9.4 ng/ml at 0.75 hours compared with 36.9 +/- 3.4 ng/ml at 1.5 hours after the combination without docusate.,"The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),[ng] / [ml],36.9,162708,DB00316,Acetaminophen
,30496738,Peak time (Tmax),"All preparations showed slower APAP absorption than reported for humans: Peak time (Tmax) = 12 h for Intestine 2-OC and 6 h for Intestine/Liver 2-OC in both static and dynamic conditions, against reported Tmax of 0,33 to 1,4 h after oral administration to humans.",Acetaminophen absorption and metabolism in an intestine/liver microphysiological system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30496738/),h,12,167114,DB00316,Acetaminophen
,30496738,Peak time (Tmax),"All preparations showed slower APAP absorption than reported for humans: Peak time (Tmax) = 12 h for Intestine 2-OC and 6 h for Intestine/Liver 2-OC in both static and dynamic conditions, against reported Tmax of 0,33 to 1,4 h after oral administration to humans.",Acetaminophen absorption and metabolism in an intestine/liver microphysiological system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30496738/),h,6,167115,DB00316,Acetaminophen
,30496738,Tmax,"All preparations showed slower APAP absorption than reported for humans: Peak time (Tmax) = 12 h for Intestine 2-OC and 6 h for Intestine/Liver 2-OC in both static and dynamic conditions, against reported Tmax of 0,33 to 1,4 h after oral administration to humans.",Acetaminophen absorption and metabolism in an intestine/liver microphysiological system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30496738/),h,0,167116,DB00316,Acetaminophen
,30496738,Tmax,"All preparations showed slower APAP absorption than reported for humans: Peak time (Tmax) = 12 h for Intestine 2-OC and 6 h for Intestine/Liver 2-OC in both static and dynamic conditions, against reported Tmax of 0,33 to 1,4 h after oral administration to humans.",Acetaminophen absorption and metabolism in an intestine/liver microphysiological system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30496738/),h,"1,4",167117,DB00316,Acetaminophen
,30496738,half-life (T1/2),"The APAP half-life (T1/2) was 12 h in the dynamic Liver 2-OC, against T1/2 = 2 ± 0,4 h reported for humans.",Acetaminophen absorption and metabolism in an intestine/liver microphysiological system. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30496738/),h,12,167118,DB00316,Acetaminophen
,30496738,T1/2,"The APAP half-life (T1/2) was 12 h in the dynamic Liver 2-OC, against T1/2 = 2 ± 0,4 h reported for humans.",Acetaminophen absorption and metabolism in an intestine/liver microphysiological system. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30496738/),h,2,167119,DB00316,Acetaminophen
,33719822,AUC,"Compared to the commercial tablet, the ATSC had a larger AUC value for tramadol (55.27 ± 11.06 vs. 92.62 ± 21.52 h·ng/ml).","Acetaminophen and tramadol hydrochloride-loaded soft gelatin capsule: preparation, dissolution and pharmacokinetics in beagle dogs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33719822/),[h·ng] / [ml],55.27,168570,DB00316,Acetaminophen
,33719822,AUC,"Compared to the commercial tablet, the ATSC had a larger AUC value for tramadol (55.27 ± 11.06 vs. 92.62 ± 21.52 h·ng/ml).","Acetaminophen and tramadol hydrochloride-loaded soft gelatin capsule: preparation, dissolution and pharmacokinetics in beagle dogs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33719822/),[h·ng] / [ml],92.62,168571,DB00316,Acetaminophen
,14711849,Serum half life,Serum half life was 277 (143) minutes in the preterm infants and 172 (59) minutes in the term infants (p < 0.05).,Pharmacokinetics of single dose intravenous propacetamol in neonates: effect of gestational age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14711849/),min,277,168689,DB00316,Acetaminophen
,14711849,Serum half life,Serum half life was 277 (143) minutes in the preterm infants and 172 (59) minutes in the term infants (p < 0.05).,Pharmacokinetics of single dose intravenous propacetamol in neonates: effect of gestational age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14711849/),min,172,168690,DB00316,Acetaminophen
,14711849,Clearance,Clearance was 0.116 (0.08) litre/kg/h in the preterm infants and 0.170 (0.06) litre/kg/h in the term infants (p < 0.05).,Pharmacokinetics of single dose intravenous propacetamol in neonates: effect of gestational age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14711849/),[l] / [h·kg],0.116,168691,DB00316,Acetaminophen
,14711849,Clearance,Clearance was 0.116 (0.08) litre/kg/h in the preterm infants and 0.170 (0.06) litre/kg/h in the term infants (p < 0.05).,Pharmacokinetics of single dose intravenous propacetamol in neonates: effect of gestational age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14711849/),[l] / [h·kg],0.170,168692,DB00316,Acetaminophen
,28337667,Tmax,"Furthermore, the in vivo pharmacokinetic studies of these APAP loaded compression-coated tablets in New Zealand rabbits gave that the Tmax (12.32 ± 1.05 h) was significantly prolonged (p < 0.01), compared to that (0.89 ± 0.26 h) of common APAP tablets (Jinfuning®) after oral administration.",Self-assembled polyelectrolyte complexes films as efficient compression coating layers for controlled-releasing tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28337667/),h,12.32,168699,DB00316,Acetaminophen
,28337667,Tmax,"Furthermore, the in vivo pharmacokinetic studies of these APAP loaded compression-coated tablets in New Zealand rabbits gave that the Tmax (12.32 ± 1.05 h) was significantly prolonged (p < 0.01), compared to that (0.89 ± 0.26 h) of common APAP tablets (Jinfuning®) after oral administration.",Self-assembled polyelectrolyte complexes films as efficient compression coating layers for controlled-releasing tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28337667/),h,0.89,168700,DB00316,Acetaminophen
,12365202,Cmax,"Cmax was found to be 22.31 +/- 4.24 mcg/ml for 0730 h dosing time, while a decrease of 9.64 and 11.7% over this value was recorded for dosing time 1300 h and 2100 h respectively.",Chronopharmacokinetics of acetaminophen in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12365202/),[mcg] / [ml],22.31,170039,DB00316,Acetaminophen
,12365202,"Elimination half-life, t1/2 beta","Elimination half-life, t1/2 beta was found to be 1.68 +/- 0.67 h at 0730 h.",Chronopharmacokinetics of acetaminophen in healthy human volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12365202/),h,1.68,170040,DB00316,Acetaminophen
,24654967,volume of distribution,"The estimated pharmacokinetic population parameters were volume of distribution 0.764 ± 0.225 L/kg, elimination rate constant (ke ) 0.117 ± 0.091/h and intercompartment rate constants k12 0.607 ± 0.734/h and k21 1.105 ± 0.762/h.",Multiple intravenous doses of paracetamol result in a predictable pharmacokinetic profile in very preterm infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24654967/),[l] / [kg],0.764,170734,DB00316,Acetaminophen
,24654967,elimination rate constant (ke ),"The estimated pharmacokinetic population parameters were volume of distribution 0.764 ± 0.225 L/kg, elimination rate constant (ke ) 0.117 ± 0.091/h and intercompartment rate constants k12 0.607 ± 0.734/h and k21 1.105 ± 0.762/h.",Multiple intravenous doses of paracetamol result in a predictable pharmacokinetic profile in very preterm infants. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24654967/),1/[h],0.117,170735,DB00316,Acetaminophen
,24654967,intercompartment rate constants k12,"The estimated pharmacokinetic population parameters were volume of distribution 0.764 ± 0.225 L/kg, elimination rate constant (ke ) 0.117 ± 0.091/h and intercompartment rate constants k12 0.607 ± 0.734/h and k21 1.105 ± 0.762/h.",Multiple intravenous doses of paracetamol result in a predictable pharmacokinetic profile in very preterm infants. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24654967/),1/[h],0.607,170736,DB00316,Acetaminophen
,24654967,k21,"The estimated pharmacokinetic population parameters were volume of distribution 0.764 ± 0.225 L/kg, elimination rate constant (ke ) 0.117 ± 0.091/h and intercompartment rate constants k12 0.607 ± 0.734/h and k21 1.105 ± 0.762/h.",Multiple intravenous doses of paracetamol result in a predictable pharmacokinetic profile in very preterm infants. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24654967/),1/[h],1.105,170737,DB00316,Acetaminophen
,7489454,maximum concentration (Cmax),The mean maximum concentration (Cmax) was 0.115 (SD 0.049) mmol.l-1.,Pharmacokinetics of rectal paracetamol after major surgery in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7489454/),[mM] / [l],0.115,170999,DB00316,Acetaminophen
,7489454,Tmax,Peak concentration occurred (Tmax) at 2.3 (SD 1.2) h.,Pharmacokinetics of rectal paracetamol after major surgery in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7489454/),h,2.3,171000,DB00316,Acetaminophen
,7489454,concentration,Mean concentration was 0.07 (SD 0.03) mmol.l-1 at six h.,Pharmacokinetics of rectal paracetamol after major surgery in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7489454/),[mM] / [l],0.07,171001,DB00316,Acetaminophen
,7489454,Apparent paracetamol clearance,Apparent paracetamol clearance was 5.8 ml.min-1.kg-1.,Pharmacokinetics of rectal paracetamol after major surgery in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7489454/),[ml] / [kg·min],5.8,171002,DB00316,Acetaminophen
,9430010,time taken to reach the peak concentrations,"The time taken to reach the peak concentrations ranged from 30 to 90 min after ingestion, whereas most ROMs were emptied 120 min after ingestion.",Effect of erythromycin on gastric emptying in healthy individuals assessed by radio-opaque markers and plasma acetaminophen levels. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430010/),min,30 to 90,171588,DB00316,Acetaminophen
,9084512,AD50s,"AD50s determined by the PPT in rabbits for morphine and nalbuphine were 3.1 and 8.4 mg/kg, respectively.",Paw pressure test in the rabbit: a new animal model for the study of pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084512/),[mg] / [kg],3.1,171644,DB00316,Acetaminophen
,9084512,AD50s,"AD50s determined by the PPT in rabbits for morphine and nalbuphine were 3.1 and 8.4 mg/kg, respectively.",Paw pressure test in the rabbit: a new animal model for the study of pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084512/),[mg] / [kg],8.4,171645,DB00316,Acetaminophen
,9527730,maximum concentration of paracetamol (Cmax),"During propofol sedation the maximum concentration of paracetamol (Cmax) was 115+/-26.8 micromol/L, time to peak concentration (Tmax) 50+/-38.8 min, and the area under the curve during the first 60 min (AUC60) 4793+/-1538 micromol x min/L, versus Cmax 99+/-20.8, Tmax 69+/-41.9 and AUC60 3897+/-1310 during saline infusion.",Propofol sedation and gastric emptying in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527730/),[μM] / [l],115,171773,DB00316,Acetaminophen
,9527730,time to peak concentration (Tmax),"During propofol sedation the maximum concentration of paracetamol (Cmax) was 115+/-26.8 micromol/L, time to peak concentration (Tmax) 50+/-38.8 min, and the area under the curve during the first 60 min (AUC60) 4793+/-1538 micromol x min/L, versus Cmax 99+/-20.8, Tmax 69+/-41.9 and AUC60 3897+/-1310 during saline infusion.",Propofol sedation and gastric emptying in volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527730/),min,50,171774,DB00316,Acetaminophen
,9527730,area under the curve during the first 60 min (AUC60),"During propofol sedation the maximum concentration of paracetamol (Cmax) was 115+/-26.8 micromol/L, time to peak concentration (Tmax) 50+/-38.8 min, and the area under the curve during the first 60 min (AUC60) 4793+/-1538 micromol x min/L, versus Cmax 99+/-20.8, Tmax 69+/-41.9 and AUC60 3897+/-1310 during saline infusion.",Propofol sedation and gastric emptying in volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527730/),[min·μM] / [l],4793,171775,DB00316,Acetaminophen
,9527730,Cmax,"During propofol sedation the maximum concentration of paracetamol (Cmax) was 115+/-26.8 micromol/L, time to peak concentration (Tmax) 50+/-38.8 min, and the area under the curve during the first 60 min (AUC60) 4793+/-1538 micromol x min/L, versus Cmax 99+/-20.8, Tmax 69+/-41.9 and AUC60 3897+/-1310 during saline infusion.",Propofol sedation and gastric emptying in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527730/),,99,171776,DB00316,Acetaminophen
,9527730,Tmax,"During propofol sedation the maximum concentration of paracetamol (Cmax) was 115+/-26.8 micromol/L, time to peak concentration (Tmax) 50+/-38.8 min, and the area under the curve during the first 60 min (AUC60) 4793+/-1538 micromol x min/L, versus Cmax 99+/-20.8, Tmax 69+/-41.9 and AUC60 3897+/-1310 during saline infusion.",Propofol sedation and gastric emptying in volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527730/),,69,171777,DB00316,Acetaminophen
,9527730,AUC60,"During propofol sedation the maximum concentration of paracetamol (Cmax) was 115+/-26.8 micromol/L, time to peak concentration (Tmax) 50+/-38.8 min, and the area under the curve during the first 60 min (AUC60) 4793+/-1538 micromol x min/L, versus Cmax 99+/-20.8, Tmax 69+/-41.9 and AUC60 3897+/-1310 during saline infusion.",Propofol sedation and gastric emptying in volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527730/),,3897,171778,DB00316,Acetaminophen
,9527730,OCT,"OCT was significantly shorter during the control study, 180+/-32.4 min, than during propofol sedation, 217+/-64.9 min (P<0.05).",Propofol sedation and gastric emptying in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527730/),min,180,171779,DB00316,Acetaminophen
,9527730,OCT,"OCT was significantly shorter during the control study, 180+/-32.4 min, than during propofol sedation, 217+/-64.9 min (P<0.05).",Propofol sedation and gastric emptying in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527730/),min,217,171780,DB00316,Acetaminophen
,4055163,ED50,"The analgesic effect of paracetamol, studied in the Randall-Selitto test in rats, was not changed by methionine: ED50 was 94.6 mg/kg without methionine and 94.1 mg/kg with it.","Methionine in paracetamol tablets, a tool to reduce paracetamol toxicity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4055163/),[mg] / [kg],94.6,171961,DB00316,Acetaminophen
,4055163,ED50,"The analgesic effect of paracetamol, studied in the Randall-Selitto test in rats, was not changed by methionine: ED50 was 94.6 mg/kg without methionine and 94.1 mg/kg with it.","Methionine in paracetamol tablets, a tool to reduce paracetamol toxicity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4055163/),[mg] / [kg],94.1,171962,DB00316,Acetaminophen
,10385211,area under the blood cyclosporin concentration-time curve after oral administration (AUCpo),The area under the blood cyclosporin concentration-time curve after oral administration (AUCpo) were 4.976+/-0.847 mghL(-1) for ARF rats and 9.684+/-1.100 mghL(-1) for control rats; AUCpo in ARF was significantly reduced in a manner dependent on renal function.,Influence of glycerol-induced acute renal failure on the pharmacokinetics of cyclosporin in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10385211/),1/[mghl],4.976,172087,DB00316,Acetaminophen
,10385211,area under the blood cyclosporin concentration-time curve after oral administration (AUCpo),The area under the blood cyclosporin concentration-time curve after oral administration (AUCpo) were 4.976+/-0.847 mghL(-1) for ARF rats and 9.684+/-1.100 mghL(-1) for control rats; AUCpo in ARF was significantly reduced in a manner dependent on renal function.,Influence of glycerol-induced acute renal failure on the pharmacokinetics of cyclosporin in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10385211/),1/[mghl],9.684,172088,DB00316,Acetaminophen
,10385211,oral clearance,"The oral clearance of cyclosporin in ARF and control rats was 1.172+/-0.207 and 0.544+/-0.062Lh(-1) kg(-1), respectively, whereas total body clearance in ARF and control rats was 0.151+/-0.008 and 0.183+/-0.010Lh(-1)kg(-1), respectively.",Influence of glycerol-induced acute renal failure on the pharmacokinetics of cyclosporin in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10385211/),1/[kg·lh],1.172,172089,DB00316,Acetaminophen
,10385211,oral clearance,"The oral clearance of cyclosporin in ARF and control rats was 1.172+/-0.207 and 0.544+/-0.062Lh(-1) kg(-1), respectively, whereas total body clearance in ARF and control rats was 0.151+/-0.008 and 0.183+/-0.010Lh(-1)kg(-1), respectively.",Influence of glycerol-induced acute renal failure on the pharmacokinetics of cyclosporin in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10385211/),1/[kg·lh],0.544,172090,DB00316,Acetaminophen
,10385211,total body clearance,"The oral clearance of cyclosporin in ARF and control rats was 1.172+/-0.207 and 0.544+/-0.062Lh(-1) kg(-1), respectively, whereas total body clearance in ARF and control rats was 0.151+/-0.008 and 0.183+/-0.010Lh(-1)kg(-1), respectively.",Influence of glycerol-induced acute renal failure on the pharmacokinetics of cyclosporin in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10385211/),1/[lh],0.151,172091,DB00316,Acetaminophen
,10385211,total body clearance,"The oral clearance of cyclosporin in ARF and control rats was 1.172+/-0.207 and 0.544+/-0.062Lh(-1) kg(-1), respectively, whereas total body clearance in ARF and control rats was 0.151+/-0.008 and 0.183+/-0.010Lh(-1)kg(-1), respectively.",Influence of glycerol-induced acute renal failure on the pharmacokinetics of cyclosporin in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10385211/),1/[lh],0.183,172092,DB00316,Acetaminophen
,10385211,relative bioavailability,"The relative bioavailability of cyclosporin in ARF and control rats was 0.118 and 0.336, respectively.",Influence of glycerol-induced acute renal failure on the pharmacokinetics of cyclosporin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10385211/),,0.118,172093,DB00316,Acetaminophen
,10385211,relative bioavailability,"The relative bioavailability of cyclosporin in ARF and control rats was 0.118 and 0.336, respectively.",Influence of glycerol-induced acute renal failure on the pharmacokinetics of cyclosporin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10385211/),,0.336,172094,DB00316,Acetaminophen
,16615674,heart rate,"Her heart rate was 75 beats per minute, (bpm) and her blood pressure dropped from 70/50 to 50/00 mmHg.",Monitoring of verapamil enantiomers concentration in overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615674/),[beats] / [min],75,172338,DB00316,Acetaminophen
,16615674,serum concentrations,"On admission, R-(+)- and S-(-)-verapamil serum concentrations were 2252 ng/ml and 810 ng/ ml, respectively.",Monitoring of verapamil enantiomers concentration in overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615674/),[ng] / [ml],2252,172339,DB00316,Acetaminophen
,16615674,serum concentrations,"On admission, R-(+)- and S-(-)-verapamil serum concentrations were 2252 ng/ml and 810 ng/ ml, respectively.",Monitoring of verapamil enantiomers concentration in overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615674/),[ng] / [ml],810,172340,DB00316,Acetaminophen
,16615674,Terminal elimination half-lives,"Terminal elimination half-lives were 18.7 (21.3) and 17.0 (18.5) hours, respectively, for R-(+)- and S-(-)-verapamil.",Monitoring of verapamil enantiomers concentration in overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615674/),h,18.7,172341,DB00316,Acetaminophen
,16615674,Terminal elimination half-lives,"Terminal elimination half-lives were 18.7 (21.3) and 17.0 (18.5) hours, respectively, for R-(+)- and S-(-)-verapamil.",Monitoring of verapamil enantiomers concentration in overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615674/),h,17.0,172342,DB00316,Acetaminophen
,7579676,Bioavailability,Bioavailability of medication was significantly decreased (p < 0.01) 6 h (group 1) and 12 h (group 2) postoperatively.,Bioavailability of medication after laparoscopic cholecystectomy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7579676/),h,6,172547,DB00316,Acetaminophen
,7579676,Bioavailability,Bioavailability of medication was significantly decreased (p < 0.01) 6 h (group 1) and 12 h (group 2) postoperatively.,Bioavailability of medication after laparoscopic cholecystectomy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7579676/),h,12,172548,DB00316,Acetaminophen
,2925824,flow rate,The flow rate is 1.0 mL/min.,Determination of acetaminophen in human plasma by ion-pair reversed-phase high-performance liquid chromatography. Application to a single-dose pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2925824/),[ml] / [min],1.0,172781,DB00316,Acetaminophen
less,2925824,analysis time,"The analysis time of the assay is less than 15 min, and the limit of detection is 20 ng/mL for an 80-microL injection volume.",Determination of acetaminophen in human plasma by ion-pair reversed-phase high-performance liquid chromatography. Application to a single-dose pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2925824/),min,15,172782,DB00316,Acetaminophen
,2925824,limit of detection,"The analysis time of the assay is less than 15 min, and the limit of detection is 20 ng/mL for an 80-microL injection volume.",Determination of acetaminophen in human plasma by ion-pair reversed-phase high-performance liquid chromatography. Application to a single-dose pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2925824/),[ng] / [ml],20,172783,DB00316,Acetaminophen
,17163255,Maximum paracetamol concentration (C(max)),"Maximum paracetamol concentration (C(max)) in saliva was significantly decreased when co-administered with ciprofloxacin (19.50 vs 13.70 microg/mL, p < 0.05).",Oral ciprofloxacin affects the pharmacokinetics of paracetamol in saliva. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17163255/),[μg] / [ml],19.50,172930,DB00316,Acetaminophen
,17163255,Maximum paracetamol concentration (C(max)),"Maximum paracetamol concentration (C(max)) in saliva was significantly decreased when co-administered with ciprofloxacin (19.50 vs 13.70 microg/mL, p < 0.05).",Oral ciprofloxacin affects the pharmacokinetics of paracetamol in saliva. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17163255/),[μg] / [ml],13.70,172931,DB00316,Acetaminophen
,17163255,Time to paracetamol C(max),"Time to paracetamol C(max) was significantly increased (1.43h vs 0.77h; p < 0.05) and paracetamol half-life was prolonged (1.19 to 1.53h, p = 0.05) in the presence of ciprofloxacin, whereas the area under the concentration-time curve was not affected.",Oral ciprofloxacin affects the pharmacokinetics of paracetamol in saliva. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17163255/),h,1.43,172932,DB00316,Acetaminophen
,17163255,Time to paracetamol C(max),"Time to paracetamol C(max) was significantly increased (1.43h vs 0.77h; p < 0.05) and paracetamol half-life was prolonged (1.19 to 1.53h, p = 0.05) in the presence of ciprofloxacin, whereas the area under the concentration-time curve was not affected.",Oral ciprofloxacin affects the pharmacokinetics of paracetamol in saliva. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17163255/),h,0.77,172933,DB00316,Acetaminophen
,17163255,half-life,"Time to paracetamol C(max) was significantly increased (1.43h vs 0.77h; p < 0.05) and paracetamol half-life was prolonged (1.19 to 1.53h, p = 0.05) in the presence of ciprofloxacin, whereas the area under the concentration-time curve was not affected.",Oral ciprofloxacin affects the pharmacokinetics of paracetamol in saliva. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17163255/),h,1.19,172934,DB00316,Acetaminophen
,17163255,half-life,"Time to paracetamol C(max) was significantly increased (1.43h vs 0.77h; p < 0.05) and paracetamol half-life was prolonged (1.19 to 1.53h, p = 0.05) in the presence of ciprofloxacin, whereas the area under the concentration-time curve was not affected.",Oral ciprofloxacin affects the pharmacokinetics of paracetamol in saliva. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17163255/),h,1.53,172935,DB00316,Acetaminophen
,29898636,Time to reach maximum concentration,"Time to reach maximum concentration was 0.3, 4.8 and 3.7 h in control, 2 and 16-h pretreatment animals, respectively.",Effect of pretreatment regimens of 1-aminobenzotriazole on metabolism and gastric emptying of probe compounds in rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29898636/),h,0.3,173196,DB00316,Acetaminophen
,29898636,Time to reach maximum concentration,"Time to reach maximum concentration was 0.3, 4.8 and 3.7 h in control, 2 and 16-h pretreatment animals, respectively.",Effect of pretreatment regimens of 1-aminobenzotriazole on metabolism and gastric emptying of probe compounds in rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29898636/),h,4.8,173197,DB00316,Acetaminophen
,29898636,Time to reach maximum concentration,"Time to reach maximum concentration was 0.3, 4.8 and 3.7 h in control, 2 and 16-h pretreatment animals, respectively.",Effect of pretreatment regimens of 1-aminobenzotriazole on metabolism and gastric emptying of probe compounds in rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29898636/),h,3.7,173198,DB00316,Acetaminophen
,29898636,Time to reach maximum concentration,"Time to reach maximum concentration was 0.3, 4.8 and 3.7 h in control, 2 and 16-h pretreatment animals, respectively.",Effect of pretreatment regimens of 1-aminobenzotriazole on metabolism and gastric emptying of probe compounds in rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29898636/),h,2,173199,DB00316,Acetaminophen
,29898636,Time to reach maximum concentration,"Time to reach maximum concentration was 0.3, 4.8 and 3.7 h in control, 2 and 16-h pretreatment animals, respectively.",Effect of pretreatment regimens of 1-aminobenzotriazole on metabolism and gastric emptying of probe compounds in rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29898636/),h,16,173200,DB00316,Acetaminophen
,29898636,mean absorption time (MAT),"In the case of acetaminophen, where Tmax was not delayed, the mean absorption time (MAT) in control, 2 and 16 h ABT pretreatment groups were 0.3, 4.6 and 2.9 h, respectively, suggesting delayed absorption.",Effect of pretreatment regimens of 1-aminobenzotriazole on metabolism and gastric emptying of probe compounds in rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29898636/),h,0.3,173201,DB00316,Acetaminophen
,29898636,mean absorption time (MAT),"In the case of acetaminophen, where Tmax was not delayed, the mean absorption time (MAT) in control, 2 and 16 h ABT pretreatment groups were 0.3, 4.6 and 2.9 h, respectively, suggesting delayed absorption.",Effect of pretreatment regimens of 1-aminobenzotriazole on metabolism and gastric emptying of probe compounds in rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29898636/),h,4.6,173202,DB00316,Acetaminophen
,29898636,mean absorption time (MAT),"In the case of acetaminophen, where Tmax was not delayed, the mean absorption time (MAT) in control, 2 and 16 h ABT pretreatment groups were 0.3, 4.6 and 2.9 h, respectively, suggesting delayed absorption.",Effect of pretreatment regimens of 1-aminobenzotriazole on metabolism and gastric emptying of probe compounds in rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29898636/),h,2.9,173203,DB00316,Acetaminophen
,1820937,bioavailability,Oral paracetamol bioavailability reduction (24%) was observed by coadministration of tolmetin in the rat.,Reduction of oral bioavailability of paracetamol by tolmetin in rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820937/),%,24,173344,DB00316,Acetaminophen
,23249424,percentage drug release,CP9 (66% carbopol and compression load of 6 ton) with a percentage drug release of 89.03 after 12 hours were found to be most comparable to the marketed product in terms of similarity factor and most appropriately fits to zero-order kinetics.,"Design, development and in vitro-in vivo study of tramadol-paracetamol inlay tablets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23249424/),,89.03,174767,DB00316,Acetaminophen
,24905322,t(max),The comparison of the difference for the effervescent and conventional formulation gave an estimated decrease in t(max) of 0.5 h for paracetamol and 0.13 h for tramadol.,The pharmacokinetics of the effervescent vs. conventional tramadol/paracetamol fixed-dose combination tablet in patients after total gastric resection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24905322/),h,0.5,174987,DB00316,Acetaminophen
,24905322,t(max),The comparison of the difference for the effervescent and conventional formulation gave an estimated decrease in t(max) of 0.5 h for paracetamol and 0.13 h for tramadol.,The pharmacokinetics of the effervescent vs. conventional tramadol/paracetamol fixed-dose combination tablet in patients after total gastric resection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24905322/),h,0.13,174988,DB00316,Acetaminophen
,24846170,central,"The population mean estimate (CV%) for central (plasma) volume of distribution of parent acetaminophen (VC) was 13.9 (4.41) L, peripheral (tissue) volume of distribution (VT) was 50.9 (2.96) L, and intercompartmental clearance (Q) was 77.5 (9.29) L/h.",Population pharmacokinetics of intravenous acetaminophen and its metabolites in major surgical patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846170/),l,13.9,175330,DB00316,Acetaminophen
,24846170,peripheral,"The population mean estimate (CV%) for central (plasma) volume of distribution of parent acetaminophen (VC) was 13.9 (4.41) L, peripheral (tissue) volume of distribution (VT) was 50.9 (2.96) L, and intercompartmental clearance (Q) was 77.5 (9.29) L/h.",Population pharmacokinetics of intravenous acetaminophen and its metabolites in major surgical patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846170/),l,50.9,175331,DB00316,Acetaminophen
,24846170,intercompartmental clearance (Q),"The population mean estimate (CV%) for central (plasma) volume of distribution of parent acetaminophen (VC) was 13.9 (4.41) L, peripheral (tissue) volume of distribution (VT) was 50.9 (2.96) L, and intercompartmental clearance (Q) was 77.5 (9.29) L/h.",Population pharmacokinetics of intravenous acetaminophen and its metabolites in major surgical patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846170/),[l] / [h],77.5,175332,DB00316,Acetaminophen
,24846170,metabolic clearances,"The population mean (CV%) metabolic clearances for glucuronidation (CLPG) was 8.92 (3.25) L/h, sulfation (CLPS) was 0.903 (3.47) L/h, and oxidation (CLPO) was 0.533 (7.90) L/h.",Population pharmacokinetics of intravenous acetaminophen and its metabolites in major surgical patients. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846170/),[l] / [h],8.92,175333,DB00316,Acetaminophen
,24846170,sulfation,"The population mean (CV%) metabolic clearances for glucuronidation (CLPG) was 8.92 (3.25) L/h, sulfation (CLPS) was 0.903 (3.47) L/h, and oxidation (CLPO) was 0.533 (7.90) L/h.",Population pharmacokinetics of intravenous acetaminophen and its metabolites in major surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846170/),[l] / [h],0.903,175334,DB00316,Acetaminophen
,24846170,oxidation,"The population mean (CV%) metabolic clearances for glucuronidation (CLPG) was 8.92 (3.25) L/h, sulfation (CLPS) was 0.903 (3.47) L/h, and oxidation (CLPO) was 0.533 (7.90) L/h.",Population pharmacokinetics of intravenous acetaminophen and its metabolites in major surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846170/),[l] / [h],0.533,175335,DB00316,Acetaminophen
,24846170,urinary clearances,"The population mean (CV%) urinary clearances of parent acetaminophen (CLRP) was 0.137 (5.46) L/h, acetaminophen glucuronide (CLRG) was 3.81 (6.71) L/h, acetaminophen sulfate (CLRS) was 3.13 (4.32) L/h, and acetaminophen cysteine + mercapturate (CLRO) was 3.51 (9.98) L/h.",Population pharmacokinetics of intravenous acetaminophen and its metabolites in major surgical patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846170/),[l] / [h],0.137,175336,DB00316,Acetaminophen
,24846170,urinary clearances,"The population mean (CV%) urinary clearances of parent acetaminophen (CLRP) was 0.137 (5.46) L/h, acetaminophen glucuronide (CLRG) was 3.81 (6.71) L/h, acetaminophen sulfate (CLRS) was 3.13 (4.32) L/h, and acetaminophen cysteine + mercapturate (CLRO) was 3.51 (9.98) L/h.",Population pharmacokinetics of intravenous acetaminophen and its metabolites in major surgical patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846170/),[l] / [h],3.81,175337,DB00316,Acetaminophen
,24846170,urinary clearances,"The population mean (CV%) urinary clearances of parent acetaminophen (CLRP) was 0.137 (5.46) L/h, acetaminophen glucuronide (CLRG) was 3.81 (6.71) L/h, acetaminophen sulfate (CLRS) was 3.13 (4.32) L/h, and acetaminophen cysteine + mercapturate (CLRO) was 3.51 (9.98) L/h.",Population pharmacokinetics of intravenous acetaminophen and its metabolites in major surgical patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846170/),[l] / [h],3.13,175338,DB00316,Acetaminophen
,24846170,urinary clearances,"The population mean (CV%) urinary clearances of parent acetaminophen (CLRP) was 0.137 (5.46) L/h, acetaminophen glucuronide (CLRG) was 3.81 (6.71) L/h, acetaminophen sulfate (CLRS) was 3.13 (4.32) L/h, and acetaminophen cysteine + mercapturate (CLRO) was 3.51 (9.98) L/h.",Population pharmacokinetics of intravenous acetaminophen and its metabolites in major surgical patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846170/),[l] / [h],3.51,175339,DB00316,Acetaminophen
,21704237,"T(max,ss)","The T(max,ss) for tramadol was delayed until 3 hours after the ER treatment, compared with 1 hour after the IR treatment, whereas the T(max,ss) of acetaminophen was 30 minutes after each treatment.","Pharmacokinetics of extended-release versus conventional tramadol/acetaminophen fixed-dose combination tablets: an open-label, 2-treatment, multiple-dose, randomized-sequence crossover study in healthy korean male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704237/),h,3,176623,DB00316,Acetaminophen
,21704237,"T(max,ss)","The T(max,ss) for tramadol was delayed until 3 hours after the ER treatment, compared with 1 hour after the IR treatment, whereas the T(max,ss) of acetaminophen was 30 minutes after each treatment.","Pharmacokinetics of extended-release versus conventional tramadol/acetaminophen fixed-dose combination tablets: an open-label, 2-treatment, multiple-dose, randomized-sequence crossover study in healthy korean male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704237/),,1,176624,DB00316,Acetaminophen
,21704237,"T(max,ss)","The T(max,ss) for tramadol was delayed until 3 hours after the ER treatment, compared with 1 hour after the IR treatment, whereas the T(max,ss) of acetaminophen was 30 minutes after each treatment.","Pharmacokinetics of extended-release versus conventional tramadol/acetaminophen fixed-dose combination tablets: an open-label, 2-treatment, multiple-dose, randomized-sequence crossover study in healthy korean male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704237/),min,30,176625,DB00316,Acetaminophen
,21704237,"AUC(0-12,ss)","The mean (SD) of AUC(0-12,ss) in the IR and ER formulations was 2789.0 (507.7) and 2638.7 (469.1) µg/h/L for tramadol and 42,635.0 (8711.2) and 40,394.3 (10,127.7) µg/h/L for acetaminophen, respectively.","Pharmacokinetics of extended-release versus conventional tramadol/acetaminophen fixed-dose combination tablets: an open-label, 2-treatment, multiple-dose, randomized-sequence crossover study in healthy korean male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704237/),[μg] / [h·l],2789.0,176626,DB00316,Acetaminophen
,21704237,"AUC(0-12,ss)","The mean (SD) of AUC(0-12,ss) in the IR and ER formulations was 2789.0 (507.7) and 2638.7 (469.1) µg/h/L for tramadol and 42,635.0 (8711.2) and 40,394.3 (10,127.7) µg/h/L for acetaminophen, respectively.","Pharmacokinetics of extended-release versus conventional tramadol/acetaminophen fixed-dose combination tablets: an open-label, 2-treatment, multiple-dose, randomized-sequence crossover study in healthy korean male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704237/),[μg] / [h·l],2638.7,176627,DB00316,Acetaminophen
,21704237,"AUC(0-12,ss)","The mean (SD) of AUC(0-12,ss) in the IR and ER formulations was 2789.0 (507.7) and 2638.7 (469.1) µg/h/L for tramadol and 42,635.0 (8711.2) and 40,394.3 (10,127.7) µg/h/L for acetaminophen, respectively.","Pharmacokinetics of extended-release versus conventional tramadol/acetaminophen fixed-dose combination tablets: an open-label, 2-treatment, multiple-dose, randomized-sequence crossover study in healthy korean male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704237/),[μg] / [h·l],"42,635.0",176628,DB00316,Acetaminophen
,21704237,"AUC(0-12,ss)","The mean (SD) of AUC(0-12,ss) in the IR and ER formulations was 2789.0 (507.7) and 2638.7 (469.1) µg/h/L for tramadol and 42,635.0 (8711.2) and 40,394.3 (10,127.7) µg/h/L for acetaminophen, respectively.","Pharmacokinetics of extended-release versus conventional tramadol/acetaminophen fixed-dose combination tablets: an open-label, 2-treatment, multiple-dose, randomized-sequence crossover study in healthy korean male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704237/),[μg] / [h·l],"40,394.3",176629,DB00316,Acetaminophen
,20949310,kg1,"The final model has two gastric emptying rate constant parameters: kg1 (1.30 h(-1), RSE=53.84%, T1/2=0.53 h) for the intolerant group before prokinetic therapy and kg2 (27.8 h(-1), RSE=59.35%, T1/2=0.025 h) for both the intolerant group after prokinetic therapy and the tolerant group.",A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20949310/),1/[h],1.30,177285,DB00316,Acetaminophen
,20949310,T1/2,"The final model has two gastric emptying rate constant parameters: kg1 (1.30 h(-1), RSE=53.84%, T1/2=0.53 h) for the intolerant group before prokinetic therapy and kg2 (27.8 h(-1), RSE=59.35%, T1/2=0.025 h) for both the intolerant group after prokinetic therapy and the tolerant group.",A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20949310/),h,0.53,177286,DB00316,Acetaminophen
,20949310,kg2,"The final model has two gastric emptying rate constant parameters: kg1 (1.30 h(-1), RSE=53.84%, T1/2=0.53 h) for the intolerant group before prokinetic therapy and kg2 (27.8 h(-1), RSE=59.35%, T1/2=0.025 h) for both the intolerant group after prokinetic therapy and the tolerant group.",A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20949310/),1/[h],27.8,177287,DB00316,Acetaminophen
,20949310,T1/2,"The final model has two gastric emptying rate constant parameters: kg1 (1.30 h(-1), RSE=53.84%, T1/2=0.53 h) for the intolerant group before prokinetic therapy and kg2 (27.8 h(-1), RSE=59.35%, T1/2=0.025 h) for both the intolerant group after prokinetic therapy and the tolerant group.",A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20949310/),h,0.025,177288,DB00316,Acetaminophen
,20949310,ka,"Other parameters and estimates (RSE) in the model were ka=5.12 h(-1) (28.13%), CL=13.0 L/h (19.62%), CLD=22.6 L/h (19.78%), V1=63.8 L (12.79%) and V2=69 L (38.70%).",A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20949310/),1/[h],5.12,177289,DB00316,Acetaminophen
,20949310,CL,"Other parameters and estimates (RSE) in the model were ka=5.12 h(-1) (28.13%), CL=13.0 L/h (19.62%), CLD=22.6 L/h (19.78%), V1=63.8 L (12.79%) and V2=69 L (38.70%).",A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20949310/),[l] / [h],13.0,177290,DB00316,Acetaminophen
,20949310,CLD,"Other parameters and estimates (RSE) in the model were ka=5.12 h(-1) (28.13%), CL=13.0 L/h (19.62%), CLD=22.6 L/h (19.78%), V1=63.8 L (12.79%) and V2=69 L (38.70%).",A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20949310/),[l] / [h],22.6,177291,DB00316,Acetaminophen
,20949310,V1,"Other parameters and estimates (RSE) in the model were ka=5.12 h(-1) (28.13%), CL=13.0 L/h (19.62%), CLD=22.6 L/h (19.78%), V1=63.8 L (12.79%) and V2=69 L (38.70%).",A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20949310/),l,63.8,177292,DB00316,Acetaminophen
,20949310,V2,"Other parameters and estimates (RSE) in the model were ka=5.12 h(-1) (28.13%), CL=13.0 L/h (19.62%), CLD=22.6 L/h (19.78%), V1=63.8 L (12.79%) and V2=69 L (38.70%).",A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20949310/),l,69,177293,DB00316,Acetaminophen
,11064607,time to reach 90% of the steady state concentration,Mean (SD) time to reach 90% of the steady state concentration was 11.4 (8.6) h.,Pharmacokinetics of rectal paracetamol after repeated dosing in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11064607/),h,11.4,177468,DB00316,Acetaminophen
,21369441,T(max),"Maximum concentration was observed at 6.5 h after administration in sham group with a concentration of 439.6 ng/ml, whereas in SCI group T(max) was at 2.7 h with a concentration of 2763.9 ng/ml.",Amitriptyline pharmacokinetics in experimental spinal cord injury in the rabbit. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21369441/),h,2.7,177469,DB00316,Acetaminophen
,21369441,T(max),"Maximum concentration was observed at 6.5 h after administration in sham group with a concentration of 439.6 ng/ml, whereas in SCI group T(max) was at 2.7 h with a concentration of 2763.9 ng/ml.",Amitriptyline pharmacokinetics in experimental spinal cord injury in the rabbit. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21369441/),[ng] / [ml],2763.9,177470,DB00316,Acetaminophen
,21369441,AUC,"In SCI group, AUC was 9465.6 ng.h/ml and half life was 6 h and for control group it was 2817.4 ng.h/ml and 6.4 h, respectively.",Amitriptyline pharmacokinetics in experimental spinal cord injury in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21369441/),[h·ng] / [ml],9465.6,177471,DB00316,Acetaminophen
,21369441,half life,"In SCI group, AUC was 9465.6 ng.h/ml and half life was 6 h and for control group it was 2817.4 ng.h/ml and 6.4 h, respectively.",Amitriptyline pharmacokinetics in experimental spinal cord injury in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21369441/),h,6,177472,DB00316,Acetaminophen
,21369441,half life,"In SCI group, AUC was 9465.6 ng.h/ml and half life was 6 h and for control group it was 2817.4 ng.h/ml and 6.4 h, respectively.",Amitriptyline pharmacokinetics in experimental spinal cord injury in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21369441/),[h·ng] / [ml],2817.4,177473,DB00316,Acetaminophen
,21369441,half life,"In SCI group, AUC was 9465.6 ng.h/ml and half life was 6 h and for control group it was 2817.4 ng.h/ml and 6.4 h, respectively.",Amitriptyline pharmacokinetics in experimental spinal cord injury in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21369441/),h,6.4,177474,DB00316,Acetaminophen
,11741234,CLR,"CLR of AS was 19.5 and 12.9 (mL/min per kg) and CLf of AS was 10.4 and 6.7 mL/min per kg for homozygous and heterozygous males, respectively, which was significantly different between groups.",Disposition of acetaminophen and indocyanine green in cystic fibrosis-knockout mice. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11741234/),[ml] / [kg·min],19.5,178099,DB00316,Acetaminophen
,11741234,CLR,"CLR of AS was 19.5 and 12.9 (mL/min per kg) and CLf of AS was 10.4 and 6.7 mL/min per kg for homozygous and heterozygous males, respectively, which was significantly different between groups.",Disposition of acetaminophen and indocyanine green in cystic fibrosis-knockout mice. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11741234/),[ml] / [kg·min],12.9,178100,DB00316,Acetaminophen
,11741234,CLf,"CLR of AS was 19.5 and 12.9 (mL/min per kg) and CLf of AS was 10.4 and 6.7 mL/min per kg for homozygous and heterozygous males, respectively, which was significantly different between groups.",Disposition of acetaminophen and indocyanine green in cystic fibrosis-knockout mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11741234/),[ml] / [kg·min],10.4,178101,DB00316,Acetaminophen
,11741234,CLf,"CLR of AS was 19.5 and 12.9 (mL/min per kg) and CLf of AS was 10.4 and 6.7 mL/min per kg for homozygous and heterozygous males, respectively, which was significantly different between groups.",Disposition of acetaminophen and indocyanine green in cystic fibrosis-knockout mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11741234/),[ml] / [kg·min],6.7,178102,DB00316,Acetaminophen
,11741234,CLR,"CLR of AG was 6.3 and 4.8 mL/min per kg and CLf of AG was 9.6 and 8.9 mL/min per kg for homozygous and heterozygous males, respectively, although not reaching statistical significance.",Disposition of acetaminophen and indocyanine green in cystic fibrosis-knockout mice. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11741234/),[ml] / [kg·min],6.3,178103,DB00316,Acetaminophen
,11741234,CLR,"CLR of AG was 6.3 and 4.8 mL/min per kg and CLf of AG was 9.6 and 8.9 mL/min per kg for homozygous and heterozygous males, respectively, although not reaching statistical significance.",Disposition of acetaminophen and indocyanine green in cystic fibrosis-knockout mice. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11741234/),[ml] / [kg·min],4.8,178104,DB00316,Acetaminophen
,11741234,CLf,"CLR of AG was 6.3 and 4.8 mL/min per kg and CLf of AG was 9.6 and 8.9 mL/min per kg for homozygous and heterozygous males, respectively, although not reaching statistical significance.",Disposition of acetaminophen and indocyanine green in cystic fibrosis-knockout mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11741234/),[ml] / [kg·min],9.6,178105,DB00316,Acetaminophen
,11741234,CLf,"CLR of AG was 6.3 and 4.8 mL/min per kg and CLf of AG was 9.6 and 8.9 mL/min per kg for homozygous and heterozygous males, respectively, although not reaching statistical significance.",Disposition of acetaminophen and indocyanine green in cystic fibrosis-knockout mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11741234/),[ml] / [kg·min],8.9,178106,DB00316,Acetaminophen
,11741234,apparent volume of distribution,Homozygous females showed a higher apparent volume of distribution (96 mL/kg) relative to heterozygous females (72 mL/kg).,Disposition of acetaminophen and indocyanine green in cystic fibrosis-knockout mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11741234/),[ml] / [kg],96,178107,DB00316,Acetaminophen
,11741234,apparent volume of distribution,Homozygous females showed a higher apparent volume of distribution (96 mL/kg) relative to heterozygous females (72 mL/kg).,Disposition of acetaminophen and indocyanine green in cystic fibrosis-knockout mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11741234/),[ml] / [kg],72,178108,DB00316,Acetaminophen
,30607,availability after the first-pass hepatic extraction,"After the simultaneous administration of an iv dose of 14C-acetaminophen and an intraportal dose of 3H-acetaminophen to rats, the availability after the first-pass hepatic extraction of acetaminophen in rats was 0.56 +/- 0.05.",Complications in the estimation of hepatic blood flow in vivo by pharmacokinetic parameters. The area under the curve after the concomitant intravenous and intraperitoneal (or intraportal) administration of acetaminophen in the rat. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30607/),,0.56,178119,DB00316,Acetaminophen
,30607,Hepatic blood flow,Hepatic blood flow estimated by the area under the curve for the respective routes of administration was 78.1 +/- 16.1 ml/min/kg.,Complications in the estimation of hepatic blood flow in vivo by pharmacokinetic parameters. The area under the curve after the concomitant intravenous and intraperitoneal (or intraportal) administration of acetaminophen in the rat. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30607/),[ml] / [kg·min],78.1,178120,DB00316,Acetaminophen
,30607,area under the curve,Hepatic blood flow estimated by the area under the curve for the respective routes of administration was 78.1 +/- 16.1 ml/min/kg.,Complications in the estimation of hepatic blood flow in vivo by pharmacokinetic parameters. The area under the curve after the concomitant intravenous and intraperitoneal (or intraportal) administration of acetaminophen in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30607/),[ml] / [kg·min],78.1,178121,DB00316,Acetaminophen
,30607,apparent availabilities,"However, after the simultaneous administration of an iv tracer dose of 14C-acetaminophen and an ip dose of 3H-acetaminophen, the apparent availabilities calculated from the areas under the curve were highly variable and tended to be greater (0.73 +/- 0.11).",Complications in the estimation of hepatic blood flow in vivo by pharmacokinetic parameters. The area under the curve after the concomitant intravenous and intraperitoneal (or intraportal) administration of acetaminophen in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30607/),,0.73,178122,DB00316,Acetaminophen
,30607,hepatic blood flow,Thus the estimates of the hepatic blood flow also tended to be higher (159 +/- 65 ml/min/kg).,Complications in the estimation of hepatic blood flow in vivo by pharmacokinetic parameters. The area under the curve after the concomitant intravenous and intraperitoneal (or intraportal) administration of acetaminophen in the rat. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30607/),[ml] / [kg·min],159,178123,DB00316,Acetaminophen
,11226108,peak concentrations,"Observed peak concentrations were larger in the Ropivacaine group (4.25 [2.07-6.59 mg/L] vs 3.02 [0.98-5.82 mg/L]), but time to reach peak concentrations was comparable (5 [1-15 min] vs 5 [0-45 min] in the Ropivacaine and Bupivacaine groups, respectively).",A comparison of ropivacaine and bupivacaine for cervical plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11226108/),[mg] / [l],4.25,178162,DB00316,Acetaminophen
,11226108,peak concentrations,"Observed peak concentrations were larger in the Ropivacaine group (4.25 [2.07-6.59 mg/L] vs 3.02 [0.98-5.82 mg/L]), but time to reach peak concentrations was comparable (5 [1-15 min] vs 5 [0-45 min] in the Ropivacaine and Bupivacaine groups, respectively).",A comparison of ropivacaine and bupivacaine for cervical plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11226108/),[mg] / [l],3.02,178163,DB00316,Acetaminophen
,11226108,time to reach peak concentrations,"Observed peak concentrations were larger in the Ropivacaine group (4.25 [2.07-6.59 mg/L] vs 3.02 [0.98-5.82 mg/L]), but time to reach peak concentrations was comparable (5 [1-15 min] vs 5 [0-45 min] in the Ropivacaine and Bupivacaine groups, respectively).",A comparison of ropivacaine and bupivacaine for cervical plexus block. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11226108/),,5,178164,DB00316,Acetaminophen
,11226108,time to reach peak concentrations,"Observed peak concentrations were larger in the Ropivacaine group (4.25 [2.07-6.59 mg/L] vs 3.02 [0.98-5.82 mg/L]), but time to reach peak concentrations was comparable (5 [1-15 min] vs 5 [0-45 min] in the Ropivacaine and Bupivacaine groups, respectively).",A comparison of ropivacaine and bupivacaine for cervical plexus block. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11226108/),,5,178165,DB00316,Acetaminophen
,6897933,elimination half-life,Oral contraceptive steroid subjects had a lower elimination half-life of acetaminophen (2.12 hours) than controls (2.71 hours) (P less than .005).,Increased metabolic clearance of acetaminophen with oral contraceptive use. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6897933/),h,2.12,179262,DB00316,Acetaminophen
,6897933,elimination half-life,Oral contraceptive steroid subjects had a lower elimination half-life of acetaminophen (2.12 hours) than controls (2.71 hours) (P less than .005).,Increased metabolic clearance of acetaminophen with oral contraceptive use. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6897933/),h,2.71,179263,DB00316,Acetaminophen
,6897933,Volume of distribution,"Volume of distribution was similar for both groups (oral contraceptive group, 1.04 liters/kg; controls, 0.96 liters/kg; NS).",Increased metabolic clearance of acetaminophen with oral contraceptive use. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6897933/),[l] / [kg],1.04,179264,DB00316,Acetaminophen
,6897933,Volume of distribution,"Volume of distribution was similar for both groups (oral contraceptive group, 1.04 liters/kg; controls, 0.96 liters/kg; NS).",Increased metabolic clearance of acetaminophen with oral contraceptive use. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6897933/),[l] / [kg],0.96,179265,DB00316,Acetaminophen
,6897933,Total metabolic clearance,"Total metabolic clearance was significantly higher in oral contraceptive subjects (5.81 ml/min/kg, versus 4.12 ml/min/kg for controls; P less than .02).",Increased metabolic clearance of acetaminophen with oral contraceptive use. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6897933/),[ml] / [kg·min],5.81,179266,DB00316,Acetaminophen
,6897933,Total metabolic clearance,"Total metabolic clearance was significantly higher in oral contraceptive subjects (5.81 ml/min/kg, versus 4.12 ml/min/kg for controls; P less than .02).",Increased metabolic clearance of acetaminophen with oral contraceptive use. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6897933/),[ml] / [kg·min],4.12,179267,DB00316,Acetaminophen
,21543038,half-life of elimination,"The half-life of elimination of teicoplanin in the elimination phase is about 108 h, which is long.",The persistence of drug-induced fever by teicoplanin--a case report. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21543038/),h,108,179874,DB00316,Acetaminophen
,27127912,Cmax,"The main pharmacokinetic parameters for paracetamol after iv and po administration to patients with CP were as follows: Cmax, 19.00 [4.50] and Cmax, 9.26 [3.35]μg/ml; AUC0-t, 42.37 [13.92] and 36.68 [11.7]μg×h/mL, respectively.",Pharmacokinetics of paracetamol in patients with chronic pancreatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27127912/),[μg] / [ml],19.00,180064,DB00316,Acetaminophen
,27127912,Cmax,"The main pharmacokinetic parameters for paracetamol after iv and po administration to patients with CP were as follows: Cmax, 19.00 [4.50] and Cmax, 9.26 [3.35]μg/ml; AUC0-t, 42.37 [13.92] and 36.68 [11.7]μg×h/mL, respectively.",Pharmacokinetics of paracetamol in patients with chronic pancreatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27127912/),[μg] / [ml],9.26,180065,DB00316,Acetaminophen
,27127912,AUC0-t,"The main pharmacokinetic parameters for paracetamol after iv and po administration to patients with CP were as follows: Cmax, 19.00 [4.50] and Cmax, 9.26 [3.35]μg/ml; AUC0-t, 42.37 [13.92] and 36.68 [11.7]μg×h/mL, respectively.",Pharmacokinetics of paracetamol in patients with chronic pancreatitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27127912/),[h·μg] / [ml],42.37,180066,DB00316,Acetaminophen
,27127912,AUC0-t,"The main pharmacokinetic parameters for paracetamol after iv and po administration to patients with CP were as follows: Cmax, 19.00 [4.50] and Cmax, 9.26 [3.35]μg/ml; AUC0-t, 42.37 [13.92] and 36.68 [11.7]μg×h/mL, respectively.",Pharmacokinetics of paracetamol in patients with chronic pancreatitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27127912/),[h·μg] / [ml],36.68,180067,DB00316,Acetaminophen
,6705446,ClAP,"In contrast, sulfinpyrazone pretreatment increased ClAP by 23% (from 5.70 +/- 0.21 to 7.00 +/- 0.39 ml/min/kg) and ClAP was 46% greater in the epileptic subjects who received anticonvulsant drugs than in the control group (8.32 +/- 0.45 and 5.70 +/- 0.21 ml/ml/kg).",Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705446/),[ml] / [kg·min],5.70,180973,DB00316,Acetaminophen
,6705446,ClAP,"In contrast, sulfinpyrazone pretreatment increased ClAP by 23% (from 5.70 +/- 0.21 to 7.00 +/- 0.39 ml/min/kg) and ClAP was 46% greater in the epileptic subjects who received anticonvulsant drugs than in the control group (8.32 +/- 0.45 and 5.70 +/- 0.21 ml/ml/kg).",Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705446/),[ml] / [kg·min],7.00,180974,DB00316,Acetaminophen
,6705446,ClAP,"In contrast, sulfinpyrazone pretreatment increased ClAP by 23% (from 5.70 +/- 0.21 to 7.00 +/- 0.39 ml/min/kg) and ClAP was 46% greater in the epileptic subjects who received anticonvulsant drugs than in the control group (8.32 +/- 0.45 and 5.70 +/- 0.21 ml/ml/kg).",Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705446/),[ml] / [kg·ml],8.32,180975,DB00316,Acetaminophen
,6705446,ClAP,"In contrast, sulfinpyrazone pretreatment increased ClAP by 23% (from 5.70 +/- 0.21 to 7.00 +/- 0.39 ml/min/kg) and ClAP was 46% greater in the epileptic subjects who received anticonvulsant drugs than in the control group (8.32 +/- 0.45 and 5.70 +/- 0.21 ml/ml/kg).",Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705446/),[ml] / [kg·ml],5.70,180976,DB00316,Acetaminophen
,7634805,number of contractions,"Compared with placebo, the mean number of contractions (104 +/- 34 vs. 5 +/- 8; p = .003), the mean amplitude of contractions (52 +/- 16 vs. 20 +/- 17 mm Hg; p = .005), and the Motility Index (13.06 +/- 0.95 vs. 4.45 +/- 3.54; p = .004) were significantly increased during the first hour after erythromycin infusion compared with placebo.","Effect of erythromycin on gastric motility in mechanically ventilated critically ill patients: a double-blind, randomized, placebo-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7634805/),,104,182846,DB00316,Acetaminophen
,7634805,number of contractions,"Compared with placebo, the mean number of contractions (104 +/- 34 vs. 5 +/- 8; p = .003), the mean amplitude of contractions (52 +/- 16 vs. 20 +/- 17 mm Hg; p = .005), and the Motility Index (13.06 +/- 0.95 vs. 4.45 +/- 3.54; p = .004) were significantly increased during the first hour after erythromycin infusion compared with placebo.","Effect of erythromycin on gastric motility in mechanically ventilated critically ill patients: a double-blind, randomized, placebo-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7634805/),,5,182847,DB00316,Acetaminophen
,7634805,amplitude of contractions,"Compared with placebo, the mean number of contractions (104 +/- 34 vs. 5 +/- 8; p = .003), the mean amplitude of contractions (52 +/- 16 vs. 20 +/- 17 mm Hg; p = .005), and the Motility Index (13.06 +/- 0.95 vs. 4.45 +/- 3.54; p = .004) were significantly increased during the first hour after erythromycin infusion compared with placebo.","Effect of erythromycin on gastric motility in mechanically ventilated critically ill patients: a double-blind, randomized, placebo-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7634805/),hg·mm,52,182848,DB00316,Acetaminophen
,7634805,amplitude of contractions,"Compared with placebo, the mean number of contractions (104 +/- 34 vs. 5 +/- 8; p = .003), the mean amplitude of contractions (52 +/- 16 vs. 20 +/- 17 mm Hg; p = .005), and the Motility Index (13.06 +/- 0.95 vs. 4.45 +/- 3.54; p = .004) were significantly increased during the first hour after erythromycin infusion compared with placebo.","Effect of erythromycin on gastric motility in mechanically ventilated critically ill patients: a double-blind, randomized, placebo-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7634805/),hg·mm,20,182849,DB00316,Acetaminophen
,7634805,Motility Index,"Compared with placebo, the mean number of contractions (104 +/- 34 vs. 5 +/- 8; p = .003), the mean amplitude of contractions (52 +/- 16 vs. 20 +/- 17 mm Hg; p = .005), and the Motility Index (13.06 +/- 0.95 vs. 4.45 +/- 3.54; p = .004) were significantly increased during the first hour after erythromycin infusion compared with placebo.","Effect of erythromycin on gastric motility in mechanically ventilated critically ill patients: a double-blind, randomized, placebo-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7634805/),,13.06,182850,DB00316,Acetaminophen
,7634805,Motility Index,"Compared with placebo, the mean number of contractions (104 +/- 34 vs. 5 +/- 8; p = .003), the mean amplitude of contractions (52 +/- 16 vs. 20 +/- 17 mm Hg; p = .005), and the Motility Index (13.06 +/- 0.95 vs. 4.45 +/- 3.54; p = .004) were significantly increased during the first hour after erythromycin infusion compared with placebo.","Effect of erythromycin on gastric motility in mechanically ventilated critically ill patients: a double-blind, randomized, placebo-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7634805/),,4.45,182851,DB00316,Acetaminophen
,7634805,time to reach the peak acetaminophen concentration,The following data were noted after erythromycin was infused: a) the time to reach the peak acetaminophen concentration was shorter (32 +/- 8 vs. 171 +/- 93 mins; p = .007); b) the maximal acetaminophen concentration was higher (22.09 +/- 6.23 vs.,"Effect of erythromycin on gastric motility in mechanically ventilated critically ill patients: a double-blind, randomized, placebo-controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7634805/),min,32,182852,DB00316,Acetaminophen
,7634805,time to reach the peak acetaminophen concentration,The following data were noted after erythromycin was infused: a) the time to reach the peak acetaminophen concentration was shorter (32 +/- 8 vs. 171 +/- 93 mins; p = .007); b) the maximal acetaminophen concentration was higher (22.09 +/- 6.23 vs.,"Effect of erythromycin on gastric motility in mechanically ventilated critically ill patients: a double-blind, randomized, placebo-controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7634805/),min,171,182853,DB00316,Acetaminophen
,7634805,maximal acetaminophen concentration,The following data were noted after erythromycin was infused: a) the time to reach the peak acetaminophen concentration was shorter (32 +/- 8 vs. 171 +/- 93 mins; p = .007); b) the maximal acetaminophen concentration was higher (22.09 +/- 6.23 vs.,"Effect of erythromycin on gastric motility in mechanically ventilated critically ill patients: a double-blind, randomized, placebo-controlled study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7634805/),,22.09,182854,DB00316,Acetaminophen
,7634805,area under the concentration-time curve at 60 mins,5.38 +/- 3.80 micrograms/mL; p = .007); and c) the area under the concentration-time curve at 60 mins increased markedly (730 +/- 269 vs. 72 +/- 42 micrograms/min/mL; p = .002) as compared with placebo.,"Effect of erythromycin on gastric motility in mechanically ventilated critically ill patients: a double-blind, randomized, placebo-controlled study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7634805/),[μg] / [min·ml],730,182855,DB00316,Acetaminophen
,7634805,area under the concentration-time curve at 60 mins,5.38 +/- 3.80 micrograms/mL; p = .007); and c) the area under the concentration-time curve at 60 mins increased markedly (730 +/- 269 vs. 72 +/- 42 micrograms/min/mL; p = .002) as compared with placebo.,"Effect of erythromycin on gastric motility in mechanically ventilated critically ill patients: a double-blind, randomized, placebo-controlled study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7634805/),[μg] / [min·ml],72,182856,DB00316,Acetaminophen
,1878532,mean residence time (MRT),Values for the mean residence time (MRT) were increased from 5.2 h for an oral solution to 10.2 and 13.3 h for two GMS formulations after single dosing.,Kinetics of acetaminophen after single- and multiple-dose oral administration as a gradient matrix system to healthy male subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1878532/),h,5.2,183450,DB00316,Acetaminophen
,1878532,mean residence time (MRT),Values for the mean residence time (MRT) were increased from 5.2 h for an oral solution to 10.2 and 13.3 h for two GMS formulations after single dosing.,Kinetics of acetaminophen after single- and multiple-dose oral administration as a gradient matrix system to healthy male subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1878532/),h,10.2,183451,DB00316,Acetaminophen
,1878532,mean residence time (MRT),Values for the mean residence time (MRT) were increased from 5.2 h for an oral solution to 10.2 and 13.3 h for two GMS formulations after single dosing.,Kinetics of acetaminophen after single- and multiple-dose oral administration as a gradient matrix system to healthy male subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1878532/),h,13.3,183452,DB00316,Acetaminophen
,1878532,bioavailability,"The bioavailability, relative to the oral solution, was 91 per cent and 84 per cent for the two GMS formulations tested.",Kinetics of acetaminophen after single- and multiple-dose oral administration as a gradient matrix system to healthy male subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1878532/),%,91,183453,DB00316,Acetaminophen
,1878532,bioavailability,"The bioavailability, relative to the oral solution, was 91 per cent and 84 per cent for the two GMS formulations tested.",Kinetics of acetaminophen after single- and multiple-dose oral administration as a gradient matrix system to healthy male subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1878532/),%,84,183454,DB00316,Acetaminophen
,1878532,peak-trough-fluctuation,The peak-trough-fluctuation (per cent PTF) was 44 per cent.,Kinetics of acetaminophen after single- and multiple-dose oral administration as a gradient matrix system to healthy male subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1878532/),%,44,183455,DB00316,Acetaminophen
,6193370,total clearance,"Compared with controls, mean total clearance of acetaminophen was reduced in CHF patients (3.56 vs. 4.59 ml/min/kg, p less than 0.025), indicating reduced biotransformation capacity in this disease.",Reduced distribution and clearance of acetaminophen in patients with congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193370/),[ml] / [kg·min],3.56,183586,DB00316,Acetaminophen
,6193370,total clearance,"Compared with controls, mean total clearance of acetaminophen was reduced in CHF patients (3.56 vs. 4.59 ml/min/kg, p less than 0.025), indicating reduced biotransformation capacity in this disease.",Reduced distribution and clearance of acetaminophen in patients with congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193370/),[ml] / [kg·min],4.59,183587,DB00316,Acetaminophen
,6193370,Volume of distribution,"Volume of distribution was also significantly reduced in CHF patients (0.85 vs. 1.02 L/kg, p less than 0.05).",Reduced distribution and clearance of acetaminophen in patients with congestive heart failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193370/),[l] / [kg],0.85,183588,DB00316,Acetaminophen
,6193370,Volume of distribution,"Volume of distribution was also significantly reduced in CHF patients (0.85 vs. 1.02 L/kg, p less than 0.05).",Reduced distribution and clearance of acetaminophen in patients with congestive heart failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193370/),[l] / [kg],1.02,183589,DB00316,Acetaminophen
,6193370,elimination half-life,"Since elimination half-life depends on both volume of distribution and clearance (both of which were reduced), the half-life was similar between groups (2.87 vs. 2.34 h, NS).",Reduced distribution and clearance of acetaminophen in patients with congestive heart failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193370/),h,2.87,183590,DB00316,Acetaminophen
,6193370,half-life,"Since elimination half-life depends on both volume of distribution and clearance (both of which were reduced), the half-life was similar between groups (2.87 vs. 2.34 h, NS).",Reduced distribution and clearance of acetaminophen in patients with congestive heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193370/),h,2.87,183591,DB00316,Acetaminophen
,6193370,half-life,"Since elimination half-life depends on both volume of distribution and clearance (both of which were reduced), the half-life was similar between groups (2.87 vs. 2.34 h, NS).",Reduced distribution and clearance of acetaminophen in patients with congestive heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193370/),h,2.34,183592,DB00316,Acetaminophen
,2582712,Ki,"Studies in microsomes prepared from two human organ donors indicated that cimetidine inhibited acetaminophen reactive metabolite formation noncompetitively, with Ki values of 0.35 mmol/L and 0.32 mmol/L for the respective livers, which is 5 to 10 times the putative cimetidine concentration required for therapeutic effect.",Lack of effect of cimetidine on acetaminophen disposition in humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2582712/),[mM] / [l],0.35,184247,DB00316,Acetaminophen
,2582712,Ki,"Studies in microsomes prepared from two human organ donors indicated that cimetidine inhibited acetaminophen reactive metabolite formation noncompetitively, with Ki values of 0.35 mmol/L and 0.32 mmol/L for the respective livers, which is 5 to 10 times the putative cimetidine concentration required for therapeutic effect.",Lack of effect of cimetidine on acetaminophen disposition in humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2582712/),[mM] / [l],0.32,184248,DB00316,Acetaminophen
,7272175,Plasma concentrations,Plasma concentrations of DPH varied from 5.1 to 20.4 microgram ml-1 (mean +/- s.e.mean 12.2 +/- 0.9).,Acetanilide and paracetamol pharmacokinetics before and during phenytoin administration: genetic control of induction? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7272175/),[μg] / [ml],12.2,185007,DB00316,Acetaminophen
,7272175,SSPC,"2 The SSPC of AA before exposure to DPH varied from 0.06 to 0.67 microgram ml-1 (mean +/- s.e.mean 0.24 +/- 0.02), and following exposure from 0.03 to 0.47 microgram ml-1 (mean +/- s.e.mean 0.15 +/- 0.02).",Acetanilide and paracetamol pharmacokinetics before and during phenytoin administration: genetic control of induction? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7272175/),[μg] / [ml],0.06 to 0.67,185008,DB00316,Acetaminophen
,7272175,SSPC,"2 The SSPC of AA before exposure to DPH varied from 0.06 to 0.67 microgram ml-1 (mean +/- s.e.mean 0.24 +/- 0.02), and following exposure from 0.03 to 0.47 microgram ml-1 (mean +/- s.e.mean 0.15 +/- 0.02).",Acetanilide and paracetamol pharmacokinetics before and during phenytoin administration: genetic control of induction? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7272175/),[μg] / [ml],0.24,185009,DB00316,Acetaminophen
,7272175,SSPC,"2 The SSPC of AA before exposure to DPH varied from 0.06 to 0.67 microgram ml-1 (mean +/- s.e.mean 0.24 +/- 0.02), and following exposure from 0.03 to 0.47 microgram ml-1 (mean +/- s.e.mean 0.15 +/- 0.02).",Acetanilide and paracetamol pharmacokinetics before and during phenytoin administration: genetic control of induction? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7272175/),,0.15,185010,DB00316,Acetaminophen
,7272175,SSPC,"3 The SSPC of PL before exposure to DPH varied from 1.2 to 4.4 microgram ml-1 (mean +/- s.e.mean 2.7 +/- 0.13), and following exposure from 1.1 to 3.8 microgram ml-1 (mean +/- s.e.mean 2.2 +/- 0.13).",Acetanilide and paracetamol pharmacokinetics before and during phenytoin administration: genetic control of induction? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7272175/),[μg] / [ml],1.2 to 4.4,185011,DB00316,Acetaminophen
,7272175,SSPC,"3 The SSPC of PL before exposure to DPH varied from 1.2 to 4.4 microgram ml-1 (mean +/- s.e.mean 2.7 +/- 0.13), and following exposure from 1.1 to 3.8 microgram ml-1 (mean +/- s.e.mean 2.2 +/- 0.13).",Acetanilide and paracetamol pharmacokinetics before and during phenytoin administration: genetic control of induction? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7272175/),[μg] / [ml],2.7,185012,DB00316,Acetaminophen
,7272175,SSPC,"3 The SSPC of PL before exposure to DPH varied from 1.2 to 4.4 microgram ml-1 (mean +/- s.e.mean 2.7 +/- 0.13), and following exposure from 1.1 to 3.8 microgram ml-1 (mean +/- s.e.mean 2.2 +/- 0.13).",Acetanilide and paracetamol pharmacokinetics before and during phenytoin administration: genetic control of induction? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7272175/),,2.2,185013,DB00316,Acetaminophen
,2050181,maximum observed serum concentrations,The maximum observed serum concentrations of ibuprofen ranged from 17-42 micrograms.,Pharmacokinetics of ibuprofen in febrile children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050181/),μg,17-42,185095,DB00316,Acetaminophen
,2050181,tmax,"Mean tmax, oral clearance and elimination half life were 1.1 h, 1.2 ml.min-1.kg-1, and 1.6 h, respectively in patients at 5 mg.",Pharmacokinetics of ibuprofen in febrile children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050181/),h,1.1,185096,DB00316,Acetaminophen
,2050181,oral clearance,"Mean tmax, oral clearance and elimination half life were 1.1 h, 1.2 ml.min-1.kg-1, and 1.6 h, respectively in patients at 5 mg.",Pharmacokinetics of ibuprofen in febrile children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050181/),[ml] / [kg·min],1.2,185097,DB00316,Acetaminophen
,2050181,elimination half life,"Mean tmax, oral clearance and elimination half life were 1.1 h, 1.2 ml.min-1.kg-1, and 1.6 h, respectively in patients at 5 mg.",Pharmacokinetics of ibuprofen in febrile children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050181/),h,1.6,185098,DB00316,Acetaminophen
,24517028,AUC8,"Concomitant administration of ferrous sulphate and paracetamol, decreased AUC8 from 42.88 +/- 3.8-34.25 +/- 2.8 microg h mL(-1) (p = 0.04) and Cmax from 18.75 +/- 1.9 to 15.9 +/- 1.7 microg mL(-1) (p = 0.11), while no change in tmax (p = 0.5) was originated.",Effects of iron on the pharmacokinetics of paracetamol in saliva. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24517028/),[h·μg] / [ml],42.88,185137,DB00316,Acetaminophen
,24517028,AUC8,"Concomitant administration of ferrous sulphate and paracetamol, decreased AUC8 from 42.88 +/- 3.8-34.25 +/- 2.8 microg h mL(-1) (p = 0.04) and Cmax from 18.75 +/- 1.9 to 15.9 +/- 1.7 microg mL(-1) (p = 0.11), while no change in tmax (p = 0.5) was originated.",Effects of iron on the pharmacokinetics of paracetamol in saliva. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24517028/),[h·μg] / [ml],34.25,185138,DB00316,Acetaminophen
,24517028,Cmax,"Concomitant administration of ferrous sulphate and paracetamol, decreased AUC8 from 42.88 +/- 3.8-34.25 +/- 2.8 microg h mL(-1) (p = 0.04) and Cmax from 18.75 +/- 1.9 to 15.9 +/- 1.7 microg mL(-1) (p = 0.11), while no change in tmax (p = 0.5) was originated.",Effects of iron on the pharmacokinetics of paracetamol in saliva. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24517028/),[μg] / [ml],18.75,185139,DB00316,Acetaminophen
,24517028,Cmax,"Concomitant administration of ferrous sulphate and paracetamol, decreased AUC8 from 42.88 +/- 3.8-34.25 +/- 2.8 microg h mL(-1) (p = 0.04) and Cmax from 18.75 +/- 1.9 to 15.9 +/- 1.7 microg mL(-1) (p = 0.11), while no change in tmax (p = 0.5) was originated.",Effects of iron on the pharmacokinetics of paracetamol in saliva. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24517028/),[μg] / [ml],15.9,185140,DB00316,Acetaminophen
,8157041,clearance,Pretreatment with probenecid caused a significant decrease in paracetamol clearance (6.23 to 3.42 ml.min-1.kg-1).,The effect of probenecid on paracetamol metabolism and pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157041/),[ml] / [kg·min],6.23 to 3.42,185228,DB00316,Acetaminophen
,15692141,maximum APAP concentration ([APAP](max)),"For APAP alone, the mean parameters were: maximum APAP concentration ([APAP](max)) 71.8 microg/mL, time to peak [APAP] (t(max)) 1.71 hours, and area under the receiver operating characteristic curve (AUC(0-8)) 318.3 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),[μg] / [ml],71.8,186083,DB00316,Acetaminophen
,15692141,time to peak [APAP] (t(max)),"For APAP alone, the mean parameters were: maximum APAP concentration ([APAP](max)) 71.8 microg/mL, time to peak [APAP] (t(max)) 1.71 hours, and area under the receiver operating characteristic curve (AUC(0-8)) 318.3 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),h,1.71,186084,DB00316,Acetaminophen
,15692141,area under the receiver operating characteristic curve (AUC(0-8)),"For APAP alone, the mean parameters were: maximum APAP concentration ([APAP](max)) 71.8 microg/mL, time to peak [APAP] (t(max)) 1.71 hours, and area under the receiver operating characteristic curve (AUC(0-8)) 318.3 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),[μg-hr] / [ml],318.3,186085,DB00316,Acetaminophen
,15692141,t(max),"For APAP+DPH, the mean parameters were: [APAP](max) 67.6 microg/mL, t(max) 1.90 hours, and AUC(0-8) 297.7 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),h,1.90,186086,DB00316,Acetaminophen
,15692141,AUC(0-8),"For APAP+DPH, the mean parameters were: [APAP](max) 67.6 microg/mL, t(max) 1.90 hours, and AUC(0-8) 297.7 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),[μg-hr] / [ml],297.7,186087,DB00316,Acetaminophen
,15692141,t(max),"For APAP+OXY, the parameters were: [APAP](max) 42.9 microg/mL, t(max) 2.87 hours, and AUC(0-8) 232.1 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),h,2.87,186088,DB00316,Acetaminophen
,15692141,AUC(0-8),"For APAP+OXY, the parameters were: [APAP](max) 42.9 microg/mL, t(max) 2.87 hours, and AUC(0-8) 232.1 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),[μg-hr] / [ml],232.1,186089,DB00316,Acetaminophen
,6487489,total plasma clearance,The total plasma clearance of paracetamol and the renal clearance of the sulphate conjugate were significantly higher after the 5 than the 20 mg/kg dose (331 +/- 42 ml/min and 295 +/- 48 ml/min; 273 +/- 74 ml/min and 205 +/- 46 ml/min respectively).,The role of sulphate conjugation in the metabolism and disposition of oral and intravenous paracetamol in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487489/),[ml] / [min],331,188014,DB00316,Acetaminophen
,6487489,total plasma clearance,The total plasma clearance of paracetamol and the renal clearance of the sulphate conjugate were significantly higher after the 5 than the 20 mg/kg dose (331 +/- 42 ml/min and 295 +/- 48 ml/min; 273 +/- 74 ml/min and 205 +/- 46 ml/min respectively).,The role of sulphate conjugation in the metabolism and disposition of oral and intravenous paracetamol in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487489/),[ml] / [min],273,188015,DB00316,Acetaminophen
,6487489,renal clearance,The total plasma clearance of paracetamol and the renal clearance of the sulphate conjugate were significantly higher after the 5 than the 20 mg/kg dose (331 +/- 42 ml/min and 295 +/- 48 ml/min; 273 +/- 74 ml/min and 205 +/- 46 ml/min respectively).,The role of sulphate conjugation in the metabolism and disposition of oral and intravenous paracetamol in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487489/),[ml] / [min],295,188016,DB00316,Acetaminophen
,6487489,renal clearance,The total plasma clearance of paracetamol and the renal clearance of the sulphate conjugate were significantly higher after the 5 than the 20 mg/kg dose (331 +/- 42 ml/min and 295 +/- 48 ml/min; 273 +/- 74 ml/min and 205 +/- 46 ml/min respectively).,The role of sulphate conjugation in the metabolism and disposition of oral and intravenous paracetamol in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487489/),[ml] / [min],205,188017,DB00316,Acetaminophen
,6487489,oral systemic availability,The oral systemic availability of paracetamol was 80% and independent of dose.,The role of sulphate conjugation in the metabolism and disposition of oral and intravenous paracetamol in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487489/),%,80,188018,DB00316,Acetaminophen
below,7948182,flow rates,Microdialysis probes used in this configuration provide very high concentration recoveries and good precision at flow rates below 2 microliters min-1.,Pharmacokinetic studies using microdialysis probes in subcutaneous tissue: effects of the co-administration of ethanol and acetaminophen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7948182/),[μl] / [min],2,188101,DB00316,Acetaminophen
,28011360,metabolic ratio,NAT2 metabolic ratio was significantly reduced following peppermint consumption (0.15 ± 0.13 vs 0.14 ± 0.13; p < 0.05).,"Effects of peppermint tea consumption on the activities of CYP1A2, CYP2A6, Xanthine Oxidase, N-acetyltranferase-2 and UDP-glucuronosyltransferases-1A1/1A6 in healthy volunteers. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28011360/),,0.15,188963,DB00316,Acetaminophen
,28011360,metabolic ratio,NAT2 metabolic ratio was significantly reduced following peppermint consumption (0.15 ± 0.13 vs 0.14 ± 0.13; p < 0.05).,"Effects of peppermint tea consumption on the activities of CYP1A2, CYP2A6, Xanthine Oxidase, N-acetyltranferase-2 and UDP-glucuronosyltransferases-1A1/1A6 in healthy volunteers. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28011360/),,0.14,188964,DB00316,Acetaminophen
,17404096,half-life,Exposure to CNTO 95 seemed to increase in a greater-than-dose-proportional manner; dose-dependent mean half-life ranged from 0.26 to 6.7 days.,Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17404096/),d,0.26 to 6.7,189192,DB00316,Acetaminophen
,1804656,AUC,"After codeine alone, the t1/2 (h), AUC (mumol.l-1.h) and CLR (ml.min-1) for codeine were 2.2, 0.81, and 252 respectively.",Lack of effect of paracetamol on the pharmacokinetics and metabolism of codeine in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804656/),[ml] / [min],2.2,189673,DB00316,Acetaminophen
,1804656,AUC,"After codeine alone, the t1/2 (h), AUC (mumol.l-1.h) and CLR (ml.min-1) for codeine were 2.2, 0.81, and 252 respectively.",Lack of effect of paracetamol on the pharmacokinetics and metabolism of codeine in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804656/),[ml] / [min],0.81,189674,DB00316,Acetaminophen
,1804656,CLR,"After codeine alone, the t1/2 (h), AUC (mumol.l-1.h) and CLR (ml.min-1) for codeine were 2.2, 0.81, and 252 respectively.",Lack of effect of paracetamol on the pharmacokinetics and metabolism of codeine in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804656/),[ml] / [min],2.2,189675,DB00316,Acetaminophen
,1804656,CLR,"After codeine alone, the t1/2 (h), AUC (mumol.l-1.h) and CLR (ml.min-1) for codeine were 2.2, 0.81, and 252 respectively.",Lack of effect of paracetamol on the pharmacokinetics and metabolism of codeine in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804656/),[ml] / [min],0.81,189676,DB00316,Acetaminophen
,1804656,CLR,"After codeine alone, the t1/2 (h), AUC (mumol.l-1.h) and CLR (ml.min-1) for codeine were 2.2, 0.81, and 252 respectively.",Lack of effect of paracetamol on the pharmacokinetics and metabolism of codeine in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804656/),[ml] / [min],252,189677,DB00316,Acetaminophen
,11758634,Emax,"Pharmacodynamic population parameter estimates [population variability coefficient of variation (CV)] for a maximum analgesic effect (Emax) model, in which the greatest possible pain relief (VAS 0-10) equates to an Emax of 10, were Emax 5.17 (64%) and 50% effective concentration 9.98 mg/l (107%).",Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758634/),,10,189897,DB00316,Acetaminophen
,11758634,Emax,"Pharmacodynamic population parameter estimates [population variability coefficient of variation (CV)] for a maximum analgesic effect (Emax) model, in which the greatest possible pain relief (VAS 0-10) equates to an Emax of 10, were Emax 5.17 (64%) and 50% effective concentration 9.98 mg/l (107%).",Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758634/),,5.17,189898,DB00316,Acetaminophen
,11758634,50% effective concentration,"Pharmacodynamic population parameter estimates [population variability coefficient of variation (CV)] for a maximum analgesic effect (Emax) model, in which the greatest possible pain relief (VAS 0-10) equates to an Emax of 10, were Emax 5.17 (64%) and 50% effective concentration 9.98 mg/l (107%).",Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758634/),[mg] / [l],9.98,189899,DB00316,Acetaminophen
,11758634,half-life (t(eq)),The equilibration half-life (t(eq)) of the analgesic effect compartment was 53 min (217%).,Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758634/),min,53,189900,DB00316,Acetaminophen
,11758634,t(eq),"A placebo drug model for the effects of placebo response had a t(eq) of 1.96 h (40%), an elimination half-life of 2.06 h (50%) and a potency of 1.54 pain relief units (24%).",Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758634/),h,1.96,189901,DB00316,Acetaminophen
,11758634,elimination half-life,"A placebo drug model for the effects of placebo response had a t(eq) of 1.96 h (40%), an elimination half-life of 2.06 h (50%) and a potency of 1.54 pain relief units (24%).",Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758634/),h,2.06,189902,DB00316,Acetaminophen
,11758634,potency,"A placebo drug model for the effects of placebo response had a t(eq) of 1.96 h (40%), an elimination half-life of 2.06 h (50%) and a potency of 1.54 pain relief units (24%).",Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758634/),,1.54,189903,DB00316,Acetaminophen
,11758634,target effect compartment concentration,A target effect compartment concentration of 10 mg/l is expected to produce a pain reduction of 2.6 units.,Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758634/),[mg] / [l],10,189904,DB00316,Acetaminophen
,24944391,time to maximum concentration (Tmax),"The pharmacokinetic parameters calculated for the test versus the reference formulation were as follows: median time to maximum concentration (Tmax), 0.42 versus 0.75 hour; mean (SD) maximum plasma drug concentration (Cmax), 9.85 (2.40) μg/mL versus 8.33 (2.22) μg/mL; and mean (SD) area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞), 30.16 (8.87) μg·h/mL versus 28.49 (8.57) μg · h/mL.",A new high-absorption-rate Paracetamol 500-mg formulation: a comparative bioavailability study in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944391/),h,0.42,190132,DB00316,Acetaminophen
,24944391,time to maximum concentration (Tmax),"The pharmacokinetic parameters calculated for the test versus the reference formulation were as follows: median time to maximum concentration (Tmax), 0.42 versus 0.75 hour; mean (SD) maximum plasma drug concentration (Cmax), 9.85 (2.40) μg/mL versus 8.33 (2.22) μg/mL; and mean (SD) area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞), 30.16 (8.87) μg·h/mL versus 28.49 (8.57) μg · h/mL.",A new high-absorption-rate Paracetamol 500-mg formulation: a comparative bioavailability study in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944391/),h,0.75,190133,DB00316,Acetaminophen
,24944391,maximum plasma drug concentration (Cmax),"The pharmacokinetic parameters calculated for the test versus the reference formulation were as follows: median time to maximum concentration (Tmax), 0.42 versus 0.75 hour; mean (SD) maximum plasma drug concentration (Cmax), 9.85 (2.40) μg/mL versus 8.33 (2.22) μg/mL; and mean (SD) area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞), 30.16 (8.87) μg·h/mL versus 28.49 (8.57) μg · h/mL.",A new high-absorption-rate Paracetamol 500-mg formulation: a comparative bioavailability study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944391/),[μg] / [ml],9.85,190134,DB00316,Acetaminophen
,24944391,maximum plasma drug concentration (Cmax),"The pharmacokinetic parameters calculated for the test versus the reference formulation were as follows: median time to maximum concentration (Tmax), 0.42 versus 0.75 hour; mean (SD) maximum plasma drug concentration (Cmax), 9.85 (2.40) μg/mL versus 8.33 (2.22) μg/mL; and mean (SD) area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞), 30.16 (8.87) μg·h/mL versus 28.49 (8.57) μg · h/mL.",A new high-absorption-rate Paracetamol 500-mg formulation: a comparative bioavailability study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944391/),[μg] / [ml],8.33,190135,DB00316,Acetaminophen
,24944391,area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞),"The pharmacokinetic parameters calculated for the test versus the reference formulation were as follows: median time to maximum concentration (Tmax), 0.42 versus 0.75 hour; mean (SD) maximum plasma drug concentration (Cmax), 9.85 (2.40) μg/mL versus 8.33 (2.22) μg/mL; and mean (SD) area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞), 30.16 (8.87) μg·h/mL versus 28.49 (8.57) μg · h/mL.",A new high-absorption-rate Paracetamol 500-mg formulation: a comparative bioavailability study in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944391/),[h·μg] / [ml],30.16,190136,DB00316,Acetaminophen
,24944391,area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞),"The pharmacokinetic parameters calculated for the test versus the reference formulation were as follows: median time to maximum concentration (Tmax), 0.42 versus 0.75 hour; mean (SD) maximum plasma drug concentration (Cmax), 9.85 (2.40) μg/mL versus 8.33 (2.22) μg/mL; and mean (SD) area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞), 30.16 (8.87) μg·h/mL versus 28.49 (8.57) μg · h/mL.",A new high-absorption-rate Paracetamol 500-mg formulation: a comparative bioavailability study in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944391/),[h·μg] / [ml],28.49,190137,DB00316,Acetaminophen
,25704771,run time,"The analytes were resolved on a Gemini C18 column (4.6 mm × 250 mm; 5 μm particle size) using a gradient elution mode with a run time of 15 min, comprising re-equilibration, at 60°C (± 1°C).",Simultaneous determination of eperisone hydrochloride and paracetamol in mouse plasma by high performance liquid chromatography-photodiode array detector. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25704771/),min,15,190431,DB00316,Acetaminophen
,9286887,volume of distribution,"The volume of distribution was 385 ml/kg, and clearance normalized for bioavailability, F, was 5.46 ml x kg(-1) x min(-1).",Twenty-four-hour pharmacokinetics of rectal acetaminophen in children: an old drug with new recommendations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9286887/),[ml] / [kg],385,190766,DB00316,Acetaminophen
,9286887,"clearance normalized for bioavailability, F,","The volume of distribution was 385 ml/kg, and clearance normalized for bioavailability, F, was 5.46 ml x kg(-1) x min(-1).",Twenty-four-hour pharmacokinetics of rectal acetaminophen in children: an old drug with new recommendations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9286887/),[ml] / [kg·min],5.46,190767,DB00316,Acetaminophen
,9767504,Cmax (Tmax),"A mean dose of 13 mg/kg gave a mean Cmax (Tmax) of 7.7 mg/L (1.6 h) and 4.9 mg/L (2.0 h) following oral and rectal administration, respectively.",Relative bioavailability and plasma paracetamol profiles of Panadol suppositories in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9767504/),[mg] / [l],7.7,191142,DB00316,Acetaminophen
,9767504,Cmax (Tmax),"A mean dose of 13 mg/kg gave a mean Cmax (Tmax) of 7.7 mg/L (1.6 h) and 4.9 mg/L (2.0 h) following oral and rectal administration, respectively.",Relative bioavailability and plasma paracetamol profiles of Panadol suppositories in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9767504/),[mg] / [l],4.9,191143,DB00316,Acetaminophen
,9767504,relative rectal bioavailability,The mean relative rectal bioavailability was 78% (95% confidence interval of 55-101%).,Relative bioavailability and plasma paracetamol profiles of Panadol suppositories in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9767504/),%,78,191144,DB00316,Acetaminophen
,9767504,maximum plasma paracetamol concentrations,"A mean dose of 25 mg/kg produced mean maximum plasma paracetamol concentrations of 13.2 mg/L and 14.5 mg/L at 2.1 and 1.9 h for the hard and liquid filled suppository, respectively.",Relative bioavailability and plasma paracetamol profiles of Panadol suppositories in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9767504/),[mg] / [l],13.2,191145,DB00316,Acetaminophen
,9767504,maximum plasma paracetamol concentrations,"A mean dose of 25 mg/kg produced mean maximum plasma paracetamol concentrations of 13.2 mg/L and 14.5 mg/L at 2.1 and 1.9 h for the hard and liquid filled suppository, respectively.",Relative bioavailability and plasma paracetamol profiles of Panadol suppositories in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9767504/),[mg] / [l],14.5,191146,DB00316,Acetaminophen
,22197608,flow rate,"Following extraction, the analytes were separated on a Phenomenex Gemini C18 column (150 mm×2.0 mm, 5 μm), using a gradient of ammonium acetate 10 mM and acetonitrile with a flow rate of 300 μL/min.",Development and validation of a sensitive solid-phase-extraction (SPE) method using high-performance liquid chromatography/tandem mass spectrometry (LC-MS/MS) for determination of risedronate concentrations in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22197608/),[μl] / [min],300,191493,DB00316,Acetaminophen
,22197608,recovery,Mean recovery was 54% for risedronate and 51% for the internal standard.,Development and validation of a sensitive solid-phase-extraction (SPE) method using high-performance liquid chromatography/tandem mass spectrometry (LC-MS/MS) for determination of risedronate concentrations in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22197608/),%,54,191494,DB00316,Acetaminophen
,22197608,recovery,Mean recovery was 54% for risedronate and 51% for the internal standard.,Development and validation of a sensitive solid-phase-extraction (SPE) method using high-performance liquid chromatography/tandem mass spectrometry (LC-MS/MS) for determination of risedronate concentrations in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22197608/),%,51,191495,DB00316,Acetaminophen
,26902951,zeta potential,Optimized resveratrol solid lipid nanoparticles (RV-SLNs) (SR-1) of appropriate characteristics (particle size = 191.1 ± 10.44 nm; zeta potential= -13.56 ± 4.14 mV; entrapment efficiency = 75.23 ± 3.85%; maximum % release = 80.53 ± 3.99%) were produced.,"A novel monolithic controlled delivery system of resveratrol for enhanced hepatoprotection: nanoformulation development, pharmacokinetics and pharmacodynamics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902951/),mv,-,191496,DB00316,Acetaminophen
,26902951,zeta potential,Optimized resveratrol solid lipid nanoparticles (RV-SLNs) (SR-1) of appropriate characteristics (particle size = 191.1 ± 10.44 nm; zeta potential= -13.56 ± 4.14 mV; entrapment efficiency = 75.23 ± 3.85%; maximum % release = 80.53 ± 3.99%) were produced.,"A novel monolithic controlled delivery system of resveratrol for enhanced hepatoprotection: nanoformulation development, pharmacokinetics and pharmacodynamics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902951/),mv,13.56,191497,DB00316,Acetaminophen
,26902951,entrapment efficiency,Optimized resveratrol solid lipid nanoparticles (RV-SLNs) (SR-1) of appropriate characteristics (particle size = 191.1 ± 10.44 nm; zeta potential= -13.56 ± 4.14 mV; entrapment efficiency = 75.23 ± 3.85%; maximum % release = 80.53 ± 3.99%) were produced.,"A novel monolithic controlled delivery system of resveratrol for enhanced hepatoprotection: nanoformulation development, pharmacokinetics and pharmacodynamics. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902951/),%,75.23,191498,DB00316,Acetaminophen
,26902951,maximum % release,Optimized resveratrol solid lipid nanoparticles (RV-SLNs) (SR-1) of appropriate characteristics (particle size = 191.1 ± 10.44 nm; zeta potential= -13.56 ± 4.14 mV; entrapment efficiency = 75.23 ± 3.85%; maximum % release = 80.53 ± 3.99%) were produced.,"A novel monolithic controlled delivery system of resveratrol for enhanced hepatoprotection: nanoformulation development, pharmacokinetics and pharmacodynamics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902951/),%,80.53,191499,DB00316,Acetaminophen
,26902951,AUC0→∞,In vivo studies revealed nearly five-fold increase in the bioavailability of SR-1 (AUC0→∞=3411 ± 170.34 µg/ml/h) as compared to RV suspension (AUC0→∞=653.5 ± 30.10 µg/ml/h).,"A novel monolithic controlled delivery system of resveratrol for enhanced hepatoprotection: nanoformulation development, pharmacokinetics and pharmacodynamics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902951/),[μg] / [h·ml],3411,191500,DB00316,Acetaminophen
,26902951,AUC0→∞,In vivo studies revealed nearly five-fold increase in the bioavailability of SR-1 (AUC0→∞=3411 ± 170.34 µg/ml/h) as compared to RV suspension (AUC0→∞=653.5 ± 30.10 µg/ml/h).,"A novel monolithic controlled delivery system of resveratrol for enhanced hepatoprotection: nanoformulation development, pharmacokinetics and pharmacodynamics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902951/),[μg] / [h·ml],653.5,191501,DB00316,Acetaminophen
,17162465,oral clearance,"Following oral administration of acetaminophen (600 mg) to chimpanzees (n=2), pharmacokinetics were comparable with previously reported human values, namely mean oral clearance 0.91 vs.","Glucuronidation in the chimpanzee (Pan troglodytes): studies with acetaminophen, oestradiol and morphine. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17162465/),,0.91,192203,DB00316,Acetaminophen
,17162465,apparent volume of distribution,"0.62+/-0.05 l h-1 kg-1, apparent volume of distribution 2.29 vs.","Glucuronidation in the chimpanzee (Pan troglodytes): studies with acetaminophen, oestradiol and morphine. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17162465/),,2.29,192204,DB00316,Acetaminophen
,17162465,half-life,"1.65+/-0.25 l kg-1, and half-life 1.86 vs.","Glucuronidation in the chimpanzee (Pan troglodytes): studies with acetaminophen, oestradiol and morphine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17162465/),,1.86,192205,DB00316,Acetaminophen
,17162465,Urinary excretions,"Urinary excretions (percentage of dose) of acetaminophen, acetaminophen glucuronide and acetaminophen sulfate were also similar between chimpanzees and humans, namely 2.3 vs.","Glucuronidation in the chimpanzee (Pan troglodytes): studies with acetaminophen, oestradiol and morphine. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17162465/),,2.3,192206,DB00316,Acetaminophen
,32573795,time to maximum plasma concentration,"Ubrogepant median time to maximum plasma concentration was delayed (3 hours [range: 1-5 hours] vs 1.5 hours [range: 1-4 hours]), mean maximum plasma concentration was reduced by 24% (coefficient of variation: 37.4%) when ubrogepant was coadministered with sumatriptan (n = 29) compared with ubrogepant administered alone (N = 30).",Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32573795/),h,3,192931,DB00316,Acetaminophen
,32573795,time to maximum plasma concentration,"Ubrogepant median time to maximum plasma concentration was delayed (3 hours [range: 1-5 hours] vs 1.5 hours [range: 1-4 hours]), mean maximum plasma concentration was reduced by 24% (coefficient of variation: 37.4%) when ubrogepant was coadministered with sumatriptan (n = 29) compared with ubrogepant administered alone (N = 30).",Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32573795/),h,1.5,192932,DB00316,Acetaminophen
,32573795,time to maximum plasma concentration,"Sumatriptan area under the curve and maximum plasma concentration showed no significant change when sumatriptan was coadministered with ubrogepant (n = 29), but the sumatriptan time to maximum plasma concentration was delayed (1 hour [range: 0.5-5 hours] vs 3 hours [range: 0.5-6 hours].",Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32573795/),h,1,192933,DB00316,Acetaminophen
,32573795,time to maximum plasma concentration,"Sumatriptan area under the curve and maximum plasma concentration showed no significant change when sumatriptan was coadministered with ubrogepant (n = 29), but the sumatriptan time to maximum plasma concentration was delayed (1 hour [range: 0.5-5 hours] vs 3 hours [range: 0.5-6 hours].",Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32573795/),h,3,192934,DB00316,Acetaminophen
,11196522,plasma elimination half-life,"No significant within-patient differences were observed, especially with respect to plasma elimination half-life (2.74 +/- 0.48 and 2.77 +/- 0.32 hours, respectively), area under the concentration-time curve (82.5 +/- 21.1 and 90.1 +/- 15.2 microg x h/ml, respectively), and apparent oral clearance (3.68 +/- 0.85 and 3.28 +/- 0.52 ml/min/kg, respectively).",Single and multiple dose pharmacokinetics of acetaminophen (paracetamol) in polymedicated very old patients with rheumatic pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11196522/),h,2.74,193050,DB00316,Acetaminophen
,11196522,plasma elimination half-life,"No significant within-patient differences were observed, especially with respect to plasma elimination half-life (2.74 +/- 0.48 and 2.77 +/- 0.32 hours, respectively), area under the concentration-time curve (82.5 +/- 21.1 and 90.1 +/- 15.2 microg x h/ml, respectively), and apparent oral clearance (3.68 +/- 0.85 and 3.28 +/- 0.52 ml/min/kg, respectively).",Single and multiple dose pharmacokinetics of acetaminophen (paracetamol) in polymedicated very old patients with rheumatic pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11196522/),h,2.77,193051,DB00316,Acetaminophen
,11196522,area under the concentration-time curve,"No significant within-patient differences were observed, especially with respect to plasma elimination half-life (2.74 +/- 0.48 and 2.77 +/- 0.32 hours, respectively), area under the concentration-time curve (82.5 +/- 21.1 and 90.1 +/- 15.2 microg x h/ml, respectively), and apparent oral clearance (3.68 +/- 0.85 and 3.28 +/- 0.52 ml/min/kg, respectively).",Single and multiple dose pharmacokinetics of acetaminophen (paracetamol) in polymedicated very old patients with rheumatic pain. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11196522/),[h·μg] / [ml],82.5,193052,DB00316,Acetaminophen
,11196522,area under the concentration-time curve,"No significant within-patient differences were observed, especially with respect to plasma elimination half-life (2.74 +/- 0.48 and 2.77 +/- 0.32 hours, respectively), area under the concentration-time curve (82.5 +/- 21.1 and 90.1 +/- 15.2 microg x h/ml, respectively), and apparent oral clearance (3.68 +/- 0.85 and 3.28 +/- 0.52 ml/min/kg, respectively).",Single and multiple dose pharmacokinetics of acetaminophen (paracetamol) in polymedicated very old patients with rheumatic pain. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11196522/),[h·μg] / [ml],90.1,193053,DB00316,Acetaminophen
,11196522,apparent oral clearance,"No significant within-patient differences were observed, especially with respect to plasma elimination half-life (2.74 +/- 0.48 and 2.77 +/- 0.32 hours, respectively), area under the concentration-time curve (82.5 +/- 21.1 and 90.1 +/- 15.2 microg x h/ml, respectively), and apparent oral clearance (3.68 +/- 0.85 and 3.28 +/- 0.52 ml/min/kg, respectively).",Single and multiple dose pharmacokinetics of acetaminophen (paracetamol) in polymedicated very old patients with rheumatic pain. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11196522/),[ml] / [kg·min],3.68,193054,DB00316,Acetaminophen
,11196522,apparent oral clearance,"No significant within-patient differences were observed, especially with respect to plasma elimination half-life (2.74 +/- 0.48 and 2.77 +/- 0.32 hours, respectively), area under the concentration-time curve (82.5 +/- 21.1 and 90.1 +/- 15.2 microg x h/ml, respectively), and apparent oral clearance (3.68 +/- 0.85 and 3.28 +/- 0.52 ml/min/kg, respectively).",Single and multiple dose pharmacokinetics of acetaminophen (paracetamol) in polymedicated very old patients with rheumatic pain. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11196522/),[ml] / [kg·min],3.28,193055,DB00316,Acetaminophen
,23729801,maximum plasma concentration,"For the 30-100 mg doses, median maximum plasma concentration values ranged from 4.02 to 4.49 days.","Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23729801/),d,4.02 to 4.49,193938,DB00316,Acetaminophen
,23729801,elimination half-life,Mean elimination half-life values ranged from 5.20 to 6.83 days.,"Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23729801/),d,5.20 to 6.83,193939,DB00316,Acetaminophen
,1600594,clearance,"The low-protein diet significantly decreased doxorubicin clearance (48 +/- 3 vs 59 +/- 4 ml min-1 kg-1; P less than 0.05), prolonged the terminal elimination half-life (28 +/- 2 vs 22 +/- 2 h; P less than 0.05), and increased the area under the plasma concentration/time curve extrapolated to infinity (1722 +/- 122 vs 1405 +/- 71 ng h ml-1; P less than 0.05) as compared with the values determined for rabbits fed the standard rabbit chow (15% protein).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),[ml] / [kg·min],48,194338,DB00316,Acetaminophen
,1600594,clearance,"The low-protein diet significantly decreased doxorubicin clearance (48 +/- 3 vs 59 +/- 4 ml min-1 kg-1; P less than 0.05), prolonged the terminal elimination half-life (28 +/- 2 vs 22 +/- 2 h; P less than 0.05), and increased the area under the plasma concentration/time curve extrapolated to infinity (1722 +/- 122 vs 1405 +/- 71 ng h ml-1; P less than 0.05) as compared with the values determined for rabbits fed the standard rabbit chow (15% protein).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),[ml] / [kg·min],59,194339,DB00316,Acetaminophen
,1600594,terminal elimination half-life,"The low-protein diet significantly decreased doxorubicin clearance (48 +/- 3 vs 59 +/- 4 ml min-1 kg-1; P less than 0.05), prolonged the terminal elimination half-life (28 +/- 2 vs 22 +/- 2 h; P less than 0.05), and increased the area under the plasma concentration/time curve extrapolated to infinity (1722 +/- 122 vs 1405 +/- 71 ng h ml-1; P less than 0.05) as compared with the values determined for rabbits fed the standard rabbit chow (15% protein).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),h,28,194340,DB00316,Acetaminophen
,1600594,terminal elimination half-life,"The low-protein diet significantly decreased doxorubicin clearance (48 +/- 3 vs 59 +/- 4 ml min-1 kg-1; P less than 0.05), prolonged the terminal elimination half-life (28 +/- 2 vs 22 +/- 2 h; P less than 0.05), and increased the area under the plasma concentration/time curve extrapolated to infinity (1722 +/- 122 vs 1405 +/- 71 ng h ml-1; P less than 0.05) as compared with the values determined for rabbits fed the standard rabbit chow (15% protein).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),h,22,194341,DB00316,Acetaminophen
,1600594,area under the plasma concentration/time curve extrapolated to infinity,"The low-protein diet significantly decreased doxorubicin clearance (48 +/- 3 vs 59 +/- 4 ml min-1 kg-1; P less than 0.05), prolonged the terminal elimination half-life (28 +/- 2 vs 22 +/- 2 h; P less than 0.05), and increased the area under the plasma concentration/time curve extrapolated to infinity (1722 +/- 122 vs 1405 +/- 71 ng h ml-1; P less than 0.05) as compared with the values determined for rabbits fed the standard rabbit chow (15% protein).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),[h·ng] / [ml],1722,194342,DB00316,Acetaminophen
,1600594,area under the plasma concentration/time curve extrapolated to infinity,"The low-protein diet significantly decreased doxorubicin clearance (48 +/- 3 vs 59 +/- 4 ml min-1 kg-1; P less than 0.05), prolonged the terminal elimination half-life (28 +/- 2 vs 22 +/- 2 h; P less than 0.05), and increased the area under the plasma concentration/time curve extrapolated to infinity (1722 +/- 122 vs 1405 +/- 71 ng h ml-1; P less than 0.05) as compared with the values determined for rabbits fed the standard rabbit chow (15% protein).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),[h·ng] / [ml],1405,194343,DB00316,Acetaminophen
,1600594,terminal elimination half-life,"In addition, in rabbits fed the the low-protein diet, the terminal elimination half-life of the alcohol metabolite, doxorubicinol was prolonged (52 +/- 5 vs 40 +/- 2 h; P less than 0.05).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),h,52,194344,DB00316,Acetaminophen
,1600594,terminal elimination half-life,"In addition, in rabbits fed the the low-protein diet, the terminal elimination half-life of the alcohol metabolite, doxorubicinol was prolonged (52 +/- 5 vs 40 +/- 2 h; P less than 0.05).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),h,40,194345,DB00316,Acetaminophen
,12170052,Gastric emptying half-time,Gastric emptying half-time was significantly shorter after ingestion of 300 ml water than after ingestion of 50 ml (24 +/- 6 vs. 33 +/- 8 min).,Gastric emptying of water in term pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12170052/),min,24,195275,DB00316,Acetaminophen
,12170052,Gastric emptying half-time,Gastric emptying half-time was significantly shorter after ingestion of 300 ml water than after ingestion of 50 ml (24 +/- 6 vs. 33 +/- 8 min).,Gastric emptying of water in term pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12170052/),min,33,195276,DB00316,Acetaminophen
,12170052,Time to peak concentration,Time to peak concentration of acetaminophen was significantly shorter after ingestion of 300 ml water than after ingestion of 50 ml (25 +/- 12 vs. 41 +/- 19 min).,Gastric emptying of water in term pregnancy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12170052/),min,25,195277,DB00316,Acetaminophen
,12170052,Time to peak concentration,Time to peak concentration of acetaminophen was significantly shorter after ingestion of 300 ml water than after ingestion of 50 ml (25 +/- 12 vs. 41 +/- 19 min).,Gastric emptying of water in term pregnancy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12170052/),min,41,195278,DB00316,Acetaminophen
,2720707,serum half-life (t1/2),Pharmacokinetic studies showed a serum half-life (t1/2) ranging from 11 min to 17 min for doses from 0.04 mg/m2 to 0.16 mg/m2 and prolonged clearance with t1/2 ranging from 54 min to 70 min in the 0.20-0.28 mg/m2 dose range.,Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720707/),min,11,195730,DB00316,Acetaminophen
,2720707,serum half-life (t1/2),Pharmacokinetic studies showed a serum half-life (t1/2) ranging from 11 min to 17 min for doses from 0.04 mg/m2 to 0.16 mg/m2 and prolonged clearance with t1/2 ranging from 54 min to 70 min in the 0.20-0.28 mg/m2 dose range.,Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720707/),min,17,195731,DB00316,Acetaminophen
,2720707,clearance with,Pharmacokinetic studies showed a serum half-life (t1/2) ranging from 11 min to 17 min for doses from 0.04 mg/m2 to 0.16 mg/m2 and prolonged clearance with t1/2 ranging from 54 min to 70 min in the 0.20-0.28 mg/m2 dose range.,Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720707/),min,54,195732,DB00316,Acetaminophen
,2720707,clearance with,Pharmacokinetic studies showed a serum half-life (t1/2) ranging from 11 min to 17 min for doses from 0.04 mg/m2 to 0.16 mg/m2 and prolonged clearance with t1/2 ranging from 54 min to 70 min in the 0.20-0.28 mg/m2 dose range.,Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720707/),min,70,195733,DB00316,Acetaminophen
,2720707,t1/2,Pharmacokinetic studies showed a serum half-life (t1/2) ranging from 11 min to 17 min for doses from 0.04 mg/m2 to 0.16 mg/m2 and prolonged clearance with t1/2 ranging from 54 min to 70 min in the 0.20-0.28 mg/m2 dose range.,Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720707/),min,54,195734,DB00316,Acetaminophen
,2720707,t1/2,Pharmacokinetic studies showed a serum half-life (t1/2) ranging from 11 min to 17 min for doses from 0.04 mg/m2 to 0.16 mg/m2 and prolonged clearance with t1/2 ranging from 54 min to 70 min in the 0.20-0.28 mg/m2 dose range.,Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720707/),min,70,195735,DB00316,Acetaminophen
,11145772,AUCs,"AUCs were 298.5+/-82.5 mg-h/L (control), 77.1+/-85.2 mg-h/L (superactivated charcoal), and 81.3 +/- 71.8 mg-h/L (superactivated charcoal-cola).",Treatment of acetaminophen ingestion with a superactivated charcoal-cola mixture. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145772/),[mg-h] / [l],298.5,196938,DB00316,Acetaminophen
,11145772,AUCs,"AUCs were 298.5+/-82.5 mg-h/L (control), 77.1+/-85.2 mg-h/L (superactivated charcoal), and 81.3 +/- 71.8 mg-h/L (superactivated charcoal-cola).",Treatment of acetaminophen ingestion with a superactivated charcoal-cola mixture. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145772/),[mg-h] / [l],77.1,196939,DB00316,Acetaminophen
,11145772,AUCs,"AUCs were 298.5+/-82.5 mg-h/L (control), 77.1+/-85.2 mg-h/L (superactivated charcoal), and 81.3 +/- 71.8 mg-h/L (superactivated charcoal-cola).",Treatment of acetaminophen ingestion with a superactivated charcoal-cola mixture. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145772/),[mg-h] / [l],81.3,196940,DB00316,Acetaminophen
,26896302,maximum plasma concentrations,"The geometric mean maximum plasma concentrations of acetaminophen, codeine, and codeine-6-glucuronide were 7.95 μg/mL, 11.0 ng/mL, and 3819 ng/mL, respectively.",Pharmacokinetics and pharmacodynamics of oral acetaminophen in combination with codeine in healthy Greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896302/),[μg] / [ml],7.95,197087,DB00316,Acetaminophen
,26896302,maximum plasma concentrations,"The geometric mean maximum plasma concentrations of acetaminophen, codeine, and codeine-6-glucuronide were 7.95 μg/mL, 11.0 ng/mL, and 3819 ng/mL, respectively.",Pharmacokinetics and pharmacodynamics of oral acetaminophen in combination with codeine in healthy Greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896302/),[ng] / [ml],11.0,197088,DB00316,Acetaminophen
,26896302,maximum plasma concentrations,"The geometric mean maximum plasma concentrations of acetaminophen, codeine, and codeine-6-glucuronide were 7.95 μg/mL, 11.0 ng/mL, and 3819 ng/mL, respectively.",Pharmacokinetics and pharmacodynamics of oral acetaminophen in combination with codeine in healthy Greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896302/),[ng] / [ml],3819,197089,DB00316,Acetaminophen
,26896302,terminal half-lives,"The terminal half-lives of acetaminophen, codeine, and codeine-6-glucuronide were 0.94, 1.71, and 3.12 h.",Pharmacokinetics and pharmacodynamics of oral acetaminophen in combination with codeine in healthy Greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896302/),h,0.94,197090,DB00316,Acetaminophen
,26896302,terminal half-lives,"The terminal half-lives of acetaminophen, codeine, and codeine-6-glucuronide were 0.94, 1.71, and 3.12 h.",Pharmacokinetics and pharmacodynamics of oral acetaminophen in combination with codeine in healthy Greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896302/),h,1.71,197091,DB00316,Acetaminophen
,26896302,terminal half-lives,"The terminal half-lives of acetaminophen, codeine, and codeine-6-glucuronide were 0.94, 1.71, and 3.12 h.",Pharmacokinetics and pharmacodynamics of oral acetaminophen in combination with codeine in healthy Greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896302/),h,3.12,197092,DB00316,Acetaminophen
,29214506,peak concentration (C max),"Observed paracetamol peak concentration (C max) and area under the plasma concentration-time curve over the dosing interval (AUC0-6) were reduced when oral paracetamol was co-administered with morphine (reduced from 11.6 to 7.25 µg/mL and from 31.00 to 25.51 µg·h/mL, respectively), followed by an abruptly increased C max and AUC0-6 upon discontinuation of morphine (to 13.5 µg/mL and 52.38 µg·h/mL, respectively).",Pharmacokinetics of Oral and Intravenous Paracetamol (Acetaminophen) When Co-Administered with Intravenous Morphine in Healthy Adult Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29214506/),[μg] / [ml],11,197273,DB00316,Acetaminophen
,29214506,area under the plasma concentration-time curve over the dosing interval (AUC0-6),"Observed paracetamol peak concentration (C max) and area under the plasma concentration-time curve over the dosing interval (AUC0-6) were reduced when oral paracetamol was co-administered with morphine (reduced from 11.6 to 7.25 µg/mL and from 31.00 to 25.51 µg·h/mL, respectively), followed by an abruptly increased C max and AUC0-6 upon discontinuation of morphine (to 13.5 µg/mL and 52.38 µg·h/mL, respectively).",Pharmacokinetics of Oral and Intravenous Paracetamol (Acetaminophen) When Co-Administered with Intravenous Morphine in Healthy Adult Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29214506/),[h·μg] / [ml],31.00 to 25.51,197274,DB00316,Acetaminophen
,29214506,C max,"Observed paracetamol peak concentration (C max) and area under the plasma concentration-time curve over the dosing interval (AUC0-6) were reduced when oral paracetamol was co-administered with morphine (reduced from 11.6 to 7.25 µg/mL and from 31.00 to 25.51 µg·h/mL, respectively), followed by an abruptly increased C max and AUC0-6 upon discontinuation of morphine (to 13.5 µg/mL and 52.38 µg·h/mL, respectively).",Pharmacokinetics of Oral and Intravenous Paracetamol (Acetaminophen) When Co-Administered with Intravenous Morphine in Healthy Adult Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29214506/),[μg] / [ml],13.5,197275,DB00316,Acetaminophen
,29214506,AUC0-6,"Observed paracetamol peak concentration (C max) and area under the plasma concentration-time curve over the dosing interval (AUC0-6) were reduced when oral paracetamol was co-administered with morphine (reduced from 11.6 to 7.25 µg/mL and from 31.00 to 25.51 µg·h/mL, respectively), followed by an abruptly increased C max and AUC0-6 upon discontinuation of morphine (to 13.5 µg/mL and 52.38 µg·h/mL, respectively).",Pharmacokinetics of Oral and Intravenous Paracetamol (Acetaminophen) When Co-Administered with Intravenous Morphine in Healthy Adult Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29214506/),[h·μg] / [ml],52.38,197276,DB00316,Acetaminophen
,29214506,time to peak plasma concentration (T max),There was also a significantly prolonged mean time to peak plasma concentration (T max) after the 4th dose of oral paracetamol (2.84 h) compared to the 1st dose (1.48 h).,Pharmacokinetics of Oral and Intravenous Paracetamol (Acetaminophen) When Co-Administered with Intravenous Morphine in Healthy Adult Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29214506/),h,2.84,197277,DB00316,Acetaminophen
,29214506,time to peak plasma concentration (T max),There was also a significantly prolonged mean time to peak plasma concentration (T max) after the 4th dose of oral paracetamol (2.84 h) compared to the 1st dose (1.48 h).,Pharmacokinetics of Oral and Intravenous Paracetamol (Acetaminophen) When Co-Administered with Intravenous Morphine in Healthy Adult Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29214506/),h,1.48,197278,DB00316,Acetaminophen
,32052378,molar dose fraction,"Prediction of fetal acetaminophen clearance indicated that the median molar dose fraction converted to acetaminophen-sulphate and N-acetyl-p-benzoquinone imine was 0.8% and 0.06%, respectively.",Integration of Placental Transfer in a Fetal-Maternal Physiologically Based Pharmacokinetic Model to Characterize Acetaminophen Exposure and Metabolic Clearance in the Fetus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32052378/),%,0.8,197545,DB00316,Acetaminophen
,32052378,molar dose fraction,"Prediction of fetal acetaminophen clearance indicated that the median molar dose fraction converted to acetaminophen-sulphate and N-acetyl-p-benzoquinone imine was 0.8% and 0.06%, respectively.",Integration of Placental Transfer in a Fetal-Maternal Physiologically Based Pharmacokinetic Model to Characterize Acetaminophen Exposure and Metabolic Clearance in the Fetus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32052378/),%,0.06,197546,DB00316,Acetaminophen
,8308946,%ME,"The prediction of concentrations between 2 to 4 h and 4 to 4.5 h after ingestion with only population-based parameter estimates resulted in %ME of 17.0 and 13.2, respectively, and %MAE of 36.5 and 35.1, respectively.",Prediction of acetaminophen concentrations in overdose patients using a Bayesian pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8308946/),,17.0,198278,DB00316,Acetaminophen
,8308946,%ME,"The prediction of concentrations between 2 to 4 h and 4 to 4.5 h after ingestion with only population-based parameter estimates resulted in %ME of 17.0 and 13.2, respectively, and %MAE of 36.5 and 35.1, respectively.",Prediction of acetaminophen concentrations in overdose patients using a Bayesian pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8308946/),,13.2,198279,DB00316,Acetaminophen
,8308946,%MAE,"The prediction of concentrations between 2 to 4 h and 4 to 4.5 h after ingestion with only population-based parameter estimates resulted in %ME of 17.0 and 13.2, respectively, and %MAE of 36.5 and 35.1, respectively.",Prediction of acetaminophen concentrations in overdose patients using a Bayesian pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8308946/),,36.5,198280,DB00316,Acetaminophen
,8308946,%MAE,"The prediction of concentrations between 2 to 4 h and 4 to 4.5 h after ingestion with only population-based parameter estimates resulted in %ME of 17.0 and 13.2, respectively, and %MAE of 36.5 and 35.1, respectively.",Prediction of acetaminophen concentrations in overdose patients using a Bayesian pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8308946/),,35.1,198281,DB00316,Acetaminophen
,1752114,total plasma clearance,The total plasma clearance of acetaminophen was found to be greater (p less than 0.025) in subjects with cystic fibrosis (0.362 +/- 0.081 L/hr/kg) than in control subjects (0.247 +/- 0.022 L/hr/kg).,Disposition of drugs in cystic fibrosis. Acetaminophen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752114/),[l] / [h·kg],0.362,198339,DB00316,Acetaminophen
,1752114,total plasma clearance,The total plasma clearance of acetaminophen was found to be greater (p less than 0.025) in subjects with cystic fibrosis (0.362 +/- 0.081 L/hr/kg) than in control subjects (0.247 +/- 0.022 L/hr/kg).,Disposition of drugs in cystic fibrosis. Acetaminophen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752114/),[l] / [h·kg],0.247,198340,DB00316,Acetaminophen
,1752114,metabolic clearance,This difference in clearance was found to be primarily attributable to a greater metabolic clearance of acetaminophen to acetaminophen sulfate (0.080 +/- 0.023 L/hr/kg for subjects with cystic fibrosis and 0.045 +/- 0.008 L/hr/kg for control subjects; p less than 0.05) and to a greater metabolic clearance of acetaminophen to acetaminophen glucuronide (0.189 +/- 0.051 L/hr/kg for subjects with cystic fibrosis and 0.114 +/- 0.017 L/hr/kg for control subjects; p less than 0.05) in persons with cystic fibrosis.,Disposition of drugs in cystic fibrosis. Acetaminophen. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752114/),[l] / [h·kg],0.080,198341,DB00316,Acetaminophen
,1752114,metabolic clearance,This difference in clearance was found to be primarily attributable to a greater metabolic clearance of acetaminophen to acetaminophen sulfate (0.080 +/- 0.023 L/hr/kg for subjects with cystic fibrosis and 0.045 +/- 0.008 L/hr/kg for control subjects; p less than 0.05) and to a greater metabolic clearance of acetaminophen to acetaminophen glucuronide (0.189 +/- 0.051 L/hr/kg for subjects with cystic fibrosis and 0.114 +/- 0.017 L/hr/kg for control subjects; p less than 0.05) in persons with cystic fibrosis.,Disposition of drugs in cystic fibrosis. Acetaminophen. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752114/),[l] / [h·kg],0.045,198342,DB00316,Acetaminophen
,1752114,metabolic clearance,This difference in clearance was found to be primarily attributable to a greater metabolic clearance of acetaminophen to acetaminophen sulfate (0.080 +/- 0.023 L/hr/kg for subjects with cystic fibrosis and 0.045 +/- 0.008 L/hr/kg for control subjects; p less than 0.05) and to a greater metabolic clearance of acetaminophen to acetaminophen glucuronide (0.189 +/- 0.051 L/hr/kg for subjects with cystic fibrosis and 0.114 +/- 0.017 L/hr/kg for control subjects; p less than 0.05) in persons with cystic fibrosis.,Disposition of drugs in cystic fibrosis. Acetaminophen. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752114/),[l] / [h·kg],0.189,198343,DB00316,Acetaminophen
,1740533,half-life,The half-life of amantadine after 42 days ingestion was 15.1 +/- 2.3 hours and was not different from 14.8 +/- 4.4 hours after an acute ingestion (mean +/- SD).,Effects of chronic amantadine hydrochloride ingestion on its and acetaminophen pharmacokinetics in young adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740533/),h,15.1,198893,DB00316,Acetaminophen
,1740533,half-life,The half-life of amantadine after 42 days ingestion was 15.1 +/- 2.3 hours and was not different from 14.8 +/- 4.4 hours after an acute ingestion (mean +/- SD).,Effects of chronic amantadine hydrochloride ingestion on its and acetaminophen pharmacokinetics in young adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740533/),h,14.8,198894,DB00316,Acetaminophen
,1740533,apparent volume of distribution,"However, chronic amantadine ingestion was associated with an increased apparent volume of distribution for acetaminophen, 1.1 +/- 0.1 L/kg compared with 0.9 +/- 0.1 L/kg, when the two drugs were concurrently ingested after a 2-week washout period.",Effects of chronic amantadine hydrochloride ingestion on its and acetaminophen pharmacokinetics in young adults. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740533/),[l] / [kg],1.1,198895,DB00316,Acetaminophen
,1740533,apparent volume of distribution,"However, chronic amantadine ingestion was associated with an increased apparent volume of distribution for acetaminophen, 1.1 +/- 0.1 L/kg compared with 0.9 +/- 0.1 L/kg, when the two drugs were concurrently ingested after a 2-week washout period.",Effects of chronic amantadine hydrochloride ingestion on its and acetaminophen pharmacokinetics in young adults. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740533/),[l] / [kg],0.9,198896,DB00316,Acetaminophen
,1740533,terminal,"This difference in kinetic distribution was not reflected in terminal acetaminophen half-life, 149 +/- 54 versus 151 +/- 55 minutes for chronic and acute amantadine ingestion, respectively.",Effects of chronic amantadine hydrochloride ingestion on its and acetaminophen pharmacokinetics in young adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740533/),min,149,198897,DB00316,Acetaminophen
,1740533,half-life,"This difference in kinetic distribution was not reflected in terminal acetaminophen half-life, 149 +/- 54 versus 151 +/- 55 minutes for chronic and acute amantadine ingestion, respectively.",Effects of chronic amantadine hydrochloride ingestion on its and acetaminophen pharmacokinetics in young adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740533/),min,149,198898,DB00316,Acetaminophen
,1740533,half-life,"This difference in kinetic distribution was not reflected in terminal acetaminophen half-life, 149 +/- 54 versus 151 +/- 55 minutes for chronic and acute amantadine ingestion, respectively.",Effects of chronic amantadine hydrochloride ingestion on its and acetaminophen pharmacokinetics in young adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740533/),min,151,198899,DB00316,Acetaminophen
,1740533,Plasma acetaminophen clearance,Plasma acetaminophen clearance with chronic amantadine ingestion (5.8 +/- 2.6 mL/min/kg) was not different from that determined after acute coingestion of both drugs (4.3 +/- 1.1 mL/min/kg).,Effects of chronic amantadine hydrochloride ingestion on its and acetaminophen pharmacokinetics in young adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740533/),[ml] / [kg·min],5.8,198900,DB00316,Acetaminophen
,1740533,Plasma acetaminophen clearance,Plasma acetaminophen clearance with chronic amantadine ingestion (5.8 +/- 2.6 mL/min/kg) was not different from that determined after acute coingestion of both drugs (4.3 +/- 1.1 mL/min/kg).,Effects of chronic amantadine hydrochloride ingestion on its and acetaminophen pharmacokinetics in young adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740533/),[ml] / [kg·min],4.3,198901,DB00316,Acetaminophen
,8885124,Peak plasma concentrations,"Peak plasma concentrations and apparent oral clearance values for phenacetin did not differ between the two groups (geometric means: 3.4 micrograms/ml and 1.56 ml h-1 kg-1, respectively, for Caucasians vs. 4.7 micrograms/ml and 1.25 ml h-1 kg-1, respectively, for Chinese, after excluding one Caucasian with aberrantly low plasma phenacetin values).",The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8885124/),[μg] / [ml],3.4,199194,DB00316,Acetaminophen
,8885124,Peak plasma concentrations,"Peak plasma concentrations and apparent oral clearance values for phenacetin did not differ between the two groups (geometric means: 3.4 micrograms/ml and 1.56 ml h-1 kg-1, respectively, for Caucasians vs. 4.7 micrograms/ml and 1.25 ml h-1 kg-1, respectively, for Chinese, after excluding one Caucasian with aberrantly low plasma phenacetin values).",The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8885124/),[μg] / [ml],4.7,199195,DB00316,Acetaminophen
,8885124,apparent oral clearance,"Peak plasma concentrations and apparent oral clearance values for phenacetin did not differ between the two groups (geometric means: 3.4 micrograms/ml and 1.56 ml h-1 kg-1, respectively, for Caucasians vs. 4.7 micrograms/ml and 1.25 ml h-1 kg-1, respectively, for Chinese, after excluding one Caucasian with aberrantly low plasma phenacetin values).",The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8885124/),[ml] / [h·kg],1.56,199196,DB00316,Acetaminophen
,8885124,apparent oral clearance,"Peak plasma concentrations and apparent oral clearance values for phenacetin did not differ between the two groups (geometric means: 3.4 micrograms/ml and 1.56 ml h-1 kg-1, respectively, for Caucasians vs. 4.7 micrograms/ml and 1.25 ml h-1 kg-1, respectively, for Chinese, after excluding one Caucasian with aberrantly low plasma phenacetin values).",The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8885124/),[ml] / [h·kg],1.25,199197,DB00316,Acetaminophen
,21276042,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was approximately 60-68 mg m(-2).,A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21276042/),[mg] / [(m)^2],60-68,199569,DB00316,Acetaminophen
,21276042,peak plasma concentration (C(max),"For CA4, at 50 mg m(-2),mean (SD) peak plasma concentration (C(max) was 0.99 (0.33) mM, area under the curve from time zero to time of last quantifiable concentration (AUC(0,t)) was 1.42 (0.30) mM h and terminal elimination half-life (t(1/2)was 1.81 (0.61) h.",A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21276042/),mM,0.99,199570,DB00316,Acetaminophen
,21276042,"area under the curve from time zero to time of last quantifiable concentration (AUC(0,t))","For CA4, at 50 mg m(-2),mean (SD) peak plasma concentration (C(max) was 0.99 (0.33) mM, area under the curve from time zero to time of last quantifiable concentration (AUC(0,t)) was 1.42 (0.30) mM h and terminal elimination half-life (t(1/2)was 1.81 (0.61) h.",A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21276042/),h·mM,1.42,199571,DB00316,Acetaminophen
,21276042,terminal elimination half-life (t(1/2),"For CA4, at 50 mg m(-2),mean (SD) peak plasma concentration (C(max) was 0.99 (0.33) mM, area under the curve from time zero to time of last quantifiable concentration (AUC(0,t)) was 1.42 (0.30) mM h and terminal elimination half-life (t(1/2)was 1.81 (0.61) h.",A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21276042/),h,1.81,199572,DB00316,Acetaminophen
,21276042,C(max),"At 65 mg m-2,C(max) was 1.73 (0.62) mM,AUC(0,t) was 3.19 (1.47) mM h and t (1/2) was 1.90 (0.61) h [corrected]One patient with nasopharyngeal carcinoma had an obvious clinical response with central necrosis in the metastatic lung mass.",A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21276042/),mM,1.73,199573,DB00316,Acetaminophen
,21276042,"AUC(0,t)","At 65 mg m-2,C(max) was 1.73 (0.62) mM,AUC(0,t) was 3.19 (1.47) mM h and t (1/2) was 1.90 (0.61) h [corrected]One patient with nasopharyngeal carcinoma had an obvious clinical response with central necrosis in the metastatic lung mass.",A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21276042/),h·mM,3.19,199574,DB00316,Acetaminophen
,21276042,t (1/2),"At 65 mg m-2,C(max) was 1.73 (0.62) mM,AUC(0,t) was 3.19 (1.47) mM h and t (1/2) was 1.90 (0.61) h [corrected]One patient with nasopharyngeal carcinoma had an obvious clinical response with central necrosis in the metastatic lung mass.",A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21276042/),h,1.90,199575,DB00316,Acetaminophen
,16859057,area under the curve,"In spinal cord-injured group, area under the curve and half-life were increased from 29.1 microg/mL.hr to 38.7 microg/mL.hr and from 7.7 hr to 14.1 hr as compared with the sham-lesioned control group, respectively.",The influence of experimental spinal cord injury on carbamazepine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16859057/),[μg] / [h·ml],29.1,201975,DB00316,Acetaminophen
,16859057,area under the curve,"In spinal cord-injured group, area under the curve and half-life were increased from 29.1 microg/mL.hr to 38.7 microg/mL.hr and from 7.7 hr to 14.1 hr as compared with the sham-lesioned control group, respectively.",The influence of experimental spinal cord injury on carbamazepine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16859057/),[μg] / [h·ml],38.7,201976,DB00316,Acetaminophen
,16859057,half-life,"In spinal cord-injured group, area under the curve and half-life were increased from 29.1 microg/mL.hr to 38.7 microg/mL.hr and from 7.7 hr to 14.1 hr as compared with the sham-lesioned control group, respectively.",The influence of experimental spinal cord injury on carbamazepine pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16859057/),[μg] / [h·ml],38.7,201977,DB00316,Acetaminophen
,16859057,half-life,"In spinal cord-injured group, area under the curve and half-life were increased from 29.1 microg/mL.hr to 38.7 microg/mL.hr and from 7.7 hr to 14.1 hr as compared with the sham-lesioned control group, respectively.",The influence of experimental spinal cord injury on carbamazepine pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16859057/),h,7.7,201978,DB00316,Acetaminophen
,16859057,half-life,"In spinal cord-injured group, area under the curve and half-life were increased from 29.1 microg/mL.hr to 38.7 microg/mL.hr and from 7.7 hr to 14.1 hr as compared with the sham-lesioned control group, respectively.",The influence of experimental spinal cord injury on carbamazepine pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16859057/),h,14.1,201979,DB00316,Acetaminophen
,18840028,"time to the peak blood ciclosporin concentration at steady state (t(max)(,ss))","In diabetic patients, the time to the peak blood ciclosporin concentration at steady state (t(max)(,ss)) was prolonged (128 minutes vs 93 minutes in nondiabetic patients, p < 0.01) and, on average, the paracetamol t(max) was prolonged by 30 minutes.",Blood and plasma pharmacokinetics of ciclosporin in diabetic kidney transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840028/),min,128,202643,DB00316,Acetaminophen
,18840028,"time to the peak blood ciclosporin concentration at steady state (t(max)(,ss))","In diabetic patients, the time to the peak blood ciclosporin concentration at steady state (t(max)(,ss)) was prolonged (128 minutes vs 93 minutes in nondiabetic patients, p < 0.01) and, on average, the paracetamol t(max) was prolonged by 30 minutes.",Blood and plasma pharmacokinetics of ciclosporin in diabetic kidney transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840028/),min,93,202644,DB00316,Acetaminophen
,18840028,f(u),"The ciclosporin f(u) was numerically higher in diabetic patients (1.20 +/- 0.65% vs 0.72 +/- 0.28% in nondiabetic patients, p = 0.066); however, the unbound concentration values were essentially similar in the two groups (0.58 +/- 0.76 microg/L in diabetic patients and 0.52 +/- 0.48 microg/L in nondiabetic patients; p = 0.59).",Blood and plasma pharmacokinetics of ciclosporin in diabetic kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840028/),%,1.20,202645,DB00316,Acetaminophen
,18840028,f(u),"The ciclosporin f(u) was numerically higher in diabetic patients (1.20 +/- 0.65% vs 0.72 +/- 0.28% in nondiabetic patients, p = 0.066); however, the unbound concentration values were essentially similar in the two groups (0.58 +/- 0.76 microg/L in diabetic patients and 0.52 +/- 0.48 microg/L in nondiabetic patients; p = 0.59).",Blood and plasma pharmacokinetics of ciclosporin in diabetic kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840028/),%,0.72,202646,DB00316,Acetaminophen
,18840028,unbound concentration,"The ciclosporin f(u) was numerically higher in diabetic patients (1.20 +/- 0.65% vs 0.72 +/- 0.28% in nondiabetic patients, p = 0.066); however, the unbound concentration values were essentially similar in the two groups (0.58 +/- 0.76 microg/L in diabetic patients and 0.52 +/- 0.48 microg/L in nondiabetic patients; p = 0.59).",Blood and plasma pharmacokinetics of ciclosporin in diabetic kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840028/),[μg] / [l],0.58,202647,DB00316,Acetaminophen
,18840028,unbound concentration,"The ciclosporin f(u) was numerically higher in diabetic patients (1.20 +/- 0.65% vs 0.72 +/- 0.28% in nondiabetic patients, p = 0.066); however, the unbound concentration values were essentially similar in the two groups (0.58 +/- 0.76 microg/L in diabetic patients and 0.52 +/- 0.48 microg/L in nondiabetic patients; p = 0.59).",Blood and plasma pharmacokinetics of ciclosporin in diabetic kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840028/),[μg] / [l],0.52,202648,DB00316,Acetaminophen
,10877008,tmax,The mean tmax was significantly shorter when paracetamol effervescent tablets were taken (27 min) rather than ordinary paracetamol tablets (45 min) (P = 0.004).,Absorption of effervescent paracetamol tablets relative to ordinary paracetamol tablets in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877008/),min,27,203628,DB00316,Acetaminophen
,10877008,tmax,The mean tmax was significantly shorter when paracetamol effervescent tablets were taken (27 min) rather than ordinary paracetamol tablets (45 min) (P = 0.004).,Absorption of effervescent paracetamol tablets relative to ordinary paracetamol tablets in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877008/),min,45,203629,DB00316,Acetaminophen
,10877008,Cmax,There was no significant difference between the mean Cmax of 143 micromol/l with effervescent tablets and that of 131 micromol/l with ordinary tablets.,Absorption of effervescent paracetamol tablets relative to ordinary paracetamol tablets in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877008/),[μM] / [l],143,203630,DB00316,Acetaminophen
,10877008,Cmax,There was no significant difference between the mean Cmax of 143 micromol/l with effervescent tablets and that of 131 micromol/l with ordinary tablets.,Absorption of effervescent paracetamol tablets relative to ordinary paracetamol tablets in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877008/),[μM] / [l],131,203631,DB00316,Acetaminophen
,10877008,AUC(0-3 h),The mean AUC(0-3 h) was significantly higher with paracetamol effervescent tablets (223.8 micromol x h x l(-1)) than with ordinary tablets (198.2 micromol x h x l(-1); P = 0.003).,Absorption of effervescent paracetamol tablets relative to ordinary paracetamol tablets in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877008/),[h·μM] / [l],223.8,203632,DB00316,Acetaminophen
,10877008,AUC(0-3 h),The mean AUC(0-3 h) was significantly higher with paracetamol effervescent tablets (223.8 micromol x h x l(-1)) than with ordinary tablets (198.2 micromol x h x l(-1); P = 0.003).,Absorption of effervescent paracetamol tablets relative to ordinary paracetamol tablets in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877008/),[h·μM] / [l],198.2,203633,DB00316,Acetaminophen
,23724654,mean residence time (MRT),"The pharmacokinetic results of erdosteine and its thiol-containing active metabolite showed that the area under curve (AUC) of the thiol-containing active metabolite was 6.2 times of that of erdosteine after a single oral dose of 600 mg erdosteine tables in 32 healthy volunteers, The mean residence time (MRT) of the thiol-containing active metabolite was (7.51 +/- 0.788) h, which provided a pharmacokinetic basis for the rational dosage regimen.",[Simultaneous determination of erdosteine and its active metabolite in human plasma by liquid chromatography-tandem mass spectrometry with pre-column derivatization]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23724654/),h,7.51,204001,DB00316,Acetaminophen
,16239057,mean plasma levels,"In PAP-treated rats, mean plasma levels at 0.5, 1, 2, 4, 8 or 24h were 0.16, 0.24, 0.38, 0.50, 0.36 or 0.14 microg [(14)C]-PAP equivalents/ml, respectively.",Plasma/blood pharmacokinetics and metabolism after dermal exposure to para-aminophenol or para-phenylenediamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239057/),μg,0.16,204420,DB00316,Acetaminophen
,16239057,mean plasma levels,"In PAP-treated rats, mean plasma levels at 0.5, 1, 2, 4, 8 or 24h were 0.16, 0.24, 0.38, 0.50, 0.36 or 0.14 microg [(14)C]-PAP equivalents/ml, respectively.",Plasma/blood pharmacokinetics and metabolism after dermal exposure to para-aminophenol or para-phenylenediamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239057/),μg,0.24,204421,DB00316,Acetaminophen
,16239057,mean plasma levels,"In PAP-treated rats, mean plasma levels at 0.5, 1, 2, 4, 8 or 24h were 0.16, 0.24, 0.38, 0.50, 0.36 or 0.14 microg [(14)C]-PAP equivalents/ml, respectively.",Plasma/blood pharmacokinetics and metabolism after dermal exposure to para-aminophenol or para-phenylenediamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239057/),μg,0.38,204422,DB00316,Acetaminophen
,16239057,mean plasma levels,"In PAP-treated rats, mean plasma levels at 0.5, 1, 2, 4, 8 or 24h were 0.16, 0.24, 0.38, 0.50, 0.36 or 0.14 microg [(14)C]-PAP equivalents/ml, respectively.",Plasma/blood pharmacokinetics and metabolism after dermal exposure to para-aminophenol or para-phenylenediamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239057/),μg,0.50,204423,DB00316,Acetaminophen
,16239057,mean plasma levels,"In PAP-treated rats, mean plasma levels at 0.5, 1, 2, 4, 8 or 24h were 0.16, 0.24, 0.38, 0.50, 0.36 or 0.14 microg [(14)C]-PAP equivalents/ml, respectively.",Plasma/blood pharmacokinetics and metabolism after dermal exposure to para-aminophenol or para-phenylenediamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239057/),μg,0.36,204424,DB00316,Acetaminophen
,16239057,mean plasma levels,"In PAP-treated rats, mean plasma levels at 0.5, 1, 2, 4, 8 or 24h were 0.16, 0.24, 0.38, 0.50, 0.36 or 0.14 microg [(14)C]-PAP equivalents/ml, respectively.",Plasma/blood pharmacokinetics and metabolism after dermal exposure to para-aminophenol or para-phenylenediamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239057/),μg,0.14,204425,DB00316,Acetaminophen
,16239057,plasma half-life,"The plasma half-life was 5.95 h, the C(max) was 0.5 microg/ml, the t(max) was 4 h, and the AUC(0-infinity) was 9.27 microg-equivalentsh/ml.",Plasma/blood pharmacokinetics and metabolism after dermal exposure to para-aminophenol or para-phenylenediamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239057/),h,5.95,204426,DB00316,Acetaminophen
,16239057,C(max),"The plasma half-life was 5.95 h, the C(max) was 0.5 microg/ml, the t(max) was 4 h, and the AUC(0-infinity) was 9.27 microg-equivalentsh/ml.",Plasma/blood pharmacokinetics and metabolism after dermal exposure to para-aminophenol or para-phenylenediamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239057/),[μg] / [ml],0.5,204427,DB00316,Acetaminophen
,16239057,t(max),"The plasma half-life was 5.95 h, the C(max) was 0.5 microg/ml, the t(max) was 4 h, and the AUC(0-infinity) was 9.27 microg-equivalentsh/ml.",Plasma/blood pharmacokinetics and metabolism after dermal exposure to para-aminophenol or para-phenylenediamine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239057/),h,4,204428,DB00316,Acetaminophen
,16239057,AUC(0-infinity),"The plasma half-life was 5.95 h, the C(max) was 0.5 microg/ml, the t(max) was 4 h, and the AUC(0-infinity) was 9.27 microg-equivalentsh/ml.",Plasma/blood pharmacokinetics and metabolism after dermal exposure to para-aminophenol or para-phenylenediamine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239057/),[μg-equivalentsh] / [ml],9.27,204429,DB00316,Acetaminophen
,16239057,C(max),"In the pig, very low levels of radioactivity (C(max) of approximately 10 ng/ml) were found in the blood, and identified as APAP.",Plasma/blood pharmacokinetics and metabolism after dermal exposure to para-aminophenol or para-phenylenediamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239057/),[ng] / [ml],10,204430,DB00316,Acetaminophen
,15822577,half emptying time,"Data from 32 feedings were analyzed, with half emptying time for scintigraphic evaluation ranging from 29 to 202 minutes.",Determination of abomasal emptying rate in suckling calves by use of nuclear scintigraphy and acetaminophen absorption. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15822577/),min,29 to 202,204460,DB00316,Acetaminophen
,26535968,Tmax,"Following a single dose of hydrocodone-ER, Tmax was prolonged to approximately 6 hours at all dose levels of hydrocodone-ER compared with 2.9 hours for the IR formulation.",A pharmacokinetic evaluation of single and multiple doses of extended-release hydrocodone bitartrate in subjects experiencing surgical or osteoarthritic pain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26535968/),h,6,204674,DB00316,Acetaminophen
,26535968,Tmax,"Following a single dose of hydrocodone-ER, Tmax was prolonged to approximately 6 hours at all dose levels of hydrocodone-ER compared with 2.9 hours for the IR formulation.",A pharmacokinetic evaluation of single and multiple doses of extended-release hydrocodone bitartrate in subjects experiencing surgical or osteoarthritic pain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26535968/),h,2.9,204675,DB00316,Acetaminophen
,30770889,total larval volumes,"Paracetamol clearance, determined from elimination rate constants and reported total larval volumes of 253, 263, and 300 nL at 3, 4, and 5 dpf respectively, correlates best with higher vertebrates at 5 dpf.",Impact of post-hatching maturation on the pharmacokinetics of paracetamol in zebrafish larvae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30770889/),nl,253,205190,DB00316,Acetaminophen
,30770889,total larval volumes,"Paracetamol clearance, determined from elimination rate constants and reported total larval volumes of 253, 263, and 300 nL at 3, 4, and 5 dpf respectively, correlates best with higher vertebrates at 5 dpf.",Impact of post-hatching maturation on the pharmacokinetics of paracetamol in zebrafish larvae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30770889/),nl,263,205191,DB00316,Acetaminophen
,30770889,total larval volumes,"Paracetamol clearance, determined from elimination rate constants and reported total larval volumes of 253, 263, and 300 nL at 3, 4, and 5 dpf respectively, correlates best with higher vertebrates at 5 dpf.",Impact of post-hatching maturation on the pharmacokinetics of paracetamol in zebrafish larvae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30770889/),nl,300,205192,DB00316,Acetaminophen
,7848353,Bioavailability,"Bioavailability of paracetamol was 89 and 90% for the 500 and 1000 mg suppositories, respectively compared with that of the 500 mg reference tablets.",[Relative bioavailability of paracetamol in suppositories preparations in comparison to tablets]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848353/),%,89,205590,DB00316,Acetaminophen
,7848353,Bioavailability,"Bioavailability of paracetamol was 89 and 90% for the 500 and 1000 mg suppositories, respectively compared with that of the 500 mg reference tablets.",[Relative bioavailability of paracetamol in suppositories preparations in comparison to tablets]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848353/),%,90,205591,DB00316,Acetaminophen
,7848353,maximum paracetamol plasma concentrations (Cmax),"Mean maximum paracetamol plasma concentrations (Cmax) were 3.55 and 6.02 or 7.16 mg/l after administration of the 500 and 1000 mg suppositories or the 500 mg tablets, respectively.",[Relative bioavailability of paracetamol in suppositories preparations in comparison to tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848353/),[mg] / [l],3.55,205592,DB00316,Acetaminophen
,7848353,maximum paracetamol plasma concentrations (Cmax),"Mean maximum paracetamol plasma concentrations (Cmax) were 3.55 and 6.02 or 7.16 mg/l after administration of the 500 and 1000 mg suppositories or the 500 mg tablets, respectively.",[Relative bioavailability of paracetamol in suppositories preparations in comparison to tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848353/),[mg] / [l],6.02,205593,DB00316,Acetaminophen
,7848353,maximum paracetamol plasma concentrations (Cmax),"Mean maximum paracetamol plasma concentrations (Cmax) were 3.55 and 6.02 or 7.16 mg/l after administration of the 500 and 1000 mg suppositories or the 500 mg tablets, respectively.",[Relative bioavailability of paracetamol in suppositories preparations in comparison to tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848353/),[mg] / [l],7.16,205594,DB00316,Acetaminophen
,7848353,tmax,"These maximum concentrations were achieved 2.0, 2.7 and 0.6 h (tmax) after administration of the respective preparations.",[Relative bioavailability of paracetamol in suppositories preparations in comparison to tablets]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848353/),h,2.0,205595,DB00316,Acetaminophen
,7848353,tmax,"These maximum concentrations were achieved 2.0, 2.7 and 0.6 h (tmax) after administration of the respective preparations.",[Relative bioavailability of paracetamol in suppositories preparations in comparison to tablets]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848353/),h,2.7,205596,DB00316,Acetaminophen
,7848353,tmax,"These maximum concentrations were achieved 2.0, 2.7 and 0.6 h (tmax) after administration of the respective preparations.",[Relative bioavailability of paracetamol in suppositories preparations in comparison to tablets]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848353/),h,0.6,205597,DB00316,Acetaminophen
,7848353,HVD,"The corresponding HVD values were 4.3, 5.2 and 2.0 h, respectively.",[Relative bioavailability of paracetamol in suppositories preparations in comparison to tablets]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848353/),h,4.3,205598,DB00316,Acetaminophen
,7848353,HVD,"The corresponding HVD values were 4.3, 5.2 and 2.0 h, respectively.",[Relative bioavailability of paracetamol in suppositories preparations in comparison to tablets]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848353/),h,5.2,205599,DB00316,Acetaminophen
,7848353,HVD,"The corresponding HVD values were 4.3, 5.2 and 2.0 h, respectively.",[Relative bioavailability of paracetamol in suppositories preparations in comparison to tablets]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848353/),h,2.0,205600,DB00316,Acetaminophen
exceeded,7848353,relative bioavailabilities,After dose adjustment of the results for the 1000 mg suppositories relative bioavailabilities of paracetamol from both rectal formulations exceeded 80% of that from the tablets.,[Relative bioavailability of paracetamol in suppositories preparations in comparison to tablets]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848353/),%,80,205601,DB00316,Acetaminophen
,21440401,flow rate,"Separation was achieved on a ZORBAX Rapid Resolution High Definition (RRHD) SB-C18 (50mm×2.1mm, 1.8μm) reversed-phase column at 20°C with methanol-10mM ammonium acetate solution (65:35, v/v) at a flow rate of 1.0mL/min.",Determination of the cardioactive prototype LASSBio-294 and its metabolites in dog plasma by LC-MS/MS: application for a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21440401/),[ml] / [min],1.0,205710,DB00316,Acetaminophen
,21440401,t(1/2),"The main pharmacokinetic parameters t(1/2), C(max) and AUC(0-24) were (5.74±0.55)h, (547.66±35.12)ng/mL and (1621.77±41.66)ngh/mL, respectively.",Determination of the cardioactive prototype LASSBio-294 and its metabolites in dog plasma by LC-MS/MS: application for a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21440401/),h,5.74,205711,DB00316,Acetaminophen
,21440401,C(max),"The main pharmacokinetic parameters t(1/2), C(max) and AUC(0-24) were (5.74±0.55)h, (547.66±35.12)ng/mL and (1621.77±41.66)ngh/mL, respectively.",Determination of the cardioactive prototype LASSBio-294 and its metabolites in dog plasma by LC-MS/MS: application for a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21440401/),[ng] / [ml],547.66,205712,DB00316,Acetaminophen
,21440401,AUC(0-24),"The main pharmacokinetic parameters t(1/2), C(max) and AUC(0-24) were (5.74±0.55)h, (547.66±35.12)ng/mL and (1621.77±41.66)ngh/mL, respectively.",Determination of the cardioactive prototype LASSBio-294 and its metabolites in dog plasma by LC-MS/MS: application for a pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21440401/),[ngh] / [ml],1621.77,205713,DB00316,Acetaminophen
,8363647,unbound fractions,"Acetaminophen, AG and acetaminophen sulfate (AS) were not bound extensively in hepatic cytosol (mean +/- SD unbound fractions were 0.90 +/- 0.08, 0.97 +/- 0.08, and 0.88 +/- 0.06, respectively).","Hepatic disposition of acetaminophen and metabolites. Pharmacokinetic modeling, protein binding and subcellular distribution. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8363647/),,0.90,205804,DB00316,Acetaminophen
,8363647,unbound fractions,"Acetaminophen, AG and acetaminophen sulfate (AS) were not bound extensively in hepatic cytosol (mean +/- SD unbound fractions were 0.90 +/- 0.08, 0.97 +/- 0.08, and 0.88 +/- 0.06, respectively).","Hepatic disposition of acetaminophen and metabolites. Pharmacokinetic modeling, protein binding and subcellular distribution. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8363647/),,0.97,205805,DB00316,Acetaminophen
,8363647,unbound fractions,"Acetaminophen, AG and acetaminophen sulfate (AS) were not bound extensively in hepatic cytosol (mean +/- SD unbound fractions were 0.90 +/- 0.08, 0.97 +/- 0.08, and 0.88 +/- 0.06, respectively).","Hepatic disposition of acetaminophen and metabolites. Pharmacokinetic modeling, protein binding and subcellular distribution. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8363647/),,0.88,205806,DB00316,Acetaminophen
,31195843,area under the concentration-time curve,"At day 9, the pharmacokinetic parameters of acetaminophen in the presence of K. parviflora extract also decreased, including area under the concentration-time curve (from 1.68 ± 0.16 to 0.34 ± 0.04 mg.min/mL), the maximum concentration (from 19.10 ± 1.90 to 4.48 ± 0.56 µg/mL), and half-life (from 21.29 ± 1.36 to 10.81 ± 1.24 min).",In vivo effect of Kaempferia parviflora extract on pharmacokinetics of acetaminophen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31195843/),[mg·min] / [ml],1.68,206593,DB00316,Acetaminophen
,31195843,area under the concentration-time curve,"At day 9, the pharmacokinetic parameters of acetaminophen in the presence of K. parviflora extract also decreased, including area under the concentration-time curve (from 1.68 ± 0.16 to 0.34 ± 0.04 mg.min/mL), the maximum concentration (from 19.10 ± 1.90 to 4.48 ± 0.56 µg/mL), and half-life (from 21.29 ± 1.36 to 10.81 ± 1.24 min).",In vivo effect of Kaempferia parviflora extract on pharmacokinetics of acetaminophen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31195843/),[mg·min] / [ml],0.34,206594,DB00316,Acetaminophen
,31195843,maximum concentration,"At day 9, the pharmacokinetic parameters of acetaminophen in the presence of K. parviflora extract also decreased, including area under the concentration-time curve (from 1.68 ± 0.16 to 0.34 ± 0.04 mg.min/mL), the maximum concentration (from 19.10 ± 1.90 to 4.48 ± 0.56 µg/mL), and half-life (from 21.29 ± 1.36 to 10.81 ± 1.24 min).",In vivo effect of Kaempferia parviflora extract on pharmacokinetics of acetaminophen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31195843/),[μg] / [ml],19.10,206595,DB00316,Acetaminophen
,31195843,maximum concentration,"At day 9, the pharmacokinetic parameters of acetaminophen in the presence of K. parviflora extract also decreased, including area under the concentration-time curve (from 1.68 ± 0.16 to 0.34 ± 0.04 mg.min/mL), the maximum concentration (from 19.10 ± 1.90 to 4.48 ± 0.56 µg/mL), and half-life (from 21.29 ± 1.36 to 10.81 ± 1.24 min).",In vivo effect of Kaempferia parviflora extract on pharmacokinetics of acetaminophen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31195843/),[μg] / [ml],4.48,206596,DB00316,Acetaminophen
,31195843,half-life,"At day 9, the pharmacokinetic parameters of acetaminophen in the presence of K. parviflora extract also decreased, including area under the concentration-time curve (from 1.68 ± 0.16 to 0.34 ± 0.04 mg.min/mL), the maximum concentration (from 19.10 ± 1.90 to 4.48 ± 0.56 µg/mL), and half-life (from 21.29 ± 1.36 to 10.81 ± 1.24 min).",In vivo effect of Kaempferia parviflora extract on pharmacokinetics of acetaminophen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31195843/),min,21.29,206597,DB00316,Acetaminophen
,31195843,half-life,"At day 9, the pharmacokinetic parameters of acetaminophen in the presence of K. parviflora extract also decreased, including area under the concentration-time curve (from 1.68 ± 0.16 to 0.34 ± 0.04 mg.min/mL), the maximum concentration (from 19.10 ± 1.90 to 4.48 ± 0.56 µg/mL), and half-life (from 21.29 ± 1.36 to 10.81 ± 1.24 min).",In vivo effect of Kaempferia parviflora extract on pharmacokinetics of acetaminophen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31195843/),min,10.81,206598,DB00316,Acetaminophen
,31195843,clearance,"In addition, clearance and the elimination rate constant of acetaminophen were significantly increased (from 0.003 ± 0.000 to 0.006 ± 0.001 L/min and 0.03 ± 0.00 to 0.07 ± 0.01 min-1, respectively) in the presence of K. parviflora extract.",In vivo effect of Kaempferia parviflora extract on pharmacokinetics of acetaminophen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31195843/),[l] / [min],0.003,206599,DB00316,Acetaminophen
,31195843,clearance,"In addition, clearance and the elimination rate constant of acetaminophen were significantly increased (from 0.003 ± 0.000 to 0.006 ± 0.001 L/min and 0.03 ± 0.00 to 0.07 ± 0.01 min-1, respectively) in the presence of K. parviflora extract.",In vivo effect of Kaempferia parviflora extract on pharmacokinetics of acetaminophen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31195843/),[l] / [min],0.006,206600,DB00316,Acetaminophen
,31195843,elimination rate constant,"In addition, clearance and the elimination rate constant of acetaminophen were significantly increased (from 0.003 ± 0.000 to 0.006 ± 0.001 L/min and 0.03 ± 0.00 to 0.07 ± 0.01 min-1, respectively) in the presence of K. parviflora extract.",In vivo effect of Kaempferia parviflora extract on pharmacokinetics of acetaminophen. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31195843/),[l] / [min],0.006,206601,DB00316,Acetaminophen
,31195843,elimination rate constant,"In addition, clearance and the elimination rate constant of acetaminophen were significantly increased (from 0.003 ± 0.000 to 0.006 ± 0.001 L/min and 0.03 ± 0.00 to 0.07 ± 0.01 min-1, respectively) in the presence of K. parviflora extract.",In vivo effect of Kaempferia parviflora extract on pharmacokinetics of acetaminophen. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31195843/),1/[min],0.03,206602,DB00316,Acetaminophen
,31195843,elimination rate constant,"In addition, clearance and the elimination rate constant of acetaminophen were significantly increased (from 0.003 ± 0.000 to 0.006 ± 0.001 L/min and 0.03 ± 0.00 to 0.07 ± 0.01 min-1, respectively) in the presence of K. parviflora extract.",In vivo effect of Kaempferia parviflora extract on pharmacokinetics of acetaminophen. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31195843/),1/[min],0.07,206603,DB00316,Acetaminophen
,29978489,flow rate,"Analytes were eluted by a binary gradient mobile phase composed of water (phase A) and methanol containing 0.1% formic acid (phase B) at a flow rate of 0.3 mL/min, which was performed on a CAPCELL PAK C18 MG II column.","A reliable LC-MS/MS method for the quantification of N-acetyl-p-benzoquinoneimine, acetaminophen glutathione and acetaminophen glucuronide in mouse plasma, liver and kidney: Method validation and application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29978489/),[ml] / [min],0.3,206836,DB00316,Acetaminophen
,1190239,relative bioavailabilities,The absorption of acetaminophen from the suppositories was extremely variable and showed relative bioavailabilities of 68.4 to 87.5% when compared to the oral absorption of the drug from the tablet.,Bioavailability of acetaminophen suppositories. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1190239/),%,68.4 to 87.5,208578,DB00316,Acetaminophen
,8530713,systemic bioavailability,Oral estrogens have minimal systemic bioavailability (2% to 10%) due to gut and liver (first-pass) metabolism.,Pharmacokinetic and pharmacologic variation between different estrogen products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8530713/),%,2,209255,DB00316,Acetaminophen
,8530713,systemic bioavailability,Oral estrogens have minimal systemic bioavailability (2% to 10%) due to gut and liver (first-pass) metabolism.,Pharmacokinetic and pharmacologic variation between different estrogen products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8530713/),%,10,209256,DB00316,Acetaminophen
,8530713,terminal half lives,The terminal half lives for the different estrogen compounds (after oral or intravenous administration) vary from 1-12 hours.,Pharmacokinetic and pharmacologic variation between different estrogen products. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8530713/),h,1-12,209257,DB00316,Acetaminophen
,11185632,Cmax,"Geometric mean Cmax values for acetaminophen and R-(-)- and S-(+)-ibuprofen enantiomers were similar with and without telmisartan coadministration (12.6 micrograms/mL vs. 14.1 micrograms/mL; 17.3 micrograms/mL vs. 16.7 micrograms/mL; 19.4 micrograms/mL vs. 19.5 micrograms/mL, respectively), and values for R-(-)- as well as S-(+)-ibuprofen were bioequivalent.",Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185632/),[μg] / [ml],12.6,209874,DB00316,Acetaminophen
,11185632,Cmax,"Geometric mean Cmax values for acetaminophen and R-(-)- and S-(+)-ibuprofen enantiomers were similar with and without telmisartan coadministration (12.6 micrograms/mL vs. 14.1 micrograms/mL; 17.3 micrograms/mL vs. 16.7 micrograms/mL; 19.4 micrograms/mL vs. 19.5 micrograms/mL, respectively), and values for R-(-)- as well as S-(+)-ibuprofen were bioequivalent.",Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185632/),[μg] / [ml],14.1,209875,DB00316,Acetaminophen
,11185632,Cmax,"Geometric mean Cmax values for acetaminophen and R-(-)- and S-(+)-ibuprofen enantiomers were similar with and without telmisartan coadministration (12.6 micrograms/mL vs. 14.1 micrograms/mL; 17.3 micrograms/mL vs. 16.7 micrograms/mL; 19.4 micrograms/mL vs. 19.5 micrograms/mL, respectively), and values for R-(-)- as well as S-(+)-ibuprofen were bioequivalent.",Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185632/),[μg] / [ml],17.3,209876,DB00316,Acetaminophen
,11185632,Cmax,"Geometric mean Cmax values for acetaminophen and R-(-)- and S-(+)-ibuprofen enantiomers were similar with and without telmisartan coadministration (12.6 micrograms/mL vs. 14.1 micrograms/mL; 17.3 micrograms/mL vs. 16.7 micrograms/mL; 19.4 micrograms/mL vs. 19.5 micrograms/mL, respectively), and values for R-(-)- as well as S-(+)-ibuprofen were bioequivalent.",Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185632/),[μg] / [ml],16.7,209877,DB00316,Acetaminophen
,11185632,Cmax,"Geometric mean Cmax values for acetaminophen and R-(-)- and S-(+)-ibuprofen enantiomers were similar with and without telmisartan coadministration (12.6 micrograms/mL vs. 14.1 micrograms/mL; 17.3 micrograms/mL vs. 16.7 micrograms/mL; 19.4 micrograms/mL vs. 19.5 micrograms/mL, respectively), and values for R-(-)- as well as S-(+)-ibuprofen were bioequivalent.",Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185632/),[μg] / [ml],19.4,209878,DB00316,Acetaminophen
,11185632,Cmax,"Geometric mean Cmax values for acetaminophen and R-(-)- and S-(+)-ibuprofen enantiomers were similar with and without telmisartan coadministration (12.6 micrograms/mL vs. 14.1 micrograms/mL; 17.3 micrograms/mL vs. 16.7 micrograms/mL; 19.4 micrograms/mL vs. 19.5 micrograms/mL, respectively), and values for R-(-)- as well as S-(+)-ibuprofen were bioequivalent.",Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185632/),[μg] / [ml],19.5,209879,DB00316,Acetaminophen
,8223835,plasma concentration,The mean plasma concentration of paracetamol was 6.8 mg x l-1 after the first 24 h and subsequently varied little throughout the 10 days.,The disposition of paracetamol and its conjugates during multiple dosing in patients with end-stage renal failure maintained on haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223835/),[mg] / [l],6.8,210127,DB00316,Acetaminophen
,8223835,Apparent steady-state plasma concentrations,Apparent steady-state plasma concentrations of 60.0 mg x l-1 and 54.5 mg x l-1 were reached for the glucuronide and sulphate conjugate of paracetamol respectively by the 2nd day of treatment with little variation throughout the remainder of the study.,The disposition of paracetamol and its conjugates during multiple dosing in patients with end-stage renal failure maintained on haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223835/),[mg] / [l],60.0,210128,DB00316,Acetaminophen
,8223835,Apparent steady-state plasma concentrations,Apparent steady-state plasma concentrations of 60.0 mg x l-1 and 54.5 mg x l-1 were reached for the glucuronide and sulphate conjugate of paracetamol respectively by the 2nd day of treatment with little variation throughout the remainder of the study.,The disposition of paracetamol and its conjugates during multiple dosing in patients with end-stage renal failure maintained on haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223835/),[mg] / [l],54.5,210129,DB00316,Acetaminophen
,8223835,steady-state plasma concentrations,"The steady-state plasma concentrations of the retained cysteine and mercapturate conjugates of paracetamol were low (5.7 and 3.7 mg x l-1, respectively) and there was no evidence of accumulation of these potentially toxic metabolites.",The disposition of paracetamol and its conjugates during multiple dosing in patients with end-stage renal failure maintained on haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223835/),[mg] / [l],5.7,210130,DB00316,Acetaminophen
,8223835,steady-state plasma concentrations,"The steady-state plasma concentrations of the retained cysteine and mercapturate conjugates of paracetamol were low (5.7 and 3.7 mg x l-1, respectively) and there was no evidence of accumulation of these potentially toxic metabolites.",The disposition of paracetamol and its conjugates during multiple dosing in patients with end-stage renal failure maintained on haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223835/),[mg] / [l],3.7,210131,DB00316,Acetaminophen
,21143403,Cmax,"PEx exhibited significantly lower paracetamol Cmax (252.33 µmol/L vs 565.56 µmol/L, P= 0.0421), AUC((0-∞)) (2133 µmol/h/L vs 2637 µmol/h/L, P= 0.0004) and delayed Tmax (2.889 h vs 1.389 h, P= 0.0189) than APAP-IR.",The comparative pharmacokinetics of modified-release and immediate-release paracetamol in a simulated overdose model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21143403/),[μM] / [l],252.33,210821,DB00316,Acetaminophen
,21143403,Cmax,"PEx exhibited significantly lower paracetamol Cmax (252.33 µmol/L vs 565.56 µmol/L, P= 0.0421), AUC((0-∞)) (2133 µmol/h/L vs 2637 µmol/h/L, P= 0.0004) and delayed Tmax (2.889 h vs 1.389 h, P= 0.0189) than APAP-IR.",The comparative pharmacokinetics of modified-release and immediate-release paracetamol in a simulated overdose model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21143403/),[μM] / [l],565.56,210822,DB00316,Acetaminophen
,21143403,AUC((0-∞)),"PEx exhibited significantly lower paracetamol Cmax (252.33 µmol/L vs 565.56 µmol/L, P= 0.0421), AUC((0-∞)) (2133 µmol/h/L vs 2637 µmol/h/L, P= 0.0004) and delayed Tmax (2.889 h vs 1.389 h, P= 0.0189) than APAP-IR.",The comparative pharmacokinetics of modified-release and immediate-release paracetamol in a simulated overdose model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21143403/),[μM] / [h·l],2133,210823,DB00316,Acetaminophen
,21143403,AUC((0-∞)),"PEx exhibited significantly lower paracetamol Cmax (252.33 µmol/L vs 565.56 µmol/L, P= 0.0421), AUC((0-∞)) (2133 µmol/h/L vs 2637 µmol/h/L, P= 0.0004) and delayed Tmax (2.889 h vs 1.389 h, P= 0.0189) than APAP-IR.",The comparative pharmacokinetics of modified-release and immediate-release paracetamol in a simulated overdose model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21143403/),[μM] / [h·l],2637,210824,DB00316,Acetaminophen
,21143403,Tmax,"PEx exhibited significantly lower paracetamol Cmax (252.33 µmol/L vs 565.56 µmol/L, P= 0.0421), AUC((0-∞)) (2133 µmol/h/L vs 2637 µmol/h/L, P= 0.0004) and delayed Tmax (2.889 h vs 1.389 h, P= 0.0189) than APAP-IR.",The comparative pharmacokinetics of modified-release and immediate-release paracetamol in a simulated overdose model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21143403/),h,2.889,210825,DB00316,Acetaminophen
,21143403,Tmax,"PEx exhibited significantly lower paracetamol Cmax (252.33 µmol/L vs 565.56 µmol/L, P= 0.0421), AUC((0-∞)) (2133 µmol/h/L vs 2637 µmol/h/L, P= 0.0004) and delayed Tmax (2.889 h vs 1.389 h, P= 0.0189) than APAP-IR.",The comparative pharmacokinetics of modified-release and immediate-release paracetamol in a simulated overdose model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21143403/),h,1.389,210826,DB00316,Acetaminophen
,21143403,AUC((0-∞)),"Sulphate metabolite PK parameters for both preparations, PEx vs APAP-IR, showed similar AUC((0-∞)) (1369 µmol/h/L vs 1089 µmol/h/L), Tmax (3.889 h vs 4.444 h), Cmax (95.889 µmol/L vs 95.889 µmol/L) and t(1/2) (3.895 h vs 3.810 h).",The comparative pharmacokinetics of modified-release and immediate-release paracetamol in a simulated overdose model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21143403/),[μM] / [h·l],1369,210827,DB00316,Acetaminophen
,21143403,AUC((0-∞)),"Sulphate metabolite PK parameters for both preparations, PEx vs APAP-IR, showed similar AUC((0-∞)) (1369 µmol/h/L vs 1089 µmol/h/L), Tmax (3.889 h vs 4.444 h), Cmax (95.889 µmol/L vs 95.889 µmol/L) and t(1/2) (3.895 h vs 3.810 h).",The comparative pharmacokinetics of modified-release and immediate-release paracetamol in a simulated overdose model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21143403/),[μM] / [h·l],1089,210828,DB00316,Acetaminophen
,21143403,Tmax,"Sulphate metabolite PK parameters for both preparations, PEx vs APAP-IR, showed similar AUC((0-∞)) (1369 µmol/h/L vs 1089 µmol/h/L), Tmax (3.889 h vs 4.444 h), Cmax (95.889 µmol/L vs 95.889 µmol/L) and t(1/2) (3.895 h vs 3.810 h).",The comparative pharmacokinetics of modified-release and immediate-release paracetamol in a simulated overdose model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21143403/),h,3.889,210829,DB00316,Acetaminophen
,21143403,Tmax,"Sulphate metabolite PK parameters for both preparations, PEx vs APAP-IR, showed similar AUC((0-∞)) (1369 µmol/h/L vs 1089 µmol/h/L), Tmax (3.889 h vs 4.444 h), Cmax (95.889 µmol/L vs 95.889 µmol/L) and t(1/2) (3.895 h vs 3.810 h).",The comparative pharmacokinetics of modified-release and immediate-release paracetamol in a simulated overdose model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21143403/),h,4.444,210830,DB00316,Acetaminophen
,21143403,Cmax,"Sulphate metabolite PK parameters for both preparations, PEx vs APAP-IR, showed similar AUC((0-∞)) (1369 µmol/h/L vs 1089 µmol/h/L), Tmax (3.889 h vs 4.444 h), Cmax (95.889 µmol/L vs 95.889 µmol/L) and t(1/2) (3.895 h vs 3.810 h).",The comparative pharmacokinetics of modified-release and immediate-release paracetamol in a simulated overdose model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21143403/),[μM] / [l],95.889,210831,DB00316,Acetaminophen
,21143403,t(1/2),"Sulphate metabolite PK parameters for both preparations, PEx vs APAP-IR, showed similar AUC((0-∞)) (1369 µmol/h/L vs 1089 µmol/h/L), Tmax (3.889 h vs 4.444 h), Cmax (95.889 µmol/L vs 95.889 µmol/L) and t(1/2) (3.895 h vs 3.810 h).",The comparative pharmacokinetics of modified-release and immediate-release paracetamol in a simulated overdose model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21143403/),h,3.895,210832,DB00316,Acetaminophen
,21143403,t(1/2),"Sulphate metabolite PK parameters for both preparations, PEx vs APAP-IR, showed similar AUC((0-∞)) (1369 µmol/h/L vs 1089 µmol/h/L), Tmax (3.889 h vs 4.444 h), Cmax (95.889 µmol/L vs 95.889 µmol/L) and t(1/2) (3.895 h vs 3.810 h).",The comparative pharmacokinetics of modified-release and immediate-release paracetamol in a simulated overdose model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21143403/),h,3.810,210833,DB00316,Acetaminophen
,21143403,Cmax,"Glucuronide metabolite concentrations revealed that PEx produced a lower Cmax (257.44 µmol/L vs 335.22 µmol/L, P= 0.0239) than APAP-IR.",The comparative pharmacokinetics of modified-release and immediate-release paracetamol in a simulated overdose model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21143403/),[μM] / [l],257.44,210834,DB00316,Acetaminophen
,21143403,Cmax,"Glucuronide metabolite concentrations revealed that PEx produced a lower Cmax (257.44 µmol/L vs 335.22 µmol/L, P= 0.0239) than APAP-IR.",The comparative pharmacokinetics of modified-release and immediate-release paracetamol in a simulated overdose model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21143403/),[μM] / [l],335.22,210835,DB00316,Acetaminophen
,31194730,AUCo/AUCp plasma,"The model was also able to describe disease-mediated changes in neonates and young children (<3m postnatal age) related to meningitis and sepsis (range AUCo/AUCp plasma: 1.64-1.66, range AUCo/AUCp CSF: 1.43-1.73).",Development of a physiologically-based pharmacokinetic pediatric brain model for prediction of cerebrospinal fluid drug concentrations and the influence of meningitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194730/),,1.64-1.66,211062,DB00316,Acetaminophen
,31194730,AUCo/AUCp CSF,"The model was also able to describe disease-mediated changes in neonates and young children (<3m postnatal age) related to meningitis and sepsis (range AUCo/AUCp plasma: 1.64-1.66, range AUCo/AUCp CSF: 1.43-1.73).",Development of a physiologically-based pharmacokinetic pediatric brain model for prediction of cerebrospinal fluid drug concentrations and the influence of meningitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194730/),,1.43-1.73,211063,DB00316,Acetaminophen
,31609773,enter,"In 47 patients (median age of 6.1 mo; Q1-Q3, 1.8-20 mo) the mean enteral bioavailability was 72% (range, 11-91%).",Enteral Acetaminophen Bioavailability in Pediatric Intensive Care Patients Determined With an Oral Microtracer and Pharmacokinetic Modeling to Optimize Dosing. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31609773/),%,72,212354,DB00316,Acetaminophen
,1505153,Time of maximum serum concentrations,"Time of maximum serum concentrations for ibuprofen was 54.05 minutes versus 27.0 minutes for acetaminophen, time to maximum temperature decrease was 183 minutes for ibuprofen and 133 minutes for acetaminophen.",Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505153/),min,54.05,212929,DB00316,Acetaminophen
,1505153,Time of maximum serum concentrations,"Time of maximum serum concentrations for ibuprofen was 54.05 minutes versus 27.0 minutes for acetaminophen, time to maximum temperature decrease was 183 minutes for ibuprofen and 133 minutes for acetaminophen.",Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505153/),min,27.0,212930,DB00316,Acetaminophen
,1505153,time to maximum temperature decrease,"Time of maximum serum concentrations for ibuprofen was 54.05 minutes versus 27.0 minutes for acetaminophen, time to maximum temperature decrease was 183 minutes for ibuprofen and 133 minutes for acetaminophen.",Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505153/),min,183,212931,DB00316,Acetaminophen
,1505153,time to maximum temperature decrease,"Time of maximum serum concentrations for ibuprofen was 54.05 minutes versus 27.0 minutes for acetaminophen, time to maximum temperature decrease was 183 minutes for ibuprofen and 133 minutes for acetaminophen.",Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505153/),min,133,212932,DB00316,Acetaminophen
,28419483,maximum concentration,"Acetaminophen concentrations and pharmacokinetic parameters were these: maximum concentration 33.6 [25.7-38.7] μg/mL and minimum concentration 0.5 [0.2-2.3] μg/mL, all values below 10 μg/mL and 8 below the detection limit; half-life 1.2 [1.0-1.9] hours; area under the curve for 6 hours 34.7 [29.7-52.7] μg·h/mL; mean residence time 1.8 [1.3-2.6] hours; steady-state volume of distribution 50.8 [42.5-66.5] L; and serum and renal clearance 28.8 [18.9-33.7] L/h and 15 [11-19] mL/min, respectively.",Pharmacokinetic Study of Intravenous Acetaminophen Administered to Critically Ill Multiple-Trauma Patients at the Usual Dosage and a New Proposal for Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28419483/),[μg] / [ml],33.6,213040,DB00316,Acetaminophen
,28419483,minimum concentration,"Acetaminophen concentrations and pharmacokinetic parameters were these: maximum concentration 33.6 [25.7-38.7] μg/mL and minimum concentration 0.5 [0.2-2.3] μg/mL, all values below 10 μg/mL and 8 below the detection limit; half-life 1.2 [1.0-1.9] hours; area under the curve for 6 hours 34.7 [29.7-52.7] μg·h/mL; mean residence time 1.8 [1.3-2.6] hours; steady-state volume of distribution 50.8 [42.5-66.5] L; and serum and renal clearance 28.8 [18.9-33.7] L/h and 15 [11-19] mL/min, respectively.",Pharmacokinetic Study of Intravenous Acetaminophen Administered to Critically Ill Multiple-Trauma Patients at the Usual Dosage and a New Proposal for Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28419483/),[μg] / [ml],0.5,213041,DB00316,Acetaminophen
,28419483,half-life,"Acetaminophen concentrations and pharmacokinetic parameters were these: maximum concentration 33.6 [25.7-38.7] μg/mL and minimum concentration 0.5 [0.2-2.3] μg/mL, all values below 10 μg/mL and 8 below the detection limit; half-life 1.2 [1.0-1.9] hours; area under the curve for 6 hours 34.7 [29.7-52.7] μg·h/mL; mean residence time 1.8 [1.3-2.6] hours; steady-state volume of distribution 50.8 [42.5-66.5] L; and serum and renal clearance 28.8 [18.9-33.7] L/h and 15 [11-19] mL/min, respectively.",Pharmacokinetic Study of Intravenous Acetaminophen Administered to Critically Ill Multiple-Trauma Patients at the Usual Dosage and a New Proposal for Administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28419483/),h,1.2,213042,DB00316,Acetaminophen
,28419483,area under the curve for 6 hours,"Acetaminophen concentrations and pharmacokinetic parameters were these: maximum concentration 33.6 [25.7-38.7] μg/mL and minimum concentration 0.5 [0.2-2.3] μg/mL, all values below 10 μg/mL and 8 below the detection limit; half-life 1.2 [1.0-1.9] hours; area under the curve for 6 hours 34.7 [29.7-52.7] μg·h/mL; mean residence time 1.8 [1.3-2.6] hours; steady-state volume of distribution 50.8 [42.5-66.5] L; and serum and renal clearance 28.8 [18.9-33.7] L/h and 15 [11-19] mL/min, respectively.",Pharmacokinetic Study of Intravenous Acetaminophen Administered to Critically Ill Multiple-Trauma Patients at the Usual Dosage and a New Proposal for Administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28419483/),[h·μg] / [ml],34.7,213043,DB00316,Acetaminophen
,28419483,mean residence time,"Acetaminophen concentrations and pharmacokinetic parameters were these: maximum concentration 33.6 [25.7-38.7] μg/mL and minimum concentration 0.5 [0.2-2.3] μg/mL, all values below 10 μg/mL and 8 below the detection limit; half-life 1.2 [1.0-1.9] hours; area under the curve for 6 hours 34.7 [29.7-52.7] μg·h/mL; mean residence time 1.8 [1.3-2.6] hours; steady-state volume of distribution 50.8 [42.5-66.5] L; and serum and renal clearance 28.8 [18.9-33.7] L/h and 15 [11-19] mL/min, respectively.",Pharmacokinetic Study of Intravenous Acetaminophen Administered to Critically Ill Multiple-Trauma Patients at the Usual Dosage and a New Proposal for Administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28419483/),h,1.8,213044,DB00316,Acetaminophen
,28419483,steady-state volume of distribution,"Acetaminophen concentrations and pharmacokinetic parameters were these: maximum concentration 33.6 [25.7-38.7] μg/mL and minimum concentration 0.5 [0.2-2.3] μg/mL, all values below 10 μg/mL and 8 below the detection limit; half-life 1.2 [1.0-1.9] hours; area under the curve for 6 hours 34.7 [29.7-52.7] μg·h/mL; mean residence time 1.8 [1.3-2.6] hours; steady-state volume of distribution 50.8 [42.5-66.5] L; and serum and renal clearance 28.8 [18.9-33.7] L/h and 15 [11-19] mL/min, respectively.",Pharmacokinetic Study of Intravenous Acetaminophen Administered to Critically Ill Multiple-Trauma Patients at the Usual Dosage and a New Proposal for Administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28419483/),l,50.8,213045,DB00316,Acetaminophen
,28419483,serum,"Acetaminophen concentrations and pharmacokinetic parameters were these: maximum concentration 33.6 [25.7-38.7] μg/mL and minimum concentration 0.5 [0.2-2.3] μg/mL, all values below 10 μg/mL and 8 below the detection limit; half-life 1.2 [1.0-1.9] hours; area under the curve for 6 hours 34.7 [29.7-52.7] μg·h/mL; mean residence time 1.8 [1.3-2.6] hours; steady-state volume of distribution 50.8 [42.5-66.5] L; and serum and renal clearance 28.8 [18.9-33.7] L/h and 15 [11-19] mL/min, respectively.",Pharmacokinetic Study of Intravenous Acetaminophen Administered to Critically Ill Multiple-Trauma Patients at the Usual Dosage and a New Proposal for Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28419483/),[l] / [h],28.8,213046,DB00316,Acetaminophen
,28419483,renal clearance,"Acetaminophen concentrations and pharmacokinetic parameters were these: maximum concentration 33.6 [25.7-38.7] μg/mL and minimum concentration 0.5 [0.2-2.3] μg/mL, all values below 10 μg/mL and 8 below the detection limit; half-life 1.2 [1.0-1.9] hours; area under the curve for 6 hours 34.7 [29.7-52.7] μg·h/mL; mean residence time 1.8 [1.3-2.6] hours; steady-state volume of distribution 50.8 [42.5-66.5] L; and serum and renal clearance 28.8 [18.9-33.7] L/h and 15 [11-19] mL/min, respectively.",Pharmacokinetic Study of Intravenous Acetaminophen Administered to Critically Ill Multiple-Trauma Patients at the Usual Dosage and a New Proposal for Administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28419483/),[l] / [h],28.8,213047,DB00316,Acetaminophen
,28419483,renal clearance,"Acetaminophen concentrations and pharmacokinetic parameters were these: maximum concentration 33.6 [25.7-38.7] μg/mL and minimum concentration 0.5 [0.2-2.3] μg/mL, all values below 10 μg/mL and 8 below the detection limit; half-life 1.2 [1.0-1.9] hours; area under the curve for 6 hours 34.7 [29.7-52.7] μg·h/mL; mean residence time 1.8 [1.3-2.6] hours; steady-state volume of distribution 50.8 [42.5-66.5] L; and serum and renal clearance 28.8 [18.9-33.7] L/h and 15 [11-19] mL/min, respectively.",Pharmacokinetic Study of Intravenous Acetaminophen Administered to Critically Ill Multiple-Trauma Patients at the Usual Dosage and a New Proposal for Administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28419483/),[ml] / [min],15,213048,DB00316,Acetaminophen
,28419483,steady-state minimum concentration,"Theoretically, daily doses for a steady-state minimum concentration of 10 μg/mL would be 12.2 [7.8-16.4] g/day (166 [112-202] mg/[kg·day]); for an average steady-state concentration of 10 μg/mL, they would be 6.9 [4.5-8.1] g/day (91 [59-111] mg/[kg·day]).",Pharmacokinetic Study of Intravenous Acetaminophen Administered to Critically Ill Multiple-Trauma Patients at the Usual Dosage and a New Proposal for Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28419483/),[μg] / [ml],10,213049,DB00316,Acetaminophen
,28419483,steady-state minimum concentration,"Theoretically, daily doses for a steady-state minimum concentration of 10 μg/mL would be 12.2 [7.8-16.4] g/day (166 [112-202] mg/[kg·day]); for an average steady-state concentration of 10 μg/mL, they would be 6.9 [4.5-8.1] g/day (91 [59-111] mg/[kg·day]).",Pharmacokinetic Study of Intravenous Acetaminophen Administered to Critically Ill Multiple-Trauma Patients at the Usual Dosage and a New Proposal for Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28419483/),[g] / [d],12.2,213050,DB00316,Acetaminophen
,28419483,steady-state concentration,"Theoretically, daily doses for a steady-state minimum concentration of 10 μg/mL would be 12.2 [7.8-16.4] g/day (166 [112-202] mg/[kg·day]); for an average steady-state concentration of 10 μg/mL, they would be 6.9 [4.5-8.1] g/day (91 [59-111] mg/[kg·day]).",Pharmacokinetic Study of Intravenous Acetaminophen Administered to Critically Ill Multiple-Trauma Patients at the Usual Dosage and a New Proposal for Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28419483/),[μg] / [ml],10,213051,DB00316,Acetaminophen
,28419483,steady-state concentration,"Theoretically, daily doses for a steady-state minimum concentration of 10 μg/mL would be 12.2 [7.8-16.4] g/day (166 [112-202] mg/[kg·day]); for an average steady-state concentration of 10 μg/mL, they would be 6.9 [4.5-8.1] g/day (91 [59-111] mg/[kg·day]).",Pharmacokinetic Study of Intravenous Acetaminophen Administered to Critically Ill Multiple-Trauma Patients at the Usual Dosage and a New Proposal for Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28419483/),[g] / [d],6.9,213052,DB00316,Acetaminophen
,28419483,steady-state concentration,"Theoretically, daily doses for a steady-state minimum concentration of 10 μg/mL would be 12.2 [7.8-16.4] g/day (166 [112-202] mg/[kg·day]); for an average steady-state concentration of 10 μg/mL, they would be 6.9 [4.5-8.1] g/day (91 [59-111] mg/[kg·day]).",Pharmacokinetic Study of Intravenous Acetaminophen Administered to Critically Ill Multiple-Trauma Patients at the Usual Dosage and a New Proposal for Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28419483/),[mg] / [d·kg],91,213053,DB00316,Acetaminophen
,11762668,area under the curve (AUC,"The mean area under the curve (AUC+/-SD) for the control and the 1-, 2-, and 3-hour groups were 221 +/- 54, 154 +/- 71, 206 +/- 67 and 204 +/- 58 mg/L/h, respectively.",How long after drug ingestion is activated charcoal still effective? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762668/),[mg] / [h·l],221,213634,DB00316,Acetaminophen
,11762668,area under the curve (AUC,"The mean area under the curve (AUC+/-SD) for the control and the 1-, 2-, and 3-hour groups were 221 +/- 54, 154 +/- 71, 206 +/- 67 and 204 +/- 58 mg/L/h, respectively.",How long after drug ingestion is activated charcoal still effective? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762668/),[mg] / [h·l],154,213635,DB00316,Acetaminophen
,11762668,area under the curve (AUC,"The mean area under the curve (AUC+/-SD) for the control and the 1-, 2-, and 3-hour groups were 221 +/- 54, 154 +/- 71, 206 +/- 67 and 204 +/- 58 mg/L/h, respectively.",How long after drug ingestion is activated charcoal still effective? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762668/),[mg] / [h·l],206,213636,DB00316,Acetaminophen
,11762668,area under the curve (AUC,"The mean area under the curve (AUC+/-SD) for the control and the 1-, 2-, and 3-hour groups were 221 +/- 54, 154 +/- 71, 206 +/- 67 and 204 +/- 58 mg/L/h, respectively.",How long after drug ingestion is activated charcoal still effective? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762668/),[mg] / [h·l],204,213637,DB00316,Acetaminophen
,11762668,bioavailability,"The decrease of bioavailability at 1 hour was 30.3%, which is similar to previous studies.",How long after drug ingestion is activated charcoal still effective? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762668/),%,30.3,213638,DB00316,Acetaminophen
,1440617,peak plasma concentrations,RHA/jj rats demonstrated respective 230- and 7-fold increases in the peak plasma concentrations of ALT (17144 +/- 1014 vs 75 +/- 10) and BUN (128 +/- 23 vs 18.4 +/- 0.2) compared to congenic normal controls (RHA/++) (p < 0.05).,Biotransformation and toxicity of acetaminophen in congenic RHA rats with or without a hereditary deficiency in bilirubin UDP-glucuronosyltransferase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1440617/),,17144,214135,DB00316,Acetaminophen
,1440617,peak plasma concentrations,RHA/jj rats demonstrated respective 230- and 7-fold increases in the peak plasma concentrations of ALT (17144 +/- 1014 vs 75 +/- 10) and BUN (128 +/- 23 vs 18.4 +/- 0.2) compared to congenic normal controls (RHA/++) (p < 0.05).,Biotransformation and toxicity of acetaminophen in congenic RHA rats with or without a hereditary deficiency in bilirubin UDP-glucuronosyltransferase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1440617/),,75,214136,DB00316,Acetaminophen
,1440617,peak plasma concentrations,RHA/jj rats demonstrated respective 230- and 7-fold increases in the peak plasma concentrations of ALT (17144 +/- 1014 vs 75 +/- 10) and BUN (128 +/- 23 vs 18.4 +/- 0.2) compared to congenic normal controls (RHA/++) (p < 0.05).,Biotransformation and toxicity of acetaminophen in congenic RHA rats with or without a hereditary deficiency in bilirubin UDP-glucuronosyltransferase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1440617/),,128,214137,DB00316,Acetaminophen
,1440617,peak plasma concentrations,RHA/jj rats demonstrated respective 230- and 7-fold increases in the peak plasma concentrations of ALT (17144 +/- 1014 vs 75 +/- 10) and BUN (128 +/- 23 vs 18.4 +/- 0.2) compared to congenic normal controls (RHA/++) (p < 0.05).,Biotransformation and toxicity of acetaminophen in congenic RHA rats with or without a hereditary deficiency in bilirubin UDP-glucuronosyltransferase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1440617/),,18.4,214138,DB00316,Acetaminophen
,8803883,clearance,Parent paracetamol had a significantly slower clearance (21.9 +/- 1.4 mL/min.kg. vs. 52.8 +/- 7.3 mL/min.kg) (P < 0.01) in camels than in goats.,Comparative pharmacokinetics of paracetamol (acetaminophen) and its sulphate and glucuronide metabolites in desert camels and goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803883/),[ml] / [kg·min],21.9,214241,DB00316,Acetaminophen
,8803883,clearance,Parent paracetamol had a significantly slower clearance (21.9 +/- 1.4 mL/min.kg. vs. 52.8 +/- 7.3 mL/min.kg) (P < 0.01) in camels than in goats.,Comparative pharmacokinetics of paracetamol (acetaminophen) and its sulphate and glucuronide metabolites in desert camels and goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803883/),[ml] / [kg·min],52.8,214242,DB00316,Acetaminophen
,8803883,apparent AUC,"The apparent AUC for paracetamol in the camel following intramuscular administration was larger than that following intravenous administration, however, when the bioavailability (F) was determined, with correction for altered half-life, within the animal and between study phases it was 71 +/- 17% in goats and 105 +/- 26% in camels.",Comparative pharmacokinetics of paracetamol (acetaminophen) and its sulphate and glucuronide metabolites in desert camels and goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803883/),%,71,214243,DB00316,Acetaminophen
,8803883,bioavailability (F),"The apparent AUC for paracetamol in the camel following intramuscular administration was larger than that following intravenous administration, however, when the bioavailability (F) was determined, with correction for altered half-life, within the animal and between study phases it was 71 +/- 17% in goats and 105 +/- 26% in camels.",Comparative pharmacokinetics of paracetamol (acetaminophen) and its sulphate and glucuronide metabolites in desert camels and goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803883/),%,71,214244,DB00316,Acetaminophen
,8803883,bioavailability (F),"The apparent AUC for paracetamol in the camel following intramuscular administration was larger than that following intravenous administration, however, when the bioavailability (F) was determined, with correction for altered half-life, within the animal and between study phases it was 71 +/- 17% in goats and 105 +/- 26% in camels.",Comparative pharmacokinetics of paracetamol (acetaminophen) and its sulphate and glucuronide metabolites in desert camels and goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803883/),%,105,214245,DB00316,Acetaminophen
,26234136,recovery rate,"The serum acetaminophen was also measured with good linear relationship (y = 0.0045 x + 0.0462, R = 0.9982) and the recovery rate was 97.4%-116.7%.",[Determination of serum acetaminophen based on the diazo reaction and its application in the evaluation of gastric emptying]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26234136/),%,97.4,215607,DB00316,Acetaminophen
,26234136,recovery rate,"The serum acetaminophen was also measured with good linear relationship (y = 0.0045 x + 0.0462, R = 0.9982) and the recovery rate was 97.4%-116.7%.",[Determination of serum acetaminophen based on the diazo reaction and its application in the evaluation of gastric emptying]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26234136/),%,116.7,215608,DB00316,Acetaminophen
,33854925,plasma concentration,The mean plasma concentration of VPA in group A was: 26.9 ± 13.5 mg/L.,Evaluation of sodium valproate low dose efficacy in radicular pain management and it's relation with pharmacokinetics parameters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33854925/),[mg] / [l],26.9,216588,DB00316,Acetaminophen
,23149443,metabolic clearance,"Mean (95% confidence interval) metabolic clearance to paracetamol glucuronide increased from 0.06 (0.05-0.08) to 0.14 (0.11-0.18) L · h⁻¹ · kg⁻¹, P value <0.001 and urinary clearance increased from 0.08 (0.07-0.09) to 0.14 (0.10-0.17) L · h⁻¹ · kg⁻¹, P value 0.002.",The pharmacokinetic profile of intravenous paracetamol in adult patients undergoing major abdominal surgery. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23149443/),h⁻¹·kg⁻¹·l,0.06,216870,DB00316,Acetaminophen
,23149443,metabolic clearance,"Mean (95% confidence interval) metabolic clearance to paracetamol glucuronide increased from 0.06 (0.05-0.08) to 0.14 (0.11-0.18) L · h⁻¹ · kg⁻¹, P value <0.001 and urinary clearance increased from 0.08 (0.07-0.09) to 0.14 (0.10-0.17) L · h⁻¹ · kg⁻¹, P value 0.002.",The pharmacokinetic profile of intravenous paracetamol in adult patients undergoing major abdominal surgery. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23149443/),h⁻¹·kg⁻¹·l,0.14,216871,DB00316,Acetaminophen
,23149443,urinary clearance,"Mean (95% confidence interval) metabolic clearance to paracetamol glucuronide increased from 0.06 (0.05-0.08) to 0.14 (0.11-0.18) L · h⁻¹ · kg⁻¹, P value <0.001 and urinary clearance increased from 0.08 (0.07-0.09) to 0.14 (0.10-0.17) L · h⁻¹ · kg⁻¹, P value 0.002.",The pharmacokinetic profile of intravenous paracetamol in adult patients undergoing major abdominal surgery. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23149443/),h⁻¹·kg⁻¹·l,0.08,216872,DB00316,Acetaminophen
,23149443,urinary clearance,"Mean (95% confidence interval) metabolic clearance to paracetamol glucuronide increased from 0.06 (0.05-0.08) to 0.14 (0.11-0.18) L · h⁻¹ · kg⁻¹, P value <0.001 and urinary clearance increased from 0.08 (0.07-0.09) to 0.14 (0.10-0.17) L · h⁻¹ · kg⁻¹, P value 0.002.",The pharmacokinetic profile of intravenous paracetamol in adult patients undergoing major abdominal surgery. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23149443/),h⁻¹·kg⁻¹·l,0.14,216873,DB00316,Acetaminophen
,23149443,volume of distribution,"The mean (95% confidence interval) volume of distribution of paracetamol increased from 0.17 (0.12-0.21) to 0.43 (0.27-0.59) L · kg⁻¹, P value 0.032.",The pharmacokinetic profile of intravenous paracetamol in adult patients undergoing major abdominal surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23149443/),kg⁻¹·l,0.17,216874,DB00316,Acetaminophen
,23149443,volume of distribution,"The mean (95% confidence interval) volume of distribution of paracetamol increased from 0.17 (0.12-0.21) to 0.43 (0.27-0.59) L · kg⁻¹, P value 0.032.",The pharmacokinetic profile of intravenous paracetamol in adult patients undergoing major abdominal surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23149443/),kg⁻¹·l,0.43,216875,DB00316,Acetaminophen
,7069091,peak plasma concentration,"The mean (+/- sd) kinetic variables for absorption of AAP from tablets in young and elderly were peak plasma concentration, 11.8 (+/- 4.2) vs 10.9 (+/- 4.1) micrograms/ml; peak time, 0.79 (+/- .54) vs 0.69 (+/- .40) hours after the dose; absorption half-life, 12.6 (+/- 9.8) vs. 8.2 (+/- 5.3) minutes; and absolute systemic availability, 79 (+/- 9) vs 72 (+/- 11) per cent.",Age does not alter acetaminophen absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7069091/),[μg] / [ml],11.8,217316,DB00316,Acetaminophen
,7069091,peak plasma concentration,"The mean (+/- sd) kinetic variables for absorption of AAP from tablets in young and elderly were peak plasma concentration, 11.8 (+/- 4.2) vs 10.9 (+/- 4.1) micrograms/ml; peak time, 0.79 (+/- .54) vs 0.69 (+/- .40) hours after the dose; absorption half-life, 12.6 (+/- 9.8) vs. 8.2 (+/- 5.3) minutes; and absolute systemic availability, 79 (+/- 9) vs 72 (+/- 11) per cent.",Age does not alter acetaminophen absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7069091/),[μg] / [ml],10.9,217317,DB00316,Acetaminophen
,7069091,peak time,"The mean (+/- sd) kinetic variables for absorption of AAP from tablets in young and elderly were peak plasma concentration, 11.8 (+/- 4.2) vs 10.9 (+/- 4.1) micrograms/ml; peak time, 0.79 (+/- .54) vs 0.69 (+/- .40) hours after the dose; absorption half-life, 12.6 (+/- 9.8) vs. 8.2 (+/- 5.3) minutes; and absolute systemic availability, 79 (+/- 9) vs 72 (+/- 11) per cent.",Age does not alter acetaminophen absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7069091/),h,0.79,217318,DB00316,Acetaminophen
,7069091,peak time,"The mean (+/- sd) kinetic variables for absorption of AAP from tablets in young and elderly were peak plasma concentration, 11.8 (+/- 4.2) vs 10.9 (+/- 4.1) micrograms/ml; peak time, 0.79 (+/- .54) vs 0.69 (+/- .40) hours after the dose; absorption half-life, 12.6 (+/- 9.8) vs. 8.2 (+/- 5.3) minutes; and absolute systemic availability, 79 (+/- 9) vs 72 (+/- 11) per cent.",Age does not alter acetaminophen absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7069091/),h,0.69,217319,DB00316,Acetaminophen
,7069091,absorption half-life,"The mean (+/- sd) kinetic variables for absorption of AAP from tablets in young and elderly were peak plasma concentration, 11.8 (+/- 4.2) vs 10.9 (+/- 4.1) micrograms/ml; peak time, 0.79 (+/- .54) vs 0.69 (+/- .40) hours after the dose; absorption half-life, 12.6 (+/- 9.8) vs. 8.2 (+/- 5.3) minutes; and absolute systemic availability, 79 (+/- 9) vs 72 (+/- 11) per cent.",Age does not alter acetaminophen absorption. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7069091/),min,12.6,217320,DB00316,Acetaminophen
,7069091,absorption half-life,"The mean (+/- sd) kinetic variables for absorption of AAP from tablets in young and elderly were peak plasma concentration, 11.8 (+/- 4.2) vs 10.9 (+/- 4.1) micrograms/ml; peak time, 0.79 (+/- .54) vs 0.69 (+/- .40) hours after the dose; absorption half-life, 12.6 (+/- 9.8) vs. 8.2 (+/- 5.3) minutes; and absolute systemic availability, 79 (+/- 9) vs 72 (+/- 11) per cent.",Age does not alter acetaminophen absorption. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7069091/),min,8.2,217321,DB00316,Acetaminophen
,7069091,absolute systemic availability,"The mean (+/- sd) kinetic variables for absorption of AAP from tablets in young and elderly were peak plasma concentration, 11.8 (+/- 4.2) vs 10.9 (+/- 4.1) micrograms/ml; peak time, 0.79 (+/- .54) vs 0.69 (+/- .40) hours after the dose; absorption half-life, 12.6 (+/- 9.8) vs. 8.2 (+/- 5.3) minutes; and absolute systemic availability, 79 (+/- 9) vs 72 (+/- 11) per cent.",Age does not alter acetaminophen absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7069091/),%,79,217322,DB00316,Acetaminophen
,7069091,absolute systemic availability,"The mean (+/- sd) kinetic variables for absorption of AAP from tablets in young and elderly were peak plasma concentration, 11.8 (+/- 4.2) vs 10.9 (+/- 4.1) micrograms/ml; peak time, 0.79 (+/- .54) vs 0.69 (+/- .40) hours after the dose; absorption half-life, 12.6 (+/- 9.8) vs. 8.2 (+/- 5.3) minutes; and absolute systemic availability, 79 (+/- 9) vs 72 (+/- 11) per cent.",Age does not alter acetaminophen absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7069091/),%,72,217323,DB00316,Acetaminophen
less,7069091,Absolute bioavailability,Absolute bioavailability of both oral dosage forms was significantly less then 100 per cent in all groups.,Age does not alter acetaminophen absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7069091/),%,100,217324,DB00316,Acetaminophen
,30272138,flow rate,"Chromatographic analysis was achieved firstly by HPLC method on C18 column (150 × 4.6 mm2 i.d., 5 μm) and a mobile phase composed of ethanol:water (containing 0.1% acetic acid) (70:30, v/v) at the flow rate of 0.6 mL min-1.",Simultaneous Determination of Thalidomide and Dexamethasone in Rat Plasma by Validated HPLC and HPTLC With Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30272138/),[ml] / [min],0.6,217803,DB00316,Acetaminophen
,20211479,absolute bioavailability,"The absolute bioavailability was 42.2%, 39.0%, 44.5%, 75.5% and 91.0% in chickens, turkeys, dogs, pigs and horses, respectively.","Species comparison of oral bioavailability, first-pass metabolism and pharmacokinetics of acetaminophen. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20211479/),%,42.2,218522,DB00316,Acetaminophen
,20211479,absolute bioavailability,"The absolute bioavailability was 42.2%, 39.0%, 44.5%, 75.5% and 91.0% in chickens, turkeys, dogs, pigs and horses, respectively.","Species comparison of oral bioavailability, first-pass metabolism and pharmacokinetics of acetaminophen. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20211479/),%,39.0,218523,DB00316,Acetaminophen
,20211479,absolute bioavailability,"The absolute bioavailability was 42.2%, 39.0%, 44.5%, 75.5% and 91.0% in chickens, turkeys, dogs, pigs and horses, respectively.","Species comparison of oral bioavailability, first-pass metabolism and pharmacokinetics of acetaminophen. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20211479/),%,44.5,218524,DB00316,Acetaminophen
,20211479,absolute bioavailability,"The absolute bioavailability was 42.2%, 39.0%, 44.5%, 75.5% and 91.0% in chickens, turkeys, dogs, pigs and horses, respectively.","Species comparison of oral bioavailability, first-pass metabolism and pharmacokinetics of acetaminophen. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20211479/),%,75.5,218525,DB00316,Acetaminophen
,20211479,absolute bioavailability,"The absolute bioavailability was 42.2%, 39.0%, 44.5%, 75.5% and 91.0% in chickens, turkeys, dogs, pigs and horses, respectively.","Species comparison of oral bioavailability, first-pass metabolism and pharmacokinetics of acetaminophen. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20211479/),%,91.0,218526,DB00316,Acetaminophen
,20211479,apparent bioavailability,"After hydrolysis of metabolites by beta-glucuronidase/sulfatase, apparent bioavailability increased significantly in all species (turkeys: 72.4%, dogs: 100.5%, pigs: 102.2%), except horses (91.6%).","Species comparison of oral bioavailability, first-pass metabolism and pharmacokinetics of acetaminophen. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20211479/),%,72.4,218527,DB00316,Acetaminophen
,20211479,apparent bioavailability,"After hydrolysis of metabolites by beta-glucuronidase/sulfatase, apparent bioavailability increased significantly in all species (turkeys: 72.4%, dogs: 100.5%, pigs: 102.2%), except horses (91.6%).","Species comparison of oral bioavailability, first-pass metabolism and pharmacokinetics of acetaminophen. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20211479/),%,100.5,218528,DB00316,Acetaminophen
,20211479,apparent bioavailability,"After hydrolysis of metabolites by beta-glucuronidase/sulfatase, apparent bioavailability increased significantly in all species (turkeys: 72.4%, dogs: 100.5%, pigs: 102.2%), except horses (91.6%).","Species comparison of oral bioavailability, first-pass metabolism and pharmacokinetics of acetaminophen. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20211479/),%,102.2,218529,DB00316,Acetaminophen
,20211479,apparent bioavailability,"After hydrolysis of metabolites by beta-glucuronidase/sulfatase, apparent bioavailability increased significantly in all species (turkeys: 72.4%, dogs: 100.5%, pigs: 102.2%), except horses (91.6%).","Species comparison of oral bioavailability, first-pass metabolism and pharmacokinetics of acetaminophen. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20211479/),%,91.6,218530,DB00316,Acetaminophen
,26484583,clearance,"There was a significant alteration in the pharmacokinetics of acetylcysteine during hemodialysis; the area under the curve (AUC) decreased 41%, the mean extraction ratio was 51%, the mean hemodialytic clearance was 114.01 ml/kg/h, and a mean 166.75 mg/h was recovered in the effluent or 41% of the hourly dose.",The pharmacokinetics and extracorporeal removal of N-acetylcysteine during renal replacement therapies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26484583/),[ml] / [h·kg],114.01,219207,DB00316,Acetaminophen
,26484583,clearance,"Alteration in the pharmacokinetics of acetylcysteine during continuous venovenous hemofiltration did not appear to be significant: the AUC decreased 13%, the mean clearance was 31.77 ml/kg/h and a mean 62.12 mg/h was recovered in the effluent or 14% of the hourly dose.",The pharmacokinetics and extracorporeal removal of N-acetylcysteine during renal replacement therapies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26484583/),[ml] / [h·kg],31.77,219208,DB00316,Acetaminophen
,26484583,clearance,"Alteration in the pharmacokinetics of acetylcysteine during continuous venovenous hemofiltration did not appear to be significant: the AUC decreased 13%, the mean clearance was 31.77 ml/kg/h and a mean 62.12 mg/h was recovered in the effluent or 14% of the hourly dose.",The pharmacokinetics and extracorporeal removal of N-acetylcysteine during renal replacement therapies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26484583/),[mg] / [h],62.12,219209,DB00316,Acetaminophen
,10594475,maximum blood-ethanol concentration (Cmax ),The maximum blood-ethanol concentration (Cmax ) increased from 3.8+/-1.7 to 5.6+/-2.3 mmol l-1 (+/-s.d.) after treatment with cisapride (95% confidence interval CI on mean difference 0.28-3.28 mmol l-1 ).,Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594475/),[mM] / [l],3.8,219529,DB00316,Acetaminophen
,10594475,maximum blood-ethanol concentration (Cmax ),The maximum blood-ethanol concentration (Cmax ) increased from 3.8+/-1.7 to 5.6+/-2.3 mmol l-1 (+/-s.d.) after treatment with cisapride (95% confidence interval CI on mean difference 0.28-3.28 mmol l-1 ).,Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594475/),[mM] / [l],5.6,219530,DB00316,Acetaminophen
,10594475,area under the blood-ethanol curve (AUC),The area under the blood-ethanol curve (AUC) increased from 6.3+/-3.5 to 7.9+/-2.6 mmol l-1 h after cisapride (95% CI -0. 74-3.9 mmol l-1 h).,Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594475/),[h·mM] / [l],6.3,219531,DB00316,Acetaminophen
,10594475,area under the blood-ethanol curve (AUC),The area under the blood-ethanol curve (AUC) increased from 6.3+/-3.5 to 7.9+/-2.6 mmol l-1 h after cisapride (95% CI -0. 74-3.9 mmol l-1 h).,Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594475/),[h·mM] / [l],7.9,219532,DB00316,Acetaminophen
,10594475,Cmax,"Both Cmax and AUC were highest when the ethanol was ingested on an empty stomach (Cmax 9.5+/-1.7 mmol l-1 and AUC 14. 6+/-1.9 mmol l-1 h), compared with drinking 1 h after a meal and regardless of pretreatment with cisapride.",Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594475/),[mM] / [l],9.5,219533,DB00316,Acetaminophen
,10594475,AUC,"Both Cmax and AUC were highest when the ethanol was ingested on an empty stomach (Cmax 9.5+/-1.7 mmol l-1 and AUC 14. 6+/-1.9 mmol l-1 h), compared with drinking 1 h after a meal and regardless of pretreatment with cisapride.",Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594475/),[h·mM] / [l],14. 6,219534,DB00316,Acetaminophen
,7229957,T50%,"The dissolution rates were determined in 0.1 N HCl under sink conditions, and the T50% value for Brand A was 50 min while the values for Brands B and C were 1 min.",Comparative bioavailability of three commercial acetaminophen tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229957/),min,50,219718,DB00316,Acetaminophen
,7229957,T50%,"The dissolution rates were determined in 0.1 N HCl under sink conditions, and the T50% value for Brand A was 50 min while the values for Brands B and C were 1 min.",Comparative bioavailability of three commercial acetaminophen tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229957/),min,1,219719,DB00316,Acetaminophen
,7229957,elimination half-lives,"The calculated elimination half-lives were 4.12, 2.77, 3.14.",Comparative bioavailability of three commercial acetaminophen tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229957/),,4.12,219720,DB00316,Acetaminophen
,7229957,elimination half-lives,"The calculated elimination half-lives were 4.12, 2.77, 3.14.",Comparative bioavailability of three commercial acetaminophen tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229957/),,2.77,219721,DB00316,Acetaminophen
,7229957,elimination half-lives,"The calculated elimination half-lives were 4.12, 2.77, 3.14.",Comparative bioavailability of three commercial acetaminophen tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229957/),,3.14,219722,DB00316,Acetaminophen
,7229957,relative bioavailabilities,"The relative bioavailabilities (with respect to solution) were 82, 87, and 92% for Brands A, B, and C, respectively.",Comparative bioavailability of three commercial acetaminophen tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229957/),%,82,219723,DB00316,Acetaminophen
,7229957,relative bioavailabilities,"The relative bioavailabilities (with respect to solution) were 82, 87, and 92% for Brands A, B, and C, respectively.",Comparative bioavailability of three commercial acetaminophen tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229957/),%,87,219724,DB00316,Acetaminophen
,7229957,relative bioavailabilities,"The relative bioavailabilities (with respect to solution) were 82, 87, and 92% for Brands A, B, and C, respectively.",Comparative bioavailability of three commercial acetaminophen tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229957/),%,92,219725,DB00316,Acetaminophen
,1233222,elimination half-life (t1/2)beta,The elimination half-life (t1/2)beta varied from 37 to 74 minutes.,On the pharmacokinetics of phenacetin in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233222/),min,37 to 74,219886,DB00316,Acetaminophen
,1233222,volume of distribution (Vd)beta,The volume of distribution (Vd)beta ranged from 1.0 to 2.1 1 per kg body weight.,On the pharmacokinetics of phenacetin in man. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233222/),[1] / [kg],1.0 to 2.1,219887,DB00316,Acetaminophen
,16842311,Cmax,"Panadol Extend produced lower Cmax (0.208 mmol/L +/- 0.02 vs 0.48 mmol/L +/- 0.02, P = 0.0001) and AUC(0-12 h) when compared with APAP-IR.",Comparative pharmacokinetics of Panadol Extend and immediate-release paracetamol in a simulated overdose model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842311/),[mM] / [l],0.208,221043,DB00316,Acetaminophen
,16842311,Cmax,"Panadol Extend produced lower Cmax (0.208 mmol/L +/- 0.02 vs 0.48 mmol/L +/- 0.02, P = 0.0001) and AUC(0-12 h) when compared with APAP-IR.",Comparative pharmacokinetics of Panadol Extend and immediate-release paracetamol in a simulated overdose model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842311/),[mM] / [l],0.48,221044,DB00316,Acetaminophen
,16842311,Tmax,"Tmax was delayed with Panadol Extend (2.83 h +/- 0.26 vs 0.94 h +/- 0.17, P = 0.0001).",Comparative pharmacokinetics of Panadol Extend and immediate-release paracetamol in a simulated overdose model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842311/),h,2.83,221045,DB00316,Acetaminophen
,16842311,Tmax,"Tmax was delayed with Panadol Extend (2.83 h +/- 0.26 vs 0.94 h +/- 0.17, P = 0.0001).",Comparative pharmacokinetics of Panadol Extend and immediate-release paracetamol in a simulated overdose model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842311/),h,0.94,221046,DB00316,Acetaminophen
,16842311,Elimination t(1/2),Elimination t(1/2) was 1.69 +/- 0.09 h for APAP-IR and 1.65 +/- 0.13 h for Panadol Extend (not significant).,Comparative pharmacokinetics of Panadol Extend and immediate-release paracetamol in a simulated overdose model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842311/),h,1.69,221047,DB00316,Acetaminophen
,16842311,Elimination t(1/2),Elimination t(1/2) was 1.69 +/- 0.09 h for APAP-IR and 1.65 +/- 0.13 h for Panadol Extend (not significant).,Comparative pharmacokinetics of Panadol Extend and immediate-release paracetamol in a simulated overdose model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842311/),h,1.65,221048,DB00316,Acetaminophen
,14551178,plasma Cmax,"The plasma Cmax showed a significant increase (10.43 microg/mL [day 1] to 14.74 microg/mL [day 80]), while tmax significantly decreased (1.41 h [day 1] to 0.91 h [day 80]).",Influence of simulated weightlessness on the oral pharmacokinetics of acetaminophen as a gastric emptying probe in man: a plasma and a saliva study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14551178/),[μg] / [ml],10.43,222148,DB00316,Acetaminophen
,14551178,plasma Cmax,"The plasma Cmax showed a significant increase (10.43 microg/mL [day 1] to 14.74 microg/mL [day 80]), while tmax significantly decreased (1.41 h [day 1] to 0.91 h [day 80]).",Influence of simulated weightlessness on the oral pharmacokinetics of acetaminophen as a gastric emptying probe in man: a plasma and a saliva study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14551178/),[μg] / [ml],14.74,222149,DB00316,Acetaminophen
,14551178,tmax,"The plasma Cmax showed a significant increase (10.43 microg/mL [day 1] to 14.74 microg/mL [day 80]), while tmax significantly decreased (1.41 h [day 1] to 0.91 h [day 80]).",Influence of simulated weightlessness on the oral pharmacokinetics of acetaminophen as a gastric emptying probe in man: a plasma and a saliva study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14551178/),h,1.41,222150,DB00316,Acetaminophen
,14551178,tmax,"The plasma Cmax showed a significant increase (10.43 microg/mL [day 1] to 14.74 microg/mL [day 80]), while tmax significantly decreased (1.41 h [day 1] to 0.91 h [day 80]).",Influence of simulated weightlessness on the oral pharmacokinetics of acetaminophen as a gastric emptying probe in man: a plasma and a saliva study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14551178/),h,0.91,222151,DB00316,Acetaminophen
,3356051,peak serum concentration,The absorption of acetaminophen was incomplete (peak serum concentration: 70.8 mumol.L-1) and delayed.,Pharmacokinetics and clinical efficacy of intrarectal solution of acetaminophen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356051/),[μM] / [l],70.8,222615,DB00316,Acetaminophen
,6144210,peak,"reached a peak (10.9 and 19.8 micrograms/ml in Subjects 1 and 2, respectively) and initially declined with a half-life of about two-three hours.","The metabolism of the anti-inflammatory drug eterylate in rat, dog and man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144210/),[μg] / [ml],10.9,222732,DB00316,Acetaminophen
,6144210,peak,"reached a peak (10.9 and 19.8 micrograms/ml in Subjects 1 and 2, respectively) and initially declined with a half-life of about two-three hours.","The metabolism of the anti-inflammatory drug eterylate in rat, dog and man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144210/),[μg] / [ml],19.8,222733,DB00316,Acetaminophen
,6144210,half-life,"reached a peak (10.9 and 19.8 micrograms/ml in Subjects 1 and 2, respectively) and initially declined with a half-life of about two-three hours.","The metabolism of the anti-inflammatory drug eterylate in rat, dog and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144210/),h,two-,222734,DB00316,Acetaminophen
,6144210,peak,"reached a peak (4.3, 10.0 micrograms/ml, respectively) and declined with a half-life of about one hour.","The metabolism of the anti-inflammatory drug eterylate in rat, dog and man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144210/),[μg] / [ml],4.3,222735,DB00316,Acetaminophen
,6144210,peak,"reached a peak (4.3, 10.0 micrograms/ml, respectively) and declined with a half-life of about one hour.","The metabolism of the anti-inflammatory drug eterylate in rat, dog and man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144210/),[μg] / [ml],10.0,222736,DB00316,Acetaminophen
,6144210,half-life,"reached a peak (4.3, 10.0 micrograms/ml, respectively) and declined with a half-life of about one hour.","The metabolism of the anti-inflammatory drug eterylate in rat, dog and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144210/),h,one,222737,DB00316,Acetaminophen
,22588644,brain-to-plasma AUC(0-240) ratios,"However, brain ECF concentrations are on average fourfold higher than CSF concentrations, with average brain-to-plasma AUC(0-240) ratios of 121%, 28%, and 35% for brain ECF, CSF(LV), and CSF(CM), respectively.",Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22588644/),%,121,223904,DB00316,Acetaminophen
,22588644,brain-to-plasma AUC(0-240) ratios,"However, brain ECF concentrations are on average fourfold higher than CSF concentrations, with average brain-to-plasma AUC(0-240) ratios of 121%, 28%, and 35% for brain ECF, CSF(LV), and CSF(CM), respectively.",Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22588644/),%,28,223905,DB00316,Acetaminophen
,22588644,brain-to-plasma AUC(0-240) ratios,"However, brain ECF concentrations are on average fourfold higher than CSF concentrations, with average brain-to-plasma AUC(0-240) ratios of 121%, 28%, and 35% for brain ECF, CSF(LV), and CSF(CM), respectively.",Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22588644/),%,35,223906,DB00316,Acetaminophen
,24668698,clearance,"Based on 73 paracetamol PK estimates, a 8-fold variability in clearance (range 7.1-62.2 l/h) was documented, in part explained by a correlation (r2=0.36) between clearance (l/h) and weight.","Weight, pregnancy and oral contraceptives affect intravenous paracetamol clearance in young women. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24668698/),[l] / [h],7.1-62.2,223979,DB00316,Acetaminophen
,20007794,time-corrected AUC,"The mean (sem) time-corrected AUC on rest and activity, respectively, were: combination group 22.3 (3.2) and 28.4 (3.4); acetaminophen group 33.0 (3.1) and 40.4 (3.3); and ibuprofen group 34.8 (3.2) and 40.2 (3.4); P<0.01 for each of the four comparisons of combination vs constituent drug.",Combined acetaminophen and ibuprofen for pain relief after oral surgery in adults: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20007794/),,22.3,224220,DB00316,Acetaminophen
,20007794,time-corrected AUC,"The mean (sem) time-corrected AUC on rest and activity, respectively, were: combination group 22.3 (3.2) and 28.4 (3.4); acetaminophen group 33.0 (3.1) and 40.4 (3.3); and ibuprofen group 34.8 (3.2) and 40.2 (3.4); P<0.01 for each of the four comparisons of combination vs constituent drug.",Combined acetaminophen and ibuprofen for pain relief after oral surgery in adults: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20007794/),,28.4,224221,DB00316,Acetaminophen
,20007794,time-corrected AUC,"The mean (sem) time-corrected AUC on rest and activity, respectively, were: combination group 22.3 (3.2) and 28.4 (3.4); acetaminophen group 33.0 (3.1) and 40.4 (3.3); and ibuprofen group 34.8 (3.2) and 40.2 (3.4); P<0.01 for each of the four comparisons of combination vs constituent drug.",Combined acetaminophen and ibuprofen for pain relief after oral surgery in adults: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20007794/),,33.0,224222,DB00316,Acetaminophen
,20007794,time-corrected AUC,"The mean (sem) time-corrected AUC on rest and activity, respectively, were: combination group 22.3 (3.2) and 28.4 (3.4); acetaminophen group 33.0 (3.1) and 40.4 (3.3); and ibuprofen group 34.8 (3.2) and 40.2 (3.4); P<0.01 for each of the four comparisons of combination vs constituent drug.",Combined acetaminophen and ibuprofen for pain relief after oral surgery in adults: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20007794/),,40.4,224223,DB00316,Acetaminophen
,20007794,time-corrected AUC,"The mean (sem) time-corrected AUC on rest and activity, respectively, were: combination group 22.3 (3.2) and 28.4 (3.4); acetaminophen group 33.0 (3.1) and 40.4 (3.3); and ibuprofen group 34.8 (3.2) and 40.2 (3.4); P<0.01 for each of the four comparisons of combination vs constituent drug.",Combined acetaminophen and ibuprofen for pain relief after oral surgery in adults: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20007794/),,34.8,224224,DB00316,Acetaminophen
,20007794,time-corrected AUC,"The mean (sem) time-corrected AUC on rest and activity, respectively, were: combination group 22.3 (3.2) and 28.4 (3.4); acetaminophen group 33.0 (3.1) and 40.4 (3.3); and ibuprofen group 34.8 (3.2) and 40.2 (3.4); P<0.01 for each of the four comparisons of combination vs constituent drug.",Combined acetaminophen and ibuprofen for pain relief after oral surgery in adults: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20007794/),,40.2,224225,DB00316,Acetaminophen
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,152.3,224505,DB00316,Acetaminophen
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,152.3,224506,DB00316,Acetaminophen
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,195.1,224507,DB00316,Acetaminophen
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,138.3,224508,DB00316,Acetaminophen
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,275.2,224509,DB00316,Acetaminophen
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,230.3,224510,DB00316,Acetaminophen
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,264.2,224511,DB00316,Acetaminophen
,11217114,tmax,"However, tmax (15 min) of acetaminophen from rapidly disintegrating tablets was significantly (p<0.05) shorter than that from conventional tablets (130 min).",Pharmacokinetics of acetaminophen from rapidly disintegrating compressed tablet prepared using microcrystalline cellulose (PH-M-06) and spherical sugar granules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11217114/),min,15,227122,DB00316,Acetaminophen
,11217114,tmax,"However, tmax (15 min) of acetaminophen from rapidly disintegrating tablets was significantly (p<0.05) shorter than that from conventional tablets (130 min).",Pharmacokinetics of acetaminophen from rapidly disintegrating compressed tablet prepared using microcrystalline cellulose (PH-M-06) and spherical sugar granules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11217114/),min,130,227123,DB00316,Acetaminophen
,11217114,mean absorption time (MAT),"According to the results of moment analysis, the mean residence time (MRT) obtained between both rapidly disintegrating and conventional tablets indicates that the mean absorption time (MAT) from these tablets is approximately 60 and 90 min, respectively.",Pharmacokinetics of acetaminophen from rapidly disintegrating compressed tablet prepared using microcrystalline cellulose (PH-M-06) and spherical sugar granules. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11217114/),min,60,227124,DB00316,Acetaminophen
,11217114,mean absorption time (MAT),"According to the results of moment analysis, the mean residence time (MRT) obtained between both rapidly disintegrating and conventional tablets indicates that the mean absorption time (MAT) from these tablets is approximately 60 and 90 min, respectively.",Pharmacokinetics of acetaminophen from rapidly disintegrating compressed tablet prepared using microcrystalline cellulose (PH-M-06) and spherical sugar granules. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11217114/),min,90,227125,DB00316,Acetaminophen
,10714844,saliva concentrations,"At 1, 2, 3, and 4 h after rectal dosing the saliva concentrations (mean+/-SD) were 15.2+/-5.9 micromol/l, 33.7+/-12.5 micromol/l, 45.5+/-19.1 micromol/l, and 55.4+/-23.1 micromol/l, respectively.",High-dose rectal and oral acetaminophen in postoperative patients--serum and saliva concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10714844/),[μM] / [l],15.2,227567,DB00316,Acetaminophen
,10714844,saliva concentrations,"At 1, 2, 3, and 4 h after rectal dosing the saliva concentrations (mean+/-SD) were 15.2+/-5.9 micromol/l, 33.7+/-12.5 micromol/l, 45.5+/-19.1 micromol/l, and 55.4+/-23.1 micromol/l, respectively.",High-dose rectal and oral acetaminophen in postoperative patients--serum and saliva concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10714844/),[μM] / [l],33.7,227568,DB00316,Acetaminophen
,10714844,saliva concentrations,"At 1, 2, 3, and 4 h after rectal dosing the saliva concentrations (mean+/-SD) were 15.2+/-5.9 micromol/l, 33.7+/-12.5 micromol/l, 45.5+/-19.1 micromol/l, and 55.4+/-23.1 micromol/l, respectively.",High-dose rectal and oral acetaminophen in postoperative patients--serum and saliva concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10714844/),[μM] / [l],45.5,227569,DB00316,Acetaminophen
,10714844,saliva concentrations,"At 1, 2, 3, and 4 h after rectal dosing the saliva concentrations (mean+/-SD) were 15.2+/-5.9 micromol/l, 33.7+/-12.5 micromol/l, 45.5+/-19.1 micromol/l, and 55.4+/-23.1 micromol/l, respectively.",High-dose rectal and oral acetaminophen in postoperative patients--serum and saliva concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10714844/),[μM] / [l],55.4,227570,DB00316,Acetaminophen
,10714844,serum concentrations,"The serum concentrations at 2 and 4 h were 31.0+/-11.2 micromol/l and 54.8+/-23.8 micromol/l, respectively.",High-dose rectal and oral acetaminophen in postoperative patients--serum and saliva concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10714844/),[μM] / [l],31.0,227571,DB00316,Acetaminophen
,10714844,serum concentrations,"The serum concentrations at 2 and 4 h were 31.0+/-11.2 micromol/l and 54.8+/-23.8 micromol/l, respectively.",High-dose rectal and oral acetaminophen in postoperative patients--serum and saliva concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10714844/),[μM] / [l],54.8,227572,DB00316,Acetaminophen
,10714844,saliva concentrations,"Additional oral dosing resulted in saliva concentrations at 5, 8, and 9 h of 99.7+/-49.5 micromol/l, 106.9+/-31.7 micromol/l, and 139.3+/-55.4 micromol/l, respectively, with coincident serum concentrations of 100.1 +/- 50.2 micromol/l, 105.6+/-29.0 micromol/l, and 141.2+/-52.1 micromol/l.",High-dose rectal and oral acetaminophen in postoperative patients--serum and saliva concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10714844/),[μM] / [l],99.7,227573,DB00316,Acetaminophen
,10714844,saliva concentrations,"Additional oral dosing resulted in saliva concentrations at 5, 8, and 9 h of 99.7+/-49.5 micromol/l, 106.9+/-31.7 micromol/l, and 139.3+/-55.4 micromol/l, respectively, with coincident serum concentrations of 100.1 +/- 50.2 micromol/l, 105.6+/-29.0 micromol/l, and 141.2+/-52.1 micromol/l.",High-dose rectal and oral acetaminophen in postoperative patients--serum and saliva concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10714844/),[μM] / [l],106.9,227574,DB00316,Acetaminophen
,10714844,saliva concentrations,"Additional oral dosing resulted in saliva concentrations at 5, 8, and 9 h of 99.7+/-49.5 micromol/l, 106.9+/-31.7 micromol/l, and 139.3+/-55.4 micromol/l, respectively, with coincident serum concentrations of 100.1 +/- 50.2 micromol/l, 105.6+/-29.0 micromol/l, and 141.2+/-52.1 micromol/l.",High-dose rectal and oral acetaminophen in postoperative patients--serum and saliva concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10714844/),[μM] / [l],139.3,227575,DB00316,Acetaminophen
,20678689,therapeutic window,The reported therapeutic window of fentanyl is between 0.2 and 1.2 ng/mL.,"Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: A prospective, randomized, double-blind, placebo-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678689/),[ng] / [ml],0.2 and 1.2,227917,DB00316,Acetaminophen
,20678689,VAS scores,"Mean VAS scores at baseline were 14.8 (17.8) for the fentanyl group and 6.0 (9.7) for the placebo group (P = NS); at the time of drain removal, the corresponding VAS scores were 31.0 (20.6) and 33.8 (25.7) (P = NS).","Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: A prospective, randomized, double-blind, placebo-controlled study. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678689/),,14.8,227918,DB00316,Acetaminophen
,20678689,VAS scores,"Mean VAS scores at baseline were 14.8 (17.8) for the fentanyl group and 6.0 (9.7) for the placebo group (P = NS); at the time of drain removal, the corresponding VAS scores were 31.0 (20.6) and 33.8 (25.7) (P = NS).","Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: A prospective, randomized, double-blind, placebo-controlled study. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678689/),,6.0,227919,DB00316,Acetaminophen
,20678689,VAS,"Mean VAS scores at baseline were 14.8 (17.8) for the fentanyl group and 6.0 (9.7) for the placebo group (P = NS); at the time of drain removal, the corresponding VAS scores were 31.0 (20.6) and 33.8 (25.7) (P = NS).","Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: A prospective, randomized, double-blind, placebo-controlled study. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678689/),,31.0,227920,DB00316,Acetaminophen
,20678689,VAS,"Mean VAS scores at baseline were 14.8 (17.8) for the fentanyl group and 6.0 (9.7) for the placebo group (P = NS); at the time of drain removal, the corresponding VAS scores were 31.0 (20.6) and 33.8 (25.7) (P = NS).","Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: A prospective, randomized, double-blind, placebo-controlled study. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678689/),,33.8,227921,DB00316,Acetaminophen
,20678689,C(max),A mean estimated C(max) of 0.184 (0.069) ng/mL was reached at 13.76 (3.56) minutes after administration of intranasal fentanyl.,"Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: A prospective, randomized, double-blind, placebo-controlled study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678689/),[ng] / [ml],0.184,227922,DB00316,Acetaminophen
,20678689,C(max),The mean measured C(max) was 0.22 (0.088) ng/mL.,"Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: A prospective, randomized, double-blind, placebo-controlled study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678689/),[ng] / [ml],0.22,227923,DB00316,Acetaminophen
,10783405,area under the concentration curve,"The mean values for area under the concentration curve (+/-SD) for the control and gastric lavage groups were 195+/-31 and 154+/-52 mg/L.hour, respectively (P <.05).",Gastric lavage for liquid poisons. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10783405/),[mg] / [h·l],195,228968,DB00316,Acetaminophen
,10783405,area under the concentration curve,"The mean values for area under the concentration curve (+/-SD) for the control and gastric lavage groups were 195+/-31 and 154+/-52 mg/L.hour, respectively (P <.05).",Gastric lavage for liquid poisons. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10783405/),[mg] / [h·l],154,228969,DB00316,Acetaminophen
,16133536,AUC,"m-2 of BSA yielded an average AUC of 1,200 microM.min, with 80% of patients within the ""therapeutic"" AUC range of 900-1,500 microM.min.",Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16133536/),min·μM,"1,200",230055,DB00316,Acetaminophen
,16133536,AUC,"m-2 of BSA yielded an average AUC of 1,200 microM.min, with 80% of patients within the ""therapeutic"" AUC range of 900-1,500 microM.min.",Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16133536/),min·μM,"900-1,500",230056,DB00316,Acetaminophen
,17697035,Terminal half-life,Terminal half-life in plasma ranged from 35 to 51 min.,Enteral exsorption of acetaminophen after intravenous injection in rats: influence of activated charcoal on this clearance path. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17697035/),min,35 to 51,230391,DB00316,Acetaminophen
,17697035,area under the curve,"Correspondingly, the area under the curve did not vary much and ranged between 2.6 and 3.3 g/min./l (P = 0.392).",Enteral exsorption of acetaminophen after intravenous injection in rats: influence of activated charcoal on this clearance path. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17697035/),[g] / [·l·min],2.6 and 3.3,230392,DB00316,Acetaminophen
,17697035,excretion,The excretion of acetaminophen and metabolites into urine varied strikingly between 31% and 56% of the dose within all groups and correlated with diuresis.,Enteral exsorption of acetaminophen after intravenous injection in rats: influence of activated charcoal on this clearance path. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17697035/),%,31,230393,DB00316,Acetaminophen
,17697035,excretion,The excretion of acetaminophen and metabolites into urine varied strikingly between 31% and 56% of the dose within all groups and correlated with diuresis.,Enteral exsorption of acetaminophen after intravenous injection in rats: influence of activated charcoal on this clearance path. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17697035/),%,56,230394,DB00316,Acetaminophen
,11420329,absorption half life (t(abs)),"After modelling of the data, the following pharmacokinetic variables were calculated: absorption half life (t(abs)), 0.51 hours; volume of distribution (V/F(oral)), 0.80 litres/kg; clearance (CL/F(oral)), 0.22 litres/h; they were consistent with population pharmacokinetic studies.",Paracetamol overdose in a preterm neonate. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420329/),h,0.51,231594,DB00316,Acetaminophen
,11420329,volume of distribution (V/F(oral)),"After modelling of the data, the following pharmacokinetic variables were calculated: absorption half life (t(abs)), 0.51 hours; volume of distribution (V/F(oral)), 0.80 litres/kg; clearance (CL/F(oral)), 0.22 litres/h; they were consistent with population pharmacokinetic studies.",Paracetamol overdose in a preterm neonate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420329/),[l] / [kg],0.80,231595,DB00316,Acetaminophen
,11420329,clearance (CL/F(oral)),"After modelling of the data, the following pharmacokinetic variables were calculated: absorption half life (t(abs)), 0.51 hours; volume of distribution (V/F(oral)), 0.80 litres/kg; clearance (CL/F(oral)), 0.22 litres/h; they were consistent with population pharmacokinetic studies.",Paracetamol overdose in a preterm neonate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420329/),[l] / [h],0.22,231596,DB00316,Acetaminophen
,11420329,plasma half life (Tbeta),"The increased plasma half life (Tbeta) of 5.69 hours thus reflected normal slower metabolism in infants, rather than toxicity.",Paracetamol overdose in a preterm neonate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420329/),h,5.69,231597,DB00316,Acetaminophen
,21317433,central volume,"Population parameter estimates (between-subject variability, %) were central volume 51.9 l/70 kg (21.6%), peripheral volume of distribution 22.7 l/70 kg, clearance 5 l/h/70 kg (40%) and intercompartment clearance 16.2 l/h/70 kg.",The pharmacokinetics of intravenous paracetamol in neonates: size matters most. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21317433/),[l] / [70·kg],51.9,232546,DB00316,Acetaminophen
,21317433,peripheral volume of distribution,"Population parameter estimates (between-subject variability, %) were central volume 51.9 l/70 kg (21.6%), peripheral volume of distribution 22.7 l/70 kg, clearance 5 l/h/70 kg (40%) and intercompartment clearance 16.2 l/h/70 kg.",The pharmacokinetics of intravenous paracetamol in neonates: size matters most. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21317433/),[l] / [70·kg],22.7,232547,DB00316,Acetaminophen
,21317433,clearance,"Population parameter estimates (between-subject variability, %) were central volume 51.9 l/70 kg (21.6%), peripheral volume of distribution 22.7 l/70 kg, clearance 5 l/h/70 kg (40%) and intercompartment clearance 16.2 l/h/70 kg.",The pharmacokinetics of intravenous paracetamol in neonates: size matters most. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21317433/),[l] / [70·h·kg],5,232548,DB00316,Acetaminophen
,21317433,intercompartment clearance,"Population parameter estimates (between-subject variability, %) were central volume 51.9 l/70 kg (21.6%), peripheral volume of distribution 22.7 l/70 kg, clearance 5 l/h/70 kg (40%) and intercompartment clearance 16.2 l/h/70 kg.",The pharmacokinetics of intravenous paracetamol in neonates: size matters most. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21317433/),[l] / [70·h·kg],16.2,232549,DB00316,Acetaminophen
,21317433,Clearance,Clearance expressed as mg/kg/h increases only slightly with PMA (0.138 l/kg/h at 28 weeks' PMA to 0.167 l/kg/h at 44 weeks' PMA) and contributes only 2.2% of variance.,The pharmacokinetics of intravenous paracetamol in neonates: size matters most. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21317433/),[l] / [h·kg],0.138,232550,DB00316,Acetaminophen
,21317433,Clearance,Clearance expressed as mg/kg/h increases only slightly with PMA (0.138 l/kg/h at 28 weeks' PMA to 0.167 l/kg/h at 44 weeks' PMA) and contributes only 2.2% of variance.,The pharmacokinetics of intravenous paracetamol in neonates: size matters most. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21317433/),[l] / [h·kg],0.167,232551,DB00316,Acetaminophen
,29063343,Ultrafiltrate,"Ultrafiltrate and dialysate flow rates were 1, 2, and 3 L/h.",Acetaminophen clearance during ex vivo continuous renal replacement therapies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29063343/),[l] / [h],1,233781,DB00316,Acetaminophen
,29063343,dialysate flow rates,"Ultrafiltrate and dialysate flow rates were 1, 2, and 3 L/h.",Acetaminophen clearance during ex vivo continuous renal replacement therapies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29063343/),[l] / [h],2,233782,DB00316,Acetaminophen
,29063343,dialysate flow rates,"Ultrafiltrate and dialysate flow rates were 1, 2, and 3 L/h.",Acetaminophen clearance during ex vivo continuous renal replacement therapies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29063343/),[l] / [h],3,233783,DB00316,Acetaminophen
,9120811,partial clearance,"After iv administration of A, the mean fraction of iv dose excreted in 24-h urine as A-sulfate (75.6 versus 67.8%) and the partial clearance of A to A-sulfate (8.10 versus 6.89 mL/ min/kg) were significantly greater in SHRs than in Wistar rats.",Pharmacokinetics of acetaminophen after intravenous and oral administration to spontaneously hypertensive rats and normotensive Wistar rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120811/),[ml] / [kg·min],8.10,234068,DB00316,Acetaminophen
,9120811,partial clearance,"After iv administration of A, the mean fraction of iv dose excreted in 24-h urine as A-sulfate (75.6 versus 67.8%) and the partial clearance of A to A-sulfate (8.10 versus 6.89 mL/ min/kg) were significantly greater in SHRs than in Wistar rats.",Pharmacokinetics of acetaminophen after intravenous and oral administration to spontaneously hypertensive rats and normotensive Wistar rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120811/),[ml] / [kg·min],6.89,234069,DB00316,Acetaminophen
,9120811,fraction,"Conversely, the mean fraction of iv dose excreted in 24-h urine as A-glucuronide (9.39 versus 15.0%) and the partial clearance of A to A-glucuronide (1.01 versus 1.49 mL/min/kg) were significantly smaller in these SHRs.",Pharmacokinetics of acetaminophen after intravenous and oral administration to spontaneously hypertensive rats and normotensive Wistar rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120811/),%,9,234070,DB00316,Acetaminophen
,9120811,fraction,"Conversely, the mean fraction of iv dose excreted in 24-h urine as A-glucuronide (9.39 versus 15.0%) and the partial clearance of A to A-glucuronide (1.01 versus 1.49 mL/min/kg) were significantly smaller in these SHRs.",Pharmacokinetics of acetaminophen after intravenous and oral administration to spontaneously hypertensive rats and normotensive Wistar rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120811/),%,15,234071,DB00316,Acetaminophen
,9120811,partial clearance,"Conversely, the mean fraction of iv dose excreted in 24-h urine as A-glucuronide (9.39 versus 15.0%) and the partial clearance of A to A-glucuronide (1.01 versus 1.49 mL/min/kg) were significantly smaller in these SHRs.",Pharmacokinetics of acetaminophen after intravenous and oral administration to spontaneously hypertensive rats and normotensive Wistar rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120811/),[ml] / [kg·min],1.01,234072,DB00316,Acetaminophen
,9120811,partial clearance,"Conversely, the mean fraction of iv dose excreted in 24-h urine as A-glucuronide (9.39 versus 15.0%) and the partial clearance of A to A-glucuronide (1.01 versus 1.49 mL/min/kg) were significantly smaller in these SHRs.",Pharmacokinetics of acetaminophen after intravenous and oral administration to spontaneously hypertensive rats and normotensive Wistar rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120811/),[ml] / [kg·min],1.49,234073,DB00316,Acetaminophen
,16044107,delivery rate,"For 20 patients, the initial TTS fentanyl delivery rate was 25 or 50 microg/h.",Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),[μg] / [h],25,234545,DB00316,Acetaminophen
,16044107,delivery rate,"For 20 patients, the initial TTS fentanyl delivery rate was 25 or 50 microg/h.",Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),[μg] / [h],50,234546,DB00316,Acetaminophen
,16044107,initial delivery rate,"For 6 patients, the initial delivery rate was 75-150 microg/h.",Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),[μg] / [h],75-150,234547,DB00316,Acetaminophen
,16044107,bioavailability,A mean bioavailability of 78% was estimated; the total clearance averaged 41 L/h.,Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),%,78,234548,DB00316,Acetaminophen
,16044107,total clearance,A mean bioavailability of 78% was estimated; the total clearance averaged 41 L/h.,Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),[l] / [h],41,234549,DB00316,Acetaminophen
>,16044107,total clearance,"At the 2 highest doses, an increase of total clearance was observed (>60 L/h).",Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),[l] / [h],60,234550,DB00316,Acetaminophen
,10583039,AUC ratios,Paracetamol to phenacetin AUC ratios increased from 13.9+/-3.1 to 24.3+/-3.8 after ingestion of grape juice.,Possible enhancement of the first-pass metabolism of phenacetin by ingestion of grape juice in Chinese subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583039/),,13.9,234586,DB00316,Acetaminophen
,10583039,AUC ratios,Paracetamol to phenacetin AUC ratios increased from 13.9+/-3.1 to 24.3+/-3.8 after ingestion of grape juice.,Possible enhancement of the first-pass metabolism of phenacetin by ingestion of grape juice in Chinese subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583039/),,24.3,234587,DB00316,Acetaminophen
,3207858,first order rate constants,The values of the first order rate constants that define the absorption process have values of 4.79 and 9.73 h-1.,Choice of optimum pharmacokinetic model of orally administered paracetamol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207858/),1/[h],4.79,235244,DB00316,Acetaminophen
,3207858,first order rate constants,The values of the first order rate constants that define the absorption process have values of 4.79 and 9.73 h-1.,Choice of optimum pharmacokinetic model of orally administered paracetamol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207858/),1/[h],9.73,235245,DB00316,Acetaminophen
,20980118,flow rate,"The mobile phase was consisted of methanol-water (75:25, v/v) with a flow rate of 0.25 mL/min.",An HPLC-MS/MS method for the quantitative determination of 4-hydroxy-anethole trithione in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20980118/),[ml] / [min],0.25,235257,DB00316,Acetaminophen
,7744384,Cmax,"The Cmax in oral drop and tablet were 11.23 +/- 0.93 and 8.79 +/- 0.93mg/L, respectively; Tmax were 0.86 +/- 0.08 and 1.48 +/- 0.39h; T1/2 beta 3.03 +/- 0.79 and 2.51 +/- 1.10 h; AUC 42.35 +/- 6.20 and 40.60 +/- 6.79mg/L.h.",[Pharmacokinetics and bioavailability study on acetaminophen oral drop in healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7744384/),[mg] / [l],11.23,235458,DB00316,Acetaminophen
,7744384,Cmax,"The Cmax in oral drop and tablet were 11.23 +/- 0.93 and 8.79 +/- 0.93mg/L, respectively; Tmax were 0.86 +/- 0.08 and 1.48 +/- 0.39h; T1/2 beta 3.03 +/- 0.79 and 2.51 +/- 1.10 h; AUC 42.35 +/- 6.20 and 40.60 +/- 6.79mg/L.h.",[Pharmacokinetics and bioavailability study on acetaminophen oral drop in healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7744384/),[mg] / [l],8.79,235459,DB00316,Acetaminophen
,7744384,Tmax,"The Cmax in oral drop and tablet were 11.23 +/- 0.93 and 8.79 +/- 0.93mg/L, respectively; Tmax were 0.86 +/- 0.08 and 1.48 +/- 0.39h; T1/2 beta 3.03 +/- 0.79 and 2.51 +/- 1.10 h; AUC 42.35 +/- 6.20 and 40.60 +/- 6.79mg/L.h.",[Pharmacokinetics and bioavailability study on acetaminophen oral drop in healthy volunteers]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7744384/),h,0.86,235460,DB00316,Acetaminophen
,7744384,Tmax,"The Cmax in oral drop and tablet were 11.23 +/- 0.93 and 8.79 +/- 0.93mg/L, respectively; Tmax were 0.86 +/- 0.08 and 1.48 +/- 0.39h; T1/2 beta 3.03 +/- 0.79 and 2.51 +/- 1.10 h; AUC 42.35 +/- 6.20 and 40.60 +/- 6.79mg/L.h.",[Pharmacokinetics and bioavailability study on acetaminophen oral drop in healthy volunteers]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7744384/),h,1.48,235461,DB00316,Acetaminophen
,7744384,T1/2 beta,"The Cmax in oral drop and tablet were 11.23 +/- 0.93 and 8.79 +/- 0.93mg/L, respectively; Tmax were 0.86 +/- 0.08 and 1.48 +/- 0.39h; T1/2 beta 3.03 +/- 0.79 and 2.51 +/- 1.10 h; AUC 42.35 +/- 6.20 and 40.60 +/- 6.79mg/L.h.",[Pharmacokinetics and bioavailability study on acetaminophen oral drop in healthy volunteers]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7744384/),h,3.03,235462,DB00316,Acetaminophen
,7744384,T1/2 beta,"The Cmax in oral drop and tablet were 11.23 +/- 0.93 and 8.79 +/- 0.93mg/L, respectively; Tmax were 0.86 +/- 0.08 and 1.48 +/- 0.39h; T1/2 beta 3.03 +/- 0.79 and 2.51 +/- 1.10 h; AUC 42.35 +/- 6.20 and 40.60 +/- 6.79mg/L.h.",[Pharmacokinetics and bioavailability study on acetaminophen oral drop in healthy volunteers]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7744384/),h,2.51,235463,DB00316,Acetaminophen
,7744384,AUC,"The Cmax in oral drop and tablet were 11.23 +/- 0.93 and 8.79 +/- 0.93mg/L, respectively; Tmax were 0.86 +/- 0.08 and 1.48 +/- 0.39h; T1/2 beta 3.03 +/- 0.79 and 2.51 +/- 1.10 h; AUC 42.35 +/- 6.20 and 40.60 +/- 6.79mg/L.h.",[Pharmacokinetics and bioavailability study on acetaminophen oral drop in healthy volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7744384/),[mg] / [h·l],42.35,235464,DB00316,Acetaminophen
,7744384,AUC,"The Cmax in oral drop and tablet were 11.23 +/- 0.93 and 8.79 +/- 0.93mg/L, respectively; Tmax were 0.86 +/- 0.08 and 1.48 +/- 0.39h; T1/2 beta 3.03 +/- 0.79 and 2.51 +/- 1.10 h; AUC 42.35 +/- 6.20 and 40.60 +/- 6.79mg/L.h.",[Pharmacokinetics and bioavailability study on acetaminophen oral drop in healthy volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7744384/),[mg] / [h·l],40.60,235465,DB00316,Acetaminophen
,7744384,relative bioavailability,"When AUC in tablet was 100%, the relative bioavailability of acetaminophen oral drop was 105.58%.",[Pharmacokinetics and bioavailability study on acetaminophen oral drop in healthy volunteers]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7744384/),%,105.58,235466,DB00316,Acetaminophen
,23871018,total run time,Each sample was run at 0.5 mL/min for a total run time of 7 min/sample.,Simultaneous quantification of caffeine and its three primary metabolites in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23871018/),[min] / [sample],7,235555,DB00316,Acetaminophen
,6827475,elimination T1/2,Pharmacokinetic analysis indicated increased antipyrine elimination T1/2 during cimetidine treatment (16.7 vs. 10.9 hr; P less than .001) on the basis of decreased total metabolic clearance (0.46 vs. 0.72 ml/min/kg; P less than .001).,Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,16.7,235671,DB00316,Acetaminophen
,6827475,elimination T1/2,Pharmacokinetic analysis indicated increased antipyrine elimination T1/2 during cimetidine treatment (16.7 vs. 10.9 hr; P less than .001) on the basis of decreased total metabolic clearance (0.46 vs. 0.72 ml/min/kg; P less than .001).,Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,10.9,235672,DB00316,Acetaminophen
,6827475,total metabolic clearance,Pharmacokinetic analysis indicated increased antipyrine elimination T1/2 during cimetidine treatment (16.7 vs. 10.9 hr; P less than .001) on the basis of decreased total metabolic clearance (0.46 vs. 0.72 ml/min/kg; P less than .001).,Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],0.46,235673,DB00316,Acetaminophen
,6827475,total metabolic clearance,Pharmacokinetic analysis indicated increased antipyrine elimination T1/2 during cimetidine treatment (16.7 vs. 10.9 hr; P less than .001) on the basis of decreased total metabolic clearance (0.46 vs. 0.72 ml/min/kg; P less than .001).,Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],0.72,235674,DB00316,Acetaminophen
,6827475,T1/2,"Likewise, diazepam T1/2 was increased (58 vs. 39 hr; P less than .01) during cimetidine treatment due to decreased total metabolic clearance (0.42 vs. 0.30 ml/min/kg; P less than .01).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,58,235675,DB00316,Acetaminophen
,6827475,T1/2,"Likewise, diazepam T1/2 was increased (58 vs. 39 hr; P less than .01) during cimetidine treatment due to decreased total metabolic clearance (0.42 vs. 0.30 ml/min/kg; P less than .01).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,39,235676,DB00316,Acetaminophen
,6827475,total metabolic clearance,"Likewise, diazepam T1/2 was increased (58 vs. 39 hr; P less than .01) during cimetidine treatment due to decreased total metabolic clearance (0.42 vs. 0.30 ml/min/kg; P less than .01).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],0.42,235677,DB00316,Acetaminophen
,6827475,total metabolic clearance,"Likewise, diazepam T1/2 was increased (58 vs. 39 hr; P less than .01) during cimetidine treatment due to decreased total metabolic clearance (0.42 vs. 0.30 ml/min/kg; P less than .01).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],0.30,235678,DB00316,Acetaminophen
,6827475,T1/2,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,16.8,235679,DB00316,Acetaminophen
,6827475,T1/2,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,15.3,235680,DB00316,Acetaminophen
,6827475,clearance,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],1.03,235681,DB00316,Acetaminophen
,6827475,clearance,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],1.07,235682,DB00316,Acetaminophen
,6827475,T1/2,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,2.66,235683,DB00316,Acetaminophen
,6827475,T1/2,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,2.60,235684,DB00316,Acetaminophen
,6827475,clearance,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],4.8,235685,DB00316,Acetaminophen
,6827475,clearance,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],4.5,235686,DB00316,Acetaminophen
,6827475,LD50,"In an animal model used to assess the effect of cimetidine on acetaminophen toxicity, the LD50 of acetaminophen alone in Charles River CD-1 mice was 480 mg/kg (95% confidence interval: 436-528 mg/kg).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[mg] / [kg],480,235687,DB00316,Acetaminophen
,26018358,bioavailability,"Since acetaminophen was stable in rumen juice for 24 hr, the extremely low bioavailability (16%) was attributed to its hepatic extensive first-pass effect.",Oral pharmacokinetics of acetaminophen to evaluate gastric emptying profiles of Shiba goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26018358/),%,16,235740,DB00316,Acetaminophen
,26018358,mean absorption time,"The mean absorption time and absorption half-life were unexpectedly short (4.93 and 3.35 hr, respectively), indicating its marked absorption from the forestomach, which may have been due to its smaller molecular weight.",Oral pharmacokinetics of acetaminophen to evaluate gastric emptying profiles of Shiba goats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26018358/),h,4.93,235741,DB00316,Acetaminophen
,26018358,absorption half-life,"The mean absorption time and absorption half-life were unexpectedly short (4.93 and 3.35 hr, respectively), indicating its marked absorption from the forestomach, which may have been due to its smaller molecular weight.",Oral pharmacokinetics of acetaminophen to evaluate gastric emptying profiles of Shiba goats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26018358/),h,3.35,235742,DB00316,Acetaminophen
,27806383,T1/2,"Noncompartmental analysis described similar PK parameters in the maternal (T1/2, 84 minutes; apparent clearance [Cl/F], 28.8 L/h; apparent volume of distribution [Vd/F], 57.5 L) and fetal compartments (T1/2, 82 minutes; Cl/F, 31.2 L/h; Vd/F, 61.2 L).",Transplacental Passage of Acetaminophen in Term Pregnancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27806383/),min,84,235983,DB00316,Acetaminophen
,27806383,apparent clearance [Cl/F],"Noncompartmental analysis described similar PK parameters in the maternal (T1/2, 84 minutes; apparent clearance [Cl/F], 28.8 L/h; apparent volume of distribution [Vd/F], 57.5 L) and fetal compartments (T1/2, 82 minutes; Cl/F, 31.2 L/h; Vd/F, 61.2 L).",Transplacental Passage of Acetaminophen in Term Pregnancy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27806383/),[l] / [h],28.8,235984,DB00316,Acetaminophen
,27806383,apparent volume of distribution [Vd/F],"Noncompartmental analysis described similar PK parameters in the maternal (T1/2, 84 minutes; apparent clearance [Cl/F], 28.8 L/h; apparent volume of distribution [Vd/F], 57.5 L) and fetal compartments (T1/2, 82 minutes; Cl/F, 31.2 L/h; Vd/F, 61.2 L).",Transplacental Passage of Acetaminophen in Term Pregnancy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27806383/),l,57.5,235985,DB00316,Acetaminophen
,27806383,T1/2,"Noncompartmental analysis described similar PK parameters in the maternal (T1/2, 84 minutes; apparent clearance [Cl/F], 28.8 L/h; apparent volume of distribution [Vd/F], 57.5 L) and fetal compartments (T1/2, 82 minutes; Cl/F, 31.2 L/h; Vd/F, 61.2 L).",Transplacental Passage of Acetaminophen in Term Pregnancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27806383/),min,82,235986,DB00316,Acetaminophen
,27806383,Cl/F,"Noncompartmental analysis described similar PK parameters in the maternal (T1/2, 84 minutes; apparent clearance [Cl/F], 28.8 L/h; apparent volume of distribution [Vd/F], 57.5 L) and fetal compartments (T1/2, 82 minutes; Cl/F, 31.2 L/h; Vd/F, 61.2 L).",Transplacental Passage of Acetaminophen in Term Pregnancy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27806383/),[l] / [h],31.2,235987,DB00316,Acetaminophen
,27806383,Vd/F,"Noncompartmental analysis described similar PK parameters in the maternal (T1/2, 84 minutes; apparent clearance [Cl/F], 28.8 L/h; apparent volume of distribution [Vd/F], 57.5 L) and fetal compartments (T1/2, 82 minutes; Cl/F, 31.2 L/h; Vd/F, 61.2 L).",Transplacental Passage of Acetaminophen in Term Pregnancy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27806383/),l,61.2,235988,DB00316,Acetaminophen
,10366903,RSD%,RSD% of 0.5% have become standard for quality control assays.,Pharmacokinetic investigations with direct injection of plasma samples: possible savings using capillary electrophoresis (CE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10366903/),%,0.5,236201,DB00316,Acetaminophen
,10366903,total analysis time,"A number of pharmaceuticals (e.g. acetaminophen, salicylic acid, sulfamethoxazole, theophylline, tolbutamide, and trimethoprim) have been determined in human plasma on underivatized fused silica capillaries by MEKC without sample pretreatment, the total analysis time being only 10 min.",Pharmacokinetic investigations with direct injection of plasma samples: possible savings using capillary electrophoresis (CE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10366903/),min,10,236202,DB00316,Acetaminophen
,10366903,detection limit,"The separation system is tested in a concentration range between 10 ng/mL and 100 micrograms/mL, the detection limit being about 5 ng/mL.",Pharmacokinetic investigations with direct injection of plasma samples: possible savings using capillary electrophoresis (CE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10366903/),[ng] / [ml],5,236203,DB00316,Acetaminophen
,3621584,relative oral/intramuscular bioavailability,"The relative oral/intramuscular bioavailability of amitriptyline was only 13%, and the steady-state concentrations of this drug on four consecutive days were acutely subtherapeutic (i.e., 3.6, 3.7, 3.9, and 3.7 micrograms/L).",Decreased drug absorption in a patient with Behçet's syndrome. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621584/),%,13,237079,DB00316,Acetaminophen
,3621584,steady-state concentrations,"The relative oral/intramuscular bioavailability of amitriptyline was only 13%, and the steady-state concentrations of this drug on four consecutive days were acutely subtherapeutic (i.e., 3.6, 3.7, 3.9, and 3.7 micrograms/L).",Decreased drug absorption in a patient with Behçet's syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621584/),μ,3.6,237080,DB00316,Acetaminophen
,3621584,steady-state concentrations,"The relative oral/intramuscular bioavailability of amitriptyline was only 13%, and the steady-state concentrations of this drug on four consecutive days were acutely subtherapeutic (i.e., 3.6, 3.7, 3.9, and 3.7 micrograms/L).",Decreased drug absorption in a patient with Behçet's syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621584/),μ,3.7,237081,DB00316,Acetaminophen
,3621584,steady-state concentrations,"The relative oral/intramuscular bioavailability of amitriptyline was only 13%, and the steady-state concentrations of this drug on four consecutive days were acutely subtherapeutic (i.e., 3.6, 3.7, 3.9, and 3.7 micrograms/L).",Decreased drug absorption in a patient with Behçet's syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621584/),μ,3.9,237082,DB00316,Acetaminophen
,3723398,extraction ratio,"However, acetaminophen was transferred in both directions exclusively via a passive diffusion mechanism with an extraction ratio of 0.12 across the placenta.",Pharmacokinetic studies of the disposition of acetaminophen in the sheep maternal-placental-fetal unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723398/),,0.12,238125,DB00316,Acetaminophen
,24686129,clearance,"Median paracetamol clearance at delivery was significantly higher when compared to postpartum or non-pregnant women (11.9 vs. 6.42 and 8.4 l/h·m(2), at least p < 0.05), while an association between paracetamol clearance and estradiol was observed (R = 0.494, p < 0.0001).",Estradiol and weight are covariates of paracetamol clearance in young women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24686129/),[h·l] / [m(2],11.9,238151,DB00316,Acetaminophen
,24686129,clearance,"Median paracetamol clearance at delivery was significantly higher when compared to postpartum or non-pregnant women (11.9 vs. 6.42 and 8.4 l/h·m(2), at least p < 0.05), while an association between paracetamol clearance and estradiol was observed (R = 0.494, p < 0.0001).",Estradiol and weight are covariates of paracetamol clearance in young women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24686129/),[h·l] / [m(2],6.42,238152,DB00316,Acetaminophen
,24686129,clearance,"Median paracetamol clearance at delivery was significantly higher when compared to postpartum or non-pregnant women (11.9 vs. 6.42 and 8.4 l/h·m(2), at least p < 0.05), while an association between paracetamol clearance and estradiol was observed (R = 0.494, p < 0.0001).",Estradiol and weight are covariates of paracetamol clearance in young women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24686129/),[h·l] / [m(2],8.4,238153,DB00316,Acetaminophen
,27632065,drug uptake,Paracetamol drug uptake was quantified to be 0.289 pmole/min and paracetamol clearance was quantified to be 1.7% of the total value of the larvae.,Pharmacokinetic Modeling of Paracetamol Uptake and Clearance in Zebrafish Larvae: Expanding the Allometric Scale in Vertebrates with Five Orders of Magnitude. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27632065/),[pmole] / [min],0.289,238342,DB00316,Acetaminophen
,27632065,absolute,"With an average volume determined to be 0.290 μL, this yields an absolute clearance of 2.96 × 107 L/h, which scales reasonably well with clearance rates in higher vertebrates.",Pharmacokinetic Modeling of Paracetamol Uptake and Clearance in Zebrafish Larvae: Expanding the Allometric Scale in Vertebrates with Five Orders of Magnitude. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27632065/),[l] / [h],2.96 ×,238343,DB00316,Acetaminophen
,27632065,clearance,"With an average volume determined to be 0.290 μL, this yields an absolute clearance of 2.96 × 107 L/h, which scales reasonably well with clearance rates in higher vertebrates.",Pharmacokinetic Modeling of Paracetamol Uptake and Clearance in Zebrafish Larvae: Expanding the Allometric Scale in Vertebrates with Five Orders of Magnitude. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27632065/),[l] / [h],2.96 ×,238344,DB00316,Acetaminophen
,27632065,clearance,"With an average volume determined to be 0.290 μL, this yields an absolute clearance of 2.96 × 107 L/h, which scales reasonably well with clearance rates in higher vertebrates.",Pharmacokinetic Modeling of Paracetamol Uptake and Clearance in Zebrafish Larvae: Expanding the Allometric Scale in Vertebrates with Five Orders of Magnitude. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27632065/),[l] / [h],107,238345,DB00316,Acetaminophen
,34213088,M/P ratio,"Predicted M/P ratio for acetaminophen, alprazolam, caffeine, and digoxin were 0.83 ± 0.01, 0.45 ± 0.05, 0.70 ± 0.04, and 0.76 ± 0.02, respectively.","Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically-based pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34213088/),,0.83,239192,DB00316,Acetaminophen
,34213088,M/P ratio,"Predicted M/P ratio for acetaminophen, alprazolam, caffeine, and digoxin were 0.83 ± 0.01, 0.45 ± 0.05, 0.70 ± 0.04, and 0.76 ± 0.02, respectively.","Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically-based pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34213088/),,0.45,239193,DB00316,Acetaminophen
,34213088,M/P ratio,"Predicted M/P ratio for acetaminophen, alprazolam, caffeine, and digoxin were 0.83 ± 0.01, 0.45 ± 0.05, 0.70 ± 0.04, and 0.76 ± 0.02, respectively.","Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically-based pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34213088/),,0.70,239194,DB00316,Acetaminophen
,34213088,M/P ratio,"Predicted M/P ratio for acetaminophen, alprazolam, caffeine, and digoxin were 0.83 ± 0.01, 0.45 ± 0.05, 0.70 ± 0.04, and 0.76 ± 0.02, respectively.","Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically-based pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34213088/),,0.76,239195,DB00316,Acetaminophen
,34213088,relative infant dose,"Assuming a daily milk intake of 150 ml, the predicted relative infant dose (%) for these compounds were 4.0, 6.7, 9.9, and 86, respectively, which correspond to a daily ingestion of 2.0 ± 0.5 mg, 3.7 ± 1.2 µg, 2.1 ± 1.0 mg, and 32 ± 4.0 µg by an infant of 5 kg bodyweight.","Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically-based pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34213088/),%,4.0,239196,DB00316,Acetaminophen
,34213088,relative infant dose,"Assuming a daily milk intake of 150 ml, the predicted relative infant dose (%) for these compounds were 4.0, 6.7, 9.9, and 86, respectively, which correspond to a daily ingestion of 2.0 ± 0.5 mg, 3.7 ± 1.2 µg, 2.1 ± 1.0 mg, and 32 ± 4.0 µg by an infant of 5 kg bodyweight.","Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically-based pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34213088/),%,6.7,239197,DB00316,Acetaminophen
,34213088,relative infant dose,"Assuming a daily milk intake of 150 ml, the predicted relative infant dose (%) for these compounds were 4.0, 6.7, 9.9, and 86, respectively, which correspond to a daily ingestion of 2.0 ± 0.5 mg, 3.7 ± 1.2 µg, 2.1 ± 1.0 mg, and 32 ± 4.0 µg by an infant of 5 kg bodyweight.","Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically-based pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34213088/),%,9.9,239198,DB00316,Acetaminophen
,34213088,relative infant dose,"Assuming a daily milk intake of 150 ml, the predicted relative infant dose (%) for these compounds were 4.0, 6.7, 9.9, and 86, respectively, which correspond to a daily ingestion of 2.0 ± 0.5 mg, 3.7 ± 1.2 µg, 2.1 ± 1.0 mg, and 32 ± 4.0 µg by an infant of 5 kg bodyweight.","Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically-based pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34213088/),%,86,239199,DB00316,Acetaminophen
,34213088,relative infant dose,"Assuming a daily milk intake of 150 ml, the predicted relative infant dose (%) for these compounds were 4.0, 6.7, 9.9, and 86, respectively, which correspond to a daily ingestion of 2.0 ± 0.5 mg, 3.7 ± 1.2 µg, 2.1 ± 1.0 mg, and 32 ± 4.0 µg by an infant of 5 kg bodyweight.","Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically-based pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34213088/),%,2.1,239200,DB00316,Acetaminophen
,34213088,relative infant dose,"Assuming a daily milk intake of 150 ml, the predicted relative infant dose (%) for these compounds were 4.0, 6.7, 9.9, and 86, respectively, which correspond to a daily ingestion of 2.0 ± 0.5 mg, 3.7 ± 1.2 µg, 2.1 ± 1.0 mg, and 32 ± 4.0 µg by an infant of 5 kg bodyweight.","Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically-based pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34213088/),,32,239201,DB00316,Acetaminophen
,15285332,bioavailability,"A bioavailability of approximately 96% of that of a paracetamol solution could be achieved from gels containing an identical dose of drug formed in situ in the stomachs of rats, with appreciably lower peak plasma levels and a sustained release of drug over a period of at least 6 h.",In situ gelling pectin formulations for oral sustained delivery of paracetamol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15285332/),%,96,239448,DB00316,Acetaminophen
,8059538,plasma clearance,"2. When both drugs were given at a dose of 5 mg/kg, AP plasma clearance was reduced from 2.22 to 0.96 lh-1 kg-1.",Dose-dependent pharmacokinetic interaction between antipyrine and paracetamol in vivo and in vitro when administered as a cocktail in pig. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8059538/),1/[kg·lh],2.22,240144,DB00316,Acetaminophen
,8059538,plasma clearance,"2. When both drugs were given at a dose of 5 mg/kg, AP plasma clearance was reduced from 2.22 to 0.96 lh-1 kg-1.",Dose-dependent pharmacokinetic interaction between antipyrine and paracetamol in vivo and in vitro when administered as a cocktail in pig. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8059538/),1/[kg·lh],0.96,240145,DB00316,Acetaminophen
,8059538,apparent Km,The apparent Km value for PA glucuronidation was 40 mM with a Vmax = 54 nmol min-1 mg protein-1.,Dose-dependent pharmacokinetic interaction between antipyrine and paracetamol in vivo and in vitro when administered as a cocktail in pig. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8059538/),mM,40,240146,DB00316,Acetaminophen
,8059538,Vmax,The apparent Km value for PA glucuronidation was 40 mM with a Vmax = 54 nmol min-1 mg protein-1.,Dose-dependent pharmacokinetic interaction between antipyrine and paracetamol in vivo and in vitro when administered as a cocktail in pig. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8059538/),[-1·mg·nM] / [min],54,240147,DB00316,Acetaminophen
,8059538,Ki app,"It appeared that 4-OHA was a competitive inhibitor with a Ki app = 0.07 microM, whereas AP had no effect.",Dose-dependent pharmacokinetic interaction between antipyrine and paracetamol in vivo and in vitro when administered as a cocktail in pig. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8059538/),μM,0.07,240148,DB00316,Acetaminophen
,15787918,central volume (V2/F(oral)),"Population parameter estimates (between subject variability, %) were central volume (V2/F(oral)) 24 (55%) l x 70 kg(-1), peripheral volume of distribution (V3/F(oral)) 30 (32%) l x 70 kg(-1), clearance (CL/F(oral)) 16 (40%) l x h(-1) x 70 kg(-1) and intercompartment clearance (Q/F(oral)) 55 (116%) l x h(-1) x 70 kg(-1).",Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15787918/),[l] / [70·kg],24,240873,DB00316,Acetaminophen
,15787918,peripheral volume of distribution (V3/F(oral)),"Population parameter estimates (between subject variability, %) were central volume (V2/F(oral)) 24 (55%) l x 70 kg(-1), peripheral volume of distribution (V3/F(oral)) 30 (32%) l x 70 kg(-1), clearance (CL/F(oral)) 16 (40%) l x h(-1) x 70 kg(-1) and intercompartment clearance (Q/F(oral)) 55 (116%) l x h(-1) x 70 kg(-1).",Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15787918/),[l] / [70·kg],30,240874,DB00316,Acetaminophen
,15787918,clearance (CL/F(oral)),"Population parameter estimates (between subject variability, %) were central volume (V2/F(oral)) 24 (55%) l x 70 kg(-1), peripheral volume of distribution (V3/F(oral)) 30 (32%) l x 70 kg(-1), clearance (CL/F(oral)) 16 (40%) l x h(-1) x 70 kg(-1) and intercompartment clearance (Q/F(oral)) 55 (116%) l x h(-1) x 70 kg(-1).",Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15787918/),[l] / [70·h·kg],16,240875,DB00316,Acetaminophen
,15787918,intercompartment clearance (Q/F(oral)),"Population parameter estimates (between subject variability, %) were central volume (V2/F(oral)) 24 (55%) l x 70 kg(-1), peripheral volume of distribution (V3/F(oral)) 30 (32%) l x 70 kg(-1), clearance (CL/F(oral)) 16 (40%) l x h(-1) x 70 kg(-1) and intercompartment clearance (Q/F(oral)) 55 (116%) l x h(-1) x 70 kg(-1).",Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15787918/),[l] / [70·h·kg],55,240876,DB00316,Acetaminophen
,15787918,Clearance,Clearance increased from 27 weeks PCA (1.87 l x h(-1) 70 kg(-1)) to reach 84% of the mature value by 1 year of age (standardized to a 70 kg person using allometric '1/4 power' models).,Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15787918/),[l] / [70·h·kg],1.87,240877,DB00316,Acetaminophen
,15787918,Peripheral volume of distribution,Peripheral volume of distribution decreased from 27 weeks PCA (45.0 l x 70 kg(-1)) to reach 110% of its mature value by 6 months of age.,Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15787918/),[l] / [70·kg],45.0,240878,DB00316,Acetaminophen
,15787918,K(a),"A rate constant representing hydrolysis of propacetamol to paracetamol (K(a) 96 h(-1)) was size related, but not age related.",Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15787918/),1/[h],96,240879,DB00316,Acetaminophen
,15787918,relative bioavailability,The relative bioavailability of intravenous propacetamol compared with an oral elixir was 0.5.,Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15787918/),,0.5,240880,DB00316,Acetaminophen
,15787918,serum concentration,A mean paracetamol serum concentration of 10 mg x l(-1) is achieved in children 2-15 years given a standard dose of propacetamol 30 mg x kg(-1) 6 h.,Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15787918/),,10,240881,DB00316,Acetaminophen
,8522929,T,"Postmortem central blood concentrations were as follows: T = 3 h: 200.8 +/- 129.2 micrograms/mL, T = 6 h: 100.8 +/- 39.6 micrograms/mL and T = 12 h: 480.8 +/- 128.8 micrograms/mL.",Postmortem acetaminophen pharmacokinetics: an experimental study of site and time-dependent concentration changes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522929/),[μg] / [ml],200.8,241714,DB00316,Acetaminophen
,8522929,T,"Postmortem central blood concentrations were as follows: T = 3 h: 200.8 +/- 129.2 micrograms/mL, T = 6 h: 100.8 +/- 39.6 micrograms/mL and T = 12 h: 480.8 +/- 128.8 micrograms/mL.",Postmortem acetaminophen pharmacokinetics: an experimental study of site and time-dependent concentration changes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522929/),[μg] / [ml],480.8,241715,DB00316,Acetaminophen
,8522929,T,"Postmortem peripheral site results were: T = 3 h: 50.2 +/- 21.4 micrograms/mL, T = 6 h: 100.8 +/- 18.1 and T = 12 h: 117.7 +/- 37.2 micrograms/mL.",Postmortem acetaminophen pharmacokinetics: an experimental study of site and time-dependent concentration changes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522929/),[μg] / [ml],50.2,241716,DB00316,Acetaminophen
,8522929,T,"Postmortem peripheral site results were: T = 3 h: 50.2 +/- 21.4 micrograms/mL, T = 6 h: 100.8 +/- 18.1 and T = 12 h: 117.7 +/- 37.2 micrograms/mL.",Postmortem acetaminophen pharmacokinetics: an experimental study of site and time-dependent concentration changes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522929/),,100.8,241717,DB00316,Acetaminophen
,8522929,T,"Postmortem peripheral site results were: T = 3 h: 50.2 +/- 21.4 micrograms/mL, T = 6 h: 100.8 +/- 18.1 and T = 12 h: 117.7 +/- 37.2 micrograms/mL.",Postmortem acetaminophen pharmacokinetics: an experimental study of site and time-dependent concentration changes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522929/),[μg] / [ml],117.7,241718,DB00316,Acetaminophen
,21263015,systemic exposure,"The mean systemic exposure in the rat model was 18.72 mM·h (range, 9.92-30.02 mM·h), compared to the mean systemic exposure found in treated children (14.48 mM·h; range, 6.22-32.96 mM·h).",N-acetylcysteine as a novel prophylactic treatment for ifosfamide-induced nephrotoxicity in children: translational pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21263015/),h·mM,18.72,242019,DB00316,Acetaminophen
,21263015,systemic exposure,"The mean systemic exposure in the rat model was 18.72 mM·h (range, 9.92-30.02 mM·h), compared to the mean systemic exposure found in treated children (14.48 mM·h; range, 6.22-32.96 mM·h).",N-acetylcysteine as a novel prophylactic treatment for ifosfamide-induced nephrotoxicity in children: translational pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21263015/),h·mM,14.48,242020,DB00316,Acetaminophen
,8739815,total,"The total (bound plus unbound) plasma clearance of frusemide during hypoxaemia (arterial oxygen tension, PaO2 < or = 50 Torr) was not significantly different from the value during normoxaemia (PaO2 > or = 60 Torr) [76.9 and 62.4 ml.min-1].",The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [min],76.9,242537,DB00316,Acetaminophen
,8739815,total,"The total (bound plus unbound) plasma clearance of frusemide during hypoxaemia (arterial oxygen tension, PaO2 < or = 50 Torr) was not significantly different from the value during normoxaemia (PaO2 > or = 60 Torr) [76.9 and 62.4 ml.min-1].",The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [min],62.4,242538,DB00316,Acetaminophen
,8739815,unbound) plasma clearance,"The total (bound plus unbound) plasma clearance of frusemide during hypoxaemia (arterial oxygen tension, PaO2 < or = 50 Torr) was not significantly different from the value during normoxaemia (PaO2 > or = 60 Torr) [76.9 and 62.4 ml.min-1].",The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [min],76.9,242539,DB00316,Acetaminophen
,8739815,unbound) plasma clearance,"The total (bound plus unbound) plasma clearance of frusemide during hypoxaemia (arterial oxygen tension, PaO2 < or = 50 Torr) was not significantly different from the value during normoxaemia (PaO2 > or = 60 Torr) [76.9 and 62.4 ml.min-1].",The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [min],62.4,242540,DB00316,Acetaminophen
,8739815,volume of distribution,The volume of distribution was not affected by acute hypoxaemia (121 ml.kg-1 without and 109 ml.kg-1 with oxygen; P > 0.05).,The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [kg],121,242541,DB00316,Acetaminophen
,8739815,volume of distribution,The volume of distribution was not affected by acute hypoxaemia (121 ml.kg-1 without and 109 ml.kg-1 with oxygen; P > 0.05).,The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [kg],109,242542,DB00316,Acetaminophen
,8739815,Renal,"Renal and non-renal clearances of frusemide were similar during the period of hypoxaemia (31 and 38 ml.min-1, respectively) compared to respective values during supplemental oxygen delivery (29 and 32 ml.min-1).",The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [min],31,242543,DB00316,Acetaminophen
,8739815,Renal,"Renal and non-renal clearances of frusemide were similar during the period of hypoxaemia (31 and 38 ml.min-1, respectively) compared to respective values during supplemental oxygen delivery (29 and 32 ml.min-1).",The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [min],38,242544,DB00316,Acetaminophen
,8739815,Renal,"Renal and non-renal clearances of frusemide were similar during the period of hypoxaemia (31 and 38 ml.min-1, respectively) compared to respective values during supplemental oxygen delivery (29 and 32 ml.min-1).",The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [min],29,242545,DB00316,Acetaminophen
,8739815,non-renal clearances,"Renal and non-renal clearances of frusemide were similar during the period of hypoxaemia (31 and 38 ml.min-1, respectively) compared to respective values during supplemental oxygen delivery (29 and 32 ml.min-1).",The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [min],38,242546,DB00316,Acetaminophen
,8739815,non-renal clearances,"Renal and non-renal clearances of frusemide were similar during the period of hypoxaemia (31 and 38 ml.min-1, respectively) compared to respective values during supplemental oxygen delivery (29 and 32 ml.min-1).",The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [min],29,242547,DB00316,Acetaminophen
,8739815,non-renal clearances,"Renal and non-renal clearances of frusemide were similar during the period of hypoxaemia (31 and 38 ml.min-1, respectively) compared to respective values during supplemental oxygen delivery (29 and 32 ml.min-1).",The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [min],32,242548,DB00316,Acetaminophen
,8739815,absolute bioavailability,The absolute bioavailability of frusemide during hypoxaemia (0.62) was not different to that obtained during normoxaemia (0.56).,The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),,0.62,242549,DB00316,Acetaminophen
,8739815,absolute bioavailability,The absolute bioavailability of frusemide during hypoxaemia (0.62) was not different to that obtained during normoxaemia (0.56).,The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),,0.56,242550,DB00316,Acetaminophen
,26588196,steady-state area under the plasma concentration-time curve,"Co-administration of lamotrigine and paracetamol decreased the steady-state area under the plasma concentration-time curve of lamotrigine by 20% (95% CI 10%, 25%; P < 0.001) from 166 to 127 μmol l(-1) .",Paracetamol decreases steady-state exposure to lamotrigine by induction of glucuronidation in healthy subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26588196/),[μM] / [l],166,243835,DB00316,Acetaminophen
,26588196,steady-state area under the plasma concentration-time curve,"Co-administration of lamotrigine and paracetamol decreased the steady-state area under the plasma concentration-time curve of lamotrigine by 20% (95% CI 10%, 25%; P < 0.001) from 166 to 127 μmol l(-1) .",Paracetamol decreases steady-state exposure to lamotrigine by induction of glucuronidation in healthy subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26588196/),[μM] / [l],127,243836,DB00316,Acetaminophen
,26588196,formation clearance,"Concomitant administration of paracetamol increased the formation clearance of lamotrigine glucuronide conjugates by 45% (95% CI 18%, 79%, P = 0.005) from 1.7 to 2.8 l h(-1) , while the trough value of lamotrigine was reduced by 25% (95% CI 12%, 36%, P = 0.003) from 5.3 to 3.9 μmol l(-1) .",Paracetamol decreases steady-state exposure to lamotrigine by induction of glucuronidation in healthy subjects. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26588196/),[l] / [h],1,243837,DB00316,Acetaminophen
,26588196,trough,"Concomitant administration of paracetamol increased the formation clearance of lamotrigine glucuronide conjugates by 45% (95% CI 18%, 79%, P = 0.005) from 1.7 to 2.8 l h(-1) , while the trough value of lamotrigine was reduced by 25% (95% CI 12%, 36%, P = 0.003) from 5.3 to 3.9 μmol l(-1) .",Paracetamol decreases steady-state exposure to lamotrigine by induction of glucuronidation in healthy subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26588196/),[μM] / [l],5.3,243838,DB00316,Acetaminophen
,26588196,trough,"Concomitant administration of paracetamol increased the formation clearance of lamotrigine glucuronide conjugates by 45% (95% CI 18%, 79%, P = 0.005) from 1.7 to 2.8 l h(-1) , while the trough value of lamotrigine was reduced by 25% (95% CI 12%, 36%, P = 0.003) from 5.3 to 3.9 μmol l(-1) .",Paracetamol decreases steady-state exposure to lamotrigine by induction of glucuronidation in healthy subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26588196/),[μM] / [l],3,243839,DB00316,Acetaminophen
,9365971,Cmax (maximum plasma concentration),Pharmacokinetic parameters were (mean +/- SD): Cmax (maximum plasma concentration) of 8.38 +/- 3.92 micrograms.,Plasma concentrations after rectal administration of acetaminophen in preterm neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9365971/),μg,8.38,246948,DB00316,Acetaminophen
,9365971,Tmax (time to reach maximum plasma concentration),ml-1 and Tmax (time to reach maximum plasma concentration) of 78.0 +/- 40.2 min.,Plasma concentrations after rectal administration of acetaminophen in preterm neonates. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9365971/),min,78.0,246949,DB00316,Acetaminophen
,7201813,k1,A was more than twice as fast (k1 = 0.762 h-1) as that from prep.,[On the pharmacokinetics and bioavailability of paracetamol in suppositories for paediatry (author's transl)]. ,"λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7201813/),1/[h],0.762,246955,DB00316,Acetaminophen
,7201813,B (k1,"B (k1 = 0.348 h-1), resulting in an obviously higher maximum blood level.",[On the pharmacokinetics and bioavailability of paracetamol in suppositories for paediatry (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7201813/),1/[h],0.348,246956,DB00316,Acetaminophen
,6632001,percent of,The percent of the administered dose excreted in the urine during the first 6 h was 17.5 for the male rat versus 24.5 for the female rat.,Hepatotoxicity and metabolism of acetaminophen in male and female rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6632001/),,17.5,247435,DB00316,Acetaminophen
,6632001,percent of,The percent of the administered dose excreted in the urine during the first 6 h was 17.5 for the male rat versus 24.5 for the female rat.,Hepatotoxicity and metabolism of acetaminophen in male and female rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6632001/),,24.5,247436,DB00316,Acetaminophen
,6632001,excreted,The percent of the administered dose excreted in the urine during the first 6 h was 17.5 for the male rat versus 24.5 for the female rat.,Hepatotoxicity and metabolism of acetaminophen in male and female rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6632001/),,17.5,247437,DB00316,Acetaminophen
,6632001,excreted,The percent of the administered dose excreted in the urine during the first 6 h was 17.5 for the male rat versus 24.5 for the female rat.,Hepatotoxicity and metabolism of acetaminophen in male and female rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6632001/),,24.5,247438,DB00316,Acetaminophen
,27118212,relative bioavailability,The relative bioavailability of oral syrup was 84.4 % (95 % CI 68.2-95.1 %) compared to intramuscular administration.,Pharmacokinetic properties of intramuscular versus oral syrup paracetamol in Plasmodium falciparum malaria. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27118212/),%,84.4,248459,DB00316,Acetaminophen
,27118212,Relative oral bioavailability,Relative oral bioavailability compared to intramuscular dosing was estimated as 84.4 % (95 % CI 68.2-95.1 %).,Pharmacokinetic properties of intramuscular versus oral syrup paracetamol in Plasmodium falciparum malaria. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27118212/),%,84.4,248460,DB00316,Acetaminophen
,17993749,"distribution coefficient, alpha","Levofloxacin was rapidly distributed from blood to the tissue compartment as evidenced by the high values of the distribution coefficient, alpha (17.3 +/- 1.65 /h) and the ratio of K(12)/K(21) (1.83 +/- 0.12).",Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993749/),1/[h],17.3,250061,DB00316,Acetaminophen
,17993749,ratio of K(12)/K(21),"Levofloxacin was rapidly distributed from blood to the tissue compartment as evidenced by the high values of the distribution coefficient, alpha (17.3 +/- 1.65 /h) and the ratio of K(12)/K(21) (1.83 +/- 0.12).",Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993749/),,1.83,250062,DB00316,Acetaminophen
,17993749,AUC,The values of AUC and Vd(area) were 12.7 +/- 0.12 microg.h/ml and 0.63 +/- 0.01 l/kg.,Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993749/),[h·μg] / [ml],12.7,250063,DB00316,Acetaminophen
,17993749,Vd(area),The values of AUC and Vd(area) were 12.7 +/- 0.12 microg.h/ml and 0.63 +/- 0.01 l/kg.,Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993749/),[l] / [kg],0.63,250064,DB00316,Acetaminophen
,17993749,ratio of the AUC/ MIC,The high ratio of the AUC/ MIC (126.9 +/- 1.18) obtained in this study indicated the excellent antibacterial activity of levofloxacin in calves.,Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993749/),,126.9,250065,DB00316,Acetaminophen
,17993749,elimination half-life,"The elimination half-life, MRT and total body clearance were 1.38 +/- 0.01 h, 1.88 +/- 0.01 h and 0.32 +/- 0.003 l/kg/h, respectively.",Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993749/),h,1.38,250066,DB00316,Acetaminophen
,17993749,MRT,"The elimination half-life, MRT and total body clearance were 1.38 +/- 0.01 h, 1.88 +/- 0.01 h and 0.32 +/- 0.003 l/kg/h, respectively.",Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993749/),h,1.88,250067,DB00316,Acetaminophen
,17993749,total body clearance,"The elimination half-life, MRT and total body clearance were 1.38 +/- 0.01 h, 1.88 +/- 0.01 h and 0.32 +/- 0.003 l/kg/h, respectively.",Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993749/),[l] / [h·kg],0.32,250068,DB00316,Acetaminophen
,2328311,Eo,The first-pass effect after oral administration (oral extraction) was extensive (Eo = 0.34-0.50) at all doses administered.,First-pass metabolism of acetaminophen in rats after low and high doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328311/),,0.34-0.50,250244,DB00316,Acetaminophen
,7062293,steady-state plasma concentrations,"A 6-hr infusion of acetaminophen, at 36 mg/kg/hr, produced steady-state plasma concentrations of about 20 micrograms/ml within 2 hr in renal failure (ureter-ligated) animals, whereas in normal animals the plasma concentrations increased continuously to about 100 micrograms/ml at 6 hr.",Effect of experimental renal failure on sulfate retention and acetaminophen pharmacokinetics in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7062293/),[μg] / [ml],20,250483,DB00316,Acetaminophen
,7062293,Free sulfate concentrations,Free sulfate concentrations in serum at the end of the infusion were about 0.2 mM in normal animals and generally greater than 1 mM in the renal failure animals.,Effect of experimental renal failure on sulfate retention and acetaminophen pharmacokinetics in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7062293/),mM,0.2,250484,DB00316,Acetaminophen
,24134534,total clearance,"A single run of 3-4 h of haemodialysis removed 10-20 g of acetaminophen (48-80% of remaining body burden), reduced serum acetaminophen concentrations by 56-84% (total clearance 3.4-7.8 mL/kg/min), accelerated native acetaminophen clearance (mean elimination half-life 580 min pre-dialysis, 120 min during and 340 min post-dialysis) and corrected acidemia.",Antidote removal during haemodialysis for massive acetaminophen overdose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24134534/),[ml] / [kg·min],3.4-7.8,250716,DB00316,Acetaminophen
,24134534,elimination half-life,"A single run of 3-4 h of haemodialysis removed 10-20 g of acetaminophen (48-80% of remaining body burden), reduced serum acetaminophen concentrations by 56-84% (total clearance 3.4-7.8 mL/kg/min), accelerated native acetaminophen clearance (mean elimination half-life 580 min pre-dialysis, 120 min during and 340 min post-dialysis) and corrected acidemia.",Antidote removal during haemodialysis for massive acetaminophen overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24134534/),min,580,250717,DB00316,Acetaminophen
,24134534,elimination half-life,"A single run of 3-4 h of haemodialysis removed 10-20 g of acetaminophen (48-80% of remaining body burden), reduced serum acetaminophen concentrations by 56-84% (total clearance 3.4-7.8 mL/kg/min), accelerated native acetaminophen clearance (mean elimination half-life 580 min pre-dialysis, 120 min during and 340 min post-dialysis) and corrected acidemia.",Antidote removal during haemodialysis for massive acetaminophen overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24134534/),min,120,250718,DB00316,Acetaminophen
,24134534,elimination half-life,"A single run of 3-4 h of haemodialysis removed 10-20 g of acetaminophen (48-80% of remaining body burden), reduced serum acetaminophen concentrations by 56-84% (total clearance 3.4-7.8 mL/kg/min), accelerated native acetaminophen clearance (mean elimination half-life 580 min pre-dialysis, 120 min during and 340 min post-dialysis) and corrected acidemia.",Antidote removal during haemodialysis for massive acetaminophen overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24134534/),min,340,250719,DB00316,Acetaminophen
,24134534,Extraction ratios,Extraction ratios of acetylcysteine across the dialysis circuit ranged from 73% to 87% (dialysance 3.0 to 5.3 mL/kg/min).,Antidote removal during haemodialysis for massive acetaminophen overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24134534/),%,73,250720,DB00316,Acetaminophen
,24134534,Extraction ratios,Extraction ratios of acetylcysteine across the dialysis circuit ranged from 73% to 87% (dialysance 3.0 to 5.3 mL/kg/min).,Antidote removal during haemodialysis for massive acetaminophen overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24134534/),%,87,250721,DB00316,Acetaminophen
,30633373,clearance,Acetaminophen clearance in a typical child of 6.1 kg is 0.96 L/h and volume of distribution 7.96 L.,Population Pharmacokinetic Modeling of Acetaminophen and Metabolites in Children After Cardiac Surgery With Cardiopulmonary Bypass. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30633373/),[l] / [h],0.96,251099,DB00316,Acetaminophen
,30633373,volume of distribution,Acetaminophen clearance in a typical child of 6.1 kg is 0.96 L/h and volume of distribution 7.96 L.,Population Pharmacokinetic Modeling of Acetaminophen and Metabolites in Children After Cardiac Surgery With Cardiopulmonary Bypass. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30633373/),l,7.96,251100,DB00316,Acetaminophen
,10631416,volume of distribution,"Population parameter estimates with coefficient of variation (CV%), standardized to a 70 kg person, for a one-compartment model with first order input, lag time and first order elimination were volume of distribution 127l (28) and clearance 26.4 l/h (29) Rectal paracetamol had an absorption half-life (Tabs) of 2.02 h (31) with a lag time of 0.28 h.",Pharmacokinetics of paracetamol in adults after cardiac surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631416/),l,127,251213,DB00316,Acetaminophen
,10631416,clearance,"Population parameter estimates with coefficient of variation (CV%), standardized to a 70 kg person, for a one-compartment model with first order input, lag time and first order elimination were volume of distribution 127l (28) and clearance 26.4 l/h (29) Rectal paracetamol had an absorption half-life (Tabs) of 2.02 h (31) with a lag time of 0.28 h.",Pharmacokinetics of paracetamol in adults after cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631416/),[l] / [h],26.4,251214,DB00316,Acetaminophen
,10631416,absorption half-life (Tabs),"Population parameter estimates with coefficient of variation (CV%), standardized to a 70 kg person, for a one-compartment model with first order input, lag time and first order elimination were volume of distribution 127l (28) and clearance 26.4 l/h (29) Rectal paracetamol had an absorption half-life (Tabs) of 2.02 h (31) with a lag time of 0.28 h.",Pharmacokinetics of paracetamol in adults after cardiac surgery. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631416/),h,2.02,251215,DB00316,Acetaminophen
,10631416,lag time,"Population parameter estimates with coefficient of variation (CV%), standardized to a 70 kg person, for a one-compartment model with first order input, lag time and first order elimination were volume of distribution 127l (28) and clearance 26.4 l/h (29) Rectal paracetamol had an absorption half-life (Tabs) of 2.02 h (31) with a lag time of 0.28 h.",Pharmacokinetics of paracetamol in adults after cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631416/),h,0.28,251216,DB00316,Acetaminophen
,10631416,absorption half-life,The absorption half-life for the oral preparation was 1.49 h (81) with a lag time of 0.17 h.,Pharmacokinetics of paracetamol in adults after cardiac surgery. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631416/),h,1.49,251217,DB00316,Acetaminophen
,10631416,lag time,The absorption half-life for the oral preparation was 1.49 h (81) with a lag time of 0.17 h.,Pharmacokinetics of paracetamol in adults after cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631416/),h,0.17,251218,DB00316,Acetaminophen
,10631416,relative bioavailability,The relative bioavailability of the rectal compared to the oral formulation was 0.98 (18).,Pharmacokinetics of paracetamol in adults after cardiac surgery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631416/),,0.98,251219,DB00316,Acetaminophen
,12697478,dissolution rates,"The 15-min dissolution rates of 5 kinds of paracetamol tablets were 100.43+/-2.61, 99.76+/-1.97, 96.47+/-3.52, 89.58+/-1.85, and 85.85+/-1.83 respectively, with their bioavailability of 86.34+/-10.06, 85.82+/-11.21, 87.10+/-10.86, 81.71+/-12.34, and 76.53+/-11.73 respectively, showing obvious linear relationship between them, which conformed to the equation y = 0.6122x + 25.175, r = 0.9642.",Relationship between dissolution rate and bioavailability of paracetamol tablet. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12697478/),,100.43,251274,DB00316,Acetaminophen
,12697478,dissolution rates,"The 15-min dissolution rates of 5 kinds of paracetamol tablets were 100.43+/-2.61, 99.76+/-1.97, 96.47+/-3.52, 89.58+/-1.85, and 85.85+/-1.83 respectively, with their bioavailability of 86.34+/-10.06, 85.82+/-11.21, 87.10+/-10.86, 81.71+/-12.34, and 76.53+/-11.73 respectively, showing obvious linear relationship between them, which conformed to the equation y = 0.6122x + 25.175, r = 0.9642.",Relationship between dissolution rate and bioavailability of paracetamol tablet. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12697478/),,99.76,251275,DB00316,Acetaminophen
,12697478,dissolution rates,"The 15-min dissolution rates of 5 kinds of paracetamol tablets were 100.43+/-2.61, 99.76+/-1.97, 96.47+/-3.52, 89.58+/-1.85, and 85.85+/-1.83 respectively, with their bioavailability of 86.34+/-10.06, 85.82+/-11.21, 87.10+/-10.86, 81.71+/-12.34, and 76.53+/-11.73 respectively, showing obvious linear relationship between them, which conformed to the equation y = 0.6122x + 25.175, r = 0.9642.",Relationship between dissolution rate and bioavailability of paracetamol tablet. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12697478/),,96.47,251276,DB00316,Acetaminophen
,12697478,dissolution rates,"The 15-min dissolution rates of 5 kinds of paracetamol tablets were 100.43+/-2.61, 99.76+/-1.97, 96.47+/-3.52, 89.58+/-1.85, and 85.85+/-1.83 respectively, with their bioavailability of 86.34+/-10.06, 85.82+/-11.21, 87.10+/-10.86, 81.71+/-12.34, and 76.53+/-11.73 respectively, showing obvious linear relationship between them, which conformed to the equation y = 0.6122x + 25.175, r = 0.9642.",Relationship between dissolution rate and bioavailability of paracetamol tablet. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12697478/),,89.58,251277,DB00316,Acetaminophen
,12697478,dissolution rates,"The 15-min dissolution rates of 5 kinds of paracetamol tablets were 100.43+/-2.61, 99.76+/-1.97, 96.47+/-3.52, 89.58+/-1.85, and 85.85+/-1.83 respectively, with their bioavailability of 86.34+/-10.06, 85.82+/-11.21, 87.10+/-10.86, 81.71+/-12.34, and 76.53+/-11.73 respectively, showing obvious linear relationship between them, which conformed to the equation y = 0.6122x + 25.175, r = 0.9642.",Relationship between dissolution rate and bioavailability of paracetamol tablet. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12697478/),,85.85,251278,DB00316,Acetaminophen
,12697478,bioavailability,"The 15-min dissolution rates of 5 kinds of paracetamol tablets were 100.43+/-2.61, 99.76+/-1.97, 96.47+/-3.52, 89.58+/-1.85, and 85.85+/-1.83 respectively, with their bioavailability of 86.34+/-10.06, 85.82+/-11.21, 87.10+/-10.86, 81.71+/-12.34, and 76.53+/-11.73 respectively, showing obvious linear relationship between them, which conformed to the equation y = 0.6122x + 25.175, r = 0.9642.",Relationship between dissolution rate and bioavailability of paracetamol tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12697478/),,86.34,251279,DB00316,Acetaminophen
,12697478,bioavailability,"The 15-min dissolution rates of 5 kinds of paracetamol tablets were 100.43+/-2.61, 99.76+/-1.97, 96.47+/-3.52, 89.58+/-1.85, and 85.85+/-1.83 respectively, with their bioavailability of 86.34+/-10.06, 85.82+/-11.21, 87.10+/-10.86, 81.71+/-12.34, and 76.53+/-11.73 respectively, showing obvious linear relationship between them, which conformed to the equation y = 0.6122x + 25.175, r = 0.9642.",Relationship between dissolution rate and bioavailability of paracetamol tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12697478/),,85.82,251280,DB00316,Acetaminophen
,12697478,bioavailability,"The 15-min dissolution rates of 5 kinds of paracetamol tablets were 100.43+/-2.61, 99.76+/-1.97, 96.47+/-3.52, 89.58+/-1.85, and 85.85+/-1.83 respectively, with their bioavailability of 86.34+/-10.06, 85.82+/-11.21, 87.10+/-10.86, 81.71+/-12.34, and 76.53+/-11.73 respectively, showing obvious linear relationship between them, which conformed to the equation y = 0.6122x + 25.175, r = 0.9642.",Relationship between dissolution rate and bioavailability of paracetamol tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12697478/),,87.10,251281,DB00316,Acetaminophen
,12697478,bioavailability,"The 15-min dissolution rates of 5 kinds of paracetamol tablets were 100.43+/-2.61, 99.76+/-1.97, 96.47+/-3.52, 89.58+/-1.85, and 85.85+/-1.83 respectively, with their bioavailability of 86.34+/-10.06, 85.82+/-11.21, 87.10+/-10.86, 81.71+/-12.34, and 76.53+/-11.73 respectively, showing obvious linear relationship between them, which conformed to the equation y = 0.6122x + 25.175, r = 0.9642.",Relationship between dissolution rate and bioavailability of paracetamol tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12697478/),,81.71,251282,DB00316,Acetaminophen
,12697478,bioavailability,"The 15-min dissolution rates of 5 kinds of paracetamol tablets were 100.43+/-2.61, 99.76+/-1.97, 96.47+/-3.52, 89.58+/-1.85, and 85.85+/-1.83 respectively, with their bioavailability of 86.34+/-10.06, 85.82+/-11.21, 87.10+/-10.86, 81.71+/-12.34, and 76.53+/-11.73 respectively, showing obvious linear relationship between them, which conformed to the equation y = 0.6122x + 25.175, r = 0.9642.",Relationship between dissolution rate and bioavailability of paracetamol tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12697478/),,76.53,251283,DB00316,Acetaminophen
,25724644,Tmax,The acetaminophen Tmax was also not impacted under all treatment conditions but increased from 0.75 to 2.00 h when administered 1 h after food.,Assessment of pharmacokinetic drug-drug interaction between pradigastat and acetaminophen in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724644/),h,0.75,251636,DB00316,Acetaminophen
,25724644,Tmax,The acetaminophen Tmax was also not impacted under all treatment conditions but increased from 0.75 to 2.00 h when administered 1 h after food.,Assessment of pharmacokinetic drug-drug interaction between pradigastat and acetaminophen in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724644/),h,2.00,251637,DB00316,Acetaminophen
,7075126,Absolute volume of distribution (Vd),"Absolute volume of distribution (Vd) was greater in obese than in control men (109 and 77 l, P less than 0.05) and greater in control men than in control women (77 and 52 l, P less than 0.05), but Vd corrected for TBW was smaller in obese than in control men (0.81 and 1.09 l/kg TBW, P less than 0.05) and smaller in obese than control women (0.71 and 0.95 l/kg TBW, P less than 0.05).","Obesity, sex, and acetaminophen disposition. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075126/),l,109,253353,DB00316,Acetaminophen
,7075126,Absolute volume of distribution (Vd),"Absolute volume of distribution (Vd) was greater in obese than in control men (109 and 77 l, P less than 0.05) and greater in control men than in control women (77 and 52 l, P less than 0.05), but Vd corrected for TBW was smaller in obese than in control men (0.81 and 1.09 l/kg TBW, P less than 0.05) and smaller in obese than control women (0.71 and 0.95 l/kg TBW, P less than 0.05).","Obesity, sex, and acetaminophen disposition. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075126/),l,77,253354,DB00316,Acetaminophen
,7075126,Absolute volume of distribution (Vd),"Absolute volume of distribution (Vd) was greater in obese than in control men (109 and 77 l, P less than 0.05) and greater in control men than in control women (77 and 52 l, P less than 0.05), but Vd corrected for TBW was smaller in obese than in control men (0.81 and 1.09 l/kg TBW, P less than 0.05) and smaller in obese than control women (0.71 and 0.95 l/kg TBW, P less than 0.05).","Obesity, sex, and acetaminophen disposition. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075126/),l,52,253355,DB00316,Acetaminophen
,7075126,Vd,"Absolute volume of distribution (Vd) was greater in obese than in control men (109 and 77 l, P less than 0.05) and greater in control men than in control women (77 and 52 l, P less than 0.05), but Vd corrected for TBW was smaller in obese than in control men (0.81 and 1.09 l/kg TBW, P less than 0.05) and smaller in obese than control women (0.71 and 0.95 l/kg TBW, P less than 0.05).","Obesity, sex, and acetaminophen disposition. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075126/),[l] / [kg],0.81,253356,DB00316,Acetaminophen
,7075126,Vd,"Absolute volume of distribution (Vd) was greater in obese than in control men (109 and 77 l, P less than 0.05) and greater in control men than in control women (77 and 52 l, P less than 0.05), but Vd corrected for TBW was smaller in obese than in control men (0.81 and 1.09 l/kg TBW, P less than 0.05) and smaller in obese than control women (0.71 and 0.95 l/kg TBW, P less than 0.05).","Obesity, sex, and acetaminophen disposition. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075126/),[l] / [kg],1.09,253357,DB00316,Acetaminophen
,7075126,Vd,"Absolute volume of distribution (Vd) was greater in obese than in control men (109 and 77 l, P less than 0.05) and greater in control men than in control women (77 and 52 l, P less than 0.05), but Vd corrected for TBW was smaller in obese than in control men (0.81 and 1.09 l/kg TBW, P less than 0.05) and smaller in obese than control women (0.71 and 0.95 l/kg TBW, P less than 0.05).","Obesity, sex, and acetaminophen disposition. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075126/),[l] / [kg],0.71,253358,DB00316,Acetaminophen
,7075126,Vd,"Absolute volume of distribution (Vd) was greater in obese than in control men (109 and 77 l, P less than 0.05) and greater in control men than in control women (77 and 52 l, P less than 0.05), but Vd corrected for TBW was smaller in obese than in control men (0.81 and 1.09 l/kg TBW, P less than 0.05) and smaller in obese than control women (0.71 and 0.95 l/kg TBW, P less than 0.05).","Obesity, sex, and acetaminophen disposition. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075126/),[l] / [kg],0.95,253359,DB00316,Acetaminophen
,7075126,Absolute metabolic clearance,"Absolute metabolic clearance was greater in obese than in control men (484 and 323 ml/min, P less than 0.05), in obese than in control women (312 and 227 ml/min, P less than 0.05), and in control men than women (323 and 227 ml/min, P less than 0.05).","Obesity, sex, and acetaminophen disposition. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075126/),[ml] / [min],484,253360,DB00316,Acetaminophen
,7075126,Absolute metabolic clearance,"Absolute metabolic clearance was greater in obese than in control men (484 and 323 ml/min, P less than 0.05), in obese than in control women (312 and 227 ml/min, P less than 0.05), and in control men than women (323 and 227 ml/min, P less than 0.05).","Obesity, sex, and acetaminophen disposition. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075126/),[ml] / [min],323,253361,DB00316,Acetaminophen
,7075126,Absolute metabolic clearance,"Absolute metabolic clearance was greater in obese than in control men (484 and 323 ml/min, P less than 0.05), in obese than in control women (312 and 227 ml/min, P less than 0.05), and in control men than women (323 and 227 ml/min, P less than 0.05).","Obesity, sex, and acetaminophen disposition. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075126/),[ml] / [min],312,253362,DB00316,Acetaminophen
,7075126,Absolute metabolic clearance,"Absolute metabolic clearance was greater in obese than in control men (484 and 323 ml/min, P less than 0.05), in obese than in control women (312 and 227 ml/min, P less than 0.05), and in control men than women (323 and 227 ml/min, P less than 0.05).","Obesity, sex, and acetaminophen disposition. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075126/),[ml] / [min],227,253363,DB00316,Acetaminophen
,8483845,half-life,The half-life for acetaminophen was determined to be 20.9 +/- 1.0 min (n = 6) for a 2 mg/kg dosing.,Pharmacokinetic monitoring in subcutaneous tissue using in vivo capillary ultrafiltration probes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8483845/),min,20.9,253490,DB00316,Acetaminophen
,8483845,half-life of elimination,The half-life of elimination for theophylline was determined to be 3.0 +/- 0.1 hr (n = 4) for a 4 mg/kg dose.,Pharmacokinetic monitoring in subcutaneous tissue using in vivo capillary ultrafiltration probes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8483845/),h,3.0,253491,DB00316,Acetaminophen
,8483845,constant flow rate,The capillary ultrafiltration probes exhibited a constant flow rate of 2.4 +/- 0.1 microL/min and removed 50 nL/min/mm of fluid from the extracellular space.,Pharmacokinetic monitoring in subcutaneous tissue using in vivo capillary ultrafiltration probes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8483845/),[μl] / [min],2.4,253492,DB00316,Acetaminophen
,15225168,area under the curve concentration-time,"Patients showed a higher mean area under the curve concentration-time (67.4 +/- 22.4 mg h/L vs. 38.8 +/- 4.3 mg h/L; P = 0.01), a lower clearance (166.7 +/- 85.0 mL/min vs. 367.8 +/- 62.5 mL/min; P = 0.01) and higher elimination half-life (3.8 +/- 1.1 h vs. 2.0 +/- 0.4 h; P = 0.01) of acetaminophen than healthy volunteers.",Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15225168/),[h·mg] / [l],67.4,253995,DB00316,Acetaminophen
,15225168,area under the curve concentration-time,"Patients showed a higher mean area under the curve concentration-time (67.4 +/- 22.4 mg h/L vs. 38.8 +/- 4.3 mg h/L; P = 0.01), a lower clearance (166.7 +/- 85.0 mL/min vs. 367.8 +/- 62.5 mL/min; P = 0.01) and higher elimination half-life (3.8 +/- 1.1 h vs. 2.0 +/- 0.4 h; P = 0.01) of acetaminophen than healthy volunteers.",Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15225168/),[h·mg] / [l],38.8,253996,DB00316,Acetaminophen
,15225168,clearance,"Patients showed a higher mean area under the curve concentration-time (67.4 +/- 22.4 mg h/L vs. 38.8 +/- 4.3 mg h/L; P = 0.01), a lower clearance (166.7 +/- 85.0 mL/min vs. 367.8 +/- 62.5 mL/min; P = 0.01) and higher elimination half-life (3.8 +/- 1.1 h vs. 2.0 +/- 0.4 h; P = 0.01) of acetaminophen than healthy volunteers.",Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15225168/),[ml] / [min],166.7,253997,DB00316,Acetaminophen
,15225168,clearance,"Patients showed a higher mean area under the curve concentration-time (67.4 +/- 22.4 mg h/L vs. 38.8 +/- 4.3 mg h/L; P = 0.01), a lower clearance (166.7 +/- 85.0 mL/min vs. 367.8 +/- 62.5 mL/min; P = 0.01) and higher elimination half-life (3.8 +/- 1.1 h vs. 2.0 +/- 0.4 h; P = 0.01) of acetaminophen than healthy volunteers.",Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15225168/),[ml] / [min],367.8,253998,DB00316,Acetaminophen
,15225168,elimination half-life,"Patients showed a higher mean area under the curve concentration-time (67.4 +/- 22.4 mg h/L vs. 38.8 +/- 4.3 mg h/L; P = 0.01), a lower clearance (166.7 +/- 85.0 mL/min vs. 367.8 +/- 62.5 mL/min; P = 0.01) and higher elimination half-life (3.8 +/- 1.1 h vs. 2.0 +/- 0.4 h; P = 0.01) of acetaminophen than healthy volunteers.",Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15225168/),h,3.8,253999,DB00316,Acetaminophen
,15225168,elimination half-life,"Patients showed a higher mean area under the curve concentration-time (67.4 +/- 22.4 mg h/L vs. 38.8 +/- 4.3 mg h/L; P = 0.01), a lower clearance (166.7 +/- 85.0 mL/min vs. 367.8 +/- 62.5 mL/min; P = 0.01) and higher elimination half-life (3.8 +/- 1.1 h vs. 2.0 +/- 0.4 h; P = 0.01) of acetaminophen than healthy volunteers.",Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15225168/),h,2.0,254000,DB00316,Acetaminophen
,24577931,retention time,"The retention time for pefloxacin 18±1 min and paracetamol were approximately 6±1 min, respectively.",Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24577931/),min,18,254395,DB00316,Acetaminophen
,24577931,retention time,"The retention time for pefloxacin 18±1 min and paracetamol were approximately 6±1 min, respectively.",Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24577931/),min,6,254396,DB00316,Acetaminophen
,24577931,AUC0-∞,"The value of AUC0-∞ in control was 67.355±3.174μg.h/ml, in treatment 61.242±3.868μg.h/ml along with relative bioavailability =91.395±4.864.",Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24577931/),[h·μg] / [ml],67.355,254397,DB00316,Acetaminophen
,24577931,AUC0-∞,"The value of AUC0-∞ in control was 67.355±3.174μg.h/ml, in treatment 61.242±3.868μg.h/ml along with relative bioavailability =91.395±4.864.",Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24577931/),[h·μg] / [ml],61.242,254398,DB00316,Acetaminophen
,24577931,relative bioavailability,"The value of AUC0-∞ in control was 67.355±3.174μg.h/ml, in treatment 61.242±3.868μg.h/ml along with relative bioavailability =91.395±4.864.",Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24577931/),,91.395,254399,DB00316,Acetaminophen
,24577931,maximum plasma concentrations,Under the control and treatment condition the mean maximum plasma concentrations were found to be 4.679±0.248 μg/ml and 4.6595±0.266 μg/ml respectively.,Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24577931/),[μg] / [ml],4.679,254400,DB00316,Acetaminophen
,24577931,maximum plasma concentrations,Under the control and treatment condition the mean maximum plasma concentrations were found to be 4.679±0.248 μg/ml and 4.6595±0.266 μg/ml respectively.,Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24577931/),[μg] / [ml],4.6595,254401,DB00316,Acetaminophen
,24577931,T(max),The average T(max) for plasma concentrations was 1.819±0.1743hr and 1.605 ±0.1134hr respectively.,Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24577931/),h,1.819,254402,DB00316,Acetaminophen
,24577931,T(max),The average T(max) for plasma concentrations was 1.819±0.1743hr and 1.605 ±0.1134hr respectively.,Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24577931/),h,1.605,254403,DB00316,Acetaminophen
,24577931,biological half-lives,The biological half-lives in the two phases of studies were found to be 7.953±0.33hr in control and 7.7257±0.355hr in treatment.,Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24577931/),h,7.953,254404,DB00316,Acetaminophen
,24577931,biological half-lives,The biological half-lives in the two phases of studies were found to be 7.953±0.33hr in control and 7.7257±0.355hr in treatment.,Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24577931/),h,7.7257,254405,DB00316,Acetaminophen
,23503706,time to maximum concentration (tmax),The time to maximum concentration (tmax) varied from 0.5 to 24 hours (median 12 hours) according to which peak predominated.,The pharmacokinetics and safety of an intraoperative bupivacaine-collagen implant (XaraColl(®)) for postoperative analgesia in women following total abdominal hysterectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23503706/),h,12,254654,DB00316,Acetaminophen
,23503706,maximum concentration (Cmax),"The mean maximum concentration (Cmax) was 0.22 μg/mL and the maximum individual Cmax was 0.44 μg/mL, which are well below the established systemic toxicity threshold.",The pharmacokinetics and safety of an intraoperative bupivacaine-collagen implant (XaraColl(®)) for postoperative analgesia in women following total abdominal hysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23503706/),[μg] / [ml],0.22,254655,DB00316,Acetaminophen
,23503706,maximum individual Cmax,"The mean maximum concentration (Cmax) was 0.22 μg/mL and the maximum individual Cmax was 0.44 μg/mL, which are well below the established systemic toxicity threshold.",The pharmacokinetics and safety of an intraoperative bupivacaine-collagen implant (XaraColl(®)) for postoperative analgesia in women following total abdominal hysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23503706/),[μg] / [ml],0.44,254656,DB00316,Acetaminophen
,10325815,T1/2,"As serum concentration was still in the therapeutic range for some infants in group 1, elimination half life (T1/2) could not be determined in all infants: T1/2 was 11.0 +/- 5.7 in 11 infants in group 1 and 4.8 +/- 1.2 hours in group 2.",Pharmacokinetics and metabolism of rectally administered paracetamol in preterm neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10325815/),h,11.0,255411,DB00316,Acetaminophen
,10325815,T1/2,"As serum concentration was still in the therapeutic range for some infants in group 1, elimination half life (T1/2) could not be determined in all infants: T1/2 was 11.0 +/- 5.7 in 11 infants in group 1 and 4.8 +/- 1.2 hours in group 2.",Pharmacokinetics and metabolism of rectally administered paracetamol in preterm neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10325815/),h,4.8,255412,DB00316,Acetaminophen
,10325815,glucuronide:sulphate ratio,The glucuronide:sulphate ratio was 0.12 +/- 0.09 (group 1) and 0.28 +/- 0.35 (group 2).,Pharmacokinetics and metabolism of rectally administered paracetamol in preterm neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10325815/),,0.12,255413,DB00316,Acetaminophen
,10325815,glucuronide:sulphate ratio,The glucuronide:sulphate ratio was 0.12 +/- 0.09 (group 1) and 0.28 +/- 0.35 (group 2).,Pharmacokinetics and metabolism of rectally administered paracetamol in preterm neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10325815/),,0.28,255414,DB00316,Acetaminophen
,30758744,Cmax,"The geometric means of Cmax for ASA, SA and paracetamol were similar in the test (3.71, 15.8 and 2.42 µg/ml, respectively) and reference groups (3.89, 15.8, 2.42 µg/ml, respectively).",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[μg] / [ml],3.71,255499,DB00316,Acetaminophen
,30758744,Cmax,"The geometric means of Cmax for ASA, SA and paracetamol were similar in the test (3.71, 15.8 and 2.42 µg/ml, respectively) and reference groups (3.89, 15.8, 2.42 µg/ml, respectively).",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[μg] / [ml],15.8,255500,DB00316,Acetaminophen
,30758744,Cmax,"The geometric means of Cmax for ASA, SA and paracetamol were similar in the test (3.71, 15.8 and 2.42 µg/ml, respectively) and reference groups (3.89, 15.8, 2.42 µg/ml, respectively).",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[μg] / [ml],2.42,255501,DB00316,Acetaminophen
,30758744,Cmax,"The geometric means of Cmax for ASA, SA and paracetamol were similar in the test (3.71, 15.8 and 2.42 µg/ml, respectively) and reference groups (3.89, 15.8, 2.42 µg/ml, respectively).",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[μg] / [ml],3.89,255502,DB00316,Acetaminophen
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],2.86,255503,DB00316,Acetaminophen
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],60.5,255504,DB00316,Acetaminophen
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],7.68,255505,DB00316,Acetaminophen
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],2.96,255506,DB00316,Acetaminophen
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],59.1,255507,DB00316,Acetaminophen
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],7.77,255508,DB00316,Acetaminophen
,32486088,disintegration times,"The study showed that the in vivo disintegration times of Panadol and Panadol Rapid were 24.7 and 16.5 min, respectively, when determined by capsule endoscopy, which corresponded to the pharmacokinetic data.",The Use of Capsule Endoscopy to Determine Tablet Disintegration In Vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486088/),min,24.7,255696,DB00316,Acetaminophen
,32486088,disintegration times,"The study showed that the in vivo disintegration times of Panadol and Panadol Rapid were 24.7 and 16.5 min, respectively, when determined by capsule endoscopy, which corresponded to the pharmacokinetic data.",The Use of Capsule Endoscopy to Determine Tablet Disintegration In Vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486088/),min,16.5,255697,DB00316,Acetaminophen
,32486088,disintegration times,"By contrast, the in vitro disintegration times of the same formulations were 5.5 and 4.0 min, respectively, when determined by the Ph. Eur. disintegration test.",The Use of Capsule Endoscopy to Determine Tablet Disintegration In Vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486088/),min,5.5,255698,DB00316,Acetaminophen
,32486088,disintegration times,"By contrast, the in vitro disintegration times of the same formulations were 5.5 and 4.0 min, respectively, when determined by the Ph. Eur. disintegration test.",The Use of Capsule Endoscopy to Determine Tablet Disintegration In Vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486088/),min,4.0,255699,DB00316,Acetaminophen
,6512918,plasma half-life (t1/2,"Relative to Group II, treatment with NAC (Group I) enhanced the elimination of AP from the body as indicated by the decreased plasma half-life (t1/2 = 1.06 h for Group I v. 1.78 h for Group II) and a higher elimination rate constant (beta = 0.67/h for Group I v. 0.40/h for Group II).",Effect of antidotal N-acetylcysteine on the pharmacokinetics of acetaminophen in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512918/),h,1.06,256688,DB00316,Acetaminophen
,6512918,plasma half-life (t1/2,"Relative to Group II, treatment with NAC (Group I) enhanced the elimination of AP from the body as indicated by the decreased plasma half-life (t1/2 = 1.06 h for Group I v. 1.78 h for Group II) and a higher elimination rate constant (beta = 0.67/h for Group I v. 0.40/h for Group II).",Effect of antidotal N-acetylcysteine on the pharmacokinetics of acetaminophen in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512918/),h,1.78,256689,DB00316,Acetaminophen
,6512918,elimination rate constant (beta,"Relative to Group II, treatment with NAC (Group I) enhanced the elimination of AP from the body as indicated by the decreased plasma half-life (t1/2 = 1.06 h for Group I v. 1.78 h for Group II) and a higher elimination rate constant (beta = 0.67/h for Group I v. 0.40/h for Group II).",Effect of antidotal N-acetylcysteine on the pharmacokinetics of acetaminophen in dogs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512918/),1/[h],0.67,256690,DB00316,Acetaminophen
,6512918,elimination rate constant (beta,"Relative to Group II, treatment with NAC (Group I) enhanced the elimination of AP from the body as indicated by the decreased plasma half-life (t1/2 = 1.06 h for Group I v. 1.78 h for Group II) and a higher elimination rate constant (beta = 0.67/h for Group I v. 0.40/h for Group II).",Effect of antidotal N-acetylcysteine on the pharmacokinetics of acetaminophen in dogs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512918/),1/[h],0.40,256691,DB00316,Acetaminophen
,6512918,area under plasma concentration curve,Changes in the area under plasma concentration curve data (AUC = 0.39 mg.h/ml for Group I v. 0.65 mg.h/ml for Group II) were associated with a 61% increase in total body clearance of AP in Group I.,Effect of antidotal N-acetylcysteine on the pharmacokinetics of acetaminophen in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512918/),[h·mg] / [ml],0.39,256692,DB00316,Acetaminophen
,6512918,area under plasma concentration curve,Changes in the area under plasma concentration curve data (AUC = 0.39 mg.h/ml for Group I v. 0.65 mg.h/ml for Group II) were associated with a 61% increase in total body clearance of AP in Group I.,Effect of antidotal N-acetylcysteine on the pharmacokinetics of acetaminophen in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512918/),[h·mg] / [ml],0.65,256693,DB00316,Acetaminophen
,18787997,peak APAP concentration,AC at 1 h resulted in a 25% reduction in peak APAP concentration from 48.6 to 36.3 mcg/mL (p = 0.012) with no significant difference when given at 2 or 3 h.,Effect of delayed activated charcoal on acetaminophen concentration after simulated overdose of oxycodone and acetaminophen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18787997/),[mcg] / [ml],48.6,256793,DB00316,Acetaminophen
,18787997,peak APAP concentration,AC at 1 h resulted in a 25% reduction in peak APAP concentration from 48.6 to 36.3 mcg/mL (p = 0.012) with no significant difference when given at 2 or 3 h.,Effect of delayed activated charcoal on acetaminophen concentration after simulated overdose of oxycodone and acetaminophen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18787997/),[mcg] / [ml],36.3,256794,DB00316,Acetaminophen
,33948911,Vz/F,"Atogepant mean (SD) Vz/F and CL/F were 369.45 (255.68) L and 18.88 (9.28) L/h, respectively, when administered alone and 297.56 (196.01) L and 16.33 (6.11) L/h when co-administered with acetaminophen.",Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948911/),l,369.45,257041,DB00316,Acetaminophen
,33948911,Vz/F,"Atogepant mean (SD) Vz/F and CL/F were 369.45 (255.68) L and 18.88 (9.28) L/h, respectively, when administered alone and 297.56 (196.01) L and 16.33 (6.11) L/h when co-administered with acetaminophen.",Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948911/),l,297.56,257042,DB00316,Acetaminophen
,33948911,CL/F,"Atogepant mean (SD) Vz/F and CL/F were 369.45 (255.68) L and 18.88 (9.28) L/h, respectively, when administered alone and 297.56 (196.01) L and 16.33 (6.11) L/h when co-administered with acetaminophen.",Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948911/),[l] / [h],18.88,257043,DB00316,Acetaminophen
,33948911,CL/F,"Atogepant mean (SD) Vz/F and CL/F were 369.45 (255.68) L and 18.88 (9.28) L/h, respectively, when administered alone and 297.56 (196.01) L and 16.33 (6.11) L/h when co-administered with acetaminophen.",Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948911/),[l] / [h],16.33,257044,DB00316,Acetaminophen
,33948911,Vz/F,"Atogepant mean (SD) Vz/F and CL/F were 359.61 (247.99) L and 18.80 (7.78) L/h, respectively, when co-administered with naproxen.",Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948911/),l,359.61,257045,DB00316,Acetaminophen
,33948911,CL/F,"Atogepant mean (SD) Vz/F and CL/F were 359.61 (247.99) L and 18.80 (7.78) L/h, respectively, when co-administered with naproxen.",Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948911/),[l] / [h],18.80,257046,DB00316,Acetaminophen
,23169299,Maximum-tolerated dose (MTD),"Maximum-tolerated dose (MTD) of NGR-hTNF was previously established at 45 μg m(-2) as 1-h infusion, with dose-limiting toxicity being grade 3 infusion-related reactions.",Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23169299/),μ,45,257171,DB00316,Acetaminophen
,10648334,Maximal plasma concentrations,"Maximal plasma concentrations of 17.2 and 10.4 mg/L (P < 0.01, analysis of variance) were achieved after 4.2 and 3.6 h for the AL and AS groups, respectively.","The pharmacokinetics and analgesic efficacy of larger dose rectal acetaminophen (40 mg/kg) in adults: a double-blinded, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10648334/),[mg] / [l],17.2,258185,DB00316,Acetaminophen
,10648334,Maximal plasma concentrations,"Maximal plasma concentrations of 17.2 and 10.4 mg/L (P < 0.01, analysis of variance) were achieved after 4.2 and 3.6 h for the AL and AS groups, respectively.","The pharmacokinetics and analgesic efficacy of larger dose rectal acetaminophen (40 mg/kg) in adults: a double-blinded, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10648334/),[mg] / [l],10.4,258186,DB00316,Acetaminophen
,26818482,clearance,"In the model, acetaminophen CYP2E1-mediated clearance (cysteine and mercapturate) increased with lean body weight [LBW] (population mean [relative standard error] 0.0185 L/min [15 %], P < 0.01).",Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26818482/),[l] / [min],0.0185,258268,DB00316,Acetaminophen
,26818482,sulphation clearance,Glucuronidation clearance (0.219 L/min [5 %]) and sulphation clearance (0.0646 L/min [6 %]) also increased with LBW (P < 0.001).,Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26818482/),[l] / [min],0.0646,258269,DB00316,Acetaminophen
,16580905,area under the curve,"The analgesic effect of acetaminophen/placebo (expressed as the area under the curve of the percentage of the individual pain score reported at baseline along time [% x min]) (2145 +/- 2901 % x min) was totally inhibited by both tropisetron (89 +/- 1747 % x min, P = .007) and granisetron (45 +/- 2020 % x min, P = .002).",Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580905/),%·min,2145,258653,DB00316,Acetaminophen
,16580905,area under the curve,"The analgesic effect of acetaminophen/placebo (expressed as the area under the curve of the percentage of the individual pain score reported at baseline along time [% x min]) (2145 +/- 2901 % x min) was totally inhibited by both tropisetron (89 +/- 1747 % x min, P = .007) and granisetron (45 +/- 2020 % x min, P = .002).",Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580905/),%·min,89,258654,DB00316,Acetaminophen
,16580905,area under the curve,"The analgesic effect of acetaminophen/placebo (expressed as the area under the curve of the percentage of the individual pain score reported at baseline along time [% x min]) (2145 +/- 2901 % x min) was totally inhibited by both tropisetron (89 +/- 1747 % x min, P = .007) and granisetron (45 +/- 2020 % x min, P = .002).",Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580905/),%·min,45,258655,DB00316,Acetaminophen
,26334726,relative bioavailability,The relative bioavailability of paracetamol (93.78%) and ibuprofen (96.45%) confirmed the pharmacokinetic equivalence of the oral and IV formulations of the fixed-dose combination.,Pharmacokinetics and Bioavailability of a Fixed-Dose Combination of Ibuprofen and Paracetamol after Intravenous and Oral Administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26334726/),%,93.78,259716,DB00316,Acetaminophen
,26334726,relative bioavailability,The relative bioavailability of paracetamol (93.78%) and ibuprofen (96.45%) confirmed the pharmacokinetic equivalence of the oral and IV formulations of the fixed-dose combination.,Pharmacokinetics and Bioavailability of a Fixed-Dose Combination of Ibuprofen and Paracetamol after Intravenous and Oral Administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26334726/),%,96.45,259717,DB00316,Acetaminophen
,25227283,maximum concentration (C max),"In nine patients, [(14)C]AAP and metabolites in blood samples were detectable at expected concentrations: median (range) maximum concentration (C max) [(14)C]AAP 1.68 (0.75-4.76) ng/L, [(14)C]AAP-Glu 0.88 (0.34-1.55) ng/L, and [(14)C]AAP-4Sul 0.81 (0.29-2.10) ng/L.",Pediatric microdose study of [(14)C]paracetamol to study drug metabolism using accelerated mass spectrometry: proof of concept. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227283/),[ng] / [l],1.68,260153,DB00316,Acetaminophen
,25227283,maximum concentration (C max),"In nine patients, [(14)C]AAP and metabolites in blood samples were detectable at expected concentrations: median (range) maximum concentration (C max) [(14)C]AAP 1.68 (0.75-4.76) ng/L, [(14)C]AAP-Glu 0.88 (0.34-1.55) ng/L, and [(14)C]AAP-4Sul 0.81 (0.29-2.10) ng/L.",Pediatric microdose study of [(14)C]paracetamol to study drug metabolism using accelerated mass spectrometry: proof of concept. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227283/),[ng] / [l],0.88,260154,DB00316,Acetaminophen
,25227283,maximum concentration (C max),"In nine patients, [(14)C]AAP and metabolites in blood samples were detectable at expected concentrations: median (range) maximum concentration (C max) [(14)C]AAP 1.68 (0.75-4.76) ng/L, [(14)C]AAP-Glu 0.88 (0.34-1.55) ng/L, and [(14)C]AAP-4Sul 0.81 (0.29-2.10) ng/L.",Pediatric microdose study of [(14)C]paracetamol to study drug metabolism using accelerated mass spectrometry: proof of concept. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227283/),[ng] / [l],0.81,260155,DB00316,Acetaminophen
,25227283,C max,"Dose-normalized oral [(14)C]AAP C max approached median intravenous average concentrations (C av): 8.41 mg/L (3.75-23.78 mg/L) and 8.87 mg/L (3.45-12.9 mg/L), respectively.",Pediatric microdose study of [(14)C]paracetamol to study drug metabolism using accelerated mass spectrometry: proof of concept. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227283/),[mg] / [l],8.41,260156,DB00316,Acetaminophen
,25227283,C max,"Dose-normalized oral [(14)C]AAP C max approached median intravenous average concentrations (C av): 8.41 mg/L (3.75-23.78 mg/L) and 8.87 mg/L (3.45-12.9 mg/L), respectively.",Pediatric microdose study of [(14)C]paracetamol to study drug metabolism using accelerated mass spectrometry: proof of concept. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227283/),[mg] / [l],8.87,260157,DB00316,Acetaminophen
,25227283,concentrations (C av),"Dose-normalized oral [(14)C]AAP C max approached median intravenous average concentrations (C av): 8.41 mg/L (3.75-23.78 mg/L) and 8.87 mg/L (3.45-12.9 mg/L), respectively.",Pediatric microdose study of [(14)C]paracetamol to study drug metabolism using accelerated mass spectrometry: proof of concept. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227283/),[mg] / [l],8.41,260158,DB00316,Acetaminophen
,25227283,concentrations (C av),"Dose-normalized oral [(14)C]AAP C max approached median intravenous average concentrations (C av): 8.41 mg/L (3.75-23.78 mg/L) and 8.87 mg/L (3.45-12.9 mg/L), respectively.",Pediatric microdose study of [(14)C]paracetamol to study drug metabolism using accelerated mass spectrometry: proof of concept. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227283/),[mg] / [l],8.87,260159,DB00316,Acetaminophen
,21485673,Maximum median plasma concentrations,Maximum median plasma concentrations were 19 mg.l(-1) (interquartile range 15 to 23 mg.,Randomised controlled trial comparing oral and intravenous paracetamol (acetaminophen) plasma levels when given as preoperative analgesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21485673/),[mg] / [l],19,260579,DB00316,Acetaminophen
,7461859,extraction efficiency,The extraction efficiency of the hollow-fiber dialyzers averaged 47.5%.,Hemodialysis of acetaminophen in uremic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7461859/),%,47.5,261018,DB00316,Acetaminophen
,7461859,clearance,The mean dialysis clearance of 112 ml/min measured with blood as the body fluid of reference was confirmed by calculation of clearance using dialysate measurement.,Hemodialysis of acetaminophen in uremic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7461859/),[ml] / [min],112,261019,DB00316,Acetaminophen
,7461859,half-life,The beta phase had a mean half-life of 1.6 hours in our patients on hemodialysis compared with 2.0 hours reported for both normal patients and uremic patients.,Hemodialysis of acetaminophen in uremic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7461859/),h,1.6,261020,DB00316,Acetaminophen
,7461859,half-life,The beta phase had a mean half-life of 1.6 hours in our patients on hemodialysis compared with 2.0 hours reported for both normal patients and uremic patients.,Hemodialysis of acetaminophen in uremic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7461859/),h,2.0,261021,DB00316,Acetaminophen
,1748542,tmax,"Food significantly delays tmax of diclofenac (without food: [mean +/- SD] 0.8 +/- 0.5 h, range: 0.5 +/- 2 h; with food: 2.4 +/- 0.9 h, range: 1.5-4 h) and diminishes Cmax (without food: 1,125 +/- 765 ng/ml, range: 95-2,100 ng/ml; with food: 434 +/- 151 ng/ml, range: 250-555 ng/ml).",The influence of food on the absorption of diclofenac as a pure substance. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1748542/),h,0.8,262921,DB00316,Acetaminophen
,1748542,tmax,"Food significantly delays tmax of diclofenac (without food: [mean +/- SD] 0.8 +/- 0.5 h, range: 0.5 +/- 2 h; with food: 2.4 +/- 0.9 h, range: 1.5-4 h) and diminishes Cmax (without food: 1,125 +/- 765 ng/ml, range: 95-2,100 ng/ml; with food: 434 +/- 151 ng/ml, range: 250-555 ng/ml).",The influence of food on the absorption of diclofenac as a pure substance. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1748542/),h,2.4,262922,DB00316,Acetaminophen
,1748542,Cmax,"Food significantly delays tmax of diclofenac (without food: [mean +/- SD] 0.8 +/- 0.5 h, range: 0.5 +/- 2 h; with food: 2.4 +/- 0.9 h, range: 1.5-4 h) and diminishes Cmax (without food: 1,125 +/- 765 ng/ml, range: 95-2,100 ng/ml; with food: 434 +/- 151 ng/ml, range: 250-555 ng/ml).",The influence of food on the absorption of diclofenac as a pure substance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1748542/),[ng] / [ml],"1,125",262923,DB00316,Acetaminophen
,1748542,Cmax,"Food significantly delays tmax of diclofenac (without food: [mean +/- SD] 0.8 +/- 0.5 h, range: 0.5 +/- 2 h; with food: 2.4 +/- 0.9 h, range: 1.5-4 h) and diminishes Cmax (without food: 1,125 +/- 765 ng/ml, range: 95-2,100 ng/ml; with food: 434 +/- 151 ng/ml, range: 250-555 ng/ml).",The influence of food on the absorption of diclofenac as a pure substance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1748542/),[ng] / [ml],434,262924,DB00316,Acetaminophen
,1748542,AUC,"The AUC is not influenced (without food: 1,217 +/- 368 ng/ml x h; with food: 1,037 +/- 267 ng/ml x h).",The influence of food on the absorption of diclofenac as a pure substance. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1748542/),[ng] / [h·ml],"1,217",262925,DB00316,Acetaminophen
,1748542,AUC,"The AUC is not influenced (without food: 1,217 +/- 368 ng/ml x h; with food: 1,037 +/- 267 ng/ml x h).",The influence of food on the absorption of diclofenac as a pure substance. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1748542/),[ng] / [h·ml],"1,037",262926,DB00316,Acetaminophen
,32953880,retention times,"The HPLC/UV analysis of the decoction revealed the presence of dihydroxycoumarin, quinine, and scopoletin with the following retention times: 2.6, 5.1, and 7.01 min, respectively.",Hepatoprotective Activity of Leptadenia hastata (Asclepiadaceae) on Acetaminophen-Induced Toxicity in Mice: In Vivo Study and Characterization of Bioactive Compounds through Molecular Docking Approaches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32953880/),min,2.6,263341,DB00316,Acetaminophen
,32953880,retention times,"The HPLC/UV analysis of the decoction revealed the presence of dihydroxycoumarin, quinine, and scopoletin with the following retention times: 2.6, 5.1, and 7.01 min, respectively.",Hepatoprotective Activity of Leptadenia hastata (Asclepiadaceae) on Acetaminophen-Induced Toxicity in Mice: In Vivo Study and Characterization of Bioactive Compounds through Molecular Docking Approaches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32953880/),min,5.1,263342,DB00316,Acetaminophen
,32953880,retention times,"The HPLC/UV analysis of the decoction revealed the presence of dihydroxycoumarin, quinine, and scopoletin with the following retention times: 2.6, 5.1, and 7.01 min, respectively.",Hepatoprotective Activity of Leptadenia hastata (Asclepiadaceae) on Acetaminophen-Induced Toxicity in Mice: In Vivo Study and Characterization of Bioactive Compounds through Molecular Docking Approaches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32953880/),min,7.01,263343,DB00316,Acetaminophen
,1356724,formation clearance,Probenecid significantly decreased the formation clearance of AG from 3.65 +/- 0.434 to 1.94 +/- 0.441 ml/min/kg and the renal clearance of AS from 9.32 +/- 2.26 to 3.15 +/- 1.21 ml/min/kg.,Probenecid-impaired biliary excretion of acetaminophen glucuronide and sulfate in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356724/),[ml] / [kg·min],3.65,264096,DB00316,Acetaminophen
,1356724,formation clearance,Probenecid significantly decreased the formation clearance of AG from 3.65 +/- 0.434 to 1.94 +/- 0.441 ml/min/kg and the renal clearance of AS from 9.32 +/- 2.26 to 3.15 +/- 1.21 ml/min/kg.,Probenecid-impaired biliary excretion of acetaminophen glucuronide and sulfate in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356724/),[ml] / [kg·min],1.94,264097,DB00316,Acetaminophen
,1356724,renal clearance,Probenecid significantly decreased the formation clearance of AG from 3.65 +/- 0.434 to 1.94 +/- 0.441 ml/min/kg and the renal clearance of AS from 9.32 +/- 2.26 to 3.15 +/- 1.21 ml/min/kg.,Probenecid-impaired biliary excretion of acetaminophen glucuronide and sulfate in the rat. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356724/),[ml] / [kg·min],9.32,264098,DB00316,Acetaminophen
,1356724,renal clearance,Probenecid significantly decreased the formation clearance of AG from 3.65 +/- 0.434 to 1.94 +/- 0.441 ml/min/kg and the renal clearance of AS from 9.32 +/- 2.26 to 3.15 +/- 1.21 ml/min/kg.,Probenecid-impaired biliary excretion of acetaminophen glucuronide and sulfate in the rat. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356724/),[ml] / [kg·min],3.15,264099,DB00316,Acetaminophen
,2758103,oral extraction ratio,A mean oral extraction ratio of 0.49 was obtained.,"Gastrointestinal, liver, and lung extraction ratio of acetaminophen in the rat after high dose administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758103/),,0.49,264361,DB00316,Acetaminophen
,2758103,relative extraction ratio,"The mean relative extraction ratio of the gastrointestinal tract, liver, and lung were 0.52, 0.07, and 0, respectively, indicating a major contribution due to the gastrointestinal tract.","Gastrointestinal, liver, and lung extraction ratio of acetaminophen in the rat after high dose administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758103/),,0.52,264362,DB00316,Acetaminophen
,2758103,relative extraction ratio,"The mean relative extraction ratio of the gastrointestinal tract, liver, and lung were 0.52, 0.07, and 0, respectively, indicating a major contribution due to the gastrointestinal tract.","Gastrointestinal, liver, and lung extraction ratio of acetaminophen in the rat after high dose administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758103/),,0.07,264363,DB00316,Acetaminophen
,2758103,relative extraction ratio,"The mean relative extraction ratio of the gastrointestinal tract, liver, and lung were 0.52, 0.07, and 0, respectively, indicating a major contribution due to the gastrointestinal tract.","Gastrointestinal, liver, and lung extraction ratio of acetaminophen in the rat after high dose administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758103/),,0,264364,DB00316,Acetaminophen
,7002186,systemic availability,The mean systemic availability is about 75%.,Kinetics and metabolism of paracetamol and phenacetin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7002186/),%,75,264393,DB00316,Acetaminophen
,7002186,plasma half-life,2 Paracetamol is extensively metabolized and the plasma half-life is 1.5-2.5 hours.,Kinetics and metabolism of paracetamol and phenacetin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7002186/),h,1.5-2.5,264394,DB00316,Acetaminophen
,3346841,plasma half-life,Interruption of the EHC caused lorazepam plasma half-life to shorten (3.4 vs.,Enterohepatic circulation of lorazepam and acetaminophen conjugates in ponies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3346841/),,3.4,264761,DB00316,Acetaminophen
,3346841,clearance to,"2.3 hr with the EHC intact, P less than .1), clearance to increase (9.2 vs.",Enterohepatic circulation of lorazepam and acetaminophen conjugates in ponies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3346841/),,9.2,264762,DB00316,Acetaminophen
,3346841,total area under the plasma concentration curve,"12.3 ml/min/kg, P less than .1) and total area under the plasma concentration curve for lorazepam glucuronide to decrease (210 vs. 310 ng/ml X hr, P less than .06).",Enterohepatic circulation of lorazepam and acetaminophen conjugates in ponies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3346841/),[ng] / [h·ml],210,264763,DB00316,Acetaminophen
,3346841,total area under the plasma concentration curve,"12.3 ml/min/kg, P less than .1) and total area under the plasma concentration curve for lorazepam glucuronide to decrease (210 vs. 310 ng/ml X hr, P less than .06).",Enterohepatic circulation of lorazepam and acetaminophen conjugates in ponies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3346841/),[ng] / [h·ml],310,264764,DB00316,Acetaminophen
,8826536,peak concentrations (Cmax),"After administration of 8.64 g propylene glycol to 10 adults and 173 mg/kg body weight to 4 children, peak concentrations (Cmax) of 199 mg/l and 171 mg/l respectively were reached (tmax) after 1.5 hr and 1.0 hr.",Pharmacokinetics of propylene glycol after rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826536/),[mg] / [l],199,265788,DB00316,Acetaminophen
,8826536,peak concentrations (Cmax),"After administration of 8.64 g propylene glycol to 10 adults and 173 mg/kg body weight to 4 children, peak concentrations (Cmax) of 199 mg/l and 171 mg/l respectively were reached (tmax) after 1.5 hr and 1.0 hr.",Pharmacokinetics of propylene glycol after rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826536/),[mg] / [l],171,265789,DB00316,Acetaminophen
,8826536,tmax,"After administration of 8.64 g propylene glycol to 10 adults and 173 mg/kg body weight to 4 children, peak concentrations (Cmax) of 199 mg/l and 171 mg/l respectively were reached (tmax) after 1.5 hr and 1.0 hr.",Pharmacokinetics of propylene glycol after rectal administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826536/),h,1.5,265790,DB00316,Acetaminophen
,8826536,tmax,"After administration of 8.64 g propylene glycol to 10 adults and 173 mg/kg body weight to 4 children, peak concentrations (Cmax) of 199 mg/l and 171 mg/l respectively were reached (tmax) after 1.5 hr and 1.0 hr.",Pharmacokinetics of propylene glycol after rectal administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826536/),h,1.0,265791,DB00316,Acetaminophen
,8826536,terminal half-lives (t1/2),"The average terminal half-lives (t1/2) in adults and children were respectively 2.8 hr and 2.6 hr, total body clearance (CI/F) 0.20 l/hr*kg and 0.21 l/h*kg and apparent volume of distribution (VD/F) 0.79 l/kg and 0.77 l/kg.",Pharmacokinetics of propylene glycol after rectal administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826536/),h,2.8,265792,DB00316,Acetaminophen
,8826536,terminal half-lives (t1/2),"The average terminal half-lives (t1/2) in adults and children were respectively 2.8 hr and 2.6 hr, total body clearance (CI/F) 0.20 l/hr*kg and 0.21 l/h*kg and apparent volume of distribution (VD/F) 0.79 l/kg and 0.77 l/kg.",Pharmacokinetics of propylene glycol after rectal administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826536/),h,2.6,265793,DB00316,Acetaminophen
,8826536,total body clearance (CI/F),"The average terminal half-lives (t1/2) in adults and children were respectively 2.8 hr and 2.6 hr, total body clearance (CI/F) 0.20 l/hr*kg and 0.21 l/h*kg and apparent volume of distribution (VD/F) 0.79 l/kg and 0.77 l/kg.",Pharmacokinetics of propylene glycol after rectal administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826536/),[l] / [h·kg],0.20,265794,DB00316,Acetaminophen
,8826536,total body clearance (CI/F),"The average terminal half-lives (t1/2) in adults and children were respectively 2.8 hr and 2.6 hr, total body clearance (CI/F) 0.20 l/hr*kg and 0.21 l/h*kg and apparent volume of distribution (VD/F) 0.79 l/kg and 0.77 l/kg.",Pharmacokinetics of propylene glycol after rectal administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826536/),[l] / [h·kg],0.21,265795,DB00316,Acetaminophen
,8826536,apparent volume of distribution (VD/F),"The average terminal half-lives (t1/2) in adults and children were respectively 2.8 hr and 2.6 hr, total body clearance (CI/F) 0.20 l/hr*kg and 0.21 l/h*kg and apparent volume of distribution (VD/F) 0.79 l/kg and 0.77 l/kg.",Pharmacokinetics of propylene glycol after rectal administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826536/),[l] / [kg],0.79,265796,DB00316,Acetaminophen
,8826536,apparent volume of distribution (VD/F),"The average terminal half-lives (t1/2) in adults and children were respectively 2.8 hr and 2.6 hr, total body clearance (CI/F) 0.20 l/hr*kg and 0.21 l/h*kg and apparent volume of distribution (VD/F) 0.79 l/kg and 0.77 l/kg.",Pharmacokinetics of propylene glycol after rectal administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826536/),[l] / [kg],0.77,265797,DB00316,Acetaminophen
,12860494,half-life,"Mean nateglinide half-life was similar for all 5 treatments (range, 81.3-94.6 minutes).",The effect of nateglinide taken with food on gastric emptying rates in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12860494/),min,81.3-94.6,266093,DB00316,Acetaminophen
lower,3763369,absolute bioavailability,"Considering the urinary excretion data, it is concluded that the tablets release their contents completely; the absolute bioavailability, however, calculated from plasma concentrations, is lower than 100%, indicating a first-pass effect.",Bioavailability of paracetamol after oral administration to healthy volunteers. Influence of caffeine on rate and extent of absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3763369/),%,100,267692,DB00316,Acetaminophen
less,19281996,total run-time,The total run-time was less than 18 min.,Two-dimensional liquid chromatography-ion trap mass spectrometry for the simultaneous determination of ketorolac enantiomers and paracetamol in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19281996/),min,18,268619,DB00316,Acetaminophen
,19281996,extraction recoveries,"The mean extraction recoveries were 60%, 72% and 76% for paracetamol, R-ketorolac and S-ketorolac, respectively.",Two-dimensional liquid chromatography-ion trap mass spectrometry for the simultaneous determination of ketorolac enantiomers and paracetamol in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19281996/),%,60,268620,DB00316,Acetaminophen
,19281996,extraction recoveries,"The mean extraction recoveries were 60%, 72% and 76% for paracetamol, R-ketorolac and S-ketorolac, respectively.",Two-dimensional liquid chromatography-ion trap mass spectrometry for the simultaneous determination of ketorolac enantiomers and paracetamol in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19281996/),%,72,268621,DB00316,Acetaminophen
,19281996,extraction recoveries,"The mean extraction recoveries were 60%, 72% and 76% for paracetamol, R-ketorolac and S-ketorolac, respectively.",Two-dimensional liquid chromatography-ion trap mass spectrometry for the simultaneous determination of ketorolac enantiomers and paracetamol in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19281996/),%,76,268622,DB00316,Acetaminophen
,33336850,∆AUC,"Compared with Lispro, ADO09 reduced postprandial blood glucose (ppBG) excursions by more than 95% in the first hour postmeal (mean ± SD ∆AUC BG 0-1 h: 1.4 ± 9.9 mg*h/dL vs. 43.5 ± 15.3 mg*h/dL; p < .0001).","ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336850/),[h·mg] / [dl],1.4,268693,DB00316,Acetaminophen
,33336850,Maximum ppBG,Maximum ppBG was significantly improved with ADO09 (∆BGmax 87.0 ± 35.5 mg/dL) versus both Lispro (109.2 ± 31.1 mg/dL; p = .0133) and Ins&Pram (109.4 ± 44.3 mg/dL; p = .0357).,"ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336850/),[mg] / [dl],87.0,268694,DB00316,Acetaminophen
,33336850,Maximum ppBG,Maximum ppBG was significantly improved with ADO09 (∆BGmax 87.0 ± 35.5 mg/dL) versus both Lispro (109.2 ± 31.1 mg/dL; p = .0133) and Ins&Pram (109.4 ± 44.3 mg/dL; p = .0357).,"ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336850/),[mg] / [dl],109.2,268695,DB00316,Acetaminophen
,33336850,Maximum ppBG,Maximum ppBG was significantly improved with ADO09 (∆BGmax 87.0 ± 35.5 mg/dL) versus both Lispro (109.2 ± 31.1 mg/dL; p = .0133) and Ins&Pram (109.4 ± 44.3 mg/dL; p = .0357).,"ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336850/),[mg] / [dl],109.4,268696,DB00316,Acetaminophen
,19879084,run time,"After sample preparation by liquid-liquid extraction, the analytes and internal standard (diphenhydramine) were analyzed by reversed-phase HPLC on a Venusil Mp-C(18) column (50mmx4.6mm, 5microm) using formic acid:10mM ammonium acetate:methanol (1:40:60, v/v/v) as mobile phase in a run time of 2.6min.","Simultaneous quantitation of paracetamol, caffeine, pseudoephedrine, chlorpheniramine and cloperastine in human plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879084/),min,2.6,268828,DB00316,Acetaminophen
,25342929,central volume (V1),"A three-compartment linear disposition model revealed that the population parameter estimates (between subject variability,%) were central volume (V1) 24.6 (55.5%) L/70 kg with peripheral volumes of distribution V2 23.1 (49.6%) L/70 kg and V3 30.6 (78.9%) L/70 kg.",Covariates of intravenous paracetamol pharmacokinetics in adults. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342929/),[l] / [70·kg],24.6,268887,DB00316,Acetaminophen
,25342929,peripheral volumes of distribution V2,"A three-compartment linear disposition model revealed that the population parameter estimates (between subject variability,%) were central volume (V1) 24.6 (55.5%) L/70 kg with peripheral volumes of distribution V2 23.1 (49.6%) L/70 kg and V3 30.6 (78.9%) L/70 kg.",Covariates of intravenous paracetamol pharmacokinetics in adults. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342929/),[l] / [70·kg],23.1,268888,DB00316,Acetaminophen
,25342929,V3,"A three-compartment linear disposition model revealed that the population parameter estimates (between subject variability,%) were central volume (V1) 24.6 (55.5%) L/70 kg with peripheral volumes of distribution V2 23.1 (49.6%) L/70 kg and V3 30.6 (78.9%) L/70 kg.",Covariates of intravenous paracetamol pharmacokinetics in adults. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342929/),[l] / [70·kg],30.6,268889,DB00316,Acetaminophen
,25342929,Clearance (CL),Clearance (CL) was 16.7 (24.6%) L/h/70 kg and inter-compartment clearances were Q2 67.3 (25.7%) L/h/70 kg and Q3 2.04 (71.3%) L/h/70 kg.,Covariates of intravenous paracetamol pharmacokinetics in adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342929/),[l] / [70·h·kg],16.7,268890,DB00316,Acetaminophen
,25342929,Q2,Clearance (CL) was 16.7 (24.6%) L/h/70 kg and inter-compartment clearances were Q2 67.3 (25.7%) L/h/70 kg and Q3 2.04 (71.3%) L/h/70 kg.,Covariates of intravenous paracetamol pharmacokinetics in adults. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342929/),[l] / [70·h·kg],67.3,268891,DB00316,Acetaminophen
,25342929,Q3,Clearance (CL) was 16.7 (24.6%) L/h/70 kg and inter-compartment clearances were Q2 67.3 (25.7%) L/h/70 kg and Q3 2.04 (71.3%) L/h/70 kg.,Covariates of intravenous paracetamol pharmacokinetics in adults. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342929/),[l] / [70·h·kg],2.04,268892,DB00316,Acetaminophen
,8296,plasma half-life,"Pretreatment with 3-MC decreased the plasma half-life of phenacetin, after iv administration, from 28 min to 4.5 min and reduced the systemic bioavailability of phenacetin, after oral administration, from 45% in control rats to 6% in 3-MC-treated rats.",Effect of 3-methylcholanthrene pretreatment on the bioavailability of phenacetin in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8296/),min,28,269140,DB00316,Acetaminophen
,8296,plasma half-life,"Pretreatment with 3-MC decreased the plasma half-life of phenacetin, after iv administration, from 28 min to 4.5 min and reduced the systemic bioavailability of phenacetin, after oral administration, from 45% in control rats to 6% in 3-MC-treated rats.",Effect of 3-methylcholanthrene pretreatment on the bioavailability of phenacetin in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8296/),min,4.5,269141,DB00316,Acetaminophen
,8296,systemic bioavailability,"Pretreatment with 3-MC decreased the plasma half-life of phenacetin, after iv administration, from 28 min to 4.5 min and reduced the systemic bioavailability of phenacetin, after oral administration, from 45% in control rats to 6% in 3-MC-treated rats.",Effect of 3-methylcholanthrene pretreatment on the bioavailability of phenacetin in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8296/),%,45,269142,DB00316,Acetaminophen
,8296,systemic bioavailability,"Pretreatment with 3-MC decreased the plasma half-life of phenacetin, after iv administration, from 28 min to 4.5 min and reduced the systemic bioavailability of phenacetin, after oral administration, from 45% in control rats to 6% in 3-MC-treated rats.",Effect of 3-methylcholanthrene pretreatment on the bioavailability of phenacetin in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8296/),%,6,269143,DB00316,Acetaminophen
,23412078,UGE0-6h,"Compared with placebo, canagliflozin treatment reduced postprandial plasma glucose and insulin excursions (incremental 0- to 2-h area under the curve [AUC0-2h] reductions of 35% and 43%, respectively; P < 0.001 for both), increased 0- to 6-h urinary glucose excretion (UGE0-6h, 18.2 ± 5.6 vs. <0.2 g; P < 0.001), and delayed RaO.","Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23412078/),g,18.2,269383,DB00316,Acetaminophen
,23412078,total AUC Ra,"Over 2 to 6 h, canagliflozin increased RaO such that total AUC RaO over 0 to 6 h was <6% lower versus placebo (960 vs. 1,018 mg/kg; P = 0.003).","Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23412078/),[mg] / [kg],960,269384,DB00316,Acetaminophen
,23412078,total AUC Ra,"Over 2 to 6 h, canagliflozin increased RaO such that total AUC RaO over 0 to 6 h was <6% lower versus placebo (960 vs. 1,018 mg/kg; P = 0.003).","Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23412078/),[mg] / [kg],"1,018",269385,DB00316,Acetaminophen
,9193346,elimination half-life (t1/2),"CPT-11 exhibited a mean elimination half-life (t1/2) of 8.8 hours, an average clearance (CL) of 14.6 L/h/m2, and a mean volume of distribution at steady-state (Vdss) of 136 L/m2.",Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193346/),h,8.8,269712,DB00316,Acetaminophen
,9193346,clearance (CL),"CPT-11 exhibited a mean elimination half-life (t1/2) of 8.8 hours, an average clearance (CL) of 14.6 L/h/m2, and a mean volume of distribution at steady-state (Vdss) of 136 L/m2.",Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193346/),[l] / [h·m2],14.6,269713,DB00316,Acetaminophen
,9193346,volume of distribution at steady-state (Vdss),"CPT-11 exhibited a mean elimination half-life (t1/2) of 8.8 hours, an average clearance (CL) of 14.6 L/h/m2, and a mean volume of distribution at steady-state (Vdss) of 136 L/m2.",Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193346/),[l] / [m2],136,269714,DB00316,Acetaminophen
,9193346,plasma availabilities,"SN-38 and SN-38G had low plasma availabilities (3% and 10% relative to CPT-11), with mean t1/2 values of 11.6 and 10.5 hours, respectively.",Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193346/),%,3,269715,DB00316,Acetaminophen
,9193346,plasma availabilities,"SN-38 and SN-38G had low plasma availabilities (3% and 10% relative to CPT-11), with mean t1/2 values of 11.6 and 10.5 hours, respectively.",Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193346/),%,10,269716,DB00316,Acetaminophen
,9193346,t1/2,"SN-38 and SN-38G had low plasma availabilities (3% and 10% relative to CPT-11), with mean t1/2 values of 11.6 and 10.5 hours, respectively.",Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193346/),h,11.6,269717,DB00316,Acetaminophen
,9193346,t1/2,"SN-38 and SN-38G had low plasma availabilities (3% and 10% relative to CPT-11), with mean t1/2 values of 11.6 and 10.5 hours, respectively.",Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193346/),h,10.5,269718,DB00316,Acetaminophen
,15849845,t(+15),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,5.4,269747,DB00316,Acetaminophen
,15849845,t(+15),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,3.3,269748,DB00316,Acetaminophen
,15849845,t(+30),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,6.7,269749,DB00316,Acetaminophen
,15849845,t(+30),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,3.7,269750,DB00316,Acetaminophen
,15849845,t(+60),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,7.7,269751,DB00316,Acetaminophen
,15849845,t(+60),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,5.1,269752,DB00316,Acetaminophen
,15849845,t(+120),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,8.5,269753,DB00316,Acetaminophen
,15849845,t(+120),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,5.2,269754,DB00316,Acetaminophen
,15849845,AUC,The AUC value was 34% larger in the metoclopramide group vs control group (574-/+296 vs 429-/+309; P=0.027).,Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,574,269755,DB00316,Acetaminophen
,15849845,AUC,The AUC value was 34% larger in the metoclopramide group vs control group (574-/+296 vs 429-/+309; P=0.027).,Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,429,269756,DB00316,Acetaminophen
,1516606,time to 90% emptying,The time to 90% emptying on the gamma scan was increased significantly from 40 min to 65 min in the presence of levodopa.,The influence of levodopa on gastric emptying in healthy elderly volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516606/),min,40,269805,DB00316,Acetaminophen
,1516606,time to 90% emptying,The time to 90% emptying on the gamma scan was increased significantly from 40 min to 65 min in the presence of levodopa.,The influence of levodopa on gastric emptying in healthy elderly volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516606/),min,65,269806,DB00316,Acetaminophen
,1204276,biologic half-life,The biologic half-life of acetaminophen ranged from 119 to 147 min on an interdialysis day and was decreased by 42% to 53% during hemodialysis.,Effect of hemodialysis on kinetics of acetaminophen elimination by anephric patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1204276/),min,119 to 147,270508,DB00316,Acetaminophen
,1204276,extraction ratios,"Individual mean dialyzer extraction ratios, based on assay of plasma samples from blood flowing into and out of the dialysis unit, were 0.46 to 0.78 for acetaminophen, 0.53 to 0.57 for acetaminophen glucuronide, 0.13 to 0.60 for acetaminophen sulfate, and 0.70 to 0.87 for urea nitrogen.",Effect of hemodialysis on kinetics of acetaminophen elimination by anephric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1204276/),,0.46 to 0.78,270509,DB00316,Acetaminophen
,1204276,extraction ratios,"Individual mean dialyzer extraction ratios, based on assay of plasma samples from blood flowing into and out of the dialysis unit, were 0.46 to 0.78 for acetaminophen, 0.53 to 0.57 for acetaminophen glucuronide, 0.13 to 0.60 for acetaminophen sulfate, and 0.70 to 0.87 for urea nitrogen.",Effect of hemodialysis on kinetics of acetaminophen elimination by anephric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1204276/),,0.53 to 0.57,270510,DB00316,Acetaminophen
,1204276,extraction ratios,"Individual mean dialyzer extraction ratios, based on assay of plasma samples from blood flowing into and out of the dialysis unit, were 0.46 to 0.78 for acetaminophen, 0.53 to 0.57 for acetaminophen glucuronide, 0.13 to 0.60 for acetaminophen sulfate, and 0.70 to 0.87 for urea nitrogen.",Effect of hemodialysis on kinetics of acetaminophen elimination by anephric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1204276/),,0.13 to 0.60,270511,DB00316,Acetaminophen
,1204276,extraction ratios,"Individual mean dialyzer extraction ratios, based on assay of plasma samples from blood flowing into and out of the dialysis unit, were 0.46 to 0.78 for acetaminophen, 0.53 to 0.57 for acetaminophen glucuronide, 0.13 to 0.60 for acetaminophen sulfate, and 0.70 to 0.87 for urea nitrogen.",Effect of hemodialysis on kinetics of acetaminophen elimination by anephric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1204276/),,0.70 to 0.87,270512,DB00316,Acetaminophen
,15171517,tmax,"The absorption of paracetamol was rapid with mean tmax of 0.875 +/- 0.44 h (range, 0.5-1.5 h) and was 20 times faster than elimination rate.",Pharmacokinetics and saliva secretion of paracetamol in healthy male Nigerians. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15171517/),h,0.875,270607,DB00316,Acetaminophen
,15171517,Cmax,The Cmax varied between 11.46 and 26.44 microg mL(-1) with three of the subjects having Cmax greater than the 20 microg mL(-1) limit for therapeutic level.,Pharmacokinetics and saliva secretion of paracetamol in healthy male Nigerians. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15171517/),[μg] / [ml],11.46 and 26.44,270608,DB00316,Acetaminophen
greater,15171517,Cmax,The Cmax varied between 11.46 and 26.44 microg mL(-1) with three of the subjects having Cmax greater than the 20 microg mL(-1) limit for therapeutic level.,Pharmacokinetics and saliva secretion of paracetamol in healthy male Nigerians. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15171517/),[μg] / [ml],20,270609,DB00316,Acetaminophen
above,15171517,t(1/2),"The elimination half-life was slightly longer than previous reports, with four subjects having t(1/2) above 3 h.",Pharmacokinetics and saliva secretion of paracetamol in healthy male Nigerians. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15171517/),h,3,270610,DB00316,Acetaminophen
,15171517,S/P ratio,The plasma levels were higher than saliva in all the subjects studied with variable S/P ratio of 0.64 +/- 0.1 in contrast to ealier reports of S/P ratios above unity.,Pharmacokinetics and saliva secretion of paracetamol in healthy male Nigerians. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15171517/),,0.64,270611,DB00316,Acetaminophen
above,15171517,S/P ratios,The plasma levels were higher than saliva in all the subjects studied with variable S/P ratio of 0.64 +/- 0.1 in contrast to ealier reports of S/P ratios above unity.,Pharmacokinetics and saliva secretion of paracetamol in healthy male Nigerians. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15171517/),,unity,270612,DB00316,Acetaminophen
,22713959,biological half life (t1/2β),"When used with paracetamol, the value of biological half life (t1/2β) of INH was significantly decreased (p<0.05) from 2.391 ± 0.216 to 2.17 ± 3.46 hours.",Effect of paracetamol on pharmacokinetics of isoniazid in Teddy goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22713959/),h,2.391,271107,DB00316,Acetaminophen
,22713959,biological half life (t1/2β),"When used with paracetamol, the value of biological half life (t1/2β) of INH was significantly decreased (p<0.05) from 2.391 ± 0.216 to 2.17 ± 3.46 hours.",Effect of paracetamol on pharmacokinetics of isoniazid in Teddy goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22713959/),h,2.17,271108,DB00316,Acetaminophen
,22713959,apparent volume of distribution (Vd),The value for apparent volume of distribution (Vd) was also significantly decreased (p<0.05) from 0.905 ± 0.327 to 0.786 ± 0.161 L/kg and total body clearance (CL) was increased insignificantly (p>0.05) from 3.59 ± 2.03 to 4.04 ± 2.61 mL/min/kg.,Effect of paracetamol on pharmacokinetics of isoniazid in Teddy goats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22713959/),[l] / [kg],0.905,271109,DB00316,Acetaminophen
,22713959,apparent volume of distribution (Vd),The value for apparent volume of distribution (Vd) was also significantly decreased (p<0.05) from 0.905 ± 0.327 to 0.786 ± 0.161 L/kg and total body clearance (CL) was increased insignificantly (p>0.05) from 3.59 ± 2.03 to 4.04 ± 2.61 mL/min/kg.,Effect of paracetamol on pharmacokinetics of isoniazid in Teddy goats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22713959/),[l] / [kg],0.786,271110,DB00316,Acetaminophen
,22713959,total body clearance (CL),The value for apparent volume of distribution (Vd) was also significantly decreased (p<0.05) from 0.905 ± 0.327 to 0.786 ± 0.161 L/kg and total body clearance (CL) was increased insignificantly (p>0.05) from 3.59 ± 2.03 to 4.04 ± 2.61 mL/min/kg.,Effect of paracetamol on pharmacokinetics of isoniazid in Teddy goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22713959/),[ml] / [kg·min],3.59,271111,DB00316,Acetaminophen
,22713959,total body clearance (CL),The value for apparent volume of distribution (Vd) was also significantly decreased (p<0.05) from 0.905 ± 0.327 to 0.786 ± 0.161 L/kg and total body clearance (CL) was increased insignificantly (p>0.05) from 3.59 ± 2.03 to 4.04 ± 2.61 mL/min/kg.,Effect of paracetamol on pharmacokinetics of isoniazid in Teddy goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22713959/),[ml] / [kg·min],4.04,271112,DB00316,Acetaminophen
,28933266,steady state paracetamol concentration (Cssmean,"Because evidence supports the use of the same target mean steady state paracetamol concentration (Cssmean, 9-11 mg/L) for pain relief in neonates compared to older children and adults, dosing regimens based on this Cssmean were evaluated in a two-step approach.",Intravenous Paracetamol Dosing Guidelines for Pain Management in (pre)term Neonates Using the Paediatric Study Decision Tree. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933266/),[mg] / [l],9-11,272223,DB00316,Acetaminophen
,28933266,Cssmean,"For typical term neonates, dosages specified in packaging (labels) resulted in Cssmean below target (7.65 mg/L), while dosages from investigator-initiated studies resulted in either a Cssmean above (15.31), or around the target (11.78 and 10.21) for (pre)term neonates >32 weeks.",Intravenous Paracetamol Dosing Guidelines for Pain Management in (pre)term Neonates Using the Paediatric Study Decision Tree. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933266/),[mg] / [l],7.65,272224,DB00316,Acetaminophen
above,28933266,Cssmean,"For typical term neonates, dosages specified in packaging (labels) resulted in Cssmean below target (7.65 mg/L), while dosages from investigator-initiated studies resulted in either a Cssmean above (15.31), or around the target (11.78 and 10.21) for (pre)term neonates >32 weeks.",Intravenous Paracetamol Dosing Guidelines for Pain Management in (pre)term Neonates Using the Paediatric Study Decision Tree. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933266/),,15.31,272225,DB00316,Acetaminophen
above,28933266,Cssmean,"For typical term neonates, dosages specified in packaging (labels) resulted in Cssmean below target (7.65 mg/L), while dosages from investigator-initiated studies resulted in either a Cssmean above (15.31), or around the target (11.78 and 10.21) for (pre)term neonates >32 weeks.",Intravenous Paracetamol Dosing Guidelines for Pain Management in (pre)term Neonates Using the Paediatric Study Decision Tree. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933266/),,11.78,272226,DB00316,Acetaminophen
above,28933266,Cssmean,"For typical term neonates, dosages specified in packaging (labels) resulted in Cssmean below target (7.65 mg/L), while dosages from investigator-initiated studies resulted in either a Cssmean above (15.31), or around the target (11.78 and 10.21) for (pre)term neonates >32 weeks.",Intravenous Paracetamol Dosing Guidelines for Pain Management in (pre)term Neonates Using the Paediatric Study Decision Tree. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933266/),,10.21,272227,DB00316,Acetaminophen
,2744070,plasma half-life,The mean plasma half-life of paracetamol from 2 to 8 h was similar in the 3 groups (2.1 to 2.3 h) but from 8 to 24 h it disappeared much more slowly in the renal failure patients (half-life 11.7 compared with 4.9 h in the healthy volunteers).,Paracetamol disposition and metabolite kinetics in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2744070/),h,2.1 to 2.3,272999,DB00316,Acetaminophen
,2744070,half-life,The mean plasma half-life of paracetamol from 2 to 8 h was similar in the 3 groups (2.1 to 2.3 h) but from 8 to 24 h it disappeared much more slowly in the renal failure patients (half-life 11.7 compared with 4.9 h in the healthy volunteers).,Paracetamol disposition and metabolite kinetics in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2744070/),h,11.7,273000,DB00316,Acetaminophen
,2744070,half-life,The mean plasma half-life of paracetamol from 2 to 8 h was similar in the 3 groups (2.1 to 2.3 h) but from 8 to 24 h it disappeared much more slowly in the renal failure patients (half-life 11.7 compared with 4.9 h in the healthy volunteers).,Paracetamol disposition and metabolite kinetics in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2744070/),h,4.9,273001,DB00316,Acetaminophen
,2744070,plasma half-lives,Plasma concentrations of paracetamol glucuronide and sulphate conjugates were greatly increased in the patients with moderate renal failure and the mean plasma half-lives were 30.5 and 21.8 h respectively compared with about 3 h in the healthy volunteers.,Paracetamol disposition and metabolite kinetics in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2744070/),h,30.5,273002,DB00316,Acetaminophen
,2744070,plasma half-lives,Plasma concentrations of paracetamol glucuronide and sulphate conjugates were greatly increased in the patients with moderate renal failure and the mean plasma half-lives were 30.5 and 21.8 h respectively compared with about 3 h in the healthy volunteers.,Paracetamol disposition and metabolite kinetics in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2744070/),h,21.8,273003,DB00316,Acetaminophen
,2744070,plasma half-lives,Plasma concentrations of paracetamol glucuronide and sulphate conjugates were greatly increased in the patients with moderate renal failure and the mean plasma half-lives were 30.5 and 21.8 h respectively compared with about 3 h in the healthy volunteers.,Paracetamol disposition and metabolite kinetics in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2744070/),h,3,273004,DB00316,Acetaminophen
,9706948,Cmax,"Tramadol had measurable but statistically insignificant inhibitory effects on gastric emptying compared with saline (mean +/- SEM: Cmax 22.4 +/- 2.2 vs 26.8 +/- 2.5 mg/L [P = 0.19], Tmax 33 +/- 5.4 vs 19.5 +/- 2.3 min [P = 0.054] for tramadol versus saline, respectively).","A comparison of the effects of intravenous tramadol, codeine, and morphine on gastric emptying in human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706948/),[mg] / [l],22.4,273696,DB00316,Acetaminophen
,9706948,Cmax,"Tramadol had measurable but statistically insignificant inhibitory effects on gastric emptying compared with saline (mean +/- SEM: Cmax 22.4 +/- 2.2 vs 26.8 +/- 2.5 mg/L [P = 0.19], Tmax 33 +/- 5.4 vs 19.5 +/- 2.3 min [P = 0.054] for tramadol versus saline, respectively).","A comparison of the effects of intravenous tramadol, codeine, and morphine on gastric emptying in human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706948/),[mg] / [l],26.8,273697,DB00316,Acetaminophen
,9706948,Tmax,"Tramadol had measurable but statistically insignificant inhibitory effects on gastric emptying compared with saline (mean +/- SEM: Cmax 22.4 +/- 2.2 vs 26.8 +/- 2.5 mg/L [P = 0.19], Tmax 33 +/- 5.4 vs 19.5 +/- 2.3 min [P = 0.054] for tramadol versus saline, respectively).","A comparison of the effects of intravenous tramadol, codeine, and morphine on gastric emptying in human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706948/),min,33,273698,DB00316,Acetaminophen
,9706948,Tmax,"Tramadol had measurable but statistically insignificant inhibitory effects on gastric emptying compared with saline (mean +/- SEM: Cmax 22.4 +/- 2.2 vs 26.8 +/- 2.5 mg/L [P = 0.19], Tmax 33 +/- 5.4 vs 19.5 +/- 2.3 min [P = 0.054] for tramadol versus saline, respectively).","A comparison of the effects of intravenous tramadol, codeine, and morphine on gastric emptying in human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706948/),min,19.5,273699,DB00316,Acetaminophen
,9706948,Tmax,The Tmax value for codeine (63.3 +/- 11.7) was greater than that for tramadol (P = 0.034).,"A comparison of the effects of intravenous tramadol, codeine, and morphine on gastric emptying in human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706948/),,63.3,273700,DB00316,Acetaminophen
